CodeList |
CodeListItem |
NCI attributes |
OID | Name (CDISC Submission Value) | DataType Extensible | NCI Code | CDISC Synonym | CDISC Definition | Preferred Term |
---|---|---|---|---|---|---|
CDISC Submission Value [ODM:CodedValue] | ||||||
CL.C66767.ACN | Action Taken with Study Treatment (ACN) | text Extensible: No | C66767 | Action Taken with Study Treatment | Action Taken with Study Treatment | CDISC SDTM Action Taken with Study Treatment Terminology |
DOSE INCREASED | C49503 | An indication that a medication schedule was modified by addition; either by changing the frequency, strength or amount. (NCI) | Dose Increased | |||
DOSE NOT CHANGED | C49504 | An indication that a medication schedule was maintained. (NCI) | Dose Not Changed | |||
DOSE REDUCED | C49505 | An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount. (NCI) | Dose Reduced | |||
DRUG INTERRUPTED | C49501 | An indication that a medication schedule was modified by temporarily terminating a prescribed regimen of medication. (NCI) | Drug Interrupted | |||
DRUG WITHDRAWN | C49502 | An indication that a medication schedule was modified through termination of a prescribed regimen of medication. (NCI) | Drug Withdrawn | |||
NOT APPLICABLE | C48660 | NA;Not Applicable | Determination of a value is not relevant in the current context. (NCI) | Not Applicable | ||
UNKNOWN | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
Back to top | ||||||
CL.C66768.OUT | Outcome of Event (OUT) | text Extensible: No | C66768 | Outcome of Event | A condition or event that is attributed to the adverse event and is the result or conclusion of the adverse event. (NCI) | CDISC SDTM Adverse Event Outcome Terminology |
FATAL | C48275 | Grade 5;5;FATAL | The termination of life as a result of an adverse event. (NCI) | Death Related to Adverse Event | ||
NOT RECOVERED/NOT RESOLVED | C49494 | One of the possible results of an adverse event outcome that indicates that the event has not improved or recuperated. (NCI) | Not Recovered or Not Resolved | |||
RECOVERED/RESOLVED | C49498 | One of the possible results of an adverse event outcome that indicates that the event has improved or recuperated. (NCI) | Recovered or Resolved | |||
RECOVERED/RESOLVED WITH SEQUELAE | C49495 | One of the possible results of an adverse event outcome where the subject recuperated but retained pathological conditions resulting from the prior disease or injury. (NCI) | Recovered or Resolved with Sequelae | |||
RECOVERING/RESOLVING | C49496 | One of the possible results of an adverse event outcome that indicates that the event is improving. (NCI) | Recovering or Resolving | |||
UNKNOWN | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
Back to top | ||||||
CL.C66781.AGEU | Age Unit (AGEU) | text Extensible: No | C66781 | Age Unit | Those units of time that are routinely used to express the age of a subject. | CDISC SDTM Age Unit Terminology |
DAYS | C25301 | Day | The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours. This also refers to a specific day. (NCI) | Day | ||
HOURS | C25529 | Hour;hr | A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day. (NCI) | Hour | ||
MONTHS | C29846 | One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks. (NCI) | Month | |||
WEEKS | C29844 | Any period of seven consecutive days. (NCI) | Week | |||
YEARS | C29848 | Year | The period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period. (NCI) | Year | ||
Back to top | ||||||
CL.C66797.IECAT | Category for Inclusion/Exclusion (IECAT) | text Extensible: No | C66797 | Category for Inclusion/Exclusion | A collection of criteria on which subjects are evaluated and that must be met by all study subjects. (NCI) | CDISC SDTM Category for Inclusion And Or Exclusion Terminology |
EXCLUSION | C25370 | List of characteristics in a protocol, any one of which may exclude a potential subject from participation in a study. (CDISC glossary) | Exclusion Criteria | |||
INCLUSION | C25532 | The criteria in a protocol that prospective subjects must meet to be eligible for participation in a study. NOTE: Exclusion and inclusion criteria define the study population. See also exclusion criteria. (CDISC glossary) | Inclusion Criteria | |||
Back to top | ||||||
CL.C66784.TOXGRV3 | Common Terminology Criteria for Adverse Events V3.0 (TOXGRV3) | text Extensible: No | C66784 | Common Terminology Criteria for Adverse Events V3.0 | A standard terminology developed to report adverse events occurring in cancer clinical trials. Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration. The CTCAE contain a grading scale for each adverse event term representing the severity of the event. (NCI) | CDISC SDTM Common Terminology Criteria for Adverse Event Grade Terminology V3.0 |
1 | C41338 | Grade 1;1 | A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. | Mild Adverse Event | ||
2 | C41339 | Grade 2;2 | A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. | Moderate Adverse Event | ||
3 | C41340 | Grade 3;3 | A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. | Severe Adverse Event | ||
4 | C41337 | Grade 4;4;LIFE THREATENING | An adverse event, and/or its immediate sequelae, which is associated with an imminent risk of death or which is associated with physical or mental disabilities that affect or limit the ability of a person to perform activities of daily living (eating, ambulation, toileting, etc.) See NCI Common Terminology Criteria for Adverse Events. | Life Threatening or Disabling Adverse Event | ||
5 | C48275 | Grade 5;5;FATAL | The termination of life as a result of an adverse event. (NCI) | Death Related to Adverse Event | ||
Back to top | ||||||
CL.C87162.TOXGRV4 | Common Terminology Criteria for Adverse Events V4.0 (TOXGRV4) | text Extensible: No | C87162 | Common Terminology Criteria for Adverse Events V4.0 | The version 4.0 standard terminology developed to report adverse events occurring in cancer clinical trials. Common terminology criteria for adverse events (CTCAE) are used to study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration. The CTCAE contain a grading scale for each adverse event term representing the severity of the event. (NCI) | CDISC SDTM Common Terminology Criteria for Adverse Event Grade Terminology Version 4.0 |
0 | C75533 | ABSENT;Grade 0;0 | Grade 0 is universally defined as absence of Adverse Events or within normal limits or values. | Absent Adverse Event | ||
1 | C84263 | MILD;Grade 1;1 | An adverse event that is asymptomatic; or involves mild or minor symptoms; or is of marginal clinical relevance; or consists of clinical or diagnostic observations alone; or for which intervention is not indicated; or for which only non-prescription intervention is indicated. | Mild Adverse Event | ||
2 | C84264 | MODERATE;Grade 2;2 | An adverse event for which only minimal, local, or noninvasive intervention (e.g. packing, cautery) is indicated; or that limits instrumental activities of daily living (ADLs, e.g., shopping, laundry, transportation, or ability to conduct finances). | Moderate Adverse Event | ||
3 | C84265 | SEVERE;Grade 3;3 | An adverse event that is medically significant but not life-threatening; or for which inpatient care or prolongation of hospitalization are indicated; or that is an important medical event that does not result in hospitalization, but may jeopardize the patient or may require intervention either to prevent hospitalization, to prevent the AE from becoming life-threatening or causing death; or that is disabling; or that results in persistent or significant disability, incapacity, or limitation of self care activities of daily living (ADLs, e.g., getting in and out of bed, dressing, eating, getting around inside, bathing, or using the toilet). | Severe Adverse Event | ||
4 | C84266 | LIFE THREATENING;Grade 4;4 | An adverse event that has life-threatening consequences; for which urgent intervention is indicated; that puts the patient at risk of death at the time of the event if immediate intervention is not undertaken; or that causes blindness or deafness. | Life Threatening Adverse Event | ||
5 | C48275 | FATAL;Grade 5;5 | The termination of life as a result of an adverse event. (NCI) | Death Related to Adverse Event | ||
Back to top | ||||||
CL.C66785.TCNTRL | Control Type (TCNTRL) | text Extensible: Yes | C66785 | Control Type | Comparator against which the study treatment is evaluated (e.g., concurrent (placebo, no treatment, dose-response, active), external (historical, published literature). | CDISC SDTM Control Type Terminology |
ACTIVE | C49649 | A type of control, which has a demonstrated effect, administered as a comparator, to subjects in a clinical trial. [From ICH E10]. | Active Control | |||
NONE | C41132 | No person or thing, nobody, not any. (NCI) | None | |||
PLACEBO | C49648 | Use of an inactive compound identical in appearance to drug or treatment being tested in experimental research, which may or may not be known to the physician and/or subject, administered to distinguish between drug action and suggestive effect of the drug or treatment under study. The effects of the active drug or treatment are compared to the effects of the placebo. (NCI) | Placebo Control | |||
Back to top | ||||||
CL.C66786.COUNTRY | Country (COUNTRY) | text Extensible: No | C66786 | Country | A collective generic term that refers here to a wide variety of dependencies, areas of special sovereignty, uninhabited islands, and other entities in addition to the traditional countries or independent states. (NCI) | CDISC SDTM Country Terminology |
ABW | C17884 | ARUBA | Island in the Caribbean Sea, north of Venezuela. (NCI) | Aruba | ||
AFG | C16267 | AFGHANISTAN | A country in Southern Asia, north and west of Pakistan, east of Iran. (NCI) | Afghanistan | ||
AGO | C16292 | ANGOLA | A country in Southern Africa, bordering the South Atlantic Ocean, between Namibia and Democratic Republic of the Congo. (NCI) | Angola | ||
AIA | C20133 | ANGUILLA | An island in the Caribbean Sea, east of Puerto Rico. (NCI) | Anguilla | ||
ALA | C44481 | ALAND ISLANDS | An archipelago in the Baltic Sea at the entrance to the Gulf of Bothnia between Sweden and Finland. (NCI) | Aland Islands | ||
ALB | C16271 | ALBANIA | A country in Southeastern Europe, bordering the Adriatic Sea and Ionian Sea, between Greece and Serbia and Montenegro. (NCI) | Albania | ||
AND | C16289 | ANDORRA | A country in Southwestern Europe, between France and Spain. (NCI) | Andorra | ||
ARE | C17232 | UNITED ARAB EMIRATES | A country in the Middle East, bordering the Gulf of Oman and the Persian Gulf, between Oman and Saudi Arabia. (NCI) | United Arab Emirates | ||
ARG | C16305 | ARGENTINA | A country in Southern South America, bordering the South Atlantic Ocean, between Chile and Uruguay. (NCI) | Argentina | ||
ARM | C16306 | ARMENIA | A country in Southwestern Asia, east of Turkey. (NCI) | Armenia | ||
ASM | C17739 | AMERICAN SAMOA | A group of islands in the South Pacific Ocean, about half way between Hawaii and New Zealand. (NCI) | American Samoa | ||
ATA | C18007 | ANTARCTICA | The continent lying mostly south of the Antarctic Circle. (NCI) | Antarctica | ||
ATF | C20105 | FRENCH SOUTHERN TERRITORIES | Islands in the southern Indian Ocean, south of Africa, about equidistant between Africa, Antarctica, and Australia. (NCI) | French Southern Territories | ||
ATG | C16303 | ANTIGUA AND BARBUDA | Islands between the Caribbean Sea and the North Atlantic Ocean, east-southeast of Puerto Rico. (NCI) | Antigua and Barbuda | ||
AUS | C16311 | AUSTRALIA | The continent between the Indian Ocean and the South Pacific Ocean. (NCI) | Australia | ||
AUT | C16312 | AUSTRIA | A country in Central Europe, north of Italy and Slovenia. (NCI) | Austria | ||
AZE | C16316 | AZERBAIJAN | A country in Southwestern Asia, bordering the Caspian Sea, between Iran and Russia. (NCI) | Azerbaijan | ||
BDI | C16371 | BURUNDI | A country in Central Africa, east of Democratic Republic of the Congo. (NCI) | Burundi | ||
BEL | C16329 | BELGIUM | A country in Western Europe, bordering the North Sea, between France and the Netherlands. (NCI) | Belgium | ||
BEN | C16333 | BENIN REPUBLIC;BENIN | A country in Western Africa, bordering the North Atlantic Ocean, between Nigeria and Togo. (NCI) | Benin | ||
BFA | C16369 | BURKINA FASO | A country in Western Africa, north of Ghana. (NCI) | Burkina Faso | ||
BGD | C16323 | BANGLADESH | A country in Southern Asia, bordering the Bay of Bengal, between Burma and India. (NCI) | Bangladesh | ||
BGR | C16368 | BULGARIA | A country in Southeastern Europe, bordering the Black Sea, between Romania and Turkey. (NCI) | Bulgaria | ||
BHR | C16322 | BAHRAIN | An archipelago in the Persian Gulf, east of Saudi Arabia. (NCI) | Bahrain | ||
BHS | C16321 | BAHAMAS | A chain of islands in the North Atlantic Ocean, southeast of Florida. (NCI) | Bahamas | ||
BIH | C16361 | BOSNIA-HERZEGOVINA;BOSNIA AND HERZEGOVINA | A country in Southeastern Europe, bordering the Adriatic Sea and Croatia. (NCI) | Bosnia and Herzegovina | ||
BLM | C83609 | SAINT BARTHELEMY | An island in the Caribbean sea, between Saint Martin and Saint Kitts and Nevis. (NCI) | Saint Barthelemy | ||
BLR | C16372 | BELARUS | A country in Eastern Europe, east of Poland. (NCI) | Belarus | ||
BLZ | C16331 | BELIZE | A country in Central America, bordering the Caribbean Sea, between Guatemala and Mexico. (NCI) | Belize | ||
BMU | C16334 | BERMUDA | A group of islands in the North Atlantic Ocean, east of South Carolina. (NCI) | Bermuda | ||
BOL | C16359 | BOLIVIA;BOLIVIA, PLURINATIONAL STATE OF | A country in Central South America, southwest of Brazil. (NCI) | Bolivia, Plurinational State of | ||
BRA | C16364 | BRAZIL | A country in Eastern South America, bordering the Atlantic Ocean. (NCI) | Brazil | ||
BRB | C16324 | BARBADOS | An island between the Caribbean Sea and the North Atlantic Ocean, northeast of Venezuela. (NCI) | Barbados | ||
BRN | C16367 | BRUNEI;BRUNEI DARUSSALAM | A country in Southeastern Asia, bordering the South China Sea and Malaysia. (NCI) | Brunei Darussalam | ||
BTN | C16336 | BHUTAN | A country in Southern Asia, between China and India. (NCI) | Bhutan | ||
BVT | C20104 | BOUVET ISLAND | An island in the South Atlantic Ocean, south-southwest of the Cape of Good Hope (South Africa). (NCI) | Bouvet Island | ||
BWA | C16363 | BOTSWANA | A country in Southern Africa, north of South Africa. (NCI) | Botswana | ||
CAF | C16409 | CENTRAL AFRICAN REPUBLIC | A country in Central Africa, north of Democratic Republic of the Congo. (NCI) | Central African Republic | ||
CAN | C16380 | CANADA | A country in Northern North America, bordering the North Atlantic Ocean on the east, North Pacific Ocean on the west, and the Arctic Ocean on the north, north of the conterminous US. (NCI) | Canada | ||
CCK | C16445 | COCOS (KEELING) ISLANDS | A group of islands in the Indian Ocean, south of Indonesia, about halfway from Australia to Sri Lanka. (NCI) | Cocos (Keeling) Islands | ||
CHE | C17181 | SWITZERLAND | A country in Central Europe, east of France, north of Italy. (NCI) | Switzerland | ||
CHL | C16427 | CHILE | A country in Southern South America, bordering the South Atlantic Ocean and South Pacific Ocean, between Argentina and Peru. (NCI) | Chile | ||
CHN | C16428 | CHINA | A country in Eastern Asia, bordering the East China Sea, Korea Bay, Yellow Sea, and South China Sea, between North Korea and Vietnam. (NCI) | China | ||
CIV | C16762 | COTE D'IVOIRE | A country in Western Africa, bordering the North Atlantic Ocean, between Ghana and Liberia. (NCI) | Cote d'Ivoire | ||
CMR | C16379 | CAMEROON | A country in Western Africa, bordering the Bight of Biafra, between Equatorial Guinea and Nigeria. (NCI) | Cameroon | ||
COD | C17266 | DEMOCRATIC REPUBLIC OF THE CONGO;CONGO, THE DEMOCRATIC REPUBLIC OF | A country in Central Africa, northeast of Angola. (NCI) | Congo, the Democratic Republic of the | ||
COG | C16467 | CONGO | A country in Western Africa, bordering the South Atlantic Ocean, between Angola and Gabon. (NCI) | Congo | ||
COK | C16469 | COOK ISLANDS | A group of islands in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand. (NCI) | Cook Islands | ||
COL | C16449 | COLOMBIA | A country in Northern South America, bordering the Caribbean Sea, between Panama and Venezuela, and bordering the North Pacific Ocean, between Ecuador and Panama. (NCI) | Colombia | ||
COM | C16458 | COMOROS | A group of islands in the Mozambique Channel, about two-thirds of the way between northern Madagascar and northern Mozambique. (NCI) | Comoros | ||
CPV | C16382 | CAPE VERDE | A group of islands in the North Atlantic Ocean, west of Senegal. (NCI) | Cape Verde | ||
CRI | C16470 | COSTA RICA | A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Nicaragua and Panama. (NCI) | Costa Rica | ||
CUB | C16477 | CUBA | An island between the Caribbean Sea and the North Atlantic Ocean, 150 km south of Key West, Florida. (NCI) | Cuba | ||
CXR | C44482 | CHRISTMAS ISLAND | An Australian-administered island in the eastern Indian Ocean south of Java, Indonesia. (NCI) | Christmas Island | ||
CYM | C16391 | CAYMAN ISLANDS | An island group in the Caribbean Sea, nearly one-half of the way from Cuba to Honduras. (NCI) | Cayman Islands | ||
CYP | C16480 | CYPRUS | An island in the Mediterranean Sea, south of Turkey. (NCI) | Cyprus | ||
CZE | C17668 | CZECH REPUBLIC | A country in Central Europe, southeast of Germany. (NCI) | Czech Republic | ||
DEU | C16636 | GERMANY | A country in Central Europe, bordering the Baltic Sea and the North Sea, between the Netherlands and Poland, south of Denmark. (NCI) | Germany | ||
DJI | C16506 | DJIBOUTI | A country in Eastern Africa, bordering the Gulf of Aden and the Red Sea, between Eritrea and Somalia. (NCI) | Djibouti | ||
DMA | C16519 | DOMINICA | An island between the Caribbean Sea and the North Atlantic Ocean, about one-half of the way from Puerto Rico to Trinidad and Tobago. (NCI) | Dominica | ||
DNK | C16496 | DENMARK | A country in Northern Europe, bordering the Baltic Sea and the North Sea, on a peninsula north of Germany (Jutland); also includes two major islands (Sjaelland and Fyn). (NCI) | Denmark | ||
DOM | C16520 | DOMINICAN REPUBLIC | A country comprising the eastern two-thirds of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, east of Haiti. (NCI) | Dominican Republic | ||
DZA | C16274 | ALGERIA | A country in Northern Africa, bordering the Mediterranean Sea, between Morocco and Tunisia. (NCI) | Algeria | ||
ECU | C16528 | ECUADOR | A country in Western South America, bordering the Pacific Ocean at the Equator, between Colombia and Peru. (NCI) | Ecuador | ||
EGY | C16530 | EGYPT | A country in Northern Africa, bordering the Mediterranean Sea, between Libya and the Gaza Strip. (NCI) | Egypt | ||
ERI | C16558 | ERITREA | A country in Eastern Africa, bordering the Red Sea, between Djibouti and Sudan. (NCI) | Eritrea | ||
ESH | C20113 | WESTERN SAHARA | A country in Northern Africa, bordering the North Atlantic Ocean, between Mauritania and Morocco. (NCI) | Western Sahara | ||
ESP | C17152 | SPAIN | A country in Southwestern Europe, bordering the Bay of Biscay, Mediterranean Sea, North Atlantic Ocean, and Pyrenees Mountains, southwest of France. (NCI) | Spain | ||
EST | C16562 | ESTONIA | A country in Eastern Europe, bordering the Baltic Sea and Gulf of Finland, between Latvia and Russia. (NCI) | Estonia | ||
ETH | C16563 | ETHIOPIA | A country in Eastern Africa, west of Somalia. (NCI) | Ethiopia | ||
FIN | C16584 | FINLAND | A country in Northern Europe, bordering the Baltic Sea, Gulf of Bothnia, and Gulf of Finland, between Sweden and Russia. (NCI) | Finland | ||
FJI | C16582 | FIJI | An island group in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand. (NCI) | Fiji | ||
FLK | C17954 | FALKLAND ISLANDS;FALKLAND ISLANDS (MALVINAS) | Islands in the South Atlantic Ocean, east of southern Argentina. (NCI) | Falkland Islands (Malvinas) | ||
FRA | C16592 | FRANCE | A country in Western Europe, bordering the Bay of Biscay and English Channel, between Belgium and Spain, southeast of the UK; bordering the Mediterranean Sea, between Italy and Spain. (NCI) | France | ||
FRO | C16573 | FAROE ISLANDS | An island group between the Norwegian Sea and the North Atlantic Ocean, about one-half of the way from Iceland to Norway. (NCI) | Faroe Islands | ||
FSM | C17881 | MICRONESIA, FEDERATED STATES OF | An island group in the North Pacific Ocean, about three-quarters of the way from Hawaii to Indonesia. (NCI) | Micronesia, Federated States of | ||
GAB | C16596 | GABON | A country in Western Africa, bordering the Atlantic Ocean at the Equator, between Republic of the Congo and Equatorial Guinea. (NCI) | Gabon | ||
GBR | C17233 | UNITED KINGDOM | A country in Western Europe, comprising islands, including the northern one-sixth of the island of Ireland, between the North Atlantic Ocean and the North Sea, northwest of France. (NCI) | United Kingdom | ||
GEO | C16634 | GEORGIA | A country in Southwestern Asia, bordering the Black Sea, between Turkey and Russia. (NCI) | Georgia | ||
GGY | C64375 | GUERNSEY | The island of Guernsey and the other Channel Islands represent the last remnants of the medieval Dukedom of Normandy, which held sway in both France and England. Guernsey is a British crown dependency, but is not part of the UK. (NCI) | Guernsey | ||
GHA | C26330 | GHANA | A country in Western Africa, bordering the Gulf of Guinea, between Cote d'Ivoire and Togo. (NCI) | Ghana | ||
GIB | C16638 | GIBRALTAR | A dependency in Southwestern Europe, bordering the Strait of Gibraltar, on the southern coast of Spain. (NCI) | Gibraltar | ||
GIN | C16655 | GUINEA | A country in Western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Sierra Leone. (NCI) | Guinea | ||
GLP | C16651 | GUADELOUPE | Islands in the eastern Caribbean Sea, southeast of Puerto Rico. (NCI) | Guadeloupe | ||
GMB | C16598 | GAMBIA | A country in Western Africa, bordering the North Atlantic Ocean and Senegal. (NCI) | Gambia | ||
GNB | C16656 | GUINEA-BISSAU | A country in Western Africa, bordering the North Atlantic Ocean, between Guinea and Senegal. (NCI) | Guinea-Bissau | ||
GNQ | C16557 | EQUATORIAL GUINEA | A country in Western Africa, bordering the Bight of Biafra, between Cameroon and Gabon; composed of a mainland portion and five inhabited islands. (NCI) | Equatorial Guinea | ||
GRC | C16645 | GREECE | A country in Southern Europe, bordering the Aegean Sea, Ionian Sea, and the Mediterranean Sea, between Albania and Turkey. (NCI) | Greece | ||
GRD | C16647 | GRENADA | An island between the Caribbean Sea and Atlantic Ocean, north of Trinidad and Tobago. (NCI) | Grenada | ||
GRL | C16646 | GREENLAND | An island between the Arctic Ocean and the North Atlantic Ocean, northeast of Canada. (NCI) | Greenland | ||
GTM | C16654 | GUATEMALA | A country in Central America, bordering the Caribbean Sea, between Honduras and Belize and bordering the North Pacific Ocean, between El Salvador and Mexico. (NCI) | Guatemala | ||
GUF | C16593 | FRENCH GUIANA | A country in Northern South America, bordering the North Atlantic Ocean, between Brazil and Suriname. (NCI) | French Guiana | ||
GUM | C16652 | GUAM | Island in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines. (NCI) | Guam | ||
GUY | C16657 | GUYANA | A country in Northern South America, bordering the North Atlantic Ocean, between Suriname and Venezuela. (NCI) | Guyana | ||
HKG | C16695 | HONG KONG | A special administrative region of China, bordering the South China Sea and China. (NCI) | Hong Kong | ||
HMD | C20106 | HEARD ISLAND AND MCDONALD ISLANDS | Islands in the Indian Ocean, about two-thirds of the way from Madagascar to Antarctica. (NCI) | Heard Island and McDonald Islands | ||
HND | C16694 | HONDURAS | A country in Central America, bordering the Caribbean Sea, between Guatemala and Nicaragua and bordering the North Pacific Ocean, between El Salvador and Nicaragua. (NCI) | Honduras | ||
HRV | C16474 | CROATIA | A country in Southeastern Europe, bordering the Adriatic Sea, between Bosnia and Herzegovina and Slovenia. (NCI) | Croatia | ||
HTI | C16660 | HAITI | A country comprising the western one-third of the island of Hispaniola, between the Caribbean Sea and the North Atlantic Ocean, west of the Dominican Republic. (NCI) | Haiti | ||
HUN | C16699 | HUNGARY | A country in Central Europe, northwest of Romania. (NCI) | Hungary | ||
IDN | C16728 | INDONESIA | A country in Southeastern Asia, comprising the archipelago between the Indian Ocean and the Pacific Ocean. (NCI) | Indonesia | ||
IND | C16727 | INDIA | A country in Southern Asia, bordering the Arabian Sea and the Bay of Bengal, between Burma and Pakistan. (NCI) | India | ||
IMN | C44480 | ISLE OF MAN | An island in the Irish Sea, between Great Britain and Ireland. (NCI) | Isle of Man | ||
IOT | C16365 | BRITISH INDIAN OCEAN TERRITORY | An archipelago in the Indian Ocean, about one-half the way from Africa to Indonesia. (NCI) | British Indian Ocean Territory | ||
IRL | C16757 | IRELAND | A country in Western Europe, occupying five-sixths of the island of Ireland in the North Atlantic Ocean, west of Great Britain. (NCI) | Ireland | ||
IRN | C16755 | IRAN | A country in the Middle East, bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan. (NCI) | Iran, Islamic Republic of | ||
IRQ | C16756 | IRAQ | A country in the Middle East, bordering the Persian Gulf, between Iran and Kuwait. (NCI) | Iraq | ||
ISL | C16704 | ICELAND | A country in Northern Europe, island between the Greenland Sea and the North Atlantic Ocean, northwest of the UK. (NCI) | Iceland | ||
ISR | C16760 | ISRAEL | A country in the Middle East, bordering the Mediterranean Sea, between Egypt and Lebanon. (NCI) | Israel | ||
ITA | C16761 | ITALY | A country in Southern Europe, occupying a peninsula extending into the central Mediterranean Sea, northeast of Tunisia. (NCI) | Italy | ||
JAM | C16763 | JAMAICA | An island in the Caribbean Sea, south of Cuba. (NCI) | Jamaica | ||
JOR | C16765 | JORDAN | A country in the Middle East, northwest of Saudi Arabia. (NCI) | Jordan | ||
JPN | C16764 | JAPAN | A country in Eastern Asia, occupying an island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. (NCI) | Japan | ||
JEY | C64374 | JERSEY | Jersey and the other Channel Islands represent the last remnants of the medieval Dukedom of Normandy that held sway in both France and England. Jersey is a British crown dependency, but is not part of the UK. (NCI) | Jersey | ||
KAZ | C20107 | KAZAKHSTAN | A country in Central Asia, northwest of China. (NCI) | Kazakhstan | ||
KEN | C16769 | KENYA | A country in Eastern Africa, bordering the Indian Ocean, between Somalia and Tanzania. (NCI) | Kenya | ||
KGZ | C16771 | KYRGYZSTAN | A country in Central Asia, west of China. (NCI) | Kyrgyzstan | ||
KHM | C16378 | CAMBODIA | A country in Southeastern Asia, bordering the Gulf of Thailand, between Thailand, Vietnam, and Laos. (NCI) | Cambodia | ||
KIR | C16639 | KIRIBATI | A group of 33 coral atolls in the Pacific Ocean, straddling the equator; the capital Tarawa is about one-half of the way from Hawaii to Australia. (NCI) | Kiribati | ||
KNA | C17885 | SAINT KITTS AND NEVIS | Islands in the Caribbean Sea, about one-third of the way from Puerto Rico to Trinidad and Tobago. (NCI) | Saint Kitts and Nevis | ||
KOR | C16774 | SOUTH KOREA;KOREA, REPUBLIC OF | A country in Eastern Asia, occupying the southern half of the Korean Peninsula, bordering the Sea of Japan and the Yellow Sea. (NCI) | Korea, Republic of | ||
KWT | C16775 | KUWAIT | A country in the Middle East, bordering the Persian Gulf, between Iraq and Saudi Arabia. (NCI) | Kuwait | ||
LAO | C16780 | LAO PEOPLE'S DEMOCRATIC REPUBLIC | A country in Southeastern Asia, northeast of Thailand, west of Vietnam. (NCI) | Lao People's Democratic Republic | ||
LBN | C16784 | LEBANON | A country in the Middle East, bordering the Mediterranean Sea, between Israel and Syria. (NCI) | Lebanon | ||
LBR | C16791 | LIBERIA | A country in Western Africa, bordering the North Atlantic Ocean, between Cote d'Ivoire and Sierra Leone. (NCI) | Liberia | ||
LBY | C16793 | LIBYA | A country in Northern Africa, bordering the Mediterranean Sea, between Egypt and Tunisia. (NCI) | Libya | ||
LCA | C17113 | SAINT LUCIA | A country in the Caribbean, occupying an island between the Caribbean Sea and North Atlantic Ocean, north of Trinidad and Tobago. (NCI) | Saint Lucia | ||
LIE | C16794 | LIECHTENSTEIN | A country in Central Europe, between Austria and Switzerland. (NCI) | Liechtenstein | ||
LKA | C17163 | SRI LANKA | A country in Southern Asia, occupying an island in the Indian Ocean, south of India. (NCI) | Sri Lanka | ||
LSO | C16787 | LESOTHO | A country in Southern Africa, an enclave of South Africa. (NCI) | Lesotho | ||
LTU | C16799 | LITHUANIA | A country in Eastern Europe, bordering the Baltic Sea, between Latvia and Russia. (NCI) | Lithuania | ||
LUX | C16803 | LUXEMBOURG | A country in Western Europe, between France, Belgium, and Germany. (NCI) | Luxembourg | ||
LVA | C16783 | LATVIA | A country in Eastern Europe, bordering the Baltic Sea, between Estonia and Lithuania. (NCI) | Latvia | ||
MAC | C16807 | MACAO | A country in Eastern Asia, bordering the South China Sea and China. (NCI) | Macao | ||
MAF | C83610 | SAINT MARTIN, FRENCH;SAINT MARTIN (FRENCH PART) | An island in the Caribbean sea, between Anguilla and Saint Barthelemy. (NCI) | Saint Martin (French Part) | ||
MAR | C16878 | MOROCCO | A country in Northern Africa, bordering the North Atlantic Ocean and the Mediterranean Sea, between Algeria and Western Sahara. (NCI) | Morocco | ||
MCO | C16874 | MONACO | A country in Western Europe, bordering the Mediterranean Sea on the southern coast of France, near the border with Italy. (NCI) | Monaco | ||
MDA | C16871 | MOLDOVA, REPUBLIC OF | A country in Eastern Europe, northeast of Romania. (NCI) | Moldova, Republic of | ||
MDG | C16808 | MADAGASCAR | A country in Southern Africa, occupying an island in the Indian Ocean, east of Mozambique. (NCI) | Madagascar | ||
MDV | C16815 | MALDIVES | A country in Southern Asia, occupying a group of atolls in the Indian Ocean, south-southwest of India. (NCI) | Maldives | ||
MEX | C16850 | MEXICO | A country in Central America, bordering the Caribbean Sea and the Gulf of Mexico, between Belize and the US and bordering the North Pacific Ocean, between Guatemala and the US. (NCI) | Mexico | ||
MHL | C16822 | MARSHALL ISLANDS | A group of atolls and reefs in the North Pacific Ocean, about one-half of the way from Hawaii to Australia. (NCI) | Marshall Islands | ||
MKD | C17654 | REPUBLIC OF MACEDONIA;MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF | A country in Southeastern Europe, north of Greece. (NCI) | Macedonia, the Former Yugoslav Republic of | ||
MLI | C16816 | MALI | A country in Western Africa, southwest of Algeria. (NCI) | Mali | ||
MLT | C16817 | MALTA | A country in Southern Europe, occupying islands in the Mediterranean Sea, south of Sicily (Italy). (NCI) | Malta | ||
MMR | C16370 | MYANMAR | A country in Southeastern Asia, bordering the Andaman Sea and the Bay of Bengal, between Bangladesh and Thailand. (NCI) | Myanmar | ||
MNE | C64378 | MONTENEGRO | A republic in Southeastern Europe, bordering the Adriatic Sea, between Albania and Bosnia and Herzegovina. Formerly part of Serbia and Montenegro (Federation Republic of Yugoslavia). (NCI) | Montenegro | ||
MNG | C16875 | MONGOLIA | A country in Northern Asia, between China and Russia. (NCI) | Mongolia | ||
MNP | C17882 | NORTHERN MARIANA ISLANDS | A country in the Pacific, comprising islands in the North Pacific Ocean, about three-quarters of the way from Hawaii to the Philippines. (NCI) | Northern Mariana Islands | ||
MOZ | C16882 | MOZAMBIQUE | A country in Southern Africa, bordering the Mozambique Channel, between South Africa and Tanzania. (NCI) | Mozambique | ||
MRT | C16826 | MAURITANIA | A country in Northern Africa, bordering the North Atlantic Ocean, between Senegal and Western Sahara. (NCI) | Mauritania | ||
MSR | C16876 | MONTSERRAT | A country in the Caribbean, occupying an island in the Caribbean Sea, southeast of Puerto Rico. (NCI) | Montserrat | ||
MTQ | C16823 | MARTINIQUE | An island in the Caribbean Sea, north of Trinidad and Tobago. (NCI) | Martinique | ||
MUS | C16827 | MAURITIUS | A country in Southern Africa, occupying an island in the Indian Ocean, east of Madagascar. (NCI) | Mauritius | ||
MWI | C16813 | MALAWI | A country in Southern Africa, east of Zambia. (NCI) | Malawi | ||
MYS | C16814 | MALAYSIA | A country in Southeastern Asia, occupying a peninsula and the northern one-third of the island of Borneo, bordering Indonesia and the South China Sea, south of Vietnam. (NCI) | Malaysia | ||
MYT | C16828 | MAYOTTE | A country in Southern Africa, occupying an island in the Mozambique Channel, about one-half of the way from northern Madagascar to northern Mozambique. (NCI) | Mayotte | ||
NAM | C16891 | NAMIBIA | A country in Southern Africa, bordering the South Atlantic Ocean, between Angola and South Africa. (NCI) | Namibia | ||
NCL | C16913 | NEW CALEDONIA | A country in the Pacific, comprised of islands in the South Pacific Ocean, east of Australia. (NCI) | New Caledonia | ||
NER | C16916 | NIGER | A country in Western Africa, southeast of Algeria. (NCI) | Niger | ||
NFK | C16919 | NORFOLK ISLAND | A country in the Pacific, occupying an island in the South Pacific Ocean, east of Australia. (NCI) | Norfolk Island | ||
NGA | C16917 | NIGERIA | A country in Western Africa, bordering the Gulf of Guinea, between Benin and Cameroon. (NCI) | Nigeria | ||
NIC | C16915 | NICARAGUA | A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Costa Rica and Honduras. (NCI) | Nicaragua | ||
NIU | C16918 | NIUE | A country in the Pacific, occupying an island in the South Pacific Ocean, east of Tonga. (NCI) | Niue | ||
NLD | C16903 | NETHERLANDS | A country in Western Europe, bordering the North Sea, between Belgium and Germany. (NCI) | Netherlands | ||
NOR | C16920 | NORWAY | A country in Northern Europe, bordering the North Sea and the North Atlantic Ocean, west of Sweden. (NCI) | Norway | ||
NPL | C16901 | NEPAL | A country in Southern Asia, between China and India. (NCI) | Nepal | ||
NRU | C16896 | NAURU | A country in Oceania, occupying an island in the South Pacific Ocean, south of the Marshall Islands. (NCI) | Nauru | ||
NZL | C16914 | NEW ZEALAND | A country in the Pacific, comprised of islands in the South Pacific Ocean, southeast of Australia. (NCI) | New Zealand | ||
OMN | C16933 | OMAN | A country in the Middle East, bordering the Arabian Sea, Gulf of Oman, and Persian Gulf, between Yemen and the United Arab Emirates. (NCI) | Oman | ||
PAK | C16949 | PAKISTAN | A country in Southern Asia, bordering the Arabian Sea, between India on the east and Iran and Afghanistan on the west and China in the north. (NCI) | Pakistan | ||
PAN | C16951 | PANAMA | A country in Central America, bordering both the Caribbean Sea and the North Pacific Ocean, between Colombia and Costa Rica. (NCI) | Panama | ||
PCN | C16993 | PITCAIRN | A country in the Pacific, comprised of islands in the South Pacific Ocean, about midway between Peru and New Zealand. (NCI) | Pitcairn | ||
PER | C16972 | PERU | A country in Western South America, bordering the South Pacific Ocean, between Chile and Ecuador. (NCI) | Peru | ||
PHL | C16978 | PHILIPPINES | A country in Southeastern Asia, comprised of an archipelago between the Philippine Sea and the South China Sea, east of Vietnam. (NCI) | Philippines | ||
PLW | C17733 | PALAU | A country in the Pacific, comprising a group of islands in the North Pacific Ocean, southeast of the Philippines. (NCI) | Palau | ||
PNG | C16952 | PAPUA NEW GUINEA | A country in Southeastern Asia, comprising a group of islands and including the eastern half of the island of New Guinea, between the Coral Sea and the South Pacific Ocean, east of Indonesia. (NCI) | Papua New Guinea | ||
POL | C17002 | POLAND | A country in Central Europe, east of Germany. (NCI) | Poland | ||
PRI | C17043 | PUERTO RICO | An island between the Caribbean Sea and the North Atlantic Ocean, east of the Dominican Republic. (NCI) | Puerto Rico | ||
PRK | C16773 | NORTH KOREA;KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF | A country in Eastern Asia, occupying the northern half of the Korean Peninsula, bordering the Korea Bay and the Sea of Japan, between China and South Korea. (NCI) | Korea, Democratic People's Republic of | ||
PRT | C17006 | PORTUGAL | A country in Southwestern Europe, bordering the North Atlantic Ocean, west of Spain. (NCI) | Portugal | ||
PRY | C16953 | PARAGUAY | A country in Central South America, northeast of Argentina. (NCI) | Paraguay | ||
PSE | C20110 | PALESTINIAN TERRITORY, OCCUPIED | A collective name for the West Bank and the Gaza Strip, two territories in Palestine. (NCI) | Palestinian Territory, Occupied | ||
PYF | C16594 | FRENCH POLYNESIA | An archipelago in the South Pacific Ocean, about one-half of the way from South America to Australia. (NCI) | French Polynesia | ||
QAT | C17045 | QATAR | A country in the Middle East, occupying a peninsula bordering the Persian Gulf and Saudi Arabia. (NCI) | Qatar | ||
REU | C17095 | REUNION | A country in Southern Africa, occupying an island in the Indian Ocean, east of Madagascar. (NCI) | Reunion | ||
ROU | C17108 | ROMANIA | A country in Southeastern Europe, bordering the Black Sea, between Bulgaria and Ukraine. (NCI) | Romania | ||
RUS | C17111 | RUSSIAN FEDERATION | A country in Northern Asia (that part west of the Urals is sometimes included with Europe), bordering the Arctic Ocean, between Europe and the North Pacific Ocean. (NCI) | Russian Federation | ||
RWA | C17112 | RWANDA | A country in Central Africa, east of Democratic Republic of the Congo. (NCI) | Rwanda | ||
SAU | C17117 | SAUDI ARABIA | A country in the Middle East, bordering the Persian Gulf and the Red Sea, north of Yemen. (NCI) | Saudi Arabia | ||
SRB | C64377 | SERBIA | A republic in Southeastern Europe, bordering the Adriatic Sea, between Albania and Bosnia and Herzegovina. Formerly part of Serbia and Montenegro (Federation Republic of Yugoslavia). (NCI) | Serbia | ||
SDN | C17170 | SUDAN | A country in Northern Africa, bordering the Red Sea, between Egypt and Eritrea. (NCI) | Sudan | ||
SEN | C17121 | SENEGAL | A country in Western Africa, bordering the North Atlantic Ocean, between Guinea-Bissau and Mauritania. (NCI) | Senegal | ||
SGP | C17134 | SINGAPORE | A country in Southeastern Asia, comprised of islands between Malaysia and Indonesia. (NCI) | Singapore | ||
SGS | C20111 | SOUTH GEORGIA AND THE SOUTH SANDWICH ISLANDS | A group of islands in the South Atlantic Ocean, east of the tip of South America. (NCI) | South Georgia and the South Sandwich Islands | ||
SHN | C17164 | SAINT HELENA;SAINT HELENA, ASCENSION AND TRISTAN DA CUNHA | Islands in the South Atlantic Ocean, about midway between South America and Africa. (NCI) | Saint Helena, Ascension and Tristan da Cunha | ||
SJM | C17178 | SVALBARD AND JAN MAYEN | Islands between the Arctic Ocean, Barents Sea, Greenland Sea, and Norwegian Sea, northeast of Iceland and north of Norway. (NCI) | Svalbard and Jan Mayen | ||
SLB | C17148 | SOLOMON ISLANDS | A group of islands in the South Pacific Ocean, east of Papua New Guinea. (NCI) | Solomon Islands | ||
SLE | C17130 | SIERRA LEONE | A country in Western Africa, bordering the North Atlantic Ocean, between Guinea and Liberia. (NCI) | Sierra Leone | ||
SLV | C16532 | EL SALVADOR | A country in Central America, bordering the North Pacific Ocean, between Guatemala and Honduras. (NCI) | El Salvador | ||
SMR | C17115 | SAN MARINO | A country in Southern Europe, an enclave in central Italy. (NCI) | San Marino | ||
SOM | C17149 | SOMALIA | A country in Eastern Africa, bordering the Gulf of Aden and the Indian Ocean, east of Ethiopia. (NCI) | Somalia | ||
SPM | C17165 | SAINT PIERRE AND MIQUELON | A country in Northern North America, comprised of islands in the North Atlantic Ocean, south of Newfoundland (Canada). (NCI) | Saint Pierre and Miquelon | ||
STP | C17116 | SAO TOME AND PRINCIPE | A country in Western Africa, comprised of islands in the Gulf of Guinea, straddling the Equator, west of Gabon. (NCI) | Sao Tome and Principe | ||
SUR | C17175 | SURINAME | A country in Northern South America, bordering the North Atlantic Ocean, between French Guiana and Guyana. (NCI) | Suriname | ||
SVK | C17669 | SLOVAKIA | A country in Central Europe, south of Poland. (NCI) | Slovakia | ||
SVN | C17138 | SLOVENIA | A country in Central Europe, bordering the Adriatic Sea, between Austria and Croatia. (NCI) | Slovenia | ||
SWE | C17180 | SWEDEN | A country in Northern Europe, bordering the Baltic Sea, Gulf of Bothnia, Kattegat, and Skagerrak, between Finland and Norway. (NCI) | Sweden | ||
SWZ | C17179 | SWAZILAND | A country in Southern Africa, between Mozambique and South Africa. (NCI) | Swaziland | ||
SYC | C17129 | SEYCHELLES | A country in Eastern Africa, comprised of a group of islands in the Indian Ocean, northeast of Madagascar. (NCI) | Seychelles | ||
SYR | C17182 | SYRIAN ARAB REPUBLIC | A country in the Middle East, bordering the Mediterranean Sea, between Lebanon and Turkey. (NCI) | Syrian Arab Republic | ||
TCA | C17224 | TURKS AND CAICOS ISLANDS | Two island groups in the North Atlantic Ocean, southeast of The Bahamas. (NCI) | Turks and Caicos Islands | ||
TCD | C16412 | CHAD | A country in Central Africa, south of Libya. (NCI) | Chad | ||
TGO | C17202 | TOGO | A country in Western Africa, bordering the Bight of Benin, between Benin and Ghana. (NCI) | Togo | ||
THA | C17192 | THAILAND | A country in Southeastern Asia, bordering the Andaman Sea and the Gulf of Thailand, southeast of Burma. (NCI) | Thailand | ||
TJK | C17183 | TAJIKISTAN | A country in Central Asia, west of China. (NCI) | Tajikistan | ||
TKL | C17704 | TOKELAU | A group of three atolls in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand. (NCI) | Tokelau | ||
TKM | C17223 | TURKMENISTAN | A country in Central Asia, bordering the Caspian Sea, between Iran and Kazakhstan. (NCI) | Turkmenistan | ||
TLS | C17200 | TIMOR-LESTE | A country in Southeastern Asia, northwest of Australia in the Lesser Sunda Islands at the eastern end of the Indonesian archipelago. East Timor includes the eastern half of the island of Timor, the Oecussi (Ambeno) region on the northwest portion of the island of Timor, and the islands of Pulau Atauro and Pulau Jaco. (NCI) | Timor-Leste | ||
TON | C17205 | TONGA | An archipelago in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand. (NCI) | Tonga | ||
TTO | C17217 | TRINIDAD AND TOBAGO | Islands between the Caribbean Sea and the North Atlantic Ocean, northeast of Venezuela. (NCI) | Trinidad and Tobago | ||
TUN | C17221 | TUNISIA | A country in Northern Africa, bordering the Mediterranean Sea, between Algeria and Libya. (NCI) | Tunisia | ||
TUR | C17222 | TURKEY | A country in southeastern Europe and southwestern Asia (that portion of Turkey west of the Bosporus is geographically part of Europe), bordering the Black Sea, between Bulgaria and Georgia, and bordering the Aegean Sea and the Mediterranean Sea, between Greece and Syria. (NCI) | Turkey | ||
TUV | C17225 | TUVALU | An island group consisting of nine coral atolls in the South Pacific Ocean, about one-half of the way from Hawaii to Australia. (NCI) | Tuvalu | ||
TWN | C17184 | TAIWAN | A group of islands bordering the East China Sea, Philippine Sea, South China Sea, and Taiwan Strait, north of the Philippines, off the southeastern coast of China. (NCI) | Taiwan, Province of China | ||
TZA | C17185 | TANZANIA, UNITED REPUBLIC OF | A country in Eastern Africa, bordering the Indian Ocean, between Kenya and Mozambique. (NCI) | Tanzania, United Republic of | ||
UGA | C17228 | UGANDA | A country in Eastern Africa, west of Kenya. (NCI) | Uganda | ||
UKR | C17229 | UKRAINE | A country in Eastern Europe, bordering the Black Sea, between Poland and Russia. (NCI) | Ukraine | ||
UMI | C20112 | UNITED STATES MINOR OUTLYING ISLANDS | The U.S. Minor Outlying Islands consist of Baker Island, Howland Island, Jarvis Island, Johnston Atoll, Kingman Reef, Midway Island, Navassa Island, Palmyra Atoll, and Wake Island (Wake Atoll). (NCI) | United States Minor Outlying Islands | ||
URY | C17244 | URUGUAY | A country in Southern South America, bordering the South Atlantic Ocean, between Argentina and Brazil. (NCI) | Uruguay | ||
USA | C17234 | UNITED STATES | A country in North America, bordering both the North Atlantic Ocean and the North Pacific Ocean, between Canada and Mexico. (NCI) | United States | ||
UZB | C17246 | UZBEKISTAN | A country in Central Asia, north of Afghanistan. (NCI) | Uzbekistan | ||
VAT | C17249 | VATICAN CITY STATE | An enclave of Rome (Italy). (NCI) | Holy See (Vatican City State) | ||
VCT | C17114 | SAINT VINCENT AND THE GRENADINES | A country in the Caribbean, comprised of islands in the Caribbean Sea, north of Trinidad and Tobago. (NCI) | Saint Vincent and the Grenadines | ||
VEN | C17250 | VENEZUELA;VENEZUELA, BOLIVARIAN REPUBLIC OF | A country in Northern South America, bordering the Caribbean Sea and the North Atlantic Ocean, between Colombia and Guyana. (NCI) | Venezuela, Bolivian Republic of | ||
VGB | C17653 | VIRGIN ISLANDS, BRITISH | Islands between the Caribbean Sea and the North Atlantic Ocean, east of Puerto Rico. (NCI) | Virgin Islands, British | ||
VIR | C17255 | VIRGIN ISLANDS, U.S. | Islands between the Caribbean Sea and the North Atlantic Ocean, east of Puerto Rico. (NCI) | Virgin Islands, U.S. | ||
VNM | C17252 | VIETNAM;VIET NAM | A country in Southeastern Asia, bordering the Gulf of Thailand, Gulf of Tonkin, and South China Sea, alongside China, Laos, and Cambodia. (NCI) | Viet Nam | ||
VUT | C17247 | VANUATU | A group of islands in the South Pacific Ocean, about three-quarters of the way from Hawaii to Australia. (NCI) | Vanuatu | ||
WLF | C17259 | WALLIS AND FUTUNA | Islands in the South Pacific Ocean, about two-thirds of the way from Hawaii to New Zealand. (NCI) | Wallis and Futuna | ||
WSM | C17740 | SAMOA | A group of islands in the South Pacific Ocean, about one-half of the way from Hawaii to New Zealand. (NCI) | Samoa | ||
YEM | C17264 | YEMEN | A country in the Middle East, bordering the Arabian Sea, Gulf of Aden, and Red Sea, between Oman and Saudi Arabia. (NCI) | Yemen | ||
ZAF | C17151 | SOUTH AFRICA | A country in Southern Africa, at the southern tip of the continent of Africa. (NCI) | South Africa | ||
ZMB | C17267 | ZAMBIA | A country in Southern Africa, east of Angola. (NCI) | Zambia | ||
ZWE | C17268 | ZIMBABWE | A country in Southern Africa, between South Africa and Zambia. (NCI) | Zimbabwe | ||
SXM | C101226 | SINT MAARTEN (DUTCH);SINT MAARTEN (DUTCH PART) | The southern portion of an island in the Caribbean sea, between Anguilla and Saint Barthelemy. (NCI) | Sint Maarten (Dutch Part) | ||
BES | C101224 | Bonaire, Sint Eustatius and Saba | Three Caribbean islands that are part of the Lesser Antilles; Bonaire is east of Aruba and Curacao off the coast of Venezuela, Sint Eustatius and Saba are located south of Sint Maarten and northeast of Saint Kitts and Nevis. (NCI) | Bonaire, Sint Eustatius and Saba | ||
CUW | C101225 | Curacao | An island nation located in the Caribbean Sea off the coast of Venezuela. (NCI) | Curacao | ||
SSD | C97351 | South Sudan | A northeastern African country located in the Sahel region and bordered by Sudan in the north, Uganda and Kenya in the south and Ethiopia in the west. (NCI) | South Sudan | ||
Back to top | ||||||
CL.C66787.TDIGRP | Diagnosis Group (TDIGRP) | text Extensible: Yes | C66787 | Diagnosis Group | A grouping of individuals on the basis of a shared procedure or disease, or lack thereof (e.g. healthy volunteers, type 2 diabetic subjects, subjects with renal cell cancer). Standardized naming systems are available that define the groups within which a subject should be placed. (NCI) | CDISC SDTM Diagnosis Group Terminology |
HEALTHY SUBJECTS | C49651 | An individual who is or becomes a participant in a research study and has no significant health-related issues. (NCI) | Healthy Subject | |||
Back to top | ||||||
CL.C66788.DICTNAM | Dictionary Name (DICTNAM) | text Extensible: Yes | C66788 | Dictionary Name | A name given to a reference source that lists words and gives their meaning. (NCI) | CDISC SDTM Dictionary Name Terminology |
COSTART | C49471 | Coding Symbols for a Thesaurus of Adverse Reaction Terms | A terminology developed and used by the Food and Drug Administration (FDA) for the coding, filing and retrieving of post marketing adverse reaction reports. (NCI) | Thesaurus of Adverse Reaction Term Coding Symbols | ||
ICD | C49474 | International Classification of Diseases | A system of categories to which morbid entries are assigned according to established criteria. Included is the entire range of conditions in a manageable number of categories, grouped to facilitate mortality reporting. It is produced by the World Health Organization (from ICD-10, p1). The Clinical Modifications, produced by the United States Dept. of Health and Human Services, are larger extensions used for morbidity and general epidemiological purposes, primarily in the U.S. (MSH2005_2004_10_12) | International Classification of Diseases | ||
LOINC | C49476 | Logical Observation Identifiers Names and Codes | Published by The Regenstrief Institute, the Logical Observation Identifiers Names and Codes covers clinical and clinical laboratory terminology. (NCI) | Logical Observation Identifiers Names and Codes | ||
MedDRA | C43820 | Medical Dictionary for Regulatory Activities | MedDRA is an international medical terminology designed to support the classification, retrieval, presentation, and communication of medical information throughout the medical product regulatory cycle. MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The MedDRA Maintenance and Support Services Organization (MSSO) holds a contract with the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) to maintain and support the implementation of the terminology. (NCI) | MedDRA | ||
SNOMED | C53489 | Systematized Nomenclature of Medicine | A multiaxial, hierarchical classification system for diseases in man developed by the College of American Pathologists. (NCI) | Systematized Nomenclature of Medicine | ||
WHOART | C49468 | World Health Organization Adverse Reaction Terms | A terminology implemented by the World Health Organization to describe adverse reactions to a prescribed medication or treatment regimen. (NCI) | World Health Organization Adverse Reaction Terminology | ||
WHODD | C49475 | World Health Organization Drug Dictionary | A reference source of drugs and drug associated information maintained by the World Health Organization. (NCI) | World Health Organization Drug Dictionary | ||
Back to top | ||||||
CL.C66789.ND | Not Done (ND) | text Extensible: No | C66789 | Not Done | Indicates a task, process or examination that has either not been initiated or completed. (NCI) | CDISC SDTM Not Done Terminology |
NOT DONE | C49484 | Indicates a task, process or examination that has either not been initiated or completed. (NCI) | Not Done | |||
Back to top | ||||||
CL.C66790.ETHNIC | Ethnic Group (ETHNIC) | text Extensible: No | C66790 | Ethnic Group | A social group characterized by a distinctive social and cultural tradition maintained from generation to generation, a common history and origin and a sense of identification with the group; members of the group have distinctive features in their way of life, shared experiences and often a common genetic heritage; these features may be reflected in their experience of health and disease. (NCI) | CDISC SDTM Ethnic Group Terminology |
HISPANIC OR LATINO | C17459 | A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. (NCI) | Hispanic or Latino | |||
NOT HISPANIC OR LATINO | C41222 | A person not of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race. An arbitrary ethnic classification. (NCI) | Not Hispanic or Latino | |||
NOT REPORTED | C43234 | Not reported | Not provided or available. | Not Stated | ||
UNKNOWN | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
Back to top | ||||||
CL.C66726.FRM | Pharmaceutical Dosage Form (FRM) | text Extensible: Yes | C66726 | Pharmaceutical Dosage Form | The form of the completed pharmaceutical product, e.g. tablet, capsule, injection, elixir, suppository. Dosage form can have a significant effect on the onset, duration and intensity of the pharmacological action of a drug. A pharmaceutical dosage form controls the rate at which the drug is released into the biological fluids. This release rate affects its intrinsic absorption pattern and therefore, the bioavailability of the drug. | CDISC SDTM Pharmaceutical Dosage Form Terminology |
AEROSOL | C42887 | aer | A product that is packaged under pressure and contains therapeutically active ingredients that are released upon activation of an appropriate valve system; it is intended for topical application to the skin as well as local application into the nose (nasal aerosols), mouth (lingual aerosols), or lungs (inhalation aerosols). (FDA) | Aerosol Dosage Form | ||
AEROSOL, FOAM | C42888 | A dosage form containing one or more active ingredients, surfactants, aqueous or non-aqueous liquids, and the propellants; if the propellant is in the internal (discontinuous) phase (i.e., of the oil-in-water type), a stable foam is discharged, and if the propellant is in the external (continuous) phase (i.e., of the water-in-oil type), a spray or a quick-breaking foam is discharged. (FDA) | Aerosol Foam Dosage Form | |||
AEROSOL, METERED | C42960 | A pressurized dosage form consisting of metered dose valves which allow for the delivery of a uniform quantity of spray upon each activation. (NCI) | Metered Aerosol Dosage Form | |||
AEROSOL, POWDER | C42971 | A product that is packaged under pressure and contains therapeutically active ingredients, in the form of a powder, that are released upon activation of an appropriate valve system. (NCI) | Powder Aerosol Dosage Form | |||
AEROSOL, SPRAY | C42889 | An aerosol product which utilizes a compressed gas as the propellant to provide the force necessary to expel the product as a wet spray; it is applicable to solutions of medicinal agents in aqueous solvents. (NCI) | Aerosol Spray Dosage Form | |||
BAR, CHEWABLE | C42892 | A solid dosage form usually in the form of a rectangle that is meant to be chewed. (NCI) | Chewable Bar Dosage Form | |||
BEAD | C42890 | A solid dosage form in the shape of a small ball. (NCI) | Bead Dosage Form | |||
BEAD, IMPLANT, EXTENDED RELEASE | C43451 | A small sterile solid mass consisting of a highly purified drug intended for implantation in the body which would allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form. (NCI) | Extended Release Bead Implant Dosage Form | |||
BLOCK | C42891 | Solid dosage form, usually in the shape of a square or rectangle. (NCI) | Block Dosage Form | |||
CAPLET | C97197 | A solid dosage form in which a tablet has been compacted into capsule shape. | Caplet Dosage Form | |||
CAPSULE | C25158 | cap | A solid pharmaceutical dosage form that contains medicinal agent within either a hard or soft soluble container or shell, usually used for the oral administration of medicine. The shells are made of a suitable form of gelatin or other substance. (NCI) | Capsule Dosage Form | ||
CAPSULE, COATED | C42895 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or "shell" made from a suitable form of gelatin; additionally, the capsule is covered in a designated coating. (FDA) | Coated Capsule Dosage Form | |||
CAPSULE, COATED PELLETS | C42896 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or "shell" made from a suitable form of gelatin; the drug itself is in the form of granules to which varying amounts of coating have been applied. (NCI) | Coated Pellet in Capsule Dosage Form | |||
CAPSULE, COATED, EXTENDED RELEASE | C42917 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or "shell" made from a suitable form of gelatin; additionally, the capsule is covered in a designated coating, and which releases a drug (or drugs) in such a manner to allow at least a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form. (FDA) | Extended Release Coated Capsule Dosage Form | |||
CAPSULE, DELAYED RELEASE | C42902 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug (or drugs) at a time other than promptly after administration. Enteric-coated articles are delayed release dosage forms. (NCI) | Delayed Release Capsule Dosage Form | |||
CAPSULE, DELAYED RELEASE PELLETS | C42904 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or "shell" made from a suitable form of gelatin; the drug itself is in the form of granules to which enteric coating has been applied, thus delaying release of the drug until its passage into the intestines. (FDA) | Delayed Release Pellet in Capsule Dosage Form | |||
CAPSULE, EXTENDED RELEASE | C42916 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin, and which releases a drug (or drugs) in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form. (NCI) | Extended Release Capsule Dosage Form | |||
CAPSULE, FILM COATED, EXTENDED RELEASE | C42928 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container or "shell" made from a suitable form of gelatin; additionally, the capsule is covered in a designated film coating, and which releases a drug (or drugs) in such a manner to allow at least a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form. (FDA) | Extended Release Film Coated Capsule Dosage Form | |||
CAPSULE, GELATIN COATED | C42936 | A solid dosage form in which the drug is enclosed within either a hard or soft soluble container made from a suitable form of gelatin; through a banding process, the capsule is coated with additional layers of gelatin so as to form a complete seal. (NCI) | Gelatin Coated Capsule Dosage Form | |||
CAPSULE, LIQUID FILLED | C42954 | A solid dosage form in which the drug is enclosed within a soluble, gelatin shell which is plasticized by the addition of a polyol, such as sorbitol or glycerin, and is therefore of a somewhat thicker consistency than that of a hard shell capsule; typically, the active ingredients are dissolved or suspended in a liquid vehicle. (NCI) | Liquid Filled Capsule Dosage Form | |||
CEMENT | C45414 | A substance that serves to produce solid union between two surfaces. (NCI) | Cement Dosage Form | |||
CIGARETTE | C42678 | A narrow tube filled with material that is capable to burn with release of therapeutically-active substance(s) during the process of smoking. Cigarette is a very efficient drug-delivery inhaler system for fast-acting substances. (FDA) | Cigarette Dosage Form | |||
CLOTH | C60884 | A large piece of relatively flat, absorbent material that contains a drug. It is typically used for applying medication or for cleansing. (FDA) | Cloth Dosage Form | |||
CONCENTRATE | C60891 | A liquid preparation of increased strength and reduced volume which is usually diluted prior to administration. (NCI) | Concentrated Dosage Form | |||
CONE | C42900 | A solid dosage form bounded by a circular base and the surface formed by line segments joining every point of the boundary of the base to a common vertex. A cone (usually containing antibiotics) is normally placed below the gingiva after a dental extraction. (NCI) | Cone Dosage Form | |||
CORE, EXTENDED RELEASE | C42919 | An ocular system placed in the eye from which the drug diffuses through a membrane at a constant rate over a specified period. (NCI) | Extended Release Core Dosage Form | |||
CREAM | C28944 | A semisolid emulsion of either the oil-in-water or the water-in-oil type, ordinarily intended for topical use. (NCI) | Cream Dosage Form | |||
CREAM, AUGMENTED | C60897 | A cream dosage form that enhances drug delivery. Augmentation does not refer to the strength of the drug in the dosage form. NOTE: CDER has decided to refrain from expanding the use of this dosage form due to difficulties in setting specific criteria that must be met to be considered augmented. (FDA) | Augmented Cream Dosage Form | |||
CRYSTAL | C42901 | A naturally produced angular solid of definite form in which the ultimate units from which it is built up are systematically arranged; they are usually evenly spaced on a regular space lattice. (FDA) | Crystal Dosage Form | |||
CULTURE | C45415 | The propagation of microorganisms or of living tissue cells in special media conducive to their growth. (NCI) | Culture Dosage Form | |||
DIAPHRAGM | C47890 | A device usually dome-shaped, worn during copulation over the cervical mouth for prevention of conception or infection. (NCI) | Vaginal Diaphragm Dosage Form | |||
DISC | C43525 | A circular plate-like organ or structure. (FDA) | Disc Dosage Form | |||
DOUCHE | C42679 | A liquid preparation, intended for the irrigative cleansing of the vagina, that is prepared from powders, liquid solutions, or liquid concentrates and contains one or more chemical substances dissolved in a suitable solvent or mutually miscible solvents. (NCI) | Douche Dosage Form | |||
DRESSING | C42763 | The application of various materials for protecting a wound.(FDA) | Dressing Dosage Form | |||
DRUG DELIVERY SYSTEM | C17423 | Modern technology, distributed with or as a part of a drug product that allows for the uniform release or targeting of drugs to the body. (FDA) | Drug Delivery System | |||
ELIXIR | C42912 | A clear, pleasantly flavored, sweetened hydroalcoholic liquid containing dissolved medicinal agents; it is intended for oral use. (NCI) | Elixir Dosage Form | |||
EMULSION | C42913 | A dosage form consisting of a two-phase system comprised of at least two immiscible liquids (1), one of which is dispersed as droplets (internal or dispersed phase) within the other liquid (external or continuous phase), generally stabilized with one or more emulsifying agents. Note 1: A liquid is pourable; it flows and conforms to its container at room temperature. It displays Newtonian or pseudoplastic flow behavior. Note 2: Emulsion is used as a dosage form term unless a more specific term is applicable, e.g. cream, lotion, ointment. (NCI) | Emulsion Dosage Form | |||
ENEMA | C42915 | A rectal preparation for therapeutic, diagnostic, or nutritive purposes. (NCI) | Enema Dosage Form | |||
EXTRACT | C42929 | A concentrated preparation of vegetable or animal drugs obtained by removal of the active constituents of the respective drugs with a suitable menstrua, evaporation of all or nearly all of the solvent, and adjustment of the residual masses or powders to the prescribed standards. (NCI) | Extract Dosage Form | |||
FIBER, EXTENDED RELEASE | C60926 | A slender and elongated solid thread-like substance that delivers drug in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form. (FDA) | Extended Release Fiber Dosage Form | |||
FILM | C42932 | A thin layer or coating. (NCI) | Film Dosage Form | |||
FILM, EXTENDED RELEASE | C42920 | A drug delivery system in the form of a film that releases the drug over an extended period in such a way as to maintain constant drug levels in the blood or target tissue. (NCI) | Extended Release Film Dosage Form | |||
FILM, SOLUBLE | C42984 | A thin layer or coating which is susceptible to being dissolved when in contact with a liquid. (NCI) | Soluble Film Dosage Form | |||
FOR SOLUTION | C60927 | A product, usually a solid, intended for solution prior to administration. (FDA) | Dosage Form For Solution | |||
FOR SUSPENSION | C60928 | A product, usually a solid, intended for suspension prior to administration. (FDA) | Dosage Form For Suspension | |||
FOR SUSPENSION, EXTENDED RELEASE | C60929 | A product, usually a solid, intended for suspension prior to administration; once the suspension is administered, the drug will be released at a constant rate over a specified period. (FDA) | Extended Release Dosage Form For Suspension | |||
GAS | C42933 | Any elastic aeriform fluid in which the molecules are separated from one another and have free paths. (NCI) | Gas Dosage Form | |||
GEL | C42934 | A semisolid (1) dosage form that contains a gelling agent to provide stiffness to a solution or a colloidal dispersion (2). A gel may contain suspended particles. Note 1: A semisolid is not pourable; it does not flow or conform to its container at room temperature. It does not flow at low shear stress and generally exhibits plastic flow behavior. Note 2: A colloidal dispersion is a system in which particles of colloidal dimension (i.e., typically between 1 nm and 1 micrometer) are distributed uniformly throughout a liquid. (FDA) | Gel Dosage Form | |||
GEL, DENTIFRICE | C42906 | A combination of a dentifrice (formulation intended to clean and/or polish the teeth, and which may contain certain additional agents), and a gel. It is used with a toothbrush for the purpose of cleaning and polishing the teeth. (NCI) | Dentifrice Gel Dosage Form | |||
GEL, METERED | C60930 | A gel preparation, with metered dose valves, which allow for the delivery of a uniform quantity of gel upon each activation. (FDA) | Metered Gel Dosage Form | |||
GENERATOR | C48193 | An apparatus for the formation of vapor or gas from a liquid or solid by heat or chemical action. The term GENERATOR also applies to radioactive columns from which radionuclides are provided. (NCI) | Generator Dosage Form | |||
GLOBULE | C42937 | Also called pellets or pilules, are made of pure sucrose, lactose, or other polysaccharides. They are formed into small globular masses of various sizes, and are medicated by placing them in a vial and adding the liquid drug attenuation in the proportion not less than one percent (v/w). After shaking, the medicated globules are dried at temperatures not to exceed 40 degrees Centigrade. (NCI) | Globule Dosage Form | |||
GRAFT | C45416 | A slip of skin or of other tissue for implantation. (NCI) | Graft Dosage Form | |||
GRANULE | C42938 | A small particle or grain. (NCI) | Granule Dosage Form | |||
GRANULE, DELAYED RELEASE | C42903 | A small medicinal particle or grain to which an enteric or other coating has been applied, thus delaying release of the drug until its passage into the intestines. (NCI) | Delayed Release Granule Dosage Form | |||
GRANULE, EFFERVESCENT | C42909 | A small particle or grain containing a medicinal agent in a dry mixture usually composed of sodium bicarbonate, citric acid, and tartaric acid which, when in contact with water, has the capability to release gas, resulting in effervescence. (NCI) | Effervescent Granule Dosage Form | |||
GRANULE, FOR SOLUTION | C42939 | A small medicinal particle or grain made available in its more stable dry form, to be reconstituted with solvent just before dispensing; the granules are so prepared to contain not only the medicinal agent, but the colorants, flavorants, and any other desired pharmaceutic ingredient. (NCI) | Granule For Solution Dosage Form | |||
GRANULE, FOR SUSPENSION | C42940 | A small medicinal particle or grain made available in its more stable dry form, to be reconstituted with solvent just before dispensing to form a suspension; the granules are so prepared to contain not only the medicinal agent, but the colorants, flavorants, and any other desired pharmaceutic ingredient. (NCI) | Granule For Suspension Dosage Form | |||
GRANULE, FOR SUSPENSION, EXTENDED RELEASE | C42921 | A small medicinal particle or grain made available in its more stable dry form, to be reconstituted with solvent just before dispensing to form a suspension; the extended release system achieves slow release of the drug over an extended period of time and maintains constant drug levels in the blood or target tissue. (NCI) | Extended Release Granule For Suspension Dosage Form | |||
GUM | C42941 | A mucilaginous excretion from various plants. (NCI) | Gum Dosage Form | |||
GUM, CHEWING | C42894 | A sweetened and flavored insoluble plastic material of various shapes which when chewed, releases a drug substance into the oral cavity. (NCI) | Chewing Gum Dosage Form | |||
GUM, RESIN | C42978 | Natural mixture of gum and resin, usually obtained as exudations from plants. (NCI) | Resin Gum Dosage Form | |||
IMPLANT | C42942 | A material containing drug intended to be inserted securely and deeply in a living site for growth, slow release, or formation of an organic union. (NCI) | Implant Dosage Form | |||
INHALANT | C42944 | A special class of inhalations consisting of a drug or combination of drugs, that by virtue of their high vapor pressure, can be carried by an air current into the nasal passage where they exert their effect; the container from which the inhalant generally is administered is known as an inhaler. (NCI) | Inhalant Dosage Form | |||
INJECTABLE, LIPOSOMAL | C60931 | An injection, which either consists of or forms liposomes (a lipid bilayer vesicle usually composed of phospholipids which is used to encapsulate an active drug substance). (FDA) | Liposomal Injection Dosage Form | |||
INJECTION | C42946 | A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP. (NCI) | Injectable Dosage Form | |||
INJECTION, EMULSION | C42914 | An emulsion consisting of a sterile, pyrogen-free preparation intended to be administered parenterally. (FDA) | Emulsion for Injection Dosage Form | |||
INJECTION, LIPID COMPLEX | C42950 | [definition pending](FDA) | Injectable Lipid Complex Dosage Form | |||
INJECTION, POWDER, FOR SOLUTION | C42974 | A sterile preparation intended for reconstitution to form a solution for parenteral use. (NCI) | Powder For Injectable Solution Dosage Form | |||
INJECTION, POWDER, FOR SUSPENSION | C42976 | A sterile preparation intended for reconstitution to form a suspension for parenteral use. (NCI) | Powder For Injectable Suspension Dosage Form | |||
INJECTION, POWDER, FOR SUSPENSION, EXTENDED RELEASE | C42977 | A dried preparation intended for reconstitution to form a suspension for parenteral use which has been formulated in a manner to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g., as a solution). (FDA) | Powder For Injectable Extended Release Suspension Dosage Form | |||
INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION | C42959 | A sterile freeze dried preparation intended for reconstitution for parenteral use which has been formulated in a manner that would allow liposomes (a lipid bilayer vesicle usually composed of phospholipids which is used to encapsulate an active drug substance, either within a lipid bilayer or in an aqueous space) to be formed upon reconstitution. (NCI) | Lyophilized Powder For Injectable Liposomal Suspension Dosage Form | |||
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | C42957 | A dosage form intended for the solution prepared by lyophilization ('freeze drying'), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections. (NCI) | Lyophilized Powder For Injectable Solution Dosage Form | |||
INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION | C42958 | A liquid preparation, intended for parenteral use, that contains solids suspended in a suitable fluid medium and conforms in all respects to the requirements for Sterile Suspensions; the medicinal agents intended for the suspension are prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures. (FDA) | Lyophilized Powder For Injectable Suspension Dosage Form | |||
INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION, EXTENDED RELEASE | C42956 | A sterile freeze dried preparation intended for reconstitution for parenteral use which has been formulated in a manner to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g., as a solution). (NCI) | Lyophilized Powder For Extended Release Injectable Suspension Dosage Form | |||
INJECTION, SOLUTION | C42945 | A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection. (NCI) | Injectable Solution Dosage Form | |||
INJECTION, SOLUTION, CONCENTRATE | C42899 | A sterile preparation for parenteral use which, upon the addition of suitable solvents, yields a solution conforming in all respects to the requirements for Injections. (NCI) | Concentrated Injectable Solution Dosage Form | |||
INJECTION, SUSPENSION | C42995 | A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa. (NCI) | Injectable Suspension Dosage Form | |||
INJECTION, SUSPENSION, EXTENDED RELEASE | C42926 | A sterile preparation intended for parenteral use which has been formulated in a manner to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g., as a solution or a prompt drug-releasing, conventional solid dosage form). (NCI) | Injectable Extended Release Suspension Dosage Form | |||
INJECTION, SUSPENSION, LIPOSOMAL | C42951 | A liquid parenteral pharmaceutical dosage form structured as a multilamellar composition of concentric phospholipid spheres that encapsulate the drug (drug delivery systems) separated by layers of water. Drug release is facilitated and controlled by in vivo erosion of the liposomes. To further increase the in vivo circulation time, liposomes in some preparations are covalently derivatized with PEG to produce PEGylated or stealth liposomes. Covalent attachment of drugs to the outer surface of liposomes can potentially serve as a delayed-release product. (NCI) | Injectable Liposomal Suspension Dosage Form | |||
INJECTION, SUSPENSION, SONICATED | C42988 | A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. In addition, the product is sonicated while a gas is bubbled through the suspension, and this results in the formation of microspheres by the solid particles. (NCI) | Injectable Sonicated Suspension Dosage Form | |||
INSERT | C60933 | A specially formulated and shaped non-encapsulated solid preparation intended to be placed into a non-rectal orifice of the body, where drug is released, generally for localized effects. (FDA) | Insert Dosage Form | |||
INSERT, EXTENDED RELEASE | C42922 | A specially formulated and shaped solid preparation (e.g., ring, tablet, or stick) intended to be placed in the vagina by special inserters, where the medication is released, generally for localized effects; the extended release preparation is designed to allow a reduction in dosing frequency. (NCI) | Extended Release Insert Dosage Form | |||
INTRAUTERINE DEVICE | C47915 | A device inserted and left in the uterus to prevent effective conception. (NCI) | Intrauterine Device Dosage Form | |||
IRRIGANT | C42947 | A sterile solution intended to bathe or flush open wounds or body cavities; they're used topically, never parenterally. (NCI) | Irrigant Dosage Form | |||
JELLY | C42948 | A class of gels--semisolid systems which consist of suspensions made up of either small inorganic particles or large organic molecules interpenetrated by a liquid--in which the structural coherent matrix contains a high portion of liquid, usually water. (NCI) | Jelly Dosage Form | |||
KIT | C47916 | A packaged collection of related material. (NCI) | Kit Dosage Form | |||
LINER, DENTAL | C45413 | A material applied to the inside of the dental cavity, for protection or insulation of the surface. (FDA) | Dental Liner Dosage Form | |||
LINIMENT | C42949 | A solution or mixture of various substances in oil, alcoholic solutions of soap, or emulsions intended for external application. (NCI) | Liniment Dosage Form | |||
LIPSTICK | C42952 | A waxy solid, usually colored cosmetic, in stick form for the lips. (NCI) | Lipstick Dosage Form | |||
LIQUID | C42953 | A dosage form consisting of a pure chemical in its liquid state. This dosage form term should not be applied to solutions. Note: A liquid is pourable; it flows and conforms to its container at room temperature. It displays Newtonian or pseudoplastic flow behavior.(FDA) | Liquid Dosage Form | |||
LIQUID, EXTENDED RELEASE | C60934 | A liquid that delivers a drug in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form. (FDA) | Extended Release Liquid Dosage Form | |||
LOTION | C29167 | An emulsion, liquid (1) dosage form. This dosage form is generally for external application to the skin (2). Note 1: A liquid is pourable; it flows and conforms to its container at room temperature. It displays Newtonian or pseudoplastic flow behavior. Note 2: Previously the definition of a lotion was: The term lotion has been used to categorize many topical suspensions, solutions, and emulsions intended for application to the skin. The current definition of a lotion is restricted to an emulsion. (FDA) | Lotion Dosage Form | |||
LOTION, AUGMENTED | C60957 | A lotion dosage form that enhances drug delivery. Augmentation does not refer to the strength of the drug in the dosage form. NOTE: CDER has decided to refrain from expanding the use of this dosage form due to difficulties in setting specific criteria that must be met to be considered augmented. (FDA) | Augmented Lotion Dosage Form | |||
LOTION/SHAMPOO | C60958 | A lotion dosage form which has a soap or detergent that is usually used to clean the hair and scalp; it is often used as a vehicle for dermatologic agents. (FDA) | Lotion Shampoo Dosage Form | |||
LOZENGE | C42955 | A solid preparation containing one or more medicaments, usually in a flavored, sweetened base which is intended to dissolve or disintegrate slowly in the mouth. A lollipop is a lozenge on a stick.(FDA) | Lozenge Dosage Form | |||
MOUTHWASH | C29269 | An aqueous solution which is most often used for its deodorant, refreshing, or antiseptic effect. (NCI) | Mouthwash Dosage Form | |||
NOT APPLICABLE | C48624 | The use of a dosage form term is not relevant or appropriate. (NCI) | Dosage Form Not Applicable | |||
OIL | C42965 | An unctuous, combustible substance which is liquid, or easily liquefiable, on warming, and is soluble in ether but insoluble in water. Such substances, depending on their origin, are classified as animal, mineral, or vegetable oils. (NCI) | Oil Dosage Form | |||
OINTMENT | C42966 | oint | A suspension or emulsion, semisolid (1) dosage form, usually containing < 20% water and volatiles (2) and > 50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes. Note 1: A semisolid is not pourable; it does not flow or conform to its container at room temperature. It does not flow at low shear stress and generally exhibits plastic flow behavior. Note 2: Percent water and volatiles are measured by a loss on drying test in which the sample is heated at 105 degrees C until constant weight is achieved. (FDA) | Ointment Dosage Form | ||
OINTMENT, AUGMENTED | C60984 | An ointment dosage form that enhances drug delivery. Augmentation does not refer to the strength of the drug in the dosage form. NOTE: CDER has decided to refrain from expanding the use of this dosage form due to difficulties in setting specific criteria that must be met to be considered augmented. (FDA) | Augmented Ointment Dosage Form | |||
PACKING | C47887 | A material, usually covered by or impregnated with a drug, that is inserted into a body cavity or between the tooth enamel and the gingival margin. (FDA) | Packing Dosage Form | |||
PASTE | C42967 | A semisolid dosage form, containing a large proportion (20 - 50%) of solids finely dispersed in a fatty vehicle. This dosage form is generally for external application to the skin or mucous membranes. Note: A semisolid is not pourable; it does not flow or conform to its container at room temperature. It does not flow at low shear stress and generally exhibits plastic flow behavior. (NCI) | Paste Dosage Form | |||
PASTE, DENTIFRICE | C42907 | A paste formulation intended to clean and/or polish the teeth, and which may contain certain additional agents. (NCI) | Dentifrice Paste Dosage Form | |||
PASTILLE | C60985 | An aromatic preparation, often with a pleasing flavor, usually intended to dissolve in the mouth. (FDA) | Pastille Dosage Form | |||
PATCH | C42968 | A drug delivery system that often contains an adhesive backing that is usually applied to an external site on the body. Its ingredients either passively diffuse from, or are actively transported from, some portion of the patch. Depending upon the patch, the ingredients are either delivered to the outer surface of the body or into the body. A patch is sometimes synonymous with the terms Extended Release Film and System. (FDA) | Patch Dosage Form | |||
PATCH, EXTENDED RELEASE | C42923 | A drug delivery system in the form of a patch that releases the drug in such a manner that a reduction in dosing frequency compared to that drug presented as a conventional dosage form (e.g., a solution or a prompt drug-releasing, conventional solid dosage form). (NCI) | Extended Release Patch Dosage Form | |||
PATCH, EXTENDED RELEASE, ELECTRICALLY CONTROLLED | C42911 | A drug delivery system in the form of a patch which is controlled by an electric current that releases the drug in such a manner that a reduction in dosing frequency compared to that drug presented as a conventional dosage form (e.g., a solution or a prompt drug-releasing, conventional solid dosage form). (NCI) | Electrically Controlled Extended Release Patch Dosage Form | |||
PELLET | C42969 | A small sterile solid mass consisting of a highly purified drug (with or without excipients) made by the formation of granules, or by compression and molding. (NCI) | Pellet Dosage Form | |||
PELLET, IMPLANTABLE | C42943 | A small sterile solid mass consisting of a highly purified drug (with or without excipients) made by the formation of granules, or by compression and molding; they are intended for implantation in the body (usually subcutaneously) for the purpose of providing continuous release of the drug over long periods of time. (FDA) | Implantable Pellet Dosage Form | |||
PELLETS, COATED, EXTENDED RELEASE | C42918 | A solid dosage form in which the drug itself is in the form of granules to which varying amounts of coating have been applied, and which releases a drug (or drugs) in such a manner to allow a reduction in dosing frequency as compared to that drug (or drugs) presented as a conventional dosage form. (NCI) | Extended Release Coated Pellet Dosage Form | |||
PILL | C25394 | A dose of medicine in the form of a small pellet. (NCI) | Pill Dosage Form | |||
PLASTER | C42970 | Substance intended for external application made of such materials and of such consistency as to adhere to the skin and attach to a dressing; plasters are intended to afford protection and support and/or to furnish an occlusion and macerating action and to bring medication into close contact with the skin. (FDA) | Plaster Dosage Form | |||
POULTICE | C47913 | A soft, moist mass of meal, herbs, seed, etc., usually applied hot in cloth that consists of gruel-like consistency. (NCI) | Poultice Dosage Form | |||
POWDER | C42972 | An intimate mixture of dry, finely divided drugs and/or chemicals that may be intended for internal or external use. (NCI) | Powder Dosage Form | |||
POWDER, DENTIFRICE | C42908 | A powder formulation intended to clean and/or polish the teeth, and which may contain certain additional agents. (NCI) | Dentifrice Powder Dosage Form | |||
POWDER, FOR SOLUTION | C42973 | An intimate mixture of dry, finely divided drugs and/or chemicals, which, upon the addition of suitable vehicles, yields a solution. (NCI) | Powder for Solution Dosage Form | |||
POWDER, FOR SUSPENSION | C42975 | An intimate mixture of dry, finely divided drugs and/or chemicals, which, upon the addition of suitable vehicles, yields a suspension (a liquid preparation containing the solid particles dispersed in the liquid vehicle). (NCI) | Powder for Suspension Dosage Form | |||
POWDER, METERED | C42961 | A powder dosage form that is situated inside a container that has a mechanism to deliver a specified quantity. (NCI) | Metered Powder Dosage Form | |||
RING | C60988 | A small circular object with a vacant circular center that is usually intended to be placed in the body by special inserters, where the medication is released, generally for localized effects. (FDA) | Ring Dosage Form | |||
RINSE | C42979 | A liquid used to cleanse by flushing. (NCI) | Rinse Dosage Form | |||
SALVE | C42980 | A thick ointment or cerate (a fat or wax based preparation with a consistency between an ointment and a plaster). (NCI) | Salve Dosage Form | |||
SHAMPOO | C42981 | A liquid soap or detergent used to clean the hair and scalp and is often used as a vehicle for dermatologic agents. (NCI) | Shampoo Dosage Form | |||
SHAMPOO, SUSPENSION | C42982 | A liquid soap or detergent containing one or more solid, insoluble substances dispersed in a liquid vehicle that is used to clean the hair and scalp and is often used as a vehicle for dermatologic agents. (NCI) | Shampoo Suspension Dosage Form | |||
SOAP | C42983 | Any compound of one or more fatty acids, or their equivalents, with an alkali; soap is detergent and is much employed in liniments, enemas, and in making pills. It is also a mild aperient, antacid and antiseptic. (NCI) | Soap Dosage Form | |||
SOLUTION | C42986 | A clear, homogeneous liquid dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents. Note: A liquid is pourable; it flows and conforms to its container at room temperature. It displays Newtonian or pseudoplastic flow behavior. (FDA) | Solution Dosage Form | |||
SOLUTION, CONCENTRATE | C42898 | A liquid preparation (i.e., a substance that flows readily in its natural state) that contains a drug dissolved in a suitable solvent or mixture of mutually miscible solvents; the drug has been strengthened by the evaporation of its non-active parts. (NCI) | Concentrated Solution Dosage Form | |||
SOLUTION, FOR SLUSH | C42987 | A solution for the preparation of an iced saline slush, which is administered by irrigation and used to induce regional hypothermia (in conditions such as certain open heart and kidney surgical procedures) by its direct application. (NCI) | Solution For Slush Dosage Form | |||
SOLUTION, GEL FORMING / DROPS | C60994 | A solution, which after usually being administered in a drop-wise fashion, forms a gel. (FDA) | Gel Forming Drop Solution Dosage Form | |||
SOLUTION, GEL FORMING, EXTENDED RELEASE | C42935 | A solution that forms a gel when it comes in contact with ocular fluid, and which allows at least a reduction in dosing frequency. (FDA) | Extended Release Gel Forming Solution Dosage Form | |||
SOLUTION/ DROPS | C60992 | A solution which is usually administered in a drop-wise fashion. (FDA) | Drop Solution Dosage Form | |||
SPONGE | C47912 | A porous, interlacing, absorbent material that contains a drug. It is typically used for applying or introducing medication, or for cleansing. A sponge usually retains its shape. (FDA) | Sponge Dosage Form | |||
SPRAY | C42989 | A liquid minutely divided as by a jet of air or steam. (NCI) | Spray Dosage Form | |||
SPRAY, METERED | C42962 | A non-pressurized dosage form consisting of valves which allow the dispensing of a specified quantity of spray upon each activation. (NCI) | Metered Spray Dosage Form | |||
SPRAY, SUSPENSION | C42990 | A liquid preparation containing solid particles dispersed in a liquid vehicle and in the form of coarse droplets or as finely divided solids to be applied locally, most usually to the nasal-pharyngeal tract, or topically to the skin. (NCI) | Spray Suspension Dosage Form | |||
STICK | C42991 | A dosage form prepared in a relatively long and slender often cylindrical form. (NCI) | Stick Dosage Form | |||
STRIP | C47914 | A long narrow piece of material. (FDA) | Strip Dosage Form | |||
SUPPOSITORY | C42993 | supp | A solid body of various weights and shapes, adapted for introduction into the rectal, vaginal, or urethral orifice of the human body; they usually melt, soften, or dissolve at body temperature. (FDA) | Suppository Dosage Form | ||
SUPPOSITORY, EXTENDED RELEASE | C42924 | A drug delivery system in the form of a suppository that allows at least a reduction in dosing frequency. (NCI) | Extended Release Suppository Dosage Form | |||
SUSPENSION | C42994 | susp | A liquid dosage form that contains solid particles dispersed in a liquid vehicle. Note: A liquid is pourable; it flows and conforms to its container at room temperature. It displays Newtonian or pseudoplastic flow behavior. (FDA) | Suspension Dosage Form | ||
SUSPENSION, EXTENDED RELEASE | C42925 | A liquid preparation consisting of solid particles dispersed throughout a liquid phase in which the particles are not soluble; the suspension has been formulated in a manner to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form (e.g., as a solution or a prompt drug-releasing, conventional solid dosage form). (NCI) | Extended Release Suspension Dosage Form | |||
SUSPENSION/DROPS | C60995 | A suspension which is usually administered in a dropwise fashion. (FDA) | Drop Suspension Dosage Form | |||
SUTURE | C47889 | A strand or fiber used to hold wound edges in apposition during healing. (NCI) | Suture Dosage Form | |||
SWAB | C47898 | A small piece of relatively flat absorbent material that contains a drug. A swab may also be attached to one end of a small stick. A swab is typically used for applying medication or for cleansing. (FDA) | Swab Dosage Form | |||
SYRUP | C42996 | An oral solution containing high concentrations of sucrose or other sugars; the term has also been used to include any other liquid dosage form prepared in a sweet and viscid vehicle, including oral suspensions. (NCI) | Syrup Dosage Form | |||
TABLET | C42998 | tab | A solid dosage form containing medicinal substances with or without suitable diluents. (NCI) | Tablet Dosage Form | ||
TABLET, CHEWABLE | C42893 | A solid dosage form containing medicinal substances with or without suitable diluents that is intended to be chewed, producing a pleasant tasting residue in the oral cavity that is easily swallowed and does not leave a bitter or unpleasant after-taste. (NCI) | Chewable Tablet Dosage Form | |||
TABLET, COATED | C42897 | A solid dosage form that contains medicinal substances with or without suitable diluents and is covered with a designated coating. (NCI) | Coated Tablet Dosage Form | |||
TABLET, COATED PARTICLES | C60997 | A solid dosage form containing a conglomerate of medicinal particles that have each been covered with a coating. (FDA) | Tablet Coated Particle Dosage Form | |||
TABLET, DELAYED RELEASE | C42905 | A solid dosage form which releases a drug (or drugs) at a time other than promptly after administration. Enteric-coated articles are delayed release dosage forms. (NCI) | Delayed Release Tablet Dosage Form | |||
TABLET, DELAYED RELEASE PARTICLES | C42997 | A solid dosage form containing a conglomerate of medicinal particles that have been covered with a coating which releases a drug (or drugs) at a time other than promptly after administration. Enteric-coated articles are delayed release dosage forms. (NCI) | Delayed Release Particle Tablet Dosage Form | |||
TABLET, EFFERVESCENT | C42910 | A solid dosage form containing mixtures of acids (e.g., citric acid, tartaric acid) and sodium bicarbonate, which release carbon dioxide when dissolved in water; it is intended to be dissolved or dispersed in water before administration. (FDA) | Effervescent Tablet Dosage Form | |||
TABLET, EXTENDED RELEASE | C42927 | A solid dosage form containing a drug which allows at least a reduction in dosing frequency as compared to that drug presented in conventional dosage form. (NCI) | Extended Release Tablet Dosage Form | |||
TABLET, FILM COATED | C42931 | A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer. (NCI) | Film Coated Tablet Dosage Form | |||
TABLET, FILM COATED, EXTENDED RELEASE | C42930 | A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer; the tablet is formulated in such manner as to make the contained medicament available over an extended period of time following ingestion. (FDA) | Film Coated Extended Release Tablet Dosage Form | |||
TABLET, FOR SOLUTION | C61004 | A tablet that forms a solution when placed in a liquid. (FDA) | Tablet For Solution Dosage Form | |||
TABLET, FOR SUSPENSION | C61005 | A tablet that forms a suspension when placed in a liquid (formerly referred to as a Dispersible Tablet). (FDA) | Tablet For Suspension Dosage Form | |||
TABLET, MULTILAYER | C42964 | A solid dosage form containing medicinal substances that have been compressed to form a multiple-layered tablet or a tablet-within-a-tablet, the inner tablet being the core and the outer portion being the shell. (NCI) | Multilayered Tablet Dosage Form | |||
TABLET, MULTILAYER, EXTENDED RELEASE | C42963 | A solid dosage form containing medicinal substances that have been compressed to form a multiple-layered tablet or a tablet-within-a-tablet, the inner tablet being the core and the outer portion being the shell, which, additionally, is covered in a designated coating; the tablet is formulated in such manner as to allow at least a reduction in dosing frequency as compared to that drug presented as a conventional dosage form. (NCI) | Multilayered Extended Release Tablet Dosage Form | |||
TABLET, ORALLY DISINTEGRATING | C42999 | A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue. (NCI) | Orally Disintegrating Tablet Dosage Form | |||
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE | C61006 | A solid dosage form containing medicinal substances which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue, but which releases a drug (or drugs) at a time other than promptly after administration. (FDA) | Orally Disintegrating Delayed Release Tablet Dosage Form | |||
TABLET, SOLUBLE | C42985 | A solid dosage form that contains medicinal substances with or without suitable diluents and possesses the ability to dissolve in fluids. (NCI) | Soluble Tablet Dosage Form | |||
TABLET, SUGAR COATED | C42992 | A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a colored or an uncolored water-soluble sugar. (NCI) | Sugar Coated Tablet Dosage Form | |||
TAMPON | C47892 | A plug made of cotton, sponge, or oakum variously used in surgery to plug the nose, vagina, etc., for the control of hemorrhage or the absorption of secretions. (NCI) | Tampon Dosage Form | |||
TAPE | C47897 | A narrow woven fabric, or a narrow extruded synthetic (such as plastic), usually with an adhesive on one or both sides. (NCI) | Tape Dosage Form | |||
TINCTURE | C43000 | An alcoholic or hydroalcoholic solution prepared from vegetable materials or from chemical substances. (NCI) | Tincture Dosage Form | |||
TROCHE | C43001 | A discoid-shaped solid containing the medicinal agent in a suitably flavored base; troches are placed in the mouth where they slowly dissolve, liberating the active ingredients. (NCI) | Troche Dosage Form | |||
UNASSIGNED | C43002 | A dosage form has yet to be assigned. (NCI) | Unassigned Dosage Form | |||
WAFER | C43003 | A thin slice of material containing a medicinal agent. (NCI) | Wafer Dosage Form | |||
Back to top | ||||||
CL.C66727.NCOMPLT | Completion/Reason for Non-Completion (NCOMPLT) | text Extensible: Yes | C66727 | Completion/Reason for Non-Completion | The status of the subject's completion of the study or a segment of the study, or the reason the subject discontinued the study or segment of the study. | CDISC SDTM Reason for Non-Completion Terminology |
ADVERSE EVENT | C41331 | Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. NOTE: For further information, see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. [Modified from ICH E2A] Synonyms: side effect, adverse experience. See also serious adverse event, serious adverse experience. (CDISC glossary) | Adverse Event | |||
COMPLETED | C25250 | To possess every necessary or normal part or component or step; having come or been brought to a conclusion. (NCI) | Complete | |||
DEATH | C28554 | The absence of life or state of being dead. (NCI) | Death | |||
LACK OF EFFICACY | C48226 | The lack of expected or desired effect related to a therapy. (NCI) | Lack of Efficacy | |||
LOST TO FOLLOW-UP | C48227 | The loss or lack of continuation of a subject to follow-up. | Lost To Follow-up | |||
NON-COMPLIANCE WITH STUDY DRUG | C49631 | An indication that a subject has not agreed with or followed the instructions related to the study medication. (NCI) | Non-Compliance With Study Drug | |||
OTHER | C17649 | Other | Different than the one(s) previously specified or mentioned. (NCI) | Other | ||
PHYSICIAN DECISION | C48250 | A position, opinion or judgment reached after consideration by a physician with reference to subject. (NCI) | Physician Decision | |||
PREGNANCY | C25742 | Pregnancy is the state or condition of having a developing embryo or fetus in the body (uterus), after union of an ovum and spermatozoon, during the period from conception to birth. (NCI) | Pregnancy | |||
PROGRESSIVE DISEASE | C35571 | A disease process that is increasing in scope or severity. (NCI) | Progressive Disease | |||
PROTOCOL VIOLATION | C48251 | An event or decision that stands in contrast to the guidelines set out by the protocol. (NCI) | Protocol Violation | |||
RECOVERY | C25746 | A healing process and/or an outcome implying relative health. The term is typically used in the context of direct and indirect effects of sickness or injury. (NCI) | Recovery | |||
SCREEN FAILURE | C49628 | The potential subject who does not meet one or more criteria required for participation in a trial. | Trial Screen Failure | |||
STUDY TERMINATED BY SPONSOR | C49632 | An indication that a clinical study was stopped by its sponsor. (NCI) | Study Terminated By Sponsor | |||
TECHNICAL PROBLEMS | C49633 | A problem with some technical aspect of a clinical study, usually related to an instrument. (NCI) | Technical Problem | |||
WITHDRAWAL BY SUBJECT | C49634 | An indication that a study participant has removed itself from the study. (NCI) | Withdrawal by Subject | |||
WITHDRAWAL BY PARENT/GUARDIAN | C102355 | An indication that a study participant has been removed from the study by the parent or legal guardian. | Study Subject Withdrawal by Parent or Guardian | |||
DISEASE RELAPSE | C38155 | Recurrent Disease | The return of a disease after a period of remission. | Recurrent Disease | ||
FAILURE TO MEET RANDOMIZATION CRITERIA | C105448 | An indication that the subject has been unable to fulfill/satisfy the criteria required for assignment into a randomized group. | Failure to Meet Randomization Criteria | |||
Back to top | ||||||
CL.C66728.STENRF | Relation to Reference Period (STENRF) | text Extensible: No | C66728 | Relation to Reference Period | The relative relationship of a timepoint to a reference timepoint. | CDISC SDTM Relation to Reference Period Terminology |
AFTER | C38008 | The time period following a point or another period of time. (NCI) | Post | |||
BEFORE | C25629 | Earlier in time or order. (NCI) | Prior | |||
DURING | C25490 | At some point in a given period of time. (NCI) | During | |||
DURING/AFTER | C49640 | Within a certain period of time or after a certain point or period in time. (NCI) | During Or After | |||
U | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
COINCIDENT | C25456 | Occurring or operating at the same time. | Concurrent | |||
ONGOING | C53279 | Continuous | Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption. (NCI) | Continue | ||
Back to top | ||||||
CL.C66729.ROUTE | Route of Administration (ROUTE) | text Extensible: Yes | C66729 | Route of Administration | The course by which a substance was administered in order to reach the site of action in the body. | CDISC SDTM Route of Administration Terminology |
AURICULAR (OTIC) | C38192 | Administration to or by way of the ear. (FDA) | Auricular Route of Administration | |||
BUCCAL | C38193 | Administration directed toward the cheek, generally from within the mouth. (FDA) | Buccal Route of Administration | |||
CONJUNCTIVAL | C38194 | Administration to the conjunctiva, the delicate membrane that lines the eyelids and covers the exposed surface of the eyeball. (FDA) | Conjunctival Route of Administration | |||
CUTANEOUS | C38675 | Administration to the skin. (FDA) | Cutaneous Route of Administration | |||
DENTAL | C38197 | Administration to a tooth or teeth. (FDA) | Dental Route of Administration | |||
ELECTRO-OSMOSIS | C38633 | Administration of through the diffusion of substance through a membrane in an electric field. (FDA) | Electro-osmosis Route of Administration | |||
ENDOCERVICAL | C38205 | Administration within the canal of the cervix uteri. Synonymous with the term intracervical. (FDA) | Endocervical Route of Administration | |||
ENDOSINUSIAL | C38206 | Administration within the nasal sinuses of the head. (FDA) | Endosinusial Route of Administration | |||
ENDOTRACHEAL | C38208 | Intratracheal Route of Administration | Administration directly into the trachea. Synonymous with the term intratracheal. (FDA) | Endotracheal Route of Administration | ||
ENTERAL | C38209 | Administration directly into the intestines. (FDA) | Enteral Route of Administration | |||
EPIDURAL | C38210 | Administration upon or over the dura mater. (FDA) | Epidural Route of Administration | |||
EXTRA-AMNIOTIC | C38211 | Administration to the outside of the membrane enveloping the fetus. (FDA) | Extraamniotic Route of Administration | |||
EXTRACORPOREAL | C38212 | Administration outside of the body. (FDA) | Extracorporeal Circulation Route of Administration | |||
HEMODIALYSIS | C38200 | Administration through hemodialysate fluid. (FDA) | Administration Via Hemodialysis | |||
INFILTRATION | C38215 | Administration that results in substances passing into tissue spaces or into cells. (FDA) | Infiltration Route of Administration | |||
INTERSTITIAL | C38219 | Administration to or in the interstices of a tissue. (FDA) | Interstitial Route of Administration | |||
INTRA-ABDOMINAL | C38220 | Administration within the abdomen. (FDA) | Intraabdominal Route of Administration | |||
INTRA-AMNIOTIC | C38221 | Administration within the amnion. (FDA) | Intraamniotic Route of Administration | |||
INTRA-ARTERIAL | C38222 | Administration within an artery or arteries. (FDA) | Intraarterial Route of Administration | |||
INTRA-ARTICULAR | C38223 | Administration within a joint. (FDA) | Intraarticular Route of Administration | |||
INTRABILIARY | C38224 | Administration within the bile, bile ducts or gallbladder. (FDA) | Intrabiliary Route of Administration | |||
INTRABRONCHIAL | C38225 | Administration within a bronchus. (FDA) | Intrabronchial Route of Administration | |||
INTRABURSAL | C38226 | Administration within a bursa. (FDA) | Intrabursal Route of Administration | |||
INTRACARDIAC | C38227 | Administration within the heart. (FDA) | Intracardiac Route of Administration | |||
INTRACARTILAGINOUS | C38228 | Administration within a cartilage; endochondral. (FDA) | Intracartilaginous Route of Administration | |||
INTRACAUDAL | C38229 | Administration within the cauda equina. (FDA) | Intracaudal Route of Administration | |||
INTRACAVERNOUS | C38230 | Administration within a pathologic cavity, such as occurs in the lung in tuberculosis. (FDA) | Intracavernous Route of Administration | |||
INTRACAVITARY | C38231 | Administration within a non-pathologic cavity, such as that of the cervix, uterus, or penis, or such as that is formed as the result of a wound. (FDA) | Intracavitary Route of Administration | |||
INTRACEREBRAL | C38232 | Administration within the cerebrum. (FDA) | Intracerebral Route of Administration | |||
INTRACISTERNAL | C38233 | Administration within the cisterna magna cerebellomedularis. (FDA) | Intracisternal Route of Administration | |||
INTRACORNEAL | C38234 | Administration within the cornea (the transparent structure forming the anterior part of the fibrous tunic of the eye). (FDA) | Intracorneal Route of Administration | |||
INTRACORONAL, DENTAL | C38217 | Administration of a drug within a portion of a tooth which is covered by enamel and which is separated from the roots by a slightly constricted region known as the neck. (FDA) | Intracoronal Dental Route of Administration | |||
INTRACORONARY | C38218 | Administration within the coronary arteries. (FDA) | Intracoronary Route of Administration | |||
INTRACORPORUS CAVERNOSUM | C38235 | Administration within the dilatable spaces of the corporus cavernosa of the penis. (FDA) | Intracorporus Cavernosum Route of Administration | |||
INTRADERMAL | C38238 | Administration within the dermis. (FDA) | Intradermal Route of Administration | |||
INTRADISCAL | C38239 | Administration within a disc. (FDA) | Intradiscal Route of Administration | |||
INTRADUCTAL | C38240 | Administration within the duct of a gland. (FDA) | Intraductal Route of Administration | |||
INTRADUODENAL | C38241 | Administration within the duodenum. (FDA) | Intraduodenal Route of Administration | |||
INTRADURAL | C38242 | Administration within or beneath the dura. (FDA) | Intradural Route of Administration | |||
INTRAEPIDERMAL | C38243 | Administration within the epidermis. (FDA) | Intraepidermal Route of Administration | |||
INTRAESOPHAGEAL | C38245 | Administration within the esophagus. (FDA) | Intraesophageal Route of Administration | |||
INTRAGASTRIC | C38246 | Administration within the stomach. (FDA) | Intragastric Route of Administration | |||
INTRAGINGIVAL | C38247 | Administration within the gingivae. (FDA) | Intragingival Route of Administration | |||
INTRAILEAL | C38249 | Administration within the distal portion of the small intestine, from the jejunum to the cecum. (FDA) | Intraileal Route of Administration | |||
INTRALESIONAL | C38250 | Administration within or introduced directly into a localized lesion. (FDA) | Intralesional Route of Administration | |||
INTRALUMINAL | C38251 | Administration within the lumen of a tube. (FDA) | Intraluminal Route of Administration | |||
INTRALYMPHATIC | C38252 | Administration within the lymph. (FDA) | Intralymphatic Route of Administration | |||
INTRAMEDULLARY | C38253 | Administration within the marrow cavity of a bone. (FDA) | Intramedullary Route of Administration | |||
INTRAMENINGEAL | C38254 | Administration within the meninges (the three membranes that envelope the brain and spinal cord). (FDA) | Intrameningeal Route of Administration | |||
INTRAMUSCULAR | C28161 | Administration within a muscle. (FDA) | Intramuscular Route of Administration | |||
INTRAOCULAR | C38255 | Administration within the eye. (FDA) | Intraocular Route of Administration | |||
INTRAOVARIAN | C38256 | Administration within the ovary. (FDA) | Intraovarian Route of Administration | |||
INTRAPERICARDIAL | C38257 | Administration within the pericardium. (FDA) | Intrapericardial Route of Administration | |||
INTRAPERITONEAL | C38258 | Administration within the peritoneal cavity. (FDA) | Intraperitoneal Route of Administration | |||
INTRAPLEURAL | C38259 | Administration within the pleura. (FDA) | Intrapleural Route of Administration | |||
INTRAPROSTATIC | C38260 | Administration within the prostate gland. (FDA) | Intraprostatic Route of Administration | |||
INTRAPULMONARY | C38261 | Administration within the lungs or its bronchi. (FDA) | Intrapulmonary Route of Administration | |||
INTRASINAL | C38262 | Administration within the nasal or periorbital sinuses. (FDA) | Intrasinal Route of Administration | |||
INTRASPINAL | C38263 | Administration within the vertebral column. (FDA) | Intraspinal Route of Administration | |||
INTRASYNOVIAL | C38264 | Administration within the synovial cavity of a joint. (FDA) | Intrasynovial Route of Administration | |||
INTRATENDINOUS | C38265 | Administration within a tendon. (FDA) | Intratendinous Route of Administration | |||
INTRATESTICULAR | C38266 | Administration within the testicle. (FDA) | Intratesticular Route of Administration | |||
INTRATHECAL | C38267 | Administration within the cerebrospinal fluid at any level of the cerebrospinal axis, including injection into the cerebral ventricles. (FDA) | Intrathecal Route of Administration | |||
INTRATHORACIC | C38207 | Administration within the thorax (internal to the ribs); synonymous with the term endothoracic. (FDA) | Endothoracic Route of Administration | |||
INTRATUBULAR | C38268 | Administration within the tubules of an organ. (FDA) | Intratubular Route of Administration | |||
INTRATUMOR | C38269 | Intratumor Route of Administration | Administration within a tumor. (FDA) | Intratumoral Route of Administration | ||
INTRATYMPANIC | C38270 | Administration within the auris media. (FDA) | Intratympanic Route of Administration | |||
INTRAUTERINE | C38272 | Administration within the uterus. (FDA) | Intrauterine Route of Administration | |||
INTRAVASCULAR | C38273 | Administration within a vessel or vessels. (FDA) | Intravascular Route of Administration | |||
INTRAVENOUS | C38276 | Administration within or into a vein or veins. (FDA) | Intravenous Route of Administration | |||
INTRAVENOUS BOLUS | C38274 | Administration within or into a vein or veins all at once. (FDA) | Intravenous Bolus | |||
INTRAVENOUS DRIP | C38279 | Administration within or into a vein or veins over a sustained period of time. (FDA) | Intravenous Drip | |||
INTRAVENTRICULAR | C38277 | Administration within a ventricle. (FDA) | Intraventricular Route of Administration | |||
INTRAVESICAL | C38278 | Administration within the bladder. (FDA) | Intravesical Route of Administration | |||
INTRAVITREAL | C38280 | Administration within the vitreous body of the eye. (FDA) | Intravitreal Route of Administration | |||
IONTOPHORESIS | C38203 | Administration by means of an electric current where ions of soluble salts migrate into the tissues of the body. (FDA) | Iontophoresis Route of Administration | |||
IRRIGATION | C38281 | Administration to bathe or flush open wounds or body cavities. (FDA) | Irrigation-Route of Administration | |||
LARYNGEAL | C38282 | Administration directly upon the larynx. (FDA) | Laryngeal Route of Administration | |||
NASAL | C38284 | Intranasal Route of Administration | Administration to the nose; administered by way of the nose. (FDA) | Nasal Route of Administration | ||
NASOGASTRIC | C38285 | Administration through the nose and into the stomach, usually by means of a tube. (FDA) | Nasogastric Route of Administration | |||
NOT APPLICABLE | C48623 | Routes of administration are not applicable. (FDA) | Route of Administration Not Applicable | |||
OCCLUSIVE DRESSING TECHNIQUE | C38286 | Administration by the topical route which is then covered by a dressing which occludes the area. (FDA) | Occlusive Dressing Technique | |||
OPHTHALMIC | C38287 | Administration to the external eye. (FDA) | Ophthalmic Route of Administration | |||
ORAL | C38288 | PO;Intraoral Route of Administration | Administration to or by way of the mouth. (FDA) | Oral Route of Administration | ||
OROPHARYNGEAL | C38289 | Administration directly to the mouth and pharynx. (FDA) | Oropharyngeal Route of Administration | |||
OTHER | C38290 | Administration is different from others on this list. (FDA) | Other Route of Administration | |||
PARENTERAL | C38291 | Administration by injection, infusion, or implantation. (FDA) | Parenteral Route of Administration | |||
PERCUTANEOUS | C38676 | Administration through the skin. (FDA) | Percutaneous Route of Administration | |||
PERIARTICULAR | C38292 | Administration around a joint. (FDA) | Periarticular Route of Administration | |||
PERIDURAL | C38677 | Administration to the outside of the dura mater of the spinal cord. (FDA) | Peridural Route of Administration | |||
PERINEURAL | C38293 | Administration surrounding a nerve or nerves. (FDA) | Perineural Route of Administration | |||
PERIODONTAL | C38294 | Administration around a tooth. (FDA) | Periodontal Route of Administration | |||
RECTAL | C38295 | Administration to the rectum. (FDA) | Rectal Route of Administration | |||
RESPIRATORY (INHALATION) | C38216 | Administration within the respiratory tract by inhaling orally or nasally for local or systemic effect. (FDA) | Inhalation Route of Administration | |||
RETROBULBAR | C38296 | Administration behind the pons or behind the eyeball. (FDA) | Retrobulbar Route of Administration | |||
SOFT TISSUE | C38198 | Administration into any soft tissue. (FDA) | Soft Tissue Route Of Administration | |||
SUBARACHNOID | C38297 | Administration beneath the arachnoid. (FDA) | Subarachnoid Route of Administration | |||
SUBCONJUNCTIVAL | C38298 | Administration beneath the conjunctiva. (FDA) | Subconjunctival Route of Administration | |||
SUBCUTANEOUS | C38299 | SC | Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL. (FDA) | Subcutaneous Route of Administration | ||
SUBLINGUAL | C38300 | Administration beneath the tongue. (FDA) | Sublingual Route of Administration | |||
SUBMUCOSAL | C38301 | Administration beneath the mucous membrane. (FDA) | Submucosal Route of Administration | |||
TOPICAL | C38304 | TOP | Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL. (FDA) | Topical Route of Administration | ||
TRANSDERMAL | C38305 | Administration through the dermal layer of the skin to the systemic circulation by diffusion. (FDA) | Transdermal Route of Administration | |||
TRANSMUCOSAL | C38283 | Administration across the mucosa. (FDA) | Mucosal Route of Administration | |||
TRANSPLACENTAL | C38307 | Administration through or across the placenta. (FDA) | Transplacental Route of Administration | |||
TRANSTRACHEAL | C38308 | Administration through the wall of the trachea. (FDA) | Transtracheal Route of Administration | |||
TRANSTYMPANIC | C38309 | Administration across or through the tympanic cavity. (FDA) | Transtympanic Route of Administration | |||
UNASSIGNED | C38310 | Route of administration has not yet been assigned. (FDA) | Unassigned Route of Administration | |||
UNKNOWN | C38311 | Route of administration is unknown. (FDA) | Unknown Route of Administration | |||
URETERAL | C38312 | Administration into the ureter. (FDA) | Ureteral Route of Administration | |||
URETHRAL | C38271 | Administration into the urethra. (FDA) | Intraurethral Route of Administration | |||
VAGINAL | C38313 | Administration into the vagina. (FDA) | Vaginal Route of Administration | |||
DIETARY | C78373 | Administration by way of food stuff. (NCI) | Dietary Route of Administration | |||
ORAL GAVAGE | C78374 | Administration through the mouth and into the stomach, usually by means of a tube. (NCI) | Oral Gavage Route of Administration | |||
INTRASTOMAL | C65138 | Administration into a stoma. | Administration via Stoma | |||
INTRAJEJUNAL | C102399 | Administration into the jejunum. | Intrajejunal Route of Administration | |||
INTRAPALATAL | C102400 | Administration into the palate. | Intrapalatal Route of Administration | |||
OROMUCOSAL | C64906 | Administration across the mucosa of the oral cavity. | Oromucosal Route of Administration | |||
INTRACAMERAL | C64984 | Administration by injection directly into the anterior chamber of the eye. | Intracameral Route of Administration | |||
SUBTENON | C94636 | Administration by injection through the membrane covering the muscles and nerves at the back of the eyeball. | Subtenon Route of Administration | |||
Back to top | ||||||
CL.C66769.AESEV | Severity/Intensity Scale for Adverse Events (AESEV) | text Extensible: No | C66769 | Severity/Intensity Scale for Adverse Events | A scale that defines the degree or state of disease existing in a patient as a result of the occurrence of an adverse event. (NCI) | CDISC SDTM Severity Intensity Scale for Adverse Event Terminology |
MILD | C41338 | Grade 1;1 | A type of adverse event that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. | Mild Adverse Event | ||
MODERATE | C41339 | Grade 2;2 | A type of adverse event that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. | Moderate Adverse Event | ||
SEVERE | C41340 | Grade 3;3 | A type of adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. | Severe Adverse Event | ||
Back to top | ||||||
CL.C66731.SEX | Sex (SEX) | text Extensible: No | C66731 | Sex | The assemblage of physical properties or qualities by which male is distinguished from female; the physical difference between male and female; the distinguishing peculiarity of male or female. (NCI) | CDISC SDTM Sex of Individual Terminology |
F | C16576 | Female | A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both. (NCI) | Female | ||
M | C20197 | Male | A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both. (NCI) | Male | ||
U | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
UN | C45908 | Undifferentiated | A person (one of unisexual specimens) who is born with genitalia and/or secondary sexual characteristics of indeterminate sex, or which combine features of both sexes. (NCI) | Intersex | ||
Back to top | ||||||
CL.C66732.SEXPOP | Sex of Participants (SEXPOP) | text Extensible: No | C66732 | Sex of Participants | The specific sex, either male, female, or mixed of the subject group being studied. (NCI) | CDISC SDTM Sex of Study Group Terminology |
BOTH | C49636 | One and the other; relating to or being two in conjunction. (NCI) | Both | |||
F | C16576 | Female | A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both. (NCI) | Female | ||
M | C20197 | Male | A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both. (NCI) | Male | ||
Back to top | ||||||
CL.C66733.SIZE | Size (SIZE) | text Extensible: Yes | C66733 | Size | The physical magnitude of something. (NCI) | CDISC SDTM Size Terminology |
LARGE | C49508 | Of considerable or relatively great size, extent, or capacity. (NCI) | Large | |||
MEDIUM | C49507 | Mid-way between small and large in number, quantity, magnitude or extent. (NCI) | Medium | |||
SMALL | C25376 | Limited in number, quantity, magnitude or extent. (NCI) | Small | |||
Back to top | ||||||
CL.C66734.DOMAIN | Domain Abbreviation (DOMAIN) | text Extensible: Yes | C66734 | Domain Abbreviation | A unique, 2-character domain code used in the regulatory submission process. The domain abbreviation is used consistently throughout the submission, i.e. in the dataset name, as the value of the domain variable within the dataset, and as a prefix for most variable names in the dataset. (CDISC Glossary) | CDISC SDTM Submission Domain Abbreviation Terminology |
AD | C49563 | Analysis Dataset | Datasets used for statistical analysis and reporting by the sponsor. These are submitted in addition to the data tabulation datasets. | Analysis Dataset Domain | ||
AE | C49562 | Adverse Events | Adverse events may be captured either as free text or a pre-specified list of terms. | Adverse Event Domain | ||
AU | C49565 | Autopsy | Additional data about deaths, specific to findings from autopsies. | Autopsy Domain | ||
BM | C49566 | Bone Measurements | Findings resulting from evaluations of bone mineral density. | Bone Measurements Domain | ||
BR | C49567 | Biopsy | Findings resulting from biopsies. | Biopsy Domain | ||
CE | C85441 | Clinical Events | A dataset used to capture clinical events of interest that would not be classified as adverse events. | Clinical Events Domain | ||
CM | C49568 | Concomitant Meds | Case report form (CRF) data that captures the Concomitant and Prior Medications/Therapies used by the subject. Examples are the Concomitant Medications/Therapies given on an as needed basis and the usual Background Medications/Therapies given for a condition. | Concomitant Medication Domain | ||
CO | C49569 | Comments | The Comments dataset accommodates two sources of comments: 1) those collected alongside other data on topical case report form (CRF) pages such as Adverse Events and 2) those collected on a separate page specifically dedicated to comments. | Comment Domain | ||
DA | C49578 | Drug Accountability | Data regarding the accountability of study drug, such as information on the receipt, dispensing, return, and packaging. | Drug Accountability Domain | ||
DM | C49572 | Demographics | The Demographics domain includes a set of essential standard variables that describe each subject in a clinical study. It is the parent domain for all other observations for human clinical subjects. | Demographics Domain | ||
DS | C49576 | Disposition | A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to disposition. (NCI) | Disposition Domain | ||
DV | C49585 | Protocol Deviations | The intent of the domain is to capture protocol violations and deviations during the course of the study and will store only those criteria violation by or deviated from by the subject and not a response to each violation or deviation. | Protocol Deviations Domain | ||
EG | C49626 | Electrocardiogram | Findings related to the collection of ECG data, including position of the subject, method of evaluation, all cycle measurements and all findings from the ECG including an overall interpretation if collected or derived. | Electrocardiogram Domain | ||
EX | C49587 | Exposure | The Exposure domain model records the details of a subject's exposure to protocol-specified study treatment. Study treatment may be any intervention that is prospectively defined as a test material within a study, and is typically but not always supplied to the subject. | Exposure Domain | ||
FA | C85442 | Findings About Events or Interventions | A dataset used to capture the findings about an event or intervention that cannot be represented within an event or intervention record or as a supplemental qualifier. | Findings About Events or Interventions Domain | ||
FH | C49588 | Family History | A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to family history. (NCI) | Family History Domain | ||
HU | C49589 | Healthcare Resource Utilization | Healthcare resource utilization data such as subject visits to physicians, hospitalizations, and nursing home stays. | Healthcare Resource Utilization Domain | ||
IE | C61536 | Inclusion/Exclusion | The intent of the domain model is to only collect those criteria that cause the subject to be in violation of the inclusion/exclusion criteria not a response to each criterion. | Inclusion Exclusion Domain | ||
LB | C49592 | Laboratory Data | Laboratory test findings including, but is not limited to hematology, clinical chemistry and urinalysis data. This domain does not include microbiology or pharmacokinetic data, which are stored in separate domains. | Laboratory Data Domain | ||
MB | C49602 | Microbiology | Microbiology specimen findings, including gram stain results, and organisms found. | Microbiology Specimen Domain | ||
MH | C49603 | Medical History | The medical history dataset includes the subject's prior history at the start of the trial. Examples of subject medical history information could include general medical history, gynecological history, and primary diagnosis. | Medical History Domain | ||
ML | C49604 | Meal Data | Information regarding the subject's meal consumption, such as fluid intake, amounts, form (solid or liquid state), frequency, etc., typically used for pharmacokinetic analysis. | Meal Data Domain | ||
MS | C61531 | Microbiology Susceptibility | This includes microbiology susceptibility test results, plus results of any other organism-related tests. | Microbiology Susceptibility Domain | ||
OM | C49605 | Organ Measurements | Findings from organ measurement evaluations. | Organ Measurement Domain | ||
PC | C49606 | Pharmacokinetic Concentration | Concentrations of drugs/metabolites in fluids or tissues as a function of time. | Pharmacokinetic Concentration Domain | ||
PE | C49608 | Physical Exam | Findings collected during a physical examination of the subject. It has findings that are discovered that are related to body systems. Does not include vital signs measurements, which are stored in the vital signs domain. | Physical Exam Domain | ||
PG | C61529 | Pharmacogenomics | Pharmacogenomics findings that initially focus on genotype and gene expression data. | Pharmacogenomics Domain | ||
PP | C49607 | Pharmacokinetic Parameters | Pharmacokinetic parameters derived from pharmacokinetic concentration-time (PC) data. | Pharmacokinetic Parameters Domain | ||
QS | C49609 | Questionnaires | Questionnaire data may include, but are not limited to the following: subject reported outcomes, validated or non-validated questionnaires, and validated or non-validated diaries (i.e. data with a common topicality). | Questionnaire Domain | ||
SC | C49610 | Subject Characteristics | The subject characteristics domain is for data not collected in other domains that is subject-related. | Subject Characteristics Domain | ||
SE | C49616 | Subject Element | The subject element table describes the actual order of elements followed by the subject, together with the start date/time and end date/time for each element. | Subject Element Domain | ||
SG | C49611 | Surgery | Surgical information. | Surgery Domain | ||
SK | C49612 | Skin Test | Findings from diagnostic skin tests. | Skin Test Domain | ||
SL | C49613 | Sleep Polysomnography Data | Findings from diagnostic sleep tests (polysomnography). | Sleep Polysomnography Domain | ||
SU | C49615 | Substance Use | The intent of the domain is to capture substance use information that may be used to assess the efficacy and/or safety of therapies that look to mitigate the effects of chronic substance use. | Substance Use Domain | ||
SV | C49617 | Subject Visits | The subject visits table describes the actual start and end data/time for each visit of each individual subject. | Subject Visits Domain | ||
TA | C49618 | Trial Arms | The trial arms table describes each planned arm in the trial. An arm is described as an ordered sequence of elements. | Trial Arms Domain | ||
TE | C49619 | Trial Elements | The trial elements table describes the element code that is unique for each element, the element description, and the rules for starting and ending an element. | Trial Elements Domain | ||
TI | C49620 | Trial Inclusion/Exclusion Criteria | The trial summary information domain is not subject oriented. It contains one record for each of the inclusion and exclusion criteria for the trial. | Trial Inclusion and Exclusion Criteria Domain | ||
TS | C53483 | Trial Summary | The trial summary information domain is not subject oriented. It contains one record for each trial summary characteristic. | Trial Summary Domain | ||
TV | C49621 | Trial Visits | The trial visits table describes the planned order and number of visits in the study within each arm. | Trial Visits Domain | ||
VS | C49622 | Vital Signs | Measurements including but not limited to blood pressure, temperature, respiration, body surface area, BMI, height and weight. | Vital Signs Domain | ||
BG | C95083 | Body Weight Gain | Body weight gain is the actual difference between two body weight measurements for any given interval for a subject. This is most commonly shown as the difference between two consecutive body weight measurements. | Body Weight Gain Domain | ||
BH | C95084 | Behavioral | This domain captures behavioral testing measurements on individual subjects. | Behavioral Domain | ||
BW | C95085 | Body Weight | This domain captures body weights collected for subjects during the study and at the end of the study (terminal body weights). | Body Weight Domain | ||
CL | C95086 | Clinical Observation | This domain captures clinical sign information including ophthalmology, physical examination, and dermal examination collected in life while executing the study. | Clinical Observation Domain | ||
DD | C95087 | Death Diagnosis | This domain captures the diagnosis of the cause of death for a subject. | Death Diagnosis Domain | ||
DP | C95088 | Developmental Milestone | This domain captures the outcome of developmental milestone testing during a scheduled period of observation. | Developmental Milestone Domain | ||
FE | C95089 | Fertility | This domain captures test results relative to male and female fertility. | Fertility Domain | ||
FW | C95090 | Food And Water | This domain captures food/water consumption of animals in the study. The data in this domain is derived data. | Food and Water Consumption Domain | ||
FX | C95091 | Fetal and Neonatal Developmental Morphology | This domain captures observations for fetal and pup morphological examinations. | Fetal and Neonatal Developmental Morphology Domain | ||
IC | C95092 | Implantation Classification | The Implantation Classification domain provides a record for each implantation identified for the scheduled cesarean section component of a study. | Implantation Classification Domain | ||
LR | C95093 | Cesarean Section and Delivery Litter Results | This domain captures litter based results in female animals for cesarean section and/or delivery components of a study, including litter survival during preweaning. | Cesarean Section and Delivery Litter Results Domain | ||
MA | C95094 | Macroscopic Findings | The gross pathology findings recorded at necropsy. | Macroscopic Findings Domain | ||
MI | C95095 | Microscopic Findings | The histopathology findings and microscopic evaluations recorded. | Microscopic Findings Domain | ||
PM | C95097 | Palpable Masses | This domain captures information of any palpable masses examined during the experimental phase. | Palpable Masses Domain | ||
SJ | C95099 | Subject Stages | The Subject Stages domain captures subject level non-treatment related blocks of time known as stages, such as Gestation, Lactation and Premating. | Subject Stages Domain | ||
TF | C95100 | Tumor Findings | This domain captures the tumor findings of the nonclinical subject. | Tumor Findings Domain | ||
TP | C95101 | Trial Paths | The trial paths domain is not subject oriented. This domain provides the complete planned non-treatment related sequences of stages for each path in a study. | Trial Paths Domain | ||
TT | C95102 | Trial Stages | The trial stages domain is not subject oriented. It captures non-treatment related planned blocks of time known as stages, such as Gestation, Lactation and Premating. | Trial Stages Domain | ||
TX | C95103 | Trial Sets | The trial stages domain is not subject oriented. It contains one record for each trial set characteristic including experimental factors, treatment factors, inherent characteristics, or distinct sponsor designations. | Trial Sets Domain | ||
CV | C102605 | Cardiovascular System Findings | A domain for physiological findings related to the cardiovascular system, including the heart, blood vessels and lymphatic vessels. | Cardiovascular System Findings Domain | ||
DE | C102616 | Device Events | A domain for device-related events. | Device Events Domain | ||
DI | C102618 | Device Identifiers | A domain for the submission of information that identifies a specific device unit. | Device Identifiers Domain | ||
DO | C102619 | Device Properties | A domain for the characteristics of the device that do not vary over the course of the study. | Device Properties Domain | ||
DR | C102620 | Device to Subject Relationship | A domain for the linkage of each subject to the device(s) to which they may have been exposed. | Device to Subject Relationship Domain | ||
DT | C102621 | Device Tracking and Disposition | A domain for logistics and disposition information specific to a given device. | Device Tracking and Disposition Domain | ||
DU | C102622 | Device-In-Use | A domain for the findings for the values of measurements and settings that are intentionally set on a device when it is in use. These are characteristics that exist for the device, and have a specific setting for a use instance. | Device-In-Use Domain | ||
DX | C102617 | Device Exposure | A domain for a subject's exposure to a medical device under study. | Device Exposure Domain | ||
ED | C102630 | Endocrine System Findings | A domain for physiological findings related to the endocrine system, including the glands and cells that make hormones that are released directly into the blood and travel to tissues and organs all over the body. | Endocrine System Findings Domain | ||
FF | C102637 | Fetal Findings | Fetal examinations and measurements for nonclinical developmental and reproductive toxicology studies. | Fetal Findings Domain | ||
GI | C102640 | Gastrointestinal System Findings | A domain for physiological findings related to the gastrointestinal system, including the esophagus, stomach, small and large intestine, anus, liver, biliary tract and pancreas. | Gastrointestinal System Findings Domain | ||
HM | C102641 | Hematopoietic System Findings | A domain for physiological findings related to the hematopoietic system, including the bone marrow and lymph nodes involved in the production of blood. | Hematopoietic System Findings Domain | ||
IG | C102651 | Integumentary System Findings | A domain for physiological findings related to the integumentary system, including the epidermis, dermis, all of the derivatives of the epidermis, hairs, nails, sudoriferous and sebaceous glands, and mammary glands. | Integumentary System Findings Domain | ||
IM | C102649 | Immune System Findings | A domain for physiological findings related to the immune system, including the thymus, spleen and tonsils. | Immune System Findings Domain | ||
MK | C102674 | Musculoskeletal Findings, Connective and Soft Tissue Findings | A domain for physiological findings related to the system of muscles, tendons, ligaments, bones, joints and associated tissues. | Musculoskeletal Findings, Connective and Soft Tissue Findings Domain | ||
MO | C102671 | Morphology Findings | A domain relevant to the science of the form and structure of an organism or of its parts. | Morphology Findings Domain | ||
NV | C102677 | Nervous System Findings | A domain for physiological findings related to the nervous system, including the brain, spinal cord, the cranial and spinal nerves, autonomic ganglia and plexuses. | Nervous System Findings Domain | ||
PA | C102694 | Pairing Events | Nonclinical pairing records for the fertility component of a study. | Pairing Events Domain | ||
PR | C102700 | Procedure | A domain relevant to an interventional activity that is intended to have diagnostic, preventive, therapeutic, or palliative effects. | Procedure Domain | ||
PY | C102678 | Nonclinical Pregnancy Results | Pregnancy results of female nonclinical subjects. | Nonclinical Pregnancy Results Domain | ||
RE | C95098 | Respiratory System Findings | A domain for physiological findings related to the respiratory system, including the organs that are involved in breathing such as the nose, throat, larynx, trachea, bronchi and lungs. | Respiratory Domain | ||
RP | C102707 | Reproductive System Findings | A domain for physiological findings related to the male and female reproductive systems. | Reproductive System Findings Domain | ||
RS | C102722 | Tumor Response | A domain for tumor response evaluations determined from the data in the tumor results domain. | Tumor Response Domain | ||
UR | C102726 | Urinary System Findings | A domain for physiological findings related to the urinary tract, including the organs involved in the creation and excretion of urine such as the kidneys, ureters, bladder and urethra. | Urinary System Findings Domain | ||
Back to top | ||||||
CL.C66735.TBLIND | Trial Blinding Schema (TBLIND) | text Extensible: Yes | C66735 | Trial Blinding Schema | The name of a code list that contains terms to define the type of blinding for the trial. (NCI) | CDISC SDTM Trial Blinding Schema Terminology |
DOUBLE BLIND | C15228 | A study in which neither the subject nor the investigator nor the research team interacting with the subject or data during the trial knows what treatment a subject is receiving. (CDISC glossary) | Double Blind Study | |||
OPEN LABEL | C49659 | A trial in which subjects and investigators know which product each subject is receiving; opposite of a blinded or double-blind study. (CDISC glossary) | Open Label Study | |||
SINGLE BLIND | C28233 | A study in which one party, either the investigator or the subject, does not know which medication or placebo is administered to the subject; also called singlemasked study. (CDISC glossary) | Single Blind Study | |||
Back to top | ||||||
CL.C66736.TINDTP | Trial Indication Type (TINDTP) | text Extensible: Yes | C66736 | Trial Indication Type | The name of a code list that contains terms to define the type of trial, e.g. cure or prevention. (NCI) | CDISC SDTM Trial Indication Type Terminology |
CURE | C49654 | A type of study protocol designed to evaluate intervention(s) aimed to cure a disease or condition. (NCI) | Cure Study | |||
DIAGNOSIS | C49653 | A type of study protocol designed to evaluate intervention(s) aimed at identifying a disease or condition. (NCI) | Diagnosis Study | |||
MITIGATION | C49655 | A type of study designed to identify actions necessary to eliminate or reduce the risk to human life or well-being as a result of a particular medication or treatment regimen. (NCI) | Adverse Effect Mitigation Study | |||
PREVENTION | C49657 | A type of study designed to identify actions necessary to permanently eliminate or reduce the long-term risk to human life as a result of a particular medication or treatment regimen. | Prevention Study | |||
TREATMENT | C49656 | A type of study protocol designed to evaluate intervention(s) for treatment of disease, syndrome or condition. | Treatment Study | |||
Back to top | ||||||
CL.C66737.TPHASE | Trial Phase (TPHASE) | text Extensible: Yes | C66737 | Trial Phase | Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed. (NCI) | CDISC SDTM Trial Phase Terminology |
Phase I Trial | C15600 | Trial Phase 1;1 | The initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects. NOTE: These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies. The total number of subjects and patients included in Phase I studies varies with the drug, but is generally in the range of 20 to 80. Phase 1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes. [After FDA CDER Handbook, ICH E8] (CDISC glossary) | Phase I Trial | ||
Phase I/II Trial | C15693 | Trial Phase 1-2;1-2 | A class of clinical study that combines elements characteristic of traditional Phase I and Phase II trials. See also Phase I, Phase II. | Phase I/II Trial | ||
Phase II Trial | C15601 | Trial Phase 2;2 | Phase 2. Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. NOTE: Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects. [After FDA CDER Handbook, ICH E8] (CDISC glossary) | Phase II Trial | ||
Phase II/III Trial | C15694 | Trial Phase 2-3;2-3 | A class of clinical study that combines elements characteristic of traditional Phase II and Phase III trials. | Phase II/III Trial | ||
Phase IIa Trial | C49686 | Trial Phase 2A;2A | A clinical research protocol generally referred to as a pilot or feasibility trial that aims to prove the concept of the new intervention in question. (NCI) | Phase IIa Trial | ||
Phase IIb Trial | C49688 | Trial Phase 2B;2B | A clinical research protocol generally referred to as a well-controlled and pivotal trial that aims to prove the mechanism of action of the new intervention in question. A pivotal study will generally be well-controlled, randomized, of adequate size, and whenever possible, double-blind. (NCI) | Phase IIb Trial | ||
Phase III Trial | C15602 | Trial Phase 3;3 | Phase 3. Studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather the additional information about effectiveness and safety that is needed to confirm efficacy and evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. NOTE: Phase 3 studies usually include from several hundred to several thousand subjects. [After FDA CDER Handbook, ICH E8] (CDISC glossary) | Phase III Trial | ||
Phase IIIa Trial | C49687 | Trial Phase 3A;3A | A classification typically assigned retrospectively to a Phase III trial upon determination by regulatory authorities of a need for a Phase III B trial. (NCI) | Phase IIIa Trial | ||
Phase IIIb Trial | C49689 | Trial Phase 3B;3B | A subcategory of Phase III trials done near the time of approval to elicit additional findings. NOTE: Dossier review may continue while associated Phase IIIB trials are conducted. These trials may be required as a condition of regulatory authority approval. | Phase IIIb Trial | ||
Phase IV Trial | C15603 | Trial Phase 4;4 | Phase 4. Postmarketing (Phase 4) studies to delineate additional information about the drug's risks, benefits, and optimal use that may be requested by regulatory authorities in conjunction with marketing approval. NOTE: These studies could include, but would not be limited to, studying different doses or schedules of administration than were used in Phase 2 studies, use of the drug in other patient populations or other stages of the disease, or use of the drug over a longer period of time. [After FDA CDER Handbook, ICH E8] (CDISC glossary) | Phase IV Trial | ||
Phase V Trial | C47865 | Trial Phase 5;5 | Postmarketing surveillance is sometimes referred to as Phase V. | Phase V Trial | ||
NA | C48660 | NA | Determination of a value is not relevant in the current context. (NCI) | Not Applicable | ||
Back to top | ||||||
CL.C66738.TSPARMCD | Trial Summary Parameter Test Code (TSPARMCD) | text Extensible: Yes | C66738 | Trial Summary Parameter Test Code | Individual characteristics of a clinical trial, e.g. description of trial design, trial blinding schema, and primary objective of trial. (NCI) | CDISC SDTM Trial Summary Parameter Terminology by Code |
ADDON | C49703 | Added on to Existing Treatments | The addition of a therapeutic product to the existing regimen in a clinical trial, where both entities remain as discrete products. | Test Product Added to Existing Treatment | ||
AGEMAX | C49694 | Planned Maximum Age of Subjects | The anticipated maximum age of the subjects to be entered in a clinical trial. (NCI) | Planned Maximum Age of Subjects | ||
AGEMIN | C49693 | Planned Minimum Age of Subjects | The anticipated minimum age of the subjects to be entered in a clinical trial. (NCI) | Planned Minimum Age of Subjects | ||
AGESPAN | C20587 | Age Span | Subgroups of populations based on age. (NCI) | Age Group | ||
DOSE | C25488 | Dose per Administration | The amount of drug administered to a patient or test subject at one time or the total quantity administered. [AMA Manual of Style] (CDISC Glossary) | Dose | ||
LENGTH | C49697 | Trial Length | Planned length of observation for a single subject. | Trial Length | ||
PLANSUB | C49692 | Planned Number of Subjects;Planned Enrollment;Target Enrollment;Anticipated Enrollment | The planned number of subjects to be entered in a clinical trial. (NCI) | Planned Subject Number | ||
RANDOM | C25196 | Trial is Randomized | The process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. NOTE: Unequal randomization is used to allocate subjects into groups at a differential rate; for example, three subjects may be assigned to a treatment group for every one assigned to the control group. [ICH E6 1.48] See also balanced study. (CDISC glossary) | Randomization | ||
ROUTE | C38114 | Route of Administration | The course by which a substance was administered in order to reach the site of action in the body. | Route of Administration | ||
SEXPOP | C49696 | Sex of Participants | The specific sex, either male, female, or mixed of the subject group being studied. (NCI) | Sex of Study Group | ||
STOPRULE | C49698 | Study Stop Rules | The rule, regulation and/or condition that determines the point in time when a clinical trial will be terminated. (NCI) | Study Stop Rules | ||
TBLIND | C49658 | Trial Blinding Schema | The name of a code list that contains terms to define the type of blinding for the trial. (NCI) | Trial Blinding Schema | ||
TCNTRL | C49647 | Control Type | Comparator against which the study treatment is evaluated (e.g., concurrent (placebo, no treatment, dose-response, active), external (historical, published literature). | Control Type | ||
TDIGRP | C49650 | Diagnosis Group | A grouping of individuals on the basis of a shared procedure or disease, or lack thereof (e.g. healthy volunteers, type 2 diabetic subjects, subjects with renal cell cancer). Standardized naming systems are available that define the groups within which a subject should be placed. (NCI) | Diagnosis Group | ||
TINDTP | C49652 | Trial Indication Type | The name of a code list that contains terms to define the type of trial, e.g. cure or prevention. (NCI) | Trial Indication Type | ||
TITLE | C49802 | Trial Title | The name of a clinical trial. (NCI) | Trial Title | ||
TPHASE | C48281 | Trial Phase Classification | Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed. (NCI) | Trial Phase | ||
TTYPE | C49660 | Trial Type | The type of clinical trial performed e.g. efficacy, safety. (NCI) | Trial Type | ||
CURTRT | C85582 | Current Therapy or Treatment | The literal identifier of the therapy or medication that is currently being given per protocol. | Current Therapy | ||
OBJPRIM | C85826 | Trial Primary Objective | The principal purpose of the trial. | Trial Primary Objective | ||
OBJSEC | C85827 | Trial Secondary Objective | The auxiliary purpose of the trial. | Trial Secondary Objective | ||
SPONSOR | C70793 | Clinical Study Sponsor;Study Sponsor;Sponsor | An entity that is responsible for the initiation, management, and/or financing of a clinical study. | Clinical Study Sponsor | ||
COMPTRT | C68612 | Comparative Treatment Name | A therapeutically active agent that is intended to provide reference measurements for the experimental protocol of a clinical trial. | Active Comparator Drug | ||
DOSU | C73558 | Dose Units | The unit of measure for the dosage form. | Dosage Form Unit | ||
DOSFRQ | C89081 | Dosing Frequency | The number of doses administered per a specific interval. | Dose Frequency | ||
INDIC | C41184 | Trial Indication | The basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication). | Indication | ||
TRT | C41161 | Investigational Therapy or Treatment | The investigational product under study. | Protocol Agent | ||
ACTSUB | C98703 | Actual Number of Subjects | Actual number of subjects enrolled; may include subjects who were not randomized. | Actual Subject Number | ||
ADAPT | C98704 | Adaptive Design | Indicate if the study includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and hypotheses based on analysis of data (usually interim data) from subjects in the study. | Adaptive Design | ||
CRMDUR | C98715 | Confirmed Response Minimum Duration | The protocol specified minimum amount of time needed to meet the definition of a confirmed response to treatment. | Confirmed Response Minimum Duration | ||
DCUTDESC | C98718 | Data Cutoff Description | Text that describes the cutoff date. | Data Cutoff Date Description | ||
DCUTDTC | C98717 | Data Cutoff Date | A date which indicates any data collected by this date will be used for analysis. | Data Cutoff Date | ||
FCNTRY | C98770 | Planned Country of Investigational Sites | The country name of planned study facility which has received IRB approval. | Planned Country of Investigational Site | ||
HLTSUBJI | C98737 | Healthy Subject Indicator | Indicate if persons who have not had the condition(s) being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements, may participate in the study. | Healthy Subject Indicator | ||
INTMODEL | C98746 | Intervention Model | The trial design developed to compare treatment groups. | Intervention Model | ||
INTTYPE | C98747 | Intervention Type | The kind of product or procedure studied in a trial. | Intervention Type | ||
NARMS | C98771 | Planned Number of Arms | The planned number of intervention groups. | Planned Number of Arms | ||
OUTMSEXP | C98724 | Exploratory Outcome Measure | Exploratory measures that will be used to evaluate the intervention(s) or, for observational studies, that are exploratory of the study. | Exploratory Outcome Measure | ||
OUTMSPRI | C98772 | Primary Outcome Measure | The primary measurement(s) or observation(s) used to measure the effect of experimental variables in a study, or for observational studies, to describe patterns of diseases or traits or associations with exposures, risk factors or treatment. These are the outcome measures used to assess the primary objective(s). | Primary Outcome Measure | ||
OUTMSSEC | C98781 | Secondary Outcome Measure | Other key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures used to assess the secondary objective(s). | Secondary Outcome Measure | ||
PCLAS | C98768 | Pharmacological Class of Invest. Therapy | The pharmacological class of the investigational product. | Pharmacological Class of Investigational Therapy | ||
RANDQT | C98775 | Randomization Quotient | The randomization quotient is the number of planned subjects to be exposed to investigational therapy, independent of dose or other factors, divided by the total number of planned subjects. | Randomization Quotient | ||
REGID | C98714 | Registry Identifier | Identification numbers assigned to the protocol by ct.gov, EudraCT, or other registries. | Clinical Trial Registry Identifier | ||
SDMDUR | C98783 | Stable Disease Minimum Duration | The protocol specified minimum amount of time needed to meet the definition of stable disease. | Stable Disease Minimum Duration | ||
SENDTC | C90462 | Study End Date | Final date on which data was collected for any subject (Date/Time of End of Participation, RFPENDTC) based on the protocol. | Study End Date | ||
SSTDTC | C69208 | Study Start Date | The earliest date of informed consent among any subject (Date/Time of Informed Consent, RFICDTC) that enrolled in the study. For studies conducted without informed consent (ie. emergency use) use the date of treatment. Dates for subjects who were screen failures are not included. | Study Date | ||
STYPE | C15320 | Study Type | Describes the role the study plays in determining the interventions a subject receives. | Study Design | ||
Back to top | ||||||
CL.C67152.TSPARM | Trial Summary Parameter Test Name (TSPARM) | text Extensible: Yes | C67152 | Trial Summary Parameter Test Name | Individual characteristics of a clinical trial, e.g. description of trial design, trial blinding schema, and primary objective of trial. (NCI) | CDISC SDTM Trial Summary Parameter Terminology by Name |
Added on to Existing Treatments | C49703 | Added on to Existing Treatments | The addition of a therapeutic product to the existing regimen in a clinical trial, where both entities remain as discrete products. | Test Product Added to Existing Treatment | ||
Planned Maximum Age of Subjects | C49694 | Planned Maximum Age of Subjects | The anticipated maximum age of the subjects to be entered in a clinical trial. (NCI) | Planned Maximum Age of Subjects | ||
Planned Minimum Age of Subjects | C49693 | Planned Minimum Age of Subjects | The anticipated minimum age of the subjects to be entered in a clinical trial. (NCI) | Planned Minimum Age of Subjects | ||
Age Span | C20587 | Age Span | Subgroups of populations based on age. (NCI) | Age Group | ||
Dose per Administration | C25488 | Dose per Administration | The amount of drug administered to a patient or test subject at one time or the total quantity administered. [AMA Manual of Style] (CDISC Glossary) | Dose | ||
Trial Length | C49697 | Trial Length | Planned length of observation for a single subject. | Trial Length | ||
Planned Number of Subjects | C49692 | Planned Number of Subjects;Planned Enrollment;Target Enrollment;Anticipated Enrollment | The planned number of subjects to be entered in a clinical trial. (NCI) | Planned Subject Number | ||
Trial is Randomized | C25196 | Trial is Randomized | The process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. NOTE: Unequal randomization is used to allocate subjects into groups at a differential rate; for example, three subjects may be assigned to a treatment group for every one assigned to the control group. [ICH E6 1.48] See also balanced study. (CDISC glossary) | Randomization | ||
Route of Administration | C38114 | Route of Administration | The course by which a substance was administered in order to reach the site of action in the body. | Route of Administration | ||
Sex of Participants | C49696 | Sex of Participants | The specific sex, either male, female, or mixed of the subject group being studied. (NCI) | Sex of Study Group | ||
Study Stop Rules | C49698 | Study Stop Rules | The rule, regulation and/or condition that determines the point in time when a clinical trial will be terminated. (NCI) | Study Stop Rules | ||
Trial Blinding Schema | C49658 | Trial Blinding Schema | The name of a code list that contains terms to define the type of blinding for the trial. (NCI) | Trial Blinding Schema | ||
Control Type | C49647 | Control Type | Comparator against which the study treatment is evaluated (e.g., concurrent (placebo, no treatment, dose-response, active), external (historical, published literature). | Control Type | ||
Diagnosis Group | C49650 | Diagnosis Group | A grouping of individuals on the basis of a shared procedure or disease, or lack thereof (e.g. healthy volunteers, type 2 diabetic subjects, subjects with renal cell cancer). Standardized naming systems are available that define the groups within which a subject should be placed. (NCI) | Diagnosis Group | ||
Trial Indication Type | C49652 | Trial Indication Type | The name of a code list that contains terms to define the type of trial, e.g. cure or prevention. (NCI) | Trial Indication Type | ||
Trial Title | C49802 | Trial Title | The name of a clinical trial. (NCI) | Trial Title | ||
Trial Phase Classification | C48281 | Trial Phase Classification | Clinical trials are broken into three or four phases: Phase I tests a new drug or treatment for safety in a small group; Phase II expands the study to a larger group of people; Phase III expands the study to an even larger group of people to measure whether the treatment actually benefits patients, and whether its benefits exceed its risks; and Phase IV takes place after the drug or treatment has been licensed and marketed. (NCI) | Trial Phase | ||
Trial Type | C49660 | Trial Type | The type of clinical trial performed e.g. efficacy, safety. (NCI) | Trial Type | ||
Current Therapy or Treatment | C85582 | Current Therapy or Treatment | The literal identifier of the therapy or medication that is currently being given per protocol. | Current Therapy | ||
Trial Primary Objective | C85826 | Trial Primary Objective | The principal purpose of the trial. | Trial Primary Objective | ||
Trial Secondary Objective | C85827 | Trial Secondary Objective | The auxiliary purpose of the trial. | Trial Secondary Objective | ||
Clinical Study Sponsor | C70793 | Clinical Study Sponsor;Study Sponsor;Sponsor | An entity that is responsible for the initiation, management, and/or financing of a clinical study. | Clinical Study Sponsor | ||
Comparative Treatment Name | C68612 | Comparative Treatment Name | A therapeutically active agent that is intended to provide reference measurements for the experimental protocol of a clinical trial. | Active Comparator Drug | ||
Dose Units | C73558 | Dose Units | The unit of measure for the dosage form. | Dosage Form Unit | ||
Dosing Frequency | C89081 | Dosing Frequency | The number of doses administered per a specific interval. | Dose Frequency | ||
Trial Indication | C41184 | Trial Indication | The basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication). | Indication | ||
Investigational Therapy or Treatment | C41161 | Investigational Therapy or Treatment | The investigational product under study. | Protocol Agent | ||
Actual Number of Subjects | C98703 | Actual Number of Subjects | Actual number of subjects enrolled; may include subjects who were not randomized. | Actual Subject Number | ||
Adaptive Design | C98704 | Adaptive Design | Indicate if the study includes a prospectively planned opportunity for modification of one or more specified aspects of the study design and hypotheses based on analysis of data (usually interim data) from subjects in the study. | Adaptive Design | ||
Confirmed Response Minimum Duration | C98715 | Confirmed Response Minimum Duration | The protocol specified minimum amount of time needed to meet the definition of a confirmed response to treatment. | Confirmed Response Minimum Duration | ||
Data Cutoff Description | C98718 | Data Cutoff Description | Text that describes the cutoff date. | Data Cutoff Date Description | ||
Data Cutoff Date | C98717 | Data Cutoff Date | A date which indicates any data collected by this date will be used for analysis. | Data Cutoff Date | ||
Planned Country of Investigational Sites | C98770 | Planned Country of Investigational Sites | The country name of planned study facility which has received IRB approval. | Planned Country of Investigational Site | ||
Healthy Subject Indicator | C98737 | Healthy Subject Indicator | Indicate if persons who have not had the condition(s) being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements, may participate in the study. | Healthy Subject Indicator | ||
Intervention Model | C98746 | Intervention Model | The trial design developed to compare treatment groups. | Intervention Model | ||
Intervention Type | C98747 | Intervention Type | The kind of product or procedure studied in a trial. | Intervention Type | ||
Planned Number of Arms | C98771 | Planned Number of Arms | The planned number of intervention groups. | Planned Number of Arms | ||
Exploratory Outcome Measure | C98724 | Exploratory Outcome Measure | Exploratory measures that will be used to evaluate the intervention(s) or, for observational studies, that are exploratory of the study. | Exploratory Outcome Measure | ||
Primary Outcome Measure | C98772 | Primary Outcome Measure | The primary measurement(s) or observation(s) used to measure the effect of experimental variables in a study, or for observational studies, to describe patterns of diseases or traits or associations with exposures, risk factors or treatment. These are the outcome measures used to assess the primary objective(s). | Primary Outcome Measure | ||
Secondary Outcome Measure | C98781 | Secondary Outcome Measure | Other key measures that will be used to evaluate the intervention(s) or, for observational studies, that are a focus of the study. These are the outcome measures used to assess the secondary objective(s). | Secondary Outcome Measure | ||
Pharmacological Class of Invest. Therapy | C98768 | Pharmacological Class of Invest. Therapy | The pharmacological class of the investigational product. | Pharmacological Class of Investigational Therapy | ||
Randomization Quotient | C98775 | Randomization Quotient | The randomization quotient is the number of planned subjects to be exposed to investigational therapy, independent of dose or other factors, divided by the total number of planned subjects. | Randomization Quotient | ||
Registry Identifier | C98714 | Registry Identifier | Identification numbers assigned to the protocol by ct.gov, EudraCT, or other registries. | Clinical Trial Registry Identifier | ||
Stable Disease Minimum Duration | C98783 | Stable Disease Minimum Duration | The protocol specified minimum amount of time needed to meet the definition of stable disease. | Stable Disease Minimum Duration | ||
Study End Date | C90462 | Study End Date | Final date on which data was collected for any subject (Date/Time of End of Participation, RFPENDTC) based on the protocol. | Study End Date | ||
Study Start Date | C69208 | Study Start Date | The earliest date of informed consent among any subject (Date/Time of Informed Consent, RFICDTC) that enrolled in the study. For studies conducted without informed consent (ie. emergency use) use the date of treatment. Dates for subjects who were screen failures are not included. | Study Date | ||
Study Type | C15320 | Study Type | Describes the role the study plays in determining the interventions a subject receives. | Study Design | ||
Back to top | ||||||
CL.C66739.TTYPE | Trial Type (TTYPE) | text Extensible: Yes | C66739 | Trial Type | The type of clinical trial performed e.g. efficacy, safety. (NCI) | CDISC SDTM Trial Type Terminology |
BIO-AVAILABILITY | C49664 | A study of the degree to which or rate at which a drug or other substance is absorbed or becomes available at the site of physiological activity after administration. (NCI) | Bioavailability Study | |||
BIO-EQUIVALENCE | C49665 | A study most often used to compare the efficacy of different formulations to treat a given disease. It is the testing of an old versus a new formulation in healthy volunteers or subjects with the disease under study and usually in one dose. (NCI) | Therapeutic Equivalency Study | |||
EFFICACY | C49666 | A study of the relative therapeutic efficacy of treatment of a disease. Usually this is a Phase II or III study. (NCI) | Efficacy Study | |||
PHARMACODYNAMIC | C49662 | A study of the biochemical and physiological effect of a drug and the mechanism of drug action and the relationship between drug concentration and effect. (NCI) | Pharmacodynamic Study | |||
PHARMACOECONOMIC | C39493 | A study that assesses the value associated with a given drug in therapeutic and economic terms. This type of study is multidisciplinary in nature and takes into consideration the social and economic costs (resource utilization costs including direct, indirect, and intangible costs) of drug therapy in addition to its direct therapeutic benefits. Analyses relate the difference in therapeutic benefits to the difference in costs between treatment alternatives. (NCI) | Pharmacoeconomic Study | |||
PHARMACOGENOMIC | C49661 | A study of identification and analysis of genomic variations that affect the efficacy of a drug. Pharmacogenomic studies can potentially be predictive of an individual's drug-response or adverse reactions or susceptibility to iatrogenic disorders, and may also reveal new targets that can help in the design of new drugs. (NCI) | Pharmacogenomic Study | |||
PHARMACOKINETIC | C49663 | A study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body. (NCI) | Pharmacokinetic Study | |||
SAFETY | C49667 | A study that assesses the medical risks to a subject. Safety is usually assessed by examining a wide range of clinical parameters, including adverse events, vital signs, physical exam, laboratory tests. | Safety Study | |||
FOOD EFFECT | C98729 | Studies that are conducted to assess the effect of food on the rate and extent of absorption of a drug, either compared to a fasted state or to a reference drug. | Food Effect Study | |||
TOLERABILITY | C98791 | A type of safety study that assesses the degree to which overt adverse effects can be tolerated by the subject. | Tolerability Study | |||
Back to top | ||||||
CL.C66770.VSRESU | Units for Vital Signs Results (VSRESU) | text Extensible: Yes | C66770 | Units for Vital Signs Results | The unit used to record and describe the result of a test investigating a vital sign. (NCI) | CDISC SDTM Unit for Vital Sign Result Terminology |
% | C25613 | Percentage | A fraction or ratio with 100 understood as the denominator. (NCI) | Percentage | ||
BEATS/MIN | C49673 | Beats per Minute | The number of heartbeats measured per minute time. (NCI) | Beats per Minute | ||
BREATHS/MIN | C49674 | Breaths per Minute | The number of breaths (inhalation and exhalation) taken per minute time. (NCI) | Breaths per Minute | ||
C | C42559 | Degree Celsius | A unit of temperature of the temperature scale designed so that the freezing point of water is 0 degrees and the boiling point is 100 degrees at standard atmospheric pressure. The current official definition of the Celsius sets 0.01 C to be at the triple point of water and a degree to be 1/273.16 of the difference in temperature between the triple point of water and absolute zero. One degree Celsius represents the same temperature difference as one Kelvin. (NCI) | Degree Celsius | ||
cm | C49668 | Centimeter | A basic unit of length equal to one hundredth of a meter or approximately 0.393700787 inch. | Centimeter | ||
F | C44277 | Degree Fahrenheit | The Fahrenheit temperature scale is named after the German physicist Gabriel Fahrenheit (1686-1736), who proposed it in 1724. In this scale, the freezing point of water is 32 degrees Fahrenheit and the boiling point is 212 degrees, placing the boiling and melting points of water 180 degrees apart. In this scale a degree Fahrenheit is 5/9ths of a Kelvin (or of a degree Celsius), and minus 40 degrees Fahrenheit is equal to minus 40 degrees Celsius. (NCI) | Degree Fahrenheit | ||
g | C48155 | Gram | A metric unit of mass equal to one one thousandth of a kilogram. (NCI) | Gram | ||
IN | C48500 | Inch | A traditional unit of length equal to 2.54 centimeters. (NCI) | Inch | ||
kg | C28252 | Kilogram | The basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. It is the only basic unit still defined in terms of a material object, and also the only one with a prefix [kilo] already in place. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds. (NCI) | Kilogram | ||
kg/m2 | C49671 | Kilogram Per Square Meter | A unit expressed as kilogram of mass per square meter of area.(NCI) | Kilogram Per Square Meter | ||
LB | C48531 | Pound | A traditional unit of mass. By international agreement, one avoirdupois pound is equal to exactly 0.453 592 37 kilogram, 16 ounces, or 1.215 28 troy pounds. (NCI) | Pound | ||
m2 | C42569 | Square Meter | The SI unit of area measurement equal to a square whose sides are one meter long. Square meter is equal to 10,000 square centimeters; 0.01 ares; 1.196 square yards; 10.76 square feet; 1550 square inches. (NCI) | Square Meter | ||
mmHg | C49670 | Millimeter of Mercury;torr;Torr | A unit of pressure equal to 0.001316 atmosphere and equal to the pressure indicated by one millimeter rise of mercury in a barometer at the Earth's surface. (NCI) | Millimeter of Mercury | ||
ohm | C42554 | Ohm | A unit of electrical resistance equal to the resistance between two points on a conductor when a potential difference of one volt between them produces a current of one Ampere. Ohm is also used to measure impedance and reactance for complex resistance. A measurement in ohms is the reciprocal of a measurement in Siemens. (NCI) | Ohm | ||
Back to top | ||||||
CL.C66741.VSTESTCD | Vital Signs Test Code (VSTESTCD) | text Extensible: Yes | C66741 | Vital Signs Test Code | The name given to the test that analyzes a particular set of vital signs including temperature, respiratory rate, heart beat (pulse), and blood pressure. (NCI) | CDISC SDTM Vital Sign Terminology by Code |
BMI | C16358 | Body Mass Index | A general indicator of the body fat an individual is carrying based upon the ratio of weight to height. (NCI) | Body Mass Index | ||
BODYFAT | C12472 | Adipose Tissue;Body Fat;Fat Tissue | A specialized form of connective tissue consisting primarily of adipocytes (fat cells), surrounded by a meshwork of collagen fibers. (NCI) | Adipose Tissue | ||
BSA | C25157 | Body Surface Area | A measure of the 2-dimensional extent of the body surface (i.e., the skin). Body surface area (BSA) can be calculated by mathematical formula or from a chart that relates height to weight. BSA is often an important factor in dosing. (NCI) | Body Surface Area | ||
DIABP | C25299 | Diastolic Blood Pressure | The blood pressure after the contraction of the heart while the chambers of the heart refill with blood. (NCI) | Diastolic Blood Pressure | ||
FRMSIZE | C49680 | Body Frame Size | The categorization of a person's body frame into small, medium and large based on the measurement of wrist circumference or the breadth of the elbow. (NCI) | Body Frame Size | ||
HEIGHT | C25347 | Height | The vertical measurement or distance from the base to the top of an object; the vertical dimension of extension. (NCI) | Height | ||
HR | C49677 | Heart Rate | The number of heartbeats per unit of time, usually expressed as beats per minute. (NCI) | Heart Rate | ||
MAP | C49679 | Mean Arterial Pressure | The mean pressure of the blood within the arterial circulation. The arterial pressure may be directly measured by insertion of an intra-arterial catheter connected to a transducer. The mean arterial pressure (MAP) can be calculated by subsequent analysis of the waveform. MAP can be approximated without an invasive procedure using the following formula: diastolic pressure plus 1/3 of the pulse pressure, where pulse pressure is systolic pressure - diastolic pressure. (NCI) | Mean Arterial Pressure | ||
PULSE | C49676 | Pulse Rate | The rate of the pulse as observed in an artery, expressed as beats per minute. It can be measured at several anatomical sites, including the wrist, neck, temple, groin, behind the knees, or on top of the foot. (NCI) | Pulse Rate | ||
RESP | C49678 | Respiratory Rate | The rate of breathing (inhalation and exhalation) measured within in a unit time, usually expressed as breaths per minute. (NCI) | Respiratory Rate | ||
SYSBP | C25298 | Systolic Blood Pressure | The blood pressure during the contraction of the left ventricle of the heart. | Systolic Blood Pressure | ||
TEMP | C25206 | Temperature | The property of a body or region of space that determines whether or not there will be a net flow of heat into it or out of it from a neighboring body or region and in which direction (if any) the heat will flow, perceptible by living organism as a somatic sensation of cold or heat. It is a measure of the average translational kinetic energy associated with the disordered microscopic motion of atoms and molecules. Temperature is measured in one of the three standard temperature scales: Celsius, Kelvin, and Fahrenheit. (NCI) | Temperature | ||
WEIGHT | C25208 | Weight | The vertical force exerted by a mass as a result of gravity. (NCI) | Weight | ||
SAD | C87054 | Sagittal Abdominal Diameter | A standard measure of visceral obesity, or abdominal fat, which is measured from the patient's back to upper abdomen between the bottom of the rib cage and the top of the pelvic area. This measurement may be taken with the patient standing or in the supine position. (NCI) | Sagittal Abdominal Diameter | ||
KNEEHEEL | C84372 | Knee to Heel Length;Lower Leg Length | A measurement of the length of the lower leg from the top of the knee to the bottom of the heel. This measurement may be taken with a knemometer or calipers. (NCI) | Knee to Heel Length Measurement | ||
HDCIRC | C81255 | Head Circumference | A circumferential measurement of the head at the widest point, which is traditionally above the eyebrows. | Head Circumference | ||
SSSKNF | C98785 | Subscapular Skinfold Thickness | A measurement of the thickness of a pinch of skin situated below or on the underside of the scapula. (NCI) | Subscapular Skinfold Thickness | ||
TRSKNF | C98793 | Triceps Skinfold Thickness | A measurement of the thickness of a pinch of skin on the triceps. (NCI) | Triceps Skinfold Thickness | ||
FARMCIR | C100946 | Forearm Circumference | The distance around an individual's forearm. | Forearm Circumference | ||
HIPCIR | C100947 | Hip Circumference | The distance around an individual's pelvic area or hips. | Hip Circumference | ||
LBM | C71258 | Lean Body Mass | The weight of all organs and tissue in an individual less the weight of the individual's body fat. | Lean Body Mass | ||
PULSEPR | C100945 | Pulse Pressure | The change in systolic to diastolic pressure which produces a pulse. | Pulse Pressure | ||
WSTCIR | C100948 | Waist Circumference | The distance around an individual's midsection or waist. | Waist Circumference | ||
ABSKNF | C103346 | Abdominal Skinfold Thickness | A measurement for determining the subcutaneous fat layer thickness whereby a pinch of skin approximately five centimeters to the right of the umbilicus is measured using calipers. (NCI) | Abdominal Skinfold Thickness | ||
OXYSAT | C60832 | Oxygen Saturation | A measurement of the oxygen-hemoglobin saturation of a volume of blood. | Oxygen Saturation Measurement | ||
BODLNGTH | C81298 | Body Length | The linear extent in space from one end of the body to the other end, or the extent of the body from beginning to end. | Total Body Length | ||
Back to top | ||||||
CL.C67153.VSTEST | Vital Signs Test Name (VSTEST) | text Extensible: Yes | C67153 | Vital Signs Test Name | The name given to the test that analyzes a particular set of vital signs including temperature, respiratory rate, heart beat (pulse), and blood pressure. (NCI) | CDISC SDTM Vital Sign Terminology by Name |
Body Mass Index | C16358 | Body Mass Index | A general indicator of the body fat an individual is carrying based upon the ratio of weight to height. (NCI) | Body Mass Index | ||
Adipose Tissue | C12472 | Adipose Tissue;Body Fat;Fat Tissue | A specialized form of connective tissue consisting primarily of adipocytes (fat cells), surrounded by a meshwork of collagen fibers. (NCI) | Adipose Tissue | ||
Body Surface Area | C25157 | Body Surface Area | A measure of the 2-dimensional extent of the body surface (i.e., the skin). Body surface area (BSA) can be calculated by mathematical formula or from a chart that relates height to weight. BSA is often an important factor in dosing. (NCI) | Body Surface Area | ||
Diastolic Blood Pressure | C25299 | Diastolic Blood Pressure | The blood pressure after the contraction of the heart while the chambers of the heart refill with blood. (NCI) | Diastolic Blood Pressure | ||
Body Frame Size | C49680 | Body Frame Size | The categorization of a person's body frame into small, medium and large based on the measurement of wrist circumference or the breadth of the elbow. (NCI) | Body Frame Size | ||
Height | C25347 | Height | The vertical measurement or distance from the base to the top of an object; the vertical dimension of extension. (NCI) | Height | ||
Heart Rate | C49677 | Heart Rate | The number of heartbeats per unit of time, usually expressed as beats per minute. (NCI) | Heart Rate | ||
Mean Arterial Pressure | C49679 | Mean Arterial Pressure | The mean pressure of the blood within the arterial circulation. The arterial pressure may be directly measured by insertion of an intra-arterial catheter connected to a transducer. The mean arterial pressure (MAP) can be calculated by subsequent analysis of the waveform. MAP can be approximated without an invasive procedure using the following formula: diastolic pressure plus 1/3 of the pulse pressure, where pulse pressure is systolic pressure - diastolic pressure. (NCI) | Mean Arterial Pressure | ||
Pulse Rate | C49676 | Pulse Rate | The rate of the pulse as observed in an artery, expressed as beats per minute. It can be measured at several anatomical sites, including the wrist, neck, temple, groin, behind the knees, or on top of the foot. (NCI) | Pulse Rate | ||
Respiratory Rate | C49678 | Respiratory Rate | The rate of breathing (inhalation and exhalation) measured within in a unit time, usually expressed as breaths per minute. (NCI) | Respiratory Rate | ||
Systolic Blood Pressure | C25298 | Systolic Blood Pressure | The blood pressure during the contraction of the left ventricle of the heart. | Systolic Blood Pressure | ||
Temperature | C25206 | Temperature | The property of a body or region of space that determines whether or not there will be a net flow of heat into it or out of it from a neighboring body or region and in which direction (if any) the heat will flow, perceptible by living organism as a somatic sensation of cold or heat. It is a measure of the average translational kinetic energy associated with the disordered microscopic motion of atoms and molecules. Temperature is measured in one of the three standard temperature scales: Celsius, Kelvin, and Fahrenheit. (NCI) | Temperature | ||
Weight | C25208 | Weight | The vertical force exerted by a mass as a result of gravity. (NCI) | Weight | ||
Sagittal Abdominal Diameter | C87054 | Sagittal Abdominal Diameter | A standard measure of visceral obesity, or abdominal fat, which is measured from the patient's back to upper abdomen between the bottom of the rib cage and the top of the pelvic area. This measurement may be taken with the patient standing or in the supine position. (NCI) | Sagittal Abdominal Diameter | ||
Knee to Heel Length | C84372 | Knee to Heel Length;Lower Leg Length | A measurement of the length of the lower leg from the top of the knee to the bottom of the heel. This measurement may be taken with a knemometer or calipers. (NCI) | Knee to Heel Length Measurement | ||
Head Circumference | C81255 | Head Circumference | A circumferential measurement of the head at the widest point, which is traditionally above the eyebrows. | Head Circumference | ||
Subscapular Skinfold Thickness | C98785 | Subscapular Skinfold Thickness | A measurement of the thickness of a pinch of skin situated below or on the underside of the scapula. (NCI) | Subscapular Skinfold Thickness | ||
Triceps Skinfold Thickness | C98793 | Triceps Skinfold Thickness | A measurement of the thickness of a pinch of skin on the triceps. (NCI) | Triceps Skinfold Thickness | ||
Forearm Circumference | C100946 | Forearm Circumference | The distance around an individual's forearm. | Forearm Circumference | ||
Hip Circumference | C100947 | Hip Circumference | The distance around an individual's pelvic area or hips. | Hip Circumference | ||
Lean Body Mass | C71258 | Lean Body Mass | The weight of all organs and tissue in an individual less the weight of the individual's body fat. | Lean Body Mass | ||
Pulse Pressure | C100945 | Pulse Pressure | The change in systolic to diastolic pressure which produces a pulse. | Pulse Pressure | ||
Waist Circumference | C100948 | Waist Circumference | The distance around an individual's midsection or waist. | Waist Circumference | ||
Abdominal Skinfold Thickness | C103346 | Abdominal Skinfold Thickness | A measurement for determining the subcutaneous fat layer thickness whereby a pinch of skin approximately five centimeters to the right of the umbilicus is measured using calipers. (NCI) | Abdominal Skinfold Thickness | ||
Oxygen Saturation | C60832 | Oxygen Saturation | A measurement of the oxygen-hemoglobin saturation of a volume of blood. | Oxygen Saturation Measurement | ||
Body Length | C81298 | Body Length | The linear extent in space from one end of the body to the other end, or the extent of the body from beginning to end. | Total Body Length | ||
Back to top | ||||||
CL.C66742.NY | No Yes Response (NY) | text Extensible: No | C66742 | No Yes Response | A term that is used to indicate a question with permissible values of yes/no/unknown/not applicable. | CDISC SDTM Yes No Unknown or Not Applicable Response Terminology |
N | C49487 | No | The non-affirmative response to a question. (NCI) | No | ||
NA | C48660 | NA | Determination of a value is not relevant in the current context. (NCI) | Not Applicable | ||
U | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
Y | C49488 | Yes | The affirmative response to a question. (NCI) | Yes | ||
Back to top | ||||||
CL.C65047.LBTESTCD | Laboratory Test Code (LBTESTCD) | text Extensible: Yes | C65047 | Laboratory Test Code | Terminology used for Laboratory Tests of the CDISC Standard Data Tabulation Model. | CDISC SDTM Laboratory Test Terminology by Code |
ANISO | C74797 | Anisocytes | A measurement of the inequality in the size of the red blood cells in a whole blood specimen. | Anisocyte Measurement | ||
POIKILO | C79602 | Poikilocytes | A measurement of the odd-shaped erythrocytes in a whole blood specimen. | Poikilocyte Measurement | ||
BILI | C38037 | Bilirubin;Total Bilirubin | A measurement of the total bilirubin in a biological specimen. | Total Bilirubin Measurement | ||
APTT | C38462 | Activated Partial Thromboplastin Time | A measurement of the length of time that it takes for clotting to occur when reagents are added to a plasma specimen. The test is partial due to the absence of tissue factor (Factor III) from the reaction mixture. | Partial Thromboplastin Time | ||
GLUC | C105585 | Glucose | A measurement of the glucose in a biological specimen. | Glucose Measurement | ||
PH | C45997 | pH | A measure of the acidity or alkalinity of a fluid on a scale of 0 to 14.(NCI) | pH | ||
RBC | C51946 | Erythrocytes;Red Blood Cells | A measurement of the total erythrocytes in a biological specimen. | Erythrocyte Count | ||
RETI | C51947 | Reticulocytes | A measurement of the reticulocytes in a biological specimen. | Reticulocyte Count | ||
WBC | C51948 | Leukocytes;White Blood Cells | A measurement of the leukocytes in a biological specimen. | Leukocyte Count | ||
LYM | C51949 | Lymphocytes | A measurement of the lymphocytes in a biological specimen. | Lymphocyte Count | ||
PLAT | C51951 | Platelets | A measurement of the platelets in a biological specimen. | Platelet Count | ||
BUN | C61019 | Blood Urea Nitrogen | A measurement of the urea nitrogen in a blood specimen. | Blood Urea Nitrogen Measurement | ||
CHOL | C105586 | Cholesterol;Total Cholesterol | A measurement of the cholesterol in a biological specimen. | Cholesterol Measurement | ||
HDL | C105587 | HDL Cholesterol | A measurement of the high density lipoprotein cholesterol in a biological specimen. | High Density Lipoprotein Cholesterol Measurement | ||
LDL | C105588 | LDL Cholesterol | A measurement of the low density lipoprotein cholesterol in a biological specimen. | Low Density Lipoprotein Cholesterol Measurement | ||
PT | C62656 | Prothrombin Time | A blood clotting measurement that evaluates the extrinsic pathway of coagulation. | Prothrombin Time | ||
NEUT | C63321 | Neutrophils | A measurement of the neutrophils in a biological specimen. | Absolute Neutrophil Count | ||
ALB | C64431 | Albumin;Microalbumin | A measurement of the albumin protein in a biological specimen. | Albumin Measurement | ||
ALP | C64432 | Alkaline Phosphatase | A measurement of the alkaline phosphatase in a biological specimen. | Alkaline Phosphatase Measurement | ||
ALT | C64433 | Alanine Aminotransferase;SGPT | A measurement of the alanine aminotransferase in a biological specimen. | Alanine Aminotransferase Measurement | ||
AMYLASE | C64434 | Amylase | A measurement of the total enzyme amylase in a biological specimen. | Amylase Measurement | ||
AST | C64467 | Aspartate Aminotransferase;SGOT | A measurement of the aspartate aminotransferase in a biological specimen. | Aspartate Aminotransferase Measurement | ||
BACT | C64469 | Bacteria | A measurement of the bacteria in a biological specimen. | Bacterial Count | ||
BASO | C64470 | Basophils | A measurement of the basophils in a biological specimen. | Total Basophil Count | ||
BASOLE | C64471 | Basophils/Leukocytes | A relative measurement (ratio or percentage) of the basophils to leukocytes in a biological specimen. | Basophil To Leukocyte Ratio | ||
BILDIR | C64481 | Direct Bilirubin | A measurement of the conjugated or water-soluble bilirubin in a biological specimen. | Direct Bilirubin Measurement | ||
BILIND | C64483 | Indirect Bilirubin | A measurement of the unconjugated or non-water-soluble bilirubin in a biological specimen. | Indirect Bilirubin Measurement | ||
BLASTLE | C64487 | Blasts/Leukocytes | A relative measurement (ratio or percentage) of the blasts to leukocytes in a biological specimen. | Blast To Leukocyte Ratio | ||
CA | C64488 | Calcium | A measurement of the calcium in a biological specimen. | Calcium Measurement | ||
CK | C64489 | Creatine Kinase | A measurement of the total creatine kinase in a biological specimen. | Creatine Kinase Measurement | ||
CKBB | C64490 | Creatine Kinase BB | A measurement of the homozygous B-type creatine kinase in a biological specimen. | Creatine Kinase BB Measurement | ||
CKMB | C64491 | Creatine Kinase MB | A measurement of the heterozygous MB-type creatine kinase in a biological specimen. | Creatine Kinase MB Measurement | ||
CKMM | C64494 | Creatine Kinase MM | A measurement of the homozygous M-type creatine kinase in a biological specimen. | Creatine Kinase MM Measurement | ||
CL | C64495 | Chloride | A measurement of the chloride in a biological specimen. | Chloride Measurement | ||
CO2 | C64545 | Carbon Dioxide | A measurement of the carbon dioxide gas in a biological specimen. | Carbon Dioxide Measurement | ||
COLOR | C64546 | Color | A measurement of the color of a biological specimen. | Color Assessment | ||
CREAT | C64547 | Creatinine | A measurement of the creatinine in a biological specimen. | Creatinine Measurement | ||
CRP | C64548 | C Reactive Protein | A measurement of the C reactive protein in a biological specimen. | C-Reactive Protein Measurement | ||
ELLIPCY | C64549 | Elliptocytes;Ovalocytes | A measurement of the elliptically shaped erythrocytes in a biological specimen. | Elliptocyte Count | ||
EOS | C64550 | Eosinophils | A measurement of the eosinophils in a biological specimen. | Eosinophil Count | ||
EOSLE | C64604 | Eosinophils/Leukocytes | A relative measurement (ratio or percentage) of the eosinophils to leukocytes in a biological specimen. | Eosinophil To Leukocyte Ratio | ||
EPIC | C64605 | Epithelial Cells | A measurement of the epithelial cells in a biological specimen. | Epithelial Cell Count | ||
FIBRINO | C64606 | Fibrinogen | A measurement of the fibrinogen in a biological specimen. | Fibrinogen Measurement | ||
HCT | C64796 | Hematocrit | The percentage of a whole blood specimen that is composed of red blood cells (erythrocytes). | Hematocrit | ||
MCH | C64797 | Ery. Mean Corpuscular Hemoglobin | A quantitative measurement of the mean amount of hemoglobin per erythrocyte in a biological specimen. | Erythrocyte Mean Corpuscular Hemoglobin | ||
MCHC | C64798 | Ery. Mean Corpuscular HGB Concentration | A quantitative measurement of the mean amount of hemoglobin per erythrocytes in a specified volume of a biological specimen. | Erythrocyte Mean Corpuscular Hemoglobin Concentration | ||
MCV | C64799 | Ery. Mean Corpuscular Volume | A quantitative measurement of the mean volume of erythrocytes in a biological specimen. | Erythrocyte Mean Corpuscular Volume | ||
RDW | C64800 | Erythrocytes Distribution Width | A value derived from mean corpuscular volume and the standard deviation of the red blood cell volume in a whole blood specimen. | Erythrocyte Distribution Width Measurement | ||
TEARDCY | C64801 | Dacryocytes;Tear Shaped Erythrocytes;Teardrop Cells | A measurement of dacryocytes in a biological specimen. | Dacryocyte Analysis | ||
HPOCROM | C64802 | Hypochromia | An observation which indicates that the hemoglobin concentration in a red blood cell specimen has fallen below a specified level. | Hypochromia | ||
POLYCHR | C64803 | Polychromasia | A measurement of the blue-staining characteristic of newly generated erythrocytes. | Polychromasia | ||
INR | C64805 | Prothrombin Intl. Normalized Ratio | A ratio that represents the prothrombin time for a plasma specimen, divided by the result for a control plasma specimen, further standardized for the International Sensitivity Index of the tissue factor (thromboplastin) used in the test. | International Normalized Ratio of Prothrombin Time | ||
VLDL | C105589 | VLDL Cholesterol | A measurement of the very low density lipoprotein cholesterol in a biological specimen. | Very Low Density Lipoprotein Cholesterol Measurement | ||
LIPASE | C64807 | Triacylglycerol Lipase | A measurement of the pancreatic lipase in a biological specimen. | Triacylglycerol Lipase Measurement | ||
SODIUM | C64809 | Sodium | A measurement of the sodium in a biological specimen. | Sodium Measurement | ||
NITRITE | C64810 | Nitrite | A measurement of the nitrite in a urine specimen. | Nitrite Measurement | ||
TRIG | C64812 | Triglycerides | A measurement of the triglycerides in a biological specimen. | Triglyceride Measurement | ||
TSH | C64813 | Thyrotropin | A measurement of the thyrotropin in a biological specimen. | Thyrotropin Measurement | ||
URATE | C64814 | Urate;Uric Acid | A measurement of the urate in a biological specimen. | Urate Measurement | ||
UREA | C64815 | Urea | A measurement of the urea in a biological specimen. | Urea Measurement | ||
UROBIL | C64816 | Urobilinogen | A measurement of the urobilinogen in a biological specimen. | Urobilinogen Measurement | ||
VITB12 | C64817 | Vitamin B12 | A measurement of the Vitamin B12 in a serum specimen. | Vitamin B12 Measurement | ||
LYMAT | C64818 | Lymphocytes Atypical | A measurement of the atypical lymphocytes in a biological specimen. | Atypical Lymphocyte Count | ||
LYMATLE | C64819 | Lymphocytes Atypical/Leukocytes | A relative measurement (ratio or percentage) of the atypical lymphocytes to leukocytes in a biological specimen. | Atypical Lymphocyte To Leukocyte Ratio | ||
LYMLE | C64820 | Lymphocytes/Leukocytes | A relative measurement (ratio or percentage) of the lymphocytes to leukocytes in a biological specimen. | Lymphocyte To Leukocyte Ratio | ||
MACROCY | C64821 | Macrocytes | A measurement of the macrocytes in a biological specimen. | Macrocyte Count | ||
MICROCY | C64822 | Microcytes | A measurement of the microcytes in a biological specimen. | Microcyte Count | ||
MONO | C64823 | Monocytes | A measurement of the monocytes in a biological specimen. | Monocyte Count | ||
MONOLE | C64824 | Monocytes/Leukocytes | A relative measurement (ratio or percentage) of the monocytes to leukocytes in a biological specimen. | Monocyte To Leukocyte Ratio | ||
MYBLALE | C64825 | Myeloblasts/Leukocytes | A relative measure (ratio or percentage) of the myeloblasts to leukocytes in a biological specimen. | Myeloblast To Leukocyte Ratio | ||
MYCYLE | C64826 | Myelocytes/Leukocytes | A relative measurement (ratio or percentage) of the myelocytes to leukocytes in a biological specimen. | Myelocyte To Leukocyte Ratio | ||
NEUTLE | C64827 | Neutrophils/Leukocytes | A relative measurement (ratio or percentage) of the neutrophils to leukocytes in a biological specimen. | Neutrophil To Leukocyte Ratio | ||
RETIRBC | C64828 | Reticulocytes/Erythrocytes | A relative measurement (ratio or percentage) of reticulocytes to erythrocytes in a biological specimen. | Reticulocyte To Erythrocyte Ratio | ||
PRLYMLE | C64829 | Prolymphocytes/Leukocytes | A relative measurement (ratio or percentage) of prolymphocytes to leukocytes in a biological specimen. | Prolymphocyte To Leukocyte Ratio | ||
NEUTB | C64830 | Neutrophils Band Form | A measurement of the banded neutrophils in a biological specimen. | Neutrophil Band Form Count | ||
NEUTBLE | C64831 | Neutrophils Band Form/Leukocytes | A relative measurement (ratio or percentage) of the banded neutrophils to leukocytes in a biological specimen. | Neutrophil Band Form To Leukocyte Ratio | ||
SPGRAV | C64832 | Specific Gravity | A ratio of the density of a fluid to the density of water. | Specific Gravity | ||
MG | C64840 | Magnesium | A measurement of the magnesium in a biological specimen. | Magnesium Measurement | ||
GGT | C64847 | Gamma Glutamyl Transferase | A measurement of the gamma glutamyl transferase in a biological specimen. | Gamma Glutamyl Transpeptidase Measurement | ||
HGB | C64848 | Hemoglobin | A measurement of the hemoglobin in a biological specimen. | Hemoglobin Measurement | ||
HBA1C | C64849 | Hemoglobin A1C | A measurement of the glycosylated hemoglobin in a biological specimen. | Glycosylated Hemoglobin Measurement | ||
HBSAG | C64850 | HBsAg;Hepatitis B Virus Surface Antigen | A measurement of the surface antigen reaction of a biological specimen to the Hepatitis B virus. | Hepatitis B Virus Surface Antigen Measurement | ||
HCG | C64851 | Choriogonadotropin Beta;Pregnancy Test | A measurement of the Choriogonadotropin Beta in a biological specimen. | Choriogonadotropin Beta Measurement | ||
K | C64853 | Potassium | A measurement of the potassium in a biological specimen. | Potassium Measurement | ||
KETONES | C64854 | Ketones | A measurement of the ketones in a biological specimen. | Ketone Measurement | ||
LDH | C64855 | Lactate Dehydrogenase | A measurement of the lactate dehydrogenase in a biological specimen. | Lactate Dehydrogenase Measurement | ||
LEUKASE | C64856 | Leukocyte Esterase | A measurement of the enzyme which indicates the presence of white blood cells in a biological specimen. | Leukocyte Esterase Measurement | ||
PHOS | C64857 | Phosphate;Phosphorus;Inorganic Phosphate | A measurement of the phosphate in a biological specimen. | Phosphate Measurement | ||
PROT | C64858 | Protein | A measurement of a group of complex organic macromolecules composed of one or more alpha-L-amino acid chains in a biological specimen. | Total Protein Measurement | ||
PSA | C17634 | Prostate Specific Antigen | A measurement of the prostate specific antigen in a biological specimen. | Prostate Specific Antigen Measurement | ||
CREATCLR | C25747 | Creatinine Clearance | A measurement of the volume of serum or plasma that would be cleared of creatinine by excretion of urine for a specified unit of time (e.g. one minute). | Creatinine Clearance | ||
HAIRYCE | C74604 | Hairy Cells | A measurement of the hairy cells (b-cell lymphocytes with hairy projections from the cytoplasm) in a biological specimen. | Hairy Cell Count | ||
BLAST | C74605 | Blasts | A measurement of the blast cells in a biological specimen. | Blast Count | ||
CD19 | C103808 | CD19 | A count of the CD19 expressing cells per unit in a biological specimen. | CD19 Expressing Cell Count | ||
CD3 | C103809 | CD3 | A count of the CD3 expressing cells per unit in a biological specimen. | CD3 Expressing Cell Count | ||
CD4 | C103810 | CD4 | A count of the CD4 expressing cells per unit in a biological specimen. | CD4 Expressing Cell Count | ||
CD8 | C103811 | CD8 | A count of the CD8 expressing cells per unit in a biological specimen. | CD8 Expressing Cell Count | ||
DOHLE | C74610 | Dohle Bodies | A measurement of the Dohle bodies (blue-gray, basophilic, leukocyte inclusions located in the peripheral cytoplasm of neutrophils) in a biological specimen. | Dohle Body Measurement | ||
ESR | C74611 | Erythrocyte Sedimentation Rate;Biernacki Reaction | The distance (e.g. millimeters) that red blood cells settle in unclotted blood over a specified unit of time (e.g. one hour). | Erythrocyte Sedimentation Rate Measurement | ||
HYPSEGCE | C74612 | Hypersegmented Cells | A measurement of the hypersegmented (more than five lobes) neutrophils in a biological specimen. | Hypersegmented Neutrophil Measurement | ||
LYMMCE | C74613 | Lymphoma Cells | A measurement of the malignant lymphocytes in a biological specimen. | Lymphoma Cell Count | ||
MAYHEG | C74614 | May-Hegglin Anomaly | A measurement of the May-Hegglin anomaly in a blood sample. This anomaly is characterized by large, misshapen platelets and the presence of Dohle bodies in leukocytes. | May-Hegglin Anomaly Measurement | ||
METAMY | C74615 | Metamyelocytes | A measurement of the metamyelocytes (small, myelocytic neutrophils with an indented nucleus) in a biological specimen. | Metamyelocyte Count | ||
PAPPEN | C74616 | Pappenheimer Bodies | A measurement of the cells containing Pappenheimer Bodies (violet or blue staining ferritin granules usually found along the periphery of the red blood cells) in a biological specimen. | Pappenheimer Body Count | ||
PELGERH | C74617 | Pelger Huet Anomaly | A measurement of the Pelger Huet Anomaly (nuclei of neutrophils and eosinophils appear rod-like, spherical or dumbbell shaped) in a biological specimen. | Pelger Huet Anomaly Measurement | ||
LYMPL | C74618 | Plasmacytoid Lymphocytes;Plymphocytes | A measurement of the plasmacytoid lymphocytes (lymphocytes with peripherally clumped chromatin and often deep blue cytoplasm, and that appear similar to plasma cells) in a biological specimen. | Plasmacytoid Lymphocyte Count | ||
PLSPCE | C74619 | Precursor Plasma Cells;Plasmablast | A measurement of the precursor (blast stage) plasma cells (antibody secreting cells derived from B cells via antigen stimulation) in a biological specimen. | Precursor Plasma Cell Count | ||
PROLYM | C74620 | Prolymphocytes | A measurement of the prolymphocytes in a biological specimen. | Prolymphocyte Count | ||
PROMONO | C74621 | Promonocytes | A measurement of the promonocytes in a biological specimen. | Promonocyte Count | ||
PROMY | C74622 | Promyelocytes | A measurement of the promyelocytes (immature myelocytes) in a biological specimen. | Promyelocyte Count | ||
ROULEAUX | C74624 | Rouleaux Formation | A measurement of the number of stacking red blood cells within a biological specimen. | Rouleaux Formation Count | ||
SEZCE | C74625 | Sezary Cells | A measurement of the Sezary cells (atypical lymphocytes with cerebriform nuclei) in a biological specimen. | Sezary Cell Count | ||
SCKLCE | C74626 | Sickle Cells | A measurement of the sickle cells (sickle shaped red blood cells) in a biological specimen. | Sickle Cell Count | ||
SMDGCE | C74627 | Smudge Cells;Basket Cells | A measurement of the smudge cells (the nuclear remnant of a ruptured white blood cell) in a biological specimen. | Smudge Cell Count | ||
NEUTVAC | C74628 | Vacuolated Neutrophils | A measurement of the neutrophils containing small vacuoles in a biological specimen. | Vacuolated Neutrophil Count | ||
BLASTLM | C74630 | Leukemic Blasts | A measurement of the leukemic blasts (lymphoblasts that remain in an immature state even when outside the bone marrow) in a biological specimen. | Leukemic Blast Count | ||
MONOBL | C74631 | Monoblasts | A measurement of the monoblast cells in a biological specimen. | Monoblast Count | ||
MYBLA | C74632 | Myeloblasts | A measurement of the myeloblast cells in a biological specimen. | Myeloblast Count | ||
ACANTRBC | C74633 | Acanthocytes/Erythrocytes | A relative measurement (ratio or percentage) of acanthocytes to all erythrocytes in a biological specimen. | Acanthocyte to Erythrocyte Ratio Measurement | ||
BTECERBC | C74634 | Bite Cells/Erythrocytes | A relative measurement (ratio or percentage) of bite cells (erythrocytes with the appearance of a bite having been removed, due to oxidative hemolysis) to all erythrocytes in a biological specimen . | Bite Cell to Erythrocyte Ratio Measurement | ||
CD19LY | C103812 | CD19/Lymphocytes | A relative measurement (ratio or percentage) of CD19 expressing cells to all lymphocytes in a biological specimen. | CD19 Cell to Lymphocyte Ratio Measurement | ||
CD3LY | C103813 | CD3/Lymphocytes | A relative measurement (ratio or percentage) of CD3 expressing cells to all lymphocytes in a biological specimen. | CD3 Cell to Lymphocyte Ratio Measurement | ||
CD4CD8 | C103814 | CD4/CD8 | A relative measurement (ratio or percentage) of CD4 expressing cells to the CD8 expressing cells in a biological specimen. | CD4 Cell to CD8 Cell Ratio Measurement | ||
CD4LY | C103815 | CD4/Lymphocytes | A relative measurement (ratio or percentage) of CD4 expressing cells to all lymphocytes in a biological specimen. | CD4 Cell to Lymphocyte Ratio Measurement | ||
CD8LY | C103816 | CD8/Lymphocytes | A relative measurement (ratio or percentage) of CD8 expressing cells to all lymphocytes in a biological specimen. | CD8 Cell to Lymphocyte Ratio Measurement | ||
HRYCELY | C74640 | Hairy Cells/Lymphocytes | A relative measurement (ratio or percentage) of the hairy cells (b-cell lymphocytes with hairy projections from the cytoplasm) to all lymphocytes in a biological specimen . | Hairy Cell to Lymphocyte Ratio Measurement | ||
BLSTLMLY | C74641 | Leukemic Blasts/Lymphocytes | A relative measurement (ratio or percentage) of the leukemic blasts (immature lymphoblasts) to mature lymphocytes in a biological specimen. | Leukemic Blast to Lymphocyte Ratio Measurement | ||
MLIGCEBC | C74643 | Malignant Cells, NOS/Blood Cells | A relative measurement (ratio or percentage) of the malignant cells of all types to all blood cells in a biological specimen. | Malignant Cell to Blood Cell Ratio Measurement | ||
METAMYLE | C74645 | Metamyelocytes/Leukocytes | A relative measurement (ratio or percentage) of the metamyelocytes (small, myelocytic neutrophils with an indented nucleus) to all leukocytes in a biological specimen. | Metamyelocyte to Leukocyte Ratio Measurement | ||
MONOBLLE | C74646 | Monoblasts/Leukocytes | A relative measurement (ratio or percentage) of the monoblasts to leukocytes in a biological specimen. | Monoblast to Leukocyte Ratio Measurement | ||
RBCNURBC | C74647 | Nucleated Erythrocytes/Erythrocytes;Nucleated Red Blood Cells/Erythrocytes | A relative measurement (ratio or percentage) of the nucleated erythrocytes (large, immature nucleated erythrocytes) to all erythrocytes in a biological specimen. | Nucleated Red Blood Cell to Erythrocyte Ratio Measurement | ||
LYMPLLY | C74648 | Plasmacytoid Lymphocytes/Lymphocytes | A relative measurement (ratio or percentage) of the plasmacytoid lymphocytes (lymphocytes with peripherally clumped chromatin and often deep blue cytoplasm, and that appear similar to plasma cells) to all lymphocytes in a biological specimen. | Plasmacytoid Lymphocyte to Lymphocyte Ratio Measurement | ||
POIKRBC | C74649 | Poikilocytes/Erythrocytes | A relative measurement (ratio or percentage) of the poikilocytes, or irregularly shaped erythrocytes, to all erythrocytes in a biological specimen. | Poikilocyte to Erythrocyte Ratio Measurement | ||
PLSPCELY | C74650 | Precursor Plasma Cells/Lymphocytes | A relative measurement (ratio or percentage) of the precursor (blast stage) plasma cells (antibody secreting cells derived from B cells via antigen stimulation) to all lymphocytes in a biological specimen. | Precursor Plasma Cell to Lymphocyte Ratio Measurement | ||
PROLYMLY | C74651 | Prolymphocytes/Lymphocytes | A relative measurement (ratio or percentage) of the prolymphocytes to all lymphocytes in a biological specimen. | Prolymphocyte to Lymphocyte Ratio Measurement | ||
PROMONLE | C74652 | Promonocytes/Leukocytes | A relative measurement (ratio or percentage) of the promonocytes to all leukocytes in a biological specimen. | Promonocyte to Lymphocyte Ratio Measurement | ||
PROMYLE | C74653 | Promyelocytes/Leukocytes | A relative measurement (ratio or percentage) of the promyelocytes (immature myelocytes) to all leukocytes in a biological specimen. | Promyelocyte to Lymphocyte Ratio Measurement | ||
LYMRCTLY | C74654 | Reactive Lymphocytes/Lymphocytes | A relative measurement (ratio or percentage) of the reactive lymphocytes (lymphocytes which have become large due to an antigen reaction) to all lymphocytes in a biological specimen. | Reactive Lymphocyte to Lymphocyte Ratio Measurement | ||
SEZCELY | C74655 | Sezary Cells/Lymphocytes | A relative measurement (ratio or percentage of the Sezary cells (atypical lymphocytes with cerebriform nuclei) to all lymphocytes in a biological specimen. | Sezary Cell to Lymphocyte Ratio Measurement | ||
SCKCERBC | C74656 | Sickle Cells/Erythrocytes | A relative measurement (ratio or percentage) of the sickle cells (sickle shaped red blood cells) to all erythrocytes in a biological specimen. | Sickle Cell to Erythrocyte Ratio Measurement | ||
AUERRODS | C74657 | Auer Rods | A measurement of the Auer rods (elongated needle structures that are found in the cytoplasm of leukemic blasts and are formed by clumps of azurophilic granular material) in a biological specimen. | Auer Rod Measurement | ||
HELMETCE | C74658 | Helmet Cells | A measurement of the Helmet cells (specialized Keratocytes with two projections on either end that are tapered and hornlike) in a biological specimen. | Helmet Cell Count | ||
LGUNSCE | C74659 | Large Unstained Cells | A measurement of the large, peroxidase-negative cells which cannot be further characterized (i.e. as large lymphocytes, virocytes, or stem cells) present in a biological specimen. | Large Unstained Cell Count | ||
MLIGCE | C74660 | Malignant Cells, NOS | A measurement of the malignant cells of all types in a biological specimen. | Malignant Cell Count | ||
PLSMCE | C74661 | Mature Plasma Cells;Plasmacytes | A measurement of the mature plasma cells (plasmacytes) in a biological specimen. | Mature Plasma Cell Count | ||
MYCY | C74662 | Myelocytes | A measurement of the myelocytes in a biological specimen. | Myelocyte Count | ||
SPERM | C74663 | Spermatozoa | A measurement of the spermatozoa cells present in a biological specimen. | Spermatozoa Cell Count | ||
YEAST | C74664 | Yeast Cells | A measurement of the yeast cells present in a biological specimen. | Yeast Cell Measurement | ||
CYAMORPH | C74665 | Amorphous Crystals | A measurement of the amorphous (Note: phosphate or urate, depending on pH) crystals present in a biological specimen. | Amorphous Crystal Measurement | ||
AMORPHSD | C74666 | Amorphous Sediment;Amorphous Debris | A measurement of the amorphous sediment present in a biological specimen. | Amorphous Sediment Measurement | ||
BICARB | C74667 | Bicarbonate;HCO3 | A measurement of the bicarbonate in a biological specimen. | Bicarbonate Measurement | ||
CYBILI | C74668 | Bilirubin Crystals | A measurement of the bilirubin crystals present in a biological specimen. | Bilirubin Crystal Measurement | ||
CYCACAR | C74669 | Calcium Carbonate Crystals | A measurement of the calcium carbonate crystals present in a biological specimen. | Calcium Carbonate Crystal Measurement | ||
CYCAOXA | C74670 | Calcium Oxalate Crystals | A measurement of the calcium oxalate crystals present in a biological specimen. | Calcium Oxalate Crystal Measurement | ||
CYCAPHOS | C74671 | Calcium Phosphate Crystals | A measurement of the calcium phosphate crystals present in a biological specimen. | Calcium Phosphate Crystal Measurement | ||
CYCHOL | C74672 | Cholesterol Crystals | A measurement of the cholesterol crystals present in a biological specimen. | Cholesterol Crystal Measurement | ||
CRYSTALS | C74673 | Crystals | A statement that indicates crystals were looked for in a biological specimen. | Crystal Present Or Absent | ||
CYCYSTIN | C74674 | Cystine Crystals | A measurement of the cystine crystals present in a biological specimen. | Cystine Crystal Measurement | ||
VITB9 | C74676 | Folic Acid;Vitamin B9 | A measurement of the folic acid in a biological specimen. | Folic Acid Measurement | ||
CARNITF | C74677 | Carnitine, Free | A measurement of the free carnitine in a biological specimen. | Free Carnitine Measurement | ||
FRUCT | C74678 | Fructosamine;Glycated Serum Protein | A measurement of the fructosamine in a biological specimen. | Fructosamine Measurement | ||
IRON | C74679 | Iron;FE | A measurement of the iron in a biological specimen. | Iron Measurement | ||
CYLEUC | C74680 | Leucine Crystals | A measurement of the leucine crystals present in a biological specimen. | Leucine Crystal Measurement | ||
CYMSU | C74681 | Monosodium Urate Crystals | A measurement of the monosodium urate crystals present in a biological specimen. | Monosodium Urate Crystal Measurement | ||
CARNIT | C74682 | Carnitine | A measurement of the total carnitine in a biological specimen. | Total Carnitine Measurement | ||
CYTYRO | C74683 | Tyrosine Crystals | A measurement of the triple phosphate crystals present in a biological specimen. | Tyrosine Crystal Measurement | ||
CYURIAC | C74684 | Uric Acid Crystals | A measurement of the uric acid crystals present in a biological specimen. | Uric Acid Crystal Measurement | ||
ANIONG | C74685 | Anion Gap | A computed estimate of the unmeasured anions (those other than the chloride and bicarbonate anions) in a biological specimen. | Anion Gap Measurement | ||
OCCBLD | C74686 | Occult Blood | A measurement of the blood in body products such as a stool sample, not detectable on gross examination. | Occult Blood Measurement | ||
AMPHET | C74687 | Amphetamine | A measurement of any amphetamine class drug present in a biological specimen. | Amphetamine Drug Class Measurement | ||
BARB | C74688 | Barbiturates | A measurement of any barbiturate class drug present in a biological specimen. | Barbiturate Drug Class Measurement | ||
CANNAB | C74689 | Cannabinoids | A measurement of any cannabinoid class drug present in a biological specimen. | Cannabinoid Drug Class Measurement | ||
COCAINE | C74690 | Cocaine | A measurement of the cocaine present in a biological specimen. | Cocaine Measurement | ||
EPIROCE | C74698 | Round Epithelial Cells | A measurement of the round epithelial cells present in a biological specimen. | Round Epithelial Cell Count | ||
ACANT | C74699 | Acanthocytes | A measurement of the acanthocytes in a biological specimen. | Acanthocyte Count | ||
BITECE | C74700 | Bite Cells | A measurement of the bite cells (erythrocytes with the appearance of a bite having been removed, due to oxidative hemolysis) in a biological specimen . | Bite Cell Count | ||
BURRCE | C74701 | Burr Cells;Keratocytes | A measurement of the Burr cells (erythrocytes characterized by the presence of small, blunt projections evenly distributed across the cell surface) in a biological specimen. | Burr Cell Count | ||
CABOT | C74702 | Cabot Rings | A measurement of the Cabot rings (red-purple staining, threadlike, ring or figure 8 shaped filaments in an erythrocyte) in a biological specimen. | Cabot Ring Count | ||
CRENCE | C74703 | Crenated Cells;Echinocytes | A measurement of the Burr cells (erythrocytes characterized by the presence of multiple small, sharp projections evenly distributed across the cell surface) in a biological specimen. | Crenated Cell Measurement | ||
HOWJOL | C74704 | Howell-Jolly Bodies | A measurement of the Howell-Jolly bodies (spherical, blue-black condensed DNA inclusions within the body of a red blood cell that appear under Wright-stain) in a biological specimen. | Howell-Jolly Body Measurement | ||
RBCNUC | C74705 | Nucleated Erythrocytes;Nucleated Red Blood Cells | A measurement of the nucleated erythrocytes (large, immature nucleated erythrocytes) in a biological specimen. | Nucleated Red Blood Cell Count | ||
SCHISTO | C74706 | Schistocytes | A measurement of the schistocytes (fragmented red blood cells) in a biological specimen. | Schistocyte Count | ||
SPHERO | C74707 | Spherocytes | A measurement of the spherocytes (small, sphere-shaped red blood cells) in a biological specimen. | Spherocyte Count | ||
STOMCY | C74708 | Stomatocytes | A measurement of the stomatocytes (red blood cells with an oval or rectangular area of central pallor, producing the appearance of a cell mouth) in a biological specimen. | Stomatocyte Count | ||
HEINZ | C74709 | Heinz Bodies;Heinz-Erhlich Bodies | A measurement of the Heinz bodies (small round inclusions within the body of a red blood cell) in a biological specimen. | Heinz-Ehrlich Body Measurement | ||
HAAB | C92534 | Hepatitis A Virus Antibody | A measurement of the antibody reaction of a biological specimen to the Hepatitis A virus. | Hepatitis A Antibody Measurement | ||
HBSAB | C74711 | Anti-HBs;HBsAb;Hepatitis B Virus Surface Antibody | A measurement of the surface antibody reaction of a biological specimen to the Hepatitis B virus. | Hepatitis B Surface Antibody Measurement | ||
HCAB | C92535 | Hepatitis C Virus Antibody | A measurement of the antibody reaction of a biological specimen to the Hepatitis C virus. | Hepatitis C Antibody Measurement | ||
HIV1AB | C74713 | HIV-1 Antibody | A measurement of the antibody reaction of a biological specimen to the HIV-1 virus. | HIV-1 Antibody Measurement | ||
HIV12AB | C74714 | HIV-1/2 Antibody | A measurement of the antibody reaction of a biological specimen to the either the HIV-1 or HIV-2 virus. | HIV-1 HIV-2 Antibody Measurement | ||
HIV2AB | C74715 | HIV-2 Antibody | A measurement of the antibody reaction of a biological specimen to the HIV-2 virus. | HIV-2 Antibody Measurement | ||
RPR | C74716 | Rapid Plasma Reagin | A measurement of the antibodies produced by cellular damage caused by Treponema pallidum (syphilis) in a biological specimen. | Rapid Plasma Reagin Measurement | ||
RF | C74717 | Rheumatoid Factor | A measurement of the rheumatoid factor antibody in a biological specimen. | Rheumatoid Factor Measurement | ||
IBCT | C74718 | Total Iron Binding Capacity | A measurement of the amount of iron needed to fully saturate the transferrin in a biological specimen. | Total Iron Binding Capacity | ||
IBCU | C74719 | Unsaturated Iron Binding Capacity | A measurement of the binding capacity of unsaturated iron in a biological specimen. | Unsaturated Iron Binding Capacity Measurement | ||
MUCTHR | C74721 | Mucous Threads | A measurement of the mucous threads present in a biological specimen. | Mucous Thread Measurement | ||
TURB | C74723 | Turbidity | A measurement of the opacity of a biological specimen. | Turbidity Measurement | ||
HAVVLD | C92541 | HAV Viral Load | A measurement of the hepatitis A viral load in a biological specimen. | Hepatitis A Viral Load Measurement | ||
HBVVLD | C92542 | HBV Viral Load | A measurement of the hepatitis B viral load in a biological specimen. | Hepatitis B Viral Load Measurement | ||
HCVVLD | C92543 | HCV Viral Load | A measurement of the hepatitis C viral load in a biological specimen. | Hepatitis C Viral Load Measurement | ||
HIVVLD | C92544 | HIV Viral Load | A measurement of the HIV viral load in a biological specimen. | HIV Viral Load Measurement | ||
PLATGNT | C74728 | Giant Platelets | A measurement of the giant (larger than 7um in diameter) platelets in a biological specimen. | Giant Platelet Count | ||
PLATLRG | C74729 | Large Platelets | A measurement of the large (between 4 um and 7um in diameter) platelets in a biological specimen. | Large Platelet Count | ||
MPV | C74730 | Mean Platelet Volume | A measurement of the average size of the platelets present in a blood sample. | Mean Platelet Volume Measurement | ||
ALDOLASE | C74731 | Aldolase | A measurement of the aldolase enzyme in a biological specimen. | Aldolase Measurement | ||
AFP | C74732 | Alpha Fetoprotein | A measurement of the alpha fetoprotein in a biological specimen. | Alpha-fetoprotein Measurement | ||
APOA1 | C74733 | Apolipoprotein A1 | A measurement of the apolipoprotein A1 in the high density lipoproteins of a biological specimen. | Apolipoprotein A1 Measurement | ||
APOB | C74734 | Apolipoprotein B | A measurement of the apolipoprotein B in the low density lipoproteins of a biological specimen. | Apolipoprotein B Measurement | ||
BNP | C74735 | Brain Natriuretic Peptide;B-Type Natriuretic Peptide | A measurement of the brain (B-type) natriuretic peptide in a biological specimen. | Brain Natriuretic Peptide Measurement | ||
CPEPTIDE | C74736 | C-peptide | A measurement of the C (connecting) peptide of insulin in a biological specimen. | C-peptide Measurement | ||
FERRITIN | C74737 | Ferritin | A measurement of the ferritin in a biological specimen. | Ferritin Measurement | ||
GLOBUL | C74738 | Globulin | A measurement of the globulin protein in a biological specimen. | Globulin Protein Measurement | ||
GLUTAM | C74739 | Glutamate;Glutamic Acid | A measurement of the glutamate in a biological specimen. | Glutamate Measurement | ||
HAPTOG | C74740 | Haptoglobin | A measurement of the haptoglobin protein in a biological specimen. | Haptoglobin Protein Measurement | ||
HOMOCY | C74741 | Homocysteine | A measurement of the homocysteine amino acid in a biological specimen. | Homocysteine Acid Measurement | ||
NTELOP | C74743 | N-telopeptide | A measurement of the N-telopeptide in a biological specimen. | N-telopeptide Measurement | ||
OSTEOC | C74744 | Osteocalcin | A measurement of the osteocalcin in a biological specimen. | Osteocalcin Measurement | ||
SHBG | C74745 | Sex Hormone Binding Globulin;Sex Hormone Binding Protein | A measurement of the sex hormone binding (globulin) protein in a biological specimen. | Sex Hormone Binding Protein Measurement | ||
TBG | C74746 | Thyroxine Binding Globulin | A measurement of the thyroxine binding globulin protein in a biological specimen. | Thyroxine Binding Globulin Protein Measurement | ||
T3 | C74747 | Triiodothyronine;Total T3 | A measurement of the total (free and bound) triiodothyronine in a biological specimen. | Triiodothyronine Measurement | ||
T3UP | C74748 | Triiodothyronine Uptake | A measurement of the binding of triiodothyonine to thyroxine binding globulin protein in a biological specimen. | Triiodothyronine Uptake Measurement | ||
TROPONI | C74749 | Troponin I | A measurement of the actin binding troponin in a biological specimen. | Troponin I Measurement | ||
TROPONT | C74750 | Troponin T | A measurement of the tropomyosin binding troponin in a biological specimen. | Troponin T Measurement | ||
TNF | C74751 | Tumor Necrosis Factor;Tumor Necrosis Factor alpha | A measurement of the total tumor necrosis factor (cachexin) cytokine in a biological specimen. | Tumor Necrosis Factor Measurement | ||
BUNCREAT | C74753 | BUN/Creatinine | A relative measurement (ratio or percentage) (ratio) of the blood urea nitrogen (BUN) to the creatinine in a biological specimen. | Blood Urea Nitrogen To Creatinine Ratio Measurement | ||
CYHIPPAC | C74754 | Hippuric Acid Crystals | A measurement of the hippuric acid crystals present in a biological specimen. | Hippuric Acid Crystal Measurement | ||
CYSULFA | C74755 | Sulfa Crystals | A measurement of the sulfa crystals present in a biological specimen. | Sulfa Crystal Measurement | ||
CYTRPHOS | C74756 | Triple Phosphate Crystals | A measurement of the triple phosphate crystals present in a biological specimen. | Triple Phosphate Crystal Measurement | ||
CYUNCLA | C74757 | Unclassified Crystals | A measurement of the unclassifiable crystals present in a biological specimen. | Unclassified Crystal Measurement | ||
CYAMMBIU | C105590 | Ammonium Biurate Crystals;Ammonium Urate Crystals;Acid Ammonium Urate Crystals | A measurement of the ammonium biurate crystals present in a biological specimen. | Ammonium Biurate Crystals Measurement | ||
CYAMMOX | C74759 | Ammonium Oxalate Crystals | A measurement of the ammonium oxalate crystals present in a urine specimen. | Urine Ammonium Oxalate Crystal Measurement | ||
ALBCREAT | C74761 | Albumin/Creatinine;Microalbumin/Creatinine Ratio | A relative measurement (ratio or percentage) of the albumin to the creatinine in a biological specimen. | Albumin To Creatinine Protein Ratio Measurement | ||
CSBACT | C74762 | Bacterial Casts | A measurement of the bacterial casts present in a biological specimen. | Bacterial Cast Measurement | ||
CASTS | C74763 | Casts | A statement that indicates casts were looked for in a biological specimen. | Cast Present Or Absent | ||
CSCELL | C74764 | Cellular Casts | A measurement of the cellular (white blood cell, red blood cell, epithelial and bacterial) casts present in a biological specimen. | Cellular Cast Measurement | ||
CSGRANC | C74765 | Granular Coarse Casts | A measurement of the coarse granular casts present in a biological specimen. | Coarse Granular Cast Measurement | ||
CSFAT | C74766 | Fatty Casts | A measurement of the fatty casts present in a biological specimen. | Fatty Cast Measurement | ||
CSGRAN | C74768 | Granular Casts | A measurement of the granular (coarse and fine) casts present in a biological specimen. | Granular Cast Measurement | ||
CSGRANF | C74769 | Granular Fine Casts | A measurement of the fine granular casts present in a biological specimen. | Granular Fine Cast Measurement | ||
CSHYAL | C74770 | Hyaline Casts | A measurement of the hyaline casts present in a biological specimen. | Hyaline Cast Measurement | ||
CSMIX | C74771 | Mixed Casts | A measurement of the mixed (the cast contains a mixture of cell types) casts present in a biological specimen. | Mixed Cast Count | ||
CSRBC | C74772 | RBC Casts | A measurement of the red blood cell casts present in a biological specimen. | Red Blood Cell Cast Measurement | ||
EPISQCE | C74773 | Squamous Epithelial Cells | A measurement of the squamous epithelial cells present in a biological specimen. | Squamous Epithelial Cell Count | ||
EPISQTCE | C74774 | Squamous Transitional Epithelial Cells;Epithelial Cells | A measurement of the squamous transitional epithelial cells present in a biological specimen. | Squamous Transitional Epithelial Cell Count | ||
EPITUCE | C74775 | Tubular Epithelial Cells;Renal Tubular Epithelial Cells | A measurement of the tubular epithelial cells present in a biological specimen. | Tubular Epithelial Cell Count | ||
CSUNCLA | C74776 | Unclassified Casts | A measurement of the unclassifiable casts present in a biological specimen. | Unclassified Cast Measurement | ||
CSWAX | C74777 | Waxy Casts | A measurement of the waxy casts present in a biological specimen. | Waxy Cell Cast Measurement | ||
CSWBC | C74778 | WBC Casts | A measurement of the white blood cell casts present in a biological specimen. | White Blood Cell Cast Measurement | ||
CSEPI | C74779 | Epithelial Casts | A measurement of the epithelial cell casts present in a biological specimen. | Epithelial-Cast Measurement | ||
ACTH | C74780 | Adrenocorticotropic Hormone | A measurement of the adrenocorticotropic hormone in a biological specimen. | Adrenocorticotropic Hormone Measurement | ||
CORTISOL | C74781 | Cortisol;Total Cortisol | A measurement of the cortisol in a biological specimen. | Cortisol Measurement | ||
ESTRDIOL | C74782 | Estradiol;Oestradiol | A measurement of the estradiol in a biological specimen. | Estradiol Measurement | ||
FSH | C74783 | Follicle Stimulating Hormone | A measurement of the follicle stimulating hormone (FSH) in a biological specimen. | Follicle Stimulating Hormone Measurement | ||
PTHFG | C74784 | Parathyroid Hormone, Fragmented | A measurement of the fragmented parathyroid hormone in a biological specimen. | Fragmented Parathyroid Hormone Measurement | ||
TESTOSFR | C74785 | Testosterone, Free | A measurement of the free testosterone in a biological specimen. | Free Testosterone Measurement | ||
T4FR | C74786 | Thyroxine, Free;Free T4 | A measurement of the free thyroxine in a biological specimen. | Free Thyroxine Measurement | ||
T3FR | C74787 | Triiodothyronine, Free;Free T3 | A measurement of the free triiodothyronine in a biological specimen. | Free Triiodothyronine Measurement | ||
INSULIN | C74788 | Insulin | A measurement of the insulin in a biological specimen. | Insulin Measurement | ||
PTHI | C74789 | Parathyroid Hormone, Intact | A measurement of the intact parathyroid hormone (consisting of amino acids 1-84 or 7-84) in a biological specimen. | Intact Parathyroid Hormone Measurement | ||
LH | C74790 | Luteinizing Hormone | A measurement of the luteinizing hormone in a biological specimen. | Luteinizing Hormone Measurement | ||
PROGEST | C74791 | Progesterone | A measurement of the progesterone hormone in a biological specimen. | Progesterone Measurement | ||
SOMATRO | C80360 | Somatotrophin;Growth Hormone | A measurement of the somatotrophin (growth) hormone in a biological specimen. | Somatotropin Measurement | ||
TESTOS | C74793 | Testosterone;Total Testosterone | A measurement of the total (free and bound) testosterone in a biological specimen. | Total Testosterone Measurement | ||
T4 | C74794 | Thyroxine;Total T4 | A measurement of the total (free and bound) thyroxine in a biological specimen. | Total Thyroxine Measurement | ||
OPIATE | C74796 | Opiate | A measurement of any opiate class drug present in a biological specimen. | Opiate Measurement | ||
LYMMCELY | C74910 | Lymphoma Cells/Lymphocytes | A relative measurement (ratio or percentage) of the malignant lymphocytes to all lymphocytes in a biological specimen. | Lymphoma Cell to Lymphocyte Ratio Measurement | ||
PLSMCELY | C74911 | Mature Plasma Cells/Lymphocytes | A relative measurement (ratio or percentage) of the mature plasma cells (plasmacytes) to all lymphocytes in a biological specimen. | Mature Plasma Cell to Lymphocyte Ratio Measurement | ||
CYACIDU | C74912 | Acid Urate Crystals | A measurement of the acid urate crystals present in a biological specimen. | Acid Urate Crystal Measurement | ||
ADSDNA | C74913 | Anti-Double Stranded DNA | A measurement of the anti-double stranded DNA antibody in a biological specimen. | Anti-Double Stranded DNA Measurement | ||
ANA | C74916 | Antinuclear Antibodies | A measurement of the antinuclear antibodies (antibodies that attack the body's own tissue) in a biological specimen. | Antinuclear Antibody Measurement | ||
NCTD5P | C79437 | 5 Prime Nucleotidase;5'-Ribonucleotide Phosphohydrolase | A measurement of the 5'-nucleotidase in a biological specimen. | 5 Prime Nucleotidase Measurement | ||
SIXMAM | C74876 | 6-Monoacetylmorphine | A measurement of the 6-monoacetylmorphine present in a biological specimen. | 6-Monoacetylmorphine Measurement | ||
ACH | C74838 | Acetylcholine | A measurement of the acetylcholine hormone in a biological specimen. | Acetylcholine Measurement | ||
ADPNCTN | C74839 | Adiponectin | A measurement of the adiponectin hormone in a biological specimen. | Adiponectin Measurement | ||
ALBGLOB | C74894 | Albumin/Globulin | The ratio of albumin to globulin in a biological specimen. | Albumin to Globulin Ratio Measurement | ||
ALDSTRN | C74841 | Aldosterone | A measurement of the aldosterone hormone in a biological specimen. | Aldosterone Measurement | ||
ALPCREAT | C79438 | Alkaline Phosphatase/Creatinine | A relative measurement (ratio or percentage) of the alkaline phosphatase to creatinine in a biological specimen. | Alkaline Phosphatase to Creatinine Ratio Measurement | ||
GSTAL | C79433 | Alpha Glutathione-S-Transferase | A measurement of the alpha form of glutathione S-transferase in a biological specimen. | Alpha Glutathione-S-Transferase Measurement | ||
AMMONIA | C74799 | Ammonia;NH3 | A measurement of the ammonia in a biological specimen. | Ammonia Measurement | ||
ANDSTNDL | C74842 | Androstenediol | A measurement of the androstenediol metabolite in a biological specimen. | Androstenediol Metabolite Measurement | ||
ANDSTNDN | C74843 | Androstenedione;4-Androstenedione | A measurement of the androstenedione hormone in a biological specimen. | Androstenedione Measurement | ||
ANGTNS1 | C74844 | Angiotensin I | A measurement of the angiotensin I hormone in a biological specimen. | Angiotensin I Measurement | ||
ANGTNS2 | C74845 | Angiotensin II | A measurement of the angiotensin II hormone in a biological specimen. | Angiotensin II Measurement | ||
ANGTNSGN | C74846 | Angiotensinogen;Angiotensin Precursor | A measurement of the angiotensinogen hormone in a biological specimen. | Angiotensinogen Measurement | ||
ANTIDPRS | C74691 | Antidepressants | A measurement of any antidepressant class drug present in a biological specimen. | Antidepressant Measurement | ||
ADH | C74847 | Antidiuretic Hormone;Vasopressin | A measurement of the antidiuretic hormone in a biological specimen. | Antidiuretic Hormone Measurement | ||
ANP | C74886 | Atrial Natriuretic Peptide;Atriopeptin | A measurement of the atrial natriuretic peptide in a biological specimen. | Atrial Natriuretic Peptide Measurement | ||
BNZDZPN | C74692 | Benzodiazepine | A measurement of any benzodiazepine class drug present in a biological specimen. | Benzodiazepine Measurement | ||
BILEAC | C74800 | Bile Acid;Bile Salts;Bile Acids;Bile Salt | A measurement of the total bile acids in a biological specimen. | Bile Acid Measurement | ||
CLCTONN | C74848 | Calcitonin | A measurement of the calcitonin hormone in a biological specimen. | Calcitonin Measurement | ||
CLCTRIOL | C74849 | Calcitriol | A measurement of the calcitriol hormone in a biological specimen. | Calcitriol Measurement | ||
CACREAT | C79439 | Calcium/Creatinine | A relative measurement (ratio or percentage) of the calcium to creatinine in a biological specimen. | Calcium to Creatinine Ratio Measurement | ||
CLCREAT | C79440 | Chloride/Creatinine | A relative measurement (ratio or percentage) of the chloride to creatinine in a biological specimen. | Chloride to Creatinine Ratio Measurement | ||
CCK | C74850 | Cholecystokinin;Pancreozymin | A measurement of the cholecystokinin hormone in a biological specimen. | Cholecystokinin Measurement | ||
CODEINE | C74877 | Codeine | A measurement of the codeine present in a biological specimen. | Codeine Measurement | ||
CRTRONE | C79434 | Corticosterone | A measurement of corticosterone in a biological specimen. | Corticosterone Measurement | ||
CRH | C74851 | Corticotropin Releasing Hormone;Corticotropin Releasing Factor | A measurement of the corticotropin releasing hormone in a biological specimen. | Corticotropin Releasing Hormone Measurement | ||
CKBBCK | C79466 | Creatine Kinase BB/Total Creatine Kinase | A relative measurement (ratio or percentage) of the BB-type creatine kinase to total creatine kinase in a biological specimen. | Creatine Kinase BB to Total Creatine Kinase Ratio Measurement | ||
CKMBCK | C79441 | Creatine Kinase MB/Total Creatine Kinase | A relative measurement (ratio or percentage) of the MB-type creatine kinase to total creatine kinase in a biological specimen. | Creatine Kinase MB to Total Creatine Kinase Ratio Measurement | ||
CKMMCK | C79442 | Creatine Kinase MM/Total Creatine Kinase | A relative measurement (ratio or percentage) of the MM-type creatine kinase to total creatine kinase in a biological specimen. | Creatine Kinase MM to Total Creatine Kinase Ratio Measurement | ||
DHEA | C74852 | Dehydroepiandrosterone;Dehydroisoandrosterone | A measurement of the dehydroepiandrosterone hormone in a biological specimen. | Dehydroepiandrosterone Measurement | ||
DPD | C79443 | Deoxypyridinoline | A measurement of the deoxypyridinoline in a biological specimen. | Deoxypyridinoline Measurement | ||
DPDCREAT | C79444 | Deoxypyridinoline/Creatinine | A relative measurement (ratio or percentage) of the deoxypyridinoline to creatinine in a biological specimen. | Deoxypyridinoline to Creatinine Ratio Measurement | ||
DIHYDCDN | C74878 | Dihydrocodeine | A measurement of the dihydrocodeine present in a biological specimen. | Dihydrocodeine Measurement | ||
DHT | C74853 | Dihydrotestosterone;Androstanalone | A measurement of the dihydrotestosterone hormone in a biological specimen. | Dihydrotestosterone Measurement | ||
DOPAMINE | C74854 | Dopamine | A measurement of the dopamine hormone in a biological specimen. | Dopamine Measurement | ||
EPIN | C79445 | Epinephrine;Adrenaline | A measurement of the epinephrine hormone in a biological specimen. | Epinephrine Measurement | ||
EPO | C74855 | Erythropoietin;Hematopoietin | A measurement of the erythropoietin hormone in a biological specimen. | Erythropoietin Measurement | ||
ESTRIOL | C74856 | Estriol;Oestriol | A measurement of the estriol hormone in a biological specimen. | Estriol Measurement | ||
ESTRONE | C74857 | Estrone;Oestrone | A measurement of the estrone hormone in a biological specimen. | Estrone Measurement | ||
ETHANOL | C74693 | Ethanol;Alcohol | A measurement of the ethanol present in a biological specimen. | Ethanol Measurement | ||
GGTCREAT | C79446 | Gamma Glutamyl Transferase/Creatinine | A relative measurement (ratio or percentage) of the gamma glutamyl transferase to creatinine in a biological specimen. | Gamma Glutamyl Transferase to Creatinine Ratio Measurement | ||
GASTRIN | C74858 | Gastrin | A measurement of the gastrin hormone in a biological specimen. | Gastrin Measurement | ||
GLUCAGON | C74859 | Glucagon | A measurement of the glucagon hormone in a biological specimen. | Glucagon Measurement | ||
GLUCCRT | C79447 | Glucose/Creatinine | A relative measurement (ratio or percentage) of the glucose to creatinine in a biological specimen. | Glucose to Creatinine Ratio Measurement | ||
GLDH | C79448 | Glutamate Dehydrogenase | A measurement of the glutamate dehydrogenase in a biological specimen. | Glutamate Dehydrogenase Measurement | ||
GSTCREAT | C79435 | Glutathione-S-Transferase/Creatinine | A relative measurement (ratio or percentage) of the glutathione S-transferase to creatinine in a biological specimen. | Glutathione-S-Transferase to Creatinine Ratio Measurement | ||
GNRH | C74860 | Gonadotropin Releasing Hormone;Luteinising Hormone Releasing Hormone | A measurement of the gonadotropin releasing hormone in a biological specimen. | Gonadotropin Releasing Hormone Measurement | ||
GRWHIH | C74861 | Growth Hormone Inhibiting Hormone;Somatostatin | A measurement of the growth hormone inhibiting hormone in a biological specimen. | Growth Hormone Inhibiting Hormone Measurement | ||
GRWHRH | C74862 | Growth Hormone Releasing Hormone;Somatocrinin | A measurement of the growth hormone releasing hormone in a biological specimen. | Growth Hormone Releasing Hormone Measurement | ||
HVA | C74863 | Homovanillic Acid | A measurement of the homovanillic acid metabolite in a biological specimen. | Homovanillic Acid Measurement | ||
HYDCDN | C74879 | Hydrocodone | A measurement of the hydrocodone present in a biological specimen. | Hydrocodone Measurement | ||
HYDMRPHN | C74880 | Hydromorphone | A measurement of the hydromorphone present in a biological specimen. | Hydromorphone Measurement | ||
IGF1 | C74864 | Insulin-like Growth Factor-1 | A measurement of the insulin-like growth factor-1 in a biological specimen. | Insulin Like Growth Factor-1 Measurement | ||
IGF2 | C74865 | Insulin-like Growth Factor-2 | A measurement of the insulin-like growth factor-2 in a biological specimen. | Insulin Like Growth Factor-2 Measurement | ||
INTLK1 | C74805 | Interleukin 1 | A measurement of the interleukin 1 in a biological specimen. | Interleukin 1 Measurement | ||
INTLK10 | C74806 | Interleukin 10 | A measurement of the interleukin 10 in a biological specimen. | Interleukin 10 Measurement | ||
INTLK11 | C74807 | Interleukin 11 | A measurement of the interleukin 11 in a biological specimen. | Interleukin 11 Measurement | ||
INTLK12 | C74808 | Interleukin 12 | A measurement of the interleukin 12 in a biological specimen. | Interleukin 12 Measurement | ||
INTLK13 | C74809 | Interleukin 13 | A measurement of the interleukin 13 in a biological specimen. | Interleukin 13 Measurement | ||
INTLK14 | C74810 | Interleukin 14 | A measurement of the interleukin 14 in a biological specimen. | Interleukin 14 Measurement | ||
INTLK15 | C74811 | Interleukin 15 | A measurement of the interleukin 15 in a biological specimen. | Interleukin 15 Measurement | ||
INTLK16 | C74812 | Interleukin 16 | A measurement of the interleukin 16 in a biological specimen. | Interleukin 16 Measurement | ||
INTLK17 | C74813 | Interleukin 17 | A measurement of the interleukin 17 in a biological specimen. | Interleukin 17 Measurement | ||
INTLK18 | C74814 | Interleukin 18 | A measurement of the interleukin 18 in a biological specimen. | Interleukin 18 Measurement | ||
INTLK19 | C74815 | Interleukin 19 | A measurement of the interleukin 19 in a biological specimen. | Interleukin 19 Measurement | ||
INTLK2 | C74816 | Interleukin 2 | A measurement of the interleukin 2 in a biological specimen. | Interleukin 2 Measurement | ||
INTLK20 | C74817 | Interleukin 20 | A measurement of the interleukin 20 in a biological specimen. | Interleukin 20 Measurement | ||
INTLK21 | C74818 | Interleukin 21 | A measurement of the interleukin 21 in a biological specimen. | Interleukin 21 Measurement | ||
INTLK22 | C74819 | Interleukin 22 | A measurement of the interleukin 22 in a biological specimen. | Interleukin 22 Measurement | ||
INTLK23 | C74820 | Interleukin 23 | A measurement of the interleukin 23 in a biological specimen. | Interleukin 23 Measurement | ||
INTLK24 | C74821 | Interleukin 24 | A measurement of the interleukin 24 in a biological specimen. | Interleukin 24 Measurement | ||
INTLK25 | C74822 | Interleukin 25 | A measurement of the interleukin 25 in a biological specimen. | Interleukin 25 Measurement | ||
INTLK26 | C74823 | Interleukin 26 | A measurement of the interleukin 26 in a biological specimen. | Interleukin 26 Measurement | ||
INTLK27 | C74824 | Interleukin 27 | A measurement of the interleukin 27 in a biological specimen. | Interleukin 27 Measurement | ||
INTLK28 | C74825 | Interleukin 28 | A measurement of the interleukin 28 in a biological specimen. | Interleukin 28 Measurement | ||
INTLK29 | C74826 | Interleukin 29 | A measurement of the interleukin 29 in a biological specimen. | Interleukin 29 Measurement | ||
INTLK3 | C74827 | Interleukin 3 | A measurement of the interleukin 3 in a biological specimen. | Interleukin 3 Measurement | ||
INTLK30 | C74828 | Interleukin 30 | A measurement of the interleukin 30 in a biological specimen. | Interleukin 30 Measurement | ||
INTLK31 | C74829 | Interleukin 31 | A measurement of the interleukin 31 in a biological specimen. | Interleukin 31 Measurement | ||
INTLK32 | C74830 | Interleukin 32 | A measurement of the interleukin 32 in a biological specimen. | Interleukin 32 Measurement | ||
INTLK33 | C74831 | Interleukin 33 | A measurement of the interleukin 33 in a biological specimen. | Interleukin 33 Measurement | ||
INTLK4 | C74832 | Interleukin 4 | A measurement of the interleukin 4 in a biological specimen. | Interleukin 4 Measurement | ||
INTLK5 | C74833 | Interleukin 5 | A measurement of the interleukin 5 in a biological specimen. | Interleukin 5 Measurement | ||
INTLK6 | C74834 | Interleukin 6 | A measurement of the interleukin 6 in a biological specimen. | Interleukin 6 Measurement | ||
INTLK7 | C74835 | Interleukin 7 | A measurement of the interleukin 7 in a biological specimen. | Interleukin 7 Measurement | ||
INTLK8 | C74836 | Interleukin 8 | A measurement of the interleukin 8 in a biological specimen. | Interleukin 8 Measurement | ||
INTLK9 | C74837 | Interleukin 9 | A measurement of the interleukin 9 in a biological specimen. | Interleukin 9 Measurement | ||
LDH1 | C74887 | LDH Isoenzyme 1 | A measurement of the lactate dehydrogenase isoenzyme 1 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 1 Measurement | ||
LDH2 | C74888 | LDH Isoenzyme 2 | A measurement of the lactate dehydrogenase isoenzyme 2 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 2 Measurement | ||
LDH3 | C74889 | LDH Isoenzyme 3 | A measurement of the lactate dehydrogenase isoenzyme 3 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 3 Measurement | ||
LDH4 | C74890 | LDH Isoenzyme 4 | A measurement of the lactate dehydrogenase isoenzyme 4 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 4 Measurement | ||
LDH5 | C74891 | LDH Isoenzyme 5 | A measurement of the lactate dehydrogenase isoenzyme 5 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 5 Measurement | ||
LDHCREAT | C79449 | Lactate Dehydrogenase/Creatinine | A relative measurement (ratio or percentage) of the lactate dehydrogenase to creatinine in a biological specimen. | Lactate Dehydrogenase to Creatinine Ratio Measurement | ||
LACTICAC | C79450 | Lactic Acid;2-hydroxypropanoic acid;Lactate | A measurement of the lactic acid in a biological specimen. | Lactic Acid Measurement | ||
LGLUCLE | C79467 | Large Unstained Cells/Leukocytes | A relative measure (ratio or percentage) of the large unstained cells to leukocytes in a biological specimen. | Large Unstained Cells to Leukocytes Ratio Measurement | ||
LDH1LDH | C79451 | LDH Isoenzyme 1/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 1 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 1 to LDH Ratio Measurement | ||
LDH2LDH | C79452 | LDH Isoenzyme 2/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 2 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 2 to LDH Ratio Measurement | ||
LDH3LDH | C79453 | LDH Isoenzyme 3/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 3 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 3 to LDH Ratio Measurement | ||
LDH4LDH | C79454 | LDH Isoenzyme 4/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 4 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 4 to LDH Ratio Measurement | ||
LDH5LDH | C79455 | LDH Isoenzyme 5/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 5 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 5 to LDH Ratio Measurement | ||
LEPTIN | C74866 | Leptin | A measurement of the leptin hormone in a biological specimen. | Leptin Measurement | ||
MGCREAT | C79456 | Magnesium/Creatinine | A relative measurement (ratio or percentage) of the magnesium to creatinine in a biological specimen. | Magnesium to Creatinine Ratio Measurement | ||
MLATONIN | C74867 | Melatonin | A measurement of the melatonin hormone in a biological specimen. | Melatonin Measurement | ||
METHDN | C74881 | Methadone | A measurement of the methadone present in a biological specimen. | Methadone Measurement | ||
METHQLDN | C74882 | Methaqualone | A measurement of the methaqualone present in a biological specimen. | Methaqualone Measurement | ||
MORPHINE | C74883 | Morphine | A measurement of the morphine present in a biological specimen. | Morphine Measurement | ||
GSTMU | C79457 | Mu Glutathione-S-Transferase | A measurement of the mu form of glutathione S-transferase in a biological specimen. | Mu Glutathione-S-Transferase Measurement | ||
GSTMUCRT | C79458 | Mu Glutathione-S-Transferase/Creatinine | A relative measurement (ratio or percentage) of the mu gamma glutamyl transpeptidase to creatinine in a biological specimen. | Mu Glutathione-S-Transferase to Creatinine Ratio Measurement | ||
MGB | C79436 | Myoglobin | A measurement of myoglobin in a biological specimen. | Myoglobin Measurement | ||
NAG | C79459 | N-Acetyl Glucosamide;N-Acetyl Glucosamine | A measurement of N-acetyl glucosamide in a biological specimen. | N-Acetyl Glucosamide Measurement | ||
NAGCREAT | C79460 | N-Acetyl Glucosamide/Creatinine | A relative measurement (ratio or percentage) of the N-acetyl glucosamide to creatinine in a biological specimen. | N-Acetyl Glucosamide to Creatinine Ratio Measurement | ||
NPY | C74892 | Neuropeptide Y | A measurement of the neuropeptide Y in a biological specimen. | Neuropeptide Y Measurement | ||
NOREPIN | C74868 | Noradrenaline;Norepinephrine | A measurement of the norepinephrine hormone in a biological specimen. | Noradrenaline Measurement | ||
OSMLTY | C74801 | Osmolality | A measurement of the osmoles of solute per unit of biological specimen. | Osmolality Measurement | ||
OXYCDN | C74884 | Oxycodone;Oxycontin | A measurement of the oxycodone present in a biological specimen. | Oxycodone Measurement | ||
OXYTOCIN | C74869 | Oxytocin;Oxytoxin | A measurement of the oxytocin hormone in a biological specimen. | Oxytocin Measurement | ||
PCP | C74694 | Phencyclidine;Phenylcyclohexylpiperidine | A measurement of the phencyclidine present in a biological specimen. | Phencyclidine Measurement | ||
PHENTHZ | C74695 | Phenothiazine;Dibenzothiazine | A measurement of the phenothiazine present in a biological specimen. | Phenothiazine Measurement | ||
PHOSCRT | C79461 | Phosphate/Creatinine | A relative measurement (ratio or percentage) of the phosphate to creatinine in a biological specimen. | Phosphate to Creatinine Ratio Measurement | ||
KCREAT | C79462 | Potassium/Creatinine | A relative measurement (ratio or percentage) of the potassium to creatinine in a biological specimen. | Potassium to Creatinine Ratio Measurement | ||
PROLCTN | C74870 | Prolactin | A measurement of the prolactin hormone in a biological specimen. | Prolactin Measurement | ||
PROPOX | C74885 | Propoxyphene | A measurement of the propoxyphene present in a biological specimen. | Propoxyphene Measurement | ||
PROTCRT | C79463 | Protein/Creatinine | A relative measurement (ratio or percentage) of the protein to creatinine in a biological specimen. | Protein to Creatinine Ratio Measurement | ||
PSDEPHD | C74696 | Pseudoephedrine | A measurement of the pseudoephedrine present in a biological specimen. | Pseudoephedrine Measurement | ||
LYMRCT | C74629 | Reactive Lymphocytes | A measurement of the reactive lymphocytes (lymphocytes which have become large due to an antigen reaction) in a biological specimen. | Reactive Lymphocyte Count Measurement | ||
RENIN | C74893 | Renin;Angiotensinogenase | A measurement of the renin in a biological specimen. | Renin Measurement | ||
SECRETIN | C74871 | Secretin | A measurement of the secretin hormone in a biological specimen. | Secretin Measurement | ||
SRTONIN | C74872 | Serotonin | A measurement of the serotonin hormone in a biological specimen. | Serotonin Measurement | ||
NACREAT | C79464 | Sodium/Creatinine | A relative measurement (ratio or percentage) of the sodium to creatinine in a biological specimen. | Sodium to Creatinine Ratio Measurement | ||
SDH | C79465 | Sorbitol Dehydrogenase | A measurement of the sorbitol dehydrogenase in a biological specimen. | Sorbitol Dehydrogenase Measurement | ||
THRMPTN | C74873 | Thrombopoietin | A measurement of the thrombopoietin hormone in a biological specimen. | Thrombopoietin Measurement | ||
TRH | C74874 | Thyrotropin Releasing Hormone;Thyrotropin Releasing Factor | A measurement of the thyrotropin releasing hormone in a biological specimen. | Thyrotropin Releasing Hormone Measurement | ||
VMA | C74875 | Vanillyl Mandelic Acid;Vanilmandelic Acid | A measurement of the vanillyl mandelic acid metabolite in a biological specimen. | Vanillyl Mandelic Acid Measurement | ||
VITA | C74895 | Vitamin A;Retinol | A measurement of the Vitamin A in a biological specimen. | Vitamin A Measurement | ||
VITB1 | C74896 | Thiamine;Vitamin B1 | A measurement of the thiamine in a biological specimen. | Vitamin B1 Measurement | ||
VITB17 | C74897 | Vitamin B17;Amygdalin | A measurement of the Vitamin B17 in a biological specimen. | Vitamin B17 Measurement | ||
VITB2 | C74898 | Riboflavin;Vitamin B2 | A measurement of the riboflavin in a biological specimen. | Vitamin B2 Measurement | ||
VITB3 | C74899 | Niacin;Vitamin B3 | A measurement of the niacin in a biological specimen. | Vitamin B3 Measurement | ||
VITB5 | C74900 | Vitamin B5;Pantothenic Acid | A measurement of the Vitamin B5 in a biological specimen. | Vitamin B5 Measurement | ||
VITB6 | C74901 | Vitamin B6;Pyridoxine | A measurement of the Vitamin B6 in a biological specimen. | Vitamin B6 Measurement | ||
VITB7 | C74902 | Vitamin B7;Biotin | A measurement of the Vitamin B7 in a biological specimen. | Vitamin B7 Measurement | ||
VITC | C74903 | Vitamin C;Ascorbic Acid | A measurement of the Vitamin C in a biological specimen. | Vitamin C Measurement | ||
VITD2 | C74904 | Vitamin D2;Ergocalciferol | A measurement of the Vitamin D2 in a biological specimen. | Vitamin D2 Measurement | ||
VITD3 | C74905 | Vitamin D3;Cholecalciferol | A measurement of the Vitamin D3 in a biological specimen. | Vitamin D3 Measurement | ||
VITE | C74906 | Vitamin E | A measurement of the Vitamin E in a biological specimen. | Vitamin E Measurement | ||
VITK | C74907 | Vitamin K;Naphthoquinone | A measurement of the total Vitamin K in a biological specimen. | Vitamin K Measurement | ||
VOLUME | C74720 | Volume | A measurement of the volume of a biological specimen. | Volume Measurement | ||
A1ANTRYP | C80167 | Alpha-1 Antitrypsin;Serum Trypsin Inhibitor | A measurement of the alpha-1 antitrypsin in a biological specimen. | Alpha-1 Antitrypsin Measurement | ||
A2MACG | C80168 | Alpha-2 Macroglobulin | A measurement of the alpha-2 macroglobulin in a biological specimen. | Alpha-2 Macroglobulin Measurement | ||
ACE | C80169 | Angiotensin Converting Enzyme | A measurement of the angiotensin converting enzyme in a biological specimen. | Angiotensin Converting Enzyme Measurement | ||
ACPHOS | C80163 | Acid Phosphatase | A measurement of the acid phosphatase in a biological specimen. | Acid Phosphatase Measurement | ||
AMA | C81975 | Antimitochondrial Antibodies;Mitochondrial Antibody | A measurement of the antimitochondrial antibodies in a biological specimen. | Antimitochondrial Antibody Measurement | ||
AMYLB42 | C84809 | Amyloid Beta 42;Amyloid Beta 42 Protein;Amyloid Beta 1-42 | A measurement of amyloid beta protein which is composed of peptides 1 to 42 in a biological specimen. | Beta Amyloid 42 Measurement | ||
AMYLOIDB | C81999 | Amyloid, Beta;Beta Amyloid | A measurement of the total amyloid beta in a biological specimen. | Beta Amyloid Measurement | ||
AMYLOIDP | C81998 | Amyloid P | A measurement of the total amyloid P in a biological specimen. | Amyloid P Measurement | ||
ANGLOBDR | C81974 | Antiglobulin Test, Direct;Direct Coombs Test | A measurement of the antibody or complement-coated erythrocytes in a biological specimen in vivo. | Direct Antiglobulin Test | ||
ANTHRM | C81958 | Antithrombin;Antithrombin III;Antithrombin Activity;Antithrombin III Activity | A measurement of the antithrombin activity in a biological specimen. | Antithrombin Measurement | ||
ANTHRMAG | C81977 | Antithrombin Antigen;Antithrombin III Antigen | A measurement of the antithrombin antigen in a biological specimen. | Antithrombin Antigen Measurement | ||
APOA2 | C82000 | Apolipoprotein AII | A measurement of the apolipoprotein AII in a biological specimen. | Apolipoprotein AII Measurement | ||
APOC3 | C82001 | Apolipoprotein CIII | A measurement of the apolipoprotein CIII in a biological specimen. | Apolipoprotein CIII Measurement | ||
APOE | C82002 | Apolipoprotein E | A measurement of the apolipoprotein E in a biological specimen. | Apolipoprotein E Measurement | ||
APOH | C82003 | Apolipoprotein H | A measurement of the apolipoprotein H in a biological specimen. | Apolipoprotein H Measurement | ||
APPEAR | C25377 | Specimen Appearance | The outward or visible aspect of a specimen. | Appearance | ||
ASCAB | C81976 | Anti-Saccharomyces cerevisiae Antibody | A measurement of the anti-Saccharomyces cerevisiae antibody in a biological specimen. | Anti-Saccharomyces cerevisiae Antibody Measurement | ||
ASTAG | C81978 | Aspartate Aminotransferase Antigen;SGOT Antigen | A measurement of the aspartate aminotransferase antigen in a biological specimen. | Aspartate Aminotransferase Antigen Measurement | ||
B2GLYAB | C81979 | Beta-2 Glycoprotein Antibody | A measurement of the beta-2 glycoprotein antibody in a biological specimen. | Beta-2 Glycoprotein Antibody Measurement | ||
B2MICG | C81980 | Beta-2 Microglobulin | A measurement of the beta-2 microglobulin in a biological specimen. | Beta-2 Microglobulin Measurement | ||
BDNF | C82004 | Brain-Derived Neurotrophic Factor | A measurement of the brain-derived neurotrophic factor in a biological specimen. | Brain-Derived Neurotrophic Factor Measurement | ||
BNPPRO | C82032 | ProB-type Natriuretic Peptide;proBNP;Pro-Brain Natriuretic Peptide | A measurement of the proB-type natriuretic peptide in a biological specimen. | ProB-Type Natriuretic Peptide Measurement | ||
C1QAB | C80173 | Complement C1q Antibody | A measurement of the complement C1q antibody in a biological specimen. | Complement C1q Antibody Measurement | ||
C3 | C80174 | Complement C3 | A measurement of the complement C3 in a biological specimen. | Complement C3 Measurement | ||
C3A | C80175 | Complement C3a;ASP, Complement C3 DesArg, Acetylation-stimulating Protein | A measurement of the complement C3a in a biological specimen. | Complement C3a Measurement | ||
C3B | C80176 | Complement C3b | A measurement of the complement C3b in a biological specimen. | Complement C3b Measurement | ||
C4 | C80177 | Complement C4 | A measurement of the complement C4 in a biological specimen. | Complement C4 Measurement | ||
C4A | C80178 | Complement C4a | A measurement of the complement C4a in a biological specimen. | Complement C4a Measurement | ||
C5A | C80179 | Complement C5a | A measurement of the complement C5a in a biological specimen. | Complement C5a Measurement | ||
CA125AG | C81981 | Cancer Antigen 125 | A measurement of the cancer antigen 125 in a biological specimen. | Cancer Antigen 125 Measurement | ||
CA19_9AG | C81982 | Cancer Antigen 19-9 | A measurement of the cancer antigen 19-9 in a biological specimen. | Cancer Antigen 19-9 Measurement | ||
CAION | C81948 | Calcium, Ionized | A measurement of the ionized calcium in a biological specimen. | Ionized Calcium Measurement | ||
CALPRO | C82005 | Calprotectin | A measurement of the calprotectin in a biological specimen. | Calprotectin Measurement | ||
CBB | C80172 | Complement Bb | A measurement of the complement Bb in a biological specimen. | Complement Bb Measurement | ||
CD40 | C82006 | CD40 | A count of the CD40 cells per unit in a biological specimen. | CD40 Measurement | ||
CD40L | C82007 | CD40 Ligand | A count of the CD40 ligand cells per unit in a biological specimen. | CD40 Ligand Measurement | ||
CEA | C81983 | Carcinoembryonic Antigen | A measurement of the carcinoembryonic antigen in a biological specimen. | Carcinoembryonic Antigen Measurement | ||
CHOLHDL | C80171 | Cholesterol/HDL-Cholesterol | A relative measurement (ratio or percentage) of total cholesterol to high-density lipoprotein cholesterol (HDL-C) in a biological specimen. | Cholesterol to HDL-Cholesterol Ratio Measurement | ||
CTOT | C80160 | Complement Total | A measurement of the total complement in a biological specimen. | Complement Measurement | ||
CTXI | C82038 | Type I Collagen C-Telopeptides;Type I Collagen X-linked C-telopeptide | A measurement of the type I collagen C-telopeptides in a biological specimen. | Type I Collagen C-Telopeptide Measurement | ||
CTXII | C82040 | Type II Collagen C-Telopeptides | A measurement of the type II collagen C-telopeptides in a biological specimen. | Type II Collagen C-Telopeptide Measurement | ||
CYSTARCH | C81951 | Starch Crystals | A measurement of the starch crystals in a biological specimen. | Starch Crystal Measurement | ||
DDIMER | C82621 | D-Dimer | A measurement of the d-dimers in a biological specimen. | D-Dimer Measurement | ||
DNAAB | C81973 | Anti-DNA Antibodies;Anti-ds-DNA Antibodies | A measurement of the anti-DNA antibodies in a biological specimen. | Anti-DNA Antibody Measurement | ||
EGF | C82009 | Epidermal Growth Factor | A measurement of the epidermal growth factor in a biological specimen. | Epidermal Growth Factor Measurement | ||
ELA1 | C82028 | Pancreatic Elastase 1 | A measurement of the pancreatic elastase 1 in a biological specimen. | Pancreatic Elastase Measurement | ||
ELA1PMN | C82029 | Pancreatic Elastase 1, Polymorphonuclear | A measurement of the polymorphonuclear pancreatic elastase 1 in a biological specimen. | Polymorphonuclear Pancreatic Elastase Measurement | ||
ELA2 | C82026 | Neutrophil Elastase | A measurement of the neutrophil elastase in a biological specimen. | Neutrophil Elastase Measurement | ||
ELA2PMN | C82027 | Neutrophil Elastase, Polymorphonuclear | A measurement of the polymorphonuclear neutrophil elastase in a biological specimen. | Polymorphonuclear Neutrophil Elastase Measurement | ||
ENA78 | C82010 | Epith Neutrophil-Activating Peptide 78 | A measurement of the epithelial neutrophil-activating peptide in a biological specimen. | Epithelial Neutrophil-Activating Peptide 78 Measurement | ||
ENDOTH1 | C82008 | Endothelin-1 | A measurement of the endothelin-1 in a biological specimen. | Endothelin-1 Measurement | ||
ENRAGE | C82011 | Extracell Newly Ident RAGE Bind Protein;S100 Calcium Binding Protein A12 | A measurement of the extracellular newly identified RAGE (receptor for advanced glycation end products) binding protein in a biological specimen. | Extracell Newly Ident RAGE Bind Protein Measurement | ||
EOSMM | C84819 | Eosinophilic Metamyelocytes | A measurement of the eosinphilic metamyelocytes in a biological specimen. | Eosinophilic Metamyelocyte Count | ||
EOSMYL | C84821 | Eosinophilic Myelocytes | A measurement of the eosinophilic myelocytes in a biological specimen. | Eosinophilic Myelocyte Count | ||
EOTAXIN1 | C81952 | Eotaxin-1;Chemokine Ligand 11 | A measurement of the eotaxin-1 in a biological specimen. | Eotaxin-1 Measurement | ||
EOTAXIN2 | C81953 | Eotaxin-2;Chemokine Ligand 24 | A measurement of the eotaxin-2 in a biological specimen. | Eotaxin-2 Measurement | ||
EOTAXIN3 | C81954 | Eotaxin-3;Chemokine Ligand 26 | A measurement of the eotaxin-3 in a biological specimen. | Eotaxin-3 Measurement | ||
ESTRIOLF | C81963 | Estriol, Free | A measurement of the free estriol in a biological specimen. | Free Estriol Measurement | ||
FABP1 | C82012 | Fatty Acid Binding Protein 1 | A measurement of the fatty acid binding protein 1 in a biological specimen. | Fatty Acid Binding Protein 1 Measurement | ||
FACTIII | C81959 | Factor III;Tissue Factor, CD142 | A measurement of the factor III in a biological specimen. | Factor III Measurement | ||
FACTVII | C81960 | Factor VII;Proconvertin;Stable Factor | A measurement of the factor VII in a biological specimen. | Factor VII Measurement | ||
FACTVIII | C81961 | Factor VIII;Anti-hemophilic Factor | A measurement of the factor VIII in a biological specimen. | Factor VIII Measurement | ||
FATACFR | C80200 | Free Fatty Acid;Non-Esterified Fatty Acid, Free | A measurement of the total non-esterified fatty acids in a biological specimen. | Non-esterified Fatty Acids Measurement | ||
FATACFRS | C80206 | Free Fatty Acid, Saturated;Non-esterified Fatty Acid, Saturated | A measurement of the saturated non-esterified fatty acids in a biological specimen. | Saturated Non-esterified Fatty Acids Measurement | ||
FATACFRU | C80209 | Free Fatty Acid, Unsaturated;Non-esterified Fatty Acid, Unsaturated | A measurement of the unsaturated non-esterified fatty acids in a biological specimen. | Unsaturated Non-esterified Fatty Acids Measurement | ||
FATBODOV | C81947 | Fat Bodies, Oval | A measurement of the oval-shaped fat bodies, usually renal proximal tubular cells with lipid aggregates in the cytoplasm, in a biological specimen. | Oval Fat Body Measurement | ||
FDP | C82013 | Fibrin Degradation Products | A measurement of the fibrin degradation products in a biological specimen. | Fibrin Degradation Products Measurement | ||
FGFBF | C82014 | Fibroblast Growth Factor Basic Form;FGF2 | A measurement of the basic form of fibroblast growth factor in a biological specimen. | Fibroblast Growth Factor Basic Form Measurement | ||
G6PD | C80184 | Glucose-6-Phosphate Dehydrogenase | A measurement of the glucose-6-phosphate dehydrogenase in a biological specimen. | Glucose-6-Phosphate Dehydrogenase Measurement | ||
GAD1 | C82015 | Glutamic Acid Decarboxylase 1;Glutamic Acid Decarboxylase 67 | A measurement of the glutamic acid decarboxylase 1 in a biological specimen. | Glutamic Acid Decarboxylase 1 Measurement | ||
GAD2 | C82016 | Glutamic Acid Decarboxylase 2;Glutamic Acid Decarboxylase 65 | A measurement of the glutamic acid decarboxylase 2 in a biological specimen. | Glutamic Acid Decarboxylase 2 Measurement | ||
GAD2AB | C82017 | Glutamic Acid Decarboxylase 2 Antibody;Glutamic Acid Decarboxylase 65 Antibody | A measurement of the glutamic acid decarboxylase 2 antibody in a biological specimen. | Glutamic Acid Decarboxylase 2 Antibody Measurement | ||
GALANIN | C80182 | Galanin | A measurement of the galanin in a biological specimen. | Galanin Measurement | ||
GCSF | C82018 | Granulocyte Colony Stimulating Factor | A measurement of the granulocyte colony stimulating factor in a biological specimen. | Granulocyte Colony Stimulating Factor Measurement | ||
GLP1 | C80183 | Glucagon-Like Peptide-1;Total Glucagon-Like Peptide-1 | A measurement of the total glucagon-like peptide-1 in a biological specimen. | Glucagon-like Peptide-1 Measurement | ||
GLP1AC | C80164 | Glucagon-Like Peptide-1, Active Form | A measurement of the active form of glucagon-like peptide-1 in a biological specimen. | Active Glucagon-like Peptide-1 Measurement | ||
GMCSF | C82019 | Granulocyte Macrophage Colony Stm Factor | A measurement of the granulocyte macrophage colony stimulating factor in a biological specimen. | Granulocyte Macrophage Colony Stm Factor Measurement | ||
GOLD | C80186 | Gold | A measurement of the gold in a biological specimen. | Gold Measurement | ||
GST | C80185 | Glutathione S-Transferase, Total | A measurement of the total glutathione-s-transferase in a biological specimen. | Glutathione-S-Transferase Measurement | ||
GSTALCRT | C80166 | Glutathione S-Transferase, Alpha/Creat | A relative measurement (ratio or percentage) of the alpha glutathione-S-transferase to creatinine in a biological specimen. | Alpha Glutathione-S-Transferase to Creatinine Ratio Measurement | ||
GSTPI | C80203 | Glutathione S-Transferase, Pi | A measurement of the Pi glutathione-s-transferase in a biological specimen. | Pi Glutathione S-Transferase Measurement | ||
GSTTH | C80207 | Glutathione S-Transferase, Theta | A measurement of the theta glutathione-s-transferase in a biological specimen. | Theta Glutathione S-Transferase Measurement | ||
GUSA | C80165 | Glucuronidase, Alpha | A measurement of the alpha glucuronidase in a biological specimen. | Alpha Glucuronidase Measurement | ||
GUSB | C80170 | Glucuronidase, Beta | A measurement of the beta glucuronidase in a biological specimen. | Beta Glucuronidase Measurement | ||
HDL2 | C80187 | HDL-Cholesterol Subclass 2 | A measurement of the high-density lipoprotein (HDL) cholesterol subclass 2 in a biological specimen. | HDL-Cholesterol Subclass 2 Measurement | ||
HDL3 | C80188 | HDL-Cholesterol Subclass 3 | A measurement of the high-density lipoprotein (HDL) cholesterol subclass 3 in a biological specimen. | HDL-Cholesterol Subclass 3 Measurement | ||
HISTAMIN | C80189 | Histamine | A measurement of the histamine in a biological specimen. | Histamine Measurement | ||
HTPHAB | C81984 | Heterophile Antibodies | A measurement of the heterophile antibodies in a biological specimen. | Heterophile Antibody Measurement | ||
HYPRLN | C80190 | Hydroxyproline | A measurement of the total hydroxyproline in a biological specimen. | Hydroxyproline Measurement | ||
IC512AB | C81985 | Islet Cell 512 Antibody | A measurement of the islet cell 512 antibody in a biological specimen. | Islet Cell 512 Antibody Measurement | ||
IC512AG | C81986 | Islet Cell 512 Antigen | A measurement of the islet cell 512 antigen in a biological specimen. | Islet Cell 512 Antigen Measurement | ||
IFNA | C81994 | Interferon Alpha | A measurement of the interferon alpha in a biological specimen. | Interferon Alpha Measurement | ||
IFNB | C81995 | Interferon Beta | A measurement of the interferon beta in a biological specimen. | Interferon Beta Measurement | ||
IFNG | C81996 | Interferon Gamma | A measurement of the interferon gamma in a biological specimen. | Interferon Gamma Measurement | ||
IGA | C81969 | Immunoglobulin A | A measurement of the Immunoglobulin A in a biological specimen. | Immunoglobulin A Measurement | ||
IGE | C81970 | Immunoglobulin E | A measurement of the Immunoglobulin E in a biological specimen. | Immunoglobulin E Measurement | ||
IGG | C81971 | Immunoglobulin G | A measurement of the Immunoglobulin G in a biological specimen. | Immunoglobulin G Measurement | ||
IGM | C81972 | Immunoglobulin M | A measurement of the Immunoglobulin M in a biological specimen. | Immunoglobulin M Measurement | ||
INDICAN | C82044 | Indican | A measurement of the indican present in a biological specimen. | Indican Measurement | ||
INGAPAB | C81987 | Islet Neogenesis Assoc Protein Antibody | A measurement of the islet neogenesis associated protein antibody in a biological specimen. | Islet Neogenesis Associated Protein Antibody Measurement | ||
INHIBINA | C82020 | Inhibin A | A measurement of the inhibin A in a biological specimen. | Inhibin A Measurement | ||
ISOPRF2 | C80180 | F2-Isoprostane | A measurement of the F2-isoprostane in a biological specimen. | F2 Isoprostane Measurement | ||
LPA | C82022 | Lipoprotein-a | A measurement of the lipoprotein-a in a biological specimen. | Lipoprotein a Measurement | ||
LTF | C82021 | Lactoferrin;Lactotransferrin | A measurement of the lactoferrin in a biological specimen. | Lactoferrin Measurement | ||
LYMPHOTC | C81955 | Lymphotactin;Chemokine Ligand 1 | A measurement of the lymphotactin in a biological specimen. | Lymphotactin Measurement | ||
MCP1 | C82025 | Monocyte Chemotactic Protein 1 | A measurement of the monocyte chemotactic protein 1 in a biological specimen. | Monocyte Chemotactic Protein 1 Measurement | ||
MCSF | C80191 | Macrophage Colony Stimulating Factor | A measurement of the macrophage colony stimulating factor in a biological specimen. | Macrophage Colony Stimulating Factor Measurement | ||
MDC | C81956 | Macrophage-Derived Chemokine;Chemokine Ligand 22 | A measurement of the macrophage-derived chemokine in a biological specimen. | Macrophage-Derived Chemokine Measurement | ||
MIP1A | C82023 | Macrophage Inflammatory Protein 1 Alpha;Chemokine Ligand 3 | A measurement of the macrophage inflammatory protein 1 alpha in a biological specimen. | Macrophage Inflammatory Protein 1 Alpha Measurement | ||
MIP1B | C82024 | Macrophage Inflammatory Protein 1 Beta;Chemokine Ligand 4 | A measurement of the macrophage inflammatory protein 1 beta in a biological specimen. | Macrophage Inflammatory Protein 1 Beta Measurement | ||
MMP1 | C80192 | Matrix Metalloproteinase 1;Interstitial Collagenase | A measurement of the matrix metalloproteinase 1 in a biological specimen. | Matrix Metalloproteinase 1 Measurement | ||
MMP2 | C80193 | Matrix Metalloproteinase 2;Gelatinase A | A measurement of the matrix metalloproteinase 2 in a biological specimen. | Matrix Metalloproteinase 2 Measurement | ||
MMP3 | C80194 | Matrix Metalloproteinase 3;Stromelysin 1 | A measurement of the matrix metalloproteinase 3 in a biological specimen. | Matrix Metalloproteinase 3 Measurement | ||
MMP7 | C80195 | Matrix Metalloproteinase 7;Matrilysin | A measurement of the matrix metalloproteinase 7 in a biological specimen. | Matrix Metalloproteinase 7 Measurement | ||
MMP8 | C80196 | Matrix Metalloproteinase 8;Neutrophil Collagenase | A measurement of the matrix metalloproteinase 8 in a biological specimen. | Matrix Metalloproteinase 8 Measurement | ||
MMP9 | C80197 | Matrix Metalloproteinase 9;Gelatinase B | A measurement of the matrix metalloproteinase 9 in a biological specimen. | Matrix Metalloproteinase 9 Measurement | ||
MPO | C80198 | Myeloperoxidase | A measurement of the myeloperoxidase in a biological specimen. | Myeloperoxidase Measurement | ||
NEOPTERN | C80199 | Neopterin | A measurement of the neopterin in a biological specimen. | Neopterin Measurement | ||
NEUTMM | C84822 | Neutrophilic Metamyelocytes | A measurement of the neutrophilic metamyelocytes in a biological specimen. | Neutrophilic Metamyelocyte Count | ||
NEUTMY | C84823 | Neutrophilic Myelocytes | A measurement of the neutrophilic myelocytes in a biological specimen. | Neutrophilic Myelocyte Count | ||
NEUTSG | C81997 | Neutrophils, Segmented | A measurement of the segmented neutrophils in a biological specimen. | Segmented Neutrophil Count | ||
NEUTSGLE | C82045 | Neutrophils, Segmented/Leukocytes | A relative measurement (ratio or percentage) of segmented neutrophils to leukocytes in a biological specimen. | Segmented Neutrophil to Leukocyte Ratio Measurement | ||
NTXI | C82039 | Type I Collagen N-Telopeptides | A measurement of the type I collagen N-telopeptides in a biological specimen. | Type I Collagen N-Telopeptide Measurement | ||
NTXII | C82041 | Type II Collagen N-Telopeptides | A measurement of the type II collagen N-telopeptides in a biological specimen. | Type II Collagen N-Telopeptide Measurement | ||
PAI1 | C82030 | Plasminogen Activator Inhibitor-1 | A measurement of the plasminogen activator inhibitor-1 in a biological specimen. | Plasminogen Activator Inhibitor-1 Measurement | ||
PAI1AG | C81989 | Plasminogen Activator Inhibitor-1 AG | A measurement of the plasminogen activator inhibitor-1 antigen in a biological specimen. | Plasminogen Activator Inhibitor-1 Antigen Measurement | ||
PAP | C80204 | Prostatic Acid Phosphatase | A measurement of the prostatic acid phosphatase in a biological specimen. | Prostatic Acid Phosphatase Measurement | ||
PAPPA | C82031 | Pregnancy-Associated Plasma Protein-A | A measurement of the pregnancy-associated plasma protein-A in a biological specimen. | Pregnancy-Associated Plasma Protein-A Measurement | ||
PCO2 | C82625 | Partial Pressure Carbon Dioxide | A measurement of the pressure of carbon dioxide in a biological specimen. | Partial Pressure of Carbon Dioxide Measurement | ||
PDW | C81962 | Platelet Distribution Width | A measurement of the range of platelet sizes in a biological specimen. | Platelet Distribution Width | ||
PEMAB | C81988 | Pemphigoid Antibodies | A measurement of the pemphigoid antibodies in a biological specimen. | Pemphigoid Antibody Measurement | ||
PICP | C82033 | Procollagen Type I Carboxy Term Peptide | A measurement of the procollagen-1 carboxy-terminal peptide in a biological specimen. | Procollagen Type I Carboxy Terminal Peptide Measurement | ||
PNCTPP | C80201 | Pancreatic Polypeptide | A measurement of the pancreatic polypeptide in a biological specimen. | Pancreatic Polypeptide Measurement | ||
PO2 | C71251 | Partial Pressure Oxygen | A measurement of the pressure of oxygen in a biological specimen. | Partial Pressure of Oxygen Measurement | ||
PROINSUL | C81967 | Proinsulin | A measurement of the proinsulin in a biological specimen. | Proinsulin Measurement | ||
PTF1_2 | C82034 | Prothrombin Fragments 1 + 2 | A measurement of the prothrombin fragments 1 and 2 in a biological specimen. | Prothrombin Fragments 1 and 2 Measurement | ||
PTHCT | C81964 | Parathyroid Hormone, C-Terminal | A measurement of the C-terminal fragment of parathyroid hormone in a biological specimen. | C-Terminal Parathyroid Hormone Measurement | ||
PTHMM | C81965 | Parathyroid Hormone, Mid-Molecule | A measurement of the mid-molecule fragment of parathyroid hormone in a biological specimen. | Mid-Molecule Parathyroid Hormone Measurement | ||
PTHNT | C81966 | Parathyroid Hormone, N-Terminal | A measurement of the N-terminal fragment of parathyroid hormone in a biological specimen. | N-Terminal Parathyroid Hormone Measurement | ||
PYRIDNLN | C80211 | Pyridinoline | A measurement of the pyridinoline in a biological specimen. | Pyridinoline Measurement | ||
PYY | C80202 | Peptide YY;Peptide Tyrosine Tyrosine | A measurement of the peptide YY in a biological specimen. | Peptide YY Measurement | ||
RANTES | C81957 | Reg upon Act Normal T-cell Exprd Secrtd;Chemokine Ligand 5 | A measurement of the RANTES (regulated on activation, normally, T-cell expressed, and secreted) chemokine in a biological specimen. | Reg upon Act Normal T-cell Exprd Secrtd Measurement | ||
RBCNUCLE | C82046 | Nucleated Erythrocytes/Leukocytes | A relative measurement (ratio or percentage) of nucleated erythrocytes to leukocytes in a biological specimen. | Nucleated Erythrocyte to Leukocyte Ratio Measurement | ||
RESISTIN | C80205 | Resistin | A measurement of the resistin in a biological specimen. | Resistin Measurement | ||
RT3 | C81968 | Triiodothyronine, Reverse | A measurement of the reverse triiodothyronine in a biological specimen. | Reverse Triiodothyronine Measurement | ||
SCF | C82035 | Stem Cell Factor;KIT Ligand | A measurement of the stem cell factor in a biological specimen. | Stem Cell Factor Measurement | ||
TFERRIN | C82037 | Transferrin | A measurement of the transferrin in a biological specimen. | Transferrin Measurement | ||
THYAB | C81990 | Thyroid Antibodies | A measurement of the thyroid antibodies in a biological specimen. | Thyroid Antibody Measurement | ||
THYAMAB | C81991 | Thyroid Antimicrosomal Antibodies | A measurement of the thyroid antimicrosomal antibodies in a biological specimen. | Thyroid Antimicrosomal Antibody Measurement | ||
THYATAB | C81992 | Thyroid Antithyroglobulin Antibodies | A measurement of the thyroid antithyroglobulin antibodies in a biological specimen. | Thyroid Antithyroglobulin Antibody Measurement | ||
TIMP1 | C82036 | Tissue Inhibitor of Metalloproteinase 1 | A measurement of the tissue inhibitor of metalloproteinase 1 in a biological specimen. | Tissue Inhibitor of Metalloproteinase 1 Measurement | ||
TPAAG | C81993 | Tissue Plasminogen Activator Antigen | A measurement of the tissue plasminogen activator antigen in a biological specimen. | Tissue Plasminogen Activator Antigen Measurement | ||
TPRONP | C84811 | Non-Phosphorylated Tau Protein | A measurement of the non-phosphorylated Tau protein in a biological specimen. | Nonphosphorylated Tau Protein Measurement | ||
TPROT | C84810 | Tau Protein;Total Tau Protein | A measurement of the total Tau protein in a biological specimen. | Tau Protein Measurement | ||
TPROTP | C84812 | Phosphorylated Tau Protein | A measurement of the phosphorylated Tau protein in a biological specimen. | Phosphorylated Tau Protein Measurement | ||
TRAP | C80208 | Total Radical-Trap Antioxidant Potential | A measurement of the ability of the antioxidants in a biological specimen to buffer free radicals in a suspension. | Total Radical-Trap Antioxidant Potential Measurement | ||
TT | C80365 | Thrombin Time | A measurement of the time it takes a plasma sample to clot after adding the active enzyme thrombin. (NCI) | Thrombin Time | ||
VCAM1 | C82042 | Vascular Cell Adhesion Molecule 1 | A measurement of the vascular cell adhesion molecule 1 in a biological specimen. | Vascular Cell Adhesion Molecule 1 Measurement | ||
VEGF | C92514 | Vascular Endothelial Growth Factor | A measurement of the vascular endothelial growth factor in a biological specimen. | Vascular Endohelial Growth Factor Measurement | ||
VISC | C75912 | Viscosity | The resistance of a liquid to sheer forces and flow. (NCI) | Viscosity | ||
VITD | C84818 | Vitamin D;Total Vitamin D | A measurement of the total Vitamin D in a biological specimen. | Vitamin D Measurement | ||
ZINC | C80210 | Zinc | A measurement of the zinc in a biological specimen. | Zinc Measurement | ||
CORTFR | C88113 | Cortisol, Free | A measurement of the free, unbound cortisol in a biological specimen. | Free Cortisol Measurement | ||
VITDAT | C92267 | 1, 25-Dihydroxyvitamin D;Active Vitamin D | A measurement of the total active Vitamin D in a biological specimen. | 1, 25-Dihydroxyvitamin D Measurement | ||
VITDIT | C92268 | 25-Hydroxyvitamin D;Inactive Vitamin D | A measurement of the total inactive Vitamin D in a biological specimen. | 25-Hydroxyvitamin D Measurement | ||
ACETOAC | C92247 | Acetoacetic Acid;Acetoacetate | A measurement of the acetoacetic acid in a biological specimen. | Acetoacetic Acid Measurement | ||
ACYLCAOX | C92286 | Acyl Coenzyme A Oxidase;Fatty Acyl Coenzyme A Oxidase;Acyl CoA Oxidase | A measurement of the acyl coenzyme A oxidase in a biological specimen. | Acyl Coenzyme A Oxidase Measurement | ||
GLOBA1 | C92252 | Alpha-1 Globulin;A1-Globulin | A measurement of the proteins contributing to the alpha 1 fraction in a biological specimen. | Alpha-1 Globulin Measurement | ||
GLOBA1PT | C92253 | Alpha-1 Globulin/Total Protein | A relative measurement (ratio or percentage) of alpha-1-fraction proteins to total proteins in a biological specimen. | Alpha-1 Globulin to Total Protein Ratio Measurement | ||
GLOBA2 | C92254 | Alpha-2 Globulin;A2-Globulin | A measurement of the proteins contributing to the alpha 2 fraction in a biological specimen. | Alpha-2 Globulin Measurement | ||
GLOBA2PT | C92255 | Alpha-2 Globulin/Total Protein | A relative measurement (ratio or percentage) of alpha-2-fraction proteins to total proteins in a biological specimen. | Alpha-2 Globulin to Total Protein Ratio Measurement | ||
CYAMPPH | C92243 | Amorphous Phosphate Crystals | A measurement of the amorphous phosphate crystals in a biological specimen. | Amorphous Phosphate Crystals Measurement | ||
CYAMPURT | C92244 | Amorphous Urate Crystals | A measurement of the amorphous urate crystals in a biological specimen. | Amorphous Urate Crystals Measurement | ||
ASSDNA | C92269 | Anti-Single Stranded DNA IgG | A measurement of the anti-single stranded DNA IgG antibody in a biological specimen. | Anti-Single Stranded DNA IgG Measurement | ||
APOE4 | C92293 | Apolipoprotein E4 | A measurement of the apolipoprotein E4 in a biological specimen. | Apolipoprotein E4 Measurement | ||
GLOBB | C92256 | Beta Globulin | A measurement of the proteins contributing to the beta fraction in a biological specimen. | Beta Globulin Measurement | ||
GLOBBPT | C92294 | Beta Globulin/Total Protein | A relative measurement (ratio or percentage) of beta fraction proteins to total proteins in a biological specimen. | Beta Globulin to Total Protein Ratio Measurement | ||
ALPBS | C92287 | Bone Specific Alkaline Phosphatase | A measurement of the bone specific alkaline phosphatase isoform in a biological specimen. | Bone Specific Alkaline Phosphatase Measurement | ||
CARNITAT | C92288 | Carnitine Acetyl Transferase | A measurement of the carnitine acetyl transferase in a biological specimen. | Carnitine Acetyl Transferase Measurement | ||
CPNIGAAB | C92432 | Chlamydia pneumoniae IgA Antibody | A measurement of the Chlamydia pneumoniae IgA antibody in a biological specimen. | Chlamydia pneumoniae IgA Antibody Measurement | ||
CPNIGMAB | C92433 | Chlamydia pneumoniae IgM Antibody | A measurement of the Chlamydia pneumoniae IgM in a biological specimen. | Chlamydia pneumoniae IgM Antibody Measurement | ||
CHOLINES | C92289 | Cholinesterase | A measurement of the cholinesterase in a biological specimen. | Cholinesterase Measurement | ||
CITRATE | C92248 | Citrate | A measurement of the citrate in a biological specimen. | Citrate Measurement | ||
COTININE | C92249 | Cotinine | A measurement of the cotinine in a biological specimen. | Cotinine Measurement | ||
CYSTATC | C92290 | Cystatin C | A measurement of the cystatin C in a biological specimen. | Cystatin C Measurement | ||
RBCCLMP | C92245 | Erythrocyte Cell Clumps;Red Blood Cell Clumps;RBC Clumps | A measurement of red blood cell clumps in a biological specimen. | Erythrocyte Cell Clumps Measurement | ||
RBCMORPH | C92296 | Erythrocyte Cell Morphology;Red Blood Cell Morphology;RBC Morphology | An examination or assessment of the form and structure of red blood cells. | Erythrocyte Cell Morphology | ||
ENAAB | C92270 | Anti-ENA;Extractable Nuclear Antigen Antibody | A measurement of the extractable nuclear antigen antibody in a biological specimen. | Extractable Nuclear Antigen Antibody Measurement | ||
GLOBG | C92257 | Gamma Globulin | A measurement of the proteins contributing to the gamma fraction in a biological specimen. | Gamma Globulin Measurement | ||
GLOBGPT | C92295 | Gamma Globulin/Total Protein | A relative measurement (ratio or percentage) of gamma fraction proteins to total proteins in a biological specimen. | Gamma Globulin to Total Protein Ratio Measurement | ||
GFR | C90505 | Glomerular Filtration Rate | A kidney function test that measures the fluid volume that is filtered from the kidney glomeruli to the Bowman's capsule per unit of time. | Glomerular Filtration Rate | ||
HGBA | C92258 | Hemoglobin A | A measurement of the hemoglobin A in a biological specimen. | Hemoglobin A Measurement | ||
HGBA2 | C92259 | Hemoglobin A2 | A measurement of the hemoglobin A2 in a biological specimen. | Hemoglobin A2 Measurement | ||
HGBB | C92260 | Hemoglobin B | A measurement of the hemoglobin B in a biological specimen. | Hemoglobin B Measurement | ||
HGBC | C92261 | Hemoglobin C | A measurement of the hemoglobin C in a biological specimen. | Hemoglobin C Measurement | ||
HGBF | C92262 | Hemoglobin F;Fetal Hemoglobin | A measurement of the hemoglobin F in a biological specimen. | Hemoglobin F Measurement | ||
HAABIGM | C92271 | Hepatitis A Virus Antibody IgM | A measurement of hepatitis A virus antibody IgM in a biological specimen. | Hepatitis A Virus Antibody IgM Measurement | ||
HGRNA | C92272 | Hepatitis G RNA | A measurement of the Hepatitis G RNA in a biological specimen. | Hepatitis G RNA Measurement | ||
HIVIMONA | C92263 | HIV-1 Group M and O Nucleic Acid | A measurement of the HIV-1 group M and O nucleic acids in a biological specimen. | HIV-1 Group M and O Nucleic Acid Measurement | ||
HIVIOAB | C92264 | HIV-1 Group O Antibody | A measurement of the HIV-1 group O antibody in a biological specimen. | HIV-1 Group O Antibody Measurement | ||
HIVI24AG | C92265 | HIV-1 p24 Antigen | A measurement of the HIV-1 p24 antigen in a biological specimen. | HIV-1 p24 Antigen Measurement | ||
HIV2NUAC | C92266 | HIV-2 Nucleic Acid | A measurement of the HIV-2 nucleic acids in a biological specimen. | HIV-2 Nucleic Acid Measurement | ||
IAH1N1VL | C92273 | Influenza A H1N1 Viral Load | A measurement of the Influenza A H1N1 viral load in a biological specimen. | Influenza A H1N1 Viral Load Measurement | ||
INFAVLD | C92274 | Influenza A Viral Load | A measurement of the Influenza A viral load in a biological specimen. | Influenza A Viral Load Measurement | ||
LPNAG | C92275 | Legionella pneumophila Antigen | A measurement of the Legionella pneumophila antigen in a biological specimen. | Legionella pneumophila Antigen Measurement | ||
LPNIGGAB | C92276 | Legionella pneumophila IgG Antibody | A measurement of the Legionella pneumophila IgG antibody in a biological specimen. | Legionella pneumophila IgG Antibody Measurement | ||
LPNGMAB | C92277 | Legionella pneumophila IgG IgM Antibody | A measurement of the Legionella pneumophila IgG and IgM in a biological specimen. | Legionella pneumophila IgG IgM Antibody Measurement | ||
LPNIGMAB | C92278 | Legionella pneumophila IgM Antibody | A measurement of the Legionella pneumophila IgM antibody in a biological specimen. | Legionella pneumophila IgM Antibody Measurement | ||
WBCMORPH | C92297 | Leukocyte Cell Morphology;White Blood Cell Morphology;WBC Morphology | An examination or assessment of the form and structure of white blood cells. | Leukocyte Cell Morphology | ||
WBCCLMP | C92246 | Leukocyte Cell Clumps;White Blood Cell Clumps;WBC Clumps | A measurement of white blood cell clumps in a biological specimen. | Leukocyte Cell Clumps Measurement | ||
MCPROT | C92291 | Monoclonal Immunoglobulin Protein;Paraprotein | A measurement of homogenous immunoglobulin resulting from the proliferation of a single clone of plasma cells in a biological specimen. | Monoclonal Protein Measurement | ||
MYTBGIR | C92241 | Mycobacterium tuberculosis IFN Gamma Response | A measurement of the amount of interferon gamma that is released when Mycobacterium tuberculosis antigen is incubated with a biological specimen, usually blood. Increased amounts of interferon gamma suggests a prior or existing M. tuberculosis infection. | Mycobacterium tuberculosis Interferon Gamma Response | ||
MYTBNUAC | C92279 | Mycobacterium tuberculosis Nucleic Acid | A measurement of the Mycobacterium tuberculosis nucleic acid in a biological specimen. | Mycobacterium tuberculosis Nucleic Acid Measurement | ||
MYPCERPC | C92242 | Myeloid/Erythroid Ratio | A relative measurement (ratio or percentage) of myeloid progenitor cells to erythrocyte precursor cells in a biological specimen. | Myeloid to Erythroid Ratio Measurement | ||
MPOAB | C92280 | Myeloperoxidase Antibody | A measurement of the myeloperoxidase antibody in a biological specimen. | Myeloperoxidase Antibody Measurement | ||
NGON | C92298 | Neisseria gonorrhoeae Screening | Examination of a biological specimen to detect the presence of Neisseria gonorrhoeae. | Neisseria gonorrhoeae Screening | ||
OSMRTY | C74802 | Osmolarity | A measurement of the osmoles of solute per liter of solution. | Osmolarity Measurement | ||
OXALATE | C92250 | Oxalate;Ethanedioate | A measurement of the oxalate in a biological specimen. | Oxalate Measurement | ||
PROTOSML | C92240 | Protein/Osmolality;Protein/Osmolality Ratio | A relative measurement (ratio or percentage) of total proteins to the osmolality of a biological specimen. | Protein to Osmolality Ratio Measurement | ||
SJSSAAB | C92236 | Ro Antibody;Sjogrens SS-A Antibody | A measurement of the Sjogrens SS-A antibody in a biological specimen. | Sjogren's SS-A Antibody Measurement | ||
SJSSBAB | C92237 | La Antibody;Sjogrens SS-B Antibody | A measurement of the Sjogrens SS-B antibody in a biological specimen. | Sjogren's SS-B Antibody Measurement | ||
SMTHAB | C92281 | Smith Antibody | A measurement of the Smith antibody in a biological specimen. | Smith Antibody Measurement | ||
STRPLOAB | C92282 | Streptolysin O Antibody;Antistreptolysin O | A measurement of Streptolysin O Antibody in a biological specimen. | Streptolysin O Antibody Measurement | ||
EPITCE | C92251 | Transitional Epithelial Cells | A measurement of the transitional epithelial cells present in a biological specimen. | Transitional Epithelial Cells Measurement | ||
TRICH | C92238 | Trichomonas | Examination of a biological specimen to detect the presence of any protozoan belonging to the Trichomonas genus. | Trichomonas Screening | ||
TRYPTASE | C92292 | Tryptase | A measurement of the tryptase in a biological specimen. | Tryptase Measurement | ||
MYBLAT1 | C92283 | Type I Myeloblasts | A measurement of type I myeloblast cells per unit of a biological specimen. | Type I Myeloblasts Measurement | ||
MYBLAT2 | C92284 | Type II Myeloblasts | A measurement of type II myeloblast cells per unit of a biological specimen. | Type II Myeloblasts Measurement | ||
MYBLAT3 | C92285 | Type III Myeloblasts | A measurement of type III myeloblast cells per unit of a biological specimen. | Type III Myeloblasts Measurement | ||
YEASTHYP | C92239 | Yeast Hyphae | Examination of a biological specimen to detect the presence of any yeast cells that are in the long, filamentous and branching phase of growth. | Yeast Hyphae Screening | ||
SVCAM1 | C92533 | Soluble Vascular Cell Adhesion Molecule 1 | A measurement of the soluble vascular cell adhesion molecule 1 in a biological specimen. | Soluble Vascular Cell Adhesion Molecule 1 | ||
AFPL3AFP | C96565 | A Fetoprotein L3/A Fetoprotein | A relative measurement (ratio or percentage) of alpha fetoprotein L3 to total alpha fetoprotein in a biological specimen. | Alpha Fetoprotein L3 to Total Alpha Fetoprotein Ratio Measurement | ||
ACHRAB | C96559 | Acetylcholine Receptor Antibody | A measurement of the acetylcholine receptor antibody in a biological specimen. | Acetylcholine Receptor Antibody Measurement | ||
ACHE | C96560 | Acetylcholinesterase | A measurement of the acetylcholinesterase in a biological specimen. | Acetylcholinesterase Measurement | ||
AFPL1 | C96562 | Alpha Fetoprotein L1 | A measurement of the alpha fetoprotein L1 in a biological specimen. | Alpha Fetoprotein L1 Measurement | ||
AFPL2 | C96563 | Alpha Fetoprotein L2 | A measurement of the alpha fetoprotein L2 in a biological specimen. | Alpha Fetoprotein L2 Measurement | ||
AFPL3 | C96564 | Alpha Fetoprotein L3 | A measurement of the alpha fetoprotein L3 in a biological specimen. | Alpha Fetoprotein L3 Measurement | ||
STIPBASO | C96567 | Basophilic Stippling | A measurement of the basophilic stippling in a biological specimen. | Basophilic Stippling Measurement | ||
BNZLCGN | C75350 | Benzoylecgonine;Cocaine Metabolite | A measurement of the benzoylecgonine in a biological specimen. | Benzoylecgonine Measurement | ||
BHYXBTR | C96568 | Beta-Hydroxybutyrate;B-Hydroxybutyrate;3-Hydroxybutyrate | A measurement of the total Beta-hydroxybutyrate in a biological specimen. | Beta-Hydroxybutyrate Measurement | ||
CSBROAD | C96588 | Broad Casts | A measurement of the broad casts in a biological specimen. | Broad Casts Measurement | ||
CACLR | C96589 | Calcium Clearance | A measurement of the volume of serum or plasma that would be cleared of calcium by excretion of urine for a specified unit of time (e.g. one minute). | Calcium Clearance Measurement | ||
CASULPH | C96590 | Calcium Sulphate | A measurement of the calcium sulphate in a biological specimen. | Calcium Sulphate Measurement | ||
CARBXHGB | C96591 | Carboxyhemoglobin | A measurement of the carboxyhemoglobin in a biological specimen. | Carboxyhemoglobin Measurement | ||
CEC | C96592 | Circulating Endothelial Cells | A measurement of the circulating endothelial cells in a biological specimen. | Circulating Endothelial Cell Count | ||
CTC | C96593 | Circulating Tumor Cells | A measurement of the circulating tumor cells in a biological specimen. | Circulating Tumor Cell Count | ||
CLARITY | C96594 | Clarity | A measurement of the transparency of a biological specimen. | Clarity Measurement | ||
CCPAB | C96595 | Cyclic Citrullinated Peptide Antibody | A measurement of the cyclic citrullinated peptide antibody in a biological specimen. | Cyclic Citrullinated Peptide Antibody Measurement | ||
CMVIGGAB | C96596 | Cytomegalovirus IgG Antibody | A measurement of the cytomegalovirus IgG antibody in a biological specimen. | Cytomegalovirus IgG Antibody Measurement | ||
CMVIGMAB | C96597 | Cytomegalovirus IgM Antibody | A measurement of the cytomegalovirus IgM antibody in a biological specimen. | Cytomegalovirus IgM Antibody Measurement | ||
DHEAS | C96629 | Dehydroepiandrosterone Sulfate;DHEA-S;sDHEA;DHEA Sulfate | A measurement of the sulfated Dehydroepiandrosterone in a biological specimen. | Sulfated DHEA Measurement | ||
DRVVT | C96696 | Dilute Russell's Viper Venom Time;Lupus Anticoagulant Test | A measurement of the time it takes a plasma sample to clot after adding dilute Russell's viper venom. | Dilute Russell's Viper Venom Time Measurement | ||
ECCENTCY | C96598 | Eccentrocytes | A measurement of the eccentrocytes (erythrocytes in which the hemoglobin is localized to a particular portion of the cell, noticeable as localized staining) in a biological specimen. | Eccentrocyte Count | ||
EBCIGGAB | C96600 | Epstein-Barr Capsid IgG Antibody | A measurement of the Epstein-Barr capsid IgG antibody in a biological specimen. | Epstein-Barr Capsid IgG Antibody Measurement | ||
EBCIGMAB | C96601 | Epstein-Barr Capsid IgM Antibody | A measurement of the Epstein-Barr capsid IgM antibody in a biological specimen. | Epstein-Barr Capsid IgM Antibody Measurement | ||
EBEAG | C96602 | Epstein-Barr Early Antigen | A measurement of the Epstein-Barr early antigen in a biological specimen. | Epstein-Barr Early Antigen Measurement | ||
EBNAB | C96603 | Epstein-Barr Nuclear Antibody | A measurement of the Epstein-Barr nuclear antibody in a biological specimen. | Epstein-Barr Nuclear Antibody Measurement | ||
EBNAG | C96604 | Epstein-Barr Nuclear Antigen | A measurement of the Epstein-Barr nuclear antigen in a biological specimen. | Epstein-Barr Nuclear Antigen Measurement | ||
RBCGHOST | C96605 | Erythrocyte Ghosts;RBC Ghosts | A measurement of the erythrocyte ghosts (erythrocytes in which hemoglobin has been removed through hemolysis) in a biological specimen. | Erythrocyte Ghost Count | ||
FACTII | C96626 | Factor II;Prothrombin | A measurement of the Factor II in a biological specimen. | Prothrombin Measurement | ||
FAT | C96648 | Fat | A measurement of the fat in a biological specimen. | Fat Measurement | ||
FGF23 | C96650 | Fibroblast Growth Factor 23;Phosphatonin | A measurement of the fibroblast growth factor 23 in a biological specimen. | Fibroblast Growth Factor 23 Measurement | ||
NEUTGT | C96651 | Giant Neutrophils | A measurement of the giant neutrophils in a biological specimen. | Giant Neutrophil Count | ||
GLUCCLR | C96652 | Glucose Clearance | A measurement of the volume of serum or plasma that would be cleared of glucose by excretion of urine for a specified unit of time (e.g. one minute). | Glucose Clearance Measurement | ||
GADAB | C96653 | Glutamic Acid Decarboxylase Antibody;GAD Antibody | A measurement of the glutamic acid decarboxylase antibody in a biological specimen. | Glutamic Acid Decarboxylase Antibody Measurement | ||
GRAN | C96654 | Granulocytes | A measurement of the granulocytes in a biological specimen. | Granulocyte Count | ||
HBCAB | C96660 | Hepatitis B Virus Core Antibody | A measurement of the hepatitis B virus core antibody in a biological specimen. | Hepatitis B Virus Core Antibody Measurement | ||
HBCIGMAB | C96661 | Hepatitis B Virus Core IgM Antibody | A measurement of the hepatitis B virus core IgM antibody in a biological specimen. | Hepatitis B Virus Core IgM Antibody Measurement | ||
HBEAB | C96662 | Hepatitis B Virus e Antibody | A measurement of the hepatitis B e antibody in a biological specimen. | Hepatitis B Virus e Antibody Measurement | ||
HBEAG | C96663 | Hepatitis B Virus e Antigen | A measurement of the hepatitis B e antigen in a biological specimen. | Hepatitis B Virus e Antigen Measurement | ||
HDAB | C96664 | Hepatitis D Virus Antibody;Hepatitis Delta Antibody | A measurement of the hepatitis D virus antibody in a biological specimen. | Hepatitis D Virus Antibody Measurement | ||
HEIGMAB | C96665 | Hepatitis E Virus IgM Antibody | A measurement of the hepatitis E virus IgM antibody in a biological specimen. | Hepatitis E Virus IgM Antibody Measurement | ||
HS1IGGAB | C96697 | Herpes Simplex Virus 1 IgG Antibody;HSV-1 IgG Antibody | A measurement of the herpes simplex virus 1 IgG antibody in a biological specimen. | Herpes Simplex Virus 1 IgG Antibody Measurement | ||
HS12GGAB | C96698 | Herpes Simplex Virus 1/2 IgG Antibody;HSV-1/2 IgG Ab | A measurement of the herpes simplex virus 1 and 2 IgG antibody in a biological specimen. | Herpes Simplex Virus 1/2 IgG Antibody Measurement | ||
HS12GMAB | C96666 | Herpes Simplex Virus 1/2 IgM Antibody;HSV-1/2 IgM Ab | A measurement of the herpes simplex virus 1 and 2 IgM antibody in a biological specimen. | Herpes Simplex Virus 1/2 IgM Antibody Measurement | ||
HS2IGGAB | C96667 | Herpes Simplex Virus 2 IgG Antibody;HSV-2 IgG Antibody | A measurement of the herpes simplex virus 2 IgG antibody in a biological specimen. | Herpes Simplex Virus 2 IgG Antibody Measurement | ||
HEXK | C96668 | Hexokinase | A measurement of the hexokinase in a biological specimen. | Hexokinase Measurement | ||
HYPERCHR | C96669 | Hyperchromia | A measurement of the prevalence of the erthrocytes with an elevated hemoglobin concentration. | Hyperchromia Measurement | ||
BASOIM | C96670 | Immature Basophils | A measurement of the immature basophils in a biological specimen. | Immature Basophil Count | ||
BASOIMLE | C96671 | Immature Basophils/Leukocytes | A relative measurement (ratio or percentage) of immature basophils to total leukocytes in a biological specimen. | Immature Basophil to Leukocyte Ratio Measurement | ||
CELLSIM | C96672 | Immature Cells | A measurement of the total immature cells in a blood specimen. | Immature Cell Count | ||
EOSIM | C96673 | Immature Eosinophils | A measurement of the immature eosinophils in a biological specimen. | Immature Eosinophil Count | ||
EOSIMLE | C96674 | Immature Eosinophils/Leukocytes | A relative measurement (ratio or percentage) of immature eosinophils to total leukocytes in a biological specimen. | Immature Eosinophil to Leukocyte Ratio Measurement | ||
GRANIM | C96675 | Immature Granulocytes | A measurement of the total immature granulocytes in a biological specimen. | Immature Granulocyte Count | ||
MONOIM | C96676 | Immature Monocytes | A measurement of the immature monocytes in a biological specimen. | Immature Monocyte Count | ||
MONOIMLE | C96677 | Immature Monocytes/Leukocytes | A relative measurement (ratio or percentage) of immature monocytes to total leukocytes in a biological specimen. | Immature Monocyte to Leukocyte Ratio Measurement | ||
NEUTIM | C96678 | Immature Neutrophils | A measurement of the total immature neutrophils in a biological specimen. | Immature Neutrophil Count | ||
PLSIMCE | C96679 | Immature Plasma Cells | A measurement of the immature plasma cells in a biological specimen. | Immature Plasma Cell Count | ||
PLSIMCLY | C96680 | Immature Plasma Cells/Lymphocytes | A relative measurement (ratio or percentage) of immature plasma cells to total lymphocytes in a biological specimen. | Immature Plasma Cell to Lymphocyte Ratio Measurement | ||
INHIBINB | C96681 | Inhibin B | A measurement of the inhibin B in a biological specimen. | Inhibin B Measurement | ||
KURLOFCE | C96682 | Kurloff Cells | A measurement of the large secretory granule-containing immune cells in a biological specimen taken from members of certain genera of the Caviidae family. | Kurloff Cells Measurement | ||
LKM1AB | C96683 | Liver Kidney Microsomal Type 1 Antibody;LKM-1 | A measurement of the liver kidney microsomal type 1 antibody in a biological specimen. | Liver Kidney Microsomal Type 1 Antibody Measurement | ||
MPC | C96686 | Mean Platelet Component | A measurement of the mean platelet component (platelet activity) in a blood specimen. | Mean Platelet Component Measurement | ||
KRCYMG | C96688 | Megakaryocytes | A measurement of the megakaryocytes per unit of a biological specimen. | Megakaryocyte Count | ||
HGBMET | C96689 | Methemoglobin | A measurement of the methemoglobin in a biological specimen. | Methemoglobin Measurement | ||
MMA | C96690 | Methylmalonic Acid | A measurement of the methylmalonic acid in a biological specimen. | Methylmalonic Acid Measurement | ||
BNPPRONT | C96610 | N-Terminal ProB-type Natriuretic Peptide;NT proBNP II;N-terminal pro-Brain Natriuretic Peptide | A measurement of the N-terminal proB-type natriuretic peptide in a biological specimen. | N-Terminal ProB-type Natriuretic Peptide Measurement | ||
OXYCAP | C96614 | Oxygen Capacity | A measurement of the maximum amount of oxygen that can be combined chemically with hemoglobin in a volume of blood. | Oxygen Capacity Measurement | ||
OXYSAT | C60832 | Oxygen Saturation | A measurement of the oxygen-hemoglobin saturation of a volume of blood. | Oxygen Saturation Measurement | ||
HGBOXY | C96616 | Oxyhemoglobin | A measurement of the oxyhemoglobin in a biological specimen. | Oxyhemoglobin Measurement | ||
PB19GGAB | C96617 | Parvovirus B19 IgG Antibody | A measurement of the Parvovirus B19 IgG antibody in a biological specimen. | Parvovirus B19 IgG Antibody Measurement | ||
PB19GMAB | C96618 | Parvovirus B19 IgM Antibody | A measurement of the Parvovirus B19 IgM antibody in a biological specimen. | Parvovirus B19 IgM Antibody Measurement | ||
PHOSLPD | C96623 | Phospholipid | A measurement of the phospholipids in a biological specimen. | Phospholipid Measurement | ||
PLATCLMP | C96624 | Platelet Clumps;PLT Clumps | A measurement of the platelet clumps in a biological specimen. | Platelet Clumps Count | ||
P1NP | C96625 | Procollagen 1 N-Terminal Propeptide;Amino-terminal propeptide of type 1 procollagen;P1NP Aminoterm Type 1 | A measurement of the procollagen 1 N-terminal propeptide in a biological specimen. | Procollagen 1 N-Terminal Propeptide Measurement | ||
RPTLTIME | C96628 | Reptilase Time | A measurement of the time it takes a plasma sample to clot after adding the active enzyme reptilase. | Reptilase Time Measurement | ||
TRGTCE | C96636 | Leptocytes;Target Cells;Codocytes;Mexican Hat Cells | A measurement of the target cells in a biological specimen. | Target Cell Count | ||
THYPXD | C96639 | Thyroperoxidase;Thyroid Peroxidase | A measurement of the thyroperoxidase in a biological specimen. | Thyroperoxidase Measurement | ||
THYPXDAB | C96638 | Thyroperoxidase Antibody | A measurement of the thyroperoxidase antibody in a biological specimen. | Thyroperoxidase Antibody Measurement | ||
TOXGRAN | C96641 | Toxic Granulation | A measurement of the toxic granulation in neutrophilic blood cells. | Toxic Granulation Measurement | ||
UREACRT | C96645 | Urea/Creatinine | A relative measurement (ratio or percentage) of the urea to creatinine in a biological specimen. | Urea to Creatinine Ratio Measurement | ||
ADVVLD | C98705 | ADV Viral Load | A measurement of the adenovirus viral load in a biological specimen. | Adenovirus Viral Load Measurement | ||
AFACTXAA | C98706 | Anti-Factor Xa Activity | A measurement of the anti-activated Factor X in a biological specimen. This test is used to monitor low molecular weight or unfractionated heparin levels in a biological specimen. | Anti-Factor Xa Activity Measurement | ||
AMYLASEP | C98767 | Amylase, Pancreatic | A measurement of the pancreatic enzyme amylase in a biological specimen. | Pancreatic Amylase Measurement | ||
AMYLASES | C98780 | Amylase, Salivary | A measurement of the salivary enzyme amylase in a biological specimen. | Salivary Amylase Measurement | ||
APTTSTND | C98862 | Activated PTT/Standard | A relative measurement (ratio or percentage) of the subject's partial thromboplastin time to a standard or control partial thromboplastin time. | Activated PTT/Standard Ratio Measurement | ||
BASOCE | C98865 | Basophils/Total Cells | A relative measurement (ratio or percentage) of the basophils to total cells in a biological specimen (for example a bone marrow specimen). | Basophil to Total CellRatio Measurement | ||
BKVVLD | C98710 | BKV Viral Load | A measurement of the BK virus viral load in a biological specimen. | BK Virus Viral Load Measurement | ||
BLSTMBCE | C98761 | Myeloblasts/Total Cells | A relative measurement (ratio or percentage) of the myeloblasts to total cells in a biological specimen (for example a bone marrow specimen). | Myeloblast to Total Cell Ratio Measurement | ||
BLSTMGK | C98752 | Megakaryoblasts | A measurement of the megakaryoblasts in a biological specimen. | Megakaryoblast Cell Count | ||
BLSTMKCE | C98753 | Megakaryoblasts/Total Cells | A relative measurement (ratio or percentage) of the megakaryoblasts to total cells in a biological specimen (for example a bone marrow specimen). | Megakaryoblast to Total Cell Ratio Measurement | ||
BLSTNMCE | C98764 | Normoblasts/Total Cells | A relative measurement (ratio or percentage) of the normoblasts to total cells in a biological specimen (for example a bone marrow specimen). | Normoblast to Total Cell Ratio Measurement | ||
BLSTPNCE | C98870 | Pronormoblasts/Total Cells | A relative measurement (ratio or percentage) of the pronormoblasts to total cells in a biological specimen (for example a bone marrow specimen). | Pronormoblast to Total CellRatio Measurement | ||
CMVVLD | C98716 | CMV Viral Load | A measurement of the cytomegalovirus viral load in a biological specimen. | Cytomegalovirus Viral Load Measurement | ||
EBVVLD | C98721 | EBV Viral Load | A measurement of the Epstein-Barr virus viral load in a biological specimen. | Epstein-Barr Virus Viral Load Measurement | ||
EOSCE | C98720 | Eosinophils/Total Cells | A relative measurement (ratio or percentage) of the eosinophils to total cells in a biological specimen (for example a bone marrow specimen). | Eosinophils to Total Cell Ratio Measurement | ||
FACTIX | C98725 | Factor IX;Christmas Factor | A measurement of the factor IX in a biological specimen. | Factor IX Measurement | ||
FACTV | C98726 | Factor V;Labile Factor | A measurement of the factor V in a biological specimen. | Factor V Measurement | ||
FACTVW | C98799 | von Willebrand Factor;von Willebrand Factor Antigen | A measurement of the von Willebrand factor in a biological specimen. | von Willebrand Factor Measurement | ||
FACTX | C98727 | Factor X | A measurement of the factor X in a biological specimen. | Factor X Measurement | ||
FATDROP | C98728 | Fat Droplet | A measurement of the triglyceride aggregates within a biological specimen. | Fat Droplet Measurement | ||
GFRBSA | C98734 | Glomerular Filtration Rate Adj for BSA | A measurement of the glomerular filtration rate adjusted for body size. | Glomerular Filtration Rate Adjusted for BSA | ||
GFRBSCRT | C98735 | GFR from Creatinine Adjusted for BSA | An estimation of the glomerular filtration rate adjusted for body size based on creatinine. | Glomerular Filtration Rate from Creatinine Adjusted for BSA | ||
GFRBSCYC | C98736 | GFR from Cystatin C Adjusted for BSA | An estimation of the glomerular filtration rate adjusted for body size based on cystatin C. | Glomerular Filtration Rate from Cystatin C Adjusted for BSA | ||
GRANCE | C98866 | Granulocytes/Total Cells | A relative measurement (ratio or percentage) of the granulocytes to total cells in a biological specimen (for example a bone marrow specimen). | Granulocyte to Total CellRatio Measurement | ||
HASIGEAB | C98740 | Human Anti-Sheep IgE Antibody | A measurement of the human anti-sheep IgE antibodies in a biological specimen. | Human Anti-Sheep IgE Antibody Measurement | ||
HASIGGAB | C98741 | Human Anti-Sheep IgG Antibody | A measurement of the human anti-sheep IgG antibodies in a biological specimen. | Human Anti-Sheep IgG Antibody Measurement | ||
HASIGMAB | C98742 | Human Anti-Sheep IgM Antibody | A measurement of the human anti-sheep IgM antibodies in a biological specimen. | Human Anti-Sheep IgM Antibody Measurement | ||
HMOSIDRN | C96659 | Hemosiderin | A measurement of the hemosiderin complex in a biological specimen. | Hemosiderin Measurement | ||
HS1IGMAB | C98738 | Herpes Simplex Virus 1 IgM Antibody | A measurement of the Herpes Simplex virus 1 IgM antibodies in a biological specimen. | Herpes Simplex Virus 1 IgM Antibody Measurement | ||
HS2IGMAB | C98739 | Herpes Simplex Virus 2 IgM Antibody | A measurement of the Herpes Simplex virus 2 IgM antibodies in a biological specimen. | Herpes Simplex Virus 2 IgM Antibody Measurement | ||
IGD | C98745 | Immunoglobulin D | A measurement of the Immunoglobulin D in a biological specimen. | Immunoglobulin D Measurement | ||
INLCLR | C98748 | Inulin Clearance | A measurement of the volume of serum or plasma that would be cleared of inulin by excretion of urine for a specified unit of time (e.g. one minute). | Inulin Clearance | ||
IOTCLR | C98749 | Iothalamate Clearance | A measurement of the volume of serum or plasma that would be cleared of iothalamate by excretion of urine for a specified unit of time (e.g. one minute). | Iothalamate Clearance | ||
IOTCLRBS | C98750 | Iothalamate Clearance Adjusted for BSA | A measurement of the volume of serum or plasma that would be cleared of iothalamate by excretion of urine for a specified unit of time (e.g. one minute), adjusted for body size. | Iothalamate Clearance Adjusted for BSA | ||
KLCFR | C98730 | Kappa Light Chain, Free | A measurement of the free kappa light chain in a biological specimen. | Free Kappa Light Chain Measurement | ||
KLCLLCFR | C98731 | Kappa Lt Chain,Free/Lambda Lt Chain,Free | A relative measurement (ratio or percentage) of the free kappa light chain to the free lambda light chain in a biological specimen. | Free Kappa Light Chain to Free Lambda Light Chain Ratio Measurement | ||
KRCYMGCE | C98867 | Megakaryocytes/Total Cells | A relative measurement (ratio or percentage) of the megakaryocytes to total cells in a biological specimen (for example a bone marrow specimen). | Megakaryocyte to Total CellRatio Measurement | ||
LLCFR | C98732 | Lambda Light Chain, Free | A measurement of the free lambda light chain in a biological specimen. | Free Lambda Light Chain Measurement | ||
LYMCE | C98751 | Lymphocytes/Total Cells | A relative measurement (ratio or percentage) of the lymphocytes to total cells in a biological specimen (for example a bone marrow specimen). | Lymphocyte to Total Cell Ratio Measurement | ||
METAMYCE | C98754 | Metamyelocytes/Total Cells | A relative measurement (ratio or percentage ) of the metamyelocytes (small, myelocytic neutrophils with an indented nucleus) to total cells in a biological specimen (for example a bone marrow specimen). | Metamyelocyte to Total Cell Ratio Measurement | ||
MONOCE | C98872 | Monocytes/Total Cells | A relative measurement (ratio or percentage) of the monocytes to total cells in a biological specimen (for example a bone marrow specimen). | Monocytes to Total CellRatioMeasurement | ||
MYCYCE | C98868 | Myelocytes/Total Cells | A relative measurement (ratio or percentage) of the myelocytes to total cells in a biological specimen (for example a bone marrow specimen). | Myelocyte to Total CellRatio Measurement | ||
NEUTCE | C98763 | Neutrophils/Total Cells | A relative measurement (ratio or percentage) of the neutrophils to total cells in a biological specimen (for example a bone marrow specimen). | Neutrophil to Total Cell Ratio Measurement | ||
NKCE | C98762 | Natural Killer Cells | A measurement of the total natural killer cells in a biological specimen. | Natural Killer Cell Count | ||
PLSMCECE | C98869 | Plasma Cells/Total Cells | A relative measurement (ratio or percentage) of the mature plasma cells (plasmacytes) to total cells in a biological specimen (for example a bone marrow specimen). | Plasma Cell to Total CellRatio Measurement | ||
PROMYCE | C98773 | Promyelocytes/Total Cells | A relative measurement (ratio or percentage) of the promyelocytes (immature myelocytes) to total cells in a biological specimen (for example a bone marrow specimen). | Promyelocyte to Total Cell Ratio Measurement | ||
PTA | C98774 | Prothrombin Activity;Factor II Activity | A measurement of the biological activity of prothrombin in a biological specimen. | Prothrombin Activity Measurement | ||
RETIHGB | C98776 | Reticulocyte Hemoglobin | A measurement of the amount of hemoglobin in reticulocytes. | Reticulocyte Hemoglobin Measurement | ||
TFRRNSAT | C98792 | Transferrin Saturation | A measurement of the iron bound to transferrin in a biological specimen. | Transferrin Saturation Measurement | ||
VZVIGAAB | C98795 | Varicella Zoster Virus IgA Antibody | A measurement of the Varicella Zoster virus IgA antibodies in a biological specimen. | Varicella Zoster Virus IgA Antibody Measurement | ||
VZVIGGAB | C98796 | Varicella Zoster Virus IgG Antibody | A measurement of the Varicella Zoster virus IgG antibodies in a biological specimen. | Varicella Zoster Virus IgG Antibody Measurement | ||
VZVIGMAB | C98797 | Varicella Zoster Virus IgM Antibody | A measurement of the Varicella Zoster virus IgM antibodies in a biological specimen. | Varicella Zoster Virus IgM Antibody Measurement | ||
DHPG | C101017 | 3,4-Dihydroxyphenylglycol;3.4 Dihydroxyphenylglycol | A measurement of the catecholamine metabolite, 3,4-Dihydroxyphenylglycol in a biological specimen. | 3,4-Dihydroxyphenylglycol Measurement | ||
APROTCRS | C100471 | Activated Protein C Resistance;Factor V Leiden Screen | A measurement of the resistance in the anticoagulation response to activated protein C in a biological specimen. | Activated Protein C Resistance Measurement | ||
APTTSPTT | C100421 | Activated PTT/Standard PTT;Activated Partial Thromboplastin Time/Standard Thromboplastin Time | A relative measurement (ratio or percentage) of the subject's activated partial thromboplastin time to a standard or control partial thromboplastin time. | Activated PTT to Standard PTT Ratio Measurement | ||
AAP | C100430 | Alanine Aminopeptidase | A measurement of the alanine aminopeptidase in a biological specimen. | Alanine Aminopeptidase Measurement | ||
A1AGLP | C100429 | Alpha-1 Acid Glycoprotein | A measurement of the alpha-1 acid glycoprotein in a biological specimen. | Alpha-1 Acid Glycoprotein Measurement | ||
A1MICG | C100461 | Alpha-1 Microglobulin;Protein HC | A measurement of the alpha-1 microglobulin in a biological specimen. | Alpha-1 Microglobulin Measurement | ||
A1MCREAT | C100462 | Alpha-1 Microglobulin/Creatinine | A relative measurement (ratio or percentage) of the alpha-1 microglobulin to creatinine in a biological specimen. | Alpha-1 Microglobulin to Creatinine Ratio Measurement | ||
APOC2 | C100427 | Apolipoprotein C2;Apolipoprotein CII | A measurement of the apolipoprotein C2 in a biological specimen. | Apolipoprotein C2 Measurement | ||
APOJ | C100428 | Apolipoprotein J;Clusterin | A measurement of the apolipoprotein J in a biological specimen. | Apolipoprotein J Measurement | ||
BETACRTN | C100472 | Beta Carotene;b-Carotene;Beta Carotin | A measurement of the beta carotene in a biological specimen. | Beta Carotene Measurement | ||
BTP | C100426 | Beta-Trace Protein | A measurement of the beta-trace protein in a biological specimen. | Beta-Trace Protein Measurement | ||
CDT | C101016 | Carbohydrate-Deficient Transferrin | A measurement of transferrin with a reduced number of carbohydrate moieties in a biological specimen. | Carbohydrate-Deficient Transferrin Measurement | ||
CRLPLSMN | C100432 | Ceruloplasmin;Caeruloplasmin | A measurement of ceruloplasmin in a biological specimen. | Ceruloplasmin Measurement | ||
CH50 | C100423 | Complement CH50;Total Hemolytic Complement;CH50 | A measurement of the complement required to lyse 50 percent of red blood cells in a biological specimen. | CH50 Measurement | ||
CXCR3 | C100431 | Chemokine (C-X-C Motif) Receptor 3;GPR9, CD183, CXCR3 | A measurement of the CXCR3, chemokine (C-X-C motif) receptor 3, in a biological specimen. | Chemokine Receptor CXCR3 Measurement | ||
CTRIGAAB | C100464 | Chlamydia trachomatis IgA Antibody | A measurement of the Chlamydia trachomatis IgA antibody in a biological specimen. | Chlamydia trachomatis IgA Antibody Measurement | ||
CTRIGGAB | C100466 | Chlamydia trachomatis IgG Antibody | A measurement of the Chlamydia trachomatis IgG antibody in a biological specimen. | Chlamydia trachomatis IgG Antibody Measurement | ||
CTRIGMAB | C100465 | Chlamydia trachomatis IgM Antibody | A measurement of the Chlamydia trachomatis IgM antibody in a biological specimen. | Chlamydia trachomatis IgM Antibody Measurement | ||
DTPACLR | C100441 | DTPA Clearance | A measurement of the volume of serum or plasma that would be cleared of Diethylenetriamine pentaacetate (DTPA) through its excretion for a specified unit of time. | Diethylene Triamine Pentaacetic Acid Clearance | ||
DNASEBAB | C100463 | DNase-B Antibody;Anti-Dnase B | A measurement of Dnase-B antibody in a biological specimen. | DNase-B Antibody Measurement | ||
ECT | C100422 | Ecarin Clotting Time | A measurement of the activity of thrombin inhibitors in a biological specimen based on the generation of meizothrombin. | Ecarin Clotting Time Measurement | ||
EDTACLR | C100440 | EDTA Clearance | A measurement of the volume of serum or plasma that would be cleared of Ethylenediamine tetraacetic acid (EDTA) through its excretion for a specified unit of time. | EDTA Clearance | ||
GLYCRLFR | C100448 | Free Glycerol;Free Glycerin | A measurement of the amount of unbound glycerol in a biological specimen. | Free Glycerol Measurement | ||
GFRBSB2M | C100450 | GFR from B-2 Microglobulin Adj for BSA | A measurement of the glomerular filtration rate (GFR) based on the clearance of beta-2 microglobulin after adjusting it for the body surface area. | Glomerular Filtration Rate from B-2 Microglobulin Adjusted for BSA Measurement | ||
GFRBSBTP | C100449 | GFR from Beta-Trace Protein Adj for BSA | A measurement of the glomerular filtration rate (GFR) based on the clearance of beta-trace protein after adjusting it for the body surface area. | Glomerular Filtration Rate from Beta-Trace Protein Adjusted for BSA Measurement | ||
HDLCLDLC | C100425 | HDL Cholesterol/LDL Cholesterol Ratio | A relative measurement (ratio or percentage) of the amount of HDL cholesterol compared to LDL cholesterol in a biological specimen. | HDL Cholesterol to LDL Cholesterol Ratio Measurement | ||
HLAB27AG | C100460 | HLA-B27 Antigen;Human Leukocyte Antigen B27 | A measurement of the human leukocyte antigen B27 (HLA-B27) in a biological specimen. | HLA-B27 Antigen Measurement | ||
HOMAIR | C100447 | Homostat Model Assess of Insulin Rstn;Homeostatic Model Assessment of Insulin Resistance | An assessment of beta-cell function and insulin resistance based on fasting blood glucose and insulin concentrations. | Homeostatic Model Assessment of Insulin Resistance | ||
GRANIMLE | C100445 | Immature Granulocytes/Leukocytes | A relative measurement (ratio or percentage) of the immature granulocytes to leukocytes in a biological specimen (for example a bone marrow specimen). | Immature Granulocytes to Leukocytes Ratio Measurement | ||
LYMIM | C100444 | Immature Lymphocytes | A measurement of the immature lymphocytes in a biological specimen. | Immature Lymphocytes Measurement | ||
LYMIMLE | C100443 | Immature Lymphocytes/Leukocytes | A relative measurement (ratio or percentage) of the immature lymphocytes to leukocytes in a biological specimen. | Immature Lymphocytes to Leukocytes Ratio Measurement | ||
NEUTIMLE | C100442 | Immature Neutrophils/Leukocytes | A relative measurement (ratio or percentage) of the immature neutrophils to leukocytes in a biological specimen. | Immature Neutrophils to Leukocytes Ratio Measurement | ||
IOHEXCLR | C100439 | Iohexol Clearance | A measurement of the volume of serum or plasma that would be cleared of Iohexol through excretion for a specified unit of time. | Iohexol Clearance | ||
JO1AB | C100459 | Jo-1 Antibody | A measurement of the Jo-1 antibody in a biological specimen. | Jo-1 Antibody Measurement | ||
KIM1 | C100433 | Kidney Injury Molecule-1;KIM-1;Hepatitis A Virus Cellular Receptor 1 | A measurement of the kidney injury molecule-1 (Kim-1) in a biological specimen. | Kidney Injury Molecule-1 Measurement | ||
LKM1IAAB | C100456 | Liver Kidney Microsomal Type 1 IgA Ab | A measurement of the liver kidney microsomal type 1 IgA antibodies in a biological specimen. | Liver Kidney Microsomal Type 1 IgA Antibody Measurement | ||
LKM1IGAB | C100454 | Liver Kidney Microsomal Type 1 IgG Ab | A measurement of the liver kidney microsomal type 1 IgG antibodies in a biological specimen. | Liver Kidney Microsomal Type 1 IgG Antibody Measurement | ||
LKM1IMAB | C100455 | Liver Kidney Microsomal Type 1 IgM Ab | A measurement of the liver kidney microsomal type 1 IgM antibodies in a biological specimen. | Liver Kidney Microsomal Type 1 IgM Antibody Measurement | ||
NPAP | C100434 | Non-Prostatic Acid Phosphatase | A measurement of the non-prostatic acid phosphatase in a biological specimen. | Non-Prostatic Acid Phosphatase Measurement | ||
OVAPARS | C100452 | Ova and Parasite | A measurement of the parasites and ova in a biological specimen. | Ova and Parasite Measurement | ||
PEPSNGA | C100469 | Pepsinogen A;PGA | A measurement of the pepsinogen A in a biological specimen. | Pepsinogen A Measurement | ||
PEPSNGC | C100470 | Pepsinogen C;PGC | A measurement of the pepsinogen C in a biological specimen. | Pepsinogen C Measurement | ||
PEPSNGI | C100467 | Pepsinogen I;PGI | A measurement of the pepsinogen I in a biological specimen. | Pepsinogen I Measurement | ||
PEPSNGII | C100468 | Pepsinogen II;PGII | A measurement of the pepsinogen II in a biological specimen. | Pepsinogen II Measurement | ||
PEPSNG | C100122 | Pepsinogen | A measurement of the pepsinogen in a biological specimen. | Pepsinogen Measurement | ||
PLSMDM | C100453 | Plasmodium | Examination of a biological specimen to detect the presence of any protozoan belonging to the Plasmodium genus. | Plasmodium Measurement | ||
PLATHCT | C100424 | Platelet Hematocrit;Thrombocytocrit | A relative measurement (ratio or percentage) of the proportion of the volume of blood taken up by platelets. | Platelet Hematocrit Measurement | ||
PREALB | C100435 | Prealbumin | A measurement of the prealbumin in a biological specimen. | Prealbumin Measurement | ||
PERTHRBL | C100446 | Proerythroblast | A measurement of the proerythroblasts in a biological specimen. | Proerythroblast Measurement | ||
PROTS | C100436 | Protein S | A measurement of the protein S in a biological specimen. | Protein S Measurement | ||
RBP | C100437 | Retinol Binding Protein | A measurement of the total retinol binding protein in a biological specimen. | Retinol Binding Protein Measurement | ||
RNPAB | C100457 | Ribonucleoprotein Antibody;RNP Antibody | A measurement of the ribonucleoprotein antibody in a biological specimen. | Ribonucleoprotein Antibody Measurement | ||
BLSTRSID | C100419 | Ringed Sideroblasts | A measurement of the ringed sideroblasts (abnormal nucleated erythroblasts with a large number of iron deposits in the perinuclear mitochondria, forming a ring around the nucleus) in a biological specimen. | Ringed Sideroblast Measurement | ||
SCL70AB | C100458 | Scl-70 Antibody;Scleroderma-70 Antibody | A measurement of the Scl-70 antibody in a biological specimen. | Scl-70 Antibody Measurement | ||
BLSTSID | C100418 | Sideroblast | A measurement of the sideroblasts (nucleated erythroblasts with iron granules in the cytoplasm) in a biological specimen. | Sideroblast Measurement | ||
SLTFRNRC | C100438 | Soluble Transferrin Receptor | A measurement of the soluble transferrin receptor in a biological specimen. | Soluble Transferrin Receptor Measurement | ||
TRCYANDP | C100420 | Tricyclic Antidepressants | A measurement of tricyclic antidepressants in a biological specimen. | Tricyclic Antidepressant Measurement | ||
ADP | C102257 | Adenosine Diphosphate | A measurement of the adenosine diphosphate in a biological specimen. | Adenosine Diphosphate Measurement | ||
APLAB | C102258 | Antiphospholipid Antibodies | A measurement of the antiphospholipid antibodies in a biological specimen. | Antiphospholipid Antibody Measurement | ||
ARA | C102259 | Arachidonic Acid | A measurement of the arachidonic acid present in a biological specimen. | Arachidonic Acid Measurement | ||
CD34 | C102260 | CD34 | A measurement of the CD34 expressing cells per unit in a biological specimen. | CD34 Measurement | ||
CLUECE | C102261 | Clue Cells | A measurement of the clue cells in a biological specimen. | Clue Cell Count | ||
AMPHETD | C102262 | Dextroamphetamine;d-amphetamine | A measurement of the dextroamphetamine in a biological specimen. | Dextroamphetamine Measurement | ||
DRUGSCR | C78139 | Drug Screen | An indication of the presence or absence of recreational drugs or drugs of abuse in a biological specimen. | Drug Test | ||
ETP | C102266 | Endogenous Thrombin Potential | A measurement of the total concentration of thrombin generated in the presence of a substrate in a plasma or blood sample. | Endogenous Thrombin Potential Measurement | ||
ETPAUC | C102263 | ETP Area Under Curve;Endogenous Thrombin Potential Area Under Curve | A measurement of the area under the thrombin generation curve. | Endogenous Thrombin Potential Area Under Curve Measurement | ||
ETPLT | C102264 | ETP Lag Time;Endogenous Thrombin Potential Lag Time | A measurement of time from the start of the thrombin generation test to the point where a predetermined amount of thrombin is generated. | Endogenous Thrombin Potential Lag Time Measurement | ||
ETPLTR | C102265 | ETP Lag Time Relative;Endogenous Thrombin Potential Lag Time Relative | A relative measurement (ratio or percentage) of time from the start of the thrombin generation test to the point where a predetermined amount of thrombin is generated. | Endogenous Thrombin Potential Lag Time Relative Measurement | ||
ETPPH | C102267 | ETP Peak Height;Endogenous Thrombin Potential Peak Height | A measurement of the maximum concentration of thrombin generated during a thrombin generation test. | Endogenous Thrombin Potential Peak Height Measurement | ||
ETPPHR | C102268 | ETP Peak Height Relative;Endogenous Thrombin Potential Peak Height Relative | A relative (ratio or percentage) of the maximum concentration of thrombin generated during a thrombin generation test. | Endogenous Thrombin Potential Peak Height Relative Measurement | ||
ETPTP | C102269 | ETP Time to Peak;Endogenous Thrombin Potential Time to Peak | A measurement of the time it takes to generate the maximum concentration of thrombin. | Endogenous Thrombin Potential Time to Peak Measurement | ||
ETPTPR | C102270 | ETP Time to Peak Relative;Endogenous Thrombin Potential Time to Peak Relative | A relative (ratio or percentage) measurement of the time it takes to generate the maximum concentration of thrombin. | Endogenous Thrombin Potential Time to Peak Relative Measurement | ||
FACTVL | C102271 | Factor V Leiden | A measurement of the Factor V Leiden in a biological specimen. | Factor V Leiden Measurement | ||
FACTXIV | C102272 | Factor XIV;Autoprothrombin IIA;Protein C;Protein C Antigen | A measurement of the factor XIV in a biological specimen. | Factor XIV Measurement | ||
RETCRRBC | C102274 | HCT Corrected Reticulocytes/Erythrocytes | A relative measurement (ratio or percentage) of the hematocrit corrected reticulocytes to erythrocytes in a biological specimen. | Hematocrit Corrected Reticulocytes to Erythrocytes Ratio Measurement | ||
RETIHCR | C102273 | Hematocrit Corrected Reticulocytes | A measurement of the hematocrit corrected reticulocytes in a biological specimen. | Hematocrit Corrected Reticulocyte Count | ||
HYDROGEN | C102275 | Hydrogen | A measurement of the hydrogen in a biological specimen. | Hydrogen Measurement | ||
IRF | C102276 | Immature Reticulocyte Fraction | A measurement of the immature reticulocyte fraction present in a biological specimen. | Immature Reticulocyte Fraction Measurement | ||
APTTLAS | C102277 | Lupus Anticoagulant Sensitive APTT;APTT-LA | A measurement of the length of time that it takes for clotting to occur when a lupus sensitive reagent is added to a plasma specimen. | Lupus Anticoagulant Sensitive APTT Measurement | ||
BLSTLY | C102278 | Lymphoblasts | A measurement of the lymphoblasts (immature cells that differentiate to form lymphocytes) in a biological specimen. | Lymphoblast Count | ||
METHAMPH | C75348 | Methamphetamine | A measurement of the methamphetamine drug present in a biological specimen. | Methamphetamine Measurement | ||
P50OXYGN | C102279 | P50 Oxygen | A measurement of the partial pressure of oxygen when hemoglobin is half saturated in a biological specimen. | P50 Oxygen Measurement | ||
IL2SRA | C102280 | Soluble Interleukin 2 Receptor Activity | A measurement of the soluble interleukin 2 receptor activity in a biological specimen. | Soluble Interleukin 2 Receptor Activity Measurement | ||
SPERMMTL | C102281 | Sperm Motility | A measurement of the sperm capable of forward, progressive movement in a semen specimen. | Sperm Motility Measurement | ||
CONDUCTU | C102282 | Urine Conductivity | A measurement of the urine conductivity which is a non-linear function of the electrolyte concentration in the urine. | Urine Conductivity | ||
TXB2_D11 | C103344 | 11-Dehydro-Thromboxane B2 | A measurement of the 11-dehydro-thromboxane B2 in a biological specimen. | 11-Dehydro-Thromboxane B2 Measurement | ||
DOPAC | C103345 | 3,4-Dihydroxyphenylacetic Acid | A measurement of the 3,4-dihydroxyphenylacetic acid in a biological specimen. | 3,4-Dihydroxyphenylacetic Acid Measurement | ||
MDMA | C75359 | 3,4-methylenedioxymethamphetamine;Ecstasy | A measurement of the 3,4-methylenedioxymethamphetamine (MDMA) in a biological specimen. | 3,4-Methylenedioxymethamphetamine Measurement | ||
ACT | C103348 | Activated Clot Time;Activated Clotting Time;Coagulation Activated | A measurement of the inhibition of blood coagulation in response to anticoagulant therapies. | Activated Coagulation Time | ||
ALBPROT | C103453 | Albumin/Total Protein | A relative measurement (ratio or percentage) of the albumin to total protein in a biological specimen. | Albumin to Total Protein Ratio Measurement | ||
ALTCPHRL | C103349 | Alpha Tocopherol | A measurement of the alpha tocopherol in a biological specimen. | Alpha Tocopherol Measurement | ||
ATPVITE | C103350 | Vitamin E Alpha Tocopherol | A relative measurement (ratio or percentage) of alpha-tocopherol to the total vitamin E in a biological specimen. | Alpha Tocopherol to Vitamin E Ratio Measurement | ||
APLSMA2 | C103351 | Alpha-2 Plasmin Inhibitor | A measurement of the alpha-2 antiplasmin in a biological specimen. | Alpha-2 Antiplasmin Measurement | ||
AMYLB38 | C103352 | Amyloid Beta 38;Amyloid Beta 38 Protein;Amyloid Beta 1-38 | A measurement of amyloid beta protein which is composed of peptides 1 to 38 in a biological specimen. | Amyloid Beta 1-38 Measurement | ||
AMYLB40 | C103353 | Amyloid Beta 40;Amyloid Beta 40 Protein;Amyloid Beta 1-40 | A measurement of amyloid beta protein which is composed of peptides 1 to 40 in a biological specimen. | Amyloid Beta 1-40 Measurement | ||
ANGLBIND | C91372 | Antiglobulin Test, Indirect;Indirect Coombs Test | A test that uses Coombs' reagent to detect the presence of anti-erythrocyte antibodies in a biological specimen. | Indirect Antiglobulin Test | ||
APOA4 | C103354 | Apolipoprotein A4 | A measurement of the apolipoprotein A4 in a biological specimen. | Apolipoprotein A4 Measurement | ||
APOA5 | C103355 | Apolipoprotein A5 | A measurement of the apolipoprotein A5 in a biological specimen. | Apolipoprotein A5 Measurement | ||
APOBAPA1 | C103356 | Apolipoprotein B/Apolipoprotein A1 | A relative measurement (ratio or percentage) of the Apolipoprotein B to Apolipoprotein A1 in a biological specimen. | Apolipoprotein B to Apolipoprotein A1 Ratio Measurement | ||
CATNINB | C103357 | Beta Catenin | A measurement of the beta catenin in a biological specimen. | Beta Catenin Measurement | ||
B2G1GGAB | C103358 | Beta-2 Glycoprotein 1 IgG Antibody | A measurement of the Beta-2 glycoprotein 1 IgG antibodies in a biological specimen. | Beta-2 Glycoprotein 1 IgG Antibody Measurement | ||
B2G1GMAB | C103359 | Beta-2 Glycoprotein 1 IgM Antibody | A measurement of the Beta-2 glycoprotein 1 IgM antibodies in a biological specimen. | Beta-2 Glycoprotein 1 IgM Antibody Measurement | ||
CAPHOSPD | C103360 | Calcium - Phosphorus Product | A measurement of the product of the calcium and phosphate measurements in a biological specimen. | Calcium and Phosphorus Product Measurement | ||
CA1AG | C103361 | Cancer Antigen 1 | A measurement of the cancer antigen 1 in a biological specimen. | Cancer Antigen 1 Measurement | ||
CA15_3AG | C103362 | Cancer Antigen 15-3 | A measurement of the cancer antigen 15-3 in a biological specimen. | Cancer Antigen 15-3 Measurement | ||
CRDIGMAB | C103363 | Cardiolipin IgM Antibody | A measurement of the cardiolipin IgM antibodies in a biological specimen. | Cardiolipin IgM Antibody Measurement | ||
CD1 | C103364 | CD1 | A count of the CD1 expressing cells per unit of a biological specimen. | CD1 Expressing Cell Measurement | ||
CD14 | C103365 | CD14 | A count of the CD14 expressing cells per unit of a biological specimen. | CD14 Expressing Cell Measurement | ||
CD2 | C103366 | CD2 | A count of the CD2 expressing cells per unit of a biological specimen. | CD2 Expressing Cell Measurement | ||
CD2LY | C103367 | CD2/Lymphocytes | A relative measurement (ratio or percentage) of CD2 expressing cells to all lymphocytes in a biological specimen. | CD2 Expressing Cell to Lymphocyte Ratio Measurement | ||
CD20 | C103368 | CD20 | A count of the CD20 expressing cells per unit of a biological specimen. | CD20 Expressing Cell Measurement | ||
CD5 | C103369 | CD5 | A count of the CD5 expressing cells per unit of a biological specimen. | CD5 Expressing Cell Measurement | ||
CD56 | C103370 | CD56 | A count of the CD56 expressing cells per unit of a biological specimen. | CD56 Expressing Cell Measurement | ||
CETPA | C103380 | Cholesteryl Ester Transfer Protein Act | A measurement of the biological activity of cholesteryl ester transfer protein in a biological specimen. | Cholesteryl Ester Transfer Protein Activity Measurement | ||
CDFTXN | C103381 | Clostridium difficile Toxin | A measurement of the Clostridium difficile toxin in a biological specimen. | Clostridium difficile Toxin Measurement | ||
CTTIGGAB | C103382 | Clostridium tetani IgG Antibody | A measurement of the Clostridium tetani IgG antibody in a biological specimen. | Clostridium tetani IgG Antibody Measurement | ||
COL4 | C103383 | Collagen Type IV | A measurement of the collagen type IV in a biological specimen. | Collagen Type IV Measurement | ||
DRVVTRT | C103386 | Lupus Anticoagulant Ratio | A relative measurement (ratio or percentage) of the dilute Russell's viper venom time in a subject sample to a control sample. | Dilute Russell's Viper Venom Time to Control Ratio Measurement | ||
DPPIVA | C103387 | DPPIV Activity | A measurement of the biological activity of dipeptidyl peptidase-4 in a biological specimen. | Dipeptidyl Peptidase-4 Activity Measurement | ||
DPTIGGAB | C103388 | Diphtheria IgG Antibody | A measurement of the Diphtheria IgG antibodies in a biological specimen. | Diphtheria IgG Antibody Measurement | ||
FACTIXA | C103395 | Christmas Factor Activity | A measurement of the biological activity of factor IX in a biological specimen. | Factor IX Activity Measurement | ||
FACTVA | C103396 | Labile Factor Activity | A measurement of the biological activity of factor V in a biological specimen. | Factor V Activity Measurement | ||
FACTVIIA | C103397 | Proconvertin Activity;Stable Factor Activity | A measurement of the biological activity of factor VII in a biological specimen. | Factor VII Activity Measurement | ||
FCTVIIAA | C103398 | Factor VIIa Activity | A measurement of the biological activity of factor VIIa in a biological specimen. | Factor VIIa Activity Measurement | ||
FCTVIIIA | C103399 | Anti-hemophilic Factor Activity | A measurement of the biological activity of factor VIII in a biological specimen. | Factor VIII Activity Measurement | ||
HDLPSZ | C103402 | HDL Particle Size | A measurement of the average particle size of high-density lipoprotein in a biological specimen. | HDL Particle Size Measurement | ||
HPLIGGAB | C103403 | Helicobacter pylori IgG Antibody | A measurement of the Helicobacter pylori IgG antibody in a biological specimen. | Helicobacter pylori IgG Antibody Measurement | ||
HBDNA | C103404 | Hepatitis B DNA | A measurement of hepatitis B virus DNA in a biological specimen. | Hepatitis B DNA Measurement | ||
HALBAB | C103405 | Human Albumin Antibody | A measurement of the human albumin antibody in a biological specimen. | Human Albumin Antibody Measurement | ||
HAMAB | C103406 | HAMA | A measurement of the human anti-mouse antibody in a biological specimen. | Human Anti-Mouse Antibody Measurement | ||
BLASTIMM | C103407 | Lymphocytes, Immunoblastic | A measurement of the immunoblasts in a biological specimen. | Immunoblast Count | ||
IAIGGAB | C103408 | Influenza A IgG Antibody | A measurement of the Influenza A IgG antibody in a biological specimen. | Influenza A IgG Antibody Measurement | ||
IBIGGAB | C103409 | Influenza B IgG Antibody | A measurement of the Influenza B IgG antibody in a biological specimen. | Influenza B IgG Antibody Measurement | ||
ILE | C103410 | Isoleucine | A measurement of the isoleucine in a biological specimen. | Isoleucine Measurement | ||
LDLPSZ | C103412 | LDL Particle Size | A measurement of the average particle size of low-density lipoprotein in a biological specimen. | LDL Particle Size Measurement | ||
LTB4 | C103413 | Leukotriene B4 | A measurement of the leukotriene B4 in a biological specimen. | Leukotriene B4 Measurement | ||
LTD4 | C103414 | Leukotriene D4 | A measurement of the leukotriene D4 in a biological specimen. | Leukotriene D4 Measurement | ||
LTE4 | C103415 | Leukotriene E4 | A measurement of the leukotriene E4 in a biological specimen. | Leukotriene E4 Measurement | ||
LSD | C75354 | Lysergic Acid Diethylamide;Acid | A measurement of the lysergic acid diethylamine (LSD) in a biological specimen. | Lysergide Measurement | ||
MYELINAB | C103418 | Myelin Antibodies | A measurement of the myelin antibodies in a biological specimen. | Myelin Antibodies Measurement | ||
NAGASE | C103419 | NAG;Beta-N-acetyl-D-glucosaminidase | A measurement of the N-acetyl-beta-D-glucosaminidase in a biological specimen. | N-acetyl-beta-D-glucosaminidase Measurement | ||
PTHW | C103451 | Parathyroid Hormone, Whole | A measurement of the whole parathyroid hormone (consisting of amino acids 1-84) in a biological specimen. | Whole Parathyroid Hormone Measurement | ||
PLATAGGR | C103427 | Platelet Function | A measurement of the association of platelets to one another via adhesion molecules in a biological sample. | Platelet Aggregation Measurement | ||
PCT | C103430 | Procalcitonin | A measurement of the procalcitonin in a biological specimen. | Procalcitonin Measurement | ||
PG | C103343 | Total Prostaglandin | A measurement of the total prostaglandin in a biological specimen. | Prostaglandin Measurement | ||
PGD2 | C103431 | Prostaglandin D2 | A measurement of the prostaglandin D2 in a biological specimen. | Prostaglandin D2 Measurement | ||
PGD2S | C103432 | Prostaglandin D2 Synthase | A measurement of the prostaglandin D2 synthase in a biological specimen. | Prostaglandin D2 Synthase Measurement | ||
PGES | C103433 | Prostaglandin E Synthase | A measurement of the prostaglandin E synthase in a biological specimen. | Prostaglandin E Synthase Measurement | ||
PGE1 | C103434 | Prostaglandin E1 | A measurement of the prostaglandin E1 in a biological specimen. | Prostaglandin E1 Measurement | ||
PGE2 | C103435 | Prostaglandin E2 | A measurement of the prostaglandin E2 in a biological specimen. | Prostaglandin E2 Measurement | ||
PGF1A | C103436 | Prostaglandin F1 Alpha | A measurement of the prostaglandin F1 alpha in a biological specimen. | Prostaglandin F1 Alpha Measurement | ||
PGF2A | C103437 | Prostaglandin F2 Alpha | A measurement of the prostaglandin F2 alpha in a biological specimen. | Prostaglandin F2 Alpha Measurement | ||
RUBIGGAB | C103440 | Rubella IgG Antibody | A measurement of the Rubella IgG antibody in a biological specimen. | Rubella IgG Antibody Measurement | ||
TXB2 | C103445 | Thromboxane B2 | A measurement of the thromboxane B2 in a biological specimen. | Thromboxane B2 Measurement | ||
TGLOB | C103446 | TG | A measurement of the thyroglobulin in a biological specimen. | Thyroglobulin Measurement | ||
VITECHOL | C103448 | Vitamin E/Cholesterol | A relative measurement (ratio or percentage) of vitamin E to total cholesterol in a biological specimen. | Vitamin E to Cholesterol Ratio Measurement | ||
VITK1 | C103449 | Phylloquinone;Phytomenadione | A measurement of the Vitamin K1 in a biological specimen. | Vitamin K1 Measurement | ||
VLDLPSZ | C103450 | VLDL Particle Size | A measurement of the average particle size of very-low-density lipoprotein in a biological specimen. | VLDL Particle Size Measurement | ||
APP | C105438 | Amyloid Precursor Beta;Amyloid Beta Precursor;Amyloid Precursor Protein;Amyloid Beta Precursor Protein | A measurement of the amyloid beta precursor protein present in a biological specimen. | Amyloid Beta Precursor Protein Measurement | ||
BLSTLYLE | C105444 | Lymphoblasts/Leukocytes | A relative measurement (ratio or percentage) of the lymphoblasts to leukocytes in a biological specimen. | Lymphoblast to Leukocyte Ratio Measurement | ||
CD11A | C105439 | CD11a;CD11A | A count of the CD11a expressing cells per unit of a biological specimen. | CD11A Expressing Cell Count | ||
CD11B | C105440 | CD11b;CD11B | A count of the CD11b expressing cells per unit of a biological specimen. | CD11B Expressing Cell Count | ||
CYSTINE | C105441 | Cystine | A measurement of the cystine in a biological specimen. | Cystine Measurement | ||
FACTXIVA | C105442 | Protein C Activity;Factor XIV Activity | A measurement of the factor XIV activity in a biological specimen. | Factor XIV Activity Measurement | ||
FBRTST | C105443 | FibroTest Score;FibroSURE Score | A biomarker test that measures liver pathology through the assessment of a six-parameter blood test (for Alpha-2-macroglobulin, Haptoglobin, Apolipoprotein A1, Gamma-glutamyl transpeptidase (GGT), Total bilirubin, and Alanine aminotransferase (ALT)), taking into account the age and gender of the patient. | FibroTest Score Measurement | ||
SEDEXAM | C105744 | Sediment Examination;Sediment Analysis;Microscopic Sediment Analysis | An observation, assessment or examination of the sediment in a biological specimen. | Sediment Analysis | ||
THEOPHYL | C105445 | Theophylline | A measurement of the Theophylline present in a biological specimen. | Theophylline Measurement | ||
Back to top | ||||||
CL.C67154.LBTEST | Laboratory Test Name (LBTEST) | text Extensible: Yes | C67154 | Laboratory Test Name | Terminology used for Laboratory Tests of the CDISC Standard Data Tabulation Model. | CDISC SDTM Laboratory Test Terminology by Name |
Anisocytes | C74797 | Anisocytes | A measurement of the inequality in the size of the red blood cells in a whole blood specimen. | Anisocyte Measurement | ||
Poikilocytes | C79602 | Poikilocytes | A measurement of the odd-shaped erythrocytes in a whole blood specimen. | Poikilocyte Measurement | ||
Bilirubin | C38037 | Bilirubin;Total Bilirubin | A measurement of the total bilirubin in a biological specimen. | Total Bilirubin Measurement | ||
Activated Partial Thromboplastin Time | C38462 | Activated Partial Thromboplastin Time | A measurement of the length of time that it takes for clotting to occur when reagents are added to a plasma specimen. The test is partial due to the absence of tissue factor (Factor III) from the reaction mixture. | Partial Thromboplastin Time | ||
Glucose | C105585 | Glucose | A measurement of the glucose in a biological specimen. | Glucose Measurement | ||
pH | C45997 | pH | A measure of the acidity or alkalinity of a fluid on a scale of 0 to 14.(NCI) | pH | ||
Erythrocytes | C51946 | Erythrocytes;Red Blood Cells | A measurement of the total erythrocytes in a biological specimen. | Erythrocyte Count | ||
Reticulocytes | C51947 | Reticulocytes | A measurement of the reticulocytes in a biological specimen. | Reticulocyte Count | ||
Leukocytes | C51948 | Leukocytes;White Blood Cells | A measurement of the leukocytes in a biological specimen. | Leukocyte Count | ||
Lymphocytes | C51949 | Lymphocytes | A measurement of the lymphocytes in a biological specimen. | Lymphocyte Count | ||
Platelets | C51951 | Platelets | A measurement of the platelets in a biological specimen. | Platelet Count | ||
Blood Urea Nitrogen | C61019 | Blood Urea Nitrogen | A measurement of the urea nitrogen in a blood specimen. | Blood Urea Nitrogen Measurement | ||
Cholesterol | C105586 | Cholesterol;Total Cholesterol | A measurement of the cholesterol in a biological specimen. | Cholesterol Measurement | ||
HDL Cholesterol | C105587 | HDL Cholesterol | A measurement of the high density lipoprotein cholesterol in a biological specimen. | High Density Lipoprotein Cholesterol Measurement | ||
LDL Cholesterol | C105588 | LDL Cholesterol | A measurement of the low density lipoprotein cholesterol in a biological specimen. | Low Density Lipoprotein Cholesterol Measurement | ||
Prothrombin Time | C62656 | Prothrombin Time | A blood clotting measurement that evaluates the extrinsic pathway of coagulation. | Prothrombin Time | ||
Neutrophils | C63321 | Neutrophils | A measurement of the neutrophils in a biological specimen. | Absolute Neutrophil Count | ||
Albumin | C64431 | Albumin;Microalbumin | A measurement of the albumin protein in a biological specimen. | Albumin Measurement | ||
Alkaline Phosphatase | C64432 | Alkaline Phosphatase | A measurement of the alkaline phosphatase in a biological specimen. | Alkaline Phosphatase Measurement | ||
Alanine Aminotransferase | C64433 | Alanine Aminotransferase;SGPT | A measurement of the alanine aminotransferase in a biological specimen. | Alanine Aminotransferase Measurement | ||
Amylase | C64434 | Amylase | A measurement of the total enzyme amylase in a biological specimen. | Amylase Measurement | ||
Aspartate Aminotransferase | C64467 | Aspartate Aminotransferase;SGOT | A measurement of the aspartate aminotransferase in a biological specimen. | Aspartate Aminotransferase Measurement | ||
Bacteria | C64469 | Bacteria | A measurement of the bacteria in a biological specimen. | Bacterial Count | ||
Basophils | C64470 | Basophils | A measurement of the basophils in a biological specimen. | Total Basophil Count | ||
Basophils/Leukocytes | C64471 | Basophils/Leukocytes | A relative measurement (ratio or percentage) of the basophils to leukocytes in a biological specimen. | Basophil To Leukocyte Ratio | ||
Direct Bilirubin | C64481 | Direct Bilirubin | A measurement of the conjugated or water-soluble bilirubin in a biological specimen. | Direct Bilirubin Measurement | ||
Indirect Bilirubin | C64483 | Indirect Bilirubin | A measurement of the unconjugated or non-water-soluble bilirubin in a biological specimen. | Indirect Bilirubin Measurement | ||
Blasts/Leukocytes | C64487 | Blasts/Leukocytes | A relative measurement (ratio or percentage) of the blasts to leukocytes in a biological specimen. | Blast To Leukocyte Ratio | ||
Calcium | C64488 | Calcium | A measurement of the calcium in a biological specimen. | Calcium Measurement | ||
Creatine Kinase | C64489 | Creatine Kinase | A measurement of the total creatine kinase in a biological specimen. | Creatine Kinase Measurement | ||
Creatine Kinase BB | C64490 | Creatine Kinase BB | A measurement of the homozygous B-type creatine kinase in a biological specimen. | Creatine Kinase BB Measurement | ||
Creatine Kinase MB | C64491 | Creatine Kinase MB | A measurement of the heterozygous MB-type creatine kinase in a biological specimen. | Creatine Kinase MB Measurement | ||
Creatine Kinase MM | C64494 | Creatine Kinase MM | A measurement of the homozygous M-type creatine kinase in a biological specimen. | Creatine Kinase MM Measurement | ||
Chloride | C64495 | Chloride | A measurement of the chloride in a biological specimen. | Chloride Measurement | ||
Carbon Dioxide | C64545 | Carbon Dioxide | A measurement of the carbon dioxide gas in a biological specimen. | Carbon Dioxide Measurement | ||
Color | C64546 | Color | A measurement of the color of a biological specimen. | Color Assessment | ||
Creatinine | C64547 | Creatinine | A measurement of the creatinine in a biological specimen. | Creatinine Measurement | ||
C Reactive Protein | C64548 | C Reactive Protein | A measurement of the C reactive protein in a biological specimen. | C-Reactive Protein Measurement | ||
Elliptocytes | C64549 | Elliptocytes;Ovalocytes | A measurement of the elliptically shaped erythrocytes in a biological specimen. | Elliptocyte Count | ||
Eosinophils | C64550 | Eosinophils | A measurement of the eosinophils in a biological specimen. | Eosinophil Count | ||
Eosinophils/Leukocytes | C64604 | Eosinophils/Leukocytes | A relative measurement (ratio or percentage) of the eosinophils to leukocytes in a biological specimen. | Eosinophil To Leukocyte Ratio | ||
Epithelial Cells | C64605 | Epithelial Cells | A measurement of the epithelial cells in a biological specimen. | Epithelial Cell Count | ||
Fibrinogen | C64606 | Fibrinogen | A measurement of the fibrinogen in a biological specimen. | Fibrinogen Measurement | ||
Hematocrit | C64796 | Hematocrit | The percentage of a whole blood specimen that is composed of red blood cells (erythrocytes). | Hematocrit | ||
Ery. Mean Corpuscular Hemoglobin | C64797 | Ery. Mean Corpuscular Hemoglobin | A quantitative measurement of the mean amount of hemoglobin per erythrocyte in a biological specimen. | Erythrocyte Mean Corpuscular Hemoglobin | ||
Ery. Mean Corpuscular HGB Concentration | C64798 | Ery. Mean Corpuscular HGB Concentration | A quantitative measurement of the mean amount of hemoglobin per erythrocytes in a specified volume of a biological specimen. | Erythrocyte Mean Corpuscular Hemoglobin Concentration | ||
Ery. Mean Corpuscular Volume | C64799 | Ery. Mean Corpuscular Volume | A quantitative measurement of the mean volume of erythrocytes in a biological specimen. | Erythrocyte Mean Corpuscular Volume | ||
Erythrocytes Distribution Width | C64800 | Erythrocytes Distribution Width | A value derived from mean corpuscular volume and the standard deviation of the red blood cell volume in a whole blood specimen. | Erythrocyte Distribution Width Measurement | ||
Dacryocytes | C64801 | Dacryocytes;Tear Shaped Erythrocytes;Teardrop Cells | A measurement of dacryocytes in a biological specimen. | Dacryocyte Analysis | ||
Hypochromia | C64802 | Hypochromia | An observation which indicates that the hemoglobin concentration in a red blood cell specimen has fallen below a specified level. | Hypochromia | ||
Polychromasia | C64803 | Polychromasia | A measurement of the blue-staining characteristic of newly generated erythrocytes. | Polychromasia | ||
Prothrombin Intl. Normalized Ratio | C64805 | Prothrombin Intl. Normalized Ratio | A ratio that represents the prothrombin time for a plasma specimen, divided by the result for a control plasma specimen, further standardized for the International Sensitivity Index of the tissue factor (thromboplastin) used in the test. | International Normalized Ratio of Prothrombin Time | ||
VLDL Cholesterol | C105589 | VLDL Cholesterol | A measurement of the very low density lipoprotein cholesterol in a biological specimen. | Very Low Density Lipoprotein Cholesterol Measurement | ||
Triacylglycerol Lipase | C64807 | Triacylglycerol Lipase | A measurement of the pancreatic lipase in a biological specimen. | Triacylglycerol Lipase Measurement | ||
Sodium | C64809 | Sodium | A measurement of the sodium in a biological specimen. | Sodium Measurement | ||
Nitrite | C64810 | Nitrite | A measurement of the nitrite in a urine specimen. | Nitrite Measurement | ||
Triglycerides | C64812 | Triglycerides | A measurement of the triglycerides in a biological specimen. | Triglyceride Measurement | ||
Thyrotropin | C64813 | Thyrotropin | A measurement of the thyrotropin in a biological specimen. | Thyrotropin Measurement | ||
Urate | C64814 | Urate;Uric Acid | A measurement of the urate in a biological specimen. | Urate Measurement | ||
Urea | C64815 | Urea | A measurement of the urea in a biological specimen. | Urea Measurement | ||
Urobilinogen | C64816 | Urobilinogen | A measurement of the urobilinogen in a biological specimen. | Urobilinogen Measurement | ||
Vitamin B12 | C64817 | Vitamin B12 | A measurement of the Vitamin B12 in a serum specimen. | Vitamin B12 Measurement | ||
Lymphocytes Atypical | C64818 | Lymphocytes Atypical | A measurement of the atypical lymphocytes in a biological specimen. | Atypical Lymphocyte Count | ||
Lymphocytes Atypical/Leukocytes | C64819 | Lymphocytes Atypical/Leukocytes | A relative measurement (ratio or percentage) of the atypical lymphocytes to leukocytes in a biological specimen. | Atypical Lymphocyte To Leukocyte Ratio | ||
Lymphocytes/Leukocytes | C64820 | Lymphocytes/Leukocytes | A relative measurement (ratio or percentage) of the lymphocytes to leukocytes in a biological specimen. | Lymphocyte To Leukocyte Ratio | ||
Macrocytes | C64821 | Macrocytes | A measurement of the macrocytes in a biological specimen. | Macrocyte Count | ||
Microcytes | C64822 | Microcytes | A measurement of the microcytes in a biological specimen. | Microcyte Count | ||
Monocytes | C64823 | Monocytes | A measurement of the monocytes in a biological specimen. | Monocyte Count | ||
Monocytes/Leukocytes | C64824 | Monocytes/Leukocytes | A relative measurement (ratio or percentage) of the monocytes to leukocytes in a biological specimen. | Monocyte To Leukocyte Ratio | ||
Myeloblasts/Leukocytes | C64825 | Myeloblasts/Leukocytes | A relative measure (ratio or percentage) of the myeloblasts to leukocytes in a biological specimen. | Myeloblast To Leukocyte Ratio | ||
Myelocytes/Leukocytes | C64826 | Myelocytes/Leukocytes | A relative measurement (ratio or percentage) of the myelocytes to leukocytes in a biological specimen. | Myelocyte To Leukocyte Ratio | ||
Neutrophils/Leukocytes | C64827 | Neutrophils/Leukocytes | A relative measurement (ratio or percentage) of the neutrophils to leukocytes in a biological specimen. | Neutrophil To Leukocyte Ratio | ||
Reticulocytes/Erythrocytes | C64828 | Reticulocytes/Erythrocytes | A relative measurement (ratio or percentage) of reticulocytes to erythrocytes in a biological specimen. | Reticulocyte To Erythrocyte Ratio | ||
Prolymphocytes/Leukocytes | C64829 | Prolymphocytes/Leukocytes | A relative measurement (ratio or percentage) of prolymphocytes to leukocytes in a biological specimen. | Prolymphocyte To Leukocyte Ratio | ||
Neutrophils Band Form | C64830 | Neutrophils Band Form | A measurement of the banded neutrophils in a biological specimen. | Neutrophil Band Form Count | ||
Neutrophils Band Form/Leukocytes | C64831 | Neutrophils Band Form/Leukocytes | A relative measurement (ratio or percentage) of the banded neutrophils to leukocytes in a biological specimen. | Neutrophil Band Form To Leukocyte Ratio | ||
Specific Gravity | C64832 | Specific Gravity | A ratio of the density of a fluid to the density of water. | Specific Gravity | ||
Magnesium | C64840 | Magnesium | A measurement of the magnesium in a biological specimen. | Magnesium Measurement | ||
Gamma Glutamyl Transferase | C64847 | Gamma Glutamyl Transferase | A measurement of the gamma glutamyl transferase in a biological specimen. | Gamma Glutamyl Transpeptidase Measurement | ||
Hemoglobin | C64848 | Hemoglobin | A measurement of the hemoglobin in a biological specimen. | Hemoglobin Measurement | ||
Hemoglobin A1C | C64849 | Hemoglobin A1C | A measurement of the glycosylated hemoglobin in a biological specimen. | Glycosylated Hemoglobin Measurement | ||
Hepatitis B Virus Surface Antigen | C64850 | HBsAg;Hepatitis B Virus Surface Antigen | A measurement of the surface antigen reaction of a biological specimen to the Hepatitis B virus. | Hepatitis B Virus Surface Antigen Measurement | ||
Choriogonadotropin Beta | C64851 | Choriogonadotropin Beta;Pregnancy Test | A measurement of the Choriogonadotropin Beta in a biological specimen. | Choriogonadotropin Beta Measurement | ||
Potassium | C64853 | Potassium | A measurement of the potassium in a biological specimen. | Potassium Measurement | ||
Ketones | C64854 | Ketones | A measurement of the ketones in a biological specimen. | Ketone Measurement | ||
Lactate Dehydrogenase | C64855 | Lactate Dehydrogenase | A measurement of the lactate dehydrogenase in a biological specimen. | Lactate Dehydrogenase Measurement | ||
Leukocyte Esterase | C64856 | Leukocyte Esterase | A measurement of the enzyme which indicates the presence of white blood cells in a biological specimen. | Leukocyte Esterase Measurement | ||
Phosphate | C64857 | Phosphate;Phosphorus;Inorganic Phosphate | A measurement of the phosphate in a biological specimen. | Phosphate Measurement | ||
Protein | C64858 | Protein | A measurement of a group of complex organic macromolecules composed of one or more alpha-L-amino acid chains in a biological specimen. | Total Protein Measurement | ||
Prostate Specific Antigen | C17634 | Prostate Specific Antigen | A measurement of the prostate specific antigen in a biological specimen. | Prostate Specific Antigen Measurement | ||
Creatinine Clearance | C25747 | Creatinine Clearance | A measurement of the volume of serum or plasma that would be cleared of creatinine by excretion of urine for a specified unit of time (e.g. one minute). | Creatinine Clearance | ||
Hairy Cells | C74604 | Hairy Cells | A measurement of the hairy cells (b-cell lymphocytes with hairy projections from the cytoplasm) in a biological specimen. | Hairy Cell Count | ||
Blasts | C74605 | Blasts | A measurement of the blast cells in a biological specimen. | Blast Count | ||
CD19 | C103808 | CD19 | A count of the CD19 expressing cells per unit in a biological specimen. | CD19 Expressing Cell Count | ||
CD3 | C103809 | CD3 | A count of the CD3 expressing cells per unit in a biological specimen. | CD3 Expressing Cell Count | ||
CD4 | C103810 | CD4 | A count of the CD4 expressing cells per unit in a biological specimen. | CD4 Expressing Cell Count | ||
CD8 | C103811 | CD8 | A count of the CD8 expressing cells per unit in a biological specimen. | CD8 Expressing Cell Count | ||
Dohle Bodies | C74610 | Dohle Bodies | A measurement of the Dohle bodies (blue-gray, basophilic, leukocyte inclusions located in the peripheral cytoplasm of neutrophils) in a biological specimen. | Dohle Body Measurement | ||
Erythrocyte Sedimentation Rate | C74611 | Erythrocyte Sedimentation Rate;Biernacki Reaction | The distance (e.g. millimeters) that red blood cells settle in unclotted blood over a specified unit of time (e.g. one hour). | Erythrocyte Sedimentation Rate Measurement | ||
Hypersegmented Cells | C74612 | Hypersegmented Cells | A measurement of the hypersegmented (more than five lobes) neutrophils in a biological specimen. | Hypersegmented Neutrophil Measurement | ||
Lymphoma Cells | C74613 | Lymphoma Cells | A measurement of the malignant lymphocytes in a biological specimen. | Lymphoma Cell Count | ||
May-Hegglin Anomaly | C74614 | May-Hegglin Anomaly | A measurement of the May-Hegglin anomaly in a blood sample. This anomaly is characterized by large, misshapen platelets and the presence of Dohle bodies in leukocytes. | May-Hegglin Anomaly Measurement | ||
Metamyelocytes | C74615 | Metamyelocytes | A measurement of the metamyelocytes (small, myelocytic neutrophils with an indented nucleus) in a biological specimen. | Metamyelocyte Count | ||
Pappenheimer Bodies | C74616 | Pappenheimer Bodies | A measurement of the cells containing Pappenheimer Bodies (violet or blue staining ferritin granules usually found along the periphery of the red blood cells) in a biological specimen. | Pappenheimer Body Count | ||
Pelger Huet Anomaly | C74617 | Pelger Huet Anomaly | A measurement of the Pelger Huet Anomaly (nuclei of neutrophils and eosinophils appear rod-like, spherical or dumbbell shaped) in a biological specimen. | Pelger Huet Anomaly Measurement | ||
Plasmacytoid Lymphocytes | C74618 | Plasmacytoid Lymphocytes;Plymphocytes | A measurement of the plasmacytoid lymphocytes (lymphocytes with peripherally clumped chromatin and often deep blue cytoplasm, and that appear similar to plasma cells) in a biological specimen. | Plasmacytoid Lymphocyte Count | ||
Precursor Plasma Cells | C74619 | Precursor Plasma Cells;Plasmablast | A measurement of the precursor (blast stage) plasma cells (antibody secreting cells derived from B cells via antigen stimulation) in a biological specimen. | Precursor Plasma Cell Count | ||
Prolymphocytes | C74620 | Prolymphocytes | A measurement of the prolymphocytes in a biological specimen. | Prolymphocyte Count | ||
Promonocytes | C74621 | Promonocytes | A measurement of the promonocytes in a biological specimen. | Promonocyte Count | ||
Promyelocytes | C74622 | Promyelocytes | A measurement of the promyelocytes (immature myelocytes) in a biological specimen. | Promyelocyte Count | ||
Rouleaux Formation | C74624 | Rouleaux Formation | A measurement of the number of stacking red blood cells within a biological specimen. | Rouleaux Formation Count | ||
Sezary Cells | C74625 | Sezary Cells | A measurement of the Sezary cells (atypical lymphocytes with cerebriform nuclei) in a biological specimen. | Sezary Cell Count | ||
Sickle Cells | C74626 | Sickle Cells | A measurement of the sickle cells (sickle shaped red blood cells) in a biological specimen. | Sickle Cell Count | ||
Smudge Cells | C74627 | Smudge Cells;Basket Cells | A measurement of the smudge cells (the nuclear remnant of a ruptured white blood cell) in a biological specimen. | Smudge Cell Count | ||
Vacuolated Neutrophils | C74628 | Vacuolated Neutrophils | A measurement of the neutrophils containing small vacuoles in a biological specimen. | Vacuolated Neutrophil Count | ||
Leukemic Blasts | C74630 | Leukemic Blasts | A measurement of the leukemic blasts (lymphoblasts that remain in an immature state even when outside the bone marrow) in a biological specimen. | Leukemic Blast Count | ||
Monoblasts | C74631 | Monoblasts | A measurement of the monoblast cells in a biological specimen. | Monoblast Count | ||
Myeloblasts | C74632 | Myeloblasts | A measurement of the myeloblast cells in a biological specimen. | Myeloblast Count | ||
Acanthocytes/Erythrocytes | C74633 | Acanthocytes/Erythrocytes | A relative measurement (ratio or percentage) of acanthocytes to all erythrocytes in a biological specimen. | Acanthocyte to Erythrocyte Ratio Measurement | ||
Bite Cells/Erythrocytes | C74634 | Bite Cells/Erythrocytes | A relative measurement (ratio or percentage) of bite cells (erythrocytes with the appearance of a bite having been removed, due to oxidative hemolysis) to all erythrocytes in a biological specimen . | Bite Cell to Erythrocyte Ratio Measurement | ||
CD19/Lymphocytes | C103812 | CD19/Lymphocytes | A relative measurement (ratio or percentage) of CD19 expressing cells to all lymphocytes in a biological specimen. | CD19 Cell to Lymphocyte Ratio Measurement | ||
CD3/Lymphocytes | C103813 | CD3/Lymphocytes | A relative measurement (ratio or percentage) of CD3 expressing cells to all lymphocytes in a biological specimen. | CD3 Cell to Lymphocyte Ratio Measurement | ||
CD4/CD8 | C103814 | CD4/CD8 | A relative measurement (ratio or percentage) of CD4 expressing cells to the CD8 expressing cells in a biological specimen. | CD4 Cell to CD8 Cell Ratio Measurement | ||
CD4/Lymphocytes | C103815 | CD4/Lymphocytes | A relative measurement (ratio or percentage) of CD4 expressing cells to all lymphocytes in a biological specimen. | CD4 Cell to Lymphocyte Ratio Measurement | ||
CD8/Lymphocytes | C103816 | CD8/Lymphocytes | A relative measurement (ratio or percentage) of CD8 expressing cells to all lymphocytes in a biological specimen. | CD8 Cell to Lymphocyte Ratio Measurement | ||
Hairy Cells/Lymphocytes | C74640 | Hairy Cells/Lymphocytes | A relative measurement (ratio or percentage) of the hairy cells (b-cell lymphocytes with hairy projections from the cytoplasm) to all lymphocytes in a biological specimen . | Hairy Cell to Lymphocyte Ratio Measurement | ||
Leukemic Blasts/Lymphocytes | C74641 | Leukemic Blasts/Lymphocytes | A relative measurement (ratio or percentage) of the leukemic blasts (immature lymphoblasts) to mature lymphocytes in a biological specimen. | Leukemic Blast to Lymphocyte Ratio Measurement | ||
Malignant Cells, NOS/Blood Cells | C74643 | Malignant Cells, NOS/Blood Cells | A relative measurement (ratio or percentage) of the malignant cells of all types to all blood cells in a biological specimen. | Malignant Cell to Blood Cell Ratio Measurement | ||
Metamyelocytes/Leukocytes | C74645 | Metamyelocytes/Leukocytes | A relative measurement (ratio or percentage) of the metamyelocytes (small, myelocytic neutrophils with an indented nucleus) to all leukocytes in a biological specimen. | Metamyelocyte to Leukocyte Ratio Measurement | ||
Monoblasts/Leukocytes | C74646 | Monoblasts/Leukocytes | A relative measurement (ratio or percentage) of the monoblasts to leukocytes in a biological specimen. | Monoblast to Leukocyte Ratio Measurement | ||
Nucleated Erythrocytes/Erythrocytes | C74647 | Nucleated Erythrocytes/Erythrocytes;Nucleated Red Blood Cells/Erythrocytes | A relative measurement (ratio or percentage) of the nucleated erythrocytes (large, immature nucleated erythrocytes) to all erythrocytes in a biological specimen. | Nucleated Red Blood Cell to Erythrocyte Ratio Measurement | ||
Plasmacytoid Lymphocytes/Lymphocytes | C74648 | Plasmacytoid Lymphocytes/Lymphocytes | A relative measurement (ratio or percentage) of the plasmacytoid lymphocytes (lymphocytes with peripherally clumped chromatin and often deep blue cytoplasm, and that appear similar to plasma cells) to all lymphocytes in a biological specimen. | Plasmacytoid Lymphocyte to Lymphocyte Ratio Measurement | ||
Poikilocytes/Erythrocytes | C74649 | Poikilocytes/Erythrocytes | A relative measurement (ratio or percentage) of the poikilocytes, or irregularly shaped erythrocytes, to all erythrocytes in a biological specimen. | Poikilocyte to Erythrocyte Ratio Measurement | ||
Precursor Plasma Cells/Lymphocytes | C74650 | Precursor Plasma Cells/Lymphocytes | A relative measurement (ratio or percentage) of the precursor (blast stage) plasma cells (antibody secreting cells derived from B cells via antigen stimulation) to all lymphocytes in a biological specimen. | Precursor Plasma Cell to Lymphocyte Ratio Measurement | ||
Prolymphocytes/Lymphocytes | C74651 | Prolymphocytes/Lymphocytes | A relative measurement (ratio or percentage) of the prolymphocytes to all lymphocytes in a biological specimen. | Prolymphocyte to Lymphocyte Ratio Measurement | ||
Promonocytes/Leukocytes | C74652 | Promonocytes/Leukocytes | A relative measurement (ratio or percentage) of the promonocytes to all leukocytes in a biological specimen. | Promonocyte to Lymphocyte Ratio Measurement | ||
Promyelocytes/Leukocytes | C74653 | Promyelocytes/Leukocytes | A relative measurement (ratio or percentage) of the promyelocytes (immature myelocytes) to all leukocytes in a biological specimen. | Promyelocyte to Lymphocyte Ratio Measurement | ||
Reactive Lymphocytes/Lymphocytes | C74654 | Reactive Lymphocytes/Lymphocytes | A relative measurement (ratio or percentage) of the reactive lymphocytes (lymphocytes which have become large due to an antigen reaction) to all lymphocytes in a biological specimen. | Reactive Lymphocyte to Lymphocyte Ratio Measurement | ||
Sezary Cells/Lymphocytes | C74655 | Sezary Cells/Lymphocytes | A relative measurement (ratio or percentage of the Sezary cells (atypical lymphocytes with cerebriform nuclei) to all lymphocytes in a biological specimen. | Sezary Cell to Lymphocyte Ratio Measurement | ||
Sickle Cells/Erythrocytes | C74656 | Sickle Cells/Erythrocytes | A relative measurement (ratio or percentage) of the sickle cells (sickle shaped red blood cells) to all erythrocytes in a biological specimen. | Sickle Cell to Erythrocyte Ratio Measurement | ||
Auer Rods | C74657 | Auer Rods | A measurement of the Auer rods (elongated needle structures that are found in the cytoplasm of leukemic blasts and are formed by clumps of azurophilic granular material) in a biological specimen. | Auer Rod Measurement | ||
Helmet Cells | C74658 | Helmet Cells | A measurement of the Helmet cells (specialized Keratocytes with two projections on either end that are tapered and hornlike) in a biological specimen. | Helmet Cell Count | ||
Large Unstained Cells | C74659 | Large Unstained Cells | A measurement of the large, peroxidase-negative cells which cannot be further characterized (i.e. as large lymphocytes, virocytes, or stem cells) present in a biological specimen. | Large Unstained Cell Count | ||
Malignant Cells, NOS | C74660 | Malignant Cells, NOS | A measurement of the malignant cells of all types in a biological specimen. | Malignant Cell Count | ||
Mature Plasma Cells | C74661 | Mature Plasma Cells;Plasmacytes | A measurement of the mature plasma cells (plasmacytes) in a biological specimen. | Mature Plasma Cell Count | ||
Myelocytes | C74662 | Myelocytes | A measurement of the myelocytes in a biological specimen. | Myelocyte Count | ||
Spermatozoa | C74663 | Spermatozoa | A measurement of the spermatozoa cells present in a biological specimen. | Spermatozoa Cell Count | ||
Yeast Cells | C74664 | Yeast Cells | A measurement of the yeast cells present in a biological specimen. | Yeast Cell Measurement | ||
Amorphous Crystals | C74665 | Amorphous Crystals | A measurement of the amorphous (Note: phosphate or urate, depending on pH) crystals present in a biological specimen. | Amorphous Crystal Measurement | ||
Amorphous Sediment | C74666 | Amorphous Sediment;Amorphous Debris | A measurement of the amorphous sediment present in a biological specimen. | Amorphous Sediment Measurement | ||
Bicarbonate | C74667 | Bicarbonate;HCO3 | A measurement of the bicarbonate in a biological specimen. | Bicarbonate Measurement | ||
Bilirubin Crystals | C74668 | Bilirubin Crystals | A measurement of the bilirubin crystals present in a biological specimen. | Bilirubin Crystal Measurement | ||
Calcium Carbonate Crystals | C74669 | Calcium Carbonate Crystals | A measurement of the calcium carbonate crystals present in a biological specimen. | Calcium Carbonate Crystal Measurement | ||
Calcium Oxalate Crystals | C74670 | Calcium Oxalate Crystals | A measurement of the calcium oxalate crystals present in a biological specimen. | Calcium Oxalate Crystal Measurement | ||
Calcium Phosphate Crystals | C74671 | Calcium Phosphate Crystals | A measurement of the calcium phosphate crystals present in a biological specimen. | Calcium Phosphate Crystal Measurement | ||
Cholesterol Crystals | C74672 | Cholesterol Crystals | A measurement of the cholesterol crystals present in a biological specimen. | Cholesterol Crystal Measurement | ||
Crystals | C74673 | Crystals | A statement that indicates crystals were looked for in a biological specimen. | Crystal Present Or Absent | ||
Cystine Crystals | C74674 | Cystine Crystals | A measurement of the cystine crystals present in a biological specimen. | Cystine Crystal Measurement | ||
Vitamin B9 | C74676 | Folic Acid;Vitamin B9 | A measurement of the folic acid in a biological specimen. | Folic Acid Measurement | ||
Carnitine, Free | C74677 | Carnitine, Free | A measurement of the free carnitine in a biological specimen. | Free Carnitine Measurement | ||
Fructosamine | C74678 | Fructosamine;Glycated Serum Protein | A measurement of the fructosamine in a biological specimen. | Fructosamine Measurement | ||
Iron | C74679 | Iron;FE | A measurement of the iron in a biological specimen. | Iron Measurement | ||
Leucine Crystals | C74680 | Leucine Crystals | A measurement of the leucine crystals present in a biological specimen. | Leucine Crystal Measurement | ||
Monosodium Urate Crystals | C74681 | Monosodium Urate Crystals | A measurement of the monosodium urate crystals present in a biological specimen. | Monosodium Urate Crystal Measurement | ||
Carnitine | C74682 | Carnitine | A measurement of the total carnitine in a biological specimen. | Total Carnitine Measurement | ||
Tyrosine Crystals | C74683 | Tyrosine Crystals | A measurement of the triple phosphate crystals present in a biological specimen. | Tyrosine Crystal Measurement | ||
Uric Acid Crystals | C74684 | Uric Acid Crystals | A measurement of the uric acid crystals present in a biological specimen. | Uric Acid Crystal Measurement | ||
Anion Gap | C74685 | Anion Gap | A computed estimate of the unmeasured anions (those other than the chloride and bicarbonate anions) in a biological specimen. | Anion Gap Measurement | ||
Occult Blood | C74686 | Occult Blood | A measurement of the blood in body products such as a stool sample, not detectable on gross examination. | Occult Blood Measurement | ||
Amphetamine | C74687 | Amphetamine | A measurement of any amphetamine class drug present in a biological specimen. | Amphetamine Drug Class Measurement | ||
Barbiturates | C74688 | Barbiturates | A measurement of any barbiturate class drug present in a biological specimen. | Barbiturate Drug Class Measurement | ||
Cannabinoids | C74689 | Cannabinoids | A measurement of any cannabinoid class drug present in a biological specimen. | Cannabinoid Drug Class Measurement | ||
Cocaine | C74690 | Cocaine | A measurement of the cocaine present in a biological specimen. | Cocaine Measurement | ||
Round Epithelial Cells | C74698 | Round Epithelial Cells | A measurement of the round epithelial cells present in a biological specimen. | Round Epithelial Cell Count | ||
Acanthocytes | C74699 | Acanthocytes | A measurement of the acanthocytes in a biological specimen. | Acanthocyte Count | ||
Bite Cells | C74700 | Bite Cells | A measurement of the bite cells (erythrocytes with the appearance of a bite having been removed, due to oxidative hemolysis) in a biological specimen . | Bite Cell Count | ||
Burr Cells | C74701 | Burr Cells;Keratocytes | A measurement of the Burr cells (erythrocytes characterized by the presence of small, blunt projections evenly distributed across the cell surface) in a biological specimen. | Burr Cell Count | ||
Cabot Rings | C74702 | Cabot Rings | A measurement of the Cabot rings (red-purple staining, threadlike, ring or figure 8 shaped filaments in an erythrocyte) in a biological specimen. | Cabot Ring Count | ||
Crenated Cells | C74703 | Crenated Cells;Echinocytes | A measurement of the Burr cells (erythrocytes characterized by the presence of multiple small, sharp projections evenly distributed across the cell surface) in a biological specimen. | Crenated Cell Measurement | ||
Howell-Jolly Bodies | C74704 | Howell-Jolly Bodies | A measurement of the Howell-Jolly bodies (spherical, blue-black condensed DNA inclusions within the body of a red blood cell that appear under Wright-stain) in a biological specimen. | Howell-Jolly Body Measurement | ||
Nucleated Erythrocytes | C74705 | Nucleated Erythrocytes;Nucleated Red Blood Cells | A measurement of the nucleated erythrocytes (large, immature nucleated erythrocytes) in a biological specimen. | Nucleated Red Blood Cell Count | ||
Schistocytes | C74706 | Schistocytes | A measurement of the schistocytes (fragmented red blood cells) in a biological specimen. | Schistocyte Count | ||
Spherocytes | C74707 | Spherocytes | A measurement of the spherocytes (small, sphere-shaped red blood cells) in a biological specimen. | Spherocyte Count | ||
Stomatocytes | C74708 | Stomatocytes | A measurement of the stomatocytes (red blood cells with an oval or rectangular area of central pallor, producing the appearance of a cell mouth) in a biological specimen. | Stomatocyte Count | ||
Heinz Bodies | C74709 | Heinz Bodies;Heinz-Erhlich Bodies | A measurement of the Heinz bodies (small round inclusions within the body of a red blood cell) in a biological specimen. | Heinz-Ehrlich Body Measurement | ||
Hepatitis A Virus Antibody | C92534 | Hepatitis A Virus Antibody | A measurement of the antibody reaction of a biological specimen to the Hepatitis A virus. | Hepatitis A Antibody Measurement | ||
Hepatitis B Virus Surface Antibody | C74711 | Anti-HBs;HBsAb;Hepatitis B Virus Surface Antibody | A measurement of the surface antibody reaction of a biological specimen to the Hepatitis B virus. | Hepatitis B Surface Antibody Measurement | ||
Hepatitis C Virus Antibody | C92535 | Hepatitis C Virus Antibody | A measurement of the antibody reaction of a biological specimen to the Hepatitis C virus. | Hepatitis C Antibody Measurement | ||
HIV-1 Antibody | C74713 | HIV-1 Antibody | A measurement of the antibody reaction of a biological specimen to the HIV-1 virus. | HIV-1 Antibody Measurement | ||
HIV-1/2 Antibody | C74714 | HIV-1/2 Antibody | A measurement of the antibody reaction of a biological specimen to the either the HIV-1 or HIV-2 virus. | HIV-1 HIV-2 Antibody Measurement | ||
HIV-2 Antibody | C74715 | HIV-2 Antibody | A measurement of the antibody reaction of a biological specimen to the HIV-2 virus. | HIV-2 Antibody Measurement | ||
Rapid Plasma Reagin | C74716 | Rapid Plasma Reagin | A measurement of the antibodies produced by cellular damage caused by Treponema pallidum (syphilis) in a biological specimen. | Rapid Plasma Reagin Measurement | ||
Rheumatoid Factor | C74717 | Rheumatoid Factor | A measurement of the rheumatoid factor antibody in a biological specimen. | Rheumatoid Factor Measurement | ||
Total Iron Binding Capacity | C74718 | Total Iron Binding Capacity | A measurement of the amount of iron needed to fully saturate the transferrin in a biological specimen. | Total Iron Binding Capacity | ||
Unsaturated Iron Binding Capacity | C74719 | Unsaturated Iron Binding Capacity | A measurement of the binding capacity of unsaturated iron in a biological specimen. | Unsaturated Iron Binding Capacity Measurement | ||
Mucous Threads | C74721 | Mucous Threads | A measurement of the mucous threads present in a biological specimen. | Mucous Thread Measurement | ||
Turbidity | C74723 | Turbidity | A measurement of the opacity of a biological specimen. | Turbidity Measurement | ||
HAV Viral Load | C92541 | HAV Viral Load | A measurement of the hepatitis A viral load in a biological specimen. | Hepatitis A Viral Load Measurement | ||
HBV Viral Load | C92542 | HBV Viral Load | A measurement of the hepatitis B viral load in a biological specimen. | Hepatitis B Viral Load Measurement | ||
HCV Viral Load | C92543 | HCV Viral Load | A measurement of the hepatitis C viral load in a biological specimen. | Hepatitis C Viral Load Measurement | ||
HIV Viral Load | C92544 | HIV Viral Load | A measurement of the HIV viral load in a biological specimen. | HIV Viral Load Measurement | ||
Giant Platelets | C74728 | Giant Platelets | A measurement of the giant (larger than 7um in diameter) platelets in a biological specimen. | Giant Platelet Count | ||
Large Platelets | C74729 | Large Platelets | A measurement of the large (between 4 um and 7um in diameter) platelets in a biological specimen. | Large Platelet Count | ||
Mean Platelet Volume | C74730 | Mean Platelet Volume | A measurement of the average size of the platelets present in a blood sample. | Mean Platelet Volume Measurement | ||
Aldolase | C74731 | Aldolase | A measurement of the aldolase enzyme in a biological specimen. | Aldolase Measurement | ||
Alpha Fetoprotein | C74732 | Alpha Fetoprotein | A measurement of the alpha fetoprotein in a biological specimen. | Alpha-fetoprotein Measurement | ||
Apolipoprotein A1 | C74733 | Apolipoprotein A1 | A measurement of the apolipoprotein A1 in the high density lipoproteins of a biological specimen. | Apolipoprotein A1 Measurement | ||
Apolipoprotein B | C74734 | Apolipoprotein B | A measurement of the apolipoprotein B in the low density lipoproteins of a biological specimen. | Apolipoprotein B Measurement | ||
Brain Natriuretic Peptide | C74735 | Brain Natriuretic Peptide;B-Type Natriuretic Peptide | A measurement of the brain (B-type) natriuretic peptide in a biological specimen. | Brain Natriuretic Peptide Measurement | ||
C-peptide | C74736 | C-peptide | A measurement of the C (connecting) peptide of insulin in a biological specimen. | C-peptide Measurement | ||
Ferritin | C74737 | Ferritin | A measurement of the ferritin in a biological specimen. | Ferritin Measurement | ||
Globulin | C74738 | Globulin | A measurement of the globulin protein in a biological specimen. | Globulin Protein Measurement | ||
Glutamate | C74739 | Glutamate;Glutamic Acid | A measurement of the glutamate in a biological specimen. | Glutamate Measurement | ||
Haptoglobin | C74740 | Haptoglobin | A measurement of the haptoglobin protein in a biological specimen. | Haptoglobin Protein Measurement | ||
Homocysteine | C74741 | Homocysteine | A measurement of the homocysteine amino acid in a biological specimen. | Homocysteine Acid Measurement | ||
N-telopeptide | C74743 | N-telopeptide | A measurement of the N-telopeptide in a biological specimen. | N-telopeptide Measurement | ||
Osteocalcin | C74744 | Osteocalcin | A measurement of the osteocalcin in a biological specimen. | Osteocalcin Measurement | ||
Sex Hormone Binding Globulin | C74745 | Sex Hormone Binding Globulin;Sex Hormone Binding Protein | A measurement of the sex hormone binding (globulin) protein in a biological specimen. | Sex Hormone Binding Protein Measurement | ||
Thyroxine Binding Globulin | C74746 | Thyroxine Binding Globulin | A measurement of the thyroxine binding globulin protein in a biological specimen. | Thyroxine Binding Globulin Protein Measurement | ||
Triiodothyronine | C74747 | Triiodothyronine;Total T3 | A measurement of the total (free and bound) triiodothyronine in a biological specimen. | Triiodothyronine Measurement | ||
Triiodothyronine Uptake | C74748 | Triiodothyronine Uptake | A measurement of the binding of triiodothyonine to thyroxine binding globulin protein in a biological specimen. | Triiodothyronine Uptake Measurement | ||
Troponin I | C74749 | Troponin I | A measurement of the actin binding troponin in a biological specimen. | Troponin I Measurement | ||
Troponin T | C74750 | Troponin T | A measurement of the tropomyosin binding troponin in a biological specimen. | Troponin T Measurement | ||
Tumor Necrosis Factor | C74751 | Tumor Necrosis Factor;Tumor Necrosis Factor alpha | A measurement of the total tumor necrosis factor (cachexin) cytokine in a biological specimen. | Tumor Necrosis Factor Measurement | ||
BUN/Creatinine | C74753 | BUN/Creatinine | A relative measurement (ratio or percentage) (ratio) of the blood urea nitrogen (BUN) to the creatinine in a biological specimen. | Blood Urea Nitrogen To Creatinine Ratio Measurement | ||
Hippuric Acid Crystals | C74754 | Hippuric Acid Crystals | A measurement of the hippuric acid crystals present in a biological specimen. | Hippuric Acid Crystal Measurement | ||
Sulfa Crystals | C74755 | Sulfa Crystals | A measurement of the sulfa crystals present in a biological specimen. | Sulfa Crystal Measurement | ||
Triple Phosphate Crystals | C74756 | Triple Phosphate Crystals | A measurement of the triple phosphate crystals present in a biological specimen. | Triple Phosphate Crystal Measurement | ||
Unclassified Crystals | C74757 | Unclassified Crystals | A measurement of the unclassifiable crystals present in a biological specimen. | Unclassified Crystal Measurement | ||
Ammonium Biurate Crystals | C105590 | Ammonium Biurate Crystals;Ammonium Urate Crystals;Acid Ammonium Urate Crystals | A measurement of the ammonium biurate crystals present in a biological specimen. | Ammonium Biurate Crystals Measurement | ||
Ammonium Oxalate Crystals | C74759 | Ammonium Oxalate Crystals | A measurement of the ammonium oxalate crystals present in a urine specimen. | Urine Ammonium Oxalate Crystal Measurement | ||
Albumin/Creatinine | C74761 | Albumin/Creatinine;Microalbumin/Creatinine Ratio | A relative measurement (ratio or percentage) of the albumin to the creatinine in a biological specimen. | Albumin To Creatinine Protein Ratio Measurement | ||
Bacterial Casts | C74762 | Bacterial Casts | A measurement of the bacterial casts present in a biological specimen. | Bacterial Cast Measurement | ||
Casts | C74763 | Casts | A statement that indicates casts were looked for in a biological specimen. | Cast Present Or Absent | ||
Cellular Casts | C74764 | Cellular Casts | A measurement of the cellular (white blood cell, red blood cell, epithelial and bacterial) casts present in a biological specimen. | Cellular Cast Measurement | ||
Granular Coarse Casts | C74765 | Granular Coarse Casts | A measurement of the coarse granular casts present in a biological specimen. | Coarse Granular Cast Measurement | ||
Fatty Casts | C74766 | Fatty Casts | A measurement of the fatty casts present in a biological specimen. | Fatty Cast Measurement | ||
Granular Casts | C74768 | Granular Casts | A measurement of the granular (coarse and fine) casts present in a biological specimen. | Granular Cast Measurement | ||
Granular Fine Casts | C74769 | Granular Fine Casts | A measurement of the fine granular casts present in a biological specimen. | Granular Fine Cast Measurement | ||
Hyaline Casts | C74770 | Hyaline Casts | A measurement of the hyaline casts present in a biological specimen. | Hyaline Cast Measurement | ||
Mixed Casts | C74771 | Mixed Casts | A measurement of the mixed (the cast contains a mixture of cell types) casts present in a biological specimen. | Mixed Cast Count | ||
RBC Casts | C74772 | RBC Casts | A measurement of the red blood cell casts present in a biological specimen. | Red Blood Cell Cast Measurement | ||
Squamous Epithelial Cells | C74773 | Squamous Epithelial Cells | A measurement of the squamous epithelial cells present in a biological specimen. | Squamous Epithelial Cell Count | ||
Squamous Transitional Epithelial Cells | C74774 | Squamous Transitional Epithelial Cells;Epithelial Cells | A measurement of the squamous transitional epithelial cells present in a biological specimen. | Squamous Transitional Epithelial Cell Count | ||
Tubular Epithelial Cells | C74775 | Tubular Epithelial Cells;Renal Tubular Epithelial Cells | A measurement of the tubular epithelial cells present in a biological specimen. | Tubular Epithelial Cell Count | ||
Unclassified Casts | C74776 | Unclassified Casts | A measurement of the unclassifiable casts present in a biological specimen. | Unclassified Cast Measurement | ||
Waxy Casts | C74777 | Waxy Casts | A measurement of the waxy casts present in a biological specimen. | Waxy Cell Cast Measurement | ||
WBC Casts | C74778 | WBC Casts | A measurement of the white blood cell casts present in a biological specimen. | White Blood Cell Cast Measurement | ||
Epithelial Casts | C74779 | Epithelial Casts | A measurement of the epithelial cell casts present in a biological specimen. | Epithelial-Cast Measurement | ||
Adrenocorticotropic Hormone | C74780 | Adrenocorticotropic Hormone | A measurement of the adrenocorticotropic hormone in a biological specimen. | Adrenocorticotropic Hormone Measurement | ||
Cortisol | C74781 | Cortisol;Total Cortisol | A measurement of the cortisol in a biological specimen. | Cortisol Measurement | ||
Estradiol | C74782 | Estradiol;Oestradiol | A measurement of the estradiol in a biological specimen. | Estradiol Measurement | ||
Follicle Stimulating Hormone | C74783 | Follicle Stimulating Hormone | A measurement of the follicle stimulating hormone (FSH) in a biological specimen. | Follicle Stimulating Hormone Measurement | ||
Parathyroid Hormone, Fragmented | C74784 | Parathyroid Hormone, Fragmented | A measurement of the fragmented parathyroid hormone in a biological specimen. | Fragmented Parathyroid Hormone Measurement | ||
Testosterone, Free | C74785 | Testosterone, Free | A measurement of the free testosterone in a biological specimen. | Free Testosterone Measurement | ||
Thyroxine, Free | C74786 | Thyroxine, Free;Free T4 | A measurement of the free thyroxine in a biological specimen. | Free Thyroxine Measurement | ||
Triiodothyronine, Free | C74787 | Triiodothyronine, Free;Free T3 | A measurement of the free triiodothyronine in a biological specimen. | Free Triiodothyronine Measurement | ||
Insulin | C74788 | Insulin | A measurement of the insulin in a biological specimen. | Insulin Measurement | ||
Parathyroid Hormone, Intact | C74789 | Parathyroid Hormone, Intact | A measurement of the intact parathyroid hormone (consisting of amino acids 1-84 or 7-84) in a biological specimen. | Intact Parathyroid Hormone Measurement | ||
Luteinizing Hormone | C74790 | Luteinizing Hormone | A measurement of the luteinizing hormone in a biological specimen. | Luteinizing Hormone Measurement | ||
Progesterone | C74791 | Progesterone | A measurement of the progesterone hormone in a biological specimen. | Progesterone Measurement | ||
Somatotrophin | C80360 | Somatotrophin;Growth Hormone | A measurement of the somatotrophin (growth) hormone in a biological specimen. | Somatotropin Measurement | ||
Testosterone | C74793 | Testosterone;Total Testosterone | A measurement of the total (free and bound) testosterone in a biological specimen. | Total Testosterone Measurement | ||
Thyroxine | C74794 | Thyroxine;Total T4 | A measurement of the total (free and bound) thyroxine in a biological specimen. | Total Thyroxine Measurement | ||
Opiate | C74796 | Opiate | A measurement of any opiate class drug present in a biological specimen. | Opiate Measurement | ||
Lymphoma Cells/Lymphocytes | C74910 | Lymphoma Cells/Lymphocytes | A relative measurement (ratio or percentage) of the malignant lymphocytes to all lymphocytes in a biological specimen. | Lymphoma Cell to Lymphocyte Ratio Measurement | ||
Mature Plasma Cells/Lymphocytes | C74911 | Mature Plasma Cells/Lymphocytes | A relative measurement (ratio or percentage) of the mature plasma cells (plasmacytes) to all lymphocytes in a biological specimen. | Mature Plasma Cell to Lymphocyte Ratio Measurement | ||
Acid Urate Crystals | C74912 | Acid Urate Crystals | A measurement of the acid urate crystals present in a biological specimen. | Acid Urate Crystal Measurement | ||
Anti-Double Stranded DNA | C74913 | Anti-Double Stranded DNA | A measurement of the anti-double stranded DNA antibody in a biological specimen. | Anti-Double Stranded DNA Measurement | ||
Antinuclear Antibodies | C74916 | Antinuclear Antibodies | A measurement of the antinuclear antibodies (antibodies that attack the body's own tissue) in a biological specimen. | Antinuclear Antibody Measurement | ||
5 Prime Nucleotidase | C79437 | 5 Prime Nucleotidase;5'-Ribonucleotide Phosphohydrolase | A measurement of the 5'-nucleotidase in a biological specimen. | 5 Prime Nucleotidase Measurement | ||
6-Monoacetylmorphine | C74876 | 6-Monoacetylmorphine | A measurement of the 6-monoacetylmorphine present in a biological specimen. | 6-Monoacetylmorphine Measurement | ||
Acetylcholine | C74838 | Acetylcholine | A measurement of the acetylcholine hormone in a biological specimen. | Acetylcholine Measurement | ||
Adiponectin | C74839 | Adiponectin | A measurement of the adiponectin hormone in a biological specimen. | Adiponectin Measurement | ||
Albumin/Globulin | C74894 | Albumin/Globulin | The ratio of albumin to globulin in a biological specimen. | Albumin to Globulin Ratio Measurement | ||
Aldosterone | C74841 | Aldosterone | A measurement of the aldosterone hormone in a biological specimen. | Aldosterone Measurement | ||
Alkaline Phosphatase/Creatinine | C79438 | Alkaline Phosphatase/Creatinine | A relative measurement (ratio or percentage) of the alkaline phosphatase to creatinine in a biological specimen. | Alkaline Phosphatase to Creatinine Ratio Measurement | ||
Alpha Glutathione-S-Transferase | C79433 | Alpha Glutathione-S-Transferase | A measurement of the alpha form of glutathione S-transferase in a biological specimen. | Alpha Glutathione-S-Transferase Measurement | ||
Ammonia | C74799 | Ammonia;NH3 | A measurement of the ammonia in a biological specimen. | Ammonia Measurement | ||
Androstenediol | C74842 | Androstenediol | A measurement of the androstenediol metabolite in a biological specimen. | Androstenediol Metabolite Measurement | ||
Androstenedione | C74843 | Androstenedione;4-Androstenedione | A measurement of the androstenedione hormone in a biological specimen. | Androstenedione Measurement | ||
Angiotensin I | C74844 | Angiotensin I | A measurement of the angiotensin I hormone in a biological specimen. | Angiotensin I Measurement | ||
Angiotensin II | C74845 | Angiotensin II | A measurement of the angiotensin II hormone in a biological specimen. | Angiotensin II Measurement | ||
Angiotensinogen | C74846 | Angiotensinogen;Angiotensin Precursor | A measurement of the angiotensinogen hormone in a biological specimen. | Angiotensinogen Measurement | ||
Antidepressants | C74691 | Antidepressants | A measurement of any antidepressant class drug present in a biological specimen. | Antidepressant Measurement | ||
Antidiuretic Hormone | C74847 | Antidiuretic Hormone;Vasopressin | A measurement of the antidiuretic hormone in a biological specimen. | Antidiuretic Hormone Measurement | ||
Atrial Natriuretic Peptide | C74886 | Atrial Natriuretic Peptide;Atriopeptin | A measurement of the atrial natriuretic peptide in a biological specimen. | Atrial Natriuretic Peptide Measurement | ||
Benzodiazepine | C74692 | Benzodiazepine | A measurement of any benzodiazepine class drug present in a biological specimen. | Benzodiazepine Measurement | ||
Bile Acid | C74800 | Bile Acid;Bile Salts;Bile Acids;Bile Salt | A measurement of the total bile acids in a biological specimen. | Bile Acid Measurement | ||
Calcitonin | C74848 | Calcitonin | A measurement of the calcitonin hormone in a biological specimen. | Calcitonin Measurement | ||
Calcitriol | C74849 | Calcitriol | A measurement of the calcitriol hormone in a biological specimen. | Calcitriol Measurement | ||
Calcium/Creatinine | C79439 | Calcium/Creatinine | A relative measurement (ratio or percentage) of the calcium to creatinine in a biological specimen. | Calcium to Creatinine Ratio Measurement | ||
Chloride/Creatinine | C79440 | Chloride/Creatinine | A relative measurement (ratio or percentage) of the chloride to creatinine in a biological specimen. | Chloride to Creatinine Ratio Measurement | ||
Cholecystokinin | C74850 | Cholecystokinin;Pancreozymin | A measurement of the cholecystokinin hormone in a biological specimen. | Cholecystokinin Measurement | ||
Codeine | C74877 | Codeine | A measurement of the codeine present in a biological specimen. | Codeine Measurement | ||
Corticosterone | C79434 | Corticosterone | A measurement of corticosterone in a biological specimen. | Corticosterone Measurement | ||
Corticotropin Releasing Hormone | C74851 | Corticotropin Releasing Hormone;Corticotropin Releasing Factor | A measurement of the corticotropin releasing hormone in a biological specimen. | Corticotropin Releasing Hormone Measurement | ||
Creatine Kinase BB/Total Creatine Kinase | C79466 | Creatine Kinase BB/Total Creatine Kinase | A relative measurement (ratio or percentage) of the BB-type creatine kinase to total creatine kinase in a biological specimen. | Creatine Kinase BB to Total Creatine Kinase Ratio Measurement | ||
Creatine Kinase MB/Total Creatine Kinase | C79441 | Creatine Kinase MB/Total Creatine Kinase | A relative measurement (ratio or percentage) of the MB-type creatine kinase to total creatine kinase in a biological specimen. | Creatine Kinase MB to Total Creatine Kinase Ratio Measurement | ||
Creatine Kinase MM/Total Creatine Kinase | C79442 | Creatine Kinase MM/Total Creatine Kinase | A relative measurement (ratio or percentage) of the MM-type creatine kinase to total creatine kinase in a biological specimen. | Creatine Kinase MM to Total Creatine Kinase Ratio Measurement | ||
Dehydroepiandrosterone | C74852 | Dehydroepiandrosterone;Dehydroisoandrosterone | A measurement of the dehydroepiandrosterone hormone in a biological specimen. | Dehydroepiandrosterone Measurement | ||
Deoxypyridinoline | C79443 | Deoxypyridinoline | A measurement of the deoxypyridinoline in a biological specimen. | Deoxypyridinoline Measurement | ||
Deoxypyridinoline/Creatinine | C79444 | Deoxypyridinoline/Creatinine | A relative measurement (ratio or percentage) of the deoxypyridinoline to creatinine in a biological specimen. | Deoxypyridinoline to Creatinine Ratio Measurement | ||
Dihydrocodeine | C74878 | Dihydrocodeine | A measurement of the dihydrocodeine present in a biological specimen. | Dihydrocodeine Measurement | ||
Dihydrotestosterone | C74853 | Dihydrotestosterone;Androstanalone | A measurement of the dihydrotestosterone hormone in a biological specimen. | Dihydrotestosterone Measurement | ||
Dopamine | C74854 | Dopamine | A measurement of the dopamine hormone in a biological specimen. | Dopamine Measurement | ||
Epinephrine | C79445 | Epinephrine;Adrenaline | A measurement of the epinephrine hormone in a biological specimen. | Epinephrine Measurement | ||
Erythropoietin | C74855 | Erythropoietin;Hematopoietin | A measurement of the erythropoietin hormone in a biological specimen. | Erythropoietin Measurement | ||
Estriol | C74856 | Estriol;Oestriol | A measurement of the estriol hormone in a biological specimen. | Estriol Measurement | ||
Estrone | C74857 | Estrone;Oestrone | A measurement of the estrone hormone in a biological specimen. | Estrone Measurement | ||
Ethanol | C74693 | Ethanol;Alcohol | A measurement of the ethanol present in a biological specimen. | Ethanol Measurement | ||
Gamma Glutamyl Transferase/Creatinine | C79446 | Gamma Glutamyl Transferase/Creatinine | A relative measurement (ratio or percentage) of the gamma glutamyl transferase to creatinine in a biological specimen. | Gamma Glutamyl Transferase to Creatinine Ratio Measurement | ||
Gastrin | C74858 | Gastrin | A measurement of the gastrin hormone in a biological specimen. | Gastrin Measurement | ||
Glucagon | C74859 | Glucagon | A measurement of the glucagon hormone in a biological specimen. | Glucagon Measurement | ||
Glucose/Creatinine | C79447 | Glucose/Creatinine | A relative measurement (ratio or percentage) of the glucose to creatinine in a biological specimen. | Glucose to Creatinine Ratio Measurement | ||
Glutamate Dehydrogenase | C79448 | Glutamate Dehydrogenase | A measurement of the glutamate dehydrogenase in a biological specimen. | Glutamate Dehydrogenase Measurement | ||
Glutathione-S-Transferase/Creatinine | C79435 | Glutathione-S-Transferase/Creatinine | A relative measurement (ratio or percentage) of the glutathione S-transferase to creatinine in a biological specimen. | Glutathione-S-Transferase to Creatinine Ratio Measurement | ||
Gonadotropin Releasing Hormone | C74860 | Gonadotropin Releasing Hormone;Luteinising Hormone Releasing Hormone | A measurement of the gonadotropin releasing hormone in a biological specimen. | Gonadotropin Releasing Hormone Measurement | ||
Growth Hormone Inhibiting Hormone | C74861 | Growth Hormone Inhibiting Hormone;Somatostatin | A measurement of the growth hormone inhibiting hormone in a biological specimen. | Growth Hormone Inhibiting Hormone Measurement | ||
Growth Hormone Releasing Hormone | C74862 | Growth Hormone Releasing Hormone;Somatocrinin | A measurement of the growth hormone releasing hormone in a biological specimen. | Growth Hormone Releasing Hormone Measurement | ||
Homovanillic Acid | C74863 | Homovanillic Acid | A measurement of the homovanillic acid metabolite in a biological specimen. | Homovanillic Acid Measurement | ||
Hydrocodone | C74879 | Hydrocodone | A measurement of the hydrocodone present in a biological specimen. | Hydrocodone Measurement | ||
Hydromorphone | C74880 | Hydromorphone | A measurement of the hydromorphone present in a biological specimen. | Hydromorphone Measurement | ||
Insulin-like Growth Factor-1 | C74864 | Insulin-like Growth Factor-1 | A measurement of the insulin-like growth factor-1 in a biological specimen. | Insulin Like Growth Factor-1 Measurement | ||
Insulin-like Growth Factor-2 | C74865 | Insulin-like Growth Factor-2 | A measurement of the insulin-like growth factor-2 in a biological specimen. | Insulin Like Growth Factor-2 Measurement | ||
Interleukin 1 | C74805 | Interleukin 1 | A measurement of the interleukin 1 in a biological specimen. | Interleukin 1 Measurement | ||
Interleukin 10 | C74806 | Interleukin 10 | A measurement of the interleukin 10 in a biological specimen. | Interleukin 10 Measurement | ||
Interleukin 11 | C74807 | Interleukin 11 | A measurement of the interleukin 11 in a biological specimen. | Interleukin 11 Measurement | ||
Interleukin 12 | C74808 | Interleukin 12 | A measurement of the interleukin 12 in a biological specimen. | Interleukin 12 Measurement | ||
Interleukin 13 | C74809 | Interleukin 13 | A measurement of the interleukin 13 in a biological specimen. | Interleukin 13 Measurement | ||
Interleukin 14 | C74810 | Interleukin 14 | A measurement of the interleukin 14 in a biological specimen. | Interleukin 14 Measurement | ||
Interleukin 15 | C74811 | Interleukin 15 | A measurement of the interleukin 15 in a biological specimen. | Interleukin 15 Measurement | ||
Interleukin 16 | C74812 | Interleukin 16 | A measurement of the interleukin 16 in a biological specimen. | Interleukin 16 Measurement | ||
Interleukin 17 | C74813 | Interleukin 17 | A measurement of the interleukin 17 in a biological specimen. | Interleukin 17 Measurement | ||
Interleukin 18 | C74814 | Interleukin 18 | A measurement of the interleukin 18 in a biological specimen. | Interleukin 18 Measurement | ||
Interleukin 19 | C74815 | Interleukin 19 | A measurement of the interleukin 19 in a biological specimen. | Interleukin 19 Measurement | ||
Interleukin 2 | C74816 | Interleukin 2 | A measurement of the interleukin 2 in a biological specimen. | Interleukin 2 Measurement | ||
Interleukin 20 | C74817 | Interleukin 20 | A measurement of the interleukin 20 in a biological specimen. | Interleukin 20 Measurement | ||
Interleukin 21 | C74818 | Interleukin 21 | A measurement of the interleukin 21 in a biological specimen. | Interleukin 21 Measurement | ||
Interleukin 22 | C74819 | Interleukin 22 | A measurement of the interleukin 22 in a biological specimen. | Interleukin 22 Measurement | ||
Interleukin 23 | C74820 | Interleukin 23 | A measurement of the interleukin 23 in a biological specimen. | Interleukin 23 Measurement | ||
Interleukin 24 | C74821 | Interleukin 24 | A measurement of the interleukin 24 in a biological specimen. | Interleukin 24 Measurement | ||
Interleukin 25 | C74822 | Interleukin 25 | A measurement of the interleukin 25 in a biological specimen. | Interleukin 25 Measurement | ||
Interleukin 26 | C74823 | Interleukin 26 | A measurement of the interleukin 26 in a biological specimen. | Interleukin 26 Measurement | ||
Interleukin 27 | C74824 | Interleukin 27 | A measurement of the interleukin 27 in a biological specimen. | Interleukin 27 Measurement | ||
Interleukin 28 | C74825 | Interleukin 28 | A measurement of the interleukin 28 in a biological specimen. | Interleukin 28 Measurement | ||
Interleukin 29 | C74826 | Interleukin 29 | A measurement of the interleukin 29 in a biological specimen. | Interleukin 29 Measurement | ||
Interleukin 3 | C74827 | Interleukin 3 | A measurement of the interleukin 3 in a biological specimen. | Interleukin 3 Measurement | ||
Interleukin 30 | C74828 | Interleukin 30 | A measurement of the interleukin 30 in a biological specimen. | Interleukin 30 Measurement | ||
Interleukin 31 | C74829 | Interleukin 31 | A measurement of the interleukin 31 in a biological specimen. | Interleukin 31 Measurement | ||
Interleukin 32 | C74830 | Interleukin 32 | A measurement of the interleukin 32 in a biological specimen. | Interleukin 32 Measurement | ||
Interleukin 33 | C74831 | Interleukin 33 | A measurement of the interleukin 33 in a biological specimen. | Interleukin 33 Measurement | ||
Interleukin 4 | C74832 | Interleukin 4 | A measurement of the interleukin 4 in a biological specimen. | Interleukin 4 Measurement | ||
Interleukin 5 | C74833 | Interleukin 5 | A measurement of the interleukin 5 in a biological specimen. | Interleukin 5 Measurement | ||
Interleukin 6 | C74834 | Interleukin 6 | A measurement of the interleukin 6 in a biological specimen. | Interleukin 6 Measurement | ||
Interleukin 7 | C74835 | Interleukin 7 | A measurement of the interleukin 7 in a biological specimen. | Interleukin 7 Measurement | ||
Interleukin 8 | C74836 | Interleukin 8 | A measurement of the interleukin 8 in a biological specimen. | Interleukin 8 Measurement | ||
Interleukin 9 | C74837 | Interleukin 9 | A measurement of the interleukin 9 in a biological specimen. | Interleukin 9 Measurement | ||
LDH Isoenzyme 1 | C74887 | LDH Isoenzyme 1 | A measurement of the lactate dehydrogenase isoenzyme 1 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 1 Measurement | ||
LDH Isoenzyme 2 | C74888 | LDH Isoenzyme 2 | A measurement of the lactate dehydrogenase isoenzyme 2 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 2 Measurement | ||
LDH Isoenzyme 3 | C74889 | LDH Isoenzyme 3 | A measurement of the lactate dehydrogenase isoenzyme 3 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 3 Measurement | ||
LDH Isoenzyme 4 | C74890 | LDH Isoenzyme 4 | A measurement of the lactate dehydrogenase isoenzyme 4 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 4 Measurement | ||
LDH Isoenzyme 5 | C74891 | LDH Isoenzyme 5 | A measurement of the lactate dehydrogenase isoenzyme 5 in a biological specimen. | Lactate Dehydrogenase Isoenzyme 5 Measurement | ||
Lactate Dehydrogenase/Creatinine | C79449 | Lactate Dehydrogenase/Creatinine | A relative measurement (ratio or percentage) of the lactate dehydrogenase to creatinine in a biological specimen. | Lactate Dehydrogenase to Creatinine Ratio Measurement | ||
Lactic Acid | C79450 | Lactic Acid;2-hydroxypropanoic acid;Lactate | A measurement of the lactic acid in a biological specimen. | Lactic Acid Measurement | ||
Large Unstained Cells/Leukocytes | C79467 | Large Unstained Cells/Leukocytes | A relative measure (ratio or percentage) of the large unstained cells to leukocytes in a biological specimen. | Large Unstained Cells to Leukocytes Ratio Measurement | ||
LDH Isoenzyme 1/LDH | C79451 | LDH Isoenzyme 1/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 1 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 1 to LDH Ratio Measurement | ||
LDH Isoenzyme 2/LDH | C79452 | LDH Isoenzyme 2/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 2 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 2 to LDH Ratio Measurement | ||
LDH Isoenzyme 3/LDH | C79453 | LDH Isoenzyme 3/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 3 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 3 to LDH Ratio Measurement | ||
LDH Isoenzyme 4/LDH | C79454 | LDH Isoenzyme 4/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 4 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 4 to LDH Ratio Measurement | ||
LDH Isoenzyme 5/LDH | C79455 | LDH Isoenzyme 5/LDH | A relative measurement (ratio or percentage) of the lactate dehydrogenase isoenzyme 5 to total lactate dehydrogenase in a biological specimen. | LDH Isoenzyme 5 to LDH Ratio Measurement | ||
Leptin | C74866 | Leptin | A measurement of the leptin hormone in a biological specimen. | Leptin Measurement | ||
Magnesium/Creatinine | C79456 | Magnesium/Creatinine | A relative measurement (ratio or percentage) of the magnesium to creatinine in a biological specimen. | Magnesium to Creatinine Ratio Measurement | ||
Melatonin | C74867 | Melatonin | A measurement of the melatonin hormone in a biological specimen. | Melatonin Measurement | ||
Methadone | C74881 | Methadone | A measurement of the methadone present in a biological specimen. | Methadone Measurement | ||
Methaqualone | C74882 | Methaqualone | A measurement of the methaqualone present in a biological specimen. | Methaqualone Measurement | ||
Morphine | C74883 | Morphine | A measurement of the morphine present in a biological specimen. | Morphine Measurement | ||
Mu Glutathione-S-Transferase | C79457 | Mu Glutathione-S-Transferase | A measurement of the mu form of glutathione S-transferase in a biological specimen. | Mu Glutathione-S-Transferase Measurement | ||
Mu Glutathione-S-Transferase/Creatinine | C79458 | Mu Glutathione-S-Transferase/Creatinine | A relative measurement (ratio or percentage) of the mu gamma glutamyl transpeptidase to creatinine in a biological specimen. | Mu Glutathione-S-Transferase to Creatinine Ratio Measurement | ||
Myoglobin | C79436 | Myoglobin | A measurement of myoglobin in a biological specimen. | Myoglobin Measurement | ||
N-Acetyl Glucosamide | C79459 | N-Acetyl Glucosamide;N-Acetyl Glucosamine | A measurement of N-acetyl glucosamide in a biological specimen. | N-Acetyl Glucosamide Measurement | ||
N-Acetyl Glucosamide/Creatinine | C79460 | N-Acetyl Glucosamide/Creatinine | A relative measurement (ratio or percentage) of the N-acetyl glucosamide to creatinine in a biological specimen. | N-Acetyl Glucosamide to Creatinine Ratio Measurement | ||
Neuropeptide Y | C74892 | Neuropeptide Y | A measurement of the neuropeptide Y in a biological specimen. | Neuropeptide Y Measurement | ||
Norepinephrine | C74868 | Noradrenaline;Norepinephrine | A measurement of the norepinephrine hormone in a biological specimen. | Noradrenaline Measurement | ||
Osmolality | C74801 | Osmolality | A measurement of the osmoles of solute per unit of biological specimen. | Osmolality Measurement | ||
Oxycodone | C74884 | Oxycodone;Oxycontin | A measurement of the oxycodone present in a biological specimen. | Oxycodone Measurement | ||
Oxytocin | C74869 | Oxytocin;Oxytoxin | A measurement of the oxytocin hormone in a biological specimen. | Oxytocin Measurement | ||
Phencyclidine | C74694 | Phencyclidine;Phenylcyclohexylpiperidine | A measurement of the phencyclidine present in a biological specimen. | Phencyclidine Measurement | ||
Phenothiazine | C74695 | Phenothiazine;Dibenzothiazine | A measurement of the phenothiazine present in a biological specimen. | Phenothiazine Measurement | ||
Phosphate/Creatinine | C79461 | Phosphate/Creatinine | A relative measurement (ratio or percentage) of the phosphate to creatinine in a biological specimen. | Phosphate to Creatinine Ratio Measurement | ||
Potassium/Creatinine | C79462 | Potassium/Creatinine | A relative measurement (ratio or percentage) of the potassium to creatinine in a biological specimen. | Potassium to Creatinine Ratio Measurement | ||
Prolactin | C74870 | Prolactin | A measurement of the prolactin hormone in a biological specimen. | Prolactin Measurement | ||
Propoxyphene | C74885 | Propoxyphene | A measurement of the propoxyphene present in a biological specimen. | Propoxyphene Measurement | ||
Protein/Creatinine | C79463 | Protein/Creatinine | A relative measurement (ratio or percentage) of the protein to creatinine in a biological specimen. | Protein to Creatinine Ratio Measurement | ||
Pseudoephedrine | C74696 | Pseudoephedrine | A measurement of the pseudoephedrine present in a biological specimen. | Pseudoephedrine Measurement | ||
Reactive Lymphocytes | C74629 | Reactive Lymphocytes | A measurement of the reactive lymphocytes (lymphocytes which have become large due to an antigen reaction) in a biological specimen. | Reactive Lymphocyte Count Measurement | ||
Renin | C74893 | Renin;Angiotensinogenase | A measurement of the renin in a biological specimen. | Renin Measurement | ||
Secretin | C74871 | Secretin | A measurement of the secretin hormone in a biological specimen. | Secretin Measurement | ||
Serotonin | C74872 | Serotonin | A measurement of the serotonin hormone in a biological specimen. | Serotonin Measurement | ||
Sodium/Creatinine | C79464 | Sodium/Creatinine | A relative measurement (ratio or percentage) of the sodium to creatinine in a biological specimen. | Sodium to Creatinine Ratio Measurement | ||
Sorbitol Dehydrogenase | C79465 | Sorbitol Dehydrogenase | A measurement of the sorbitol dehydrogenase in a biological specimen. | Sorbitol Dehydrogenase Measurement | ||
Thrombopoietin | C74873 | Thrombopoietin | A measurement of the thrombopoietin hormone in a biological specimen. | Thrombopoietin Measurement | ||
Thyrotropin Releasing Hormone | C74874 | Thyrotropin Releasing Hormone;Thyrotropin Releasing Factor | A measurement of the thyrotropin releasing hormone in a biological specimen. | Thyrotropin Releasing Hormone Measurement | ||
Vanillyl Mandelic Acid | C74875 | Vanillyl Mandelic Acid;Vanilmandelic Acid | A measurement of the vanillyl mandelic acid metabolite in a biological specimen. | Vanillyl Mandelic Acid Measurement | ||
Vitamin A | C74895 | Vitamin A;Retinol | A measurement of the Vitamin A in a biological specimen. | Vitamin A Measurement | ||
Thiamine | C74896 | Thiamine;Vitamin B1 | A measurement of the thiamine in a biological specimen. | Vitamin B1 Measurement | ||
Vitamin B17 | C74897 | Vitamin B17;Amygdalin | A measurement of the Vitamin B17 in a biological specimen. | Vitamin B17 Measurement | ||
Riboflavin | C74898 | Riboflavin;Vitamin B2 | A measurement of the riboflavin in a biological specimen. | Vitamin B2 Measurement | ||
Niacin | C74899 | Niacin;Vitamin B3 | A measurement of the niacin in a biological specimen. | Vitamin B3 Measurement | ||
Vitamin B5 | C74900 | Vitamin B5;Pantothenic Acid | A measurement of the Vitamin B5 in a biological specimen. | Vitamin B5 Measurement | ||
Vitamin B6 | C74901 | Vitamin B6;Pyridoxine | A measurement of the Vitamin B6 in a biological specimen. | Vitamin B6 Measurement | ||
Vitamin B7 | C74902 | Vitamin B7;Biotin | A measurement of the Vitamin B7 in a biological specimen. | Vitamin B7 Measurement | ||
Vitamin C | C74903 | Vitamin C;Ascorbic Acid | A measurement of the Vitamin C in a biological specimen. | Vitamin C Measurement | ||
Vitamin D2 | C74904 | Vitamin D2;Ergocalciferol | A measurement of the Vitamin D2 in a biological specimen. | Vitamin D2 Measurement | ||
Vitamin D3 | C74905 | Vitamin D3;Cholecalciferol | A measurement of the Vitamin D3 in a biological specimen. | Vitamin D3 Measurement | ||
Vitamin E | C74906 | Vitamin E | A measurement of the Vitamin E in a biological specimen. | Vitamin E Measurement | ||
Vitamin K | C74907 | Vitamin K;Naphthoquinone | A measurement of the total Vitamin K in a biological specimen. | Vitamin K Measurement | ||
Volume | C74720 | Volume | A measurement of the volume of a biological specimen. | Volume Measurement | ||
Alpha-1 Antitrypsin | C80167 | Alpha-1 Antitrypsin;Serum Trypsin Inhibitor | A measurement of the alpha-1 antitrypsin in a biological specimen. | Alpha-1 Antitrypsin Measurement | ||
Alpha-2 Macroglobulin | C80168 | Alpha-2 Macroglobulin | A measurement of the alpha-2 macroglobulin in a biological specimen. | Alpha-2 Macroglobulin Measurement | ||
Angiotensin Converting Enzyme | C80169 | Angiotensin Converting Enzyme | A measurement of the angiotensin converting enzyme in a biological specimen. | Angiotensin Converting Enzyme Measurement | ||
Acid Phosphatase | C80163 | Acid Phosphatase | A measurement of the acid phosphatase in a biological specimen. | Acid Phosphatase Measurement | ||
Antimitochondrial Antibodies | C81975 | Antimitochondrial Antibodies;Mitochondrial Antibody | A measurement of the antimitochondrial antibodies in a biological specimen. | Antimitochondrial Antibody Measurement | ||
Amyloid Beta 1-42 | C84809 | Amyloid Beta 42;Amyloid Beta 42 Protein;Amyloid Beta 1-42 | A measurement of amyloid beta protein which is composed of peptides 1 to 42 in a biological specimen. | Beta Amyloid 42 Measurement | ||
Amyloid, Beta | C81999 | Amyloid, Beta;Beta Amyloid | A measurement of the total amyloid beta in a biological specimen. | Beta Amyloid Measurement | ||
Amyloid P | C81998 | Amyloid P | A measurement of the total amyloid P in a biological specimen. | Amyloid P Measurement | ||
Antiglobulin Test, Direct | C81974 | Antiglobulin Test, Direct;Direct Coombs Test | A measurement of the antibody or complement-coated erythrocytes in a biological specimen in vivo. | Direct Antiglobulin Test | ||
Antithrombin | C81958 | Antithrombin;Antithrombin III;Antithrombin Activity;Antithrombin III Activity | A measurement of the antithrombin activity in a biological specimen. | Antithrombin Measurement | ||
Antithrombin Antigen | C81977 | Antithrombin Antigen;Antithrombin III Antigen | A measurement of the antithrombin antigen in a biological specimen. | Antithrombin Antigen Measurement | ||
Apolipoprotein AII | C82000 | Apolipoprotein AII | A measurement of the apolipoprotein AII in a biological specimen. | Apolipoprotein AII Measurement | ||
Apolipoprotein CIII | C82001 | Apolipoprotein CIII | A measurement of the apolipoprotein CIII in a biological specimen. | Apolipoprotein CIII Measurement | ||
Apolipoprotein E | C82002 | Apolipoprotein E | A measurement of the apolipoprotein E in a biological specimen. | Apolipoprotein E Measurement | ||
Apolipoprotein H | C82003 | Apolipoprotein H | A measurement of the apolipoprotein H in a biological specimen. | Apolipoprotein H Measurement | ||
Specimen Appearance | C25377 | Specimen Appearance | The outward or visible aspect of a specimen. | Appearance | ||
Anti-Saccharomyces cerevisiae Antibody | C81976 | Anti-Saccharomyces cerevisiae Antibody | A measurement of the anti-Saccharomyces cerevisiae antibody in a biological specimen. | Anti-Saccharomyces cerevisiae Antibody Measurement | ||
Aspartate Aminotransferase Antigen | C81978 | Aspartate Aminotransferase Antigen;SGOT Antigen | A measurement of the aspartate aminotransferase antigen in a biological specimen. | Aspartate Aminotransferase Antigen Measurement | ||
Beta-2 Glycoprotein Antibody | C81979 | Beta-2 Glycoprotein Antibody | A measurement of the beta-2 glycoprotein antibody in a biological specimen. | Beta-2 Glycoprotein Antibody Measurement | ||
Beta-2 Microglobulin | C81980 | Beta-2 Microglobulin | A measurement of the beta-2 microglobulin in a biological specimen. | Beta-2 Microglobulin Measurement | ||
Brain-Derived Neurotrophic Factor | C82004 | Brain-Derived Neurotrophic Factor | A measurement of the brain-derived neurotrophic factor in a biological specimen. | Brain-Derived Neurotrophic Factor Measurement | ||
ProB-type Natriuretic Peptide | C82032 | ProB-type Natriuretic Peptide;proBNP;Pro-Brain Natriuretic Peptide | A measurement of the proB-type natriuretic peptide in a biological specimen. | ProB-Type Natriuretic Peptide Measurement | ||
Complement C1q Antibody | C80173 | Complement C1q Antibody | A measurement of the complement C1q antibody in a biological specimen. | Complement C1q Antibody Measurement | ||
Complement C3 | C80174 | Complement C3 | A measurement of the complement C3 in a biological specimen. | Complement C3 Measurement | ||
Complement C3a | C80175 | Complement C3a;ASP, Complement C3 DesArg, Acetylation-stimulating Protein | A measurement of the complement C3a in a biological specimen. | Complement C3a Measurement | ||
Complement C3b | C80176 | Complement C3b | A measurement of the complement C3b in a biological specimen. | Complement C3b Measurement | ||
Complement C4 | C80177 | Complement C4 | A measurement of the complement C4 in a biological specimen. | Complement C4 Measurement | ||
Complement C4a | C80178 | Complement C4a | A measurement of the complement C4a in a biological specimen. | Complement C4a Measurement | ||
Complement C5a | C80179 | Complement C5a | A measurement of the complement C5a in a biological specimen. | Complement C5a Measurement | ||
Cancer Antigen 125 | C81981 | Cancer Antigen 125 | A measurement of the cancer antigen 125 in a biological specimen. | Cancer Antigen 125 Measurement | ||
Cancer Antigen 19-9 | C81982 | Cancer Antigen 19-9 | A measurement of the cancer antigen 19-9 in a biological specimen. | Cancer Antigen 19-9 Measurement | ||
Calcium, Ionized | C81948 | Calcium, Ionized | A measurement of the ionized calcium in a biological specimen. | Ionized Calcium Measurement | ||
Calprotectin | C82005 | Calprotectin | A measurement of the calprotectin in a biological specimen. | Calprotectin Measurement | ||
Complement Bb | C80172 | Complement Bb | A measurement of the complement Bb in a biological specimen. | Complement Bb Measurement | ||
CD40 | C82006 | CD40 | A count of the CD40 cells per unit in a biological specimen. | CD40 Measurement | ||
CD40 Ligand | C82007 | CD40 Ligand | A count of the CD40 ligand cells per unit in a biological specimen. | CD40 Ligand Measurement | ||
Carcinoembryonic Antigen | C81983 | Carcinoembryonic Antigen | A measurement of the carcinoembryonic antigen in a biological specimen. | Carcinoembryonic Antigen Measurement | ||
Cholesterol/HDL-Cholesterol | C80171 | Cholesterol/HDL-Cholesterol | A relative measurement (ratio or percentage) of total cholesterol to high-density lipoprotein cholesterol (HDL-C) in a biological specimen. | Cholesterol to HDL-Cholesterol Ratio Measurement | ||
Complement Total | C80160 | Complement Total | A measurement of the total complement in a biological specimen. | Complement Measurement | ||
Type I Collagen C-Telopeptides | C82038 | Type I Collagen C-Telopeptides;Type I Collagen X-linked C-telopeptide | A measurement of the type I collagen C-telopeptides in a biological specimen. | Type I Collagen C-Telopeptide Measurement | ||
Type II Collagen C-Telopeptides | C82040 | Type II Collagen C-Telopeptides | A measurement of the type II collagen C-telopeptides in a biological specimen. | Type II Collagen C-Telopeptide Measurement | ||
Starch Crystals | C81951 | Starch Crystals | A measurement of the starch crystals in a biological specimen. | Starch Crystal Measurement | ||
D-Dimer | C82621 | D-Dimer | A measurement of the d-dimers in a biological specimen. | D-Dimer Measurement | ||
Anti-DNA Antibodies | C81973 | Anti-DNA Antibodies;Anti-ds-DNA Antibodies | A measurement of the anti-DNA antibodies in a biological specimen. | Anti-DNA Antibody Measurement | ||
Epidermal Growth Factor | C82009 | Epidermal Growth Factor | A measurement of the epidermal growth factor in a biological specimen. | Epidermal Growth Factor Measurement | ||
Pancreatic Elastase 1 | C82028 | Pancreatic Elastase 1 | A measurement of the pancreatic elastase 1 in a biological specimen. | Pancreatic Elastase Measurement | ||
Pancreatic Elastase 1, Polymorphonuclear | C82029 | Pancreatic Elastase 1, Polymorphonuclear | A measurement of the polymorphonuclear pancreatic elastase 1 in a biological specimen. | Polymorphonuclear Pancreatic Elastase Measurement | ||
Neutrophil Elastase | C82026 | Neutrophil Elastase | A measurement of the neutrophil elastase in a biological specimen. | Neutrophil Elastase Measurement | ||
Neutrophil Elastase, Polymorphonuclear | C82027 | Neutrophil Elastase, Polymorphonuclear | A measurement of the polymorphonuclear neutrophil elastase in a biological specimen. | Polymorphonuclear Neutrophil Elastase Measurement | ||
Epith Neutrophil-Activating Peptide 78 | C82010 | Epith Neutrophil-Activating Peptide 78 | A measurement of the epithelial neutrophil-activating peptide in a biological specimen. | Epithelial Neutrophil-Activating Peptide 78 Measurement | ||
Endothelin-1 | C82008 | Endothelin-1 | A measurement of the endothelin-1 in a biological specimen. | Endothelin-1 Measurement | ||
Extracell Newly Ident RAGE Bind Protein | C82011 | Extracell Newly Ident RAGE Bind Protein;S100 Calcium Binding Protein A12 | A measurement of the extracellular newly identified RAGE (receptor for advanced glycation end products) binding protein in a biological specimen. | Extracell Newly Ident RAGE Bind Protein Measurement | ||
Eosinophilic Metamyelocytes | C84819 | Eosinophilic Metamyelocytes | A measurement of the eosinphilic metamyelocytes in a biological specimen. | Eosinophilic Metamyelocyte Count | ||
Eosinophilic Myelocytes | C84821 | Eosinophilic Myelocytes | A measurement of the eosinophilic myelocytes in a biological specimen. | Eosinophilic Myelocyte Count | ||
Eotaxin-1 | C81952 | Eotaxin-1;Chemokine Ligand 11 | A measurement of the eotaxin-1 in a biological specimen. | Eotaxin-1 Measurement | ||
Eotaxin-2 | C81953 | Eotaxin-2;Chemokine Ligand 24 | A measurement of the eotaxin-2 in a biological specimen. | Eotaxin-2 Measurement | ||
Eotaxin-3 | C81954 | Eotaxin-3;Chemokine Ligand 26 | A measurement of the eotaxin-3 in a biological specimen. | Eotaxin-3 Measurement | ||
Estriol, Free | C81963 | Estriol, Free | A measurement of the free estriol in a biological specimen. | Free Estriol Measurement | ||
Fatty Acid Binding Protein 1 | C82012 | Fatty Acid Binding Protein 1 | A measurement of the fatty acid binding protein 1 in a biological specimen. | Fatty Acid Binding Protein 1 Measurement | ||
Factor III | C81959 | Factor III;Tissue Factor, CD142 | A measurement of the factor III in a biological specimen. | Factor III Measurement | ||
Factor VII | C81960 | Factor VII;Proconvertin;Stable Factor | A measurement of the factor VII in a biological specimen. | Factor VII Measurement | ||
Factor VIII | C81961 | Factor VIII;Anti-hemophilic Factor | A measurement of the factor VIII in a biological specimen. | Factor VIII Measurement | ||
Free Fatty Acid | C80200 | Free Fatty Acid;Non-Esterified Fatty Acid, Free | A measurement of the total non-esterified fatty acids in a biological specimen. | Non-esterified Fatty Acids Measurement | ||
Free Fatty Acid, Saturated | C80206 | Free Fatty Acid, Saturated;Non-esterified Fatty Acid, Saturated | A measurement of the saturated non-esterified fatty acids in a biological specimen. | Saturated Non-esterified Fatty Acids Measurement | ||
Free Fatty Acid, Unsaturated | C80209 | Free Fatty Acid, Unsaturated;Non-esterified Fatty Acid, Unsaturated | A measurement of the unsaturated non-esterified fatty acids in a biological specimen. | Unsaturated Non-esterified Fatty Acids Measurement | ||
Fat Bodies, Oval | C81947 | Fat Bodies, Oval | A measurement of the oval-shaped fat bodies, usually renal proximal tubular cells with lipid aggregates in the cytoplasm, in a biological specimen. | Oval Fat Body Measurement | ||
Fibrin Degradation Products | C82013 | Fibrin Degradation Products | A measurement of the fibrin degradation products in a biological specimen. | Fibrin Degradation Products Measurement | ||
Fibroblast Growth Factor Basic Form | C82014 | Fibroblast Growth Factor Basic Form;FGF2 | A measurement of the basic form of fibroblast growth factor in a biological specimen. | Fibroblast Growth Factor Basic Form Measurement | ||
Glucose-6-Phosphate Dehydrogenase | C80184 | Glucose-6-Phosphate Dehydrogenase | A measurement of the glucose-6-phosphate dehydrogenase in a biological specimen. | Glucose-6-Phosphate Dehydrogenase Measurement | ||
Glutamic Acid Decarboxylase 1 | C82015 | Glutamic Acid Decarboxylase 1;Glutamic Acid Decarboxylase 67 | A measurement of the glutamic acid decarboxylase 1 in a biological specimen. | Glutamic Acid Decarboxylase 1 Measurement | ||
Glutamic Acid Decarboxylase 2 | C82016 | Glutamic Acid Decarboxylase 2;Glutamic Acid Decarboxylase 65 | A measurement of the glutamic acid decarboxylase 2 in a biological specimen. | Glutamic Acid Decarboxylase 2 Measurement | ||
Glutamic Acid Decarboxylase 2 Antibody | C82017 | Glutamic Acid Decarboxylase 2 Antibody;Glutamic Acid Decarboxylase 65 Antibody | A measurement of the glutamic acid decarboxylase 2 antibody in a biological specimen. | Glutamic Acid Decarboxylase 2 Antibody Measurement | ||
Galanin | C80182 | Galanin | A measurement of the galanin in a biological specimen. | Galanin Measurement | ||
Granulocyte Colony Stimulating Factor | C82018 | Granulocyte Colony Stimulating Factor | A measurement of the granulocyte colony stimulating factor in a biological specimen. | Granulocyte Colony Stimulating Factor Measurement | ||
Glucagon-Like Peptide-1 | C80183 | Glucagon-Like Peptide-1;Total Glucagon-Like Peptide-1 | A measurement of the total glucagon-like peptide-1 in a biological specimen. | Glucagon-like Peptide-1 Measurement | ||
Glucagon-Like Peptide-1, Active Form | C80164 | Glucagon-Like Peptide-1, Active Form | A measurement of the active form of glucagon-like peptide-1 in a biological specimen. | Active Glucagon-like Peptide-1 Measurement | ||
Granulocyte Macrophage Colony Stm Factor | C82019 | Granulocyte Macrophage Colony Stm Factor | A measurement of the granulocyte macrophage colony stimulating factor in a biological specimen. | Granulocyte Macrophage Colony Stm Factor Measurement | ||
Gold | C80186 | Gold | A measurement of the gold in a biological specimen. | Gold Measurement | ||
Glutathione S-Transferase, Total | C80185 | Glutathione S-Transferase, Total | A measurement of the total glutathione-s-transferase in a biological specimen. | Glutathione-S-Transferase Measurement | ||
Glutathione S-Transferase, Alpha/Creat | C80166 | Glutathione S-Transferase, Alpha/Creat | A relative measurement (ratio or percentage) of the alpha glutathione-S-transferase to creatinine in a biological specimen. | Alpha Glutathione-S-Transferase to Creatinine Ratio Measurement | ||
Glutathione S-Transferase, Pi | C80203 | Glutathione S-Transferase, Pi | A measurement of the Pi glutathione-s-transferase in a biological specimen. | Pi Glutathione S-Transferase Measurement | ||
Glutathione S-Transferase, Theta | C80207 | Glutathione S-Transferase, Theta | A measurement of the theta glutathione-s-transferase in a biological specimen. | Theta Glutathione S-Transferase Measurement | ||
Glucuronidase, Alpha | C80165 | Glucuronidase, Alpha | A measurement of the alpha glucuronidase in a biological specimen. | Alpha Glucuronidase Measurement | ||
Glucuronidase, Beta | C80170 | Glucuronidase, Beta | A measurement of the beta glucuronidase in a biological specimen. | Beta Glucuronidase Measurement | ||
HDL-Cholesterol Subclass 2 | C80187 | HDL-Cholesterol Subclass 2 | A measurement of the high-density lipoprotein (HDL) cholesterol subclass 2 in a biological specimen. | HDL-Cholesterol Subclass 2 Measurement | ||
HDL-Cholesterol Subclass 3 | C80188 | HDL-Cholesterol Subclass 3 | A measurement of the high-density lipoprotein (HDL) cholesterol subclass 3 in a biological specimen. | HDL-Cholesterol Subclass 3 Measurement | ||
Histamine | C80189 | Histamine | A measurement of the histamine in a biological specimen. | Histamine Measurement | ||
Heterophile Antibodies | C81984 | Heterophile Antibodies | A measurement of the heterophile antibodies in a biological specimen. | Heterophile Antibody Measurement | ||
Hydroxyproline | C80190 | Hydroxyproline | A measurement of the total hydroxyproline in a biological specimen. | Hydroxyproline Measurement | ||
Islet Cell 512 Antibody | C81985 | Islet Cell 512 Antibody | A measurement of the islet cell 512 antibody in a biological specimen. | Islet Cell 512 Antibody Measurement | ||
Islet Cell 512 Antigen | C81986 | Islet Cell 512 Antigen | A measurement of the islet cell 512 antigen in a biological specimen. | Islet Cell 512 Antigen Measurement | ||
Interferon Alpha | C81994 | Interferon Alpha | A measurement of the interferon alpha in a biological specimen. | Interferon Alpha Measurement | ||
Interferon Beta | C81995 | Interferon Beta | A measurement of the interferon beta in a biological specimen. | Interferon Beta Measurement | ||
Interferon Gamma | C81996 | Interferon Gamma | A measurement of the interferon gamma in a biological specimen. | Interferon Gamma Measurement | ||
Immunoglobulin A | C81969 | Immunoglobulin A | A measurement of the Immunoglobulin A in a biological specimen. | Immunoglobulin A Measurement | ||
Immunoglobulin E | C81970 | Immunoglobulin E | A measurement of the Immunoglobulin E in a biological specimen. | Immunoglobulin E Measurement | ||
Immunoglobulin G | C81971 | Immunoglobulin G | A measurement of the Immunoglobulin G in a biological specimen. | Immunoglobulin G Measurement | ||
Immunoglobulin M | C81972 | Immunoglobulin M | A measurement of the Immunoglobulin M in a biological specimen. | Immunoglobulin M Measurement | ||
Indican | C82044 | Indican | A measurement of the indican present in a biological specimen. | Indican Measurement | ||
Islet Neogenesis Assoc Protein Antibody | C81987 | Islet Neogenesis Assoc Protein Antibody | A measurement of the islet neogenesis associated protein antibody in a biological specimen. | Islet Neogenesis Associated Protein Antibody Measurement | ||
Inhibin A | C82020 | Inhibin A | A measurement of the inhibin A in a biological specimen. | Inhibin A Measurement | ||
F2-Isoprostane | C80180 | F2-Isoprostane | A measurement of the F2-isoprostane in a biological specimen. | F2 Isoprostane Measurement | ||
Lipoprotein-a | C82022 | Lipoprotein-a | A measurement of the lipoprotein-a in a biological specimen. | Lipoprotein a Measurement | ||
Lactoferrin | C82021 | Lactoferrin;Lactotransferrin | A measurement of the lactoferrin in a biological specimen. | Lactoferrin Measurement | ||
Lymphotactin | C81955 | Lymphotactin;Chemokine Ligand 1 | A measurement of the lymphotactin in a biological specimen. | Lymphotactin Measurement | ||
Monocyte Chemotactic Protein 1 | C82025 | Monocyte Chemotactic Protein 1 | A measurement of the monocyte chemotactic protein 1 in a biological specimen. | Monocyte Chemotactic Protein 1 Measurement | ||
Macrophage Colony Stimulating Factor | C80191 | Macrophage Colony Stimulating Factor | A measurement of the macrophage colony stimulating factor in a biological specimen. | Macrophage Colony Stimulating Factor Measurement | ||
Macrophage-Derived Chemokine | C81956 | Macrophage-Derived Chemokine;Chemokine Ligand 22 | A measurement of the macrophage-derived chemokine in a biological specimen. | Macrophage-Derived Chemokine Measurement | ||
Macrophage Inflammatory Protein 1 Alpha | C82023 | Macrophage Inflammatory Protein 1 Alpha;Chemokine Ligand 3 | A measurement of the macrophage inflammatory protein 1 alpha in a biological specimen. | Macrophage Inflammatory Protein 1 Alpha Measurement | ||
Macrophage Inflammatory Protein 1 Beta | C82024 | Macrophage Inflammatory Protein 1 Beta;Chemokine Ligand 4 | A measurement of the macrophage inflammatory protein 1 beta in a biological specimen. | Macrophage Inflammatory Protein 1 Beta Measurement | ||
Matrix Metalloproteinase 1 | C80192 | Matrix Metalloproteinase 1;Interstitial Collagenase | A measurement of the matrix metalloproteinase 1 in a biological specimen. | Matrix Metalloproteinase 1 Measurement | ||
Matrix Metalloproteinase 2 | C80193 | Matrix Metalloproteinase 2;Gelatinase A | A measurement of the matrix metalloproteinase 2 in a biological specimen. | Matrix Metalloproteinase 2 Measurement | ||
Matrix Metalloproteinase 3 | C80194 | Matrix Metalloproteinase 3;Stromelysin 1 | A measurement of the matrix metalloproteinase 3 in a biological specimen. | Matrix Metalloproteinase 3 Measurement | ||
Matrix Metalloproteinase 7 | C80195 | Matrix Metalloproteinase 7;Matrilysin | A measurement of the matrix metalloproteinase 7 in a biological specimen. | Matrix Metalloproteinase 7 Measurement | ||
Matrix Metalloproteinase 8 | C80196 | Matrix Metalloproteinase 8;Neutrophil Collagenase | A measurement of the matrix metalloproteinase 8 in a biological specimen. | Matrix Metalloproteinase 8 Measurement | ||
Matrix Metalloproteinase 9 | C80197 | Matrix Metalloproteinase 9;Gelatinase B | A measurement of the matrix metalloproteinase 9 in a biological specimen. | Matrix Metalloproteinase 9 Measurement | ||
Myeloperoxidase | C80198 | Myeloperoxidase | A measurement of the myeloperoxidase in a biological specimen. | Myeloperoxidase Measurement | ||
Neopterin | C80199 | Neopterin | A measurement of the neopterin in a biological specimen. | Neopterin Measurement | ||
Neutrophilic Metamyelocytes | C84822 | Neutrophilic Metamyelocytes | A measurement of the neutrophilic metamyelocytes in a biological specimen. | Neutrophilic Metamyelocyte Count | ||
Neutrophilic Myelocytes | C84823 | Neutrophilic Myelocytes | A measurement of the neutrophilic myelocytes in a biological specimen. | Neutrophilic Myelocyte Count | ||
Neutrophils, Segmented | C81997 | Neutrophils, Segmented | A measurement of the segmented neutrophils in a biological specimen. | Segmented Neutrophil Count | ||
Neutrophils, Segmented/Leukocytes | C82045 | Neutrophils, Segmented/Leukocytes | A relative measurement (ratio or percentage) of segmented neutrophils to leukocytes in a biological specimen. | Segmented Neutrophil to Leukocyte Ratio Measurement | ||
Type I Collagen N-Telopeptides | C82039 | Type I Collagen N-Telopeptides | A measurement of the type I collagen N-telopeptides in a biological specimen. | Type I Collagen N-Telopeptide Measurement | ||
Type II Collagen N-Telopeptides | C82041 | Type II Collagen N-Telopeptides | A measurement of the type II collagen N-telopeptides in a biological specimen. | Type II Collagen N-Telopeptide Measurement | ||
Plasminogen Activator Inhibitor-1 | C82030 | Plasminogen Activator Inhibitor-1 | A measurement of the plasminogen activator inhibitor-1 in a biological specimen. | Plasminogen Activator Inhibitor-1 Measurement | ||
Plasminogen Activator Inhibitor-1 AG | C81989 | Plasminogen Activator Inhibitor-1 AG | A measurement of the plasminogen activator inhibitor-1 antigen in a biological specimen. | Plasminogen Activator Inhibitor-1 Antigen Measurement | ||
Prostatic Acid Phosphatase | C80204 | Prostatic Acid Phosphatase | A measurement of the prostatic acid phosphatase in a biological specimen. | Prostatic Acid Phosphatase Measurement | ||
Pregnancy-Associated Plasma Protein-A | C82031 | Pregnancy-Associated Plasma Protein-A | A measurement of the pregnancy-associated plasma protein-A in a biological specimen. | Pregnancy-Associated Plasma Protein-A Measurement | ||
Partial Pressure Carbon Dioxide | C82625 | Partial Pressure Carbon Dioxide | A measurement of the pressure of carbon dioxide in a biological specimen. | Partial Pressure of Carbon Dioxide Measurement | ||
Platelet Distribution Width | C81962 | Platelet Distribution Width | A measurement of the range of platelet sizes in a biological specimen. | Platelet Distribution Width | ||
Pemphigoid Antibodies | C81988 | Pemphigoid Antibodies | A measurement of the pemphigoid antibodies in a biological specimen. | Pemphigoid Antibody Measurement | ||
Procollagen Type I Carboxy Term Peptide | C82033 | Procollagen Type I Carboxy Term Peptide | A measurement of the procollagen-1 carboxy-terminal peptide in a biological specimen. | Procollagen Type I Carboxy Terminal Peptide Measurement | ||
Pancreatic Polypeptide | C80201 | Pancreatic Polypeptide | A measurement of the pancreatic polypeptide in a biological specimen. | Pancreatic Polypeptide Measurement | ||
Partial Pressure Oxygen | C71251 | Partial Pressure Oxygen | A measurement of the pressure of oxygen in a biological specimen. | Partial Pressure of Oxygen Measurement | ||
Proinsulin | C81967 | Proinsulin | A measurement of the proinsulin in a biological specimen. | Proinsulin Measurement | ||
Prothrombin Fragments 1 + 2 | C82034 | Prothrombin Fragments 1 + 2 | A measurement of the prothrombin fragments 1 and 2 in a biological specimen. | Prothrombin Fragments 1 and 2 Measurement | ||
Parathyroid Hormone, C-Terminal | C81964 | Parathyroid Hormone, C-Terminal | A measurement of the C-terminal fragment of parathyroid hormone in a biological specimen. | C-Terminal Parathyroid Hormone Measurement | ||
Parathyroid Hormone, Mid-Molecule | C81965 | Parathyroid Hormone, Mid-Molecule | A measurement of the mid-molecule fragment of parathyroid hormone in a biological specimen. | Mid-Molecule Parathyroid Hormone Measurement | ||
Parathyroid Hormone, N-Terminal | C81966 | Parathyroid Hormone, N-Terminal | A measurement of the N-terminal fragment of parathyroid hormone in a biological specimen. | N-Terminal Parathyroid Hormone Measurement | ||
Pyridinoline | C80211 | Pyridinoline | A measurement of the pyridinoline in a biological specimen. | Pyridinoline Measurement | ||
Peptide YY | C80202 | Peptide YY;Peptide Tyrosine Tyrosine | A measurement of the peptide YY in a biological specimen. | Peptide YY Measurement | ||
Reg upon Act Normal T-cell Exprd Secrtd | C81957 | Reg upon Act Normal T-cell Exprd Secrtd;Chemokine Ligand 5 | A measurement of the RANTES (regulated on activation, normally, T-cell expressed, and secreted) chemokine in a biological specimen. | Reg upon Act Normal T-cell Exprd Secrtd Measurement | ||
Nucleated Erythrocytes/Leukocytes | C82046 | Nucleated Erythrocytes/Leukocytes | A relative measurement (ratio or percentage) of nucleated erythrocytes to leukocytes in a biological specimen. | Nucleated Erythrocyte to Leukocyte Ratio Measurement | ||
Resistin | C80205 | Resistin | A measurement of the resistin in a biological specimen. | Resistin Measurement | ||
Triiodothyronine, Reverse | C81968 | Triiodothyronine, Reverse | A measurement of the reverse triiodothyronine in a biological specimen. | Reverse Triiodothyronine Measurement | ||
Stem Cell Factor | C82035 | Stem Cell Factor;KIT Ligand | A measurement of the stem cell factor in a biological specimen. | Stem Cell Factor Measurement | ||
Transferrin | C82037 | Transferrin | A measurement of the transferrin in a biological specimen. | Transferrin Measurement | ||
Thyroid Antibodies | C81990 | Thyroid Antibodies | A measurement of the thyroid antibodies in a biological specimen. | Thyroid Antibody Measurement | ||
Thyroid Antimicrosomal Antibodies | C81991 | Thyroid Antimicrosomal Antibodies | A measurement of the thyroid antimicrosomal antibodies in a biological specimen. | Thyroid Antimicrosomal Antibody Measurement | ||
Thyroid Antithyroglobulin Antibodies | C81992 | Thyroid Antithyroglobulin Antibodies | A measurement of the thyroid antithyroglobulin antibodies in a biological specimen. | Thyroid Antithyroglobulin Antibody Measurement | ||
Tissue Inhibitor of Metalloproteinase 1 | C82036 | Tissue Inhibitor of Metalloproteinase 1 | A measurement of the tissue inhibitor of metalloproteinase 1 in a biological specimen. | Tissue Inhibitor of Metalloproteinase 1 Measurement | ||
Tissue Plasminogen Activator Antigen | C81993 | Tissue Plasminogen Activator Antigen | A measurement of the tissue plasminogen activator antigen in a biological specimen. | Tissue Plasminogen Activator Antigen Measurement | ||
Non-Phosphorylated Tau Protein | C84811 | Non-Phosphorylated Tau Protein | A measurement of the non-phosphorylated Tau protein in a biological specimen. | Nonphosphorylated Tau Protein Measurement | ||
Tau Protein | C84810 | Tau Protein;Total Tau Protein | A measurement of the total Tau protein in a biological specimen. | Tau Protein Measurement | ||
Phosphorylated Tau Protein | C84812 | Phosphorylated Tau Protein | A measurement of the phosphorylated Tau protein in a biological specimen. | Phosphorylated Tau Protein Measurement | ||
Total Radical-Trap Antioxidant Potential | C80208 | Total Radical-Trap Antioxidant Potential | A measurement of the ability of the antioxidants in a biological specimen to buffer free radicals in a suspension. | Total Radical-Trap Antioxidant Potential Measurement | ||
Thrombin Time | C80365 | Thrombin Time | A measurement of the time it takes a plasma sample to clot after adding the active enzyme thrombin. (NCI) | Thrombin Time | ||
Vascular Cell Adhesion Molecule 1 | C82042 | Vascular Cell Adhesion Molecule 1 | A measurement of the vascular cell adhesion molecule 1 in a biological specimen. | Vascular Cell Adhesion Molecule 1 Measurement | ||
Vascular Endothelial Growth Factor | C92514 | Vascular Endothelial Growth Factor | A measurement of the vascular endothelial growth factor in a biological specimen. | Vascular Endohelial Growth Factor Measurement | ||
Viscosity | C75912 | Viscosity | The resistance of a liquid to sheer forces and flow. (NCI) | Viscosity | ||
Vitamin D | C84818 | Vitamin D;Total Vitamin D | A measurement of the total Vitamin D in a biological specimen. | Vitamin D Measurement | ||
Zinc | C80210 | Zinc | A measurement of the zinc in a biological specimen. | Zinc Measurement | ||
Cortisol, Free | C88113 | Cortisol, Free | A measurement of the free, unbound cortisol in a biological specimen. | Free Cortisol Measurement | ||
1, 25-Dihydroxyvitamin D | C92267 | 1, 25-Dihydroxyvitamin D;Active Vitamin D | A measurement of the total active Vitamin D in a biological specimen. | 1, 25-Dihydroxyvitamin D Measurement | ||
25-Hydroxyvitamin D | C92268 | 25-Hydroxyvitamin D;Inactive Vitamin D | A measurement of the total inactive Vitamin D in a biological specimen. | 25-Hydroxyvitamin D Measurement | ||
Acetoacetic Acid | C92247 | Acetoacetic Acid;Acetoacetate | A measurement of the acetoacetic acid in a biological specimen. | Acetoacetic Acid Measurement | ||
Acyl Coenzyme A Oxidase | C92286 | Acyl Coenzyme A Oxidase;Fatty Acyl Coenzyme A Oxidase;Acyl CoA Oxidase | A measurement of the acyl coenzyme A oxidase in a biological specimen. | Acyl Coenzyme A Oxidase Measurement | ||
Alpha-1 Globulin | C92252 | Alpha-1 Globulin;A1-Globulin | A measurement of the proteins contributing to the alpha 1 fraction in a biological specimen. | Alpha-1 Globulin Measurement | ||
Alpha-1 Globulin/Total Protein | C92253 | Alpha-1 Globulin/Total Protein | A relative measurement (ratio or percentage) of alpha-1-fraction proteins to total proteins in a biological specimen. | Alpha-1 Globulin to Total Protein Ratio Measurement | ||
Alpha-2 Globulin | C92254 | Alpha-2 Globulin;A2-Globulin | A measurement of the proteins contributing to the alpha 2 fraction in a biological specimen. | Alpha-2 Globulin Measurement | ||
Alpha-2 Globulin/Total Protein | C92255 | Alpha-2 Globulin/Total Protein | A relative measurement (ratio or percentage) of alpha-2-fraction proteins to total proteins in a biological specimen. | Alpha-2 Globulin to Total Protein Ratio Measurement | ||
Amorphous Phosphate Crystals | C92243 | Amorphous Phosphate Crystals | A measurement of the amorphous phosphate crystals in a biological specimen. | Amorphous Phosphate Crystals Measurement | ||
Amorphous Urate Crystals | C92244 | Amorphous Urate Crystals | A measurement of the amorphous urate crystals in a biological specimen. | Amorphous Urate Crystals Measurement | ||
Anti-Single Stranded DNA IgG | C92269 | Anti-Single Stranded DNA IgG | A measurement of the anti-single stranded DNA IgG antibody in a biological specimen. | Anti-Single Stranded DNA IgG Measurement | ||
Apolipoprotein E4 | C92293 | Apolipoprotein E4 | A measurement of the apolipoprotein E4 in a biological specimen. | Apolipoprotein E4 Measurement | ||
Beta Globulin | C92256 | Beta Globulin | A measurement of the proteins contributing to the beta fraction in a biological specimen. | Beta Globulin Measurement | ||
Beta Globulin/Total Protein | C92294 | Beta Globulin/Total Protein | A relative measurement (ratio or percentage) of beta fraction proteins to total proteins in a biological specimen. | Beta Globulin to Total Protein Ratio Measurement | ||
Bone Specific Alkaline Phosphatase | C92287 | Bone Specific Alkaline Phosphatase | A measurement of the bone specific alkaline phosphatase isoform in a biological specimen. | Bone Specific Alkaline Phosphatase Measurement | ||
Carnitine Acetyl Transferase | C92288 | Carnitine Acetyl Transferase | A measurement of the carnitine acetyl transferase in a biological specimen. | Carnitine Acetyl Transferase Measurement | ||
Chlamydia pneumoniae IgA Antibody | C92432 | Chlamydia pneumoniae IgA Antibody | A measurement of the Chlamydia pneumoniae IgA antibody in a biological specimen. | Chlamydia pneumoniae IgA Antibody Measurement | ||
Chlamydia pneumoniae IgM Antibody | C92433 | Chlamydia pneumoniae IgM Antibody | A measurement of the Chlamydia pneumoniae IgM in a biological specimen. | Chlamydia pneumoniae IgM Antibody Measurement | ||
Cholinesterase | C92289 | Cholinesterase | A measurement of the cholinesterase in a biological specimen. | Cholinesterase Measurement | ||
Citrate | C92248 | Citrate | A measurement of the citrate in a biological specimen. | Citrate Measurement | ||
Cotinine | C92249 | Cotinine | A measurement of the cotinine in a biological specimen. | Cotinine Measurement | ||
Cystatin C | C92290 | Cystatin C | A measurement of the cystatin C in a biological specimen. | Cystatin C Measurement | ||
Erythrocyte Cell Clumps | C92245 | Erythrocyte Cell Clumps;Red Blood Cell Clumps;RBC Clumps | A measurement of red blood cell clumps in a biological specimen. | Erythrocyte Cell Clumps Measurement | ||
Erythrocyte Cell Morphology | C92296 | Erythrocyte Cell Morphology;Red Blood Cell Morphology;RBC Morphology | An examination or assessment of the form and structure of red blood cells. | Erythrocyte Cell Morphology | ||
Extractable Nuclear Antigen Antibody | C92270 | Anti-ENA;Extractable Nuclear Antigen Antibody | A measurement of the extractable nuclear antigen antibody in a biological specimen. | Extractable Nuclear Antigen Antibody Measurement | ||
Gamma Globulin | C92257 | Gamma Globulin | A measurement of the proteins contributing to the gamma fraction in a biological specimen. | Gamma Globulin Measurement | ||
Gamma Globulin/Total Protein | C92295 | Gamma Globulin/Total Protein | A relative measurement (ratio or percentage) of gamma fraction proteins to total proteins in a biological specimen. | Gamma Globulin to Total Protein Ratio Measurement | ||
Glomerular Filtration Rate | C90505 | Glomerular Filtration Rate | A kidney function test that measures the fluid volume that is filtered from the kidney glomeruli to the Bowman's capsule per unit of time. | Glomerular Filtration Rate | ||
Hemoglobin A | C92258 | Hemoglobin A | A measurement of the hemoglobin A in a biological specimen. | Hemoglobin A Measurement | ||
Hemoglobin A2 | C92259 | Hemoglobin A2 | A measurement of the hemoglobin A2 in a biological specimen. | Hemoglobin A2 Measurement | ||
Hemoglobin B | C92260 | Hemoglobin B | A measurement of the hemoglobin B in a biological specimen. | Hemoglobin B Measurement | ||
Hemoglobin C | C92261 | Hemoglobin C | A measurement of the hemoglobin C in a biological specimen. | Hemoglobin C Measurement | ||
Hemoglobin F | C92262 | Hemoglobin F;Fetal Hemoglobin | A measurement of the hemoglobin F in a biological specimen. | Hemoglobin F Measurement | ||
Hepatitis A Virus Antibody IgM | C92271 | Hepatitis A Virus Antibody IgM | A measurement of hepatitis A virus antibody IgM in a biological specimen. | Hepatitis A Virus Antibody IgM Measurement | ||
Hepatitis G RNA | C92272 | Hepatitis G RNA | A measurement of the Hepatitis G RNA in a biological specimen. | Hepatitis G RNA Measurement | ||
HIV-1 Group M and O Nucleic Acid | C92263 | HIV-1 Group M and O Nucleic Acid | A measurement of the HIV-1 group M and O nucleic acids in a biological specimen. | HIV-1 Group M and O Nucleic Acid Measurement | ||
HIV-1 Group O Antibody | C92264 | HIV-1 Group O Antibody | A measurement of the HIV-1 group O antibody in a biological specimen. | HIV-1 Group O Antibody Measurement | ||
HIV-1 p24 Antigen | C92265 | HIV-1 p24 Antigen | A measurement of the HIV-1 p24 antigen in a biological specimen. | HIV-1 p24 Antigen Measurement | ||
HIV-2 Nucleic Acid | C92266 | HIV-2 Nucleic Acid | A measurement of the HIV-2 nucleic acids in a biological specimen. | HIV-2 Nucleic Acid Measurement | ||
Influenza A H1N1 Viral Load | C92273 | Influenza A H1N1 Viral Load | A measurement of the Influenza A H1N1 viral load in a biological specimen. | Influenza A H1N1 Viral Load Measurement | ||
Influenza A Viral Load | C92274 | Influenza A Viral Load | A measurement of the Influenza A viral load in a biological specimen. | Influenza A Viral Load Measurement | ||
Legionella pneumophila Antigen | C92275 | Legionella pneumophila Antigen | A measurement of the Legionella pneumophila antigen in a biological specimen. | Legionella pneumophila Antigen Measurement | ||
Legionella pneumophila IgG Antibody | C92276 | Legionella pneumophila IgG Antibody | A measurement of the Legionella pneumophila IgG antibody in a biological specimen. | Legionella pneumophila IgG Antibody Measurement | ||
Legionella pneumophila IgG IgM Antibody | C92277 | Legionella pneumophila IgG IgM Antibody | A measurement of the Legionella pneumophila IgG and IgM in a biological specimen. | Legionella pneumophila IgG IgM Antibody Measurement | ||
Legionella pneumophila IgM Antibody | C92278 | Legionella pneumophila IgM Antibody | A measurement of the Legionella pneumophila IgM antibody in a biological specimen. | Legionella pneumophila IgM Antibody Measurement | ||
Leukocyte Cell Morphology | C92297 | Leukocyte Cell Morphology;White Blood Cell Morphology;WBC Morphology | An examination or assessment of the form and structure of white blood cells. | Leukocyte Cell Morphology | ||
Leukocyte Cell Clumps | C92246 | Leukocyte Cell Clumps;White Blood Cell Clumps;WBC Clumps | A measurement of white blood cell clumps in a biological specimen. | Leukocyte Cell Clumps Measurement | ||
Monoclonal Protein | C92291 | Monoclonal Immunoglobulin Protein;Paraprotein | A measurement of homogenous immunoglobulin resulting from the proliferation of a single clone of plasma cells in a biological specimen. | Monoclonal Protein Measurement | ||
M. tuberculosis IFN Gamma Response | C92241 | Mycobacterium tuberculosis IFN Gamma Response | A measurement of the amount of interferon gamma that is released when Mycobacterium tuberculosis antigen is incubated with a biological specimen, usually blood. Increased amounts of interferon gamma suggests a prior or existing M. tuberculosis infection. | Mycobacterium tuberculosis Interferon Gamma Response | ||
Mycobacterium tuberculosis Nucleic Acid | C92279 | Mycobacterium tuberculosis Nucleic Acid | A measurement of the Mycobacterium tuberculosis nucleic acid in a biological specimen. | Mycobacterium tuberculosis Nucleic Acid Measurement | ||
Myeloid/Erythroid Ratio | C92242 | Myeloid/Erythroid Ratio | A relative measurement (ratio or percentage) of myeloid progenitor cells to erythrocyte precursor cells in a biological specimen. | Myeloid to Erythroid Ratio Measurement | ||
Myeloperoxidase Antibody | C92280 | Myeloperoxidase Antibody | A measurement of the myeloperoxidase antibody in a biological specimen. | Myeloperoxidase Antibody Measurement | ||
Neisseria gonorrhoeae Screening | C92298 | Neisseria gonorrhoeae Screening | Examination of a biological specimen to detect the presence of Neisseria gonorrhoeae. | Neisseria gonorrhoeae Screening | ||
Osmolarity | C74802 | Osmolarity | A measurement of the osmoles of solute per liter of solution. | Osmolarity Measurement | ||
Oxalate | C92250 | Oxalate;Ethanedioate | A measurement of the oxalate in a biological specimen. | Oxalate Measurement | ||
Protein/Osmolality | C92240 | Protein/Osmolality;Protein/Osmolality Ratio | A relative measurement (ratio or percentage) of total proteins to the osmolality of a biological specimen. | Protein to Osmolality Ratio Measurement | ||
Sjogrens SS-A Antibody | C92236 | Ro Antibody;Sjogrens SS-A Antibody | A measurement of the Sjogrens SS-A antibody in a biological specimen. | Sjogren's SS-A Antibody Measurement | ||
Sjogrens SS-B Antibody | C92237 | La Antibody;Sjogrens SS-B Antibody | A measurement of the Sjogrens SS-B antibody in a biological specimen. | Sjogren's SS-B Antibody Measurement | ||
Smith Antibody | C92281 | Smith Antibody | A measurement of the Smith antibody in a biological specimen. | Smith Antibody Measurement | ||
Streptolysin O Antibody | C92282 | Streptolysin O Antibody;Antistreptolysin O | A measurement of Streptolysin O Antibody in a biological specimen. | Streptolysin O Antibody Measurement | ||
Transitional Epithelial Cells | C92251 | Transitional Epithelial Cells | A measurement of the transitional epithelial cells present in a biological specimen. | Transitional Epithelial Cells Measurement | ||
Trichomonas | C92238 | Trichomonas | Examination of a biological specimen to detect the presence of any protozoan belonging to the Trichomonas genus. | Trichomonas Screening | ||
Tryptase | C92292 | Tryptase | A measurement of the tryptase in a biological specimen. | Tryptase Measurement | ||
Type I Myeloblasts | C92283 | Type I Myeloblasts | A measurement of type I myeloblast cells per unit of a biological specimen. | Type I Myeloblasts Measurement | ||
Type II Myeloblasts | C92284 | Type II Myeloblasts | A measurement of type II myeloblast cells per unit of a biological specimen. | Type II Myeloblasts Measurement | ||
Type III Myeloblasts | C92285 | Type III Myeloblasts | A measurement of type III myeloblast cells per unit of a biological specimen. | Type III Myeloblasts Measurement | ||
Yeast Hyphae | C92239 | Yeast Hyphae | Examination of a biological specimen to detect the presence of any yeast cells that are in the long, filamentous and branching phase of growth. | Yeast Hyphae Screening | ||
Soluble Vasc Cell Adhesion Molecule 1 | C92533 | Soluble Vascular Cell Adhesion Molecule 1 | A measurement of the soluble vascular cell adhesion molecule 1 in a biological specimen. | Soluble Vascular Cell Adhesion Molecule 1 | ||
A Fetoprotein L3/A Fetoprotein | C96565 | A Fetoprotein L3/A Fetoprotein | A relative measurement (ratio or percentage) of alpha fetoprotein L3 to total alpha fetoprotein in a biological specimen. | Alpha Fetoprotein L3 to Total Alpha Fetoprotein Ratio Measurement | ||
Acetylcholine Receptor Antibody | C96559 | Acetylcholine Receptor Antibody | A measurement of the acetylcholine receptor antibody in a biological specimen. | Acetylcholine Receptor Antibody Measurement | ||
Acetylcholinesterase | C96560 | Acetylcholinesterase | A measurement of the acetylcholinesterase in a biological specimen. | Acetylcholinesterase Measurement | ||
Alpha Fetoprotein L1 | C96562 | Alpha Fetoprotein L1 | A measurement of the alpha fetoprotein L1 in a biological specimen. | Alpha Fetoprotein L1 Measurement | ||
Alpha Fetoprotein L2 | C96563 | Alpha Fetoprotein L2 | A measurement of the alpha fetoprotein L2 in a biological specimen. | Alpha Fetoprotein L2 Measurement | ||
Alpha Fetoprotein L3 | C96564 | Alpha Fetoprotein L3 | A measurement of the alpha fetoprotein L3 in a biological specimen. | Alpha Fetoprotein L3 Measurement | ||
Basophilic Stippling | C96567 | Basophilic Stippling | A measurement of the basophilic stippling in a biological specimen. | Basophilic Stippling Measurement | ||
Benzoylecgonine | C75350 | Benzoylecgonine;Cocaine Metabolite | A measurement of the benzoylecgonine in a biological specimen. | Benzoylecgonine Measurement | ||
Beta-Hydroxybutyrate | C96568 | Beta-Hydroxybutyrate;B-Hydroxybutyrate;3-Hydroxybutyrate | A measurement of the total Beta-hydroxybutyrate in a biological specimen. | Beta-Hydroxybutyrate Measurement | ||
Broad Casts | C96588 | Broad Casts | A measurement of the broad casts in a biological specimen. | Broad Casts Measurement | ||
Calcium Clearance | C96589 | Calcium Clearance | A measurement of the volume of serum or plasma that would be cleared of calcium by excretion of urine for a specified unit of time (e.g. one minute). | Calcium Clearance Measurement | ||
Calcium Sulphate | C96590 | Calcium Sulphate | A measurement of the calcium sulphate in a biological specimen. | Calcium Sulphate Measurement | ||
Carboxyhemoglobin | C96591 | Carboxyhemoglobin | A measurement of the carboxyhemoglobin in a biological specimen. | Carboxyhemoglobin Measurement | ||
Circulating Endothelial Cells | C96592 | Circulating Endothelial Cells | A measurement of the circulating endothelial cells in a biological specimen. | Circulating Endothelial Cell Count | ||
Circulating Tumor Cells | C96593 | Circulating Tumor Cells | A measurement of the circulating tumor cells in a biological specimen. | Circulating Tumor Cell Count | ||
Clarity | C96594 | Clarity | A measurement of the transparency of a biological specimen. | Clarity Measurement | ||
Cyclic Citrullinated Peptide Antibody | C96595 | Cyclic Citrullinated Peptide Antibody | A measurement of the cyclic citrullinated peptide antibody in a biological specimen. | Cyclic Citrullinated Peptide Antibody Measurement | ||
Cytomegalovirus IgG Antibody | C96596 | Cytomegalovirus IgG Antibody | A measurement of the cytomegalovirus IgG antibody in a biological specimen. | Cytomegalovirus IgG Antibody Measurement | ||
Cytomegalovirus IgM Antibody | C96597 | Cytomegalovirus IgM Antibody | A measurement of the cytomegalovirus IgM antibody in a biological specimen. | Cytomegalovirus IgM Antibody Measurement | ||
Dehydroepiandrosterone Sulfate | C96629 | Dehydroepiandrosterone Sulfate;DHEA-S;sDHEA;DHEA Sulfate | A measurement of the sulfated Dehydroepiandrosterone in a biological specimen. | Sulfated DHEA Measurement | ||
Dilute Russell's Viper Venom Time | C96696 | Dilute Russell's Viper Venom Time;Lupus Anticoagulant Test | A measurement of the time it takes a plasma sample to clot after adding dilute Russell's viper venom. | Dilute Russell's Viper Venom Time Measurement | ||
Eccentrocytes | C96598 | Eccentrocytes | A measurement of the eccentrocytes (erythrocytes in which the hemoglobin is localized to a particular portion of the cell, noticeable as localized staining) in a biological specimen. | Eccentrocyte Count | ||
Epstein-Barr Capsid IgG Antibody | C96600 | Epstein-Barr Capsid IgG Antibody | A measurement of the Epstein-Barr capsid IgG antibody in a biological specimen. | Epstein-Barr Capsid IgG Antibody Measurement | ||
Epstein-Barr Capsid IgM Antibody | C96601 | Epstein-Barr Capsid IgM Antibody | A measurement of the Epstein-Barr capsid IgM antibody in a biological specimen. | Epstein-Barr Capsid IgM Antibody Measurement | ||
Epstein-Barr Early Antigen | C96602 | Epstein-Barr Early Antigen | A measurement of the Epstein-Barr early antigen in a biological specimen. | Epstein-Barr Early Antigen Measurement | ||
Epstein-Barr Nuclear Antibody | C96603 | Epstein-Barr Nuclear Antibody | A measurement of the Epstein-Barr nuclear antibody in a biological specimen. | Epstein-Barr Nuclear Antibody Measurement | ||
Epstein-Barr Nuclear Antigen | C96604 | Epstein-Barr Nuclear Antigen | A measurement of the Epstein-Barr nuclear antigen in a biological specimen. | Epstein-Barr Nuclear Antigen Measurement | ||
Erythrocyte Ghosts | C96605 | Erythrocyte Ghosts;RBC Ghosts | A measurement of the erythrocyte ghosts (erythrocytes in which hemoglobin has been removed through hemolysis) in a biological specimen. | Erythrocyte Ghost Count | ||
Factor II | C96626 | Factor II;Prothrombin | A measurement of the Factor II in a biological specimen. | Prothrombin Measurement | ||
Fat | C96648 | Fat | A measurement of the fat in a biological specimen. | Fat Measurement | ||
Fibroblast Growth Factor 23 | C96650 | Fibroblast Growth Factor 23;Phosphatonin | A measurement of the fibroblast growth factor 23 in a biological specimen. | Fibroblast Growth Factor 23 Measurement | ||
Giant Neutrophils | C96651 | Giant Neutrophils | A measurement of the giant neutrophils in a biological specimen. | Giant Neutrophil Count | ||
Glucose Clearance | C96652 | Glucose Clearance | A measurement of the volume of serum or plasma that would be cleared of glucose by excretion of urine for a specified unit of time (e.g. one minute). | Glucose Clearance Measurement | ||
Glutamic Acid Decarboxylase Antibody | C96653 | Glutamic Acid Decarboxylase Antibody;GAD Antibody | A measurement of the glutamic acid decarboxylase antibody in a biological specimen. | Glutamic Acid Decarboxylase Antibody Measurement | ||
Granulocytes | C96654 | Granulocytes | A measurement of the granulocytes in a biological specimen. | Granulocyte Count | ||
Hepatitis B Virus Core Antibody | C96660 | Hepatitis B Virus Core Antibody | A measurement of the hepatitis B virus core antibody in a biological specimen. | Hepatitis B Virus Core Antibody Measurement | ||
Hepatitis B Virus Core IgM Antibody | C96661 | Hepatitis B Virus Core IgM Antibody | A measurement of the hepatitis B virus core IgM antibody in a biological specimen. | Hepatitis B Virus Core IgM Antibody Measurement | ||
Hepatitis B Virus e Antibody | C96662 | Hepatitis B Virus e Antibody | A measurement of the hepatitis B e antibody in a biological specimen. | Hepatitis B Virus e Antibody Measurement | ||
Hepatitis B Virus e Antigen | C96663 | Hepatitis B Virus e Antigen | A measurement of the hepatitis B e antigen in a biological specimen. | Hepatitis B Virus e Antigen Measurement | ||
Hepatitis D Virus Antibody | C96664 | Hepatitis D Virus Antibody;Hepatitis Delta Antibody | A measurement of the hepatitis D virus antibody in a biological specimen. | Hepatitis D Virus Antibody Measurement | ||
Hepatitis E Virus IgM Antibody | C96665 | Hepatitis E Virus IgM Antibody | A measurement of the hepatitis E virus IgM antibody in a biological specimen. | Hepatitis E Virus IgM Antibody Measurement | ||
Herpes Simplex Virus 1 IgG Antibody | C96697 | Herpes Simplex Virus 1 IgG Antibody;HSV-1 IgG Antibody | A measurement of the herpes simplex virus 1 IgG antibody in a biological specimen. | Herpes Simplex Virus 1 IgG Antibody Measurement | ||
Herpes Simplex Virus 1/2 IgG Antibody | C96698 | Herpes Simplex Virus 1/2 IgG Antibody;HSV-1/2 IgG Ab | A measurement of the herpes simplex virus 1 and 2 IgG antibody in a biological specimen. | Herpes Simplex Virus 1/2 IgG Antibody Measurement | ||
Herpes Simplex Virus 1/2 IgM Antibody | C96666 | Herpes Simplex Virus 1/2 IgM Antibody;HSV-1/2 IgM Ab | A measurement of the herpes simplex virus 1 and 2 IgM antibody in a biological specimen. | Herpes Simplex Virus 1/2 IgM Antibody Measurement | ||
Herpes Simplex Virus 2 IgG Antibody | C96667 | Herpes Simplex Virus 2 IgG Antibody;HSV-2 IgG Antibody | A measurement of the herpes simplex virus 2 IgG antibody in a biological specimen. | Herpes Simplex Virus 2 IgG Antibody Measurement | ||
Hexokinase | C96668 | Hexokinase | A measurement of the hexokinase in a biological specimen. | Hexokinase Measurement | ||
Hyperchromia | C96669 | Hyperchromia | A measurement of the prevalence of the erthrocytes with an elevated hemoglobin concentration. | Hyperchromia Measurement | ||
Immature Basophils | C96670 | Immature Basophils | A measurement of the immature basophils in a biological specimen. | Immature Basophil Count | ||
Immature Basophils/Leukocytes | C96671 | Immature Basophils/Leukocytes | A relative measurement (ratio or percentage) of immature basophils to total leukocytes in a biological specimen. | Immature Basophil to Leukocyte Ratio Measurement | ||
Immature Cells | C96672 | Immature Cells | A measurement of the total immature cells in a blood specimen. | Immature Cell Count | ||
Immature Eosinophils | C96673 | Immature Eosinophils | A measurement of the immature eosinophils in a biological specimen. | Immature Eosinophil Count | ||
Immature Eosinophils/Leukocytes | C96674 | Immature Eosinophils/Leukocytes | A relative measurement (ratio or percentage) of immature eosinophils to total leukocytes in a biological specimen. | Immature Eosinophil to Leukocyte Ratio Measurement | ||
Immature Granulocytes | C96675 | Immature Granulocytes | A measurement of the total immature granulocytes in a biological specimen. | Immature Granulocyte Count | ||
Immature Monocytes | C96676 | Immature Monocytes | A measurement of the immature monocytes in a biological specimen. | Immature Monocyte Count | ||
Immature Monocytes/Leukocytes | C96677 | Immature Monocytes/Leukocytes | A relative measurement (ratio or percentage) of immature monocytes to total leukocytes in a biological specimen. | Immature Monocyte to Leukocyte Ratio Measurement | ||
Immature Neutrophils | C96678 | Immature Neutrophils | A measurement of the total immature neutrophils in a biological specimen. | Immature Neutrophil Count | ||
Immature Plasma Cells | C96679 | Immature Plasma Cells | A measurement of the immature plasma cells in a biological specimen. | Immature Plasma Cell Count | ||
Immature Plasma Cells/Lymphocytes | C96680 | Immature Plasma Cells/Lymphocytes | A relative measurement (ratio or percentage) of immature plasma cells to total lymphocytes in a biological specimen. | Immature Plasma Cell to Lymphocyte Ratio Measurement | ||
Inhibin B | C96681 | Inhibin B | A measurement of the inhibin B in a biological specimen. | Inhibin B Measurement | ||
Kurloff Cells | C96682 | Kurloff Cells | A measurement of the large secretory granule-containing immune cells in a biological specimen taken from members of certain genera of the Caviidae family. | Kurloff Cells Measurement | ||
Liver Kidney Microsomal Type 1 Antibody | C96683 | Liver Kidney Microsomal Type 1 Antibody;LKM-1 | A measurement of the liver kidney microsomal type 1 antibody in a biological specimen. | Liver Kidney Microsomal Type 1 Antibody Measurement | ||
Mean Platelet Component | C96686 | Mean Platelet Component | A measurement of the mean platelet component (platelet activity) in a blood specimen. | Mean Platelet Component Measurement | ||
Megakaryocytes | C96688 | Megakaryocytes | A measurement of the megakaryocytes per unit of a biological specimen. | Megakaryocyte Count | ||
Methemoglobin | C96689 | Methemoglobin | A measurement of the methemoglobin in a biological specimen. | Methemoglobin Measurement | ||
Methylmalonic Acid | C96690 | Methylmalonic Acid | A measurement of the methylmalonic acid in a biological specimen. | Methylmalonic Acid Measurement | ||
N-Terminal ProB-type Natriuretic Peptide | C96610 | N-Terminal ProB-type Natriuretic Peptide;NT proBNP II;N-terminal pro-Brain Natriuretic Peptide | A measurement of the N-terminal proB-type natriuretic peptide in a biological specimen. | N-Terminal ProB-type Natriuretic Peptide Measurement | ||
Oxygen Capacity | C96614 | Oxygen Capacity | A measurement of the maximum amount of oxygen that can be combined chemically with hemoglobin in a volume of blood. | Oxygen Capacity Measurement | ||
Oxygen Saturation | C60832 | Oxygen Saturation | A measurement of the oxygen-hemoglobin saturation of a volume of blood. | Oxygen Saturation Measurement | ||
Oxyhemoglobin | C96616 | Oxyhemoglobin | A measurement of the oxyhemoglobin in a biological specimen. | Oxyhemoglobin Measurement | ||
Parvovirus B19 IgG Antibody | C96617 | Parvovirus B19 IgG Antibody | A measurement of the Parvovirus B19 IgG antibody in a biological specimen. | Parvovirus B19 IgG Antibody Measurement | ||
Parvovirus B19 IgM Antibody | C96618 | Parvovirus B19 IgM Antibody | A measurement of the Parvovirus B19 IgM antibody in a biological specimen. | Parvovirus B19 IgM Antibody Measurement | ||
Phospholipid | C96623 | Phospholipid | A measurement of the phospholipids in a biological specimen. | Phospholipid Measurement | ||
Platelet Clumps | C96624 | Platelet Clumps;PLT Clumps | A measurement of the platelet clumps in a biological specimen. | Platelet Clumps Count | ||
Procollagen 1 N-Terminal Propeptide | C96625 | Procollagen 1 N-Terminal Propeptide;Amino-terminal propeptide of type 1 procollagen;P1NP Aminoterm Type 1 | A measurement of the procollagen 1 N-terminal propeptide in a biological specimen. | Procollagen 1 N-Terminal Propeptide Measurement | ||
Reptilase Time | C96628 | Reptilase Time | A measurement of the time it takes a plasma sample to clot after adding the active enzyme reptilase. | Reptilase Time Measurement | ||
Target Cells | C96636 | Leptocytes;Target Cells;Codocytes;Mexican Hat Cells | A measurement of the target cells in a biological specimen. | Target Cell Count | ||
Thyroperoxidase | C96639 | Thyroperoxidase;Thyroid Peroxidase | A measurement of the thyroperoxidase in a biological specimen. | Thyroperoxidase Measurement | ||
Thyroperoxidase Antibody | C96638 | Thyroperoxidase Antibody | A measurement of the thyroperoxidase antibody in a biological specimen. | Thyroperoxidase Antibody Measurement | ||
Toxic Granulation | C96641 | Toxic Granulation | A measurement of the toxic granulation in neutrophilic blood cells. | Toxic Granulation Measurement | ||
Urea/Creatinine | C96645 | Urea/Creatinine | A relative measurement (ratio or percentage) of the urea to creatinine in a biological specimen. | Urea to Creatinine Ratio Measurement | ||
ADV Viral Load | C98705 | ADV Viral Load | A measurement of the adenovirus viral load in a biological specimen. | Adenovirus Viral Load Measurement | ||
Anti-Factor Xa Activity | C98706 | Anti-Factor Xa Activity | A measurement of the anti-activated Factor X in a biological specimen. This test is used to monitor low molecular weight or unfractionated heparin levels in a biological specimen. | Anti-Factor Xa Activity Measurement | ||
Amylase, Pancreatic | C98767 | Amylase, Pancreatic | A measurement of the pancreatic enzyme amylase in a biological specimen. | Pancreatic Amylase Measurement | ||
Amylase, Salivary | C98780 | Amylase, Salivary | A measurement of the salivary enzyme amylase in a biological specimen. | Salivary Amylase Measurement | ||
Activated PTT/Standard | C98862 | Activated PTT/Standard | A relative measurement (ratio or percentage) of the subject's partial thromboplastin time to a standard or control partial thromboplastin time. | Activated PTT/Standard Ratio Measurement | ||
Basophils/Total Cells | C98865 | Basophils/Total Cells | A relative measurement (ratio or percentage) of the basophils to total cells in a biological specimen (for example a bone marrow specimen). | Basophil to Total CellRatio Measurement | ||
BKV Viral Load | C98710 | BKV Viral Load | A measurement of the BK virus viral load in a biological specimen. | BK Virus Viral Load Measurement | ||
Myeloblasts/Total Cells | C98761 | Myeloblasts/Total Cells | A relative measurement (ratio or percentage) of the myeloblasts to total cells in a biological specimen (for example a bone marrow specimen). | Myeloblast to Total Cell Ratio Measurement | ||
Megakaryoblasts | C98752 | Megakaryoblasts | A measurement of the megakaryoblasts in a biological specimen. | Megakaryoblast Cell Count | ||
Megakaryoblasts/Total Cells | C98753 | Megakaryoblasts/Total Cells | A relative measurement (ratio or percentage) of the megakaryoblasts to total cells in a biological specimen (for example a bone marrow specimen). | Megakaryoblast to Total Cell Ratio Measurement | ||
Normoblasts/Total Cells | C98764 | Normoblasts/Total Cells | A relative measurement (ratio or percentage) of the normoblasts to total cells in a biological specimen (for example a bone marrow specimen). | Normoblast to Total Cell Ratio Measurement | ||
Pronormoblasts/Total Cells | C98870 | Pronormoblasts/Total Cells | A relative measurement (ratio or percentage) of the pronormoblasts to total cells in a biological specimen (for example a bone marrow specimen). | Pronormoblast to Total CellRatio Measurement | ||
CMV Viral Load | C98716 | CMV Viral Load | A measurement of the cytomegalovirus viral load in a biological specimen. | Cytomegalovirus Viral Load Measurement | ||
EBV Viral Load | C98721 | EBV Viral Load | A measurement of the Epstein-Barr virus viral load in a biological specimen. | Epstein-Barr Virus Viral Load Measurement | ||
Eosinophils/Total Cells | C98720 | Eosinophils/Total Cells | A relative measurement (ratio or percentage) of the eosinophils to total cells in a biological specimen (for example a bone marrow specimen). | Eosinophils to Total Cell Ratio Measurement | ||
Factor IX | C98725 | Factor IX;Christmas Factor | A measurement of the factor IX in a biological specimen. | Factor IX Measurement | ||
Factor V | C98726 | Factor V;Labile Factor | A measurement of the factor V in a biological specimen. | Factor V Measurement | ||
von Willebrand Factor | C98799 | von Willebrand Factor;von Willebrand Factor Antigen | A measurement of the von Willebrand factor in a biological specimen. | von Willebrand Factor Measurement | ||
Factor X | C98727 | Factor X | A measurement of the factor X in a biological specimen. | Factor X Measurement | ||
Fat Droplet | C98728 | Fat Droplet | A measurement of the triglyceride aggregates within a biological specimen. | Fat Droplet Measurement | ||
Glomerular Filtration Rate Adj for BSA | C98734 | Glomerular Filtration Rate Adj for BSA | A measurement of the glomerular filtration rate adjusted for body size. | Glomerular Filtration Rate Adjusted for BSA | ||
GFR from Creatinine Adjusted for BSA | C98735 | GFR from Creatinine Adjusted for BSA | An estimation of the glomerular filtration rate adjusted for body size based on creatinine. | Glomerular Filtration Rate from Creatinine Adjusted for BSA | ||
GFR from Cystatin C Adjusted for BSA | C98736 | GFR from Cystatin C Adjusted for BSA | An estimation of the glomerular filtration rate adjusted for body size based on cystatin C. | Glomerular Filtration Rate from Cystatin C Adjusted for BSA | ||
Granulocytes/Total Cells | C98866 | Granulocytes/Total Cells | A relative measurement (ratio or percentage) of the granulocytes to total cells in a biological specimen (for example a bone marrow specimen). | Granulocyte to Total CellRatio Measurement | ||
Human Anti-Sheep IgE Antibody | C98740 | Human Anti-Sheep IgE Antibody | A measurement of the human anti-sheep IgE antibodies in a biological specimen. | Human Anti-Sheep IgE Antibody Measurement | ||
Human Anti-Sheep IgG Antibody | C98741 | Human Anti-Sheep IgG Antibody | A measurement of the human anti-sheep IgG antibodies in a biological specimen. | Human Anti-Sheep IgG Antibody Measurement | ||
Human Anti-Sheep IgM Antibody | C98742 | Human Anti-Sheep IgM Antibody | A measurement of the human anti-sheep IgM antibodies in a biological specimen. | Human Anti-Sheep IgM Antibody Measurement | ||
Hemosiderin | C96659 | Hemosiderin | A measurement of the hemosiderin complex in a biological specimen. | Hemosiderin Measurement | ||
Herpes Simplex Virus 1 IgM Antibody | C98738 | Herpes Simplex Virus 1 IgM Antibody | A measurement of the Herpes Simplex virus 1 IgM antibodies in a biological specimen. | Herpes Simplex Virus 1 IgM Antibody Measurement | ||
Herpes Simplex Virus 2 IgM Antibody | C98739 | Herpes Simplex Virus 2 IgM Antibody | A measurement of the Herpes Simplex virus 2 IgM antibodies in a biological specimen. | Herpes Simplex Virus 2 IgM Antibody Measurement | ||
Immunoglobulin D | C98745 | Immunoglobulin D | A measurement of the Immunoglobulin D in a biological specimen. | Immunoglobulin D Measurement | ||
Inulin Clearance | C98748 | Inulin Clearance | A measurement of the volume of serum or plasma that would be cleared of inulin by excretion of urine for a specified unit of time (e.g. one minute). | Inulin Clearance | ||
Iothalamate Clearance | C98749 | Iothalamate Clearance | A measurement of the volume of serum or plasma that would be cleared of iothalamate by excretion of urine for a specified unit of time (e.g. one minute). | Iothalamate Clearance | ||
Iothalamate Clearance Adjusted for BSA | C98750 | Iothalamate Clearance Adjusted for BSA | A measurement of the volume of serum or plasma that would be cleared of iothalamate by excretion of urine for a specified unit of time (e.g. one minute), adjusted for body size. | Iothalamate Clearance Adjusted for BSA | ||
Kappa Light Chain, Free | C98730 | Kappa Light Chain, Free | A measurement of the free kappa light chain in a biological specimen. | Free Kappa Light Chain Measurement | ||
Kappa Lt Chain,Free/Lambda Lt Chain,Free | C98731 | Kappa Lt Chain,Free/Lambda Lt Chain,Free | A relative measurement (ratio or percentage) of the free kappa light chain to the free lambda light chain in a biological specimen. | Free Kappa Light Chain to Free Lambda Light Chain Ratio Measurement | ||
Megakaryocytes/Total Cells | C98867 | Megakaryocytes/Total Cells | A relative measurement (ratio or percentage) of the megakaryocytes to total cells in a biological specimen (for example a bone marrow specimen). | Megakaryocyte to Total CellRatio Measurement | ||
Lambda Light Chain, Free | C98732 | Lambda Light Chain, Free | A measurement of the free lambda light chain in a biological specimen. | Free Lambda Light Chain Measurement | ||
Lymphocytes/Total Cells | C98751 | Lymphocytes/Total Cells | A relative measurement (ratio or percentage) of the lymphocytes to total cells in a biological specimen (for example a bone marrow specimen). | Lymphocyte to Total Cell Ratio Measurement | ||
Metamyelocytes/Total Cells | C98754 | Metamyelocytes/Total Cells | A relative measurement (ratio or percentage ) of the metamyelocytes (small, myelocytic neutrophils with an indented nucleus) to total cells in a biological specimen (for example a bone marrow specimen). | Metamyelocyte to Total Cell Ratio Measurement | ||
Monocytes/Total Cells | C98872 | Monocytes/Total Cells | A relative measurement (ratio or percentage) of the monocytes to total cells in a biological specimen (for example a bone marrow specimen). | Monocytes to Total CellRatioMeasurement | ||
Myelocytes/Total Cells | C98868 | Myelocytes/Total Cells | A relative measurement (ratio or percentage) of the myelocytes to total cells in a biological specimen (for example a bone marrow specimen). | Myelocyte to Total CellRatio Measurement | ||
Neutrophils/Total Cells | C98763 | Neutrophils/Total Cells | A relative measurement (ratio or percentage) of the neutrophils to total cells in a biological specimen (for example a bone marrow specimen). | Neutrophil to Total Cell Ratio Measurement | ||
Natural Killer Cells | C98762 | Natural Killer Cells | A measurement of the total natural killer cells in a biological specimen. | Natural Killer Cell Count | ||
Plasma Cells/Total Cells | C98869 | Plasma Cells/Total Cells | A relative measurement (ratio or percentage) of the mature plasma cells (plasmacytes) to total cells in a biological specimen (for example a bone marrow specimen). | Plasma Cell to Total CellRatio Measurement | ||
Promyelocytes/Total Cells | C98773 | Promyelocytes/Total Cells | A relative measurement (ratio or percentage) of the promyelocytes (immature myelocytes) to total cells in a biological specimen (for example a bone marrow specimen). | Promyelocyte to Total Cell Ratio Measurement | ||
Prothrombin Activity | C98774 | Prothrombin Activity;Factor II Activity | A measurement of the biological activity of prothrombin in a biological specimen. | Prothrombin Activity Measurement | ||
Reticulocyte Hemoglobin | C98776 | Reticulocyte Hemoglobin | A measurement of the amount of hemoglobin in reticulocytes. | Reticulocyte Hemoglobin Measurement | ||
Transferrin Saturation | C98792 | Transferrin Saturation | A measurement of the iron bound to transferrin in a biological specimen. | Transferrin Saturation Measurement | ||
Varicella Zoster Virus IgA Antibody | C98795 | Varicella Zoster Virus IgA Antibody | A measurement of the Varicella Zoster virus IgA antibodies in a biological specimen. | Varicella Zoster Virus IgA Antibody Measurement | ||
Varicella Zoster Virus IgG Antibody | C98796 | Varicella Zoster Virus IgG Antibody | A measurement of the Varicella Zoster virus IgG antibodies in a biological specimen. | Varicella Zoster Virus IgG Antibody Measurement | ||
Varicella Zoster Virus IgM Antibody | C98797 | Varicella Zoster Virus IgM Antibody | A measurement of the Varicella Zoster virus IgM antibodies in a biological specimen. | Varicella Zoster Virus IgM Antibody Measurement | ||
3,4-Dihydroxyphenylglycol | C101017 | 3,4-Dihydroxyphenylglycol;3.4 Dihydroxyphenylglycol | A measurement of the catecholamine metabolite, 3,4-Dihydroxyphenylglycol in a biological specimen. | 3,4-Dihydroxyphenylglycol Measurement | ||
Activated Protein C Resistance | C100471 | Activated Protein C Resistance;Factor V Leiden Screen | A measurement of the resistance in the anticoagulation response to activated protein C in a biological specimen. | Activated Protein C Resistance Measurement | ||
Activated PTT/Standard PTT | C100421 | Activated PTT/Standard PTT;Activated Partial Thromboplastin Time/Standard Thromboplastin Time | A relative measurement (ratio or percentage) of the subject's activated partial thromboplastin time to a standard or control partial thromboplastin time. | Activated PTT to Standard PTT Ratio Measurement | ||
Alanine Aminopeptidase | C100430 | Alanine Aminopeptidase | A measurement of the alanine aminopeptidase in a biological specimen. | Alanine Aminopeptidase Measurement | ||
Alpha-1 Acid Glycoprotein | C100429 | Alpha-1 Acid Glycoprotein | A measurement of the alpha-1 acid glycoprotein in a biological specimen. | Alpha-1 Acid Glycoprotein Measurement | ||
Alpha-1 Microglobulin | C100461 | Alpha-1 Microglobulin;Protein HC | A measurement of the alpha-1 microglobulin in a biological specimen. | Alpha-1 Microglobulin Measurement | ||
Alpha-1 Microglobulin/Creatinine | C100462 | Alpha-1 Microglobulin/Creatinine | A relative measurement (ratio or percentage) of the alpha-1 microglobulin to creatinine in a biological specimen. | Alpha-1 Microglobulin to Creatinine Ratio Measurement | ||
Apolipoprotein C2 | C100427 | Apolipoprotein C2;Apolipoprotein CII | A measurement of the apolipoprotein C2 in a biological specimen. | Apolipoprotein C2 Measurement | ||
Apolipoprotein J | C100428 | Apolipoprotein J;Clusterin | A measurement of the apolipoprotein J in a biological specimen. | Apolipoprotein J Measurement | ||
Beta Carotene | C100472 | Beta Carotene;b-Carotene;Beta Carotin | A measurement of the beta carotene in a biological specimen. | Beta Carotene Measurement | ||
Beta-Trace Protein | C100426 | Beta-Trace Protein | A measurement of the beta-trace protein in a biological specimen. | Beta-Trace Protein Measurement | ||
Carbohydrate-Deficient Transferrin | C101016 | Carbohydrate-Deficient Transferrin | A measurement of transferrin with a reduced number of carbohydrate moieties in a biological specimen. | Carbohydrate-Deficient Transferrin Measurement | ||
Ceruloplasmin | C100432 | Ceruloplasmin;Caeruloplasmin | A measurement of ceruloplasmin in a biological specimen. | Ceruloplasmin Measurement | ||
Complement CH50 | C100423 | Complement CH50;Total Hemolytic Complement;CH50 | A measurement of the complement required to lyse 50 percent of red blood cells in a biological specimen. | CH50 Measurement | ||
Chemokine (C-X-C Motif) Receptor 3 | C100431 | Chemokine (C-X-C Motif) Receptor 3;GPR9, CD183, CXCR3 | A measurement of the CXCR3, chemokine (C-X-C motif) receptor 3, in a biological specimen. | Chemokine Receptor CXCR3 Measurement | ||
Chlamydia trachomatis IgA Antibody | C100464 | Chlamydia trachomatis IgA Antibody | A measurement of the Chlamydia trachomatis IgA antibody in a biological specimen. | Chlamydia trachomatis IgA Antibody Measurement | ||
Chlamydia trachomatis IgG Antibody | C100466 | Chlamydia trachomatis IgG Antibody | A measurement of the Chlamydia trachomatis IgG antibody in a biological specimen. | Chlamydia trachomatis IgG Antibody Measurement | ||
Chlamydia trachomatis IgM Antibody | C100465 | Chlamydia trachomatis IgM Antibody | A measurement of the Chlamydia trachomatis IgM antibody in a biological specimen. | Chlamydia trachomatis IgM Antibody Measurement | ||
DTPA Clearance | C100441 | DTPA Clearance | A measurement of the volume of serum or plasma that would be cleared of Diethylenetriamine pentaacetate (DTPA) through its excretion for a specified unit of time. | Diethylene Triamine Pentaacetic Acid Clearance | ||
DNase-B Antibody | C100463 | DNase-B Antibody;Anti-Dnase B | A measurement of Dnase-B antibody in a biological specimen. | DNase-B Antibody Measurement | ||
Ecarin Clotting Time | C100422 | Ecarin Clotting Time | A measurement of the activity of thrombin inhibitors in a biological specimen based on the generation of meizothrombin. | Ecarin Clotting Time Measurement | ||
EDTA Clearance | C100440 | EDTA Clearance | A measurement of the volume of serum or plasma that would be cleared of Ethylenediamine tetraacetic acid (EDTA) through its excretion for a specified unit of time. | EDTA Clearance | ||
Free Glycerol | C100448 | Free Glycerol;Free Glycerin | A measurement of the amount of unbound glycerol in a biological specimen. | Free Glycerol Measurement | ||
GFR from B-2 Microglobulin Adj for BSA | C100450 | GFR from B-2 Microglobulin Adj for BSA | A measurement of the glomerular filtration rate (GFR) based on the clearance of beta-2 microglobulin after adjusting it for the body surface area. | Glomerular Filtration Rate from B-2 Microglobulin Adjusted for BSA Measurement | ||
GFR from Beta-Trace Protein Adj for BSA | C100449 | GFR from Beta-Trace Protein Adj for BSA | A measurement of the glomerular filtration rate (GFR) based on the clearance of beta-trace protein after adjusting it for the body surface area. | Glomerular Filtration Rate from Beta-Trace Protein Adjusted for BSA Measurement | ||
HDL Cholesterol/LDL Cholesterol Ratio | C100425 | HDL Cholesterol/LDL Cholesterol Ratio | A relative measurement (ratio or percentage) of the amount of HDL cholesterol compared to LDL cholesterol in a biological specimen. | HDL Cholesterol to LDL Cholesterol Ratio Measurement | ||
HLA-B27 Antigen | C100460 | HLA-B27 Antigen;Human Leukocyte Antigen B27 | A measurement of the human leukocyte antigen B27 (HLA-B27) in a biological specimen. | HLA-B27 Antigen Measurement | ||
Homostat Model Assess of Insulin Rstn | C100447 | Homostat Model Assess of Insulin Rstn;Homeostatic Model Assessment of Insulin Resistance | An assessment of beta-cell function and insulin resistance based on fasting blood glucose and insulin concentrations. | Homeostatic Model Assessment of Insulin Resistance | ||
Immature Granulocytes/Leukocytes | C100445 | Immature Granulocytes/Leukocytes | A relative measurement (ratio or percentage) of the immature granulocytes to leukocytes in a biological specimen (for example a bone marrow specimen). | Immature Granulocytes to Leukocytes Ratio Measurement | ||
Immature Lymphocytes | C100444 | Immature Lymphocytes | A measurement of the immature lymphocytes in a biological specimen. | Immature Lymphocytes Measurement | ||
Immature Lymphocytes/Leukocytes | C100443 | Immature Lymphocytes/Leukocytes | A relative measurement (ratio or percentage) of the immature lymphocytes to leukocytes in a biological specimen. | Immature Lymphocytes to Leukocytes Ratio Measurement | ||
Immature Neutrophils/Leukocytes | C100442 | Immature Neutrophils/Leukocytes | A relative measurement (ratio or percentage) of the immature neutrophils to leukocytes in a biological specimen. | Immature Neutrophils to Leukocytes Ratio Measurement | ||
Iohexol Clearance | C100439 | Iohexol Clearance | A measurement of the volume of serum or plasma that would be cleared of Iohexol through excretion for a specified unit of time. | Iohexol Clearance | ||
Jo-1 Antibody | C100459 | Jo-1 Antibody | A measurement of the Jo-1 antibody in a biological specimen. | Jo-1 Antibody Measurement | ||
Kidney Injury Molecule-1 | C100433 | Kidney Injury Molecule-1;KIM-1;Hepatitis A Virus Cellular Receptor 1 | A measurement of the kidney injury molecule-1 (Kim-1) in a biological specimen. | Kidney Injury Molecule-1 Measurement | ||
Liver Kidney Microsomal Type 1 IgA Ab | C100456 | Liver Kidney Microsomal Type 1 IgA Ab | A measurement of the liver kidney microsomal type 1 IgA antibodies in a biological specimen. | Liver Kidney Microsomal Type 1 IgA Antibody Measurement | ||
Liver Kidney Microsomal Type 1 IgG Ab | C100454 | Liver Kidney Microsomal Type 1 IgG Ab | A measurement of the liver kidney microsomal type 1 IgG antibodies in a biological specimen. | Liver Kidney Microsomal Type 1 IgG Antibody Measurement | ||
Liver Kidney Microsomal Type 1 IgM Ab | C100455 | Liver Kidney Microsomal Type 1 IgM Ab | A measurement of the liver kidney microsomal type 1 IgM antibodies in a biological specimen. | Liver Kidney Microsomal Type 1 IgM Antibody Measurement | ||
Non-Prostatic Acid Phosphatase | C100434 | Non-Prostatic Acid Phosphatase | A measurement of the non-prostatic acid phosphatase in a biological specimen. | Non-Prostatic Acid Phosphatase Measurement | ||
Ova and Parasite | C100452 | Ova and Parasite | A measurement of the parasites and ova in a biological specimen. | Ova and Parasite Measurement | ||
Pepsinogen A | C100469 | Pepsinogen A;PGA | A measurement of the pepsinogen A in a biological specimen. | Pepsinogen A Measurement | ||
Pepsinogen C | C100470 | Pepsinogen C;PGC | A measurement of the pepsinogen C in a biological specimen. | Pepsinogen C Measurement | ||
Pepsinogen I | C100467 | Pepsinogen I;PGI | A measurement of the pepsinogen I in a biological specimen. | Pepsinogen I Measurement | ||
Pepsinogen II | C100468 | Pepsinogen II;PGII | A measurement of the pepsinogen II in a biological specimen. | Pepsinogen II Measurement | ||
Pepsinogen | C100122 | Pepsinogen | A measurement of the pepsinogen in a biological specimen. | Pepsinogen Measurement | ||
Plasmodium | C100453 | Plasmodium | Examination of a biological specimen to detect the presence of any protozoan belonging to the Plasmodium genus. | Plasmodium Measurement | ||
Platelet Hematocrit | C100424 | Platelet Hematocrit;Thrombocytocrit | A relative measurement (ratio or percentage) of the proportion of the volume of blood taken up by platelets. | Platelet Hematocrit Measurement | ||
Prealbumin | C100435 | Prealbumin | A measurement of the prealbumin in a biological specimen. | Prealbumin Measurement | ||
Proerythroblast | C100446 | Proerythroblast | A measurement of the proerythroblasts in a biological specimen. | Proerythroblast Measurement | ||
Protein S | C100436 | Protein S | A measurement of the protein S in a biological specimen. | Protein S Measurement | ||
Retinol Binding Protein | C100437 | Retinol Binding Protein | A measurement of the total retinol binding protein in a biological specimen. | Retinol Binding Protein Measurement | ||
Ribonucleoprotein Antibody | C100457 | Ribonucleoprotein Antibody;RNP Antibody | A measurement of the ribonucleoprotein antibody in a biological specimen. | Ribonucleoprotein Antibody Measurement | ||
Ringed Sideroblasts | C100419 | Ringed Sideroblasts | A measurement of the ringed sideroblasts (abnormal nucleated erythroblasts with a large number of iron deposits in the perinuclear mitochondria, forming a ring around the nucleus) in a biological specimen. | Ringed Sideroblast Measurement | ||
Scl-70 Antibody | C100458 | Scl-70 Antibody;Scleroderma-70 Antibody | A measurement of the Scl-70 antibody in a biological specimen. | Scl-70 Antibody Measurement | ||
Sideroblast | C100418 | Sideroblast | A measurement of the sideroblasts (nucleated erythroblasts with iron granules in the cytoplasm) in a biological specimen. | Sideroblast Measurement | ||
Soluble Transferrin Receptor | C100438 | Soluble Transferrin Receptor | A measurement of the soluble transferrin receptor in a biological specimen. | Soluble Transferrin Receptor Measurement | ||
Tricyclic Antidepressants | C100420 | Tricyclic Antidepressants | A measurement of tricyclic antidepressants in a biological specimen. | Tricyclic Antidepressant Measurement | ||
Adenosine Diphosphate | C102257 | Adenosine Diphosphate | A measurement of the adenosine diphosphate in a biological specimen. | Adenosine Diphosphate Measurement | ||
Antiphospholipid Antibodies | C102258 | Antiphospholipid Antibodies | A measurement of the antiphospholipid antibodies in a biological specimen. | Antiphospholipid Antibody Measurement | ||
Arachidonic Acid | C102259 | Arachidonic Acid | A measurement of the arachidonic acid present in a biological specimen. | Arachidonic Acid Measurement | ||
CD34 | C102260 | CD34 | A measurement of the CD34 expressing cells per unit in a biological specimen. | CD34 Measurement | ||
Clue Cells | C102261 | Clue Cells | A measurement of the clue cells in a biological specimen. | Clue Cell Count | ||
Dextroamphetamine | C102262 | Dextroamphetamine;d-amphetamine | A measurement of the dextroamphetamine in a biological specimen. | Dextroamphetamine Measurement | ||
Drug Screen | C78139 | Drug Screen | An indication of the presence or absence of recreational drugs or drugs of abuse in a biological specimen. | Drug Test | ||
Endogenous Thrombin Potential | C102266 | Endogenous Thrombin Potential | A measurement of the total concentration of thrombin generated in the presence of a substrate in a plasma or blood sample. | Endogenous Thrombin Potential Measurement | ||
ETP Area Under Curve | C102263 | ETP Area Under Curve;Endogenous Thrombin Potential Area Under Curve | A measurement of the area under the thrombin generation curve. | Endogenous Thrombin Potential Area Under Curve Measurement | ||
ETP Lag Time | C102264 | ETP Lag Time;Endogenous Thrombin Potential Lag Time | A measurement of time from the start of the thrombin generation test to the point where a predetermined amount of thrombin is generated. | Endogenous Thrombin Potential Lag Time Measurement | ||
ETP Lag Time Relative | C102265 | ETP Lag Time Relative;Endogenous Thrombin Potential Lag Time Relative | A relative measurement (ratio or percentage) of time from the start of the thrombin generation test to the point where a predetermined amount of thrombin is generated. | Endogenous Thrombin Potential Lag Time Relative Measurement | ||
ETP Peak Height | C102267 | ETP Peak Height;Endogenous Thrombin Potential Peak Height | A measurement of the maximum concentration of thrombin generated during a thrombin generation test. | Endogenous Thrombin Potential Peak Height Measurement | ||
ETP Peak Height Relative | C102268 | ETP Peak Height Relative;Endogenous Thrombin Potential Peak Height Relative | A relative (ratio or percentage) of the maximum concentration of thrombin generated during a thrombin generation test. | Endogenous Thrombin Potential Peak Height Relative Measurement | ||
ETP Time to Peak | C102269 | ETP Time to Peak;Endogenous Thrombin Potential Time to Peak | A measurement of the time it takes to generate the maximum concentration of thrombin. | Endogenous Thrombin Potential Time to Peak Measurement | ||
ETP Time to Peak Relative | C102270 | ETP Time to Peak Relative;Endogenous Thrombin Potential Time to Peak Relative | A relative (ratio or percentage) measurement of the time it takes to generate the maximum concentration of thrombin. | Endogenous Thrombin Potential Time to Peak Relative Measurement | ||
Factor V Leiden | C102271 | Factor V Leiden | A measurement of the Factor V Leiden in a biological specimen. | Factor V Leiden Measurement | ||
Factor XIV | C102272 | Factor XIV;Autoprothrombin IIA;Protein C;Protein C Antigen | A measurement of the factor XIV in a biological specimen. | Factor XIV Measurement | ||
HCT Corrected Reticulocytes/Erythrocytes | C102274 | HCT Corrected Reticulocytes/Erythrocytes | A relative measurement (ratio or percentage) of the hematocrit corrected reticulocytes to erythrocytes in a biological specimen. | Hematocrit Corrected Reticulocytes to Erythrocytes Ratio Measurement | ||
Hematocrit Corrected Reticulocytes | C102273 | Hematocrit Corrected Reticulocytes | A measurement of the hematocrit corrected reticulocytes in a biological specimen. | Hematocrit Corrected Reticulocyte Count | ||
Hydrogen | C102275 | Hydrogen | A measurement of the hydrogen in a biological specimen. | Hydrogen Measurement | ||
Immature Reticulocyte Fraction | C102276 | Immature Reticulocyte Fraction | A measurement of the immature reticulocyte fraction present in a biological specimen. | Immature Reticulocyte Fraction Measurement | ||
Lupus Anticoagulant Sensitive APTT | C102277 | Lupus Anticoagulant Sensitive APTT;APTT-LA | A measurement of the length of time that it takes for clotting to occur when a lupus sensitive reagent is added to a plasma specimen. | Lupus Anticoagulant Sensitive APTT Measurement | ||
Lymphoblasts | C102278 | Lymphoblasts | A measurement of the lymphoblasts (immature cells that differentiate to form lymphocytes) in a biological specimen. | Lymphoblast Count | ||
Methamphetamine | C75348 | Methamphetamine | A measurement of the methamphetamine drug present in a biological specimen. | Methamphetamine Measurement | ||
P50 Oxygen | C102279 | P50 Oxygen | A measurement of the partial pressure of oxygen when hemoglobin is half saturated in a biological specimen. | P50 Oxygen Measurement | ||
Soluble Interleukin 2 Receptor Activity | C102280 | Soluble Interleukin 2 Receptor Activity | A measurement of the soluble interleukin 2 receptor activity in a biological specimen. | Soluble Interleukin 2 Receptor Activity Measurement | ||
Sperm Motility | C102281 | Sperm Motility | A measurement of the sperm capable of forward, progressive movement in a semen specimen. | Sperm Motility Measurement | ||
Urine Conductivity | C102282 | Urine Conductivity | A measurement of the urine conductivity which is a non-linear function of the electrolyte concentration in the urine. | Urine Conductivity | ||
11-Dehydro-Thromboxane B2 | C103344 | 11-Dehydro-Thromboxane B2 | A measurement of the 11-dehydro-thromboxane B2 in a biological specimen. | 11-Dehydro-Thromboxane B2 Measurement | ||
3,4-Dihydroxyphenylacetic Acid | C103345 | 3,4-Dihydroxyphenylacetic Acid | A measurement of the 3,4-dihydroxyphenylacetic acid in a biological specimen. | 3,4-Dihydroxyphenylacetic Acid Measurement | ||
3,4-methylenedioxymethamphetamine | C75359 | 3,4-methylenedioxymethamphetamine;Ecstasy | A measurement of the 3,4-methylenedioxymethamphetamine (MDMA) in a biological specimen. | 3,4-Methylenedioxymethamphetamine Measurement | ||
Activated Coagulation Time | C103348 | Activated Clot Time;Activated Clotting Time;Coagulation Activated | A measurement of the inhibition of blood coagulation in response to anticoagulant therapies. | Activated Coagulation Time | ||
Albumin/Total Protein | C103453 | Albumin/Total Protein | A relative measurement (ratio or percentage) of the albumin to total protein in a biological specimen. | Albumin to Total Protein Ratio Measurement | ||
Alpha Tocopherol | C103349 | Alpha Tocopherol | A measurement of the alpha tocopherol in a biological specimen. | Alpha Tocopherol Measurement | ||
Alpha Tocopherol/Vitamin E | C103350 | Vitamin E Alpha Tocopherol | A relative measurement (ratio or percentage) of alpha-tocopherol to the total vitamin E in a biological specimen. | Alpha Tocopherol to Vitamin E Ratio Measurement | ||
Alpha-2 Antiplasmin | C103351 | Alpha-2 Plasmin Inhibitor | A measurement of the alpha-2 antiplasmin in a biological specimen. | Alpha-2 Antiplasmin Measurement | ||
Amyloid Beta 1-38 | C103352 | Amyloid Beta 38;Amyloid Beta 38 Protein;Amyloid Beta 1-38 | A measurement of amyloid beta protein which is composed of peptides 1 to 38 in a biological specimen. | Amyloid Beta 1-38 Measurement | ||
Amyloid Beta 1-40 | C103353 | Amyloid Beta 40;Amyloid Beta 40 Protein;Amyloid Beta 1-40 | A measurement of amyloid beta protein which is composed of peptides 1 to 40 in a biological specimen. | Amyloid Beta 1-40 Measurement | ||
Antiglobulin Test, Indirect | C91372 | Antiglobulin Test, Indirect;Indirect Coombs Test | A test that uses Coombs' reagent to detect the presence of anti-erythrocyte antibodies in a biological specimen. | Indirect Antiglobulin Test | ||
Apolipoprotein A4 | C103354 | Apolipoprotein A4 | A measurement of the apolipoprotein A4 in a biological specimen. | Apolipoprotein A4 Measurement | ||
Apolipoprotein A5 | C103355 | Apolipoprotein A5 | A measurement of the apolipoprotein A5 in a biological specimen. | Apolipoprotein A5 Measurement | ||
Apolipoprotein B/Apolipoprotein A1 | C103356 | Apolipoprotein B/Apolipoprotein A1 | A relative measurement (ratio or percentage) of the Apolipoprotein B to Apolipoprotein A1 in a biological specimen. | Apolipoprotein B to Apolipoprotein A1 Ratio Measurement | ||
Beta Catenin | C103357 | Beta Catenin | A measurement of the beta catenin in a biological specimen. | Beta Catenin Measurement | ||
Beta-2 Glycoprotein 1 IgG Antibody | C103358 | Beta-2 Glycoprotein 1 IgG Antibody | A measurement of the Beta-2 glycoprotein 1 IgG antibodies in a biological specimen. | Beta-2 Glycoprotein 1 IgG Antibody Measurement | ||
Beta-2 Glycoprotein 1 IgM Antibody | C103359 | Beta-2 Glycoprotein 1 IgM Antibody | A measurement of the Beta-2 glycoprotein 1 IgM antibodies in a biological specimen. | Beta-2 Glycoprotein 1 IgM Antibody Measurement | ||
Calcium - Phosphorus Product | C103360 | Calcium - Phosphorus Product | A measurement of the product of the calcium and phosphate measurements in a biological specimen. | Calcium and Phosphorus Product Measurement | ||
Cancer Antigen 1 | C103361 | Cancer Antigen 1 | A measurement of the cancer antigen 1 in a biological specimen. | Cancer Antigen 1 Measurement | ||
Cancer Antigen 15-3 | C103362 | Cancer Antigen 15-3 | A measurement of the cancer antigen 15-3 in a biological specimen. | Cancer Antigen 15-3 Measurement | ||
Cardiolipin IgM Antibody | C103363 | Cardiolipin IgM Antibody | A measurement of the cardiolipin IgM antibodies in a biological specimen. | Cardiolipin IgM Antibody Measurement | ||
CD1 | C103364 | CD1 | A count of the CD1 expressing cells per unit of a biological specimen. | CD1 Expressing Cell Measurement | ||
CD14 | C103365 | CD14 | A count of the CD14 expressing cells per unit of a biological specimen. | CD14 Expressing Cell Measurement | ||
CD2 | C103366 | CD2 | A count of the CD2 expressing cells per unit of a biological specimen. | CD2 Expressing Cell Measurement | ||
CD2/Lymphocytes | C103367 | CD2/Lymphocytes | A relative measurement (ratio or percentage) of CD2 expressing cells to all lymphocytes in a biological specimen. | CD2 Expressing Cell to Lymphocyte Ratio Measurement | ||
CD20 | C103368 | CD20 | A count of the CD20 expressing cells per unit of a biological specimen. | CD20 Expressing Cell Measurement | ||
CD5 | C103369 | CD5 | A count of the CD5 expressing cells per unit of a biological specimen. | CD5 Expressing Cell Measurement | ||
CD56 | C103370 | CD56 | A count of the CD56 expressing cells per unit of a biological specimen. | CD56 Expressing Cell Measurement | ||
Cholesteryl Ester Transfer Protein Act | C103380 | Cholesteryl Ester Transfer Protein Act | A measurement of the biological activity of cholesteryl ester transfer protein in a biological specimen. | Cholesteryl Ester Transfer Protein Activity Measurement | ||
Clostridium difficile Toxin | C103381 | Clostridium difficile Toxin | A measurement of the Clostridium difficile toxin in a biological specimen. | Clostridium difficile Toxin Measurement | ||
Clostridium tetani IgG Antibody | C103382 | Clostridium tetani IgG Antibody | A measurement of the Clostridium tetani IgG antibody in a biological specimen. | Clostridium tetani IgG Antibody Measurement | ||
Collagen Type IV | C103383 | Collagen Type IV | A measurement of the collagen type IV in a biological specimen. | Collagen Type IV Measurement | ||
Dilute Russell's Viper Venom Time Ratio | C103386 | Lupus Anticoagulant Ratio | A relative measurement (ratio or percentage) of the dilute Russell's viper venom time in a subject sample to a control sample. | Dilute Russell's Viper Venom Time to Control Ratio Measurement | ||
Dipeptidyl Peptidase-4 Activity | C103387 | DPPIV Activity | A measurement of the biological activity of dipeptidyl peptidase-4 in a biological specimen. | Dipeptidyl Peptidase-4 Activity Measurement | ||
Diphtheria IgG Antibody | C103388 | Diphtheria IgG Antibody | A measurement of the Diphtheria IgG antibodies in a biological specimen. | Diphtheria IgG Antibody Measurement | ||
Factor IX Activity | C103395 | Christmas Factor Activity | A measurement of the biological activity of factor IX in a biological specimen. | Factor IX Activity Measurement | ||
Factor V Activity | C103396 | Labile Factor Activity | A measurement of the biological activity of factor V in a biological specimen. | Factor V Activity Measurement | ||
Factor VII Activity | C103397 | Proconvertin Activity;Stable Factor Activity | A measurement of the biological activity of factor VII in a biological specimen. | Factor VII Activity Measurement | ||
Factor VIIa Activity | C103398 | Factor VIIa Activity | A measurement of the biological activity of factor VIIa in a biological specimen. | Factor VIIa Activity Measurement | ||
Factor VIII Activity | C103399 | Anti-hemophilic Factor Activity | A measurement of the biological activity of factor VIII in a biological specimen. | Factor VIII Activity Measurement | ||
HDL Particle Size | C103402 | HDL Particle Size | A measurement of the average particle size of high-density lipoprotein in a biological specimen. | HDL Particle Size Measurement | ||
Helicobacter pylori IgG Antibody | C103403 | Helicobacter pylori IgG Antibody | A measurement of the Helicobacter pylori IgG antibody in a biological specimen. | Helicobacter pylori IgG Antibody Measurement | ||
Hepatitis B DNA | C103404 | Hepatitis B DNA | A measurement of hepatitis B virus DNA in a biological specimen. | Hepatitis B DNA Measurement | ||
Human Albumin Antibody | C103405 | Human Albumin Antibody | A measurement of the human albumin antibody in a biological specimen. | Human Albumin Antibody Measurement | ||
Human Anti-Mouse Antibody | C103406 | HAMA | A measurement of the human anti-mouse antibody in a biological specimen. | Human Anti-Mouse Antibody Measurement | ||
Immunoblasts | C103407 | Lymphocytes, Immunoblastic | A measurement of the immunoblasts in a biological specimen. | Immunoblast Count | ||
Influenza A IgG Antibody | C103408 | Influenza A IgG Antibody | A measurement of the Influenza A IgG antibody in a biological specimen. | Influenza A IgG Antibody Measurement | ||
Influenza B IgG Antibody | C103409 | Influenza B IgG Antibody | A measurement of the Influenza B IgG antibody in a biological specimen. | Influenza B IgG Antibody Measurement | ||
Isoleucine | C103410 | Isoleucine | A measurement of the isoleucine in a biological specimen. | Isoleucine Measurement | ||
LDL Particle Size | C103412 | LDL Particle Size | A measurement of the average particle size of low-density lipoprotein in a biological specimen. | LDL Particle Size Measurement | ||
Leukotriene B4 | C103413 | Leukotriene B4 | A measurement of the leukotriene B4 in a biological specimen. | Leukotriene B4 Measurement | ||
Leukotriene D4 | C103414 | Leukotriene D4 | A measurement of the leukotriene D4 in a biological specimen. | Leukotriene D4 Measurement | ||
Leukotriene E4 | C103415 | Leukotriene E4 | A measurement of the leukotriene E4 in a biological specimen. | Leukotriene E4 Measurement | ||
Lysergic Acid Diethylamide | C75354 | Lysergic Acid Diethylamide;Acid | A measurement of the lysergic acid diethylamine (LSD) in a biological specimen. | Lysergide Measurement | ||
Myelin Antibodies | C103418 | Myelin Antibodies | A measurement of the myelin antibodies in a biological specimen. | Myelin Antibodies Measurement | ||
N-acetyl-beta-D-glucosaminidase | C103419 | NAG;Beta-N-acetyl-D-glucosaminidase | A measurement of the N-acetyl-beta-D-glucosaminidase in a biological specimen. | N-acetyl-beta-D-glucosaminidase Measurement | ||
Parathyroid Hormone, Whole | C103451 | Parathyroid Hormone, Whole | A measurement of the whole parathyroid hormone (consisting of amino acids 1-84) in a biological specimen. | Whole Parathyroid Hormone Measurement | ||
Platelet Aggregation | C103427 | Platelet Function | A measurement of the association of platelets to one another via adhesion molecules in a biological sample. | Platelet Aggregation Measurement | ||
Procalcitonin | C103430 | Procalcitonin | A measurement of the procalcitonin in a biological specimen. | Procalcitonin Measurement | ||
Prostaglandin | C103343 | Total Prostaglandin | A measurement of the total prostaglandin in a biological specimen. | Prostaglandin Measurement | ||
Prostaglandin D2 | C103431 | Prostaglandin D2 | A measurement of the prostaglandin D2 in a biological specimen. | Prostaglandin D2 Measurement | ||
Prostaglandin D2 Synthase | C103432 | Prostaglandin D2 Synthase | A measurement of the prostaglandin D2 synthase in a biological specimen. | Prostaglandin D2 Synthase Measurement | ||
Prostaglandin E Synthase | C103433 | Prostaglandin E Synthase | A measurement of the prostaglandin E synthase in a biological specimen. | Prostaglandin E Synthase Measurement | ||
Prostaglandin E1 | C103434 | Prostaglandin E1 | A measurement of the prostaglandin E1 in a biological specimen. | Prostaglandin E1 Measurement | ||
Prostaglandin E2 | C103435 | Prostaglandin E2 | A measurement of the prostaglandin E2 in a biological specimen. | Prostaglandin E2 Measurement | ||
Prostaglandin F1 Alpha | C103436 | Prostaglandin F1 Alpha | A measurement of the prostaglandin F1 alpha in a biological specimen. | Prostaglandin F1 Alpha Measurement | ||
Prostaglandin F2 Alpha | C103437 | Prostaglandin F2 Alpha | A measurement of the prostaglandin F2 alpha in a biological specimen. | Prostaglandin F2 Alpha Measurement | ||
Rubella IgG Antibody | C103440 | Rubella IgG Antibody | A measurement of the Rubella IgG antibody in a biological specimen. | Rubella IgG Antibody Measurement | ||
Thromboxane B2 | C103445 | Thromboxane B2 | A measurement of the thromboxane B2 in a biological specimen. | Thromboxane B2 Measurement | ||
Thyroglobulin | C103446 | TG | A measurement of the thyroglobulin in a biological specimen. | Thyroglobulin Measurement | ||
Vitamin E/Cholesterol | C103448 | Vitamin E/Cholesterol | A relative measurement (ratio or percentage) of vitamin E to total cholesterol in a biological specimen. | Vitamin E to Cholesterol Ratio Measurement | ||
Vitamin K1 | C103449 | Phylloquinone;Phytomenadione | A measurement of the Vitamin K1 in a biological specimen. | Vitamin K1 Measurement | ||
VLDL Particle Size | C103450 | VLDL Particle Size | A measurement of the average particle size of very-low-density lipoprotein in a biological specimen. | VLDL Particle Size Measurement | ||
Amyloid Beta Precursor Protein | C105438 | Amyloid Precursor Beta;Amyloid Beta Precursor;Amyloid Precursor Protein;Amyloid Beta Precursor Protein | A measurement of the amyloid beta precursor protein present in a biological specimen. | Amyloid Beta Precursor Protein Measurement | ||
Lymphoblasts/Leukocytes | C105444 | Lymphoblasts/Leukocytes | A relative measurement (ratio or percentage) of the lymphoblasts to leukocytes in a biological specimen. | Lymphoblast to Leukocyte Ratio Measurement | ||
CD11A | C105439 | CD11a;CD11A | A count of the CD11a expressing cells per unit of a biological specimen. | CD11A Expressing Cell Count | ||
CD11B | C105440 | CD11b;CD11B | A count of the CD11b expressing cells per unit of a biological specimen. | CD11B Expressing Cell Count | ||
Cystine | C105441 | Cystine | A measurement of the cystine in a biological specimen. | Cystine Measurement | ||
Factor XIV Activity | C105442 | Protein C Activity;Factor XIV Activity | A measurement of the factor XIV activity in a biological specimen. | Factor XIV Activity Measurement | ||
FibroTest Score | C105443 | FibroTest Score;FibroSURE Score | A biomarker test that measures liver pathology through the assessment of a six-parameter blood test (for Alpha-2-macroglobulin, Haptoglobin, Apolipoprotein A1, Gamma-glutamyl transpeptidase (GGT), Total bilirubin, and Alanine aminotransferase (ALT)), taking into account the age and gender of the patient. | FibroTest Score Measurement | ||
Sediment Examination | C105744 | Sediment Examination;Sediment Analysis;Microscopic Sediment Analysis | An observation, assessment or examination of the sediment in a biological specimen. | Sediment Analysis | ||
Theophylline | C105445 | Theophylline | A measurement of the Theophylline present in a biological specimen. | Theophylline Measurement | ||
Back to top | ||||||
CL.C71113.FREQ | Frequency (FREQ) | text Extensible: Yes | C71113 | Frequency | The terminology that includes terms pertaining to frequency within CDISC. | CDISC SDTM Frequency Terminology |
OTHER | C17649 | Other | Different than the one(s) previously specified or mentioned. (NCI) | Other | ||
UNKNOWN | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
CONTINUOUS | C53279 | Continuous | Remain in force or carry on without letup; keep or maintain in unaltered condition; exist in time or space without stop or interruption. (NCI) | Continue | ||
BID | C64496 | BD;Twice per day | Two times per day, at unspecified times. (NCI) | Twice Daily | ||
2 TIMES PER WEEK | C64497 | Twice per week;BIS | Two times per week. (NCI) | Twice Weekly | ||
QM | C64498 | Every Month;Per Month | Every month. (NCI) | Monthly | ||
PRN | C64499 | As needed | As needed. (NCI) | As Necessary | ||
Q10H | C64500 | Every 10 hours | Every ten hours. (NCI) | Every Ten Hours | ||
Q11H | C64501 | Every 11 hours | Every eleven hours. (NCI) | Every Eleven Hours | ||
Q12H | C64502 | Every 12 hours | Every twelve hours. (NCI) | Every Twelve Hours | ||
Q13H | C64503 | Every 13 hours | Every thirteen hours. (NCI) | Every Thirteen Hours | ||
Q14H | C64504 | Every 14 hours | Every fourteen hours. (NCI) | Every Fourteen Hours | ||
Q15H | C64505 | Every 15 hours | Every fifteen hours. (NCI) | Every Fifteen Hours | ||
Q16H | C64506 | Every 16 hours | Every sixteen hours. (NCI) | Every Sixteen Hours | ||
Q17H | C64507 | Every 17 hours | Every seventeen hours. (NCI) | Every Seventeen Hours | ||
Q18H | C64508 | Every 18 hours | Every eighteen hours. (NCI) | Every Eighteen Hours | ||
Q19H | C64509 | Every 19 hours | Every nineteen hours. (NCI) | Every Nineteen Hours | ||
QH | C64510 | Every hour | Every hour. (NCI) | Every Hour | ||
Q20H | C64511 | Every 20 hours | Every twenty hours. (NCI) | Every Twenty Hours | ||
Q21H | C64512 | Every 21 hours | Every twenty-one hours. (NCI) | Every Twenty-One Hours | ||
Q22H | C64513 | Every 22 hours | Every twenty-two hours. (NCI) | Every Twenty-Two Hours | ||
Q23H | C64514 | Every 23 hours | Every twenty-three hours. (NCI) | Every Twenty-Three Hours | ||
Q24H | C64515 | Every 24 hours | Every twenty-four hours. (NCI) | Every Twenty-Four Hours | ||
Q2H | C64516 | Every 2 hours | Every two hours. (NCI) | Every Two Hours | ||
Q3H | C64517 | Every 3 hours | Every three hours. (NCI) | Every Three Hours | ||
Q4H | C64518 | Every 4 hours | Every four hours. (NCI) | Every Four Hours | ||
Q5H | C64519 | Every 5 hours | Every five hours. (NCI) | Every Five Hours | ||
Q6H | C64520 | Every 6 hours | Every six hours. (NCI) | Every Six Hours | ||
Q7H | C64521 | Every 7 hours | Every seven hours. (NCI) | Every Seven Hours | ||
Q8H | C64523 | Every 8 hours | Every eight hours. (NCI) | Every Eight Hours | ||
Q9H | C64524 | Every 9 hours | Every nine hours. (NCI) | Every Nine Hours | ||
QOD | C64525 | Every other day | Every other day. (NCI) | Every Other Day | ||
TID | C64527 | 3 times per day | Three times per day. (NCI) | Three Times Daily | ||
3 TIMES PER WEEK | C64528 | Three times a week;TIS | Three times per week. (NCI) | Three Times Weekly | ||
EVERY 4 WEEKS | C64529 | Every 4 weeks;Q4S | Every four weeks. (NCI) | Every Four Weeks | ||
QID | C64530 | 4 times per day | Four times per day. (NCI) | Four Times Daily | ||
4 TIMES PER WEEK | C64531 | 4 times per week;QIS | Four times per week. (NCI) | Four Times Weekly | ||
Q3D | C64533 | Every 3 days | Every three days. (NCI) | Every Three Days | ||
Q4D | C64534 | Every 4 days | Every four days. (NCI) | Every Four Days | ||
EVERY 3 WEEKS | C64535 | Every 3 weeks;Q3S | Every three weeks. (NCI) | Every Three Weeks | ||
Q2M | C64536 | Every two months | Every two months. (NCI) | Every Two Months | ||
Q3M | C64537 | Every 3 months | Every three months. (NCI) | Every Three Months | ||
Q4M | C64538 | Every 4 months | Every four months. (NCI) | Every Four Months | ||
ONCE | C64576 | Once | A one time intervention. (NCI) | Once | ||
EVERY WEEK | C67069 | Every week;Per Week;QS | Every week. (NCI) | Weekly | ||
Q5D | C71124 | Every 5 days | Every five days. (NCI) | Every Five Days | ||
EVERY 2 WEEKS | C71127 | Every 2 weeks;Q2S | Every two weeks. (NCI) | Every Two Weeks | ||
BIM | C71129 | Twice per month | Twice per month. (NCI) | Twice Per Month | ||
INTERMITTENT | C71325 | Intermittent | Periodically stopping and starting. (NCI) | Intermittent | ||
QD | C25473 | Daily;Per Day | Occurring or done each day. (NCI) | Daily | ||
OCCASIONAL | C64954 | Occasional | Not occurring regularly or at short intervals. | Infrequent | ||
AD LIBITUM | C64636 | Ad Libitum | As much as desired. | As Much as Desired | ||
1 TIME PER WEEK | C64526 | One Time Per Week | One time per week. (NCI) | Once Weekly | ||
2 TIMES PER YEAR | C98861 | 2 Times Per Year | Two times per year. (NCI) | Two Times Yearly | ||
3 TIMES PER MONTH | C98859 | 3 Times Per Month | Three times per month. (NCI) | Three Times Monthly | ||
3 TIMES PER YEAR | C98860 | 3 Times Per Year | Three times per year. (NCI) | Three Times Yearly | ||
4 TIMES PER MONTH | C98852 | 4 Times Per Month | Four times per month. (NCI) | Four Times Monthly | ||
4 TIMES PER YEAR | C98853 | 4 Times Per Year | Four times per year. (NCI) | Four Times Yearly | ||
5 TIMES PER DAY | C98849 | 5 Times Daily | Five times per day. (NCI) | Five Times Daily | ||
5 TIMES PER MONTH | C98850 | 5 Times Per Month | Five times per month. (NCI) | Five Times Monthly | ||
5 TIMES PER WEEK | C85552 | 5 Times Per Week | Five times per week. (NCI) | Five Times Weekly | ||
5 TIMES PER YEAR | C98851 | 5 Times Per Year | Five times per year. (NCI) | Five Times Yearly | ||
6 TIMES PER DAY | C98855 | 6 Times Daily | Six times per day. (NCI) | Six Times Daily | ||
6 TIMES PER MONTH | C98856 | 6 Times Per Month | Six times per month. (NCI) | Six Times Monthly | ||
6 TIMES PER WEEK | C98857 | 6 Times Per Week | Six times per week. (NCI) | Six Times Weekly | ||
6 TIMES PER YEAR | C98858 | 6 Times Per Year | Six times per year. (NCI) | Six Times Yearly | ||
7 TIMES PER WEEK | C98854 | 7 Times Per Week | Seven times per week. (NCI) | Seven Times Weekly | ||
PA | C74924 | Per Annum;Per Year;Every Year | A frequency rate of occurrences of something within a period of time equal to three hundred sixty-five days. | Per Year | ||
EVERY 6 WEEKS | C89788 | Every 6 Weeks;Q6S | Every six weeks. (NCI) | Every Six Weeks | ||
EVERY 5 WEEKS | C103390 | Every 5 weeks;Q5S | Every five weeks. (NCI) | Every Five Weeks | ||
EVERY 8 WEEKS | C103389 | Every 8 weeks;Q8S | Every eight weeks. (NCI) | Every Eight Weeks | ||
Q6M | C89789 | Every 6 Months | Every six months. (NCI) | Every Six Months | ||
Back to top | ||||||
CL.C71148.POSITION | Position (POSITION) | text Extensible: Yes | C71148 | Position | Terminology codelist used with Body Position within CDISC. | CDISC SDTM Body Position Terminology |
SITTING | C62122 | Sitting | The state or act of one who sits; the posture of one who occupies a seat. (NCI) | Sitting | ||
PRONE | C62165 | Prone | An anterior recumbent body position whereby the person lies on its stomach and faces downward. (NCI) | Prone Position | ||
STANDING | C62166 | Standing | The act of assuming or maintaining an erect upright position. (NCI) | Standing | ||
SUPINE | C62167 | Supine | A posterior recumbent body position whereby the person lies on its back and faces upward. (NCI) | Supine Position | ||
TRENDELENBURG | C62168 | Trendelenburg | A supine position with the person inclined at an angle of 45 degrees so that the pelvis is higher than the head. (NCI) | Trendelenburg | ||
REVERSE TRENDELENBURG | C62169 | Reverse Trendelenburg | A supine position with the person inclined at an angle of 45 degrees so that the head is higher than the pelvis. (NCI) | Reverse Trendelenburg | ||
RIGHT LATERAL DECUBITUS | C62171 | Right lateral decubitus | A recumbent right lateral side position. (NCI) | Right Lateral Decubitus Position | ||
LEFT LATERAL DECUBITUS | C62172 | Left lateral decubitus | A recumbent left lateral side position. (NCI) | Left Lateral Decubitus Position | ||
FOWLERS | C62173 | Fowlers | A semi-sitting position whereby the head of an adjustable bed is elevated to the desired height, about 60-90 cm, to produce angulation of the body, usually 45 degrees to 60 degrees. Knees may or may not be bent. (NCI) | Fowler's Position | ||
SEMI-FOWLERS | C62174 | Semi-Fowlers | A semi-sitting or semi-reclined body position whereby the head is elevated on an angle of approximately 30 degrees. (NCI) | Semi-Fowler's Position | ||
UNCONSTRAINED | C90480 | Unconstrained | The ability to move body parts and limbs without physical restriction. (NCI) | Unconstrained Body Movement | ||
SLING | C92604 | Sling | A position in which the subject's body is supported by a sling. | Patient in Body Sling | ||
LATERAL DECUBITUS | C100758 | Lateral Decubitus | Lying down on one side. | Lateral Decubitus Position | ||
Back to top | ||||||
CL.C71150.EGSTRESC | ECG Result (EGSTRESC) | text Extensible: Yes | C71150 | ECG Result | Terminology codelist used with ECG Findings and Abnormalities within CDISC. | CDISC SDTM ECG Finding Terminology |
SINUS TACHYCARDIA | C26889 | Sinus tachycardia | A heart rate of more than 100 beats per minute, with its origin in the sinus node. (NCI) | Sinus Tachycardia | ||
SINUS BRADYCARDIA | C26923 | Sinus bradycardia | A heart rate of less than 60 beats per minute, with its origin in the sinus node. (NCI) | Sinus Bradycardia | ||
VENTRICULAR ARRHYTHMIA ASSOCIATED WITH LONG QT SYNDROME | C34786 | Ventricular arrhythmia associated with long QT syndrome | Long QT Syndrome includes prolongation of the corrected QT interval beyond 440 ms for adult males, 460 ms for adult females and 50 ms in the presence of ventricular depolarization abnormalities (i.e., bundle branch blocks or IVCB more than 120 ms. A normal QT interval in a resting ECG with a failure to shorten with an increase in heart rate qualifies as Long QT Syndrome. | Long QT Syndrome | ||
PRE-EXCITATION | C34940 | Pre-excitation | A condition characterized by the activation of the whole or some part of the ventricle by the transmission of an atrial impulse along an accessory pathway rather than by way of the normal specific conduction system which includes a delay at the atrioventricular node. (NCI) | Pre-Excitation Syndrome | ||
AV NODE RE-ENTRY | C35058 | AV node re-entry | A supraventricular tachycardia due to reentry along a circuit contained within the AV node. AVNRT is the most common form of supraventricular tachycardia and usually presents as a narrow QRS complex tachycardia at a rate between 150 and 250 beats per minute. (NCI) | Atrioventricular Nodal Reentry Tachycardia | ||
JUNCTIONAL TACHYCARDIA | C35059 | Junctional tachycardia | An automatic tachycardia originating in the atrioventricular junction, typically arising in the conduction tissues surrounding the atrioventricular node. A junctional tachycardia tends to be a regular, narrow complex tachycardia and usually occurs during myocardial infarction, after heart surgery, or in digitalis intoxication. The rate may range from 140 to 250 beats per minute. (NCI) | Junctional Tachycardia | ||
SUPRAVENTRICULAR TACHYCARDIA | C35061 | Supraventricular tachycardia | A generic expression for any tachycardia that originates in the atria or the atrioventricular node. (NCI) | Supraventricular Tachycardia | ||
WOLFF-PARKINSON-WHITE SYNDROME | C35132 | Wolff-Parkinson-White syndrome | A type of ventricular pre-excitation resulting from the activation of an accessory pathway known as the Bundle of Kent. This pathway presents an abnormal electrical communication from the atria to the ventricles. Wolff-Parkinson-White syndrome is characterized by a short PR interval and a long QRS interval with a delta wave. (NCI) | Wolff-Parkinson-White Syndrome | ||
ATRIAL TACHYCARDIA | C35481 | Atrial tachycardia | Any rapid heart rhythm originating in the atria. Atrial fibrillation and atrial flutter are varieties of atrial tachycardia. Atrial tachycardia is an electrical circuit originating in the upper or atrial chambers. This electrical circuit or focus takes over and generates rapid impulses across the atrial chambers. These impulses are transmitted to the ventricular chambers resulting in a rapid rate. These arrhythmias may originate from a variety of places across the atria. They may exist as an isolated problem or be related to an ongoing structural problem within the heart. (NCI) | Atrial Tachycardia | ||
ATRIAL FIBRILLATION | C50466 | Atrial fibrillation | A supraventricular arrhythmia characterized by uncoordinated atrial myocardium activation due to multiple reentry circuits with consequent deterioration of atrial mechanical function. Instead of intermittently contracting, the atria quiver continuously in a chaotic pattern, causing a totally irregular, often tachycardia ventricular rate. On the ECG it is described by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in size, shape, and timing, associated with an irregular, frequently rapid ventricular response when atrioventricular conduction is intact. (NCI) | Atrial Fibrillation | ||
3RD DEGREE AV BLOCK | C50501 | 3rd degree AV block | Complete failure of atrial electrical impulse conduction through the AV node to the ventricles. (NCI) | AV Block Third Degree | ||
TORSADES DE POINTES | C50779 | Torsades de pointes | An atypical rapid polymorphic ventricular tachycardia with a characteristic rotation of the QRS complex around the isoelectric baseline. In addition the QRS complex displays a periodic waxing and waning of amplitude on the electrogram. (NCI) | Torsades De Pointes | ||
VENTRICULAR FIBRILLATION | C50799 | Ventricular fibrillation | Ventricular Fibrillation is characterized by rapid, usually more than 300 bpm (cycle length: 180 ms or less), grossly irregular ventricular rhythm with marked variability in QRS cycle length, morphology, and amplitude. | Ventricular Fibrillation | ||
VENTRICULAR FLUTTER | C50800 | Ventricular flutter | A ventricular tachyarrhythmia characterized by a high ventricular rate (180 and 250 beats per minute) with a regular rhythm. The electrocardiogram shows large oscillating sine wave-like complexes occurring as a result of QRS complexes and T waves being merged. The P wave is not visible. (NCI) | Ventricular Flutter | ||
VENTRICULAR TACHYCARDIA | C50802 | Ventricular tachycardia | A tachycardia arising distal to bundle of His, with a rate greater than 100 beats per minute. (NCI) | Ventricular Tachycardia | ||
ATRIAL FLUTTER | C51224 | Atrial flutter | An electrocardiographic finding of an organized rhythmic contraction of the atria which is generally at a rate of 200-300 beats per minute. (NCI) | Atrial Flutter | ||
R ON T PHENOMENON | C61395 | R on T phenomenon | An electrocardiographic finding phenomena in which the R wave occurs on top of the T wave; this can trigger ventricular fibrillation or ventricular tachycardia. (NCI) | R On T Phenomenon | ||
1ST DEGREE AV BLOCK | C62015 | 1st degree AV block | A delay in the time required for the conduction of an electrical impulse through the atrioventricular (AV) node beyond 0.2 seconds; prolongation of the PR interval beyond 200 milliseconds. (NCI) | AV Block First Degree | ||
2ND DEGREE AV BLOCK | C62016 | 2nd degree AV block | Intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles. (NCI) | AV Block Second Degree | ||
VENTRICULAR TACHYCARDIA, MONOMORPHIC | C62234 | Ventricular tachycardia, monomorphic | A ventricular tachycardia in which the ventricular activation sequence is constant. The morphology of the electrocardiographic waveform is unchanging and is referred to as monomorphic. (NCI) | Monomorphic Ventricular Tachycardia | ||
VENTRICULAR TACHYCARDIA, POLYMORPHIC | C62236 | Ventricular tachycardia, polymorphic | A ventricular tachycardia in which the ventricular activation sequence is variable. The morphology of the electrocardiographic waveform is variable and is referred to as polymorphic. (NCI) | Polymorphic Ventricular Tachycardia | ||
SINUS ARRHYTHMIA | C62239 | Sinus arrhythmia | Irregularity of the heartbeat due to a variation in the sinus rhythm resulting in cyclic changes in the heart rate during breathing. This rhythm is most commonly seen with breathing due to fluctuations in parasympathetic vagal tone. During inspiration stretch receptors in the lungs stimulate the cardioinhibitory centers in the medulla via fibers in the vagus nerve. Irregularity of the heartbeat due to a variation in the sinus rhythm resulting in cyclic changes in the heart rate during breathing. This rhythm is most commonly seen with breathing due to fluctuations in parasympathetic vagal tone. During inspiration stretch receptors in the lungs stimulate the cardioinhibitory centers in the medulla via fibers in the vagus nerve. (NCI) | Sinus Arrhythmia | ||
WANDERING ATRIAL PACEMAKER | C62240 | Wandering atrial pacemaker | A condition characterized by the site of origin of impulses, controlling the heart rate, changing within the atria, including the sinus node. Variations within P waves and PR intervals occur and an irregular rate of impulse formation is observed. (NCI) | Wandering Atrial Pacemaker | ||
SINUS ARREST/PAUSE | C62242 | Sinus arrest/pause | A failure of impulse formation in the sinus node. Sinus arrest is indistinguishable from third degree sinoatrial exit block on the standard ECG. (NCI) | Sinus Arrest | ||
SINUS NODE DYSFUNCTION (BRADYCARDIA) | C62243 | Sinus node dysfunction (bradycardia) | A derangement in the normal functioning of the sinoatrial node. Typically, SA node dysfunction is manifest as sinoatrial exit block or sinus arrest, but may present as an absolute or relative bradycardia in the presence of a stressor. It may be associated with bradycardia-tachycardia syndrome. (NCI) | Sinus Node Dysfunction | ||
SICK SINUS SYNDROME | C62244 | Sick sinus syndrome | A constellation of signs and symptoms which may include syncope, fatigue, dizziness, and alternating periods of bradycardia and atrial tachycardia, which is caused by sinoatrial node dysfunction. (NCI) | Sick Sinus Syndrome | ||
ECTOPIC ATRIAL RHYTHM | C62245 | Ectopic atrial rhythm | A cardiac rhythm resulting from either an abnormal electrical focus in the atria or intra-atrial reentry. Atrial ectopic beats (AEB) refer to a contraction of the upper heart chamber which occurs before it would be expected. Atrial ectopic beats are also known as premature atrial beats, premature atrial complex (PAC), or atrial extrasystole. (NCI) | Ectopic Atrial Rhythm | ||
SHORT PR INTERVAL | C62246 | Short PR interval | A PR interval of less than 0.12 seconds. (NCI) | Short PR Interval | ||
PR PROLONGATION | C62247 | PR prolongation | A PR interval of more than 0.20 seconds in adults. (NCI) | Prolonged PR Interval | ||
ISORHYTHMIC DISSOCIATION | C62248 | Isorhythmic dissociation | A type of atrioventricular dissociation characterized by atria and ventricles beating at similar rates, although independently. (NCI) | Isorhythmic Atrioventricular Dissociation | ||
PAROXYSMAL AV BLOCK | C62250 | Paroxysmal AV block | Sudden onset AV block, often associated with preexisting conduction disorders. (NCI) | Paroxysmal Atrioventricular Block | ||
INAPPROPRIATE SINUS TACHYCARDIA | C62253 | Inappropriate sinus tachycardia | Inappropriate sinus tachycardia (IST) is a rare form of supraventricular tachycardia involving the sinus node, in which a patient has an abnormally high heart rate, occurring both at rest and in response to stressors (such as physical activity). (NCI) | Inappropriate Sinus Tachycardia | ||
PREMATURE VENTRICULAR COMPLEX | C62256 | PVC | Ectopic impulses originating in the ventricles. (NCI) | Ventricular Premature Complex | ||
PREMATURE ATRIAL COMPLEXES | C62257 | Premature atrial complexes | Ectopic impulses originating in the atria. (NCI) | Atrial Premature Complex | ||
DELTA WAVE | C62258 | Delta wave | An initial slurring (delta wave) of the QRS complex due to the presence of an accessory pathway. This characteristic EKG pattern is typically seen in Wolff-Parkinson-White syndrome. (NCI) | EKG Delta Wave | ||
VENTRICULAR COUPLET | C62259 | Ventricular couplet | Two sequential ventricular premature complexes. An otherwise normal finding, but possibly indicative of electrical heart disease particularly in comparison with a single ventricular premature complexes. (NCI) | Ventricular Couplet | ||
AV RE-ENTRANT TACHYCARDIA | C62261 | AV re-entrant tachycardia | A supraventricular tachycardia due to reentry along a circuit including a concealed AV nodal bypass tract. This tachycardia circuit proceeds in an antegrade fashion through the AV node and then is conducted retrograde through the bypass tract into the atria. (NCI) | Atrioventricular Reentrant Tachycardia | ||
ACCELERATED IDIOVENTRICULAR RHYTHM | C62266 | Accelerated idioventricular rhythm | The term accelerated idioventricular rhythm describes an ectopic ventricular rhythm with 3 or more consecutive ventricular premature beats with a rate faster than the normal ventricular intrinsic escape rate of 30 to 40 beats per minute, but slower than ventricular tachycardia. Accelerated idioventricular rhythm differs from ventricular tachycardia by additional features such as the onset with a long coupling interval and the end by a gradual decrease of the ventricular rate or increase of the sinus rate. (NCI) | Accelerated Idioventricular Rhythm | ||
LEFT ANTERIOR FASCICULAR BLOCK | C62267 | Left anterior fascicular block | An impairment of transmission of the cardiac electrical impulse along the fibers of the left anterior fascicle. In left anterior fascicular block (LAFB) the posteroinferior regions of the left ventricular endocardium are activated abnormally before the anterosuperior left ventricular area. After emerging from the posteroinferior division of the left bundle branch, the impulse first propagates in an inferior, rightward, and usually anterior direction for a short period of time. This orientation is responsible for the small Q waves in leads 1 and aVL and for the R waves in leads II, III, and aVF. (NCI) | Left Anterior Fascicular Block | ||
LEFT POSTERIOR FASCICULAR BLOCK | C62268 | Left posterior fascicular block | An impairment of transmission of the cardiac electrical impulse along the fibers of the left posterior fascicle. In pure left posterior fascicular block (LPFB), the impulse emerges from the unblocked anterosuperior division, thus producing small q waves in leads II, III, and aVF. Thereafter, the impulse moves through the electrically predominant left ventricle in an inferior and rightward direction, thus explaining the S waves in leads I and aVL as well as the R waves in leads II, III, and aVF. (NCI) | Left Posterior Fascicular Block | ||
LEFT BUNDLE BRANCH BLOCK | C62269 | Left bundle branch block | An impairment of transmission of the cardiac electrical impulse along the fibers of the left main bundle branch, or both the left anterior fascicle and left posterior fascicle. This conduction disturbance is characterized by wide (greater than 0.11s) QRS complexes. The diagnostic criteria consist of prolongation of the QRS complexes (over 0.11s) with neither a Q wave nor an S wave in lead V1 and in the properly placed V6. A wide R wave with a notch on its top (plateau) is seen in these leads. In hearts with an electrical (and anatomic) vertical position a small Q wave may be seen in AVL in the absence of MI. Right chest lead V1 may or may not show an initial R wave, but the latter should be present in lead V2. (NCI) | Left Bundle Branch Block | ||
RIGHT BUNDLE BRANCH BLOCK | C62270 | Right Bundle Branch Block | An impairment of transmission of the cardiac electrical impulse along the fibers of the right bundle branch. A "complete RBBB pattern" (with QRS duration > 0.11s) does not necessarily reflect the existence of a total conduction block in the right branch. This pattern only indicates that the entire or major parts of both ventricles are activated by the impulse emerging from the left branch. Thus, a significant degree of conduction delay ("high-grade" or "incomplete RBBB") can produce a similar pattern. (NCI) | Right Bundle Branch Block | ||
INTRAVENTRICULAR CONDUCTION DELAY, NONSPECIFIC | C62271 | Intraventricular conduction delay, nonspecific | A delay in transmission of cardiac electrical impulses in the His-Purkinje system, diagnosed when the QRS is modestly prolonged (< 120 msec) and the QRS pattern and axis are not typical of a hemiblock. The conduction delay is considered to occur beyond the Purkinje's myocardial gates and arises from slow cell-to-cell conduction. The phenomenon is common in patients with acute MI. (NCI) | Nonspecific Intraventricular Conduction Delay | ||
ST SEGMENT ABNORMALITY | C71026 | ST segment abnormality | An electrocardiographic finding of the ST segment elevation or depression which is not indicative of ischemia or infarction. (NCI) | ST Segment Abnormality | ||
ST DEPRESSION | C71027 | ST depression | An electrocardiographic finding of ST segment depression below the baseline, often described as up sloping, down sloping or horizontal. (NCI) | ST Depression | ||
ST ELEVATION | C50540 | ST elevation | An electrocardiographic finding of ST segment elevation above the baseline. (NCI) | ST Elevation | ||
ST ELEVATION PERICARDITIS | C71029 | ST elevation pericarditis | An electrocardiographic finding of ST changes consistent with pericarditis. (NCI) | ST Elevation Pericarditis | ||
J POINT ELEVATION | C71030 | J point elevation | Elevation of the J point above the baseline; the J point represents the end of ventricular depolarization and located at the terminus of the QRS complex. (NCI) | J Point Elevation | ||
NON-SPECIFIC ST-T CHANGES | C71031 | Non-specific ST-T changes | An electrocardiographic finding of changes in the ST segment and T wave that do not meet criteria for ischemia or infarction. (NCI) | Non-Specific ST-T Changes | ||
NOTCHED T-WAVES | C71032 | Notched T-waves | Any depression occurring in a positive t wave. (NCI) | Notched T-Waves | ||
POOR R WAVE PROGRESSION | C71033 | Poor R Wave Progression | Lack of progression of R wave height across precordial leads. (NCI) | Poor R Wave Progression | ||
PROLONGED QT | C71034 | Prolonged QT | A QT interval that is prolonged. The length of the QT interval varies with the heart rate. (NCI) | Prolonged QT Interval | ||
ELECTRICAL ALTERNANS | C71035 | Electrical alternans | An electrocardiographic finding in which there is an alternating pattern of any of the waveform components. (NCI) | Electrical Alternans | ||
SINOATRIAL EXIT BLOCK | C50553 | Sinoatrial exit block | A blockage of electrical conduction within the sinoatrial node resulting in the failure of impulse transmission from the sinoatrial node. (NCI) | Sinoatrial Node Exit Block | ||
ATRIAL ENLARGEMENT | C71039 | Atrial Enlargement | An electrocardiographic finding which comprises left, right or bilateral atrial enlargement. (NCI) | EKG Finding Atrial Enlargement | ||
LEFT ATRIAL ENLARGEMENT | C71040 | P-mitrale | An electrocardiographic finding suggesting underlying hypertrophy or dilatation of the left atrium. Electrocardiographic criteria used for the diagnosis of left atrial abnormality may include a bifid p wave, a biphasic p wave and/or a p wave duration of greater than 0.12 seconds. (NCI) | P-mitrale | ||
RIGHT ATRIAL ABNORMALITY | C71041 | P-pulmonale | An electrocardiographic finding suggesting underlying hypertrophy or dilatation of the right atrium. Electrocardiographic criteria used for the diagnosis of right atrial abnormality may include a peaked p wave greater than 2.5 millimeters in amplitude in the inferior leads. (NCI) | P-pulmonale | ||
ECTOPIC VENTRICULAR RHYTHM | C71042 | Ectopic ventricular rhythm | A cardiac rhythm resulting from either an abnormal electrical focus in the ventricle. Ventricular ectopic beats (VEB) refer to a contraction of the lower heart chamber which occurs before it would be expected. Ventricular ectopic beats are also known as premature ventricular beats, premature ventricular complex (PVC), or ventricular extrasystole. (NCI) | Ectopic Ventricular Rhythm | ||
ECTOPIC SUPRAVENTRICULAR RHYTHM | C71043 | Ectopic supraventricular rhythm | An electrocardiographic finding of a rhythm originating at a site other than the sinoatrial node, which is also above the atrioventricular node. (NCI) | Ectopic Supraventricular Rhythm | ||
2:1 AV BLOCK | C71044 | 2:1 AV block | A electrocardiographic finding of an electrical phenomenon in which the ratio of electrical impulse generated above the atrioventricular node to the number of impulses conducted through to the ventricles is 2:1. (NCI) | 2:1 Atrioventricular Block | ||
ATRIOVENTRICULAR DISSOCIATION | C71045 | Atrioventricular dissociation | An electrocardiographic finding in which the electrical activity of the atria and ventricles are causally independent of one another. (NCI) | Atrioventricular Dissociation | ||
BIFASCICULAR BLOCK | C71046 | Bifascicular block | An electrocardiographic finding comprising right bundle branch block and left anterior fascicular block, or right bundle branch block and left posterior fascicular block. Defects occurring in two of the three divisions of the conduction system of the heart are considered bifascicular blocks. Technically left bundle branch block may be considered a bifascicular block. (NCI) | Bifascicular Block | ||
INCOMPLETE LEFT BUNDLE BRANCH BLOCK | C71047 | Incomplete left bundle branch block | An partial impairment of transmission of the cardiac electrical impulse along the fibers of the left bundle branch. (NCI) | Incomplete Left Bundle Branch Block | ||
INCOMPLETE RIGHT BUNDLE BRANCH BLOCK | C71048 | Incomplete right bundle branch block | Various mechanisms may result in a pattern showing an incomplete right bundle branch block (RBBB). These include different degrees of conduction delay through the main trunk of the right bundle branch; increased conduction time through an elongated right bundle branch; diffuse Purkinje-myocardial delay due to right ventricular stretch or dilatation; surgical trauma or disease-related interruption of the major ramifications of the right branch (distal RBBB or right fascicular blocks); congenital variations of the distribution of the major ramifications resulting in a slight delay in the activation of the crista supraventricularis. (NCI) | Incomplete Right Bundle Branch Block | ||
INCOMPLETE BUNDLE BRANCH BLOCK | C71049 | Incomplete bundle branch block | An electrocardiographic finding of bundle branch block which does not meet the criteria for a more specific bundle branch block. (NCI) | Incomplete Bundle Branch Block | ||
MULTIFOCAL ATRIAL TACHYCARDIA | C71050 | Multifocal atrial tachycardia | An electrocardiographic finding in which the electrical axis of the p wave is variable and the rate is greater than 100 beats per minute. To meet criteria for multifocal atrial tachycardia, the p wave must exhibit three distinct morphologies on the rhythm strip. (NCI) | Multifocal Atrial Tachycardia | ||
JUNCTIONAL RHYTHM | C71051 | Junctional rhythm | An electrocardiographic finding in which the pacer of the heart is located in the AV junction, normally presenting with a narrow QRS complex and a rate of 60-100 beats per minute. (NCI) | Junctional Rhythm | ||
SUSTAINED VENTRICULAR TACHYCARDIA | C71052 | Sustained ventricular tachycardia | An electrocardiographic finding of ventricular tachycardia greater than 30 seconds in duration. (NCI) | Sustained Ventricular Tachycardia | ||
NON-SUSTAINED VENTRICULAR TACHYCARDIA | C71053 | Non-sustained ventricular tachycardia | An electrocardiographic finding of ventricular tachycardia less than 30 seconds in duration. (NCI) | Non-Sustained Ventricular Tachycardia | ||
BIGEMINY | C71054 | Bigeminy | An electrocardiographic finding of a normal QRS followed by a premature ventricular contraction; a rhythmic pairing of normal and abnormal beats originating in the ventricles in a 1-1 ratio. (NCI) | Bigeminy | ||
TRIGEMINY | C71055 | Trigeminy | An electrocardiographic finding of normal QRS followed by a premature ventricular contraction; a rhythmic pairing of normal and abnormal beats originating from the ventricles in a 1-2 ratio. (NCI) | Trigeminy | ||
VENTRICULAR TACHYCARDIA STORM | C71056 | Ventricular tachycardia storm | Multiple, temporally related, episodes of ventricular tachycardia or fibrillation, occurring three or more times in a 24 hour period. (NCI) | Ventricular Tachycardia Storm | ||
ADENOSINE-SENSITIVE VENTRICULAR TACHYCARDIA | C71057 | Adenosine-sensitive ventricular tachycardia | A condition that occurs as a result of cAMP-mediated triggered activity and typically originates from the right ventricular outflow tract (RVOT). This type of tachycardia occurs in patients with apparently normal hearts. (NCI) | Adenosine-Sensitive Ventricular Tachycardia | ||
VERAPAMIL-SENSITIVE VENTRICULAR TACHYCARDIA | C71058 | Verapamil-sensitive ventricular tachycardia | A well-recognized condition that is believed to result from triggered activity. Despite its uniform response to verapamil, however, this uncommon form of ventricular tachycardia may not be as homogeneous a condition as first believed. (NCI) | Verapamil-Sensitive Ventricular Tachycardia | ||
VENTRICULAR ARRHYTHMIA ASSOCIATED WITH BRUGADA SYNDROME | C71059 | Ventricular arrhythmia associated with Brugada syndrome | Polymorphic ventricular tachycardia in the absence of structural heart disease, associated with a baseline ECG pattern during sinus rhythm showing right bundle branch block with ST segment elevation in leads V1 through V3. It can also be characterized by documentation of ECG patterns associated with Brugada Syndrome, some of which may be unmasked when provoked with drugs. The most common genetic mutations identified for Brugada syndrome are in the sodium channel gene SCN5A. | Brugada Syndrome | ||
VENTRICULAR ARRHYTHMIA ASSOCIATED WITH SHORT QT SYNDROME | C71060 | Ventricular arrhythmia associated with short QT syndrome | Short QT Syndrome is characterized by a QT interval of less than or equal to 300 ms. | Short QT Syndrome | ||
FASCICULAR TACHYCARDIA | C71061 | Fascicular tachycardia | A distinct subgroup of idiopathic ventricular tachycardia (VT) that may be confused with either typical VT or supraventricular tachycardia (SVT). It is characterized by the absence of structural heart disease and classic electrocardiographic and electrophysiological features. It originates from the region of the posterior fascicle (or occasionally the anterior fascicle) of the left bundle branch and is partly propagated by the His-Purkinje network. It therefore produces QRS complexes of relatively short duration (0.11-0.14)s. (NCI) | Fascicular Tachycardia | ||
BUNDLE BRANCH REENTRANT TACHYCARDIA | C71062 | Bundle branch reentrant tachycardia | An uncommon form of ventricular tachycardia (VT) incorporating both bundle branches into the reentry circuit. Surface electrocardiogram (ECG) of sinus rhythm (SR) characteristically shows intraventricular conduction defects. Patients typically present with presyncope, syncope or sudden death because of VT with fast rates frequently above 200 beats per minute. The QRS morphology during VT is a typical bundle branch block pattern, usually left bundle branch block, and may be identical to that in SR. (NCI) | Bundle Branch Re-Entrant Ventricular Tachycardia | ||
IDIOPATHIC RIGHT BUNDLE BRANCH BLOCK VENTRICULAR TACHYCARDIA | C71063 | Idiopathic right bundle branch block ventricular tachycardia | Idiopathic ventricular tachycardia (VT) is a type of ventricular tachycardia occurring unrelated to any organic cardiac disease. The abnormality is probably congenital, be it a focus of abnormal automaticity or myocardial tissue that can sustain re-entry. The clinical presentation for idiopathic VT can be very much like a paroxysmal supraventricular tachycardia. That is, most patients are generally younger without overt cardiac disease and present with paroxysmal palpitations. Idiopathic ventricular tachycardia is not generally life-threatening. (NCI) | Idiopathic Right Bundle Branch Block | ||
OUTFLOW TRACT VENTRICULAR TACHYCARDIA | C71064 | Outflow tract ventricular tachycardia | Right ventricular outflow tract tachycardia (RVOT) is the most common with a female predominance. It is often exercise induced or enhanced. The site of origin is the right ventricular outflow tract and hence the electrocardiographic appearance is that of left bundle branch block and inferior axis. The mechanism is thought to be abnormal automaticity that is sensitive to adenosine. (NCI) | Right Ventricular Outflow Tract Tachycardia | ||
ACUTE ANTERIOR WALL MI | C71065 | Acute Anterior Wall Myocardial Infarction | Electrocardiographic finding showing a current of injury in leads corresponding to the anatomic region of the anterior wall of the heart. (NCI) | Acute Anterior Wall Myocardial Infarction | ||
ACUTE INFERIOR WALL MI | C71066 | Acute Inferior Wall Myocardial Infarction | Electrocardiographic finding showing a current of injury in leads corresponding to the anatomic region of the inferior wall of the heart. (NCI) | Acute Inferior Wall Myocardial Infarction | ||
ACUTE LATERAL WALL MI | C71067 | Acute Lateral Wall Myocardial Infarction | Electrocardiographic finding showing a current of injury in leads corresponding to the anatomic region of the lateral wall of the heart. (NCI) | Acute Lateral Wall Myocardial Infarction | ||
ACUTE POSTERIOR WALL MI | C71068 | Acute Posterior Wall Myocardial Infarction | Electrocardiographic finding showing a current of injury in leads corresponding to the anatomic region of the posterior wall of the heart. (NCI) | Acute Posterior Wall Myocardial Infarction | ||
ANTERIOR WALL MYOCARDIAL INFARCTION | C71069 | Anterior Wall Myocardial Infarction | Electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the anterior wall of the heart. (NCI) | Anterior Wall Myocardial Infarction | ||
INFERIOR WALL MYOCARDIAL INFARCTION | C35398 | Inferior Wall Myocardial Infarction | Electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the inferior wall of the heart. (NCI) | Inferior Wall Myocardial Infarction | ||
INTRAATRIAL CONDUCTION DELAY | C71073 | Intraatrial Conduction Delay | A delay in impulse propagation through the atria. (NCI) | Intra-Atrial Conduction Delay | ||
JUNCTIONAL BRADYCARDIA | C71074 | Junctional bradycardia | An electrocardiographic finding in which the pacer of the heart is located in the AV junction, normally presenting with a narrow QRS complex at a rate less than 60 beats per minute. (NCI) | Junctional Bradycardia | ||
LATERAL WALL MYOCARDIAL INFARCTION | C35586 | Lateral Wall Myocardial Infarction | Electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the lateral wall of the heart. (NCI) | Lateral Wall Myocardial Infarction | ||
LEFT VENTRICULAR HYPERTROPHY | C71076 | Left Ventricular Hypertrophy | Electrocardiographic findings suggestive of a hypertrophic left ventricle. (NCI) | EKG Finding Left Ventricular Hypertrophy | ||
RIGHT VENTRICULAR HYPERTROPHY | C71077 | Right ventricular Hypertrophy | Electrocardiographic findings suggestive of an enlarged right ventricle. (NCI) | EKG Finding Right Ventricular Hypertrophy | ||
LOW QRS VOLTAGE | C71078 | Low QRS voltage | An electrocardiographic finding of a QRS amplitude less than or equal to 5mm in the limb leads or QRS amplitude less than or equal to 10mm in the precordial leads. (NCI) | Low QRS Voltage | ||
NON Q WAVE MYOCARDIAL INFARCTION | C71080 | Non Q Wave Myocardial Infarction | A myocardial infarction in the absence of observable Q wave abnormalities in the ECG. (NCI) | Non Q Wave Myocardial Infarction | ||
POSTERIOR WALL MYOCARDIAL INFARCTION | C71081 | Posterior Wall Myocardial Infarction | Electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the posterior wall of the heart. (NCI) | Posterior Wall Myocardial Infarction | ||
SEPTAL MYOCARDIAL INFARCTION | C71082 | Septal myocardial infarction | Electrocardiographic findings suggesting an infarction in the anatomic location of the cardiac septum. (NCI) | Septal Myocardial Infarction | ||
T WAVE ABNORMALITY | C71083 | T wave abnormality | An electrocardiographic finding of a T wave which appears peaked, inverted, flattened or biphasic. (NCI) | T Wave Abnormality | ||
VENTRICULAR HYPERTROPHY | C71084 | Ventricular Hypertrophy | Electrocardiographic findings suggestive of enlarged cardiac ventricles. (NCI) | Ventricular Hypertrophy | ||
T WAVE INVERSION | C71085 | T Wave Inversion | An electrocardiographic finding of an inversion of the T wave from the expected axis. (NCI) | T Wave Inversion | ||
T WAVE PEAKED | C71086 | T wave peaked | An electrocardiographic finding in which the T wave appears increased in amplitude and cresting at a point. (NCI) | T Wave Peaked | ||
T WAVES BIPHASIC | C71087 | T waves biphasic | An electrocardiographic finding in which the T wave is asymmetric. (NCI) | T Waves Biphasic | ||
T WAVES FLAT | C71088 | T waves flat | An electrocardiographic finding in which the T wave appears decreased in amplitude. (NCI) | T Waves Flat | ||
U WAVES | C71089 | U waves | An electrocardiographic finding of a small hump following the T wave occurring during the final phase of Purkinje repolarization. (NCI) | U Waves | ||
WIDE QRS TACHYCARDIA | C71090 | Wide QRS tachycardia | An electrocardiographic finding of a QRS complex. (NCI) | Wide QRS Tachycardia | ||
Q AXIS, LEFT AXIS DEVIATION | C71094 | Q Axis, Left axis deviation | Q axis from -30 to -90 degrees. (NCI) | Q Axis Left Axis Deviation | ||
Q AXIS, RIGHT AXIS DEVIATION | C71095 | Q Axis, Right axis deviation | Q axis from +90 to +180 degrees. (NCI) | Q Axis Right Axis Deviation | ||
QTCB PROLONGATION >500 MSEC | C71096 | QTcB prolongation >500 msec | Corrected QT interval longer than 500 msec, in accordance with Bazett's correction formula. (NCI) | QTcB Prolongation Greater Than 500 msec | ||
QTCF PROLONGATION >500 MSEC | C71097 | QTcF prolongation >500 msec | Corrected QT interval greater than 500 msec, in accordance with Fridericia's correction formula. (NCI) | QTcF Prolongation Greater Than 500 msec | ||
AV MOBITZ I | C62017 | AV Mobitz I | Intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles, characterized by a progressively lengthening PR interval prior to the block of an atrial impulse. | AV Mobitz I | ||
AV MOBITZ II | C62018 | AV Mobitz II | Intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles, characterized by a relatively constant PR interval prior to the block of an atrial impulse. | AV Mobitz II | ||
PACED RHYTHM | C88140 | Paced Rhythm;Atrial and/or Ventricular Paced Rhythm | An electrocardiographic finding in which the cardiac rhythm is controlled by an electrical impulse from a mechanical cardiac pacemaker. | Paced Rhythm | ||
BORDERLINE QTcB | C92228 | Borderline QTcB | An electrocardiographic finding in which the QTcB is approximately 430-470 msec. There is variation among subpopulations. | Borderline QTcB | ||
BORDERLINE QTcF | C92229 | Borderline QTcF | An electrocardiographic finding in which the QTcF is approximately 430-470 msec. There is variation among subpopulations. | Borderline QTcF | ||
EARLY R WAVE PROGRESSION | C92230 | Early R Wave Progression | An electrocardiographic finding in which the amplitude of the R wave is abnormally increased in the anterior precordial leads. | Early R Wave Progression | ||
LEFT VENTRICULAR CONDUCTION DELAY | C92231 | Left Ventricular Conduction Delay | An electrocardiographic finding in which there is evidence that electrical transmission through the left ventricle is impaired. | Left Ventricular Conduction Delay | ||
PACED ATRIAL AND VENTRICULAR RHYTHM | C92232 | Paced Atrial And Ventricular Rhythm | An electrocardiographic finding in which both the atrial and ventricular rhythm is controlled by an electrical impulse from a mechanical cardiac pacemaker. | Paced Atrial And Ventricular Rhythm | ||
PACED ATRIAL RHYTHM | C92233 | Paced Atrial Rhythm | An electrocardiographic finding in which the atrial rhythm is controlled by an electrical impulse from a mechanical cardiac pacemaker. | Paced Atrial Rhythm | ||
PACED VENTRICULAR RHYTHM | C92234 | Paced Ventricular Rhythm | An electrocardiographic finding in which the ventricular rhythm is controlled by an electrical impulse from a mechanical cardiac pacemaker. | Paced Ventricular Rhythm | ||
RIGHT VENTRICULAR CONDUCTION DELAY | C92235 | Right Ventricular Conduction Delay;Right Ventricular Delay | An electrocardiographic finding in which there is evidence that electrical transmission through the right ventricle is impaired. | Right Ventricular Conduction Delay | ||
RSR PRIME | C92227 | RSR' | An electrocardiographic finding in which there are two R waves, which are two deflections above the baseline resulting from a single ventricular depolarization. The first upward deflection in the complex is the R wave. The S is the first downward deflection. A second upward deflection is called the R-prime wave. | RSR' | ||
BRADYCARDIA | C37920 | Bradycardia | Non-sinus origin slow heart rate. | Bradycardia | ||
P WAVE ABNORMALITY | C90430 | P Wave Abnormality | An electrocardiographic finding for the P wave that is atypical either for the shape, duration, amplitude, axis or polarity. Abnormality of the P wave signifies aberrant propagation of the electrical impulse through the atria. (NCI) | P Wave Abnormality | ||
P WAVE NOTCHED | C90431 | P Wave Notched | P waves with two peaks longer in duration than normal and amplitude greater than normal. (NCI) | P Wave Notched | ||
PAROXYSMAL VENTRICULAR TACHYCARDIA | C34902 | Paroxysmal Ventricular Tachycardia | An episodic form of ventricular tachycardia, with abrupt onset and termination. (NCI) | Paroxysmal Ventricular Tachycardia | ||
QRS COMPLEX ABNORMALITY | C90440 | QRS Complex Abnormality | An electrocardiographic finding for the QRS complex that is atypical either for the shape, duration, amplitude, axis or polarity. (NCI) | QRS Complex Abnormality | ||
QRS COMPLEX ABSENT | C90441 | QRS Complex Absent | A disturbance in the depolarization of the ventricular myocardium which leads to an absence of the QRS complex in the electrocardiogram tracing. (NCI) | QRS Complex Absent | ||
R WAVE ABNORMALITY | C90443 | R Wave Abnormality | An abnormal R wave that is part of the QRS complex in an electrocardiographic recording, which occurs due to a disturbance in the depolarization mechanism of the ventricular myocardium. (NCI) | R Wave Abnormality | ||
R WAVE NOTCHED | C90444 | R Wave Notched | An R wave variant in which there is a small deflection of the R wave, with changing polarity, within the QRS complex. (NCI) | R Wave Notched | ||
RESPIRATORY SINUS ARRHYTHMIA | C90450 | Respiratory Sinus Arrhythmia | The inherent change of a subject's heart rate associated with each excursion of breath, which can be traced in an electrocardiographic recording. (NCI) | Respiratory Sinus Arrhythmia | ||
S WAVE ABNORMALITY | C90451 | S Wave Abnormality | An abnormal S wave that is part of the QRS complex in an electrocardiographic recording, which occurs due to a disturbance in the depolarization of the ventricular myocardium. (NCI) | S Wave Abnormality | ||
TACHYCARDIA | C38029 | Tachycardia | An abnormally rapid heartbeat, usually applied to a heart rate above 100 per minute. | Tachycardia | ||
VENTRICULAR ESCAPE BEAT | C90483 | Ventricular Escape Beat | A compensatory ectopic beat that occurs in the ventricle after a pause in the ventricular rhythm, which is due to an absence in electrical activity to the ventricles. (NCI) | Ventricular Escape Beat | ||
ACUTE ANTEROLATERAL WALL MYOCARDIAL INFARCTION | C102591 | Acute Anterolateral Wall Myocardial Infarction | An electrocardiographic finding showing a current of injury in leads corresponding to the anatomic region of the anterolateral wall of the heart. | Acute Anterolateral Myocardial Infarction by ECG Finding | ||
ACUTE ANTEROSEPTAL WALL MYOCARDIAL INFARCTION | C102592 | Acute Anteroseptal Wall Myocardial Infarction | An electrocardiographic finding showing a current of injury in leads corresponding to the anatomic region of the anteroseptal wall of the heart. | Acute Anteroseptal Myocardial Infarction by ECG Finding | ||
ACUTE HIGH LATERAL WALL MYOCARDIAL INFARCTION | C102593 | Acute High Lateral Wall Myocardial Infarction | An electrocardiographic finding showing a current of injury in leads corresponding to the anatomic region of the high lateral wall of the heart. | Acute High Lateral Myocardial Infarction by ECG Finding | ||
ACUTE MYOCARDIAL INFARCTION | C101596 | Acute Myocardial Infarction | An electrocardiographic finding showing a current of injury without specifying the anatomic region of the heart. | Acute Myocardial Infarction by EKG Finding | ||
ACUTE RIGHT VENTRICULAR WALL MYOCARDIAL INFARCTION | C102594 | Acute Right Ventricular Wall Myocardial Infarction | An electrocardiographic finding showing a current of injury in leads corresponding to the anatomic region of the right ventricular wall of the heart. | Acute Right Ventricular Myocardial Infarction by ECG Finding | ||
ACUTE SEPTAL WALL MYOCARDIAL INFARCTION | C102595 | Acute Septal Wall Myocardial Infarction | An electrocardiographic finding showing a current of injury in leads corresponding to the anatomic region of the septal wall of the heart. | Acute Septal Myocardial Infarction by ECG Finding | ||
ADVANCED/HIGH GRADE AV BLOCK | C102642 | Advanced/High Grade AV Block | An electrocardiographic finding of intermittent failure of atrial electrical impulse conduction through the atrioventricular (AV) node to the ventricles, characterized by two or more consecutive non-conducted P waves. | High Grade Atrioventricular Block | ||
ANTEROLATERAL WALL MYOCARDIAL INFARCTION | C35303 | Anterolateral Wall Myocardial Infarction | An electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the anterolateral wall of the heart. | Anterolateral Myocardial Infarction | ||
ANTEROSEPTAL WALL MYOCARDIAL INFARCTION | C35304 | Anteroseptal Wall Myocardial Infarction | An electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the anteroseptal wall of the heart. | Anteroseptal Myocardial Infarction | ||
ATRIAL BIGEMINY | C102596 | Atrial Bigeminy | An electrocardiographic finding of a sinus beat followed by a premature atrial contraction for three or more consecutive cycles; a regularly irregular rhythm of normal and abnormal P waves in a 1-1 ratio. | Atrial Bigeminy | ||
ATRIAL COUPLETS | C102597 | Atrial Couplets | An electrocardiographic finding in which two premature atrial contractions occur in a row. | Atrial Couplet | ||
ATRIAL TRIGEMINY | C102598 | Atrial Trigeminy | An electrocardiographic finding of two sinus beats followed by a premature atrial contraction for 3 or more consecutive cycles; a regularly irregular rhythm of normal and abnormal P waves in a 2-1 ratio. | Atrial Trigeminy | ||
DEXTROCARDIA | C102623 | Dextrocardia | An electrocardiographic finding suggestive of dextrocardia with situs inversus, characterized by reversal of normal anterior R wave progression and the appearance of reversal of the right and left arm electrodes. | Dextrocardia by ECG Finding | ||
EARLY R WAVE TRANSITION | C102628 | Early R Wave Transition | An electrocardiographic finding where the amplitude of the R wave becomes greater than the amplitude of the S wave in the QRS complex at an unusually early point in the precordial leads, usually in leads V1 or V2. | Early R Wave Transition | ||
EARLY REPOLARIZATION | C102629 | Early Repolarization | An electrocardiographic finding of J point and ST segment elevation in the absence of other signs of acute ischemia that is often a normal variant. | Early Repolarization | ||
FUSION COMPLEX | C102639 | Fusion Complex | An electrocardiographic finding that occurs when electrical activation of the atria or ventricles occurs from two separate sites. This results in a P wave or QRS complex that displays merged characteristics of beats originating from the two different sites. | Fusion Complex | ||
HIGH LATERAL WALL MYOCARDIAL INFARCTION | C102643 | High Lateral Wall Myocardial Infarction | An electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the high lateral wall of the heart. | High Lateral Myocardial Infarction by ECG Finding | ||
IDIOVENTRICULAR RHYTHM | C50599 | Idioventricular Rhythm | An electrocardiographic finding of an ectopic ventricular rhythm with three or more consecutive ventricular premature beats with a rate less than 100 beats per minute. | Idioventricular Rhythm | ||
INDETERMINATE QRS AXIS | C102701 | QRS Axis Indeterminate;Indeterminate Axis;Indeterminate QRS Axis | An electrocardiographic finding in which the frontal plane QRS axis cannot be calculated. | QRS Axis Indeterminate | ||
JUNCTIONAL PREMATURE COMPLEX | C102652 | Junctional Premature Complex | An ectopic impulse originating in the AV junction presenting as a QRS complex of supraventricular origin which is not preceded by a P wave. | Junctional Premature Complex | ||
LATE R WAVE TRANSITION | C102653 | Late R Wave Transition | An electrocardiographic finding where the amplitude of the R wave does not become greater than the amplitude of the S wave until an unusually late point in the precordial leads, usually in leads V4 or V5. | Late R Wave Transition | ||
LEFT VENTRICULAR HYPERTROPHY WITH STRAIN | C102655 | Left Ventricular Hypertrophy With Strain | An electrocardiographic finding suggestive of a hypertrophied left ventricle, characterized by large QRS amplitudes, ST depression and T wave inversion. | Left Ventricular Hypertrophy with Strain by ECG Finding | ||
MYOCARDIAL INFARCTION | C101589 | Myocardial Infarction | An electrocardiographic finding showing an injury without specifying the anatomic region of the heart. | Myocardial Infarction by Electrocardiographic Finding | ||
MYOCARDIAL ISCHEMIA | C102675 | Myocardial Ischemia | An electrocardiographic finding of ST and T wave changes consistent with impaired myocardial perfusion. | Myocardial Ischemia by ECG Finding | ||
NEW ANTERIOR WALL MYOCARDIAL INFARCTION | C102732 | New Anterior Wall Myocardial Infarction | A new electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the anterior wall of the heart. | New Anterior Myocardial Infarction by ECG Finding | ||
NEW ANTEROLATERAL WALL MYOCARDIAL INFARCTION | C102733 | New Anterolateral Wall Myocardial Infarction | A new electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the anterolateral wall of the heart. | New Anterolateral Myocardial Infarction by ECG Finding | ||
NEW ANTEROSEPTAL WALL MYOCARDIAL INFARCTION | C102734 | New Anteroseptal Wall Myocardial Infarction | A new electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the anteroseptal wall of the heart. | New Anteroseptal Myocardial Infarction by ECG Finding | ||
NEW EXTENSIVE ANTERIOR WALL MYOCARDIAL INFARCTION | C102735 | New Extensive Anterior Wall Myocardial Infarction | A new electrocardiographic finding showing extensive injury in leads corresponding to the anatomic region of the anterior wall of the heart. | New Extensive Anterior Myocardial Infarction by ECG Finding | ||
NEW HIGH LATERAL WALL MYOCARDIAL INFARCTION | C102736 | New High Lateral Wall Myocardial Infarction | A new electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the high lateral wall of the heart. | New High Lateral Myocardial Infarction by ECG Finding | ||
NEW INFERIOR WALL MYOCARDIAL INFARCTION | C102737 | New Inferior Wall Myocardial Infarction | A new electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the inferior wall of the heart. | New Inferior Myocardial Infarction by ECG Finding | ||
NEW LATERAL WALL MYOCARDIAL INFARCTION | C102738 | New Lateral Wall Myocardial Infarction | A new electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the lateral wall of the heart. | New Lateral Myocardial Infarction by ECG Finding | ||
NEW MYOCARDIAL INFARCTION | C102731 | New Myocardial Infarction | A new electrocardiographic finding showing an injury in leads without specifying the anatomic region of the heart. | New Myocardial Infarction by ECG Finding | ||
NEW SEPTAL WALL MYOCARDIAL INFARCTION | C102739 | New Septal Wall Myocardial Infarction | A new electrocardiographic finding showing an injury in leads corresponding to the anatomic region of the septal wall of the heart. | New Septal Myocardial Infarction by ECG Finding | ||
NON-SUSTAINED ATRIAL TACHYCARDIA | C102680 | Non-Sustained Atrial Tachycardia | An electrocardiographic finding of an atrial rate greater than 100 beats per minute, P wave morphology which is not consistent with sinus rhythm, and which terminates in less than 30 seconds. | Non-sustained Atrial Tachycardia | ||
NORMAL SINUS RHYTHM | C102681 | Normal Sinus Rhythm | An electrocardiographic finding of an atrial rhythm which originates from the sinoatrial node that is considered normal for the population. | Normal Sinus Rhythm | ||
NORTHWEST AXIS | C102634 | Northwest Axis | Q axis from -90 to +180 degrees. | Extreme Right Axis Deviation | ||
OLD OR AGE INDETERMINATE ANTERIOR WALL MYOCARDIAL INFARCTION | C102684 | Old Or Age Indeterminate Anterior Wall Myocardial Infarction | An electrocardiographic finding showing an injury of indeterminate age in leads corresponding to the anatomic region of the anterior wall of the heart. | Old or Age Indeterminate Anterior Myocardial Infarction by ECG Finding | ||
OLD OR AGE INDETERMINATE ANTEROLATERAL WALL MYOCARDIAL INFARCTION | C102685 | Old Or Age Indeterminate Anterolateral Wall Myocardial Infarction | An electrocardiographic finding showing an injury of indeterminate age in leads corresponding to the anatomic region of the anterolateral wall of the heart. | Old or Age Indeterminate Anterolateral Myocardial Infarction by ECG Finding | ||
OLD OR AGE INDETERMINATE ANTEROSEPTAL WALL MYOCARDIAL INFARCTION | C102686 | Old Or Age Indeterminate Anteroseptal Wall Myocardial Infarction | An electrocardiographic finding showing an injury of indeterminate age in leads corresponding to the anatomic region of the anteroseptal wall of the heart. | Old or Age Indeterminate Anteroseptal Myocardial Infarction by ECG Finding | ||
OLD OR AGE INDETERMINATE EXTENSIVE ANTERIOR WALL MYOCARDIAL INFARCTION | C102687 | Old Or Age Indeterminate Extensive Anterior Wall Myocardial Infarction | An electrocardiographic finding showing extensive injury of indeterminate age in leads corresponding to the anatomic region of the anterior wall of the heart. | Old or Age Indeterminate Extensive Anterior Myocardial Infarction by ECG Finding | ||
OLD OR AGE INDETERMINATE HIGH LATERAL WALL MYOCARDIAL INFARCTION | C102688 | Old Or Age Indeterminate High Lateral Wall Myocardial Infarction | An electrocardiographic finding showing an injury of indeterminate age in leads corresponding to the anatomic region of the high lateral wall of the heart. | Old or Age Indeterminate High Lateral Myocardial Infarction by ECG Finding | ||
OLD OR AGE INDETERMINATE INFERIOR WALL MYOCARDIAL INFARCTION | C102689 | Old Or Age Indeterminate Inferior Wall Myocardial Infarction | An electrocardiographic finding showing an injury of indeterminate age in leads corresponding to the anatomic region of the inferior wall of the heart. | Old or Age Indeterminate Inferior Myocardial Infarction by ECG Finding | ||
OLD OR AGE INDETERMINATE LATERAL WALL MYOCARDIAL INFARCTION | C102690 | Old Or Age Indeterminate Lateral Wall Myocardial Infarction | An electrocardiographic finding showing an injury of indeterminate age in leads corresponding to the anatomic region of the lateral wall of the heart. | Old or Age Indeterminate Lateral Myocardial Infarction by ECG Finding | ||
OLD OR AGE INDETERMINATE POSTERIOR WALL MYOCARDIAL INFARCTION | C102691 | Old Or Age Indeterminate Posterior Wall Myocardial Infarction | An electrocardiographic finding showing an injury of indeterminate age in leads corresponding to the anatomic region of the posterior wall of the heart. | Old or Age Indeterminate Posterior Myocardial Infarction by ECG Finding | ||
OLD OR AGE INDETERMINATE RIGHT VENTRICULAR WALL MYOCARDIAL INFARCTION | C102692 | Old Or Age Indeterminate Right Ventricular Wall Myocardial Infarction | An electrocardiographic finding showing an injury of indeterminate age in leads corresponding to the anatomic region of the right ventricular wall of the heart. | Old or Age Indeterminate Right Ventricular Myocardial Infarction by ECG Finding | ||
OLD OR AGE INDETERMINATE SEPTAL WALL MYOCARDIAL INFARCTION | C102693 | Old Or Age Indeterminate Septal Wall Myocardial Infarction | An electrocardiographic finding showing an injury of indeterminate age in leads corresponding to the anatomic region of the septal wall of the heart. | Old or Age Indeterminate Septal Myocardial Infarction by ECG Finding | ||
OLD OR AGE INDETERMINATE WALL MYOCARDIAL INFARCTION | C101597 | Old Or Age Indeterminate Wall Myocardial Infarction | An electrocardiographic finding showing an injury of indeterminate age in leads corresponding to the anatomic region of the wall of the heart. | Old Myocardial Infarction by EKG Finding | ||
PREMATURE ATRIAL COMPLEXES BLOCKED | C102603 | Premature Atrial Complexes Blocked | An electrocardiographic finding of premature atrial complexes which are not conducted to the ventricle, and which are not followed by a QRS complex. | Blocked Atrial Premature Complex | ||
PREMATURE ATRIAL COMPLEXES MULTIFOCAL | C102672 | Premature Atrial Complexes Multifocal | An electrocardiographic finding of premature atrial complexes which have 2 or more distinct morphologies, suggesting origin at more than one atrial site. | Multifocal Atrial Premature Complex | ||
PREMATURE ATRIAL COMPLEXES UNIFOCAL | C102724 | Premature Atrial Complexes Unifocal | An electrocardiographic finding of premature atrial complexes which have a single distinct morphology, suggesting origin at one atrial site. | Unifocal Atrial Premature Complex | ||
PREMATURE VENTRICULAR COMPLEXES INTERPOLATED | C102604 | Premature Ventricular Complexes Interpolated | An electrocardiographic finding of a premature ventricular complex which occurs between two normal QRS complexes which have normal timing. | Blocked Ventricular Premature Complex | ||
PREMATURE VENTRICULAR COMPLEXES MULTIFOCAL | C102673 | Premature Ventricular Complexes Multifocal | An electrocardiographic finding of premature ventricular complexes which have two or more distinct morphologies, suggesting origin at more than one ventricular site. | Multifocal Ventricular Premature Complex | ||
PREMATURE VENTRICULAR COMPLEXES UNIFOCAL | C102725 | Premature Ventricular Complexes Unifocal | An electrocardiographic finding of premature ventricular complexes which have a single distinct morphology, suggesting origin at one ventricular site. | Unifocal Ventricular Premature Complex | ||
QTC PROLONGATION | C83817 | QTc Prolongation | An electrocardiographic finding of a QT interval corrected for heart rate that is prolonged. | Corrected Prolonged QT Interval | ||
REPOLARIZATION ABNORMALITY | C102574 | Repolarization Abnormality | An electrocardiographic finding of an abnormality of T wave duration or morphology or of early repolarization. | Ventricular Repolarization Abnormality | ||
REPOLARIZATION ABNORMALITY SECONDARY TO VENTRICULAR HYPERTROPHY | C102706 | Repolarization Abnormality Secondary To Ventricular Hypertrophy | An electrocardiographic finding of ST depression and T wave inversion in the presence of increased QRS amplitude which are thought to be due to left ventricular hypertrophy. | Repolarization Abnormality Secondary To Ventricular Hypertrophy | ||
SHORT QTC INTERVAL | C102709 | Short QTc Interval | An electrocardiographic finding of a QT interval corrected for heart rate that is shorter than the lower limit of normal. | Short QTc Interval | ||
SINUS RHYTHM | C100076 | Sinus Rhythm | An electrocardiographic finding of an atrial rhythm which originates from the sinoatrial node. | Sinus Rhythm | ||
T WAVE ALTERNANS | C102718 | T Wave Alternans | An electrocardiographic finding in which there are variations in the shape, amplitude, or direction of the T wave from one beat to the next. | T Wave Alternans | ||
VENTRICULAR PARASYSTOLE | C102728 | Ventricular Parasystole | An electrocardiographic finding of normal sinus rhythm coexisting with a regular ectopic ventricular rhythm. | Ventricular Parasystole | ||
Back to top | ||||||
CL.C71153.EGTESTCD | ECG Test Code (EGTESTCD) | text Extensible: Yes | C71153 | ECG Test Code | Terminology codelist used with ECG Tests within CDISC. | CDISC SDTM ECG Test Terminology by Code |
HRMAX | C39779 | Summary (Max) Heart Rate | The minimum time between successive cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate. (NCI) | Maximum Heart Rate | ||
PRMEAN | C62086 | Summary (Mean) PR Duration | The average (mean) duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave. (NCI) | EKG Mean PR Duration | ||
QRSDUR | C62087 | Summary (Mean) QRS Duration | The average (mean) duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize. (NCI) | EKG Mean QRS Duration | ||
QTMEAN | C62089 | Summary (Mean) QT Duration | The average (mean) duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave. (NCI) | EKG Mean QT Duration | ||
RRMEAN | C62090 | Summary (Mean) RR Duration | The average (mean) duration (time) of the RR interval, obtained from a set of measurements of the RR interval. The RR interval is defined as the time between successive peaks of the R wave and can be used to measure the ventricular rate. (NCI) | EKG Mean RR Duration | ||
RRMIN | C62093 | Summary (Min) RR Duration | The minimum duration (time) between successive peaks of R waves in a particular set of RR intervals. (NCI) | EKG Minimum RR Duration | ||
RRMAX | C62094 | Summary (Max) RR Duration | The maximum duration (time) between successive peaks of R waves in a particular set of RR intervals. (NCI) | EKG Maximum RR Duration | ||
HRMEAN | C62095 | Summary (Mean) Heart Rate | The average (mean) number of cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate. (NCI) | Mean Heart Rate | ||
HRMIN | C62096 | Summary (Min) Heart Rate | The maximum time between successive cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate. (NCI) | Minimum Heart Rate | ||
QTCB | C62112 | QTcB - Bazett's Correction Formula | A formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates. It is mathematically defined as: QTcB = QT/SqRootRR(seconds) and theoretically corrects the QT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | QTcB-Bazett's Correction Formula | ||
QTCF | C62113 | QTcF - Fridericia's Correction Formula | A formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates. It is mathematically defined as: QTcF = QT/CubeRootRR(seconds) and theoretically corrects the QT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | QTcF-Fridericia's Correction Formula | ||
QTCLC | C62114 | QTcLC - Linear Correction Formula | A formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates. The linear correction formula uses population-based data obtained and validated using a large cohort of subjects. This method theoretically corrects the QT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | QTcLC-Linear Correction Formula | ||
JTMEAN | C62115 | Summary (Mean) JT Interval | The average (mean) duration (time) of the JT interval, obtained from a set of measurements of the JT interval. The JT interval is defined as the time from the J point (end of ventricular depolarization, the point at which the QRS meets the ST segment) to the end of the T wave (representing the end of ventricular repolarization). (NCI) | EKG Mean JT Duration | ||
JTMIN | C62116 | Summary (Min) JT Interval | The minimum duration (time) of the JT interval, obtained from a set of measurements of the JT interval. The JT interval is defined as the time from the J point (end of ventricular depolarization, the point at which the QRS meets the ST segment) to the end of the T wave (representing the end of ventricular repolarization). (NCI) | EKG Minimum JT Duration | ||
JTMAX | C62117 | Summary (Max) JT Interval | The maximum duration (time) of the JT interval, obtained from a set of measurements of the JT interval. The JT interval is defined as the time from the J point (end of ventricular depolarization, the point at which the QRS meets the ST segment) to the end of the T wave (representing the end of ventricular repolarization). (NCI) | EKG Maximum JT Duration | ||
JTCB | C62118 | JTcB - Bazett's Correction Formula | A formula which takes into account the physiologic shortening of the JT interval which occurs as the heart rate increases, permitting comparison of the JT interval across a range of rates. It is mathematically defined as: JTcB = JT/SqRootRR(seconds) and theoretically corrects the JT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | JTcB-Bazett's Correction Formula | ||
JTCF | C62119 | JTcF - Fridericia's Correction Formula | A formula which takes into account the physiologic shortening of the JT interval which occurs as the heart rate increases, permitting comparison of the JT interval across a range of rates. It is mathematically defined as: JTcF = JT/CubeRootRR(seconds) and theoretically corrects the JT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | JTcF-Fridericia's Correction Formula | ||
JTCLC | C62120 | JTcLC - Linear Correction Formula | A formula which takes into account the physiologic shortening of the JT interval which occurs as the heart rate increases, permitting comparison of the JT interval across a range of rates. The linear correction formula uses population-based data obtained and validated using a large cohort of subjects. Using this method, the corrected JT interval is independent of the ventricular rate. (NCI) | JTcLC-Linear Correction Formula | ||
PAXIS | C62121 | Summary (Mean) P Axis | The mean (average) direction (range -180 degrees to 180 degrees) of the electrical potential generated by atrial depolarization in a particular plane (usually the frontal plane). (NCI) | EKG Mean P Axis | ||
PWAVEDUR | C62123 | Summary (Mean) P Wave Duration | The average (mean) duration (time) from the onset of atrial depolarization to the completion of atrial depolarization (length of the P wave), obtained from a set of measurements of the time from beginning to end of atrial depolarization. (NCI) | EKG Mean P Wave Duration | ||
PWAVEHT | C62124 | Summary (Mean) P Wave Height | The average (mean) height (usually measured in mm) of the maximum deflection from baseline of the P wave (representing atrial depolarization), obtained from a set of measurements of the P wave, from a single lead or set of leads. Typically this measurement is obtained by analysis of Lead II. (NCI) | EKG Mean P Wave Height | ||
PRMIN | C62125 | Summary (Min) PR Duration | The minimum duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave. (NCI) | EKG Minimum PR Duration | ||
PRMAX | C62131 | Summary (Max) PR Duration | The maximum duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave. (NCI) | EKG Maximum PR Duration | ||
QRSAXIS | C62132 | Summary (Mean) QRS Axis | The mean (average) direction of the electrical potential generated by ventricular depolarization. (NCI) | Mean QRS Axis | ||
QTMIN | C62133 | Summary (Min) QT Duration | The minimum duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave. (NCI) | Minimum QT Duration | ||
QTMAX | C62135 | Summary (Max) QT Duration | The maximum duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave. (NCI) | EKG Maximum QT Duration | ||
RWAVEAMP | C62136 | Summary (Mean) R Wave Amplitude | The average (mean) amplitude (usually in mm) of the R wave, obtained from a set of measurements of the R wave, in a particular lead or set of leads. (NCI) | EKG Mean R Wave Amplitude | ||
SWAVEAMP | C62137 | Summary (Mean) S Wave Amplitude | The average (mean) amplitude (usually in mm) of the S wave, obtained from a set of measurements of the S wave, in a particular lead or set of leads. (NCI) | EKG Mean S Wave Amplitude | ||
RSAMP | C62144 | Summary (Mean) R+S Amplitude | The average (mean) amplitude (usually in mm) of the summation of the R and S waves, obtained from a set of measurements of the R and S waves, in a particular lead or set of leads. (NCI) | EKG Mean R+S Amplitude | ||
STSEGDUR | C62145 | Summary (Mean) ST Segment Duration | The average (mean) duration (time) of the ST segment, measured from the J point at the end of the QRS complex to the beginning of the T wave. | EKG Mean ST Segment Duration | ||
TAXIS | C62146 | Summary (Mean) T Wave Axis | The mean (average) direction of the electrical potential generated by ventricular repolarization. (NCI) | EKG Mean T Wave Axis | ||
TWAVEDUR | C62147 | Summary (Mean) T Wave Duration | The average (mean) duration (time) from the onset of ventricular repolarization to the completion of ventricular repolarization (length of the T wave), obtained from a set of measurements of the time from beginning to end of ventricular repolarization. (NCI) | EKG Mean T Wave Duration | ||
TWAVAREA | C62148 | Summary (Mean) T Wave Area | The average (mean) area under the curve of the deflection from baseline of the T wave (representing ventricular repolarization), obtained from a set of measurements of the T wave, from a single lead or set of leads. (NCI) | EKG Mean T Wave Area | ||
TWAVEHT | C62149 | Summary (Mean) T Wave Height | The average (mean) height (usually measured in mm) of the maximum deflection from baseline of the T wave (representing ventricular repolarization), obtained from a set of measurements of the T wave, from a single lead or set of leads. (NCI) | EKG Mean T Wave Height | ||
VRMEAN | C62152 | Summary (Mean) Ventricular Rate | The average (mean) number of cycles of contraction and subsequent relaxation of the ventricles, usually expressed as beats per minute, obtained from a set of measurements of the ventricular rate. (NCI) | Mean Ventricular Heart Rate | ||
VRMIN | C62153 | Summary (Min) Ventricular Rate | The minimum time between successive cycles of contraction and subsequent relaxation of the ventricles, usually expressed as beats per minute, obtained from a set of measurements of the ventricular rate. (NCI) | Minimum Ventricular Heart Rate | ||
VRMAX | C62154 | Summary (Max) Ventricular Rate | The maximum time between successive cycles of contraction and subsequent relaxation of the ventricles, usually expressed as beats per minute, obtained from a set of measurements of the ventricular rate. (NCI) | Maximum Ventricular Heart Rate | ||
STDVMEAN | C62155 | Summary (Mean) ST Deviation | The average (mean) deviation (distance from baseline, positive or negative, usually measured in mm) of the ST segment, obtained from a set of measurements of the deviation of the ST segment. (NCI) | EKG Mean ST Deviation | ||
STDVMIN | C62156 | Summary (Min) ST Deviation | The minimum deviation (distance from baseline, positive or negative, usually measured in mm) of the ST segment, obtained from a set of measurements of the deviation of the ST segment. (NCI) | EKG Minimum ST Deviation | ||
STDVMAX | C62157 | Summary (Max) ST Deviation | The maximum deviation (distance from baseline, positive or negative, usually measured in mm) of the ST segment, obtained from a set of measurements of the deviation of the ST segment. (NCI) | EKG Maximum ST Deviation | ||
STELMEAN | C62158 | Summary (Mean) ST Elevation | The average (mean) elevation (positive deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the elevation of the ST segment. (NCI) | EKG Mean ST Segment Elevation | ||
STELMIN | C62159 | Summary (Min) ST Elevation | The minimum elevation (positive deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the elevation of the ST segment. (NCI) | EKG Minimum ST Segment Elevation | ||
STELMAX | C62160 | Summary (Max) ST Elevation | The maximum elevation (positive deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the elevation of the ST segment. (NCI) | EKG Maximum ST Segment Elevation | ||
STDPMEAN | C62161 | Summary (Mean) ST Depression | The average (mean) depression (negative deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the depression of the ST segment. (NCI) | EKG Mean ST Segment Depression | ||
STDPMIN | C62162 | Summary (Min) ST Depression | The minimum depression (negative deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the depression of the ST segment. (NCI) | EKG Minimum ST Segment Depression | ||
STDPMAX | C62163 | Summary (Max) ST Depression | The maximum depression (negative deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the depression of the ST segment. (NCI) | EKG Maximum ST Segment Depression | ||
QTCV | C90442 | QTcV - Van de Water's Correction Formula | A mathematic formula defined as: QTcV = QT-0.087[(60/Heart Rate)-1](seconds). It permits comparison of the QT interval across a range of rates, while accounting for the progressive shortening of the QT interval which occurs as the heart rate increases. (NCI) | QTcV Van de Water's Correction Formula | ||
INTP | C41255 | Interpretation | An act or process of elucidation; explication, or explanation of the meaning of the event or thing via the assignment of objects from the domain to the constants of a formal language, truth-values to the proposition symbols, truth-functions to the connectives, other functions to the function symbols, and extensions to the predicates, if any. The assignments are result of human logic application and are not native to the symbols of the formal language. | Interpretation | ||
QRSDURVP | C100390 | QRS Duration Ventricular Paced | The average (mean) duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval while the ventricle rhythm is controlled by an electrical impulse from a mechanical cardiac pacemaker. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize. | EKG Mean QRS Duration Ventricular Paced | ||
QTC | C100391 | QT Interval, Corrected | The time interval between the start of the Q wave and the end of the T wave in the cardiac cycle as corrected with a non-specified correction formula. | Corrected QT Interval | ||
HRMED | C102249 | Summary (Median) Heart Rate | The median number of cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate. | Median Heart Rate | ||
PRMED | C102250 | Summary (Median) PR Duration | The median duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave. | Median PR Duration | ||
QRSMED | C102251 | Summary (Median) QRS Duration | The median duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize. | Median QRS Duration | ||
QTMED | C102252 | Summary (Median) QT Duration | The median duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave. | Median QT Duration | ||
QTCFMED | C102253 | Summary (Median) QTcF | The median duration (time) of the QTc interval, obtained from a set of measurements of the QT interval and corrected using the Fridericia's correction Formula. | Median QTcF | ||
RRMED | C102254 | Summary (Median) RR Duration | The median duration (time) of the RR interval, obtained from a set of measurements of the RR interval. The RR interval is defined as the time between successive peaks of the R wave and can be used to measure the ventricular rate. | Median RR Duration | ||
Back to top | ||||||
CL.C71152.EGTEST | ECG Test Name (EGTEST) | text Extensible: Yes | C71152 | ECG Test Name | Terminology codelist used with ECG Test Names within CDISC. | CDISC SDTM ECG Test Name Terminology |
Summary (Max) Heart Rate | C39779 | Summary (Max) Heart Rate | The minimum time between successive cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate. (NCI) | Maximum Heart Rate | ||
Summary (Mean) PR Duration | C62086 | Summary (Mean) PR Duration | The average (mean) duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave. (NCI) | EKG Mean PR Duration | ||
Summary (Mean) QRS Duration | C62087 | Summary (Mean) QRS Duration | The average (mean) duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize. (NCI) | EKG Mean QRS Duration | ||
Summary (Mean) QT Duration | C62089 | Summary (Mean) QT Duration | The average (mean) duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave. (NCI) | EKG Mean QT Duration | ||
Summary (Mean) RR Duration | C62090 | Summary (Mean) RR Duration | The average (mean) duration (time) of the RR interval, obtained from a set of measurements of the RR interval. The RR interval is defined as the time between successive peaks of the R wave and can be used to measure the ventricular rate. (NCI) | EKG Mean RR Duration | ||
Summary (Min) RR Duration | C62093 | Summary (Min) RR Duration | The minimum duration (time) between successive peaks of R waves in a particular set of RR intervals. (NCI) | EKG Minimum RR Duration | ||
Summary (Max) RR Duration | C62094 | Summary (Max) RR Duration | The maximum duration (time) between successive peaks of R waves in a particular set of RR intervals. (NCI) | EKG Maximum RR Duration | ||
Summary (Mean) Heart Rate | C62095 | Summary (Mean) Heart Rate | The average (mean) number of cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate. (NCI) | Mean Heart Rate | ||
Summary (Min) Heart Rate | C62096 | Summary (Min) Heart Rate | The maximum time between successive cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate. (NCI) | Minimum Heart Rate | ||
QTcB - Bazett's Correction Formula | C62112 | QTcB - Bazett's Correction Formula | A formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates. It is mathematically defined as: QTcB = QT/SqRootRR(seconds) and theoretically corrects the QT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | QTcB-Bazett's Correction Formula | ||
QTcF - Fridericia's Correction Formula | C62113 | QTcF - Fridericia's Correction Formula | A formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates. It is mathematically defined as: QTcF = QT/CubeRootRR(seconds) and theoretically corrects the QT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | QTcF-Fridericia's Correction Formula | ||
QTcLC - Linear Correction Formula | C62114 | QTcLC - Linear Correction Formula | A formula which takes into account the physiologic shortening of the QT interval which occurs as the heart rate increases, permitting comparison of the QT interval across a range of rates. The linear correction formula uses population-based data obtained and validated using a large cohort of subjects. This method theoretically corrects the QT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | QTcLC-Linear Correction Formula | ||
Summary (Mean) JT Interval | C62115 | Summary (Mean) JT Interval | The average (mean) duration (time) of the JT interval, obtained from a set of measurements of the JT interval. The JT interval is defined as the time from the J point (end of ventricular depolarization, the point at which the QRS meets the ST segment) to the end of the T wave (representing the end of ventricular repolarization). (NCI) | EKG Mean JT Duration | ||
Summary (Min) JT Interval | C62116 | Summary (Min) JT Interval | The minimum duration (time) of the JT interval, obtained from a set of measurements of the JT interval. The JT interval is defined as the time from the J point (end of ventricular depolarization, the point at which the QRS meets the ST segment) to the end of the T wave (representing the end of ventricular repolarization). (NCI) | EKG Minimum JT Duration | ||
Summary (Max) JT Interval | C62117 | Summary (Max) JT Interval | The maximum duration (time) of the JT interval, obtained from a set of measurements of the JT interval. The JT interval is defined as the time from the J point (end of ventricular depolarization, the point at which the QRS meets the ST segment) to the end of the T wave (representing the end of ventricular repolarization). (NCI) | EKG Maximum JT Duration | ||
JTcB - Bazett's Correction Formula | C62118 | JTcB - Bazett's Correction Formula | A formula which takes into account the physiologic shortening of the JT interval which occurs as the heart rate increases, permitting comparison of the JT interval across a range of rates. It is mathematically defined as: JTcB = JT/SqRootRR(seconds) and theoretically corrects the JT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | JTcB-Bazett's Correction Formula | ||
JTcF - Fridericia's Correction Formula | C62119 | JTcF - Fridericia's Correction Formula | A formula which takes into account the physiologic shortening of the JT interval which occurs as the heart rate increases, permitting comparison of the JT interval across a range of rates. It is mathematically defined as: JTcF = JT/CubeRootRR(seconds) and theoretically corrects the JT interval to that which would be observed at a heart rate of 1 cycle per second. (NCI) | JTcF-Fridericia's Correction Formula | ||
JTcLC - Linear Correction Formula | C62120 | JTcLC - Linear Correction Formula | A formula which takes into account the physiologic shortening of the JT interval which occurs as the heart rate increases, permitting comparison of the JT interval across a range of rates. The linear correction formula uses population-based data obtained and validated using a large cohort of subjects. Using this method, the corrected JT interval is independent of the ventricular rate. (NCI) | JTcLC-Linear Correction Formula | ||
Summary (Mean) P Axis | C62121 | Summary (Mean) P Axis | The mean (average) direction (range -180 degrees to 180 degrees) of the electrical potential generated by atrial depolarization in a particular plane (usually the frontal plane). (NCI) | EKG Mean P Axis | ||
Summary (Mean) P Wave Duration | C62123 | Summary (Mean) P Wave Duration | The average (mean) duration (time) from the onset of atrial depolarization to the completion of atrial depolarization (length of the P wave), obtained from a set of measurements of the time from beginning to end of atrial depolarization. (NCI) | EKG Mean P Wave Duration | ||
Summary (Mean) P Wave Height | C62124 | Summary (Mean) P Wave Height | The average (mean) height (usually measured in mm) of the maximum deflection from baseline of the P wave (representing atrial depolarization), obtained from a set of measurements of the P wave, from a single lead or set of leads. Typically this measurement is obtained by analysis of Lead II. (NCI) | EKG Mean P Wave Height | ||
Summary (Min) PR Duration | C62125 | Summary (Min) PR Duration | The minimum duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave. (NCI) | EKG Minimum PR Duration | ||
Summary (Max) PR Duration | C62131 | Summary (Max) PR Duration | The maximum duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave. (NCI) | EKG Maximum PR Duration | ||
Summary (Mean) QRS Axis | C62132 | Summary (Mean) QRS Axis | The mean (average) direction of the electrical potential generated by ventricular depolarization. (NCI) | Mean QRS Axis | ||
Summary (Min) QT Duration | C62133 | Summary (Min) QT Duration | The minimum duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave. (NCI) | Minimum QT Duration | ||
Summary (Max) QT Duration | C62135 | Summary (Max) QT Duration | The maximum duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave. (NCI) | EKG Maximum QT Duration | ||
Summary (Mean) R Wave Amplitude | C62136 | Summary (Mean) R Wave Amplitude | The average (mean) amplitude (usually in mm) of the R wave, obtained from a set of measurements of the R wave, in a particular lead or set of leads. (NCI) | EKG Mean R Wave Amplitude | ||
Summary (Mean) S Wave Amplitude | C62137 | Summary (Mean) S Wave Amplitude | The average (mean) amplitude (usually in mm) of the S wave, obtained from a set of measurements of the S wave, in a particular lead or set of leads. (NCI) | EKG Mean S Wave Amplitude | ||
Summary (Mean) R+S Amplitude | C62144 | Summary (Mean) R+S Amplitude | The average (mean) amplitude (usually in mm) of the summation of the R and S waves, obtained from a set of measurements of the R and S waves, in a particular lead or set of leads. (NCI) | EKG Mean R+S Amplitude | ||
Summary (Mean) ST Segment Duration | C62145 | Summary (Mean) ST Segment Duration | The average (mean) duration (time) of the ST segment, measured from the J point at the end of the QRS complex to the beginning of the T wave. | EKG Mean ST Segment Duration | ||
Summary (Mean) T Wave Axis | C62146 | Summary (Mean) T Wave Axis | The mean (average) direction of the electrical potential generated by ventricular repolarization. (NCI) | EKG Mean T Wave Axis | ||
Summary (Mean) T Wave Duration | C62147 | Summary (Mean) T Wave Duration | The average (mean) duration (time) from the onset of ventricular repolarization to the completion of ventricular repolarization (length of the T wave), obtained from a set of measurements of the time from beginning to end of ventricular repolarization. (NCI) | EKG Mean T Wave Duration | ||
Summary (Mean) T Wave Area | C62148 | Summary (Mean) T Wave Area | The average (mean) area under the curve of the deflection from baseline of the T wave (representing ventricular repolarization), obtained from a set of measurements of the T wave, from a single lead or set of leads. (NCI) | EKG Mean T Wave Area | ||
Summary (Mean) T Wave Height | C62149 | Summary (Mean) T Wave Height | The average (mean) height (usually measured in mm) of the maximum deflection from baseline of the T wave (representing ventricular repolarization), obtained from a set of measurements of the T wave, from a single lead or set of leads. (NCI) | EKG Mean T Wave Height | ||
Summary (Mean) Ventricular Rate | C62152 | Summary (Mean) Ventricular Rate | The average (mean) number of cycles of contraction and subsequent relaxation of the ventricles, usually expressed as beats per minute, obtained from a set of measurements of the ventricular rate. (NCI) | Mean Ventricular Heart Rate | ||
Summary (Min) Ventricular Rate | C62153 | Summary (Min) Ventricular Rate | The minimum time between successive cycles of contraction and subsequent relaxation of the ventricles, usually expressed as beats per minute, obtained from a set of measurements of the ventricular rate. (NCI) | Minimum Ventricular Heart Rate | ||
Summary (Max) Ventricular Rate | C62154 | Summary (Max) Ventricular Rate | The maximum time between successive cycles of contraction and subsequent relaxation of the ventricles, usually expressed as beats per minute, obtained from a set of measurements of the ventricular rate. (NCI) | Maximum Ventricular Heart Rate | ||
Summary (Mean) ST Deviation | C62155 | Summary (Mean) ST Deviation | The average (mean) deviation (distance from baseline, positive or negative, usually measured in mm) of the ST segment, obtained from a set of measurements of the deviation of the ST segment. (NCI) | EKG Mean ST Deviation | ||
Summary (Min) ST Deviation | C62156 | Summary (Min) ST Deviation | The minimum deviation (distance from baseline, positive or negative, usually measured in mm) of the ST segment, obtained from a set of measurements of the deviation of the ST segment. (NCI) | EKG Minimum ST Deviation | ||
Summary (Max) ST Deviation | C62157 | Summary (Max) ST Deviation | The maximum deviation (distance from baseline, positive or negative, usually measured in mm) of the ST segment, obtained from a set of measurements of the deviation of the ST segment. (NCI) | EKG Maximum ST Deviation | ||
Summary (Mean) ST Elevation | C62158 | Summary (Mean) ST Elevation | The average (mean) elevation (positive deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the elevation of the ST segment. (NCI) | EKG Mean ST Segment Elevation | ||
Summary (Min) ST Elevation | C62159 | Summary (Min) ST Elevation | The minimum elevation (positive deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the elevation of the ST segment. (NCI) | EKG Minimum ST Segment Elevation | ||
Summary (Max) ST Elevation | C62160 | Summary (Max) ST Elevation | The maximum elevation (positive deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the elevation of the ST segment. (NCI) | EKG Maximum ST Segment Elevation | ||
Summary (Mean) ST Depression | C62161 | Summary (Mean) ST Depression | The average (mean) depression (negative deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the depression of the ST segment. (NCI) | EKG Mean ST Segment Depression | ||
Summary (Min) ST Depression | C62162 | Summary (Min) ST Depression | The minimum depression (negative deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the depression of the ST segment. (NCI) | EKG Minimum ST Segment Depression | ||
Summary (Max) ST Depression | C62163 | Summary (Max) ST Depression | The maximum depression (negative deflection from baseline, usually measured in mm) of the ST segment, obtained from a set of measurements of the depression of the ST segment. (NCI) | EKG Maximum ST Segment Depression | ||
QTcV - Van de Water's Correction Formula | C90442 | QTcV - Van de Water's Correction Formula | A mathematic formula defined as: QTcV = QT-0.087[(60/Heart Rate)-1](seconds). It permits comparison of the QT interval across a range of rates, while accounting for the progressive shortening of the QT interval which occurs as the heart rate increases. (NCI) | QTcV Van de Water's Correction Formula | ||
Interpretation | C41255 | Interpretation | An act or process of elucidation; explication, or explanation of the meaning of the event or thing via the assignment of objects from the domain to the constants of a formal language, truth-values to the proposition symbols, truth-functions to the connectives, other functions to the function symbols, and extensions to the predicates, if any. The assignments are result of human logic application and are not native to the symbols of the formal language. | Interpretation | ||
QRS Duration Ventricular Paced | C100390 | QRS Duration Ventricular Paced | The average (mean) duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval while the ventricle rhythm is controlled by an electrical impulse from a mechanical cardiac pacemaker. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize. | EKG Mean QRS Duration Ventricular Paced | ||
QT Interval, Corrected | C100391 | QT Interval, Corrected | The time interval between the start of the Q wave and the end of the T wave in the cardiac cycle as corrected with a non-specified correction formula. | Corrected QT Interval | ||
Summary (Median) Heart Rate | C102249 | Summary (Median) Heart Rate | The median number of cycles of contraction and subsequent relaxation of the heart, usually expressed as beats per minute, obtained from a set of measurements of the heart rate. | Median Heart Rate | ||
Summary (Median) PR Duration | C102250 | Summary (Median) PR Duration | The median duration (time) of the PR interval, obtained from a set of measurements of the PR interval. The PR interval is defined as the time from the beginning of the P wave (representing the onset of atrial depolarization) to the beginning of the R wave (representing the onset of ventricular depolarization). In some cases, a Q wave will precede the R wave, in which case the PR interval is measured from the beginning of the P wave to the beginning of the Q wave. | Median PR Duration | ||
Summary (Median) QRS Duration | C102251 | Summary (Median) QRS Duration | The median duration (time) of the QRS interval, obtained from a set of measurements of the QRS interval. The QRS interval is defined as the time from the beginning of the QRS complex to the end of the QRS complex, representing the time it takes for the ventricles to depolarize. | Median QRS Duration | ||
Summary (Median) QT Duration | C102252 | Summary (Median) QT Duration | The median duration (time) of the QT interval, obtained from a set of measurements of the QT interval. The QT interval is defined as the time from the beginning of the QRS complex to the end of the T wave, representing the time it takes for the ventricles to depolarize and subsequently repolarize. In some cases, the Q wave will be absent, in which case the QT interval is measured from the beginning of the R wave to the end of the T wave. | Median QT Duration | ||
Summary (Median) QTcF | C102253 | Summary (Median) QTcF | The median duration (time) of the QTc interval, obtained from a set of measurements of the QT interval and corrected using the Fridericia's correction Formula. | Median QTcF | ||
Summary (Median) RR Duration | C102254 | Summary (Median) RR Duration | The median duration (time) of the RR interval, obtained from a set of measurements of the RR interval. The RR interval is defined as the time between successive peaks of the R wave and can be used to measure the ventricular rate. | Median RR Duration | ||
Back to top | ||||||
CL.C71151.EGMETHOD | ECG Test Method (EGMETHOD) | text Extensible: Yes | C71151 | ECG Test Method | Terminology codelist used with ECG Test Methods within CDISC. | CDISC SDTM ECG Test Method Terminology |
12 LEAD UNSPECIFIED | C71101 | 12 Lead Unspecified | An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the position of the leads is unspecified. (NCI) | 12 Lead Placement Unspecified | ||
12 LEAD STANDARD | C71102 | 12 Lead Standard | An electrocardiogram (ECG) lead placement whereby 12 leads are recorded, with each lead representing an electrical view of the heart. The six leads recorded in the frontal plane are derived from the placement of 3 electrodes (RA or Right Arm, LA, or Left Arm, and LL or Left Leg). These bipolar frontal leads form the basis of Einthoven's triangle, and are represented by leads I, II, and III. Three other derived (or augmented) bipolar frontal vectors are also recorded on a standard 12-lead EKG, aVR, aVF, and aVL. 6 unipolar leads, corresponding to V1 - V6 measure the electrical activity in the horizontal plane. The placement for the V leads is as follows: V1: right 4th intercostal space,V2: left 4th intercostal space, V3: halfway between V2 and V4, V4: left 5th intercostal space, mid-clavicular line, V5: horizontal to V4, anterior axillary line, V6: horizontal to V5, mid-axillary line. (NCI) | 12 Lead Placement Standard | ||
12 LEAD MASON LIKAR | C71103 | 12 Lead Mason Likar | An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the standard lead positions have been modified for ECG recording during exercise. Exercise stress testing requires moving the limb electrodes to more central positions on the thorax. The electrodes are placed in bony prominences close to the bases of the respective limbs in order to avoid skeletal muscle artifact, provide stability for recording electrodes and to record waveforms similar to the standard limb sites. (NCI) | 12 Lead Placement Mason Likar | ||
12 LEAD MODIFIED MASON LIKAR | C71110 | 12 Lead Modified Mason Likar | An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the Mason Likar lead positions have been modified so that V1 to V6 on the chest are part of a single electrode pad. In addition, lead CM5 is substituted for lead aVR. (NCI) | 12 Lead Placement Mason Likar Modified | ||
12 LEAD SINGLE PAD | C71112 | 12 Lead Single Pad | An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the standard lead positions have been modified so that all leads on the chest are part of a single electrode pad. (NCI) | 12 Lead Placement Chest | ||
12 LEAD NON-STANDARD | C71114 | 12 Lead Non-Standard | An electrocardiogram (ECG) lead placement whereby the limb leads are placed on the torso for easier and faster application in emergency situations. (NCI) | 12 Lead Placement Non-Standard | ||
STANDARD LEADS FOR BICYCLE EXERCISE | C71115 | Standard leads for bicycle exercise. Limb leads on the back (shoulder and on the hips) | Limb leads on the back (shoulder and on the hips). (NCI) | Lead Placement Bicycle | ||
12 LEAD CABRERA | C71116 | 12 Lead Cabrera | An electrocardiogram (ECG) lead placement whereby the display of the 12 standard ECG leads is in an orderly sequence in a single horizontal display of: aVL, I, -aVR, II, aVF, III, V1 to V6. In the Cabrera display the limb lead aVR is inverted (-aVR) to obtain the same positive leftward orientation as the other 5 limbs. (NCI) | 12 Lead Placement Cabrera | ||
STANDARD LEADS ONE INTERCOSTAL SPACE HIGHER | C71117 | Standard leads one intercostal space higher | An electrocardiographic lead placement schema in which the V leads are placed one intercostal space cephalad to the position they would have in the standard lead placement schema. (NCI) | Lead Placement Standard Intercostal Space Higher | ||
FRANK LEAD SYSTEM | C71118 | Frank lead system | An electrocardiogram (ECG) lead placement for determining 3 orthogonal components X (right to left direction), Y (foot to head direction) and Z (back to front direction) of the heart. For this method a minimum of 4 electrodes are needed that represent the right arm, left arm, left leg and back. However, usually 7 electrodes are used to avoid dependence on the dipole location and facilitate interpretation. (NCI) | Lead Placement Frank | ||
MCFEE-PARUNGAO LEAD SYSTEM | C71119 | McFee-Parungao lead system | An electrocardiogram (ECG) lead placement for determining 3 orthogonal components X (back to front), Y (right to left) and Z (foot to head) of the heart. This system places the electrodes closer to the heart to achieve better orthogonality and a homogeneous lead field. (NCI) | Lead Placement McFee-Parungao | ||
CUBE LEAD SYSTEM | C71120 | Cube lead system | An electrocardiogram (ECG) lead placement that is a type of uncorrected vectorcardiograph. This lead system is based on a rectangular body axis. It uses an extra number of electrodes to make it three-dimensional. (NCI) | Lead Placement Cube | ||
BIPOLAR UNCORRECTED XYZ LEAD SYSTEM | C71121 | Bipolar uncorrected XYZ lead system | An electrocardiogram (ECG) lead placement whereby the X+ lead is placed at the right mid-axillary line ate the 4th intercostal space, X- at the left mid-axillary line at he 4th intercostal space, Y+ at the proximal left leg, Y- at the superior aspect of the manubrium, Z+ at the direct posterior to Z- and Z- at the 4th intercostal space at the left sternal margin. (NCI) | Lead Placement Bipolar Uncorrected XYZ | ||
PSEUDO-ORTHOGONAL XYZ LEAD SYSTEM | C71122 | Pseudo-orthogonal XYZ lead system | An electrocardiogram (ECG) lead placement that allows monitoring and recording of cardiac electrical activity. A V1-type lead is used whose positive electrode is localized in the 4th intercostal space, 2.5cm from the sternum. Its negative electrode is placed below the left clavicle. An addition of lead V5 and aVF can be made to facilitate interpretation. (NCI) | Lead Placement Pseudo Orthogonal XYZ | ||
12 LEAD EASI DOWER TRANSFORMATION | C71123 | 12 Lead EASI Dower Transformation | An electrocardiogram (ECG) lead placement whereby 4 chest electrodes and 1 reference electrode are used to allow for continuous monitoring at the clinical level. This placement creates a 12 lead ECG that allows the acquisition of simultaneous events in the frontal, horizontal and sagittal heart planes with the linear transformation of vectors. This system provides a three-dimensional portrayal of the heart and uses mathematical and fixed coefficients for each lead. (NCI) | Lead Placement EASI Dower Transformation | ||
12 LEAD 1 LEAD MISSING | C71125 | 12 Lead 1 Lead Missing | An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but one standard lead position is missing therefore requiring a Mortara source consistency filter. (NCI) | 12 Lead Placement 1 Lead Missing | ||
STANDARD 12-LEAD AND CM5-CC5-CH5 | C71126 | Standard 12-lead and CM5-CC5-CH5 | An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the standard lead positions have been modified so that the bipolar lead groups place the negative of the reference electrode over the manubrium (CM5), the right scapula (CB5), V5R (CC5) or on the forehead (CH5) and the active electrode at V5. (NCI) | 12 Lead Placement Standard And CC5-CM5-CH5 | ||
STANDARD 12-LEAD AND CC5-CM5-ML | C71128 | Standard 12-lead and CC5-CM5-ML | An electrocardiogram (ECG) lead placement whereby 12 leadpoints are recorded but the standard lead positions have been modified so that the negative reference is at CM5 and the active electrode is at the left leg position. (NCI) | 12 Lead Placement Standard And CC5-CM5-ML | ||
STANDARD 12-LEAD EXTENDED RIGHT | C71130 | Standard 12-lead extended to the right by V5R, V4R, V3R | An electrocardiogram (ECG) lead placement whereby the rightward oriented V leads progress from V1R, placed instead of the standard V2, to V6R. The V3 lead in the standard placement is replaced by V4R. (NCI) | 12 Lead Placement Standard Extended Right | ||
STANDARD 12-LEAD EXTENDED LEFT | C71131 | Standard 12-lead extended to the left by V7, V8, V9 | An electrocardiogram (ECG) lead placement whereby the standard lead placement is modified by having leads V7, V8 and V9. (NCI) | 12 Lead Placement Standard Extended Left | ||
VECTORCARDIOGRAPH CORRECTED | C71092 | Vectorcardiograph Corrected | A recording of the electrical activity of the heart displayed in the form of a vector loop, corrected for anatomic inconsistencies. (NCI) | Vectorcardiograph Corrected | ||
VECTORCARDIOGRAPH UNCORRECTED | C71093 | Vectorcardiograph Uncorrected | A recording of the electrical activity of the heart displayed in the form of a vector loop, uncorrected for anatomic inconsistencies. (NCI) | Vectorcardiograph Uncorrected | ||
6 LEAD STANDARD | C90350 | 6 Lead Standard | An electrocardiogram lead placement on the subject using a six electrode lead set with three standard leads and three augmented derived leads to elicit an electrical view of the heart. | 6 Lead Standard | ||
10 LEAD STANDARD | C90349 | 10 Lead Standard | An electrocardiogram lead placement on the subject using a ten electrode lead set to synthesize standard 12 lead electrocardiograph data to elicit an electrical view of the heart. | 10 Lead Standard | ||
Back to top | ||||||
CL.C71620.UNIT | Unit (UNIT) | text Extensible: Yes | C71620 | Unit | Terminology codelist used for units within CDISC. | CDISC SDTM Unit of Measure Terminology |
Gy | C18063 | Gray | A unit of absorbed radiation dose. One gray is equal to an absorbed dose of one joule per kilogram of matter, or to 100 rads.(NCI) | Gray | ||
Rad | C18064 | Rad | The special unit for absorbed radiation dose, which is the amount of energy from any type of ionizing radiation (e.g., alpha, beta, gamma, neutrons, etc.) deposited in any medium (e.g., water, tissue, air). A dose of one rad means the absorption of 100 ergs per gram of absorbing tissue. One rad is equal to 0.01 gray.(NCI) | Rad | ||
DAYS | C25301 | Day | The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours. This also refers to a specific day. (NCI) | Day | ||
HOURS | C25529 | Hour;hr | A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day. (NCI) | Hour | ||
% | C25613 | Percentage | A fraction or ratio with 100 understood as the denominator. (NCI) | Percentage | ||
mm | C28251 | Millimeter | A unit of measure equal to one thousandth of a meter. (NCI) | Millimeter | ||
kg | C28252 | Kilogram | The basic SI unit of mass. It is defined as the mass of an international prototype in the form of a platinum-iridium cylinder kept at Sevres in France. It is the only basic unit still defined in terms of a material object, and also the only one with a prefix [kilo] already in place. A kilogram is equal to 1,000 grams and 2.204 622 6 pounds. (NCI) | Kilogram | ||
mg | C28253 | Milligram | The unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015432 grain or 35.274 x 10E-6 ounce.(NCI) | Milligram | ||
mL | C28254 | Milliliter;cm3 | The unit of volume equal to one thousandth of a liter, one cubic centimeter, 10E-6 cubic meter, or approximately to 0.061 023 7 cubic inch.(NCI) | Milliliter | ||
WEEKS | C29844 | Week | Any period of seven consecutive days. (NCI) | Week | ||
MONTHS | C29846 | Month | One of the 12 divisions of a year as determined by a calendar. It corresponds to the unit of time of approximately to one cycle of the moon's phases, about 30 days or 4 weeks. (NCI) | Month | ||
YEARS | C29848 | Year | The period of time that it takes for Earth to make a complete revolution around the sun, approximately 365 days; a specific one year period. (NCI) | Year | ||
m | C41139 | Meter | A meter is defined as the length of the path traveled by light in a vacuum during a time interval of 1/299 792 458 of a second and is equal to 1.093 61 yards.(NCI) | Meter | ||
msec | C41140 | Millisecond | A unit of time, which is equal to one thousandth of a second.(NCI) | Millisecond | ||
sec | C42535 | Second | The second is a unit of time with a duration of 919 263 177 0 periods of the specified light radiation corresponding to the transition between the two hyperfine levels of the cesium 133 atom in its ground state at 0 K. According to the convention, 60 seconds constitute one minute; 3,600 seconds constitute one hour. Abbreviation Sec. is acceptable in non-scientific usage only.(NCI) | Second | ||
amp | C42536 | Ampere | A unit of electric current, named after the French physicist Andre Ampere. It is that constant current which, if maintained in two straight parallel conductors of infinite length and zero diameter separated by one meter in a vacuum, would produce between these conductors a force equal to 2(10E7) Newton per meter of length. This is dependent upon the definitions of the meter, kilogram, and second. One Ampere represents 6.24 x 10(E18) unit electric charge carriers, such as electrons, passing a specified fixed point in one second.(NCI) | Ampere | ||
cd | C42538 | Candela | The candela is the basic unit of luminous intensity. It is the luminous intensity in a given direction of a small monochromatic light source at 540 terahertz emitting 1/683 watt per steradian in that direction. This is dependent upon the definitions of the meter, kilogram, and second.(NCI) | Candela | ||
mol | C42539 | Mole | A unit defined as the amount of substance that contains as many elementary units as there are atoms in 0.012 kg of carbon-12. When the mole is used, the elementary entities must be specified and may be atoms, molecules, ions, electrons, other particles, or specified groups of such particles.(NCI) | Mole | ||
Hz | C42545 | Hertz | A unit of frequency equal to one cycle per second.(NCI) | Hertz | ||
Newton | C42546 | Newton | A unit of force which, when applied in a vacuum to a body having a mass of one kilogram, causes an acceleration of one meter per second squared. It is equal to 10E5 dynes.(NCI) | Newton | ||
Pa | C42547 | Pascal | A unit of pressure equivalent to one Newton per square meter or 10 bars or to 1.45x10(E-4) pounds per square inch.(NCI) | Pascal | ||
Joule | C42548 | Joule | A unit of electrical, mechanical, and thermal energy (as well as work and quantity of heat), equal to the work done when the point of application of a force of one Newton is displaced through a distance of one meter in the direction of the force or the work done when a current of one Ampere passes through a resistance of one ohm for one second. One joule is equal to 0.23889 gram-calorie (mean).(NCI) | Joule | ||
Watt | C42549 | Watt | A unit of power equal to the power which in one second produces or transfers the energy of one joule. The unit is used in measurements of power emitted, transferred or received as radiation, sound waves, heat flow rate, and rate of energy transfer. Equal to 1/746 of horsepower.(NCI) | Watt | ||
Coulomb | C42550 | Coulomb | A unit of quantity of electricity, equal to the quantity of charge transferred in one second across a conductor in which there is a constant current of one Ampere.(NCI) | Coulomb | ||
V | C42551 | Volt | A unit of electric potential and electromotive force, equal to the difference of electric potential between two points on a conducting wire carrying a constant current of one Ampere when the power dissipated between the points is one watt. This is equivalent to the potential difference across a resistance of one ohm when one Ampere of current flows through it.(NCI) | Volt | ||
Farad | C42552 | Farad | A unit of capacitance equal to the capacitance of a capacitor having an equal and opposite charge of one coulomb on each plate and a potential difference of one volt between the plates.(NCI) | Farad | ||
Sv | C42553 | Sievert | A unit of equivalent radiation dose. One Sv is received when the actual absorbed dose of ionizing radiation, after being multiplied by the dimensionless factors Q (the relative biological efficiency or quality factor) and N (the product of any other multiplying factors that takes into account the distribution of energy throughout the dose), is one joule per kilogram. In this scheme, the relationship between the absorbed dose of radiation D and the dose equivalent H is, therefore, given by H = QND. Both Q and N are stipulated by the International Commission on Radiological Protection. One Sv is equal to 100 rem.(NCI) | Sievert | ||
ohm | C42554 | Ohm | A unit of electrical resistance equal to the resistance between two points on a conductor when a potential difference of one volt between them produces a current of one Ampere. Ohm is also used to measure impedance and reactance for complex resistance. A measurement in ohms is the reciprocal of a measurement in Siemens. (NCI) | Ohm | ||
Siemens | C42555 | Siemens | A unit of electrical conductance, admittance, and susceptance. A conductor has a conductance of one Siemens if an electrical potential difference of one volt produces a one Ampere current in it. The conductance in Siemens is the reciprocal of its resistance in ohms.(NCI) | Siemens | ||
Weber | C42556 | Weber;V*sec;Volt Second;Volt-second | A unit of magnetic flux, equal to the flux that produces in a circuit of one turn an electromotive force of one volt, when the flux is uniformly reduced to zero within one second.(NCI) | Weber | ||
Tesla | C42557 | Tesla | A unit of magnetic flux density equal to the magnitude of the magnetic field vector necessary to produce a force of one Newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one Weber per square meter.(NCI) | Tesla | ||
Henry | C42558 | Henry | A unit of electric inductance. A coil with an inductance of one Henry requires a flux of one Weber for each Ampere of induced current. If it is the current which changes, then the induced field will generate a potential difference within the coil: if the inductance is one Henry a current change of one Ampere per second generates a potential difference of one volt. The Henry is a large unit; inductances in practical circuits are measured in millihenrys or microhenrys.(NCI) | Henry | ||
C | C42559 | Degree Celsius | A unit of temperature of the temperature scale designed so that the freezing point of water is 0 degrees and the boiling point is 100 degrees at standard atmospheric pressure. The current official definition of the Celsius sets 0.01 C to be at the triple point of water and a degree to be 1/273.16 of the difference in temperature between the triple point of water and absolute zero. One degree Celsius represents the same temperature difference as one Kelvin.(NCI) | Degree Celsius | ||
lm | C42560 | Lumen | A unit of luminous flux. It is the amount of light that falls on a unit area at unit distance from a source of one candela.(NCI) | Lumen | ||
lx | C42561 | Lux | A unit of illuminance equal to the direct illumination on a surface that is everywhere one meter from a uniform point source of one candela; a unit of illuminance that is equal to one lumen per square meter.(NCI) | Lux | ||
Bq | C42562 | Becquerel | A unit of activity of a radionuclide, equal to one nuclear disintegration or other nuclear transition from a particular energy state occurring in an amount of a radionuclide during one second-long time interval.(NCI) | Becquerel | ||
kat | C42566 | Katal | A unit for measuring catalytic (e.g. enzymatic) activity, the ability of the compound to accelerate the chemical reaction by providing a lower energy pathway between the reactants and the products. One katal is that catalytic activity which will raise the rate of reaction by one mole per second in a specified assay system. When the katal is used, the measurand should be specified by reference to the measurement procedure; the measurement procedure must identify the indicator reaction. The katal is not used to express a rate of reaction itself, which should be expressed in moles per second.(NCI) | Katal | ||
m2 | C42569 | Square Meter | The SI unit of area measurement equal to a square whose sides are one meter long. Square meter is equal to 10,000 square centimeters; 0.01 ares; 1.196 square yards; 10.76 square feet; 1550 square inches. (NCI) | Square Meter | ||
m3 | C42570 | Cubic Meter | A unit of volume or capacity equal to the volume of a cube with edges one meter in length. It is equal to 1,000 liters; 1,000 cubic decimeters; 10(E6) cubic centimeters; 25.3 cubic feet; 6.29 barrels.(NCI) | Cubic Meter | ||
m/sec | C42571 | Meter Per Second | A unit of both speed (scalar) and velocity (vector), defined as the distance of one meter travelled per unit time equal to one second.(NCI) | Meter Per Second | ||
g/L | C42576 | g/L;Gram per Liter;kg/m3;Kilogram per Cubic Metre;Microgram per Microliter;Milligram per Milliliter;ug/uL;mg/mL | A unit of mass concentration defined as the concentration of one kilogram of a substance per unit volume of the mixture equal to one cubic meter, or the concentration of one milligram of a substance per unit volume of the mixture equal to one milliliter, or one gram of a substance per one liter of the mixture. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one milliliter.(NCI) | Kilogram per Cubic Meter | ||
F | C44277 | Degree Fahrenheit | The Fahrenheit temperature scale is named after the German physicist Gabriel Fahrenheit (1686-1736), who proposed it in 1724. In this scale, the freezing point of water is 32 degrees Fahrenheit and the boiling point is 212 degrees, placing the boiling and melting points of water 180 degrees apart. In this scale a degree Fahrenheit is 5/9ths of a Kelvin (or of a degree Celsius), and minus 40 degrees Fahrenheit is equal to minus 40 degrees Celsius. (NCI) | Degree Fahrenheit | ||
pH | C45997 | pH | A measure of the acidity or alkalinity of a fluid on a scale of 0 to 14.(NCI) | pH | ||
ug | C48152 | Microgram;mcg | The unit of mass equal to one millionth of a gram or one thousandth of a milligram.(NCI) | Microgram | ||
min | C48154 | Minute Unit of Time | A unit measure of time equal to 60 seconds.(NCI) | Minute | ||
g | C48155 | Gram | A metric unit of mass equal to one one thousandth of a kilogram. (NCI) | Gram | ||
cm2 | C48460 | Square Centimeter | A unit of area measurement equal to a square measuring one centimeter on each side. One square centimeter is equal to 10E-4 square meter.(NCI) | Square Centimeter | ||
ft2 | C48461 | Square Foot | A unit of area equal to 144 square inches, 929.0304 square centimeters, or 9.290304E-2 square meters.(NCI) | Square Foot | ||
Ci | C48466 | Curie | A unit of radioactivity defined as 3.7 E10 atomic disintegrations or other nuclear transformations per second. One Curie is equal to 37 gigabecquerels.(NCI) | Curie | ||
AMPULE | C48473 | Ampule Dosing Unit | A dosing measurement based on the ampule unit.(NCI) | Ampule Dosing Unit | ||
BAG | C48474 | Bag Dosing Unit | A dosing measurement based on the bag unit.(NCI) | Bag Dosing Unit | ||
BAR | C48475 | Bar Dosing Unit | A dosing measurement based on the bar unit.(NCI) | Bar Dosing Unit | ||
BOLUS | C48476 | Bolus Dosing Unit | A dosing measurement based on the bolus unit.(NCI) | Bolus Dosing Unit | ||
BOTTLE | C48477 | Bottle Dosing Unit | A dosing measurement based on the bottle unit.(NCI) | Bottle Dosing Unit | ||
BOX | C48478 | Box Dosing Unit | A dosing measurement based on the box unit.(NCI) | Box Dosing Unit | ||
CAN | C48479 | Can Dosing Unit | A dosing measurement based on the can unit.(NCI) | Can Dosing Unit | ||
CAPSULE | C48480 | Capsule Dosing Unit;cap | A dosing measurement based on the capsule unit.(NCI) | Capsule Dosing Unit | ||
CARTRIDGE | C48481 | Cartridge Dosing Unit | A dosing measurement based on the cartridge unit.(NCI) | Cartridge Dosing Unit | ||
COAT | C48483 | Coat Dosing Unit | A dosing measurement based on the coat unit.(NCI) | Coat Dosing Unit | ||
CONTAINER | C48484 | Container Dosing Unit | A dosing measurement based on the container unit.(NCI) | Container Dosing Unit | ||
CYLINDER | C48489 | Cylinder Dosing Unit | A dosing measurement based on the cylinder unit.(NCI) | Cylinder Dosing Unit | ||
DISK | C48490 | Disk Dosing Unit | A dosing measurement based on the disk unit.(NCI) | Disk Dosing Unit | ||
DRUM | C48492 | Drum Dosing Unit | A dosing measurement based on the drum unit.(NCI) | Drum Dosing Unit | ||
grain | C48497 | Grain | A unit of mass derived from the weight of a grain and equal to one seven-thousandth of a pound, or 1/480 troy ounce, or 64.79891 milligrams. The original English grain unit based on the mass of a ripe grain barleycorn was larger the corresponding grain units of France and other European nations which were based on the weight of the smaller wheat grain.(NCI) | Grain | ||
HOMEOPATHIC DILUTION | C48498 | Homeopathic Dilution Unit | A dosing measurement based on the homeopathic dilution unit.(NCI) | Homeopathic Dilution Unit | ||
IMPLANT | C48499 | Implant Dosing Unit | A dosing measurement based on the implant unit.(NCI) | Implant Dosing Unit | ||
IN | C48500 | Inch | A traditional unit of length equal to 2.54 centimeters. (NCI) | Inch | ||
INHALATION | C48501 | Inhalation Dosing Unit | A dosing measurement based on the inhalation unit.(NCI) | Inhalation Dosing Unit | ||
JAR | C48502 | Jar Dosing Unit | A dosing measurement based on the jar unit.(NCI) | Jar Dosing Unit | ||
KALLIKREIN INHIBITOR UNIT | C48503 | Kallikrein Inhibitor Unit | A dosing measurement based on the Kallikrein inhibitor unit.(NCI) | Kallikrein Inhibitor Unit | ||
KIT | C48504 | Kit Dosing Unit | A dosing measurement based on the kit unit.(NCI) | Kit Dosing Unit | ||
L | C48505 | Liter | A unit of volume equal to a cubic decimeter, or one thousandth of cubic meter, or 1000 cubic centimeters, or approximately 61.023 744 cubic inches.(NCI) | Liter | ||
LOZENGE | C48506 | Lozenge Dosing Unit | A dosing measurement based on the lozenge unit.(NCI) | Lozenge Dosing Unit | ||
uCi | C48507 | Microcurie;mcCi | A unit of radioactivity equal to one millionth of a Curie or 37 kilobecquerels, and corresponding to a radioactivity of 37 000 atomic disintegrations per second.(NCI) | Microcurie | ||
umol | C48509 | Micromole;mcmol | A unit of amount of substance equal to one millionth (10E-6) of a mole.(NCI) | Micromole | ||
um | C48510 | Micron;mcm | A unit of length in metric system equal to 10E-6 meter, or micrometer.(NCI) | Micron | ||
mCi | C48511 | Millicurie | A unit of radioactivity equal to one thousandth of a Curie or 37 megabecquerels, and corresponding to a radioactivity of 37 millions of atomic disintegrations per second.(NCI) | Millicurie | ||
mEq | C48512 | Milliequivalent | A unit of relative amount of a substance equal to one thousandth of an equivalent weight.(NCI) | Milliequivalent | ||
mmol | C48513 | Millimole | A unit of amount of substance equal to 0.001 mole.(NCI) | Millimole | ||
ng | C48516 | Nanogram | A unit of mass equal to one billionth (10E-9) of a gram, or one millionth (10E-6) of a milligram.(NCI) | Nanogram | ||
nmol | C48517 | Nanomole | A unit of amount of substance equal to one billionth (10E-9) of a mole.(NCI) | Nanomole | ||
oz | C48519 | Ounce | A unit of mass, the avoirdupois ounce is equal to 1/16 pound, or 28.3495 grams, or 0.911 457 troy ounce.(NCI) | Ounce | ||
PACKAGE | C48520 | Package Dosing Unit;Pack Dosing Unit | A dosing measurement based on the package unit.(NCI) | Package Dosing Unit | ||
PACKET | C48521 | Packet Dosing Unit | A dosing measurement based on the packet unit.(NCI) | Packet Dosing Unit | ||
ppm | C48523 | Part per Million | A unit of measurement referring to one entity counted per one million entities.(NCI) | Part Per Million | ||
PATCH | C48524 | Patch Dosing Unit | A dosing measurement based on the patch unit.(NCI) | Patch Dosing Unit | ||
PELLET | C48525 | Pellet Dosing Unit | A dosing measurement based on the pellet unit.(NCI) | Pellet Dosing Unit | ||
%(w/v) | C48527 | Percent Weight per Volume | A percent ratio of weight to volume, defined by the equation: [weight of solute (in gm)/volume of solution (in dl)](100). Since the numerator and denominator of this ratio have different units, it is not a true percentage. A 1% w/v solution is defined as being 1 gram of solute dissolved in 100 milliliters of solvent.(NCI) | Percent Mass per Volume | ||
%(w/w) | C48528 | Percent Weight per Weight | A percent ratio of weight to weight, defined by the equation: [weight of solute (in gm)/weight of solution (in gm)](100).(NCI) | Percent Mass per Mass | ||
POUCH | C48530 | Pouch Dosing Unit | A dosing measurement based on the pouch unit.(NCI) | Pouch Dosing Unit | ||
LB | C48531 | Pound | A traditional unit of mass. By international agreement, one avoirdupois pound is equal to exactly 0.453 592 37 kilogram, 16 ounces, or 1.215 28 troy pounds. (NCI) | Pound | ||
PRESSOR UNITS | C48532 | Pressor Unit | A dosing measurement based on the pressor unit.(NCI) | Pressor Unit | ||
SCOOPFUL | C48536 | Scoopful Dosing Unit | A dosing measurement based on the scoopful unit.(NCI) | Scoopful Dosing Unit | ||
SPRAY | C48537 | Spray Dosing Unit | A dosing measurement based on the spray unit.(NCI) | Spray Dosing Unit | ||
STRIP | C48538 | Strip Dosing Unit | A dosing measurement based on the strip unit.(NCI) | Strip Dosing Unit | ||
SUPPOSITORY | C48539 | Suppository Dosing Unit | A dosing measurement based on the suppository unit.(NCI) | Suppository Dosing Unit | ||
SYRINGE | C48540 | Syringe Dosing Unit | A dosing measurement based on the syringe unit.(NCI) | Syringe Dosing Unit | ||
Tbsp | C48541 | Tablespoon Dosing Unit | A unit of volume informally used in pharmacy. The tablespoon has been standardized at 15 milliliters in US, Britain, Canada, and New Zealand, and at 20 milliliters in Australia and some European countries.(NCI) | Tablespoon Dosing Unit | ||
TABLET | C48542 | Tablet Dosing Unit;tab | A dosing measurement based on the tablet unit.(NCI) | Tablet Dosing Unit | ||
TAMPON | C48543 | Tampon Dosing Unit | A dosing measurement based on the tampon unit.(NCI) | Tampon Dosing Unit | ||
tsp | C48544 | Teaspoon Dosing Unit | A unit of volume used in pharmacy equal to 5 milliliters.(NCI) | Teaspoon Dosing Unit | ||
TRACE | C48547 | Trace Dosing Unit | An extremely small amount.(NCI) | Trace Dosing Unit | ||
TROCHE | C48548 | Troche Dosing Unit | A dosing measurement based on the troche unit.(NCI) | Troche Dosing Unit | ||
TUBE | C48549 | Tube Dosing Unit | A dosing measurement based on the tube unit.(NCI) | Tube Dosing Unit | ||
VIAL | C48551 | Vial Dosing Unit | A dosing measurement based on the vial unit.(NCI) | Vial Dosing Unit | ||
WAFER | C48552 | Wafer Dosing Unit | A dosing measurement based on the wafer unit.(NCI) | Wafer Dosing Unit | ||
yd | C48553 | Yard | A unit of length equal to 3 feet, or 36 inches, or 0.9144 meter.(NCI) | Yard | ||
mol/L | C48555 | Mole per Liter;mol/L;mmol/mL | A unit of concentration (molarity unit) equal to one mole of solute in one liter of solution.(NCI) | Mole per Liter | ||
%(v/v) | C48571 | Percent Volume per Volume;vol% | A percent ratio of volume to volume, defined by the equation: [volume of solute (in ml)/ volume of solution (in ml)](100), typically used for admixtures of solutions.(NCI) | Percent Volume per Volume | ||
IU | C48579 | International Unit | The unitage assigned by the WHO (World Health Organization) to International Biological Standards - substances, classed as biological according to the criteria provided by WHO Expert Committee on Biological Standardization (e.g. hormones, enzymes, and vaccines), to enable the results of biological and immunological assay procedures to be expressed in the same way throughout the world. The definition of an international unit is generally arbitrary and technical, and has to be officially approved by the International Conference for Unification of Formulae.(NCI) | International Unit | ||
QUANTITY SUFFICIENT | C48590 | Quantity Sufficient | A quantity of an ingredient or product needed to bring up a volume or weight of the preparation to a final amount as it is indicated in the prescription; also refers to a determination of an adequate supply of medicine to fulfill either a prescribed amount or a sufficient quantity to provide treatment over a specified time frame.(NCI) | Quantity Sufficient | ||
cm | C49668 | Centimeter | A basic unit of length equal to one hundredth of a meter or approximately 0.393700787 inch. | Centimeter | ||
mmHg | C49670 | Millimeter of Mercury;torr;Torr | A unit of pressure equal to 0.001316 atmosphere and equal to the pressure indicated by one millimeter rise of mercury in a barometer at the Earth's surface. (NCI) | Millimeter of Mercury | ||
kg/m2 | C49671 | Kilogram per Square Meter | A unit expressed as kilogram of mass per square meter of area.(NCI) | Kilogram Per Square Meter | ||
BEATS/MIN | C49673 | Beats per Minute | The number of heartbeats measured per minute time. (NCI) | Beats per Minute | ||
BREATHS/MIN | C49674 | Breaths per Minute | The number of breaths (inhalation and exhalation) taken per minute time. (NCI) | Breaths per Minute | ||
CUP | C54703 | Cup Dosing Unit | A dosing measurement based on the cup unit.(NCI) | Cup Dosing Unit | ||
atm | C54711 | Atmosphere | A unit of pressure, equal to a barometer reading of 760 mm Hg. 1 atmosphere is 101325 Pascals and 1.01325 bar. This unit of pressure is roughly equal to the average atmospheric pressure at sea level on the earth.(NCI) | Atmosphere | ||
RING | C62609 | Ring Dosing Unit | A dosing measurement based on the ring unit.(NCI) | Ring Dosing Unit | ||
mmol/L | C64387 | Millimole per Liter;umol/mL;Micromole per Milliliter;mol/m3;Mole per Cubic Meter;mcmol/mL;mmol/L;nmol/uL | A unit of concentration (molarity unit) equal to one thousandth of a mole (10E-3 mole) of solute per one liter of solution.(NCI) | Millimole per Liter | ||
pg | C64551 | Picogram | A unit of mass equal to one trillionth of a gram (10E-12 gram).(NCI) | Picogram | ||
fg | C64552 | Femtogram | A unit of mass equal to one quadrillionth of a gram (10E-15 gram).(NCI) | Femtogram | ||
ag | C64553 | Attogram | A unit of mass equal to one quintillionth of a gram (10E-18 gram).(NCI) | Attogram | ||
cg | C64554 | Centigram | A unit of mass equal to one hundredth of a gram.(NCI) | Centigram | ||
dram | C64564 | Dram | A unit of mass equal to 1/16 Avoirdupois ounce or 1/256 Avoirdupois pound. One dram equals approximately 1.7718451953125 grams.(NCI) | Dram Mass Unit | ||
kg/L | C64566 | Kilogram per Liter;g/mL;Gram per Milliliter;gram/mL;kg/L;mg/uL | A unit of mass concentration defined as the concentration of one kilogram of a substance in unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one kilogram occupies the volume one liter.(NCI) | Kilogram per Liter | ||
mg/L | C64572 | g/m3;Gram per Cubic Meter;mg/L;Microgram per Milliliter;Milligram per Liter;mcg/mL;ng/uL;ug/mL | A unit of mass concentration equal to the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of substance which mass equal to one gram occupies the volume one cubic meter.(NCI) | Microgram per Milliliter | ||
mL/min | C64777 | Milliliters per Minute | A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter travels during the period of time equal to one minute.(NCI) | Milliliter per Minute | ||
g/dL | C64783 | Gram per Deciliter;g% | A unit of mass concentration defined as the concentration of one gram of a substance per unit volume of the mixture equal to one deciliter (100 milliliters). The concept also refers to the metric unit of mass density (volumic mass) defined as the density of substance which mass equal to one gram occupies the volume one deciliter.(NCI) | Gram per Deciliter | ||
pmol | C65045 | Picomole | A unit of amount of substance equal to a trillionth (10E-12) of a mole.(NCI) | Picomole | ||
PUFF | C65060 | Puff | A means of delivering a defined dose of a therapeutic aerolized solution into either the upper or lower respiratory tract. Metered-dose inhalers or spray pumps are devices that provide a puff dose for delivery into either the oral or the nasal cavity.(NCI) | Puff Dosing Unit | ||
mm2 | C65104 | Square Millimeter | A unit of area measurement equal to a square measuring one millimeter on each side. One square millimeter is equal to 10(E-2) square centimeter and 10(E-6) square meter.(NCI) | Square Millimeter | ||
tuberculin unit | C65132 | Tuberculin Unit | An arbitrary unit of tuberculin dosage defined by comparison of clinical response with a preparation of the purified protein derivative standardized for use in humans for tuberculin skin test reaction.(NCI) | Tuberculin Unit | ||
mL/h | C66962 | Milliliters per Hour | A unit of volumetric flow rate defined as the rate at which one milliliter of matter travels during the period of time equal to one hour.(NCI) | Milliliter per Hour | ||
per sec | C66965 | Per Second | The number of occurrences of something within a second of time.(NCI) | Per Second | ||
per min | C66967 | Per Minute | The number of occurrences of something within a minute of time.(NCI) | Per Minute | ||
mg/h | C66969 | Milligram per Hour | A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter travels to a given object or space over a period of time equal to one hour.(NCI) | Milligram per Hour | ||
mg/dL | C67015 | Milligram per Deciliter;mg% | A unit of mass concentration defined as the concentration of one milligram of a substance in unit volume of the mixture equal to one cubic deciliter or 100 cubic centimeters. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one cubic deciliter or 100 cubic centimeters.(NCI) | Milligram per Deciliter | ||
cal | C67193 | Calorie | A measurement of nutritional energy. The quantity of thermal energy required to raise one gram of water one degree Centigrade under standard conditions. 1 calorie equals 4.186 joules. (NCI) | calorie | ||
kcal | C67194 | Kilogram-Calorie | A unit of energy defined as the amount of heat required to raise the temperature of one kilogram of pure water by one degree Centigrade under standard conditions (the specific heat of the water at 15 degrees Celsius and the constant pressure of 101.325 kilopascals or one atm being defined as unity), equal to approximately 4.1855 kJ. It is also is used by nutritionists in measuring the energy-producing potential of food as a unit of potential energy contained by a substance, which can be liberated when the material is oxidized, usually by combustion in the presence of oxygen.(NCI) | Calorie | ||
PFU | C67264 | Plaque Forming Unit | A measure of viable infectious entities (e.g. viral particle or group of particles) in the specimen or product defined as the smallest quantity that can produce a cytopathic effect in the host cell culture challenged with the defined inoculum, visible under the microscope or/and to the naked eye as a plaque. A number of plaque forming units (PFU) per unit volume is a conventional way to refer the titer of an infective entity in a specimen or preparation.(NCI) | Plaque Forming Unit | ||
eq | C67273 | Equivalent Weight | A unit of relative amount of a substance that combines with or displaces 8.0 grams of oxygen or 1.008 gram of hydrogen. The unit is usually expressed in grams and is equal to the amount of substance that gains or loses one mole of electrons in a redox reaction, or to the amount of substances that releases or accepts one mole of hydrogen ions in a neutralization reaction; or to the amount of electrolyte that carries one mole of positive or negative charge. This is a large unit and measurements are more often done in its derivatives, e.g. in milliequivalents.(NCI) | Equivalent Weight | ||
HPF | C67274 | High Power Field | The area visible under the maximum magnification power of the objective being used in microscopy.(NCI) | High Power Field | ||
g/m2 | C67282 | Gram per Square Meter | A unit of area density defined as a spread rate at which one gram of a substance is spread over the area of one square meter. It is equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit.(NCI) | Gram per Square Meter | ||
ug/L | C67306 | mg/m3;Microgram per Liter;Milligram per Cubic Meter;Nanogram per Milliliter;ug/L;ng/mL;mcg/L | A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one microgram occupies the volume one liter.(NCI) | Microgram per Liter | ||
LPF | C67307 | Low Power Field | The area visible in one view field of the microscope under the low magnification of the objective being used in microscopy.(NCI) | Low Power Field | ||
mV | C67324 | Millivolt | A unit of electric potential and electromotive force equal to one thousandth of a volt.(NCI) | Millivolt | ||
ng/dL | C67326 | Nanogram per Deciliter | A unit of mass concentration defined as the concentration of one nanogram of a substance in unit volume of the mixture equal to one deciliter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one nanogram occupies the volume one deciliter.(NCI) | Nanogram per Deciliter | ||
ng/L | C67327 | ug/m3;Microgram per Cubic Meter;ng/L;pg/mL | A unit of mass concentration defined as the concentration of one nanogram of a substance per one liter of the mixture, or one picogram of a substance in unit volume of the mixture equal to one milliliter, or one microgram of a substance per one cubic meter of the mixture. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of substance which mass equal to one nanogram occupies the volume one liter.(NCI) | Nanogram per Liter | ||
nm | C67328 | Nanometer | A unit of length equal to one billionth of a meter (10E-9 meter). Nanometer is used as a unit for light wavelength measurement.(NCI) | Nanometer | ||
osm | C67330 | Osmole | A unit of osmotic pressure equal to that of an ideal solution of a nondissociating substance that has a concentration of one mole of solute per liter of solution.(NCI) | Osmole | ||
psi | C67334 | Pounds per Square Inch | A unit of pressure equivalent to 6.894757 kilopascals, or 703.0696 kilograms per square meter, or 51.71507 millimeters of mercury.(NCI) | Pound per Square Inch | ||
10^6 IU | C67335 | Million International Units;Million IU | A unit of biological activity equal to 10 to the sixth power international units. | Million International Units | ||
nCi | C67352 | Nanocurie | A unit of radioactivity equal to one billionth of Curie or 37 Becquerels, and corresponding to a radioactivity of 37 atomic disintegrations per second.(NCI) | Nanocurie | ||
IU/L | C67376 | International Unit per Liter;IU/L;mIU/mL | Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one liter of system volume.(NCI) | International Unit per Liter | ||
IU/mL | C67377 | International Unit per Milliliter;kIU/L;Kilo International Unit per Liter | Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milliliter of system volume.(NCI) | International Unit per Milliliter | ||
IU/kg | C67379 | International Unit per Kilogram | An arbitrary unit of substance content expressed in international units of biological activity per one kilogram of mass of the system. It is also used as a dose calculation unit expressed in international units of biological activity per one kilogram of body mass.(NCI) | International Unit per Kilogram | ||
IU/mg | C67380 | International Unit per Milligram | Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one milligram of substance.(NCI) | International Unit per Milligram | ||
L/min | C67388 | Liters per Minute | A unit of volumetric flow rate defined as the rate at which one liter of matter travels during the period of time equal to one minute.(NCI) | Liter per Minute | ||
ug/h | C67394 | Micrograms per Hour;mcg/h | A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter travels to a given object or space over a period of time equal to one hour.(NCI) | Microgram per Hour | ||
ug/kg | C67396 | mcg/kg;Microgram per Kilogram;ng/g;ug/kg | A unit of a mass fraction expressed as a number of micrograms of substance per kilogram of mixture. The unit is also used as a dose calculation unit.(NCI) | Microgram per Kilogram | ||
ukat/L | C67397 | Microkatal per Liter;mckat/L | Unit of catalytic activity concentration defined as activity equal to one millionth of katal per one liter of the system volume.(NCI) | Microkatal per Liter | ||
mg/day | C67399 | Milligram per Day | A unit of measure referring to the ratio between mass expressed in milligrams per day.(NCI) | Milligram per 24 Hours | ||
mg/kg | C67401 | Milligram per Kilogram | A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.(NCI) | Milligram per Kilogram | ||
mg/m2 | C67402 | Milligram per Square Meter | A unit of area density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit.(NCI) | Milligram per Square Meter | ||
umol/day | C67406 | Micromoles per Day;mcmol/day | A unit of amount of substance flow rate equivalent to the rate at which one millionth of a mole of substance travels to a given object or space over a period of time equal to 24 hours.(NCI) | Micromole per 24 Hours | ||
mm/h | C67419 | Millimeter per Hour | A unit of both speed (scalar) and velocity (vector), defined as the distance of one millimeter travels per unit time equal to one hour.(NCI) | Millimeter per Hour | ||
mmol/day | C67420 | Millimole per 24 Hours | A unit of amount of substance flow rate equivalent to the rate at which one thousandth of a mole of substance travels or is delivered to a given object or space over a period of time equal to 24 hours.(NCI) | Millimole per 24 Hours | ||
nmol/L | C67432 | Nanomole per Liter | A unit of concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute in one liter of solution.(NCI) | Nanomole per Liter | ||
pmol/L | C67434 | Picomole per Liter;fmol/mL;Femtomole per Milliliter | A unit of concentration (molarity unit) equal to one trillionth of a mole (10E-12 mole) in one liter of solution.(NCI) | Picomole per Liter | ||
RNA copies/mL | C67441 | RNA Copies per Milliliter | The unit of concentration of Ribonucleic Acid (RNA) copies expressed as a number of copies in unit volume equal to one milliliter.(NCI) | RNA Copy per Milliliter | ||
mEq/day | C67471 | Milliequivalents per Day | A unit of relative amount of substance flow rate equivalent to the rate at which one thousandth of an equivalent of substance travels to a given object or space over a period of time equal to twenty four hours.(NCI) | Milliequivalent per 24 Hours | ||
mEq/L | C67474 | Milliequivalent Per Liter;mval/L;Millivalent per Liter | A concentration unit measured as a number of milliequivalents of solute per liter of solution.(NCI) | Milliequivalent per Liter | ||
mEq/kg | C67475 | Milliequivalent Per Kilogram | A unit of relative amount of substance content equivalent to the content at which one kilogram of mixture contains one thousandth of an equivalent of a component. The unit is also used as a dose calculation unit.(NCI) | Milliequivalent per Kilogram | ||
deg | C68667 | Degree Unit of Plane Angle | A unit of plane angle measurement equal to the length of the arc cut out by the angle, divided by the circumference of the circle, and multiplied by 360. The symbol for degrees is a small superscript circle. One radian is about 57 degrees and one degree is pi/180 radians.(NCI) | Degree Unit of Plane Angle | ||
dmol | C68685 | Decimole | A unit of amount of substance equal to one tenth of a mole (10E-1 mole).(NCI) | Decimole | ||
cmol | C68687 | Centimole | A unit of amount of substance equal to one hundredth of a mole (10E-2 mole).(NCI) | Centimole | ||
mmol/g | C68740 | Millimole per Gram | A unit amount of substance content (molality unit) defined as one mole of solute per one kilogram of solvent.(NCI) | Mole per Kilogram | ||
fmol | C68854 | Femtomole | A unit of amount of substance equal to one quadrillionth of a mole (10E-15 mole).(NCI) | Femtomole | ||
amol | C68855 | Attomole | A unit of amount of substance equal to one quintillionth of a mole (10E-18 mole).(NCI) | Attomole | ||
ft3 | C68859 | Standard Cubic Foot | A unit used in physical chemistry to express the amount of substance of an ideal gas in one cubic foot at 60 degrees Fahrenheit and pressure of one atmosphere.(NCI) | Standard Cubic Foot | ||
in2 | C68871 | Square Inch | A unit of area equal to the area of a square with sides of one inch. It is equal to 6.4516 square centimeters.(NCI) | Square Inch | ||
ELISA unit | C68875 | Enzyme-Linked Immunosorbent Assay Unit | A unit for measuring concentration or/and reactivity of a test substance (an antigen or antibody of interest) as defined in the literature reference standard for the particular quantitative enzyme-linked immunosorbent assay method. The enzyme-linked immunosorbent assay unit is used to express potency of immunologically active substances and products, e.g. vaccines.(NCI) | Enzyme-Linked Immunosorbent Assay Unit | ||
ELISA unit/dose | C68876 | Enzyme-Linked Immunosorbent Assay Unit per Dose | A unit for measuring potency of immunologically active substance in a product determined as reactivity in a quantitative immunoassay for particular antigen or antibody and expressed per quantity of preparation used as a single dose.(NCI) | Enzyme-Linked Immunosorbent Assay Unit per Dose | ||
ELISA unit/mL | C68877 | Enzyme-Linked Immunosorbent Assay Unit per Milliliter | A unit for measuring potency of immunologically active substance in a product determined as reactivity in a quantitative immunoassay for particular antigen or antibody and expressed per unit volume equal to one milliliter.(NCI) | Enzyme-Linked Immunosorbent Assay Unit per Milliliter | ||
Log10 ELISA unit | C68878 | Log10 Enzyme-Linked Immunosorbent Assay Unit | A logarithmic-scale (base 10) unit for measuring concentration and/or reactivity of a test substance (an antigen or antibody of interest) as defined in the literature reference for the particular quantitative enzyme-linked immunosorbent assay method.(NCI) | Log10 Enzyme-Linked Immunosorbent Assay Unit | ||
Log10 ELISA unit/dose | C68879 | Log10 Enzyme-Linked Immunosorbent Assay Unit per Dose | A logarithmic-scale (base 10) unit for measuring potency of immunologically active substance in a product determined as reactivity in a quantitative immunoassay for particular antigen or antibody and expressed per quantity of preparation used as a single dose.(NCI) | Log10 Enzyme-Linked Immunosorbent Assay Unit per Dose | ||
mol/mL | C68891 | Mole per Milliliter | A unit of concentration (molarity unit) equal to one mole of solute in one milliliter of solution.(NCI) | Mole per Milliliter | ||
mmol/kg | C68892 | Millimole per Kilogram | A unit of amount of substance content (molality unit) defined as one thousandth of mole (10E-3 mole) of solute per one kilogram of solvent.(NCI) | Millimole per Kilogram | ||
mol/g | C68893 | Mole per Gram | A unit of amount of substance content (molality unit) defined as one mole of solute per one gram of solvent.(NCI) | Mole per Gram | ||
mol/mg | C68894 | Mole per Milligram | A unit of amount of substance content (molality unit) defined as one mole of solute per one milligram of solvent.(NCI) | Mole per Milligram | ||
10^3 CFU | C68895 | Thousand Colony Forming Units;Thousand CFU | A unit of measurement of viable bacterial numbers equal to 10 to the third power colony forming units. | Thousand Colony Forming Units | ||
10^6 CFU | C68896 | Million Colony Forming Units;Million CFU | A unit of measurement of viable bacterial numbers equal to 10 to the sixth power colony forming units. | Million Colony Forming Units | ||
10^9 CFU | C68897 | Billion Colony Forming Units;Billion CFU | A unit of measurement of viable bacterial numbers equal to 10 to the ninth power colony forming units. | Billion Colony Forming Units | ||
CFU/g | C68898 | Colony Forming Unit per Gram | A unit of measurement of viable bacterial organisms in a unit mass of substance of interest defined as the number of colony forming units in one gram of substance.(NCI) | Colony Forming Unit per Gram | ||
10^3 CFU/g | C68899 | Thousand Colony Forming Units per Gram;Thousand CFU/g | A unit of measurement of viable bacterial organisms in a unit mass of substance of interest defined as the number of 10 to the third power colony forming units in one gram of substance. | Thousand Colony Forming Units per Gram | ||
10^6 CFU/g | C68900 | Million Colony Forming Units per Gram;Million CFU/g | A unit of measurement of viable bacterial organisms in a unit mass of substance of interest defined as the number of 10 to the sixth power colony forming units in one gram of substance. | Million Colony Forming Units per Gram | ||
10^9 CFU/g | C68901 | Billion Colony Forming Units per Gram;Billion CFU/g | A unit of measurement of viable bacterial organisms in a unit mass of substance of interest defined as the number of 10 to the ninth power colony forming units in one gram of substance. | Billion Colony Forming Units per Gram | ||
CFU/mL | C68902 | Colony Forming Unit per Milliliter | A unit of measurement of viable bacterial organisms in a unit volume of substance of interest defined as the number of colony forming units in one milliliter of substance.(NCI) | Colony Forming Unit per Milliliter | ||
10^3 CFU/mL | C68903 | Thousand Colony Forming Units per Milliliter;Thousand CFU/mL | A unit of measurement of viable bacterial organisms in a unit volume of substance of interest defined as the number of 10 to the third power colony forming units in one milliliter of substance. | Thousand Colony Forming Units per Milliliter | ||
10^6 CFU/mL | C68904 | Million Colony Forming Units per Milliliter;Million CFU/mL | A unit of measurement of viable bacterial organisms in a unit volume of substance of interest defined as the number of 10 to the sixth power colony forming units in one milliliter of substance. | Million Colony Forming Units per Milliliter | ||
10^9 CFU/mL | C68905 | Billion Colony Forming Units per Milliliter;Billion CFU/mL | A unit of measurement of viable bacterial organisms in a unit volume of substance of interest defined as the number of 10 to the ninth power colony forming units in one milliliter of substance. | Billion Colony Forming Units per Milliliter | ||
Gauss | C68915 | Gauss | The unit of magnetic flux density. A field of one Gauss exerts a force on a conductor, placed in the field of 0.1 dyne per Ampere of current per centimeter of conductor. One Gauss represents a magnetic flux of one Maxwell per square centimeter of cross-section perpendicular to the field. One Gauss equals 10-4 Tesla.(NCI) | Gauss | ||
kg/cm2 | C69094 | Kilogram per Square Centimeter | A unit of spread rate of a substance by mass expressed in kilograms per area unit equal to one square centimeter, used also as a measure of area density and as a dose calculation unit.(NCI) | Kilogram Per Square Centimeter | ||
g/kg | C69104 | Gram per Kilogram;mg/g;Milligram per Gram | A unit of a mass fraction expressed as a number of grams of substance per kilogram of mixture. The unit is also used as a dose calculation unit.(NCI) | Gram per Kilogram | ||
ppth | C69112 | Part per Thousand | A unit of proportion equal to 10E-3.(NCI) | Part per Thousand | ||
pm | C69148 | Picometer | A unit of length equal to one trillionth of a meter (10E-12 meter).(NCI) | Picometer | ||
uL/mL | C69175 | Microliter per Milliliter;mcL/mL | A unit of volume fraction expressed as a number of microliters of the constituent per the volume of the system represented in milliliters.(NCI) | Microliter per Milliliter | ||
nL | C69188 | Nanoliter | A unit of volume equal to one billionth of a liter (10E-9 liter).(NCI) | Nanoliter | ||
gtt | C69442 | Drop | A unit of volume equal to 0.05 milliliter (20 drops/ml).(NCI) | Medical Drop | ||
mol/mol | C70455 | Mole per Mole | A unit of fraction expressed as the ratio of the amount of substance of solute in moles to the amount of substance of the mixture in moles.(NCI) | Mole per Mole | ||
rpm | C70469 | Revolution per Minute | A unit of frequency equal to one revolution per unit of time equal to one minute.(NCI) | Revolution per Minute | ||
dyn | C70470 | Dyne | A unit of force defined as the force that accelerates a mass of one gram at the rate of one centimeter per second squared. One dyne is equal to 10E-5 Newton and 2.248E-6 pounds of force.(NCI) | Dyne | ||
log10 EID 50 | C70479 | Log10 50 Percent Embryo Infective Dose | A potency unit for measuring infectious activity of a biologic product or infectious agent equal to a base-10 logarithm of amount of product or agent preparation that causes infection in the 50% of embryos (such as chicken embryos) used in the product potency assay or pathogen activity assay.(NCI) | Log10 50 Percent Embryo Infective Dose | ||
log EID 50/dose | C70480 | Log10 50 Percent Embryo Infective Dose per Dose | A logarithmic-scale (base 10) potency unit for measuring infectious activity of a biologic product or infectious agent preparation equal to the potency at which one dose of infectious material contains one 50 percent embryo infective dose.(NCI) | Log10 50 Percent Embryo Infective Dose per Dose | ||
log10 CCID 50 | C70484 | Log10 50 Percent Cell Culture Infective Dose | A potency unit for measuring infectious activity of a biologic product or infectious agent preparation equal to a base-10 logarithm of amount of product or agent preparation that causes infection in the 50% of the cell culture-containing vessels inoculated with that dilution of infectious material in the product potency assay or pathogen activity assay.(NCI) | Log10 50 Percent Cell Culture Infective Dose | ||
log10 CCID 50/dose | C70485 | Log10 50 Percent Cell Culture Infective Dose per Dose | A logarithmic-scale (base 10) potency unit for measuring infectious activity of a biologic product or infectious agent preparation equal to the potency at which one dose of infectious material contains one 50 percent cell culture infective dose.(NCI) | Log10 50 Percent Cell Culture Infective Dose per Dose | ||
log10 TCID 50 | C70488 | Log10 50 Percent Tissue Culture Infective Dose | A potency unit for measuring infectious activity of a biologic product or infectious agent preparation equal to a base-10 logarithm of amount of product or agent preparation that causes infection in the 50% of the tissue culture-containing flasks inoculated with that dilution of infectious material in the product potency assay or pathogen activity assay.(NCI) | Log10 50 Percent Tissue Culture Infective Dose | ||
log10 TCID 50/dose | C70489 | Log10 50 Percent Tissue Culture Infective Dose per Dose | A logarithmic-scale (base 10) potency unit for measuring infectious activity of a biologic product or infectious agent preparation equal to the potency at which one dose of infectious material contains one 50 percent tissue culture infective dose.(NCI) | Log10 50 Percent Tissue Culture Infective Dose per Dose | ||
kIU | C70492 | Kilo International Unit | A unit equal to one thousand international units.(NCI) | Kilointernational Unit | ||
IU/g | C70493 | International Unit per Gram | A unit of measure of quantity of substance per unit mass, expressed in terms of the International Unit per grams.(NCI) | International Unit per Gram | ||
anti-Xa IU | C70497 | Anti-Xa Activity International Unit | A unit of unfractionated or low molecular weight heparin anticoagulation potency determined as the amount that neutralizes one unit of coagulation factor Xa preparation defined as an international biological standard by WHO (World Health Organization) First International Low Molecular Weight Heparin Reference Standard.(NCI) | Anti-Xa Activity International Unit | ||
anti-Xa IU/mL | C70498 | Anti-Xa Activity International Unit per Milliliter | A specific anticoagulation activity of unfractionated or low molecular weight heparin on factor Xa, expressed as a number of international anti-Xa heparin units per one milliliter of plasma.(NCI) | Anti-Xa Activity International Unit per Milliliter | ||
AgU/mL | C70500 | Antigen Unit per Milliliter | A measure of an antigen potency defined as a number of antigen units per one milliliter of product.(NCI) | Antigen Unit per Milliliter | ||
DAgU | C70501 | D Antigen Unit | A unit of potency of poliovirus vaccine used for poliomyelitis prevention. The unit is poliovirus type-specific.(NCI) | D Antigen Unit | ||
DAgU/mL | C70502 | D Antigen Unit per Milliliter | A unit of potency of poliovirus vaccine expressed as a number of D antigen units per one milliliter of vaccine formulation.(NCI) | D Antigen Unit per Milliliter | ||
AU/mL | C70504 | Allergy Unit per Milliliter | Unit of measure of potency of allergenic product expressed as a number of allergy units per one milliliter of formulation.(NCI) | Allergy Unit per Milliliter | ||
BAU | C70505 | Bioequivalent Allergy Unit | A unit used for standardization of an allergenic product based on evaluation of product potency against reference standard in combined in vivo (skin test) and in vitro (IgE-based ELISA) testing.(NCI) | Bioequivalent Allergy Unit | ||
tuberculin unit/mL | C70506 | Tuberculin Unit per Milliliter | A unit of biologic activity of tuberculin expressed as a number of arbitrary units of tuberculin in one milliliter of preparation.(NCI) | Tuberculin Unit per Milliliter | ||
mkat | C70507 | Millikatal | A unit of catalytic activity measurement equal to one thousandth of one katal (10E-3 katal).(NCI) | Millikatal | ||
nkat | C70508 | Nanokatal | A unit of catalytic activity measurement equal to one billionth of one katal (10E-9 katal).(NCI) | Nanokatal | ||
pkat | C70509 | Picokatal | A unit of catalytic activity measurement equal to trillionth of one katal (10E-12 katal).(NCI) | Picokatal | ||
nkat/L | C70510 | Nanokatal per Liter | A unit of catalytic activity concentration defined as the catalytic activity of the component equal to one billionth of one katal (10E-9 katal) in the unit volume of the system equal to one liter.(NCI) | Nanokatal per Liter | ||
kBq | C70511 | Kilobecquerel | A unit of radioactivity equal to one thousand nuclear disintegrations or other nuclear transformations per second, or to 10E3 Becquerels.(NCI) | Kilobecquerel | ||
MBq | C70512 | Megabecquerel | A unit of radioactivity equal to one million nuclear disintegrations or other nuclear transformations per second, or to 10E6 Becquerels.(NCI) | Megabecquerel | ||
GBq | C70513 | Gigabecquerel | A unit of radioactivity equal to one billion nuclear disintegrations or other nuclear transformations per second, or to 10E9 Becquerels.(NCI) | Gigabecquerel | ||
Bq/kg | C70521 | Becquerel per Kilogram | A unit of specific radioactivity (massic activity) equal to activity of one Becquerel of the sample with total mass of one kilogram.(NCI) | Becquerel per Kilogram | ||
Bq/g | C70522 | Becquerel per Gram | A unit of specific radioactivity (massic activity) equal to activity of one Becquerel of the sample with total mass of one gram.(NCI) | Becquerel per Gram | ||
Bq/ug | C70523 | Becquerel per Microgram;kBq/mg;Kilobecquerel per Milligram;MBq/g;Megabecquerel per Gram;Bq/mcg | A unit of specific radioactivity (massic activity) equal to activity of one Becquerel of the sample with total mass of one microgram.(NCI) | Becquerel per Microgram | ||
Bq/mg | C70524 | Becquerel per Milligram;kBq/g;Kilobecquerel per Gram | A unit of specific radioactivity (massic activity) equal to activity of one Becquerel of the sample with total mass of one milligram.(NCI) | Becquerel per Milligram | ||
GBq/g | C70525 | Gigabecquerel per Gram;kBq/ug;Kilobecquerel per Microgram | A unit of specific radioactivity (massic activity) equal to activity of one gigabecquerel of the sample with total mass of one gram.(NCI) | Gigabecquerel per Gram | ||
GBq/ug | C70526 | Gigabecquerel per microgram;MBq/ng;Megabecquerel per nanogram;GBq/mcg | A unit of specific radioactivity (massic activity) equal to activity of one gigabecquerel of the sample with total mass of one microgram.(NCI) | Gigabecquerel per Microgram | ||
GBq/mg | C70527 | Gigabecquerel per Milligram;Megabecquerel per Microgram;MBq/mcg;MBq/ug | A unit of specific radioactivity (massic activity) equal to activity of one gigabecquerel of the sample with total mass of one milligram.(NCI) | Gigabecquerel per Milligram | ||
Ci/g | C70528 | Curie per Gram;uCi/ug;Microcurie per Microgram;mCi/mg;Millicurie per Milligram | A unit of specific radioactivity (massic activity) equal to activity of one Curie of the sample with total mass of one gram.(NCI) | Curie per Gram | ||
Ci/kg | C70529 | Curie per Kilogram;uCi/mg;Microcurie per Milligram;mCi/g;Millicurie per Gram | A unit of specific radioactivity (massic activity) equal to activity of one Curie of the sample with total mass of one kilogram.(NCI) | Curie per Kilogram | ||
Ci/ug | C70530 | Curie per Microgram;Ci/mcg | A unit of specific radioactivity (massic activity) equal to activity of one Curie of the sample with total mass of one microgram.(NCI) | Curie per Microgram | ||
Ci/mg | C70531 | Curie per Milligram;mCi/ug;Millicurie per Microgram | A unit of specific radioactivity (massic activity) equal to activity of one Curie of the sample with total mass of one milligram.(NCI) | Curie per Milligram | ||
EID 50 | C70532 | 50 Percent Embryo Infective Dose | Amount of infectious agent or biological product that causes infection in the 50% of embryos such as chicken embryos used in the product potency assay or pathogen activity assay.(NCI) | 50 Percent Embryo Infective Dose | ||
EID 50/dose | C70533 | 50 Percent Embryo Infective Dose per Dose | A potency unit for measuring infectious activity of a biologic product or an infectious agent preparation equal to the potency at which one dose of infectious material contains one 50 percent embryo infective dose.(NCI) | 50 Percent Embryo Infective Dose per Dose | ||
CCID 50 | C70534 | 50 Percent Cell Culture Infective Dose | A potency unit defined as a minimal dose of infectious material at which preparation causes cytopathic effects (changes in the morphology and metabolism of cell culture cells, indicating cell death, due to suspected infection) in the 50% of the cell culture-containing vessels inoculated with that dilution of infectious material.(NCI) | 50 Percent Cell Culture Infective Dose | ||
CCID 50/dose | C70535 | 50 Percent Cell Culture Infective Dose per Dose | A potency unit equal to the potency at which one dose of preparation contains one 50 percent cell culture infective dose.(NCI) | 50 Percent Cell Culture Infective Dose per Dose | ||
TCID 50/dose | C70537 | 50 Percent Tissue Culture Infective Dose per Dose | A potency unit equal to the potency at which one dose of preparation contains one 50 percent tissue culture infective dose.(NCI) | 50 Percent Tissue Culture Infective Dose per Dose | ||
ukat | C70562 | Microkatal;mckat | A unit of catalytic activity measurement equal to one millionth of katal (10E-6 katal).(NCI) | Microkatal | ||
ppb | C70565 | Part per Billion | A unit of measure referring to one entity counted per one billion entities.(NCI) | Per Billion | ||
pptr | C70566 | Parts per Trillion | A unit of measure referring to one entity counted per one trillion entities.(NCI) | Per Trillion | ||
mCi/kg | C70570 | Millicurie per Kilogram;uCi/g;Microcurie per Gram | A unit of specific radioactivity (massic activity) equal to activity of one millicurie of the sample with total mass of one kilogram.(NCI) | Millicurie per Kilogram | ||
uCi/kg | C70571 | Microcurie per Kilogram;mcCi/kg | A unit of specific radioactivity (massic activity) equal to activity of one microcurie of the sample with total mass of one kilogram.(NCI) | Microcurie per Kilogram | ||
Roentgen | C70575 | Roentgen | A unit of exposure to ionizing radiation. One Roentgen is the amount of gamma or x-rays required to produce ions resulting in a charge of 2.58E-4 Coulombs/kilogram of air under standard conditions.(NCI) | Roentgen | ||
mEq/uL | C70578 | Milliequivalent Per Microliter | A concentration unit measured as a number of milliequivalents of solute per microliter of solution.(NCI) | Milliequivalent per Microliter | ||
mEq/g | C70580 | Milliequivalent Per Gram | A unit of relative amount of substance content equivalent to the content at which one gram of mixture contains one thousandth of an equivalent of a component. The unit is also used as a dose calculation unit.(NCI) | Milliequivalent per Gram | ||
mEq/ug | C70581 | Milliequivalent Per Microgram;mEq/mcg | A unit of relative amount of substance content equivalent to the content at which one millionth of a gram of mixture contains one thousandth of an equivalent of a component. The unit is also used as a dose calculation unit.(NCI) | Milliequivalent per Microgram | ||
Bq/L | C71165 | Becquerel per Liter | A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one Becquerel per unit volume equal to one liter.(NCI) | Becquerel per Liter | ||
Bq/uL | C71166 | Becquerel per Microliter;kBq/mL;Kilobecquerel per Milliliter;MBq/L;Megabecquerel per Liter | A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one Becquerel per unit volume equal to one millionth of a liter.(NCI) | Becquerel per Microliter | ||
Bq/mL | C71167 | Becquerel per Milliliter;kBq/L;Kilobecquerel per Liter | A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one Becquerel per unit volume equal to one milliliter or one kilobecquerel per liter.(NCI) | Becquerel per Milliliter | ||
kBq/uL | C71168 | Kilobecquerel per Microliter;GBq/L;Gigabecquerel per Liter;MBq/mL;Megabecquerel per Milliliter | A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one thousand Becquerels per unit volume equal to one millionth of a liter.(NCI) | Kilobecquerel per Microliter | ||
MBq/uL | C71169 | Megabecquerel per Microliter;GBq/mL;Gigabecquerel per Milliliter | A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one million Becquerels per unit volume equal to one millionth of a liter.(NCI) | Megabecquerel per Microliter | ||
Ci/L | C71170 | Curie per Liter;uCi/uL;Microcurie per Microliter | A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one Curie per unit volume equal to one liter.(NCI) | Curie per Liter | ||
Ci/uL | C71171 | Curie per Microliter;Ci/mcL | A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one Curie per unit volume equal to one millionth of a liter.(NCI) | Curie per Microliter | ||
Ci/mL | C71172 | Curie per Milliliter | A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one Curie per unit volume equal to one milliliter.(NCI) | Curie per Milliliter | ||
uCi/L | C71173 | Microcurie per Liter;mcCi/L | A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one millionth of a Curie per unit volume equal to one liter.(NCI) | Microcurie per Liter | ||
mCi/L | C71174 | Millicurie per Liter;uCi/mL;Microcurie per Milliliter | A unit of volumetric radioactivity concentration defined as a concentration of a radionuclide with an activity equal to one thousandth of a Curie per unit volume equal to one liter.(NCI) | Millicurie per Liter | ||
uV | C71175 | Microvolt;mcV | A unit of an electric potential and electromotive force equal to one millionth of a volt.(NCI) | Microvolt | ||
cycle/min | C71176 | Cycle per Minute | A unit of frequency equal to the frequency at which one complete execution of a periodically repeated phenomenon, alternation, event, or sequence of events occurs per unit of time equal to one minute.(NCI) | Cycle per Minute | ||
km | C71177 | Kilometer | A unit of distance equal to 1000 meters, 0.621 miles, 1094 yards, or 3281 feet.(NCI) | Kilometer | ||
Mile | C71183 | International Mile | A unit of distance equal to 5280 international feet, 1760 international yards, or 1609.344 meters.(NCI) | Mile | ||
100 IU/mL | C71185 | 100 International units/Milliliter | A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one hundred international units per one milliliter of system volume.(NCI) | 100 International Units per Milliliter | ||
10^3 organisms | C71187 | Thousand Organisms | A unit of measure of quantity of organisms expressed in 10 to the third power of organisms. | Thousand Organisms | ||
10^6 organisms | C71188 | Million Organisms | A unit of measure of quantity of organisms expressed in 10 to the sixth power of organisms. | Million Organisms | ||
10^9 organisms | C71189 | Billion Organisms | A unit of measure of quantity of organisms expressed in 10 to the ninth power of organisms. | Billion Organisms | ||
10^3 organisms/g | C71190 | Thousand Organisms per Gram;Thousand Organisms/g | A unit of measure of organism content expressed in 10 to the third power of organisms per unit of mass equal to one gram. | Thousand Organisms per Gram | ||
10^6 organisms/g | C71191 | Million Organisms per Gram;Million Organisms/g | A unit of measure of organism content expressed in 10 to the sixth power of organisms per unit of mass equal to one gram. | Million Organisms per Gram | ||
10^9 organisms/g | C71192 | Billion Organisms per Gram;Billion Organisms/g | A unit of measure of organism content expressed in 10 to the ninth power of organisms per unit of mass equal to one gram. | Billion Organisms per Gram | ||
10^6 organisms/mg | C71193 | Million Organisms per Milligram;Million Organisms/mg | A unit of measure of organism content expressed in 10 to the sixth power of organisms per unit of mass equal to one milligram. | Million Organisms per Milligram | ||
10^9 organisms/mg | C71194 | Billion Organisms per Milligram;Billion Organisms/mg | A unit of measure of organism content expressed in 10 to the ninth power of organisms per unit of mass equal to one milligram. | Billion Organisms per Milligram | ||
10^3 organisms/mL | C71195 | Thousand Organisms per Milliliter;Thousand Organisms/mL | A unit of measure of organism concentration expressed in 10 to the third power of organisms per unit of volume equal to one milliliter. | Thousand Organisms per Milliliter | ||
10^6 organisms/mL | C71196 | Million Organisms per Milliliter;Million Organisms/mL | A unit of measure of organism concentration expressed in 10 to the sixth power of organisms per unit of volume equal to one milliliter. | Million Organisms per Milliliter | ||
10^9 organisms/mL | C71197 | Billion Organisms per Milliliter;Billion Organisms/mL | A unit of measure of organism concentration expressed in 10 to the ninth power of organisms per unit of volume equal to one milliliter. | Billion Organisms per Milliliter | ||
PFU/dose | C71198 | Plaque Forming Unit per Dose | A unit of potency of a biological product expressed as a quantity of viable infectious entities capable to produce a cytopathic effect in the appropriate cell culture per a single dose of the preparation.(NCI) | Plaque Forming Unit per Dose | ||
PFU/mL | C71199 | Plaque Forming Unit per Milliliter | A unit of potency of a biological product expressed as a quantity of viable infectious entities capable to produce a cytopathic effect in the appropriate cell culture per one milliliter of the preparation.(NCI) | Plaque Forming Unit per Milliliter | ||
bel | C71200 | Bel | A logarithmic ratio unit (base-10 logarithms) used to express relative magnitude of a physical quantity (usually power or intensity) in comparison with a specified or implied reference level. Particularly, Bel is used as a unit of relative sound intensity. In the latter context it is equal to ten decibels or to approximately 1.151293 nepers.(NCI) | Bel | ||
g/cm2 | C71201 | Gram per Square Centimeter | A unit of area density defined as a spread rate at which one gram of a substance is spread over the area of one square centimeter. The unit is also used as a dose calculation unit.(NCI) | Gram per Square Centimeter | ||
kUSP | C71202 | Kilo United States Pharmacopoeia Unit | A unit of potency equal to one thousand US Pharmacopoeia Units.(NCI) | Kilo United States Pharmacopeia Unit | ||
km/h | C71203 | Kilometer Per Hour | A unit of both speed (scalar) and velocity (vector), defined as the distance of one thousand meters travelled per unit time equal to one hour.(NCI) | Kilometer per Hour | ||
NEBULE | C71204 | Nebule | A unit of measurement based on the nebule dosing unit.(NCI) | Nebule Dosing Unit | ||
ug/day | C71205 | Microgram per Day;mcg/day | A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter travels to a given object or space over a period of time equal to twenty four hours. Microgram per day is also a dose administration rate unit equal to the rate at which one millionth of a gram of a product is administered per unit of time equal to twenty four hours.(NCI) | Microgram per Day | ||
mg/kg/min | C71207 | Milligram per Kilogram per Minute | A dose calculation unit equal to one thousandth of a gram of a preparation per one kilogram of body mass administered per unit of time equal to one minute.(NCI) | Milligram per Kilogram per Minute | ||
IU/kg/h | C71209 | International units per Kilogram per Hour | A dose calculation unit equal to one international unit (an arbitrary unit of biological activity) of a product per one kilogram of body mass administered per unit of time equal to one hour.(NCI) | International Unit per Kilogram per Hour | ||
ug/kg/min | C71210 | Microgram per Kilogram per Minute;Gamma per Kilogram per Minute;gamma/kg/min;mcg/kg/min | A dose calculation unit equal to one millionth of a gram of a preparation per one kilogram of body mass administered per unit of time equal to one minute.(NCI) | Microgram per Kilogram per Minute | ||
ug/min | C71211 | Micrograms per Minute;mcg/min | A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter travels to a given object or space over a period of time equal to one minute. Microgram per minute is also a dose administration rate unit equal to the rate at which one millionth of a gram of a product is administered per unit of time equal to one minute.(NCI) | Microgram per Minute | ||
ft | C71253 | Foot | A unit of length defined by the U.S. National Bureau of Standards as 30.48 centimeters. It is equal to 0.3048 meter, 12 inches, or to approximately 0.999998 survey foot.(NCI) | International Foot | ||
FINGERTIP UNIT | C71321 | Fingertip Unit | An arbitrary dosing unit used predominantly for semisolid topical formulations such as cream, ointment, paste, etc. One fingertip unit is the amount of a product that is squeezed out from a standard tube with 5-millimeter diameter nozzle along an adult's fingertip. A fingertip length is defined from the tip of the index finger to the first finger crease. A fingertip dosing unit varies with age and size of the body. The average fingertip unit is equal to approximately 0.5 gram for an adult male and 0.4 gram for an adult female.(NCI) | Fingertip Dosing Unit | ||
SACHET | C71324 | Sachet dosing unit | A dosing unit that contains a solid pharmaceutical preparation in the form of a small packet or bag made from a flexible, often porous material.(NCI) | Sachet Dosing Unit | ||
mg/kg/h | C71362 | Milligram per Kilogram per Hour | A dose calculation unit equal to one thousandth of a gram of a preparation per one kilogram of body mass administered per unit of time equal to one hour.(NCI) | Milligram per Kilogram per Hour | ||
cycle/sec | C71480 | Cycle per Second | A unit of frequency equal to the frequency at which one complete execution of a periodically repeated phenomenon, alternation, event, or sequence of events occurs per unit of time equal to one second.(NCI) | Cycle per Second | ||
Pack Year | C73993 | A quantification of lifetime tobacco exposure defined as (number of cigarettes smoked per day x number of years smoked)/20. One pack-year is smoking 20 cigarettes a day for one year. | Pack Year | |||
U/L | C67456 | mU/mL;Unit per Liter | An arbitrary unit of substance concentration equal to the concentration at which one liter of mixture contains one unit of a substance. (NCI) | Unit per Liter | ||
U/mL | C77607 | Unit per Milliliter | An arbitrary unit of substance content expressed in unit(s) per milliliter. (NCI) | Unit per Milliliter | ||
U/g | C77606 | Unit per Gram | An arbitrary unit of substance content expressed in unit(s) per gram. (NCI) | Unit per Gram | ||
U/mg | C73780 | Unit per Milligram | An arbitrary unit of substance content expressed in unit(s) per milligram. (NCI) | Unit per Milligram | ||
U/kg | C67465 | Unit per Kilogram | An arbitrary unit of substance content expressed in units of biological activity per unit of mass equal to one kilogram. Unit per kilogram is also used as a dose calculation unit expressed in arbitrary units per one kilogram of body mass. (NCI) | Unit per Kilogram | ||
/day | C25473 | Daily;Per Day | Occurring or done each day. (NCI) | Daily | ||
/h | C66966 | Per Hour | A rate of occurrences of something within a period of time equal to sixty minutes. | /h | ||
/HPF | C96619 | per High Powered Field | A unit of measure equal to the instances of an entity per visual field of a microscope set to its maximum magnification power. | Per High Powered Field | ||
/LPF | C96620 | per Low Powered Field | A unit of measure equal to the instances of an entity per visual field of a microscope set to its minimum magnification power. | Per Low Powered Field | ||
/uL | C67254 | Per Microliter | A volume unit equal to one microliter used as a denominator to build a derived unit expressed as a ratio. (NCI) | /uL | ||
/wk | C67069 | Every week;Per Week | Every week. (NCI) | Weekly | ||
AFU | C77534 | Arbitrary Fluorescence Unit | Arbitrary unit(s) of fluorescent luminescence. (NCI) | Arbitrary Fluorescence Units | ||
amu | C64559 | Atomic Mass Unit | A small unit of mass used to express atomic and molecular masses. (NCI) | amu | ||
AU | C73686 | Absorbance Unit | A unit of optical density expressed as the absorbance of light transmitted through the medium on the logarithmic scale. (NCI) | AU | ||
AU/min | C73687 | Absorbance Unit per Minute | A unit of a speed of optical density change expressed as a logarithm of absorbance of light transmitted through a partially absorbing substance per minute. (NCI) | AU/min | ||
dL | C64697 | Deciliter | The unit of volume equal to one tenth of a liter. Accepted for use with the SI. (NCI) | dL | ||
EU | C96599 | Ehrlich Units;EU/dL | A unit of measure equal to one milligram of urobilinogen per deciliter. | Ehrlich Unit | ||
FEU | C96649 | Fibrinogen Equivalent Units | A unit of measure for the concentration of fibrin degradation products in a sample, calculated based upon the mass of fibrinogen contained within that sample. | Fibrinogen Equivalent Unit | ||
fL | C64780 | Femtoliter | The unit of volume equal 10E-15 liter. | Femtoliter | ||
fmol/g | C73711 | Femtomole per Gram | A molality unit that describes the amount of substance, expressed in femtomole(s) per gram. (NCI) | fmol/g | ||
fmol/L | C68887 | Femtomole per Liter | A unit of concentration (molarity unit) equal to one quadrillionth of a mole (10E-15 mole) of solute in one liter of solution. (NCI) | fmol/L | ||
g/animal | C73713 | Gram per Animal | A unit of measure expressed in gram(s) per animal. | g/animal | ||
g/animal/day | C73714 | Gram per Animal per Day | A unit of measure expressed in gram(s) per animal per period of time equal to twenty-four hours. | g/animal/day | ||
g/animal/wk | C73715 | Gram per Animal per Week | A unit of measure expressed in gram(s) per animal per period of time equal to seven days. | Gram per Animal per Week | ||
g/cage | C73716 | Gram per Cage | A unit of measure expressed in gram(s) per cage. | g/cage | ||
g/cage/day | C73717 | Gram per Cage per Day | A unit of measure expressed in gram(s) per cage per period of time equal to twenty-four hours. | g/cage/day | ||
g/cage/wk | C73718 | Gram per Cage per Week | A unit of measure expressed in gram(s) per cage per period of time equal to seven days. | Gram per Cage per Week | ||
g/day | C67372 | Gram per Day;g/d;gram/day;g/24h;gram/24 Hours | A dose calculation unit expressed in gram(s) per period of time equal to twenty-four hours. | Gram per 24 Hours | ||
g/g | C70453 | Gram per Gram | A unit of a mass fraction expressed as a number of grams of substance per gram of mixture. | g/g | ||
g/g/day | C73720 | Gram per Gram per Day | A unit of measure expressed in gram(s) per gram per period of time equal to twenty-four hours. | g/g/day | ||
g/kg/day | C66975 | Gram per Kilogram per Day;mg/g/day;Milligram per Gram per Day | A dose administration rate unit equal to the rate at which one gram of a product per kilogram of body mass is delivered or administered over the period of one day. (NCI) | Gram per Kilogram per Day | ||
g/m2/day | C73722 | Gram per Square Meter per Day | A dose calculation unit expressed in gram(s) per square meter per period of time equal to twenty-four hours. | g/m2/day | ||
g/mol | C73721 | Gram per Mole | A unit of mass commonly used to express the molar mass of a substance in gram(s) per mole. (NCI) | g/mol | ||
kN/cm2 | C92615 | Kilonewton per Centimeter Squared;kdyn/cm2 | The kilonewton per centimeter squared is an SI derived unit of pressure; one newton is computed as the force necessary to accelerate a mass of one gram at the rate of one centimeter per second squared. One kilonewton per centimeter squared is descriptive of the amount of force exerted in a particular area. This measurement is frequently used when describing conditions of cellular movement. (NCI) | Kilonewton per Centimeter Squared | ||
kPa | C67284 | Kilopascal | A SI derived unit of pressure equivalent to 1000 newtons per square meter or 10000 bars or to 0.145 pound per square inch. (NCI) | kPa | ||
L/kg | C73725 | Liter per Kilogram | A dose calculation unit expressed in liter(s) per kilogram. (NCI) | L/kg | ||
scm | C68858 | Standard Cubic Meter | A unit used in physical chemistry to express the amount of substance of an ideal gas in one cubic meter at standard conditions: temperature 273.15 K and pressure of one atmosphere (101.325 kilopascals).(NCI) | Standard Cubic Meter | ||
mEq/dL | C67473 | Milliequivalent per Deciliter | A concentration unit measured as a number of milliequivalents of solute per deciliter of solution. (NCI) | mEq/dL | ||
mEq/mL | C73737 | Milliequivalent per Milliliter | A concentration unit expressed in milliequivalent(s) of solute per milliliter of solution. (NCI) | mEq/mL | ||
mEq/mmol | C92616 | Milliequivalent per Millimole | A concentration unit measured as a number of one thousandth of an equivalent weight per millimole of substance. (NCI) | Milliequivalent per Milliimole | ||
MESF | C96691 | Molecules of Equivalent Soluble Fluorochromes | A unit of measure of the fluorescence intensity of a fluorochrome-labeled sample, which is equivalent to the fluorescence intensity of a solution containing an equivalent number of molecules of free fluorochrome in solution, under identical experimental conditions. | Molecule of Equivalent Soluble Fluorochrome | ||
MFI | C96687 | Median Fluorescence Intensity | A unit of measure equal to the geometric mean fluorescence intensity of a log-normal distribution of fluorescence signals. | Median Fluorescence Intensity | ||
mg/animal | C73738 | Milligram per Animal | A unit of measure expressed in milligram(s) per animal. | mg/animal | ||
mg/g/h | C73740 | Milligram per Gram per Hour | A dose calculation unit expressed in milligram(s) per gram per period of time equal to sixty minutes. (NCI) | mg/g/h | ||
mg/g/min | C73741 | Milligram per Gram per Minute | A dose calculation unit expressed in milligram(s) per gram per period of time equal to sixty seconds. (NCI) | mg/g/min | ||
mg/kg/day | C66976 | Milligram per Kilogram per Day | A dose calculation unit expressed in milligram(s) per kilogram per period of time equal to twenty-four hours. (NCI) | mg/kg/day | ||
mg/m2/day | C66974 | Milligram per Square Meter per Day | A dose calculation unit expressed in milligram(s) per square meter per period of time equal to twenty-four hours. (NCI) | mg/m2/day | ||
mg/m2/h | C73743 | Milligram per Square Meter per Hour | A dose calculation unit expressed in milligram(s) per square meter per period of time equal to sixty minutes. (NCI) | mg/m2/h | ||
mg/m2/min | C73744 | Milligram per Square Meter per Minute | A dose calculation unit expressed in milligram(s) per square meter per period of time equal to sixty seconds. (NCI) | mg/m2/min | ||
mg/min | C73742 | Milligram per Minute | Milligrams per minute. | mg/min | ||
MHz | C67314 | Megahertz | The SI derived unit of frequency; equal to one million oscillations per second or to 10E6 hertz. (NCI) | MHz | ||
mL/animal | C73746 | Milliliter per Animal | A unit of measure expressed in milliliter(s) per animal. | mL/animal | ||
mL/animal/day | C73747 | Milliliter per Animal per Day | A unit of measure expressed in milliliter(s) per animal per period of time equal to twenty-four hours. | mL/animal/day | ||
mL/animal/wk | C73748 | Milliliter per Animal per Week | A unit of measure expressed in milliliter(s) per animal per period of time equal to seven days. | Milliliter per Animal per Week | ||
mL/breath | C73749 | Milliliter per Breath | A unit of measure expressed in milliliter(s) per inspiration or expiration of breath. | mL/breath | ||
mL/cage | C73750 | Milliliter per Cage | A unit of measure expressed in milliliter(s) per cage. | mL/cage | ||
mL/cage/day | C73751 | Milliliter per Cage per Day | A unit of measure expressed in milliliter(s) per cage per period of time equal to twenty-four hours. | mL/cage/day | ||
mL/cage/wk | C73752 | Milliliter per Cage per Week | A unit of measure expressed in milliliter(s) per cage expressed per period of time equal to seven days. | Milliliter per Cage per Week | ||
mL/day | C67410 | Milliliter per Day | Milliliters per day. | mL/day | ||
mL/g | C73754 | Milliliter per Gram | A unit of measure expressed in milliliter(s) per gram. | mL/g | ||
mL/g/day | C73755 | Milliliter per Gram per Day;mL/g/day;uL/mg/day;L/day/kg;mL/day/g;uL/day/mg;L/kg/d | Liters per kilogram per day. | Milliliter per Gram per Day | ||
mL/g/h | C73756 | Milliliter per Gram per Hour | Milliliters per gram per hour. | mL/g/h | ||
mL/g/min | C73757 | Milliliter per Gram per Minute | Milliliters per gram per minute. | mL/g/min | ||
mL/kg | C67411 | Milliliter per Kilogram | A dose calculation unit equal to one milliliter of preparation per one kilogram of body mass. (NCI) | mL/kg | ||
mL/kg/day | C73758 | Milliliter per Kilogram per Day | Milliliters per kilogram per day. | mL/kg/day | ||
mL/kg/h | C73759 | Milliliter per Kilogram per Hour | Milliliters per kilogram per hour. | mL/kg/h | ||
mL/kg/min | C73760 | Milliliter per Kilogram per Minute;uL/g/min;mL/min/kg;uL/min/g;mL/kg/min | Milliliters per kilogram per minute. | mL/kg/min | ||
mL/m2 | C73761 | Milliliter per Square Meter | A unit of measure expressed in milliliter(s) per square meter. | mL/m2 | ||
mL/m2/day | C66977 | Milliliter per Square Meter per Day | A dose calculation unit expressed in milliliter(s) per square meter per period of time equal to twenty-four hours. (NCI) | mL/m2/day | ||
mL/m2/h | C73762 | Milliliter per Square Meter per Hour | A dose calculation unit expressed in milliliter(s) per square meter per period of time equal to sixty minutes. (NCI) | mL/m2/h | ||
mL/m2/min | C73763 | Milliliter per Square Meter per Minute | A dose calculation unit expressed in milliliter(s) per square meter per period of time equal to sixty seconds. (NCI) | mL/m2/min | ||
mmHg/sec | C73764 | Millimeter of Mercury per Second | A rate of inflation or deflation of a manometric device based on the unit of pressure equal to 133,332 Pa or 1.316E10-3 standard atmosphere during period of time equal to one sixtieth of a minute. (NCI) | mmHg/sec | ||
mOsm | C67318 | Milliosmole | A unit of osmotic pressure equal to one thousandth of an osmole or osmotic pressure of 0.001 molar solution of a substance that does not dissociate. (NCI) | mOsm | ||
mOsm/kg | C67427 | Milliosmole per Kilogram | A unit of osmotic pressure equal to one thousandth of an osmole per kilogram substance. | mOsm/kg | ||
mPa | C73765 | Millipascal | A SI derived unit of pressure equivalent to one thousandth of one pascal. (NCI) | mPa | ||
nmol/mL/min | C92613 | Nanomole per Milliliter per Minute | A unit of concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute in one milliliter of solution to be administered per minute of time. | Nanomole per Minute per Milliliter | ||
nsec | C73767 | Nanosecond | A unit of time equal to one billionth of a second. (NCI) | nsec | ||
pg/dL | C67331 | Picogram per Deciliter | Picograms per deciliter. | pg/dL | ||
pL | C69189 | Picoliter | A unit of volume equal to one trillionth of a liter (10E-12 liter). (NCI) | pL | ||
psec | C73768 | Picosecond | A unit of time equal to one trillionth of a second. (NCI) | psec | ||
U | C44278 | Unit | A single undivided thing occurring in the composition of something else. | U | ||
U/animal | C73773 | Unit per Animal | An arbitrary dosing unit expressed in unit(s) per animal. (NCI) | U/animal | ||
U/g/day | C73774 | Unit per Gram per Day | An arbitrary unit of substance rate expressed in unit(s) per gram per period of time equal to twenty-four hours. (NCI) | U/g/day | ||
U/g/h | C73775 | Unit per Gram per Hour | An arbitrary unit of substance rate expressed in unit(s) per gram per period of time equal to sixty minutes. (NCI) | U/g/h | ||
U/g/min | C73776 | Unit per Gram per Minute | An arbitrary unit of substance rate expressed in unit(s) per gram per period of time equal to sixty seconds. (NCI) | U/g/min | ||
U/kg/day | C73777 | Unit per kilogram per Day | An arbitrary unit of substance rate expressed in unit(s) per gram per period of time equal to twenty-four hours. (NCI) | U/kg/day | ||
U/kg/h | C73778 | Unit per Kilogram per Hour | An arbitrary unit of substance rate expressed in unit(s) per gram per period of time equal to sixty minutes. (NCI) | U/kg/h | ||
U/kg/min | C73779 | Unit per Kilogram per Minute | An arbitrary unit of substance rate expressed in unit(s) per gram per period of time equal to sixty seconds. (NCI) | U/kg/min | ||
U/m2 | C67467 | Unit per Square Meter | A unit expressed as a number of arbitrary units of substance per one square meter of a body surface area. | U/m2 | ||
U/m2/day | C73783 | Unit per Square Meter per Day | An arbitrary unit of substance rate expressed in unit(s) per square meter per period of time equal to twenty-four hours. (NCI) | U/m2/day | ||
U/m2/h | C73784 | Unit per Square Meter per Hour | An arbitrary unit of substance rate expressed in unit(s) per square meter per period of time equal to sixty minutes. (NCI) | U/m2/h | ||
U/m2/min | C73785 | Unit per Square Meter per Minute | An arbitrary unit of substance rate expressed in unit(s) per square meter per period of time equal to sixty seconds. (NCI) | U/m2/min | ||
U/mmol | C92618 | Unit per Millimole | An arbitrary unit of substance concentration equal to the concentration at which one millimole of a mixture contains one unit of a substance. (NCI) | U/mmol | ||
uEq | C73726 | Microequivalent | A unit of relative amount of a substance equal to one millionth of an equivalent weight.(NCI) | uEq | ||
ug/animal | C73728 | Microgram per Animal | A unit of measure expressed in microgram(s) per animal. | ug/animal | ||
ug/dL | C67305 | Microgram per Deciliter | A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one deciliter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one microgram occupies the volume one deciliter. (NCI) | ug/dL | ||
ug/g/day | C74921 | Microgram per Gram per Day | A dose calculation unit expressed in microgram(s) per gram per period of time equal to twenty-four hours. (NCI) | ug/g/day | ||
ug/g/h | C74922 | Microgram per Gram per Hour | A dose calculation unit expressed in microgram(s) per gram per period of time equal to sixty minutes. (NCI) | ug/g/h | ||
ug/g/min | C74923 | Microgram per Gram per Minute | A dose calculation unit expressed in microgram(s) per gram per period of time equal to sixty seconds. (NCI) | ug/g/min | ||
ug/kg/day | C73729 | Microgram per Kilogram per Day | A dose calculation unit expressed in microgram(s) per kilogram per period of time equal to twenty-four hours. (NCI) | ug/kg/day | ||
ug/kg/h | C73730 | Microgram per Kilogram per Hour | A dose calculation unit expressed in microgram(s) per kilogram per period of time equal to sixty minutes. (NCI) | ug/kg/h | ||
ug/m2 | C67312 | Microgram per Square Meter | A dose calculation unit expressed in microgram(s) per square meter. | ug/m2 | ||
ug/m2/day | C73787 | Microgram per Square Meter per Day | A dose calculation unit expressed in microgram(s) per square meter per period of time equal to twenty-four hours. (NCI) | ug/m2/day | ||
ug/m2/h | C73727 | Microgram per Square Meter per Hour | A dose calculation unit expressed in microgram(s) per square meter per period of time equal to sixty minutes. (NCI) | ug/m2/h | ||
ug/m2/min | C73733 | Microgram per Square Meter per Minute | A dose calculation unit expressed in microgram(s) per square meter per period of time equal to sixty seconds. (NCI) | ug/m2/min | ||
ug/mL/h | C75905 | Microgram per Milliliter per Hour | A dose calculation unit expressed in microgram(s) per milliliter of solution per period of time equal to sixty minutes. (NCI) | ug/mL/h | ||
uIU/mL | C67405 | Micro-International Unit per milliliter;mIU/L;mcIU/mL;uIU/mL | Microinternational units per milliliter. | uIU/mL | ||
uL | C48153 | mcL;Microliter;mm3 | A unit of volume accepted for use with the SI and equal to one millionth of a liter (10E-6 liter).(NCI) | uL | ||
um2 | C73770 | MicroSquare Meter | A SI unit of area measurement equal to a square whose sides are one micrometer long. (NCI) | Square Micrometer | ||
um3 | C67565 | Cubic Micrometer | A unit of volume equal to 10E-18 liter or one cubic micrometer. | Attoliter | ||
umol/L | C48508 | Micromole per Liter | A unit of concentration (molarity unit) equal to one one-millionth of a mole (10E-6 mole) of solute per one liter of solution. (NCI) | umol/L | ||
umol/mg/min | C73735 | Micromole per Milligram per Minute | A unit of concentration (molarity unit) equal to one millionth of a mole (10E-6 mole) per milligram of a substance per period of time equal to sixty seconds. (NCI) | umol/mg/min | ||
uOsM | C73736 | Microosmole | A unit of osmotic pressure equal to one millionth of an osmole or the osmotic pressure of a 10E-6 molar solution of a substance that does not dissociate. (NCI) | uOsM | ||
usec | C69149 | Microsecond | A unit of time equal to one millionth of a second. (NCI) | usec | ||
10^12/L | C67308 | 10^6/uL | A unit of measurement equal to 10 to the twelfth power of the number of entities per unit of volume equal to one liter. | Million per Microliter | ||
10^3 DNA copies/mL | C98788 | A unit of measurement equal to 10 to the third power of the number of deoxyribonucleic acid (DNA) copies per unit of volume equal to one milliliter. | Thousand DNA Copies per Milliliter | |||
10^3 RNA copies/mL | C98790 | A unit of measurement equal to 10 to the third power of the number of ribonucleic acid (RNA) copies per unit of volume equal to one milliliter. | Thousand RNA Copies per Milliliter | |||
10^3/hpf | C98789 | A unit of measurement equal to 10 to the third power of the number of entities per unit of area equal to one high powered field. | Thousand per High Powered Field | |||
10^4/hpf | C98787 | A unit of measurement equal to 10 to the fourth power of the number of entities per unit of area equal to one high powered field. | Ten Thousand per High Powered Field | |||
10^5/hpf | C98743 | A unit of measurement equal to 10 to the fifth power of the number of entities per unit of area equal to one high powered field. | Hundred Thousand per High Powered Field | |||
10^6 DNA copies/mL | C98756 | A unit of measurement equal to 10 to the sixth power of the number of deoxyribonucleic acid (DNA) copies per unit of volume equal to one milliliter. | Million DNA Copies per Milliliter | |||
10^6 IU/mL | C98757 | A unit of measurement equal to 10 to the sixth power of the number of international units of an entity per unit of volume equal to one milliliter. | Million International Units per Milliliter | |||
10^6 RNA copies/mL | C98760 | A unit of measurement equal to 10 to the sixth power of the number of ribonucleic acid (RNA) copies per unit of volume equal to one milliliter. | Million RNA Copies per Milliliter | |||
10^6/g | C98758 | A unit of measurement equal to 10 to the sixth power of the number of entities per unit of mass equal to one gram. | Million per Gram | |||
10^6/hpf | C98759 | A unit of measurement equal to 10 to the sixth power of the number of entities per unit of area equal to one high powered field. | Million per High Powered Field | |||
10^6/L | C67452 | 10^3/mL | A unit of measurement equal to 10 to the sixth power of the number of entities per unit of volume equal to one liter. | Thousand per Milliliter | ||
10^7/L | C98786 | 10^6/dL | A unit of measurement equal to 10 to the seventh power of the number of entities per unit of volume equal to one liter. | Ten Million per Liter | ||
10^9/L | C67255 | 10^3/uL;10^3/mm3 | A unit of measurement equal to 10 to the ninth power of the number of entities per unit of volume equal to one liter. | Billion per Liter | ||
cm H2O | C91060 | A unit of pressure defined by a column of water with a height of one centimeter, frequently used to measure central venous pressure, intracranial pressure, and for pressures during mechanical ventilation. | Centimeters of Water | |||
DNA copies/mL | C98719 | DNA Copies per Milliliter | The unit of concentration of deoxyribonucleic acid (DNA) copies expressed as a number of copies in unit volume equal to one milliliter. | DNA Copies per Milliliter | ||
L/h | C69160 | Liters per hour. | Liter per Hour | |||
mL/cm H2O | C98755 | A unit of pressure expressed in milliliter(s) per centimeter of water. (NCI) | Milliliter per Centimeter of Water | |||
PACK | C62653 | A number of individual items packaged as a unit. | Pack | |||
RATIO | C44256 | A unit of measurement for the quotient of the amount of one entity to another. | Ratio | |||
10^3 copies/mL | C100897 | The unit of concentration expressed as the number of 10 to the third power copies in unit volume equal to one milliliter. (NCI) | Thousand Copies per Milliliter | |||
10^6 copies/mL | C100898 | The unit of concentration expressed as the number of 10 to the sixth power copies in unit volume equal to one milliliter. (NCI) | Million Copies per Milliliter | |||
copies/mL | C100900 | A unit of concentration expressed as a number of copies per unit volume equal to one milliliter. | Copies per Milliliter | |||
DIOPTER | C100899 | Diopter | A unit of measurement of the optical power of a curved mirror or lens represented by the inverse of the focal length in meters. | Diopter | ||
L/s | C67390 | L/sec | Liters per second. | Liter per second | ||
mL/min/1.73m2 | C67412 | A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter travels during the period of time equal to one minute per 1.73 meters squared of body surface area. | Milliliter per Minute per 1.73 m2 of Body Surface Area | |||
mU/L | C67408 | An arbitrary unit of substance concentration equal to the concentration at which one liter of mixture contains one thousandth of a unit of a substance. | Microunit per Milliliter | |||
/month | C64498 | Every Month;Per Month | Every month. (NCI) | Monthly | ||
APPLICATION | C102404 | Application Dosing Unit | A dosing measurement based on the amount of substance applied. | Application Dosing Unit | ||
CAPFUL | C102405 | Capful Dosing Unit | A unit of measure equal to the amount that the cap on the bottle can contain. | Capful Dosing Unit | ||
dB | C102407 | Decibel | A unit of measure representing the intensity of an electrical signal or sound which is equal to ten times the logarithm of the ratio of two signals. | Decibel | ||
cm/s | C102406 | cm/sec | A unit of both speed (scalar) and velocity (vector), defined as the distance of one centimeter travelled per unit time equal to one second. (NCI) | Centimeter per Second | ||
/100 HPFs | C102695 | per 100 High Powered Fields | A unit of measurement of the number of entities per unit of area equal to one hundred high powered fields. | Per 100 High Powered Fields | ||
cells/uL | C67242 | cells/mm3 | A unit of cell concentration expressed in cells per unit of area equal to one cubic millimeter. | Cells per Microliter | ||
log10 CFU/g | C102658 | A logarithmic-scale (base 10) unit for measuring colony forming units per unit of mass equal to one gram. | Log10 Colony Forming Units per Gram | |||
log10 CFU/mL | C102659 | A logarithmic-scale (base 10) unit for measuring colony forming units per unit of volume equal to one milliliter. | Log10 Colony Forming Units per Milliliter | |||
cGy | C64693 | Centigray | The metric unit of absorbed radiation dose equal to the absorption of one hundredth of joule of radiation energy per kilogram of matter. | Centigray | ||
mL/s | C69073 | mL/sec | Milliliters per second. | Milliliter per Second | ||
/mL | C103452 | Per Milliliter | A volume unit equal to one milliliter used as a denominator to build a derived unit expressed as a ratio. (NCI) | Per Milliliter | ||
/dL | C105514 | Per Deciliter | A volume unit equal to one deciliter used as a denominator to build a derived unit expressed as a ratio. (NCI) | Per Deciliter | ||
/L | C105515 | Per Liter | A volume unit equal to one liter used as a denominator to build a derived unit expressed as a ratio. (NCI) | Per Liter | ||
/VF | C105516 | per Visual Field | A unit of measure equal to the instances of an entity per visual field of a microscope. (NCI) | Per Visual Field | ||
10^10/L | C105517 | 10^4/uL;10^7/mL;10^4/mm3 | A unit of measurement equal to 10 to the tenth power of entities per unit of volume equal to one liter. (NCI) | Ten Billion Per Liter | ||
10^11/L | C105488 | 10^5/uL;10^8/mL;10^5/mm3 | A unit of measurement equal to 10 to the eleventh power of entities per unit of volume equal to one liter. | Hundred Billion Per Liter | ||
10^12 IU/L | C105518 | Tera International Unit per Liter;TIU/L | Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of 10^12 international unit per one liter of system volume.(NCI) | Tera International Unit Per Liter | ||
10^3/L | C105519 | A unit of measurement equal to 10 to the third power of entities per unit of volume equal to one liter. | Thousand Per Liter | |||
10^4/L | C73771 | A unit of measurement equal to 10 to the fourth power of entities per unit of volume equal to one liter. | Thousand per Deciliter | |||
10^5/L | C105490 | 10^2/mL | A unit of measurement equal to 10 to the fifth power of entities per unit of volume equal to one liter. | Hundred Thousand Per Liter | ||
10^8/L | C105489 | 10^2/uL;10^5/mL;10^2/mm3 | A unit of measurement equal to 10 to the eighth power of entities per unit of volume equal to one liter. | Hundred Million Per Liter | ||
CAPLET | C64696 | Caplet Dosing Unit | A dosing measurement based on the caplet unit. | Caplet Dosing Unit | ||
cL | C69087 | Centiliter | The unit of volume equal to one hundredth of a liter or 10 milliliters or 10 cubic centimeters or 0.6102 cubic inch. | Centiliter | ||
cm/min | C105481 | Centimeters per Minute | A unit of both speed (scalar) and velocity (vector), defined as the distance of one centimeter travelled per unit time equal to one minute. (NCI) | Centimeter Per Minute | ||
cmol/L | C68886 | mmol/dL;Millimoles per Deciliter | A unit of concentration (molarity unit) equal to one centimole of solute in one liter of solution. (NCI) | Centimole Per Liter | ||
cs | C105482 | Centisecond;10^-2 sec;csec | A unit of time equal to one hundredth of a second (10E-2 seconds). (NCI) | Centisecond | ||
damol/L | C105483 | mol/dL;Moles per Deciliter;Decamole per Liter | A unit of concentration (molarity unit) equal to one decamole of solute in one liter of solution. (NCI) | Decamole Per Liter | ||
foz_br | C48577 | Fluid Ounce Imperial | A traditional unit of liquid volume equal in the British Imperial system to 1/20 pint, or 1.733871 cubic inches or 28.413063 milliliters. | Fluid Ounce British | ||
foz_us | C48494 | Fluid Ounce US | A traditional unit of liquid volume equal in the US customary system to 1/16 pint, or 1.804687 cubic inches or 29.573531 milliliters. | Fluid Ounce US | ||
fraction of 1 | C105484 | A unit for expressing a percentage as a decimal whereby the total value is measured as a fraction of the numeric 1. | Fraction of 1 | |||
g/g Creatinine | C105485 | mg/mg Creatinine | A unit of substance concentration defined as the number of grams per gram of creatinine. | Gram Per Gram of Creatinine | ||
g/mol Creatinine | C105486 | mg/mmol Creatinine | A unit of substance concentration defined as the number of grams per mole of creatinine. | Gram Per Mole of Creatinine | ||
hPa | C105487 | Hectopascal | A SI derived unit of pressure equivalent to one hundred pascals, 1 millibar or 0.0145 pounds per square inch. | Hectopascal | ||
kDa | C105491 | Kilodalton;Kilounified Atomic Mass Unit;ku | A mass unit equal to one thousand daltons. | Kilodalton | ||
kPa/L/sec | C105492 | Pa/mL/sec | A unit of resistance equal to the number of kilopascals per unit of volume equal to one liter per unit of time equal to one second. (NCI) | Kilopascal Per Liter Per Second | ||
ks | C105493 | Kilosecond;10^3 sec;ksec | A unit of time equal to one thousand seconds (10E3 seconds). (NCI) | Kilosecond | ||
L/h/m2 | C105494 | Liters per Hour per Square Meter | A unit expressed as one liter of volume per unit of time equal to one hour per square meter of area. (NCI) | Liter Per Hour Per Square Meter | ||
L/L | C105495 | Liter per Liter;mL/mL;uL/uL;dL/dL | A unit of volume concentration equal to the number of liters per unit of volume equal to one liter. | Liter Per Liter | ||
L/min/m2 | C105496 | Liters per Minute per Square Meter | A unit expressed as one liter of volume per unit of time equal to one minute per square meter of area. (NCI) | Liter Per Minute Per Square Meter | ||
mEq/g Creatinine | C105501 | A unit of relative amount of substance concentration defined as the concentration of milliequivalents per gram of creatinine. | Milliequivalent Per Gram of Creatinine | |||
mg/g Creatinine | C105502 | A unit of substance concentration defined as the number of milligrams per gram of creatinine. | Milligram Per Gram of Creatinine | |||
mL/cm | C105503 | Milliliter per Centimeter;dL/m | A unit of measure equal to the number of milliliters per unit of length equal to one centimeter. (NCI) | Milliliter per Centimeter | ||
mL/dL | C105504 | Milliliters per Deciliter | A unit of volume concentration equal to the number of milliliters per unit of volume equal to one deciliter. | Milliliter per Deciliter | ||
mL/min/mmHg | C67417 | Milliliter per Minute per Torr | A unit of measure equal to the number of milliliters per unit of time equal to one minute per unit of pressure equal to one milliter of mercury (mmHg). | Milliliter per Minute per Millimeters of Mercury | ||
mL/sec/1.73m2 | C105505 | A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter travels during the period of time equal to one second per 1.73 meters squared of body surface area. | Milliliter Per Second Per 1.73 Meter Squared | |||
mm/2h | C105509 | Millimeters per Two Hours | A unit of both speed (scalar) and velocity (vector), defined as the distance of one centimeter travelled per unit time equal to two hours. (NCI) | Millimeter per Two Hours | ||
mm/min | C105507 | Millimeters per Minute | A unit of both speed (scalar) and velocity (vector), defined as the distance of one millimeter travelled per unit time equal to one minute. (NCI) | Millimeter Per Minute | ||
mm/sec | C105508 | Millimeters per Second | A unit of both speed (scalar) and velocity (vector), defined as the distance of one millimeter travelled per unit time equal to one second. (NCI) | Millimeter Per Second | ||
mmHg/L/min | C105506 | A unit of resistance equal to the number of millimeters of mercury per unit of volume equal to one liter per unit of time equal to one minute. | Millimeter Mercury Per Liter Per Minute | |||
mmol/g Creatinine | C105510 | A unit of substance concentration defined as the concentration of millimoles of solute per gram of creatinine. | Millimole Per Gram of Creatinine | |||
mmol/mol Creatinine | C105511 | A unit of substance concentration defined as the concentration of millimoles of solute per mole of creatinine. | Millimole Per Mole of Creatinine | |||
mph | C105500 | Miles per Hour | A unit of both speed (scalar) and velocity (vector), defined as the distance of one mile travelled per unit time equal to one hour. (NCI) | Mile Per Hour | ||
mV*min | C105512 | Millivolt * Minutes | A SI derived unit of magnetic flux, equal to the flux that produces in a circuit of one turn an electromotive force of one millivolt, when the flux is uniformly reduced to zero within one minute. (NCI) | Millivolt Minute | ||
nU/cL | C105513 | Nanounit per Centiliter | An arbitrary unit of substance content expressed in nanounit(s) per centiliter. (NCI) | Nanounit Per Centiliter | ||
PA | C74924 | Per Annum;Per Year;Every Year | A frequency rate of occurrences of something within a period of time equal to three hundred sixty-five days. | Per Year | ||
pt_br | C69114 | Imperial Pint;British Pint | A traditional unit of volume equal to 20 British fluid ounces, 34.678 cubic inches or approximately 568.261 milliliters. | Pint British | ||
pt_us | C48529 | US Pint | A United States liquid unit equal to 16 US fluid ounces or 28.875 cubic inches or approximately 473.177 milliliters. | Pint | ||
titer | C67454 | Concentration of a substance in a solution as determined by the quantitative reaction with added measured volume(s) of a solution of the precisely known concentration(s) of a standard reagent. | Titer | |||
U/cL | C105520 | Unit per Centiliter | An arbitrary unit of substance content expressed in unit(s) per centiliter. | Unit Per Centiliter | ||
U/dL | C105521 | Unit per Deciliter | An arbitrary unit of substance content expressed in unit(s) per deciliter. | Unit Per Deciliter | ||
U/g Creatinine | C105523 | A unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one unit per gram of creatinine. | Unit Per Gram of Creatinine | |||
U/g HGB | C105522 | Units per Gram Hemoglobin | Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one unit per gram of hemoglobin. (NCI) | Unit Per Gram Hemoglobin | ||
ug/g Creatinine | C85744 | Nanograms per milligram of creatinine. | Microgram Per Gram of Creatinine | |||
ugEq | C105497 | Microgram Equivalent | A unit of relative amount of substance concentration equal to one millionth of a gram of an equivalent weight. (NCI) | Microgram Equivalent | ||
umol/L/sec | C105498 | Micromoles per Liter per Second | A concentration unit equal to one micromole of solute in one liter of solution per unit of time equal to one second. (NCI) | Micromole Per Liter Per Second | ||
uV*sec | C105499 | Microvolt * Seconds | A SI derived unit of magnetic flux, equal to the flux that produces in a circuit of one turn an electromotive force of one microvolt, when the flux is uniformly reduced to zero within one second. (NCI) | Microvolt Second | ||
V/sec | C105524 | Volt per Second;V/s | A SI derived rate unit equal to one volt per unit of time equal to one second. | Volt Per Second | ||
Back to top | ||||||
CL.C74456.LOC | Anatomical Location (LOC) | text Extensible: Yes | C74456 | Anatomical Location | Terminology codelist used for anatomical location within CDISC. | CDISC SDTM Anatomical Location Terminology |
LIP | C12220 | Lip | Fleshy fold which surrounds the opening of the mouth. (NCI) | Lip | ||
HARD PALATE | C12230 | Hard Palate | The bony anterior part of the roof of the mouth separating the nose from the mouth. (NCI) | Hard Palate | ||
HYPOPHARYNX | C12246 | Hypopharynx | The lower part of the pharynx that connects to the esophagus. (NCI) | Hypopharynx | ||
GASTRIC CARDIA | C12256 | Gastric Cardia | The area around the esophagogastric mucosal junction where the esophageal mucosa transitions into the gastric mucosa. (NCI) | Gastric Cardia | ||
FUNDUS OF THE STOMACH | C12257 | Fundus of the Stomach | The portion of the stomach that lies above the cardiac notch. It allows for the accumulation of gases produced by chemical digestion. (NCI) | Fundus of the Stomach | ||
BODY OF STOMACH | C12258 | Body of Stomach | The main section of the digestive tube that connects the esophagus to the small intestine. The body proper excludes the upper and lower sections of the fundus and pyloric portion respectively. (NCI) | Body of Stomach | ||
ANTRUM PYLORI | C12259 | Antrum Pylori | The initial part of the pyloric canal of the stomach. This site contains endocrine cells that produce gastrin and somatostatin. (NCI) | Antrum Pylori | ||
GREATER CURVATURE OF THE STOMACH | C12262 | Greater Curvature of the Stomach | The lateral and inferior border of the stomach. Attached to it is the greater omentum. (NCI) | Greater Curvature of the Stomach | ||
MIDDLE EAR | C12274 | Middle Ear | The part of the ear including the eardrum and ossicles. The middle ear leads to the inner ear. (NCI) | Middle Ear | ||
MAXILLARY SINUS | C12275 | Maxillary Sinus | A pyramidal-shaped, thin-walled, air-filled cavity located in the maxilla. It is lined by mucus membrane and periosteum (mucoperiosteum) which contains cilia. It is adjacent to the nasal cavity and communicates with the middle meatus of the nose. It is the largest paranasal sinus and is composed of three recesses: alveolar, zygomatic, and infraorbital. (NCI) | Maxillary Sinus | ||
ETHMOID SINUS | C12276 | Ethmoid Sinus | A sinus of the meatuses of the nasal cavity. (NCI) | Ethmoid Sinus | ||
FRONTAL SINUS | C12277 | Frontal Sinus | The paired, mucosal lined air spaces located above the orbit and communicating with the nasal passages. (NCI) | Frontal Sinus | ||
SUBGLOTTIS | C12280 | Subglottis | The area of the larynx below the vocal cords down to the trachea. (NCI) | Subglottis | ||
MANDIBLE | C12290 | Bone, Mandibular;Mandible;Inferior Maxillary Bone;Jaw | The lower jaw bone holding the lower teeth. (NCI) | Mandible | ||
SKIN OF THE TRUNK | C12295 | Skin of the Trunk | The skin or integument surrounding the trunk of the body. (NCI) | Skin of the Trunk | ||
NIPPLE | C12299 | Nipple | The pigmented protuberance on the surface of the breast through which milk is drawn from the breast. (NCI) | Nipple | ||
CERVIX UTERI | C12311 | Cervix Uteri;Uterine Cervix | The lower part of the uterus occupying the region between the isthmus of the uterus and the vagina. It is divided into supravaginal and vaginal portions. (NCI) | Cervix Uteri | ||
MYOMETRIUM | C12314 | Myometrium | The smooth muscle lining the uterus. (NCI) | Myometrium | ||
PARAMETRIUM | C12320 | Parametrium | The subserous connective tissue of the pelvic floor of the supracervical portion of the uterus. The parametrium extends laterally between the layers of the broad ligament. (NCI) | Parametrium | ||
CONJUNCTIVA | C12341 | Conjunctiva | A thin, transparent tissue divided into the palpebral conjunctiva (covering the inner side of the eye lid) and the bulbar conjunctiva (covering the eyeball). (NCI) | Conjunctiva | ||
CORNEA | C12342 | Cornea | A dome-shaped, transparent, avascular tissue covering the front of the eye. It is composed of five layers: squamous epithelium, Bowman's membrane, stroma, Descemet's membrane, and endothelium. Refraction of light contributing to eye's focusing ability is its characteristic function. It contains unmyelinated nerve endings which are responsible for the high sensitivity of the tissue. (NCI) | Cornea | ||
RETINA | C12343 | Retina | A light-sensitive membrane that lines the back wall of the eyeball. The retina is continuous with the optic nerve and this way transmits optical images to the brain. (NCI) | Retina | ||
ORBIT | C12347 | Eye Socket;Ocular Orbit;Orbit;Orbital Cavity | The bony cavity of the skull which contains the eye, anterior portion of the optic nerve, ocular muscles and ocular adnexa. Seven bones contribute to the structure of the orbit: the frontal, maxillary, zygomatic, sphenoid, lacrimal, ethmoid, and palatine bones. (NCI) | Orbit | ||
FRONTAL LOBE | C12352 | Frontal Lobe | The part of the brain located anterior to the parietal lobes at the front of each cerebral hemisphere. (NCI) | Frontal Lobe | ||
PARIETAL LOBE | C12354 | Parietal Lobe | One of the lobes of the cerebral hemisphere located superiorly to the occipital lobe and posteriorly to the frontal lobe. Cognition and visuospatial processing are its main function. (NCI) | Parietal Lobe | ||
BRAIN VENTRICLE | C12356 | Brain Ventricle | The four connected cavities (hollow spaces) centrally located within the brain that connect posteriorly with the central canal of the spinal cord. (NCI) | Brain Ventricle | ||
PELVIC LYMPH NODE | C12363 | Pelvic Lymph Node | Any lymph node within the pelvic region. (NCI) | Pelvic Lymph Node | ||
BONE | C12366 | Bone | Calcified connective tissue that forms the skeletal components of the body. (NCI) | Bone | ||
ARTERY | C12372 | Artery | A blood vessel that carries blood away from the heart. (NCI) | Artery | ||
GALLBLADDER | C12377 | Gallbladder | A pear-shaped organ located under the liver that stores and concentrates bile secreted by the liver. From the gallbladder the bile is delivered through the bile ducts into the intestine thereby aiding the digestion of fat-containing foods. (NCI) | Gallbladder | ||
GASTROINTESTINAL SYSTEM | C12378 | Gastrointestinal System | The system that includes the esophagus, stomach, small and large intestine, anus, liver, biliary tract, and pancreas. (NCI) | Gastrointestinal System | ||
LARGE INTESTINE | C12379 | Large Intestine | A muscular tube that extends from the end of the small intestine to the anus. (NCI) | Large Intestine | ||
APPENDIX | C12380 | Appendix | Small tissue projection existing as a cecal diverticulum with a questionable history of vestigial versus specialized organ. (NCI) | Appendix | ||
COLON | C12382 | Colon | The part of the large intestine measured from the cecum to the rectum consisting of ascending, transverse, descending and sigmoid portions. The purpose of the colon is to remove water from digested food prior to excretion. (NCI) | Colon | ||
SMALL INTESTINE | C12386 | Small Intestine | The section of the intestines between the pylorus and cecum. The small intestine is approximately 20 feet long and consists of the duodenum, the jejunum, and the ileum. Its main function is to absorb nutrients from food as the food is transported to the large intestine. (NCI) | Small Intestine | ||
ILEUM | C12387 | Ileum | The final section of the small intestine. (NCI) | Ileum | ||
JEJUNUM | C12388 | Jejunum | The portion of the small intestine that extends from the duodenum to the ileum. (NCI) | Jejunum | ||
ESOPHAGUS | C12389 | Esophagus | The portion of the digestive canal between the pharynx and stomach. It is about 25 cm long and consists of three parts: the cervical part, from the cricoid cartilage to the thoracic inlet; thoracic part, from thoracic inlet to the diaphragm; and abdominal part, below the diaphragm to the cardiac opening of the stomach. (NCI) | Esophagus | ||
STOMACH | C12391 | Stomach | An organ located under the diaphragm, between the liver and the spleen as well as between the esophagus and the small intestine. The stomach is the primary organ of food digestion. (NCI) | Stomach | ||
LIVER | C12392 | Liver | A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate. (NCI) | Liver | ||
PANCREAS | C12393 | Pancreas | An organ behind the lower part of the stomach that is the shape of a fish and about the size of a hand. It is a compound gland composed of both exocrine and endocrine tissues. The endocrine pancreas makes insulin so that the body can use glucose (sugar) for energy. The exocrine pancreas makes enzymes that help the body digest food. Spread all over the pancreas are areas called the Islets of Langerhans. The cells in these areas each have a special purpose. The alpha cells make glucagon, which raises the level of glucose in the blood; the beta cells make insulin; the delta cells make somatostatin. There are also PP cells and D1 cells, about which little is known. (NCI) | Pancreas | ||
EAR | C12394 | Ear | A sense organ needed for the detection of sound and for establishing balance. The outer ear consists of the auricle, the ear canal as well as the tympanic membrane. The middle ear is made up of an air-filled cavity behind the tympanic membrane that contains the ossicles (malleus, incus and stapes). The inner ear is made up of the cochlea needed for hearing and the vestibular apparatus required for balance. (NCI) | Ear | ||
THYROID GLAND | C12400 | Thyroid Gland | An endocrine gland located at the base of the neck that produces and secretes thyroxine and other hormones. Thyroxine is important for metabolic control. (NCI) | Thyroid Gland | ||
EYE | C12401 | Eye;Eyeball | The organ of sight or vision. (NCI) | Eye | ||
FALLOPIAN TUBE | C12403 | Fallopian Tube | One of a pair of tubes that extend from the uterus to each of the ovaries. Following ovulation the egg travels down the fallopian tube to the uterus where fertilization may or may not occur. (NCI) | Fallopian Tube | ||
OVARY | C12404 | Ovary | One of the paired female reproductive glands containing the ova or germ cells; the ovary's stroma is a vascular connective tissue containing numbers of ovarian follicles enclosing the ova. (NCI) | Ovary | ||
UTERUS | C12405 | Uterus;Womb | A hollow, thick-walled, muscular organ located within the pelvic cavity of a woman. Within the uterus the fertilized egg implants and the fetus develops during pregnancy. (NCI) | Uterus | ||
VAGINA | C12407 | Vagina | The female genital canal, extending from the uterus to the vulva. (NCI) | Vagina | ||
VULVA | C12408 | External Genitalia;Vulva | The external, visible part of the female genitalia surrounding the urethral and vaginal opening. The vulva includes the clitoris and inner as well as outer labia. (NCI) | Vulva | ||
PENIS | C12409 | Penis | The male organ of urination and copulation. (NCI) | Penis | ||
PROSTATE GLAND | C12410 | Prostate Gland | The walnut shaped accessory sex gland of the male reproductive system. It is located in the pelvis just below the bladder, surrounding the prostatic part of the urethra. The prostate gland secretes a fluid which is part of the semen. (NCI) | Prostate Gland | ||
TESTIS | C12412 | Testicle;Testis | Either of the paired male reproductive glands that produce the male germ cells and the male hormones. (NCI) | Testis | ||
URINARY SYSTEM | C12413 | Urinary System | The organs involved in the creation and excretion of urine. (NCI) | Urinary System | ||
BLADDER | C12414 | Bladder | The distensible sac-like organ that functions as a reservoir of urine, collecting from the kidneys and eliminating via the urethra. (NCI) | Bladder | ||
KIDNEY | C12415 | Kidney | One of the two bean-shaped organs located on each side of the spine in the retroperitoneum. The right kidney is located below the liver and the left kidney below the diaphragm. The kidneys filter and secret the metabolic products and minerals from the blood, thus maintaining the homeostasis. On the superior pole of each kidney there is an adrenal gland. Each kidney and adrenal gland is surrounded by fat. (NCI) | Kidney | ||
URETER | C12416 | Ureter | The thick-walled tube that carries urine from each kidney to the bladder. (NCI) | Ureter | ||
URETHRA | C12417 | Urethra | The tube carrying urine from the bladder to outside of the body. (NCI) | Urethra | ||
HEAD | C12419 | Head | The anterior and superior part of a human or animal bearing the mouth, the brain and sensory organs. | Head | ||
LARYNX | C12420 | Larynx | The cartilaginous structure of the respiratory tract between the pharynx and the trachea. It contains elastic vocal cords required for sound production. (NCI) | Larynx | ||
ORAL CAVITY | C12421 | Oral Cavity | The cavity located at the upper end of the alimentary canal, behind the teeth and gums that is bounded on the outside by the lips, above by the hard and soft palates and below by the tongue. (NCI) | Oral Cavity | ||
TONGUE | C12422 | Tongue | The muscular organ located in the floor of the mouth and serving as the principal organ of taste and modification of the voice in speech. (NCI) | Tongue | ||
NASOPHARYNX | C12423 | Nasopharynx | The part of the pharynx in the back of the throat, at and above the soft palate. The nasopharynx is continuous with the nasal passages. (NCI) | Nasopharynx | ||
NASAL CAVITY | C12424 | Nasal Cavity | The proximal portion of the respiratory passages on either side of the nasal septum lying between the floor of the cranium and the roof of the mouth and extending from the face to the pharynx. The nasal cavity is lined with ciliated mucosa, extending from the nares to the pharynx. (NCI) | Nasal Cavity | ||
PHARYNX | C12425 | Pharynx | A hollow tube that starts posterior to the mouth and nasal cavity and ends superior to the trachea and esophagus. (NCI) | Pharynx | ||
PAROTID GLAND | C12427 | Parotid Gland | The largest of the three paired salivary glands, located in front of the ear. (NCI) | Parotid Gland | ||
TRACHEA | C12428 | Trachea;Windpipe | The fibrocartilaginous, mucous-lined tube passing from the larynx to the bronchi. (NCI) | Trachea | ||
LIMB | C12429 | Extremities;Limb | A body region referring to an upper or lower extremity. (NCI) | Limb | ||
SPLEEN | C12432 | Spleen | An organ that is part of the hematopoietic and immune systems. It is composed of the white pulp and the red pulp and is surrounded by a capsule. It is located in the left hypochondriac region. Its functions include lymphocyte production, blood cell storage, and blood cell destruction. (NCI) | Spleen | ||
THYMUS GLAND | C12433 | Thymus Gland | A bi-lobed organ surrounded by a connective tissue capsule. It is located in the upper anterior portion of the chest, behind the sternum. It is composed predominantly of lymphocytes and fewer epithelial cells. Connective tissue septa separate the lobes into lobules. The lobules contain an outer portion (cortical zone) which is rich in lymphocytes and an inner portion (medullary zone) which is rich in epithelial cells. It is an organ essential for the development of the immune system. Its function is the maturation of the progenitor lymphoid cells to thymocytes and subsequently to mature T-cells. It reaches its greatest weight at puberty and subsequently begins to involute. (NCI) | Thymus Gland | ||
BLOOD | C12434 | Blood;Peripheral Blood | A liquid tissue with the primary function of transporting oxygen and carbon dioxide. It supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. | Blood | ||
BRAIN | C12439 | Brain;Nervous System, Brain | An organ composed of grey and white matter containing billions of neurons that is the center for intelligence and reasoning. It is protected by the bony cranium. (NCI) | Brain | ||
MEDULLA OBLONGATA | C12442 | Medulla Oblongata | The lower portion of the brainstem located between the pons and brainstem. This structure contains several descending and ascending tracts, lower cranial nerve nuclei, a significant proportion of the reticular system of the brainstem and other structures. (NCI) | Medulla Oblongata | ||
BASAL GANGLIA | C12447 | Basal Ganglia | Clusters of neurons comprising the globus pallidus, putamen, caudate, nucleus accumbens, substantia nigra and subthalamic nucleus. They are involved with high level aspects of inhibitory motor activity in coordination with the excitation commands issued from the cerebellum. (NCI) | Basal Ganglia | ||
PUTAMEN | C12452 | Putamen | The largest and most lateral of the basal ganglia lying between the lateral medullary lamina of the globus pallidus and the external capsule. It is part of the neostriatum and forms part of the lentiform nucleus along with the globus pallidus. (MeSH) | Putamen | ||
THALAMUS | C12459 | Thalamus | An ovoid mass composed predominantly of gray substance and associated laminae of white substance. The thalamus is divided into anterior, medial, and lateral parts. The function of the thalamus is to relay sensory impulses and cerebellar and basal ganglia projections to the cerebral cortex. The thalamus is positioned within the posterior part of the diencephalon forming most of each lateral wall of the third ventricle. (NCI) | Thalamus | ||
LUNG | C12468 | Lung | One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border. (NCI) | Lung | ||
SKIN | C12470 | Integument;Skin | An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages. (NCI) | Skin | ||
TYMPANIC MEMBRANE | C12502 | Tympanic Membrane | A thin membrane that separates the external auditory canal from the middle ear. The movement of the tympanic membrane in response to air pressure changes in the external ear facilitates the transmission of sound energy by causing vibration of the ossicular chain. (NCI) | Tympanic Membrane | ||
MASTOID PROCESS | C12503 | Mastoid Process | A honeycombed section of bone located near the base of the skull, protruding behind the outer ear. It is connected to the middle ear. (NCI) | Mastoid Process | ||
ABDOMINAL CAVITY | C12664 | Abdomen;Abdominal Cavity | The portion of the body that lies between the thorax and the pelvis. (NCI) | Abdominal Cavity | ||
ADRENAL GLAND | C12666 | Adrenal Gland | Suprarenal gland. A flattened, roughly triangular body resting upon the upper end of each kidney; it is one of the ductless glands furnishing internal secretions (epinephrine and norepinephrine from the medulla and steroid hormones from the cortex). (NCI) | Adrenal Gland | ||
AORTA | C12669 | Aorta | The major arterial trunk that carries oxygenated blood from the left ventricle into the ascending aorta behind the heart, the aortic arch, through the thorax as the descending aorta and through the abdomen as the abdominal aorta; it bifurcates into the left and right common iliac arteries. (NCI) | Aorta | ||
AXILLA | C12674 | Axilla | The underside concavity where the arm and the shoulder are joined. (NCI) | Axilla | ||
BILIARY TRACT | C12678 | Biliary Tract | The duct system that transports bile from its origination by hepatocytes in the liver to the small intestine. It is comprised of the common bile duct that connects the liver and gall bladder to the small intestine and the cystic duct that connects the gall bladder to the common bile duct. (NCI) | Biliary Tract | ||
BLOOD VESSEL | C12679 | Blood Vessel | A tubular structure through which the blood circulates in the body. Blood vessels constitute a network composed of arteries, arterioles, capillaries, venules, and veins. (NCI) | Blood Vessel | ||
BRACHIAL ARTERY | C12681 | Brachial Artery | An artery originating at the axillary artery and branching into the radial and ulnar arteries. (NCI) | Brachial Artery | ||
BRACHIAL PLEXUS | C12682 | Brachial Plexus | A nerve network originating from C5 to T1 that supplies cutaneous and muscular innervation to the arm and hand. (NCI) | Brachial Plexus | ||
BRONCHUS | C12683 | Bronchi;Bronchus | Tubular structure in continuation with the trachea, serving as air passage. It terminates in the lung (terminal bronchiole). (NCI) | Bronchus | ||
CAROTID ARTERY | C12687 | Carotid Artery | One of two arteries that supply oxygenated blood to the head and neck; the left common carotid branches from the aorta and the right common carotid from the innominate (brachiocephalic artery). (NCI) | Carotid Artery | ||
CERVICAL VERTEBRA | C12693 | Cervical Vertebra | Any one of the seven vertebrae that start with C1, connecting the skull to the spine, and ends with C7, which joins the cervical with the thoracic spine. (NCI) | Cervical Vertebra | ||
CLAVICLE | C12695 | Clavicle | One of a pair of bones linking the scapula and the sternum. The clavicle is part of the pectoral girdle. (NCI) | Clavicle | ||
COCCYX | C12696 | Coccyx | A small bone located at the bottom of the spine. The coccyx is a result of 3-5 fused rudimentary vertebrae. (NCI) | Coccyx | ||
EPIGLOTTIS | C12709 | Epiglottis | A small cartilagenous flap-like valve that closes over the larynx during swallowing to prevent food entering the lungs. (NCI) | Epiglottis | ||
ETHMOID BONE | C12711 | Ethmoid Bone | A light and spongy bone that is cubical in shape. This bone is positioned at the anterior part of the cranium, sitting between the two orbits, at the roof of the nose. It consists of four parts: a horizontal or cribriform plate; a perpendicular plate; and two lateral masses or labyrinths. (NCI) | Ethmoid Bone | ||
EYELID | C12713 | Eyelid;Palpebra | A thin membrane of skin with the purpose of covering and protecting an eye. (NCI) | Eyelid | ||
FEMORAL ARTERY | C12715 | Femoral Artery | An artery that starts within the inguinal region and extends to the lower extremities. (NCI) | Femoral Artery | ||
FEMORAL VEIN | C12716 | Femoral Vein | A vein that starts within the inguinal region and extends to the lower extremities. (NCI) | Femoral Vein | ||
FEMUR | C12717 | Bone, Femoral;Femur | The upper leg bone positioned between the pelvis and the knee. (NCI) | Femur | ||
FIBULA | C12718 | Fibula | The small, lateral calf bone extending from the knee to the ankle. (NCI) | Fibula | ||
GANGLION | C12719 | Ganglia;Ganglion;Neural Ganglion | A cluster of nervous tissue principally composed of neuronal cell bodies external to the central nervous system (CNS). (NCI) | Ganglion | ||
GLOTTIS | C12724 | Glottis | The space in which the vocal cords are located. (NCI) | Glottis | ||
INGUINAL REGION | C12726 | Inguinal Region | The lower region of the anterior abdominal wall located laterally to the pubic region. (NCI) | Inguinal Region | ||
HEART | C12727 | Cardiac;Heart | A hollow muscular organ which receives the blood from the veins and propels it into the arteries. It is divided by a musculomembranous septum into two halves -- right or venous and left or arterial -- each of which consists of a receiving chamber (atrium) and an ejecting chamber (ventricle). (NCI) | Heart | ||
HUMERUS | C12731 | Bone, Humeral;Humerus | The upper arm bone between the shoulder and elbow. (NCI) | Humerus | ||
INTESTINE | C12736 | Intestine | The portion of the gastrointestinal tract between the stomach and the anus. It includes the small intestine and large intestine. (NCI) | Intestine | ||
LENS | C12743 | Crystalline Lens;Lens;Lens Of Eye;Ocular Lens | A biconvex transparent structure of the eye through which light is focused on the retina. The lens sits behind the iris and is supported by the zonule, which connects it to the ciliary body. The lens is an avascular structure. (NCI) | Lens | ||
LUMBAR VERTEBRA | C12744 | Lumbar Vertebra | One of the five bones situated between the thoracic vertebrae and the sacrum in the lower part of the spine. (NCI) | Lumbar Vertebra | ||
LYMPH NODE | C12745 | Lymph Node;Lymphatic Gland | A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found through out the body. It is composed predominantly of lymphocytes and its main function is immune protection. (NCI) | Lymph Node | ||
MEDIASTINUM | C12748 | Mediastinum | A group of organs surrounded by loose connective tissue, separating the two pleural sacs, between the sternum anteriorly and the vertebral column posteriorly as well as from the thoracic inlet superiorly to the diaphragm inferiorly. The mediastinum contains the heart and pericardium, the bases of the great vessels, the trachea and bronchi, esophagus, thymus, lymph nodes, thoracic duct, phrenic and vagus nerves, and other structures and tissues. (NCI) | Mediastinum | ||
METATARSAL BONE | C12752 | Metatarsal Bone | A bone belonging to the middle part of the foot located between toes and ankle. There are 5 metatarsal bones and they are numbered from the medial side. (NCI) | Metatarsal Bone | ||
NOSE | C12756 | Nose | A structure of special sense serving as an organ of the sense of smell and as an entrance to the respiratory tract. (NCI) | Nose | ||
OPTIC NERVE | C12761 | Optic Nerve | The second cranial nerve. (NCI) | Optic Nerve | ||
PARANASAL SINUS | C12763 | Accessory Sinuses;Nasal Cavity;Nasal Sinuses;Paranasal Sinus | An air-filled cavity adjacent to the nasal cavity lined by a mucous membrane and located in the bones of the skull. There are four paranasal sinuses on each side of the face: ethmoid, frontal, maxillary, and sphenoid sinus. (NCI) | Paranasal Sinus | ||
PELVIS | C12767 | Pelvic Cavity;Pelvis;Pelvic Region | The bony, basin-shaped structure formed by the hipbones and the base of the backbone supporting the lower limbs in humans. (NCI) | Pelvis | ||
PERIPHERAL NERVE | C12768 | Peripheral Nerve | Any nerve outside the brain or spinal cord that connects with peripheral receptors or effectors. (NCI) | Peripheral Nerve | ||
PERITONEUM | C12770 | Peritoneum | The tissue that lines the wall of the abdominal cavity, intestine, and mesentery. It consists of the parietal peritoneum that covers the inside of the abdominal wall and the visceral peritoneum that covers the surface of the intestine and mesentery. (NCI) | Peritoneum | ||
RIB | C12782 | Rib | Any one of the paired bones, 12 on either side, extending from the thoracic vertebrae toward the median line on the ventral aspect of the trunk. The long curved bones which form the rib cage. Generally, ribs 1 to 7 are connected to the sternum by their costal cartilages and are called true ribs, whereas ribs 8 to 12 are termed false ribs. (NCI) | Rib | ||
SCAPULA | C12783 | Scapula;Shoulder Blade | The flat triangle-shaped bone that connects the humerus with the clavicle in the back of the shoulder. (NCI) | Scapula | ||
SCROTUM | C12785 | Scrotum | The musculocutaneous pouch that encloses the testicles. (NCI) | Scrotum | ||
LUNATE BONE | C12786 | Lunate Bone | The bone in the proximal row of carpal bones that lies between the scaphoid and triquetral bones. (NCI) | Lunate Bone | ||
SKULL | C12789 | Bone, Cranial;Cranium;Skull | The bones that form the head, made up of the bones of the braincase and face. (NCI) | Skull | ||
STERNUM | C12793 | Sterna;Sternum | The long, flat bone connecting with the cartilages of the first seven ribs and the clavicle. (NCI) | Sternum | ||
TEMPORAL BONE | C12797 | Temporal Bone | A large irregular bone situated at the base and side of the skull, connected with the mandible via the temporomandibular joint. The temporal bone consists of the squamous, tympanic and petrous parts. The petrous portion of the temporal bone contains the vestibulocochlear organ of the inner ear. (NCI) | Temporal Bone | ||
THORACIC VERTEBRA | C12798 | Thoracic Vertebra | One of 12 vertebrae in the human vertebral column. The thoracic vertebrae are situated between the seventh cervical vertebra down to the first lumbar vertebra. (NCI) | Thoracic Vertebra | ||
THORAX | C12799 | Thorax | The division of the body lying between the neck and the abdomen. (NCI) | Thorax | ||
TIBIA | C12800 | Tibia | A bone located between the femur and the tarsus, being part of the lower leg. (NCI) | Tibia | ||
TONSIL | C12802 | Tonsil | The two organs situated in the throat on either side of the narrow passage from the mouth to the pharynx. They are composed of lymphoid tissues. (NCI) | Tonsil | ||
TROCHLEAR NERVE | C12808 | Trochlear Nerve | The cranial nerve that controls the superior oblique muscle of the eye. (NCI) | Trochlear Nerve | ||
UVEA | C12811 | Uvea | The pigmented layer of the eyeball between the tough, white outer coat of the eye and the retina. (NCI) | Uvea | ||
VEIN | C12814 | Vein | A blood vessel that carries blood towards the heart. | Vein | ||
VENA CAVA | C12817 | Vena Cava | A large vein which returns blood from the head, neck and extremities to the heart. (NCI) | Vena Cava | ||
VOCAL CORD | C12822 | Vocal Cord | A pair of small bands of muscle that stretch from the thyroid cartilage in front to the arytenoid cartilage in back of the larynx. The vocal cords help prevent food entering the lungs and produce sound through vibration. (NCI) | Vocal Cord | ||
RADIAL ARTERY | C12838 | Radial Artery | The branch of the brachial artery that passes down the forearm. (NCI) | Radial Artery | ||
PLEURAL CAVITY | C12840 | Pleural Cavity | The cavity lined by the pleura, located in the thorax and contains heart and lungs. (NCI) | Pleural Cavity | ||
CORONARY ARTERY | C12843 | Coronary Artery | A principal artery that originates in the aorta. It supplies blood to the muscular tissue of the heart. (NCI) | Coronary Artery | ||
SACRAL VERTEBRA | C12853 | Sacral Vertebra | One of the usually five fused vertebrae forming the triangular bone just below the lumbar vertebrae. (NCI) | Sacral Vertebra | ||
SCAPHOID BONE | C12854 | Scaphoid Bone | A nut-shaped bone of the wrist located in the radial site of the hand. It is one of the eight carpal bones. (NCI) | Scaphoid Bone | ||
PISIFORM BONE | C12855 | Pisiform Bone | The medial bone of the proximal row of carpal bones. (NCI) | Pisiform Bone | ||
CAPITATE BONE | C12856 | Capitate Bone | The largest of eight carpal bones, located in the center of the hand. (NCI) | Capitate Bone | ||
TRAPEZIAL BONE | C12857 | Trapezial Bone | A carpal bone on the thumb side of the hand that articulates with the 1st and 2nd metacarpals. (NCI) | Trapezial Bone | ||
TRIANGULAR BONE | C12858 | Triangular Bone | A carpal bone located between the lunate and pisiform bones. (NCI) | Triangular Bone | ||
TRAPEZOID BONE | C12859 | Trapezoid Bone | A carpal bone located between the trapezium and capitate bones. (NCI) | Trapezoid Bone | ||
HAMATE BONE | C12860 | Hamate Bone | The medial bone in the distal row of carpal bones. (NCI) | Hamate Bone | ||
SUPRACLAVICULAR LYMPH NODE | C12903 | Supraclavicular Lymph Node | A lymph node which is located above the clavicle. (NCI) | Supraclavicular Lymph Node | ||
AXILLARY LYMPH NODE | C12904 | Axillary Lymph Node | One of approximately 20-30 lymph nodes in chain formation that traverse the concavity of the underarm to the clavicle. (NCI) | Axillary Lymph Node | ||
BREAST | C12971 | Breast | One of two hemispheric projections of variable size situated in the subcutaneous layer over the pectoralis major muscle on either side of the chest. (NCI) | Breast | ||
VERTEBRAL COLUMN | C12998 | Vertebral Column | A series of bones, muscles, tendons, and other tissues reaching from the base of the skull to the tailbone. The vertebral column forms the axis of the skeleton and encloses as well as protects the spinal cord and the fluid surrounding the spinal cord. (NCI) | Vertebral Column | ||
PERICARDIUM | C13005 | Pericardium | A conical membranous sac filled with serous fluid in which the heart as well as the roots of the aorta and other large blood vessels are contained. (NCI) | Pericardium | ||
BODY | C13041 | Body | The entire physical structure of an organism. It is composed of anatomic systems, regions, cavities, and spaces. (NCI) | Body | ||
JOINT | C13044 | Articulation;Joint | The connection point between two bones or skeletal elements. The joint may be fixed or movable. (NCI) | Joint | ||
LIGAMENT | C13046 | Ligament | Band of fibrous tissue connecting bone to bone or cartilage to bone thereby supporting or strengthening a joint. (NCI) | Ligament | ||
BACK | C13062 | Back | The dorsal area between the base of the neck and the sacrum. (NCI) | Back | ||
NECK | C13063 | Neck | The region that connects the head to the rest of the body. (NCI) | Neck | ||
FACE | C13071 | Face;Facial | The anterior portion of the head extending from the forehead to the chin and ear to ear. The facial structures contain the eyes, nose and mouth, cheeks and jaws. (NCI) | Face | ||
MUCOSA | C13166 | Mucosa;Mucous Membrane | The moist, inner lining of some organs and body cavities (such as the nose, mouth, lungs, and stomach). Glands in the mucosa make mucus (a thick, slippery fluid). | Mucosa | ||
GASTRIC | C13307 | Gastric | Relating to the stomach. (NCI) | Gastric | ||
ANASTOMOSIS | C15609 | Anastomosis | A natural or surgically-induced connection between tubular structures in the body. (NCI) | Anastomosis | ||
SHOULDER | C25203 | Shoulder | The region of the body between the neck and the upper arm. (NCI) | Shoulder | ||
CHEST | C25389 | Chest | The anterior side of the thorax from the neck to the abdomen. The shape of the chest is often regarded as potential insight into a disease process, as in the case of barrel chest and respiratory dysfunction. (NCI) | Chest | ||
HILAR | C25724 | Hilar | Refers to the area associated with the hilum. (NCI) | Hilar | ||
CORPUS LUTEUM | C26465 | Corpus Luteum | A group of cells that remain of the Graafian follicle following ovulation. This structure is composed of endocrine tissue and produces progesterone. This is needed to prepare the uterine lining for implantation by the fertilized egg. (NCI) | Corpus Luteum | ||
MAXILLA | C26470 | Maxilla | The upper jawbone in vertebrates: it is fused to the cranium. (NCI) | Maxilla | ||
ACETABULUM | C32042 | Acetabulum | Two cup shaped areas, one each on the lateral side of the lower pelvis that house the head of the femur to form the ball and socket joint of the hip. (NCI) | Acetabulum | ||
ACROMIOCLAVICULAR JOINT | C32047 | Acromioclavicular Joint | The junction of the upper distal end of the scapula to the distal edge of the collarbone, also known as the acromion and the clavicle. (NCI) | Acromioclavicular Joint | ||
ACROMION | C32048 | Acromion | The upper distal process of the scapula. (NCI) | Acromion | ||
ANKLE JOINT | C32078 | Ankle Joint;Ankle | A gliding joint between the distal ends of the tibia and fibula and the proximal end of the talus. (NCI) | Ankle Joint | ||
AORTIC ARCH | C32123 | Aortic Arch | The curved section of the aorta between the ascending and the descending tracts. The brachiocephalic, left common carotid and left subclavian arteries branch from the aorta at this section. (NCI) | Aortic Arch | ||
ARM | C32141 | Arm | The portion of the upper extremity between the shoulder and the elbow. For clinical purposes this term is also used to refer to the whole superior limb. (NCI) | Arm | ||
BASILIC VEIN | C32197 | Basilic Vein | One of the moderately large superficial veins of the forearm that transports blood from the hand and the medial aspect of the forearm to the axillary vein. (NCI) | Basilic Vein | ||
C1 VERTEBRA | C32239 | C1 Vertebra | The first of the seven cervical vertebrae. (NCI) | C1 Vertebra | ||
C2 VERTEBRA | C32240 | C2 Vertebra | The second of the seven cervical vertebrae. (NCI) | C2 Vertebra | ||
C3 VERTEBRA | C32241 | C3 Vertebra | The third of the seven cervical vertebrae. (NCI) | C3 Vertebra | ||
C4 VERTEBRA | C32242 | C4 Vertebra | The fourth of the seven cervical vertebrae. (NCI) | C4 Vertebra | ||
C5 VERTEBRA | C32243 | C5 Vertebra | The fifth of the seven cervical vertebrae. (NCI) | C5 Vertebra | ||
C6 VERTEBRA | C32244 | C6 Vertebra | The sixth of the seven cervical vertebrae. (NCI) | C6 Vertebra | ||
C7 VERTEBRA | C32245 | C7 Vertebra | The seventh of the seven cervical vertebrae. (NCI) | C7 Vertebra | ||
CANINE TOOTH | C32258 | Canine Tooth | A single-cusped (pointed) and usually single-rooted tooth located between the incisors and premolars. (NCI) | Canine Tooth | ||
CEPHALIC VEIN | C32286 | Cephalic Vein;Vena Cephalica | One of five superficial veins of the upper extremity, beginning at the radial aspect of the wrist area, wrapping around the forearm and emptying into the axillary vein. (NCI) | Cephalic Vein | ||
CERVICAL LYMPH NODE | C32298 | Cervical Lymph Node | Any of the lymph nodes located in the neck. (NCI) | Cervical Lymph Node | ||
COCCYGEAL VERTEBRA | C32334 | Coccygeal Vertebra | Four vertebral segments positioned at the base of the spine that are fused. (NCI) | Coccygeal Vertebra | ||
COSTAL CARTILAGE | C32391 | Costal Cartilage | The cartilage positioned between the anterior end of the rib and the sternum. Its elasticity allows the ribcage to expand while breathing. (NCI) | Costal Cartilage | ||
CUBOID BONE | C32414 | Cuboid Bone | A bone on the lateral side of the tarsus between the calcaneus and the fourth and fifth metatarsal bones. (NCI) | Cuboid Bone | ||
DORSALIS PEDIS ARTERY | C32478 | Dorsalis Pedis Artery | An artery of the dorsal surface of the foot, originating from the anterior tibial artery of the lower leg. The following arterial branches originate from the dorsalis pedis artery: the arcuate artery of the foot and deep plantar artery. (NCI) | Dorsalis Pedis Artery | ||
ELBOW JOINT | C32497 | Elbow Joint | A type of hinge joint located between the forearm and upper arm. (NCI) | Elbow Joint | ||
ENDOMETRIAL CAVITY | C32514 | Endometrial Cavity | A space inside the uterus lined by a layer of mucus membranes called the endometrium. (NCI) | Endometrial Cavity | ||
FACET JOINT | C32577 | Facet Joint | A synovial joint between two adjacent vertebrae. The facet joint links the articular process of one vertebra and the inferior articular process of the adjacent vertebra. (NCI) | Facet Joint | ||
FINGER | C32608 | Finger | Any of the digits of the hand. (NCI) | Finger | ||
FINGERNAIL | C32609 | Fingernail | The nail at the end of a finger. (NCI) | Fingernail | ||
FOOT | C32622 | Feet;Foot | The structure found below the ankle joint required for locomotion. (NCI) | Foot | ||
FOREARM | C32628 | Forearm | The structure on the upper limb, between the elbow and the wrist. (NCI) | Forearm | ||
GASTROESOPHAGEAL JUNCTION | C32668 | Gastroesophageal Junction | The anatomical location where the esophagus joins to the stomach. (NCI) | Gastroesophageal Junction | ||
GINGIVA | C32677 | Gingiva;Gum | The soft tissue surrounding the neck of individual teeth as well as covering the alveolar bone. The tissue is fibrous and continuous with the periodontal ligament and mucosal covering. (NCI) | Gingiva | ||
GLENOID FOSSA | C32682 | Glenoid Fossa | The trough in the head of the scapula that receives the head of the humerus to form the shoulder joint. (NCI) | Glenoid Fossa | ||
GREAT TROCHANTER | C32698 | Great Trochanter | A large, irregular, quadrilateral area of bone found at the neck of the femur. (NCI) | Great Trochanter | ||
HAIR | C32705 | Hair | The filamentous outgrowth of the epidermis. (NCI) | Hair | ||
HAND | C32712 | Hand | The distal portion of the upper extremity. It consists of the carpus, metacarpus, and digits. (NCI) | Hand | ||
HEAD OF THE HUMERUS | C32720 | Head of the Humerus | The upper rounded part of the humerus that fits into the glenoid cavity of the scapula. (NCI) | Head of the Humerus | ||
HIP JOINT | C32742 | Coxofemoral Joint;Hip Joint | A ball-and-socket joint between the head of the femur and the acetabulum. (NCI) | Hip Joint | ||
HYOID BONE | C32752 | Hyoid Bone | A U-shaped bone supporting the tongue. This bone is located at the base of the tongue and is suspended from the tips of the styloid processes of the temporal bones by the stylohyoid ligaments. (NCI) | Hyoid Bone | ||
ILIAC LYMPH NODE | C32761 | Iliac Lymph Node | One of the three lymph nodes of the pelvis: the superior gluteal, interior gluteal or sacral. (NCI) | Iliac Lymph Node | ||
ILIUM | C32765 | Ilium | The broad, dorsal, upper, and widest of the three principal bones composing either half of the pelvis. (NCI) | Ilium | ||
INCISOR | C32769 | Incisor | One of the teeth in front of the canines in either jaw designed for cutting or gnawing. (NCI) | Incisor | ||
INCUS | C32770 | Incus | One of the three bones comprising the middle ear. This anvil-shaped bone is positioned between the malleus and the stapes. (NCI) | Incus | ||
INGUINAL LYMPH NODE | C32801 | Inguinal Lymph Node | A superficial or deep lymph node located in the inguinal area. (NCI) | Inguinal Lymph Node | ||
INTERPHALANGEAL JOINT OF THE HAND | C32868 | Interphalangeal Joint of the Hand | The hinge synovial joints between the phalanges of the fingers. (NCI) | Interphalangeal Joint of the Hand | ||
ISCHIUM | C32884 | Ischium | The most posterior and ventral bone making up the pelvis. (NCI) | Ischium | ||
TEMPOROMANDIBULAR JOINT | C32888 | Jaw Joint;TMJ | The joint between the head of the lower mandible and the temporal bone. (NCI) | Jaw Joint | ||
KNEE JOINT | C32898 | Knee Joint;Tibiofemoral Joint | A joint connecting the lower part of the femur with the upper part of the tibia. The lower part of the femur and the upper part of the tibia are attached to each other by ligaments. Other structures of the knee joint include the upper part of the fibula, located below and parallel to the tibia, and the patella which moves as the knee bends. (NCI) | Knee Joint | ||
L1 VERTEBRA | C32899 | L1 Vertebra | The first lumbar vertebra counting from the top down. (NCI) | L1 Vertebra | ||
L2 VERTEBRA | C32900 | L2 Vertebra | The second lumbar vertebra counting from the top down. (NCI) | L2 Vertebra | ||
L3 VERTEBRA | C32901 | L3 Vertebra | The third lumbar vertebra counting from the top down. (NCI) | L3 Vertebra | ||
L4 VERTEBRA | C32902 | L4 Vertebra | The fourth lumbar vertebra counting from the top down. (NCI) | L4 Vertebra | ||
L5 VERTEBRA | C32903 | L5 Vertebra | The fifth lumbar vertebra counting from the top down. (NCI) | L5 Vertebra | ||
LACRIMAL BONE | C32906 | Lacrimal Bone | A small rectangular thin plate forming part of the medial orbit wall. It is located posterior to the frontal process of the maxilla and articulates with the inferior nasal concha, ethmoid, frontal, and maxillary bones. (NCI) | Lacrimal Bone | ||
LEG | C32974 | Leg | One of the two lower extremities in humans used for locomotion and support. (NCI) | Leg | ||
LIVER FISSURE | C32996 | Liver Fissure | A groove on the surface of the liver. | Liver Fissure | ||
LYMPH NODE HILUM | C33031 | Lymph Node Hilum | The concave side of the lymph node. (NCI) | Lymph Node Hilum | ||
MALLEUS | C33051 | Malleus | A hammer-shaped bone, part of three interconnected small bones located in the middle ear. It is attached to the inner surface of the tympanic membrane and its function is to transmit sound vibrations. (NCI) | Malleus | ||
MEDIASTINAL LYMPH NODE | C33073 | Mediastinal Lymph Node | A lymph node located in the mediastinum. Mediastinal lymph nodes are arranged in three groups, one on the lateral, another on the medial, and a third on the anterior aspect of the vessels; the third group is, however, sometimes absent. (NCI) | Mediastinal Lymph Node | ||
METATARSOPHALANGEAL JOINT | C33108 | Metatarsophalangeal Joint | A spheroid joint located between the heads of the metatarsal bone and the base of the proximal phalanx of the toe. (NCI) | Metatarsophalangeal Joint | ||
NAIL | C33156 | Nail | The cutaneous plate on the dorsal surface of the distal end of a finger or toe. (NCI) | Nail | ||
NASAL BONE | C33157 | Nasal Bone | One of two small oblong bones placed side by side at the middle and upper part of the face. (NCI) | Nasal Bone | ||
NASAL SEPTUM | C33160 | Nasal Septum | The thin wall between the two nasal cavities. (NCI) | Nasal Septum | ||
NAVICULAR BONE | C33162 | Navicular Bone | An oval-shaped bone of the tarsus found on the medial side of the foot. (NCI) | Navicular Bone | ||
NOSTRIL | C33178 | Nostril | One of the two channels of the nose, from the point where they divide to the external opening. (NCI) | Nostril | ||
OLECRANON | C33200 | Olecranon | A prominence at the proximal end of the ulna. It forms the tip of the elbow. (NCI) | Olecranon | ||
OLFACTORY MUCOSA | C33205 | Olfactory Mucosa | The part of the nasal mucosa composed of neuroepithelial tissue and mucus-producing Bowman's glands. The mucus moistens the epithelium and helps dissolve odor-containing gases. (NCI) | Olfactory Mucosa | ||
PAROTID GLAND LYMPH NODE | C33278 | Parotid Gland Lymph Node | A lymph node located close to, on, or within the parotid gland. (NCI) | Parotid Gland Lymph Node | ||
PATELLA | C33282 | Patella | A small flat triangular bone in front of the knee that articulates with the femur and protects the knee joint. (NCI) | Patella | ||
PELVIC BONE | C33287 | Pelvic Bone;Pelvis | The caudal portion of the trunk, bounded anteriorly and laterally by the two hip bones incorporating the socket portion of the hip joint for each leg. Posteriorly it is bounded by the sacrum and coccyx. (NCI) | Pelvic Bone | ||
PERINEUM | C33301 | Perineum | The area located between the anus and vulva in females, and anus and scrotum in males. (NCI) | Perineum | ||
PHARYNGEAL TONSIL | C33318 | Adenoid;Pharyngeal Tonsil | A fold of lymphatic tissue covered by ciliated epithelium at the very back of the nose, in the roof of the nasopharynx. (NCI) | Pharyngeal Tonsil | ||
PORTAL VEIN | C33343 | Hepatic Portal Vein;Portal Vein | A short thick trunk vein that transports blood containing the absorbed products of digestion from the intestine directly to the liver. (NCI) | Portal Vein | ||
PYLORIC SPHINCTER | C33433 | Pyloric Sphincter | The muscular structure at the distal portion of the stomach, opening into the duodenum. (NCI) | Pyloric Sphincter | ||
SACROILIAC JOINT | C33507 | Sacroiliac Joint | The joint located between the sacrum and the ilium. (NCI) | Sacroiliac Joint | ||
SACRUM | C33508 | Sacrum | The triangular bone, made up of 5 fused bones of the spine, located in the lower area of the spine between the fifth lumbar vertebra and the coccyx. (NCI) | Sacrum | ||
SHOULDER JOINT | C33548 | Shoulder Joint | A ball-and-socket joint at the upper end of the humerus, located at the junction of humerus and scapula. (NCI) | Shoulder Joint | ||
SINUS | C33556 | Sinus | A recess, cavity, or channel. (NCI) | Sinus | ||
STERNOCLAVICULAR JOINT | C33615 | Sternoclavicular Joint | The synovial juncture between the medial end of the clavicle and the anterior segment of the sternum. (NCI) | Sternoclavicular Joint | ||
SYNOVIAL FLUID | C33718 | Synovial Fluid;Synovia | A viscid fluid secreted by the synovial membrane, serving as a lubricant. (NCI) | Synovial Fluid | ||
T1 VERTEBRA | C33720 | T1 Vertebra | The first thoracic vertebra counting from the top down. (NCI) | T1 Vertebra | ||
T10 VERTEBRA | C33721 | T10 Vertebra | The tenth thoracic vertebra counting from the top down. (NCI) | T10 Vertebra | ||
T11 VERTEBRA | C33722 | T11 Vertebra | The eleventh thoracic vertebra counting from the top down. (NCI) | T11 Vertebra | ||
T12 VERTEBRA | C33723 | T12 Vertebra | The twelfth thoracic vertebra counting from the top down. (NCI) | T12 Vertebra | ||
T2 VERTEBRA | C33724 | T2 Vertebra | The second thoracic vertebra counting from the top down. (NCI) | T2 Vertebra | ||
T3 VERTEBRA | C33725 | T3 Vertebra | The third thoracic vertebra counting from the top down. (NCI) | T3 Vertebra | ||
T4 VERTEBRA | C33726 | T4 Vertebra | The fourth thoracic vertebra counting from the top down. (NCI) | T4 Vertebra | ||
T5 VERTEBRA | C33727 | T5 Vertebra | The fifth thoracic vertebra counting from the top down. (NCI) | T5 Vertebra | ||
T6 VERTEBRA | C33728 | T6 Vertebra | The sixth thoracic vertebra counting from the top down. (NCI) | T6 Vertebra | ||
T7 VERTEBRA | C33729 | T7 Vertebra | The seventh thoracic vertebra counting from the top down. (NCI) | T7 Vertebra | ||
T8 VERTEBRA | C33730 | T8 Vertebra | The eighth thoracic vertebra counting from the top down. (NCI) | T8 Vertebra | ||
T9 VERTEBRA | C33731 | T9 Vertebra | The ninth thoracic vertebra counting from the top down. (NCI) | T9 Vertebra | ||
TARSUS BONE | C12796 | Bone, Tarsal;Tarsus Bone;Tarsus | Any one of the seven bones forming the instep of the foot. (NCI) | Tarsal Bone | ||
THIGH | C33763 | Thigh | A part of the lower limb, located between hip and knee. (NCI) | Thigh | ||
TOE | C33788 | Toe | One of the terminal digits of the foot. (NCI) | Toe | ||
TOENAIL | C33790 | Toenail | A thin, horny translucent plate covering the end of each toe. (NCI) | Toenail | ||
TRAPEZIUS MUSCLE | C33809 | Trapezius Muscle | One of a pair of flat, large, triangular muscles that extend from the external occipital protuberance and the medial third of the superior nuchal line of the occipital bone to the middle of the back. The trapezius muscle is involved in moving the shoulder and arm. (NCI) | Trapezius Muscle | ||
TROCHANTER | C33814 | Trochanter | A bony protrusion on the femoral bone to which muscles are attached. (NCI) | Trochanter | ||
TRUNK | C33816 | Trunk | The body excluding the head and neck and limbs. (NCI) | Trunk | ||
TUNICA INTIMA | C33820 | Tunica Intima | The inner most layer of the blood vessel wall. The consistency of the intima will vary depending on the type of blood vessel, but will always have an endothelial layer with a basal lamina. It may contain collagen and elastic fibers. (NCI) | Tunica Intima | ||
VOMER | C33888 | Vomer | A thin, paired or unpaired, trapezoidal bone of the skull located in the floor of the nasal cavity. The vomer forms the posterior and inferior parts of the nasal septum. (NCI) | Vomer | ||
WRIST JOINT | C33894 | Wrist Joint | A joint between the distal end of the radius and the proximal row of carpal bones. (NCI) | Wrist Joint | ||
XIPHOID PROCESS | C33895 | Xiphoid Process | The cartilage just below the sternal body. (NCI) | Xiphoid Process | ||
GASTROINTESTINAL TRACT | C34082 | Gastrointestinal Tract | The upper gastrointestinal (GI) tract is comprised of mouth, pharynx, esophagus and stomach while the lower GI tract consists of intestines and anus. The primary function of the GI tract is to ingest, digest, absorb and ultimately excrete food stuff. (NCI) | Gastrointestinal Tract | ||
ANUS | C43362 | Anus | The lower opening of the digestive tract, lying in the cleft between the buttocks, through which fecal matter is extruded. (NCI) | Anus | ||
REGIONAL LYMPH NODE | C49018 | Regional Lymph Node | A lymph node that drains lymph from a region of interest. (NCI) | Regional Lymph Node | ||
STERNAL MANUBRIUM | C52730 | Sternal Manubrium | The upper segment of the sternum, quadrangular in shape, as well as wider superiorly and narrower inferiorly. The sternal manubrium articulates with the clavicle and first two ribs. (NCI) | Sternal Manubrium | ||
PALATINE BONE | C52745 | Palatine Bone | An irregularly shaped bone positioned at the back part of the nasal cavity between the maxilla and the pterygoid process of the sphenoid. It forms the posterior part of the hard palate and the lateral wall of the nasal fossa and helps to form the floor of the orbit as well as several adjoining parts. (NCI) | Palatine Bone | ||
LEG SKIN | C52749 | Leg Skin | The skin or integument surrounding the leg. (NCI) | Leg Skin | ||
ARM SKIN | C52754 | Arm Skin | The skin or integument covering the arm. (NCI) | Arm Skin | ||
ABDOMINAL SKIN | C52758 | Abdominal Skin | The skin or integument surrounding the abdomen. (NCI) | Abdominal Skin | ||
RIB 9 | C52759 | Rib 9 | The ninth rib counting from the top of the rib cage down. (NCI) | Rib 9 | ||
RIB 8 | C52760 | Rib 8 | The eighth rib counting from the top of the rib cage down. (NCI) | Rib 8 | ||
RIB 7 | C52761 | Rib 7 | The seventh rib counting from the top of the rib cage down. (NCI) | Rib 7 | ||
RIB 6 | C52762 | Rib 6 | The sixth rib counting from the top of the rib cage down. (NCI) | Rib 6 | ||
RIB 5 | C52763 | Rib 5 | The fifth rib counting from the top of the rib cage down. (NCI) | Rib 5 | ||
RIB 4 | C52764 | Rib 4 | The fourth rib counting from the top of the rib cage down. (NCI) | Rib 4 | ||
RIB 3 | C52765 | Rib 3 | The third rib counting from the top of the rib cage down. (NCI) | Rib 3 | ||
RIB 2 | C52766 | Rib 2 | The second rib counting from the top of the rib cage down. (NCI) | Rib 2 | ||
RIB 12 | C52767 | Rib 12 | The twelfth rib counting from the top of the rib cage down. (NCI) | Rib 12 | ||
RIB 11 | C52768 | Rib 11 | The eleventh rib counting from the top of the rib cage down. (NCI) | Rib 11 | ||
RIB 10 | C52769 | Rib 10 | The tenth rib counting from the top of the rib cage down. (NCI) | Rib 10 | ||
RIB 1 | C52770 | Rib 1 | The first rib counting from the top of the rib cage down. (NCI) | Rib 1 | ||
HAND PHALANX | C52771 | Hand Phalanx | A bone of the hand. (NCI) | Hand Phalanx | ||
FOOT PHALANX | C52772 | Foot Phalanx | A bone of the foot. (NCI) | Foot Phalanx | ||
TALUS | C52799 | Talus | The bone of the foot that connects with the tibia and fibula to form the ankle joint. (NCI) | Talus | ||
SCIATIC NERVE | C52810 | Sciatic Nerve | The longest single nerve that is formed by the merging of the ventral rami of the L4, L5, and S1 in the pelvis and passes down the lower limb where it divides into the common peroneal and tibial nerves. (NCI) | Sciatic Nerve | ||
THROAT | C54272 | Throat | The narrow passage from the mouth to the cavity at the back of the mouth. (NCI) | Throat | ||
FEMORAL NECK | C61563 | Femoral Neck | The short, constricted portion of the thigh bone between the femur head and the trochanter. (NCI) | Femoral Neck | ||
MALE GENITALIA | C61599 | Male Genitalia | Male internal and external organs of reproduction. | Male Genitalia | ||
FEMALE GENITALIA | C61600 | Female Genitalia | Female internal and external organs of reproduction. | Female Genitalia | ||
UNCINATE PROCESS OF PANCREAS | C62432 | Uncinate Process of Pancreas | A portion of the pancreas that extends behind the superior mesenteric artery and superior mesenteric vein. (NCI) | Uncinate Process of Pancreas | ||
CHEST WALL | C62484 | Chest Wall | The total system of structures outside the lungs that move as a part of breathing; it includes all structures from the skin to the parietal pleura. (NCI) | Chest Wall | ||
INFRACLAVICULAR LYMPH NODE | C63705 | Infraclavicular Lymph Node | A lymph node located in the area below the clavicle. (NCI) | Infraclavicular Lymph Node | ||
FACIAL BONE | C63706 | Facial Bone | Any bone that contributes to the facial structures, except those bones that are part of the braincase. (NCI) | Facial Bone | ||
WAIST | C64192 | Waist | The abdominal circumference at the navel. (NCI) | Waist | ||
HIP | C64193 | Hip | The lateral prominence of the pelvis from the waist to the thigh. (NCI) | Hip | ||
CELIAC LYMPH NODE | C65166 | Celiac Lymph Node | A lymph node at the base of the celiac artery. (NCI) | Celiac Lymph Node | ||
TOOTH CANAL | C66864 | Tooth Canal | The anatomic space in the root of a tooth that contains nerves, blood vessels, and connective tissue. (NCI) | Tooth Canal | ||
EPICONDYLE | C69300 | Epicondyle | A bone prominence to which ligaments and tendons of the joints are attached. (NCI) | Epicondyle | ||
APPENDICEAL TIP | C83470 | The distal end of the appendix. (NCI) | Appendiceal Tip | |||
BLADDER, DOME | C12332 | Dome of the Bladder | The upper, convex surface of the bladder. (NCI) | Dome of the Bladder | ||
BLADDER, FUNDUS | C48939 | Fundus of the Bladder | The portion of the bladder that is formed by the posterior wall and is located opposite to the bladder opening. (NCI) | Bladder Fundus | ||
BLADDER, NECK | C12336 | Neck of the Bladder | The inferior portion of the urinary bladder which is formed as the walls of the bladder converge and become contiguous with the proximal urethra. (NCI) | Bladder Neck | ||
BLADDER, TRIGONE | C12331 | Trigone of the Bladder | The triangular area in the bladder mucosa that is formed by the two ureteral orifices and the urethral orifice. (NCI) | Bladder Trigone | ||
BRAIN STEM | C12441 | Brain Stem | The part of the brain that connects the cerebral hemispheres with the spinal cord. It consists of the mesencephalon, pons, and medulla oblongata. (NCI) | Brain Stem | ||
CALCARINE SULCUS | C32252 | A cerebral fissure that originates near the occipital lobe and terminates below the corpus callosum. (NCI) | Calcarine Sulcus | |||
CECUM | C12381 | Cecal;Cecum | A blind pouch-like commencement of the colon in the right lower quadrant of the abdomen at the end of the small intestine and the start of the large intestine. (NCI) | Cecum | ||
CEREBELLUM | C12445 | The portion of the brain located at the base of the skull that is responsible for balance, equilibrium and movement. (NCI) | Cerebellum | |||
CEREBRUM | C12351 | Cerebral Hemisphere | One half of the cerebrum, the part of the brain that controls muscle functions and also controls speech, thought, emotions, reading, writing, and learning. The right hemisphere controls the muscles on the left side of the body, and the left hemisphere controls the muscles on the right side of the body. (NCI) | Cerebral Hemisphere | ||
CHOROID PLEXUS | C12694 | Choroid Plexus | Blood vessels forming villous structures in the third, fourth, and lateral ventricles of the brain. (NCI) | Choroid Plexus | ||
COLON, ASCENDING | C12265 | Ascending Colon | The first part of the colon (large intestine) that starts in the right lower quadrant of the abdomen and ends at the transverse colon in the right upper quadrant of the abdomen. (NCI) | Ascending Colon | ||
COLON, DESCENDING | C12268 | Descending Colon | The fourth portion of the large intestine (colon) that communicates with the transverse colon in the left-upper quadrant of the abdomen and the rectum below. (NCI) | Descending Colon | ||
COLON, LEFT | C33929 | Left Colon | The portion of the large intestine that includes the descending and sigmoid colon. (NCI) | Left Colon | ||
COLON, RIGHT | C12383 | Right Colon | The proximal segment of the large intestine that is located in the right side of the abdominal cavity. It includes the cecum (with the attached appendix) and the ascending colon. (NCI) | Right Colon | ||
COLON, SIGMOID | C12384 | Sigmoid Colon | The portion of the colon that connects to the descending colon above and the rectum below. (NCI) | Sigmoid Colon | ||
COLON, TRANSVERSE | C12385 | Transverse Colon | The third division of the colon (large intestine). It communicates with the ascending colon in the upper right-hand quadrant of the abdomen and the descending colon in the upper left-hand quadrant. (NCI) | Transverse Colon | ||
CORONARY ARTERY, ANTERIOR DESCENDING | C32089 | Anterior Descending Coronary Artery | A left coronary artery branch that descends on the anterior portion of the heart through the anterior interventricular groove. (NCI) | Anterior Descending Coronary Artery | ||
CORONARY ARTERY, LEFT | C12872 | Left Coronary Artery;Left Main Coronary Artery;Left Main Coronary Artery Segment;LM | A coronary artery that arises from the aorta and bifurcates into the left anterior descending artery and the left circumflex artery. (NCI) | Left Coronary Artery | ||
CORONARY ARTERY, RIGHT | C12875 | Right Coronary Artery | A coronary artery that originates above the right coronary cusp and supplies blood predominantly to the right side of the heart. (NCI) | Right Coronary Artery | ||
DUODENUM | C12263 | A jointed tube 25-30 cm long that connects the stomach to the jejunum. (NCI) | Duodenum | |||
EAR, INNER | C12499 | Cochlea;Internal Ear;Labyrinth | The portion of the ear located within the temporal bone that is involved in both hearing and balance and includes the semicircular canals, vestibule, and cochlea. (from American Heritage Dictionary online) | Internal Ear | ||
EAR, OUTER | C12292 | Auricle;External Ear | The external part of the ear. (NCI) | External Ear | ||
ENDOCARDIUM | C13004 | The layer of endothelial cells and connective tissue lining the chambers of the heart. (NCI) | Endocardium | |||
EPICARDIUM | C13164 | The outer membranous connective tissue layer of the heart tissue. (NCI) | Epicardium | |||
EPIDIDYMIS | C12328 | A crescent-like structure located in the upper and posterior surfaces of the testis. It consists of the efferent ductules and the duct of the epididymis. It facilitates the maturation of sperm that is produced in the testis. (NCI) | Epididymis | |||
ESOPHAGUS, ABDOMINAL | C12252 | Abdominal Esophagus | Clinical esophageal segment composed of smooth muscle. It corresponds to the inferior part of the lower third topographic segment of the esophagus. (NCI) | Abdominal Esophagus | ||
ESOPHAGUS, CERVICAL | C12250 | Cervical Esophagus | Clinical esophageal segment composed of skeletal muscle. It corresponds to the superior part of the upper third topographic segment of the esophagus. (NCI) | Cervical Esophagus | ||
ESOPHAGUS, LOWER THIRD | C12255 | Lower Third of the Esophagus | The lower one third of the esophagus in which the muscle layer is composed of muscle cells predominantly of the smooth type. (NCI) | Lower Third of the Esophagus | ||
ESOPHAGUS, MIDDLE THIRD | C12254 | Middle Third of the Esophagus | The middle one third of the esophagus in which the muscle layer is composed of muscle cells of the striated and smooth types. | Middle Third of the Esophagus | ||
ESOPHAGUS, THORACIC | C12251 | Thoracic Esophagus | Clinical esophageal segment composed of smooth muscle. It includes the middle third topographic segment, as well as parts of the upper and lower thirds. (NCI) | Thoracic Esophagus | ||
ESOPHAGUS, UPPER THIRD | C12253 | Upper Third of the Esophagus | The upper one third of esophagus in which the muscle layer is composed of muscle cells of the striated type. (NCI) | Upper Third of the Esophagus | ||
EXTRAHEPATIC BILE DUCT | C32573 | The portion of the biliary tract outside the liver; the common hepatic duct joins the cystic duct to form the common bile duct. (NCI) | Extrahepatic Bile Duct | |||
EYELASH | C32576 | Anyone of the short hairs that grow on the edge of the eyelid. (NCI) | Eyelash | |||
FOREBRAIN | C40185 | The largest part of the brain composed of the cerebral hemispheres, thalamus, hypothalamus, and the limbic system. (NCI) | Forebrain | |||
GASTROINTESTINAL TRACT, LOWER | C33010 | Lower Gastrointestinal Tract | The lower part of the gastrointestinal tract that includes the jejunum and ileum of the small intestine and the large intestine. (NCI) | Lower Gastrointestinal Tract | ||
GASTROINTESTINAL TRACT, UPPER | C33837 | Upper Gastrointestinal Tract | The upper part of the gastrointestinal tract that includes the esophagus, stomach, and duodenum. (NCI) | Upper Gastrointestinal Tract | ||
HAIR BULB | C32706 | The lower segment of the hair that circles the dermal papilla and the hair matrix. (NCI) | Hair Bulb | |||
HAIR FOLLICLE | C13317 | A tube-like invagination of the epidermis from which the hair shaft develops and into which the sebaceous glands open; the follicle is lined by a cellular inner and outer root sheath of epidermal origin and is invested with a fibrous sheath derived from the dermis. (NCI) | Hair Follicle | |||
HAIR ROOT | C32711 | The portion of the hair that is enclosed within the hair follicle. (NCI) | Hair Root | |||
HAIR SHAFT | C33543 | Shaft of the Hair | The segment of the hair that projects above the skin surface. (NCI) | Shaft of the Hair | ||
HEART, APEX | C32126 | Apex of the Heart | The most outer superficial part of the heart which is situated on the left 5th intercostal space. (NCI) | Apex of the Heart | ||
HEART, ATRIUM | C12728 | Cardiac Atrium | The paired upper chambers of the heart. The left atrium receives oxygenated blood from the pulmonary vein and pumps blood into the left ventricle. The right atrium receives venous deoxygenated blood from the entire body via the superior and inferior vena cavae and pumps blood into the right ventricle. (NCI) | Cardiac Atrium | ||
HEART, BASE | C48589 | Base of the Heart | The superior portion of the heart located opposite to the apical portion. It is formed mainly by the left atrium. (NCI) | Base of the Heart | ||
HEART, LEFT VENTRICLE | C12871 | Left Ventricle | The left lower chamber of the heart that receives blood from the left atrium and pumps it through the aorta to the body. (NCI) | Left Ventricle | ||
HEART, RIGHT VENTRICLE | C12870 | Right Ventricle | The lower chamber of the heart located in the right side. It receives blood from the right atrium that is no longer oxygenated and it pumps it to the pulmonary artery. (NCI) | Right Ventricle | ||
HEART, SEPTUM | C49485 | Cardiac Septum | The tissue in the heart that separates the two atria (atrial septum) and the two ventricles (ventricular septum). (NCI) | Heart Septum | ||
HEART, VENTRICLE | C12730 | Cardiac Ventricle | The lower right and left chambers of the heart. The right pumps venous blood into the lungs and the left pumps oxygenated blood into the systemic arterial circulation. (MeSH) | Cardiac Ventricle | ||
HIPPOCAMPUS | C12444 | Hippocampus | A curved gray matter structure of the temporal lobe lying on the floor of the lateral ventricle of the brain. (NCI) | Hippocampus | ||
HYPOTHALAMUS | C12458 | Hypothalamus | The supervisory center in the brain, rich in ganglia, nerve fibers, and synaptic connections. It is composed of several sections called nuclei, each of which controls a specific function. | Hypothalamus | ||
ILEUM, TERMINAL | C33757 | Terminal Ileum | The most distal section of the ileum that is continuous with the cecum. (NCI) | Terminal Ileum | ||
INTRAHEPATIC BILE DUCT | C12677 | The bile ducts that pass through and drain bile from the liver. (NCI) | Intrahepatic Bile Duct | |||
KIDNEY, CORTEX | C12739 | Renal Cortex | The outer zone of the KIDNEY, beneath the capsule, consisting of KIDNEY GLOMERULUS; KIDNEY TUBULES, DISTAL; and KIDNEY TUBULES, PROXIMAL. (MSH2001) | Renal Cortex | ||
KIDNEY, HILUM | C32740 | Hilar Area of the Kidney | The concave area of the kidney through which the renal artery enters and the renal vein and ureter exit the organ. (NCI) | Hilar Area of the Kidney | ||
KIDNEY, LOWER LOBE | C93180 | Lower Lobe of the Kidney | The lobe of the kidney located in the lowest portion of the kidney. (NCI) | Lower Lobe of Kidney | ||
KIDNEY, MEDULLA | C12740 | Renal Medulla | The internal portion of the kidney, consisting of striated conical masses, the renal pyramids, whose bases are adjacent to the cortex and whose apices form prominent papillae projecting into the lumen of the minor calyces. (MSH2001) | Renal Medulla | ||
KIDNEY, UPPER LOBE | C93179 | Upper Lobe of the Kidney | The lobe of the kidney located in the uppermost region of the kidney. (NCI) | Upper Lobe of Kidney | ||
LESSER TROCHANTER | C32982 | A cone-shaped projection in the shaft of the femur in which the iliopsoas muscle is attached. (NCI) | Lesser Trochanter | |||
LIMB, LOWER | C12742 | Lower Extremity | The limb that is composed of the hip, thigh, leg and foot. (NCI) | Lower Extremity | ||
LIMB, UPPER | C12671 | Upper Extremity | The region of the body that includes the arm, the forearm, and hand. (NCI) | Upper Extremity | ||
LIP, LOWER | C12222 | External Lower Lip | The external surface of the lower lip. (NCI) | External Lower Lip | ||
LIP, UPPER | C12221 | External Upper Lip | The external surface of the upper lip. (NCI) | External Upper Lip | ||
LUNG, HILUM | C49282 | Hilar Area of the Lung | The wedge-shaped area at the central portion of the lung through which the bronchi, vessels and nerves enter or exit the organ. (NCI) | Hilar Area of the Lung | ||
LUNG, LEFT | C32967 | Left Lung | The 2-lobed lung located on the left side of the body. (NCI) | Left Lung | ||
LUNG, LEFT LOWER LOBE | C33020 | Lower Lobe of the Left Lung | The larger lobe of the left lung, situated below and behind the oblique fissure. (NCI) | Lower Lobe of the Left Lung | ||
LUNG, LEFT UPPER LOBE | C33021 | Upper Lobe of the Left Lung | The smaller lobe of the left lung, situated above and in front the oblique fissure, which includes the apex. (NCI) | Upper Lobe of the Left Lung | ||
LUNG, RIGHT | C33483 | Right Lung | The 3-lobed lung located on the right side of the body. (NCI) | Right Lung | ||
LUNG, RIGHT LOWER LOBE | C33022 | Lower Lobe of the Right Lung | The lobe of the right lung situated below the oblique fissure. (NCI) | Lower Lobe of the Right Lung | ||
LUNG, RIGHT MIDDLE LOBE | C12286 | Middle Lobe of the Right Lung | The smallest lobe of the right lung, situated above the oblique fissure and below the horizontal fissure. (NCI) | Middle Lobe of the Right Lung | ||
LUNG, RIGHT UPPER LOBE | C33023 | Upper Lobe of the Right Lung | The lobe of the right lung, situated above the horizontal fissure, which includes the apex. (NCI) | Upper Lobe of the Right Lung | ||
MAIN BRONCHUS, LEFT | C32968 | Left Main Bronchus | One of the two main bronchi. It is narrower but longer than the right main bronchus and connects to the left lung. (NCI) | Left Main Bronchus | ||
MAIN BRONCHUS, RIGHT | C33486 | Right Main Bronchus | One of the two main bronchi. It is wider but shorter than the left main bronchus and connects to the right lung. (NCI) | Right Main Bronchus | ||
MEDIASTINUM, ANTERIOR | C32098 | Anterior Mediastinum | The area between the lungs; it contains the thymus, some lymph nodes, and vessels and branches of the internal thoracic artery. (NCI) | Anterior Mediastinum | ||
MEDIASTINUM, MIDDLE | C33123 | Middle Mediastinum | The broadest part of the lower portion of the mediastinum. It contains the heart and the great vessels. (NCI) | Middle Mediastinum | ||
MEDIASTINUM, POSTERIOR | C33368 | Posterior Mediastinum | The part of the lower portion of the mediastinum that is located behind the pericardium. (NCI) | Posterior Mediastinum | ||
MEDIASTINUM, SUPERIOR | C33684 | Superior Mediastinum | The part of the mediastinum that is located between the upper part of the sternum in the front and the upper thoracic vertebrae in the back. (NCI) | Superior Mediastinum | ||
MIDBRAIN | C12510 | Mesencephalon;Midbrain | The uppermost portion of the brainstem located between the pons and the diencephalon. The midbrain contains the cerebral peduncles, oculomotor, trochlear and red nuclei, substantia nigra and various other nuclei and tracts. (NCI) | Mesencephalon | ||
MUSCLE, DISTAL | C91405 | Distal Muscle | A muscle located away from the trunk of the body. (NCI) | Distal Muscle | ||
MUSCLE, PROXIMAL | C91404 | Proximal Muscle | A muscle located close to the trunk of the body. (NCI) | Proximal Muscle | ||
OCCIPITAL LOBE | C12355 | The posterior part of the cerebral hemisphere. (MeSH) | Occipital Lobe | |||
OLFACTORY BULB | C28401 | Olfactory Bulb | Anatomical structure located in the vertebral forebrain that receives neural input regarding odors that have been detected by cells within the nasal cavity. The axons of olfactory receptor cells extend into the olfactory bulb. (NCI) | Olfactory Bulb | ||
PANCREAS, BODY | C12270 | Body of the Pancreas | The part of the pancreas from the point where it crosses the portal vein to the point where it enters the lienorenal ligament. (NCI) | Body of the Pancreas | ||
PANCREAS, ENDOCRINE | C32509 | Endocrine Pancreas | The pancreatic tissue that contains the islets of Langerhans. It is responsible for the production and secretions of the pancreatic hormones. (NCI) | Endocrine Pancreas | ||
PANCREAS, EXOCRINE | C32546 | Exocrine Pancreas | An enzyme producing region of the pancreatic tissue containing the pancreatic acini and exocrine intralobular ducts which collectively secrete the digestive enzymes into the main pancreatic duct to drain into the duodenal part of the small intestine. (NCI) | Exocrine Pancreas | ||
PANCREAS, HEAD | C12269 | Head of the Pancreas | That portion of the pancreas lying in the concavity of the duodenum. (NCI) | Head of the Pancreas | ||
PANCREAS, TAIL | C12271 | Tail of the Pancreas | The left extremity of the pancreas within the lienorenal ligament. (NCI) | Tail of the Pancreas | ||
PARATHYROID GLAND | C12765 | One of two small paired endocrine glands, superior and inferior, usually found embedded in the connective tissue capsule on the posterior surface of the thyroid gland; these glands secrete parathyroid hormone that regulates the metabolism of calcium and phosphorus. The parenchyma is composed of chief and oxyphilic cells arranged in anastomosing cords. (NCI) | Parathyroid Gland | |||
PITUITARY GLAND | C12399 | Hypophysis Cerebri;Hypophysis | Pea-sized endocrine gland located at the base of the brain in the pituitary fossa. It produces and secretes hormones such as oxytocin and vasopressin, to regulate the activities of the hypothalamus. (NCI) | Pituitary Gland | ||
PROSTATE GLAND, LATERAL LOBE | C13092 | Lateral Lobe of the Prostate | The prostate gland lobe that is located on the lateral side of the organ. (NCI) | Lateral Lobe of the Prostate | ||
PROSTATE GLAND, MIDDLE LOBE | C13094 | Middle Lobe of the Prostate | The upper, smaller part of the prostate between the ejaculatory ducts and the urethra. (NCI) | Middle Lobe of the Prostate | ||
PROSTATE GLAND, POSTERIOR LOBE | C13093 | Posterior Lobe of the Prostate | The prostate gland lobe that is located on the posterior side of the organ. (NCI) | Posterior Lobe of the Prostate | ||
RADIUS | C12777 | Radius;Radius Bone | The long bone that extends from the lateral aspect of the elbow to the medial side of the carpus. | Radius Bone | ||
RECTUM | C12390 | The terminal portion of the gastrointestinal tract, extending from the rectosigmoid junction to the anal canal. (NCI) | Rectum | |||
SCLERA | C12784 | The white, opaque, fibrous, outer tunic of the eyeball, covering it entirely excepting the segment covered anteriorly by the cornea. It is essentially avascular but contains apertures for vessels, lymphatics, and nerves. It receives the tendons of insertion of the extraocular muscles and at the corneoscleral junction contains the canal of Schlemm. (From Cline et al., Dictionary of Visual Science, 4th ed) | Sclera | |||
SEMINAL VESICLE | C12787 | Seminal Sacs | One of the two paired glands in the male genitourinary system, posterior to the bladder and superior to the prostate gland, that produces fructose-rich seminal fluid which is a component of semen. These glands join the ipsilateral ductus deferens to form the ejaculatory duct. (NCI) | Seminal Vesicle | ||
SOFT PALATE | C12231 | A movable fold suspended from the posterior border of the hard palate. (MeSH) | Soft Palate | |||
SPLEEN, HILUM | C33601 | Splenic Hilum | The area of the spleen through which the vessels and nerves enter or exit the organ. (NCI) | Splenic Hilum | ||
SUBSTANTIA NIGRA | C12453 | Substantia Nigra | A large cell mass extending forward, over the dorsal surface of the crus cerebri, from the rostral border of the pons into the subthalamic region. It is composed of a dorsal stratum of closely spaced pigmented cells, the pars compacta, and a larger ventral region of widely scattered cells, the pars reticulata. The pars compacta includes numerous cells that project forward to the striatum (caudate nucleus and putamen) and contain dopamine, which acts as the primary neurotransmitter at the synaptic endings. Other, apparently non-dopaminergic cells project to portions of the ventral nucleus of thalamus, the superior colliculus and reticular formation. The nigrostriatal projection is reciprocated by a striatonigral fiber system with multiple neurotransmitters, chief among which is gamma-aminobutyric acid (GABA). The substantia nigra is involved in the metabolic disturbances associated with Parkinson's disease and Huntington's disease. (NCI) | Substantia Nigra | ||
TEMPORAL LOBE | C12353 | Lower lateral part of the cerebral hemisphere. (MSH2001) | Temporal Lobe | |||
THORACIC CAVITY | C12905 | Thoracic Cavity | The cavity in the vertebrate body enclosed by the ribs between the diaphragm and the neck and containing the lungs and heart. (NCI) | Thoracic Cavity | ||
THYROID GLAND ISTHMUS | C32887 | The narrow, central portion of the thyroid gland that crosses the trachea anteriorly and connects the two lobes of the gland. (NCI) | Thyroid Gland Isthmus | |||
THYROID GLAND, RIGHT LOBE | C33491 | Right Thyroid Gland Lobe | The cone-like lobe of the thyroid gland that is located in the right side of the trachea. (NCI) | Right Thyroid Gland Lobe | ||
THYROID GLAND, LEFT LOBE | C32973 | Left Thyroid Gland Lobe | The cone-like lobe of the thyroid gland that is located in the left side of the trachea. (NCI) | Left Thyroid Gland Lobe | ||
ULNA | C12809 | Ulna Bone | The long bone that extends from the elbow to the lateral side of the carpus. | Ulna | ||
URETHRA, ANTERIOR | C61125 | Anterior Portion of the Urethra | The portion of the urethra that extends from the meatus to the membranous urethra. (NCI) | Anterior Portion of the Urethra | ||
URETHRA, PENILE | C61123 | Penile Portion of the Urethra | The portion of the urethra that spans the corpus spongiosum. (NCI) | Penile Portion of the Urethra | ||
URETHRA, POSTERIOR | C61126 | Posterior Portion of the Urethra | The portion of the urethra that is located on the posterior aspect of the urogenital diaphragm. (NCI) | Posterior Portion of the Urethra | ||
URETHRA, PROSTATIC | C13101 | Prostatic Urethra | That part of the male urethra that passes through the prostate gland. (NCI) | Prostatic Urethra | ||
VAS DEFERENS | C12813 | Duct carrying spermatozoa. (NCI) | Vas Deferens | |||
BONE MARROW | C12431 | Bone Marrow | The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes. (NCI) | Bone Marrow | ||
BUTTOCK | C89806 | Buttock | Either of the fleshy mounds in the rear pelvic area of the human body formed by the gluteal muscles. | Buttock | ||
CEREBRAL CORTEX | C12443 | Cerebral Cortex | The outer layer of the cerebrum composed of neurons and unmyelinated nerve fibers. It is responsible for memory, attention, consciousness and other higher levels of mental function. | Cerebral Cortex | ||
CEREBRAL SUBCORTEX | C98712 | Cerebral Subcortex | The layer located below the cerebral cortex that includes the forebrain, midbrain and hindbrain. (NCI) | Cerebral Subcortex | ||
FOREHEAD | C89803 | Forehead | The part of the face between the eyebrows and the normal hairline. | Forehead | ||
AMYGDALA | C12440 | Amygdaloid Nucleus | An almond-shaped group of basal nuclei anterior to the inferior horn of the lateral ventricle of the brain, within the temporal lobe. The amygdala is part of the limbic system. (MESH) | Amygdala | ||
DIAPHRAGM | C12702 | Fibromuscular tissue that separates the thoracic from the abdominal cavity. It increases the volume of the thoracic cavity through contractions, thus facilitating respiration. | Diaphragm | |||
FACIAL NERVE | C12714 | Seventh Cranial Nerve | The 7th cranial nerve. The facial nerve has two parts, the larger motor root which may be called the facial nerve proper, and the smaller intermediate or sensory root. Together they provide efferent innervation to the muscles of facial expression and to the lacrimal and salivary glands, and convey afferent information for taste from the anterior two-thirds of the tongue and for touch from the external ear. (MeSH) | Facial Nerve | ||
INTERNAL MAMMARY ARTERY | C52941 | The blood vessel that supplies the breast and the anterior chest wall with arterial blood. It is located in the chest wall. (NCI) | Internal Mammary Artery | |||
JUGULAR VEIN | C12738 | Vena Jugularis | Veins in the neck which drain the brain, face, and neck into the brachiocephalic or subclavian veins. (NCI) | Jugular Vein | ||
PARA-AORTIC LYMPH NODE | C77643 | Lymph Node, Para-Aortic | A lymph node located adjacent to the lumbar region of the spine. (NCI) | Paraaortic Lymph Node | ||
PERIPANCREATIC LYMPH NODE | C77642 | A lymph node of the pancreas. (NCI) | Pancreatic Lymph Node | |||
RETROPERITONEUM | C12298 | RETROPERITIONEAL CAVITY | The back of the abdomen where the kidneys lie and the great blood vessels run. (NCI) | Retroperitoneum | ||
SAPHENOUS VEIN | C33511 | Saphenous Vein | One of two (Greater, Small) superficial veins of the leg and thigh. (NCI) | Saphenous Vein | ||
SPINAL CORD | C12464 | Medulla Spinalis | The elongated, approximately cylindrical part of the central nervous system of vertebrates that lies in the vertebral canal and from which the spinal nerves emerge. (NCI) | Spinal Cord | ||
TRIGEMINAL NERVE | C12806 | Fifth Cranial Nerve;Nervus Trigeminus;Trigeminal Nerve | The fifth set of paired nerves of the face that emerge from the brain steam. These nerves have sensory and motor functions in the face, oral cavity, and nasal cavity. (NCI) | Trigeminal Nerve | ||
VAGUS NERVE | C12812 | The 10th cranial nerve. The vagus is a mixed nerve which contains somatic afferents (from skin in back of the ear and the external auditory meatus), visceral afferents (from the pharynx, larynx, thorax, and abdomen), parasympathetic efferents (to the thorax and abdomen), and efferents to striated muscle (of the larynx and pharynx). (MSH2001) | Vagus Nerve | |||
FIRST DIAGONAL BRANCH ARTERY | C102297 | 1ST DIAG;FIRST DIAGONAL BRANCH ARTERY SEGMENT | The first artery arising from the left anterior descending (LAD) artery that supplies the anterolateral wall, when counted from proximal to distal. | First Diagonal Branch Artery | ||
FIRST LEFT POSTEROLATERAL BRANCH ARTERY | C102298 | 1ST LPL;FIRST LEFT POSTEROLATERAL BRANCH ARTERY SEGMENT | In an individual with a left-dominant heart, this is the first branch that arises from the circumflex artery atrioventricular groove continuation when counted from proximal to distal. It supplies the posterolateral wall. | First Left Posterolateral Branch Artery | ||
FIRST OBTUSE MARGINAL BRANCH ARTERY | C102299 | 1ST OM;FIRST OBTUSE MARGINAL BRANCH ARTERY SEGMENT | The first artery arising from the left circumflex artery that supplies the lateral wall, when counted from proximal to distal. | First Obtuse Marginal Branch Artery | ||
FIRST RIGHT POSTEROLATERAL ARTERY | C102300 | 1ST RPL;FIRST RIGHT POSTEROLATERAL ARTERY SEGMENT | In an individual with a right-dominant heart, this is the first branch that arises from the right coronary artery distal to the right posterior descending artery, when counted from proximal to distal. | First Right Posterolateral Artery | ||
SECOND DIAGONAL BRANCH ARTERY | C102344 | 2ND DIAG;SECOND DIAGONAL BRANCH ARTERY SEGMENT | The second artery arising from the left anterior descending (LAD) artery that supplies the anterolateral wall, when counted from proximal to distal. | Second Diagonal Branch Artery | ||
SECOND LEFT POSTEROLATERAL BRANCH ARTERY | C102345 | 2ND LPL;SECOND LEFT POSTEROLATERAL BRANCH ARTERY SEGMENT | In an individual with a left-dominant heart, this is the second branch that arises from the circumflex artery atrioventricular groove continuation when counted from proximal to distal. It supplies the posterolateral wall. | Second Left Posterolateral Branch Artery | ||
SECOND OBTUSE MARGINAL BRANCH ARTERY | C102346 | 2ND OM;SECOND OBTUSE MARGINAL BRANCH ARTERY SEGMENT | The second artery arising from the left circumflex artery that supplies the lateral wall, when counted from proximal to distal. | Second Obtuse Marginal Branch Artery | ||
SECOND RIGHT POSTEROLATERAL ARTERY | C102347 | 2ND RPL;SECOND RIGHT POSTEROLATERAL ARTERY SEGMENT | In an individual with a right-dominant heart, this is the second branch that arises from the right coronary artery distal to the right posterior descending artery, when counted from proximal to distal. | Second Right Posterolateral Artery | ||
THIRD DIAGONAL BRANCH ARTERY | C102350 | 3RD DIAG;THIRD DIAGONAL BRANCH ARTERY SEGMENT | The third artery arising from the left anterior descending (LAD) artery that supplies the anterolateral wall, when counted from proximal to distal. | Third Diagonal Branch Artery | ||
THIRD POSTEROLATERAL DESCENDING ARTERY | C102352 | 3RD LPL;THIRD POSTEROLATERAL DESCENDING ARTERY SEGMENT | In an individual with a left-dominant heart, this is the third branch that arises from the circumflex artery atrioventricular groove continuation when counted from proximal to distal. It supplies the posterolateral wall. | Third Posterolateral Descending Artery | ||
THIRD OBTUSE MARGINAL BRANCH ARTERY | C102351 | 3RD OM;THIRD OBTUSE MARGINAL BRANCH ARTERY SEGMENT | The third artery arising from the left circumflex artery that supplies the lateral wall, when counted from proximal to distal. | Third Obtuse Marginal Branch Artery | ||
THIRD RIGHT POSTEROLATERAL ARTERY | C102353 | 3RD RPL;THIRD RIGHT POSTEROLATERAL ARTERY SEGMENT | In an individual with a right-dominant heart, this is the third branch that arises from the right coronary artery distal to the right posterior descending artery, when counted from proximal to distal. | Third Right Posterolateral Artery | ||
SPINAL ACCESSORY NERVE | C32041 | ACCESSORY NERVE;CRANIAL ACCESSORY NERVE | The eleventh cranial nerve. | Accessory Nerve | ||
ACUTE MARGINAL ARTERY | C102285 | AMARG;ACUTE MARGINAL ARTERY SEGMENT(S) | The arteries that arise at the junction of the proximal and mid-right coronary artery conduit segments. | Acute Marginal Artery | ||
NUCLEUS OF DIAGONAL BAND | C97342 | BASAL NUCLEUS/DIAGONAL BAND | A brain structure that is part of the septal nuclear complex. It is connected with the hippocampus, hypothalamus and amygdala. | Nucleus of Diagonal Band | ||
CIRCUMFLEX ARTERY AV GROOVE CONTINUATION ARTERY | C102287 | CIRC AV;CIRCUMFLEX ARTERY AV GROOVE CONTINUATION ARTERY SEGMENT | The segment of the left circumflex artery that is distal to the third marginal branch, located in the atrioventricular groove. | Circumflex Artery AV Groove Continuation Artery | ||
DISTAL CIRCUMFLEX ARTERY | C102290 | DCIRC;DISTAL CIRCUMFLEX ARTERY SEGMENT | The segment of the left circumflex artery that is between the second and third obtuse marginal branches. | Distal Circumflex Artery | ||
DISTAL INTERPHALANGEAL JOINT 2 | C102291 | DIP2 | A condyloid synovial joint within the second digit of the hand connecting the middle and distal phalanges. | Distal Interphalangeal Joint 2 | ||
DISTAL INTERPHALANGEAL JOINT 3 | C102292 | DIP3 | A condyloid synovial joint within the third digit of the hand connecting the middle and distal phalanges. | Distal Interphalangeal Joint 3 | ||
DISTAL INTERPHALANGEAL JOINT 4 | C102293 | DIP4 | A condyloid synovial joint within the fourth digit of the hand connecting the middle and distal phalanges. | Distal Interphalangeal Joint 4 | ||
DISTAL INTERPHALANGEAL JOINT 5 | C102294 | DIP5 | A condyloid synovial joint within the fifth digit of the hand connecting the middle and distal phalanges. | Distal Interphalangeal Joint 5 | ||
DISTAL LAD ARTERY | C102295 | DLAD;DISTAL LAD ARTERY SEGMENT | The segment of the left anterior descending (LAD) artery that is distal to the third diagonal branch. | Distal Left Anterior Descending Artery | ||
DISTAL RIGHT CORONARY ARTERY CONDUIT | C102296 | DRCA;DISTAL RIGHT CORONARY ARTERY CONDUIT SEGMENT | The section of the right coronary artery distal to the origin of the acute marginal artery. | Distal Right Coronary Artery Conduit | ||
INTERPHALANGEAL THUMB JOINT | C102306 | IP THUMB | A condyloid synovial joint within the thumb connecting the proximal and distal phalanges. | Interphalangeal Thumb Joint | ||
INTERPHALANGEAL JOINT 1 | C102301 | IP1 | A ginglymoid (hinge) synovial joint within the first digit of the foot connecting the proximal and distal phalanges. | Interphalangeal Joint 1 | ||
INTERPHALANGEAL JOINT 2 | C102302 | IP2 | A ginglymoid (hinge) synovial joint within the second digit of the foot connecting the proximal and middle phalanges. | Interphalangeal Joint 2 | ||
INTERPHALANGEAL JOINT 3 | C102303 | IP3 | A ginglymoid (hinge) synovial joint within the third digit of the foot connecting the proximal and middle phalanges. | Interphalangeal Joint 3 | ||
INTERPHALANGEAL JOINT 4 | C102304 | IP4 | A ginglymoid (hinge) synovial joint within the fourth digit of the foot connecting the proximal and middle phalanges. | Interphalangeal Joint 4 | ||
INTERPHALANGEAL JOINT 5 | C102305 | IP5 | A ginglymoid (hinge) synovial joint within the fifth digit of the foot connecting the proximal and middle phalanges. | Interphalangeal Joint 5 | ||
LAD SEPTAL PERFORATOR ARTERY | C102313 | LAD SP;LAD SEPTAL PERFORATOR ARTERY SEGMENTS | The arteries that arise from the left anterior descending (LAD) artery that supply the interventricular septum. | Left Anterior Descending Septal Perforator Artery | ||
LATERAL FIRST DIAGONAL BRANCH ARTERY | C102307 | LAT 1ST DIAG;LATERAL FIRST DIAGONAL BRANCH ARTERY SEGMENT | The lateral branch distal to a bifurcation of the first diagonal artery. | Lateral First Diagonal Branch Artery | ||
LATERAL FIRST OBTUSE MARGINAL BRANCH ARTERY | C102308 | LAT 1ST OM;LATERAL FIRST OBTUSE MARGINAL BRANCH ARTERY SEGMENT | The lateral branch distal to a bifurcation of the first obtuse marginal artery. | Lateral First Obtuse Marginal Branch Artery | ||
LATERAL SECOND DIAGONAL BRANCH ARTERY | C102310 | LAT 2ND DIAG;LATERAL SECOND DIAGONAL BRANCH ARTERY SEGMENT | The lateral branch distal to a bifurcation of the second diagonal artery. | Lateral Second Diagonal Branch Artery | ||
LATERAL SECOND OBTUSE MARGINAL BRANCH ARTERY | C102311 | LAT 2ND OM;LATERAL SECOND OBTUSE MARGINAL BRANCH ARTERY SEGMENT | The lateral branch distal to a bifurcation of the second obtuse marginal artery. | Lateral Second Obtuse Marginal Branch Artery | ||
LATERAL THIRD DIAGONAL BRANCH ARTERY | C102312 | LAT 3RD DIAG;LATERAL THIRD DIAGONAL BRANCH ARTERY SEGMENT | The lateral branch distal to a bifurcation of the third diagonal artery. | Lateral Third Diagonal Branch Artery | ||
LATERAL THIRD OBTUSE MARGINAL BRANCH ARTERY | C102425 | LAT 3RD OM;LATERAL THIRD OBTUSE MARGINAL BRANCH ARTERY SEGMENT | The lateral branch distal to a bifurcation of the third obtuse marginal artery. | Lateral Third Obtuse Marginal Branch Artery | ||
LATERAL RAMUS INTERMEDIUS ARTERY | C102309 | LAT RAMUS;LATERAL RAMUS INTERMEDIUS ARTERY SEGMENT | The lateral branch distal to a bifurcation of the ramus intermedius artery. | Lateral Ramus Intermedius Artery | ||
LEFT POSTEROLATERAL DESCENDING ARTERY | C102314 | LPDA;LEFT POSTEROLATERAL DESCENDING ARTERY SEGMENT | In an individual with a left-dominant heart, this branch arises from the circumflex artery atrioventricular groove continuation and supplies the inferior apex of the heart. | Left Posterolateral Descending Artery | ||
MID-CIRCUMFLEX ARTERY | C102326 | MCIRC;MID-CIRCUMFLEX ARTERY SEGMENT | The segment of the left circumflex artery between the first and second marginal branches. | Mid-Circumflex Artery | ||
METACARPOPHALANGEAL JOINT 1 | C102316 | MCP1 | A condyloid synovial joint within the first digit of the hand connecting the metacarpal to the proximal phalanx. | Metacarpophalangeal Joint 1 | ||
METACARPOPHALANGEAL JOINT 2 | C102317 | MCP2 | A condyloid synovial joint within the second digit of the hand connecting the metacarpal to the proximal phalanx. | Metacarpophalangeal Joint 2 | ||
METACARPOPHALANGEAL JOINT 3 | C102318 | MCP3 | A condyloid synovial joint within the third digit of the hand connecting the metacarpal to the proximal phalanx. | Metacarpophalangeal Joint 3 | ||
METACARPOPHALANGEAL JOINT 4 | C102319 | MCP4 | A condyloid synovial joint within the fourth digit of the hand connecting the metacarpal to the proximal phalanx. | Metacarpophalangeal Joint 4 | ||
METACARPOPHALANGEAL JOINT 5 | C102320 | MCP5 | A condyloid synovial joint within the fifth digit of the hand connecting the metacarpal to the proximal phalanx. | Metacarpophalangeal Joint 5 | ||
MID-LAD ARTERY | C102328 | MLAD;MID-LAD ARTERY SEGMENT | The segment of the left anterior descending (LAD) artery between the first and third diagonal branches. | Mid-Left Anterior Descending Artery | ||
MID-RIGHT CORONARY ARTERY CONDUIT | C102329 | MRCA;MID-RIGHT CORONARY ARTERY CONDUIT SEGMENT | The section of the right coronary artery between the right ventricular artery and the acute marginal artery. | Mid-Right Coronary Artery Conduit | ||
METATARSOPHALANGEAL JOINT 1 | C102321 | MTP1 | A condyloid synovial joint within the first digit of the foot connecting metatarsal with the proximal phalanx. | Metatarsophalangeal Joint 1 | ||
METATARSOPHALANGEAL JOINT 2 | C102322 | MTP2 | A condyloid synovial joint within the second digit of the foot connecting metatarsal with the proximal phalanx. | Metatarsophalangeal Joint 2 | ||
METATARSOPHALANGEAL JOINT 3 | C102323 | MTP3 | A condyloid synovial joint within the third digit of the foot connecting metatarsal with the proximal phalanx. | Metatarsophalangeal Joint 3 | ||
METATARSOPHALANGEAL JOINT 4 | C102324 | MTP4 | A condyloid synovial joint within the fourth digit of the foot connecting metatarsal with the proximal phalanx. | Metatarsophalangeal Joint 4 | ||
METATARSOPHALANGEAL JOINT 5 | C102325 | MTP5 | A condyloid synovial joint within the fifth digit of the foot connecting metatarsal with the proximal phalanx. | Metatarsophalangeal Joint 5 | ||
PROXIMAL CIRCUMFLEX ARTERY | C102331 | PCIRC;PROXIMAL CIRCUMFLEX ARTERY SEGMENT | The section of the left circumflex coronary artery that arises from the left main coronary artery and extends to the first marginal branch. | Proximal Circumflex Artery | ||
POSTERIOR DESCENDING SEPTAL PERFORATORS ARTERY | C102348 | PDSP;POSTERIOR DESCENDING SEPTAL PERFORATORS ARTERY SEGMENT | The arteries arising from the right posterior descending artery that supply the interventricular septum. | Septal Perforator Artery | ||
PROXIMAL INTERPHALANGEAL JOINT 2 | C102332 | PIP2 | A condyloid synovial joint within the second digit of the hand connecting the proximal and middle phalanges. | Proximal Interphalangeal Joint 2 | ||
PROXIMAL INTERPHALANGEAL JOINT 3 | C102333 | PIP3 | A condyloid synovial joint within the third digit of the hand connecting the proximal and middle phalanges. | Proximal Interphalangeal Joint 3 | ||
PROXIMAL INTERPHALANGEAL JOINT 4 | C102334 | PIP4 | A condyloid synovial joint within the fourth digit of the hand connecting the proximal and middle phalanges. | Proximal Interphalangeal Joint 4 | ||
PROXIMAL INTERPHALANGEAL JOINT 5 | C102335 | PIP5 | A condyloid synovial joint within the fifth digit of the hand connecting the proximal and middle phalanges. | Proximal Interphalangeal Joint 5 | ||
PROXIMAL LAD ARTERY | C102336 | PLAD;PROXIMAL LAD ARTERY SEGMENT | The section of the left anterior descending coronary artery that arises from the left main coronary artery and extends to the first diagonal branch. | Proximal Left Anterior Descending Artery | ||
PROXIMAL RIGHT CORONARY ARTERY CONDUIT | C102337 | PRCA;PROXIMAL RIGHT CORONARY ARTERY CONDUIT SEGMENT | The section of the right coronary artery proximal to the origin of the right ventricular artery. | Proximal Right Coronary Artery Conduit | ||
RAMUS INTERMEDIUS ARTERY | C102338 | RAMUS;RAMUS ARTERY;RAMUS INTERMEDIUS ARTERY SEGMENT | An artery that arises from the left main coronary artery and is positioned between the left anterior descending coronary artery and the circumflex artery. | Ramus Intermedius Artery | ||
RIGHT POSTERIOR ATRIOVENTRICULAR ARTERY | C102341 | RPAV;RIGHT POSTERIOR ATRIOVENTRICULAR ARTERY SEGMENT | The arterial branch between the right posterior descending artery segment and the first right posterolateral segment. | Right Posterior Atrioventricular Artery | ||
RIGHT POSTERIOR DESCENDING ARTERY | C102342 | RPDA;RIGHT POSTERIOR DESCENDING ARTERY SEGMENT | In an individual with a right-dominant heart, the arterial branch that arises from the distal right coronary artery between the acute marginal artery and the first right posterolateral segment. It supplies the inferior apex of the heart. | Right Posterior Descending Artery | ||
CENTRAL NERVOUS SYSTEM | C12438 | The part of the nervous system that consists of the brain, spinal cord, and meninges. (NCI) | Central Nervous System | |||
CAUDATE NUCLEUS | C12451 | An elongated gray mass of the neostriatum located adjacent to the lateral ventricle of the brain. (MeSH) | Caudate Nucleus | |||
SYMPATHETIC GANGLIA | C12467 | A mass containing the cell bodies of sympathetic nerves. Sympathetic ganglia exist as paravertebral ganglia (located bilaterally adjacent to the spinal cord) or prevertebral ganglia (located close to the target organ). | Sympathetic Ganglion | |||
ABDUCENS NERVE | C12665 | The sixth cranial nerve. | Abducens Nerve | |||
GLOSSOPHARYNGEAL NERVE | C12723 | The ninth cranial nerve. | Glossopharyngeal Nerve | |||
HYPOGLOSSAL NERVE | C12732 | The twelfth cranial nerve. | Hypoglossal Nerve | |||
OCULOMOTOR NERVE | C12758 | The third cranial nerve. | Oculomotor Nerve | |||
OLFACTORY NERVE | C12759 | The first cranial nerve. | Olfactory Nerve | |||
OROPHARYNX | C12762 | The part of the pharynx between the soft palate and the upper portion of the epiglottis. (NCI) | Oropharynx | |||
SUBCLAVIAN VEIN | C12794 | The vein that drains the axillary vein and joins the internal jugular vein to form the brachiocephalic vein. It runs parallel to the subclavian artery. | Subclavian Vein | |||
SUPERIOR VENA CAVA | C12816 | The large vein that terminates in the right atrium and transports deoxygenated blood from the head, neck, arms, and chest to the heart. | Superior Vena Cava | |||
CORONARY VEIN | C12882 | A blood vessel in the heart which returns coronary blood to the right atrium. | Coronary Vein | |||
DORSAL MOTOR NUCLEUS | C12934 | A brain nucleus located in the medulla oblongata. (NCI) | Dorsal Motor Nucleus | |||
VESTIBULOCOCHLEAR NERVE | C12996 | The eighth cranial nerve. | Vestibulocochlear Nerve | |||
GENITALIA | C25177 | The external sex organs. (NCI) | Genitalia | |||
AXILLARY ARTERY | C32169 | An artery that originates from the subclavian artery at the lateral margin of the first rib. It supplies the brachial artery. | Axillary Artery | |||
AXILLARY VEIN | C32171 | A large blood vessel which returns blood to the heart from the lateral thorax, axilla and upper limb. Each side of the body contains one axillary vein. | Axillary Vein | |||
CORONARY SINUS | C32378 | The coronary vein that terminates in the right atrium and transports deoxygenated blood from the coronary circulation. | Coronary Sinus | |||
PARASYMPATHETIC GANGLIA | C52557 | A usually small autonomic ganglion of the parasympathetic nervous system. The majority are located near or in the organs that they innervate. (NCI) | Parasympathetic Ganglion | |||
CINGULATE CORTEX | C52713 | Part of the medial aspect of the cerebral cortex. (NCI) | Cingulate Cortex | |||
SCALP | C89807 | The skin which covers the top of the head and which is usually covered by hair. (NCI) | Scalp | |||
LOCUS CERULEUS | C97333 | A brainstem nucleus. It is the major brain site for the synthesis and secretion of norepinephrine. (NCI) | Locus Coeruleus | |||
RAPHE | C97335 | A group of nuclei that are located in the midline of the brainstem and release serotonin. (NCI) | Raphe Nuclei | |||
ENTORHINAL CORTEX | C97338 | A brain region in the medial temporal lobe near the hippocampus. (NCI) | Entorhinal Cortex | |||
MOTOR CORTEX | C97339 | A brain region that is located in the dorsal part of the precentral gyrus. (NCI) | Primary Motor Cortex | |||
PRIMARY VISUAL CORTEX | C97340 | A brain region in the occipital cortex that receives visual stimuli from the retina. (NCI) | Primary Visual Cortex | |||
PARS COMPACTA | C97341 | A part of the substantia nigra. The pars compacta nerve cells contain melanin and are involved in motor control. (NCI) | Pars Compacta | |||
PARAVERTEBRAL GANGLIA | C97925 | A cluster of neuronal cell bodies and their dendrites located just ventral and lateral to the spinal cord that give rise to the sympathetic nervous system. | Para-Spinal Ganglion | |||
CIRCUMFLEX, OBTUSE MARGINALS, LEFT POSTEROLETERAL AND LEFT POSTERIOR DESCENDING ARTERY BRANCHES | C102286 | The left circumflex coronary artery and all of its branches. | Circumflex Artery and its Branches | |||
COSTOCHONDRAL JOINT 1 | C102288 | The first hyaline cartilaginous joint between the ribs and costal cartilage. | Costochondral Joint 1 | |||
COSTOCHONDRAL JOINT 7 | C102289 | The seventh hyaline cartilaginous joint between the ribs and costal cartilage. | Costochondral Joint 7 | |||
LEFT VENTRICULAR EPICARDIUM | C102315 | The outermost layer of cardiac tissue lining of the left ventricle. | Left Ventricular Epicardium | |||
MID/DISTAL LEFT ANTERIOR DESCENDING CORONARY ARTERY AND ALL DIAGONAL CORONARY BRANCHES | C102327 | All of the arterial branches distal to the proximal left anterior descending coronary artery. | Mid-Distal Left Anterior Descending Coronary Artery and All Diagonal Coronary Branches | |||
PERIHILAR LYMPH NODE | C102330 | A lymph node located in the area around the hilum. | Perihilar Lymph Node | |||
RIGHT ATRIAL ENDOCARDIUM | C102339 | The innermost layer of endothelial cells and connective tissue that lines the right atrium. | Right Atrial Endocardium | |||
RIGHT CORONARY ARTERY, RIGHT POSTERIOR DESCENDING, RIGHT POSTERIOLATERAL AND ACUTE MARGINAL BRANCHES | C102340 | The right coronary artery and all of its branches. | Right Coronary Artery and its Branches | |||
RIGHT VENTRICULAR ENDOCARDIUM | C102343 | The innermost layer of endothelial cells and connective tissue that lines the right ventricle. | Right Ventricular Endocardium | |||
SUBLINGUAL REGION | C102349 | A body region relating to the area under or adjacent to the tongue. | Sublingual Region | |||
TRANSVERSE TARSAL JOINT | C102354 | A combination of syndesmosis and synovial joints formed by the articulation of the talus with the navicular and the calcaneus with the cuboid. | Transverse Tarsal Joint | |||
DURAL VENOUS SINUS | C102627 | Venous channels within the dura mater of the brain which receives both blood from blood vessels within the brain as well as cerebrospinal fluid then drains into the internal jugular vein. Unlike other blood vessels, dural venous sinuses lack valves and other vessel associated layers. | Dural Venous Sinus | |||
FEMALE REPRODUCTIVE SYSTEM | C12402 | The sex organs of the female. | Female Reproductive System | |||
INTRATHORACIC LYMPH NODE | C12359 | Any lymph node within the thoracic cavity. | Intrathoracic Lymph Node | |||
LINGULA OF THE LUNG | C40373 | A small tongue-like projection from the lower portion of the upper lobe of the left lung. | Lingula | |||
MALE REPRODUCTIVE SYSTEM | C12722 | The sex organs of the male. | Male Reproductive System | |||
OCCIPITAL LYMPH NODE | C98188 | A lymph node located in the back of the head adjacent to the trapezius muscle. | Occipital Lymph Node | |||
ODONTOGENIC TISSUE | C33794 | Teeth | The tissue that forms the tooth. It consists of the dental pulp, dentin, enamel, cementum, odontogenic epithelium, and periodontium. (NCI) | Odontogenic Tissue | ||
SALIVARY GLAND | C12426 | An exocrine gland that secretes saliva. Salivary glands are mostly located in and around the oral cavity. | Salivary Gland | |||
SUPERFICIAL LYMPH NODE | C102716 | A lymph node located in a superficial part of the body. | Superficial Lymph Node | |||
UPPER RESPIRATORY SYSTEM | C33839 | The sinuses and those parts of the respiratory system above the trachea. It includes the nares, nasopharynx, oropharynx, larynx, vocal cords, glottis and upper trachea. | Upper Respiratory System | |||
ILIAC CREST | C103818 | A predominate bone structure which borders the ilium wing stretching from the anterior superior iliac spine to the posterior superior iliac spine. | Iliac Crest | |||
PERICARDIAL CAVITY | C38662 | Pericardial Cavity | The potential body space formed between the parietal and visceral layers of the pericardial sac. (NCI) | Pericardial Cavity | ||
PORTAL LYMPH NODE | C77645 | Periportal Lymph Node | Lymph nodes surrounding the portal vein. (NCI) | Portal Lymph Node | ||
PERITONEAL CAVITY | C12769 | Peritoneal Cavity | The lower part of the abdomen that contains the intestines (the last part of the digestive tract), the stomach, and the liver. It is bound by thin membranes. (NCI) | Peritoneal Cavity | ||
SUDORIFEROUS GLAND | C33712 | Sweat Gland | The small coiled tubular glands in the skin that produce and secrete sweat. | Sweat Gland | ||
COMMON ILIAC LYMPH NODE | C103384 | A lymph node located adjacent to the common iliac artery. (NCI) | Common Iliac Lymph Node | |||
MEDIAN OR LOWER CERVICAL LYMPH NODE | C103417 | A lymph node located in the median or lower region of the neck. (NCI) | Median Or Lower Cervical Lymph Node | |||
PARATRACHEAL LYMPH NODE | C103426 | A lymph node located adjacent to the trachea within the mediastinum. (NCI) | Paratracheal Lymph Node | |||
POSTERIOR CERVICAL LYMPH NODE | C103428 | A lymph node located in the posterior region of the neck. (NCI) | Posterior Cervical Lymph Node | |||
PREAURICULAR LYMPH NODE | C103429 | A lymph node located anterior to the auricle of the ear. (NCI) | Preauricular Lymph Node | |||
COLON, RECTOSIGMOID | C103438 | A portion of the large intestine that includes the descending colon, sigmoid colon and rectum. | Rectosigmoid Colon | |||
RETROCRURAL LYMPH NODE | C103439 | A lymph node located within the most inferior portion of the posterior mediastinum. (NCI) | Retrocrural Lymph Node | |||
UPPER CERVICAL LYMPH NODE | C103447 | A lymph node located in the upper region of the neck. (NCI) | Upper Cervical Lymph Node | |||
MAMMARY GLAND | C12367 | Lactiferous glands consisting of fibrous tissue connecting the lobes and fatty tissue in between the lobes. | Mammary Gland | |||
PINEAL GLAND | C12398 | A small endocrine gland within the diencephalon of the brain, situated beneath the back part of the corpus callosum, that secretes melatonin. | Pineal Gland | |||
SPLENIC HILAR LYMPH NODE | C33600 | A lymph node located in the hilar region of the spleen. (NCI) | Splenic Hilar Lymph Node | |||
RECTOSIGMOID JUNCTION | C54188 | The area where the sigmoid colon joins the rectum. | Rectosigmoid Region | |||
WALDEYER'S TONSILLAR RING | C73468 | The ring of lymphoid tissue located in the pharynx, consisting of the pharyngeal, tubal, palatine, and lingual tonsils. (NCI) | Waldeyer's Tonsillar Ring | |||
EXTERNAL ILIAC LYMPH NODE | C88143 | A lymph node located along the external iliac artery. (NCI) | External Iliac Lymph Node | |||
EPITROCHLEAR LYMPH NODE | C98182 | A lymph node located above and adjacent to the elbow. (NCI) | Epitrochlear Lymph Node | |||
FEMORAL LYMPH NODE | C98183 | A lymph node located in the upper inner portion of the thigh. (NCI) | Femoral Lymph Node | |||
HILAR LYMPH NODE | C98187 | A lymph node located in the hilum of the lung within the mediastinum. | Pulmonary Hilar Lymph Node | |||
RETROPERITONEAL LYMPH NODE | C98189 | A lymph node located in the retroperitoneal space. (NCI) | Retroperitoneal Lymph Node | |||
CLITORIS | C12308 | The erectile tissue in the vulva. It is composed of the corpora cavernosa and the glans clitoris. | Clitoris | |||
LACRIMAL GLAND | C12346 | Paired, almond-shaped exocrine glands situated superior and posterior to each orbit of the eye that produce and secrete the watery serous component of tears. (NCI) | Lacrimal Gland | |||
CRANIAL NERVE | C12700 | Any of the 12 paired nerves that originate in the brain stem. (NCI) | Cranial Nerve | |||
MESENTERY | C33103 | A double layer of peritoneum that attaches to the back wall of the abdominal cavity and supports the small intestines. (NCI) | Mesentery | |||
SEBACEOUS GLAND | C33519 | Small glands located within the epidermis, and associated with the hair follicle, that produce and secrete an oily substance that lubricates the skin and hair. (NCI) | Sebaceous Gland | |||
POPLITEAL LYMPH NODE | C53146 | Lymph node located within the fat layer of the knee joint. (NCI) | Popliteal Lymph Node | |||
ABDOMINAL WALL | C77608 | The tissues that surround the organs that are present within the abdominal cavity. The abdominal wall tissue is composed of layers of fat, parietal peritoneum, fascia, and muscles. (NCI) | Abdominal Wall | |||
HEPATIC LYMPH NODE | C77640 | Any of the lymph nodes adjacent to the stomach and duodenum. (NCI) | Hepatic Lymph Node | |||
MESENTERIC LYMPH NODE | C77641 | A lymph node located in the mesentery. (NCI) | Mesenteric Lymph Node | |||
PREPUTIAL GLAND | C79432 | Exocrine glands located at the anterior aspect of the genitals of some mammals, such as mice and rats, that produce and secrete pheromones. (NCI) | Preputial Gland | |||
BRACHIAL LYMPH NODE | C92221 | An axillary lymph node along the brachial vein. (NCI) | Brachial Lymph Node | |||
ABDOMINAL LYMPH NODE | C12360 | Any lymph node within the abdomen. | Intra-Abdominal Lymph Node | |||
ACHILLES TENDON | C32043 | The tendon that connects the heel bone to the calf muscles at the back of the lower leg. (NCI) | Achilles Tendon | |||
AORTIC VALVE | C12670 | A valve that is located between and controls the flow of blood from the left ventricle of the heart and the aorta. (NCI) | Aortic Valve | |||
BILE DUCT | C12376 | Any of the ducts conveying bile between the liver and the intestine, including hepatic, cystic, and common bile duct. | Bile Duct | |||
CHEEK | C13070 | The fleshy part of the face bounded by the eyes, nose, ear, and jaw line. (NCI) | Cheek | |||
ENDOCERVIX | C12309 | The portion of the cervix which is lined by single columnar epithelium (mucosa). (NCI) | Endocervix | |||
FLOOR OF MOUTH | C54187 | The area of the mouth under the ventral surface of the tongue. | Floor of Mouth | |||
ILIAC FOSSA | C103454 | The large smooth and concave surface of the ilium. (NCI) | Iliac Fossa | |||
ISCHIAL TUBEROSITY | C105446 | The bony prominence of the lower part of the ischium. (NCI) | Ischial Tuberosity | |||
ISCHIORECTAL FOSSA | C103455 | A tetrahedral region of adipose tissue located in the ischiorectal region with its base between the tuberosity of the ischium and the lower end of the rectum and its apex at the point where the obturator fascia and the Levator ani membrane divide. | Ischiorectal Fossa | |||
MUCOSA OF THE LIP | C12226 | The lining of the fleshy folds surrounding the mouth. It is comprised of the epithelium, basement membrane, lamina propria mucosae, and lamina muscularis mucosae. (NCI) | Mucosa of the Lip | |||
OCCIPITAL SCALP | C103456 | The occipital region of the skin that covers the top of the head. (NCI) | Occipital Scalp | |||
ORAL MUCOSA | C77637 | Moist tissue lining the oral cavity, containing mucus secreting glands. | Oral Mucosa | |||
PERIANAL REGION | C99148 | The skin area around the anus. (NCI) | Perianal Region | |||
SACRAL TUBEROSITY | C105447 | The prominence on the lateral surface of the sacrum, posterior to the auricular surface of the sacrum. (NCI) | Sacral Tuberosity | |||
SKIN OF THE LIP | C12291 | The skin portion of the lip that contains hair. | Skin of the Lip | |||
SUBMANDIBULAR LYMPH NODE | C77650 | A lymph node located beneath the floor of the oral cavity. (NCI) | Submandibular Lymph Node | |||
SUBTALAR JOINT | C33653 | Talocalcaneal Joint | The plane synovial joint between the talus and calcaneus bones of the foot. | Subtalar Joint | ||
THORACIC LYMPH NODE | C33769 | Lymph node located in the thoracic cavity. (NCI) | Thoracic Lymph Node | |||
Back to top | ||||||
CL.C74558.DSCAT | Category for Disposition Event (DSCAT) | text Extensible: Yes | C74558 | Category for Disposition Event | Classifications that describe and group pertinent events that occur throughout the conduct of a clinical trial. | CDISC SDTM Category For Disposition Event Terminology |
PROTOCOL MILESTONE | C74588 | Protocol Milestone | Occurrences within some epochs that are initiated by a protocol-specified event. The most common protocol milestone is "Informed Consent Obtained" which usually documents the start of the study. | Protocol Milestone | ||
OTHER EVENT | C74589 | Other Event | Other important events that occur during a trial but are not driven by protocol requirements. | Protocol Event | ||
DISPOSITION EVENT | C74590 | Disposition Event | The group of incidents that occur during a clinical trial and describe whether a subject completed the study epoch or the reason this event did not occur. The subject's disposition is often described for each phase of the study. | Protocol Disposition Event | ||
Back to top | ||||||
CL.C76351.SKINCLAS | Skin Classification (SKINCLAS) | text Extensible: Yes | C76351 | Skin Classification | A classification system used to categorize the sensitivity of a subject's skin to sunlight. | CDISC Skin Classification Terminology |
TYPEI | C74569 | TYPE1 | Individuals who never tan and always sunburn if exposed to any appreciable amount of sunlight, primarily red headed individuals and lightly complected blondes. (Reference: Fitzpatrick TB: The validity and practicality of sun-reactive skin types I through VI. Arch. Dermatol. 1998 124: 869-871) | Fitzpatrick Skin Type I | ||
TYPEII | C74570 | TYPE2 | Individuals who frequently burn but are able to tan to a small degree after extended sun exposure. (Reference: Fitzpatrick TB: The validity and practicality of sun-reactive skin types I through VI. Arch. Dermatol. 1998 124: 869-871) | Fitzpatrick Skin Type II | ||
TYPEIII | C74571 | TYPE3 | Individuals who burn infrequently and tan readily. (Reference: Fitzpatrick TB: The validity and practicality of sun-reactive skin types I through VI. Arch. Dermatol. 1998 124: 869-871) | Fitzpatrick Skin Type III | ||
TYPEIV | C74572 | TYPE4 | Individuals who rarely burn and tan heavily with moderate sun exposures, especially individuals of Asian, American Indian, Mediterranean and Latin American descent. (Reference: Fitzpatrick TB: The validity and practicality of sun-reactive skin types I through VI. Arch. Dermatol. 1998 124: 869-871) | Fitzpatrick Skin Type IV | ||
TYPEV | C74573 | TYPE5 | Individuals who have dark constitutive pigmentation but become noticeably darker with sun exposure, especially light complected black individuals, those of Indian descent. (Reference: Fitzpatrick TB: The validity and practicality of sun-reactive skin types I through VI. Arch. Dermatol. 1998 124: 869-871) | Fitzpatrick Skin Type V | ||
TYPEVI | C74574 | TYPE6 | Individuals who have the heaviest constitutive pigmentation, especially dark skinned black individuals. (Reference: Fitzpatrick TB: The validity and practicality of sun-reactive skin types I through VI. Arch. Dermatol. 1998 124: 869-871) | Fitzpatrick Skin Type VI | ||
Back to top | ||||||
CL.C74561.SKINTYP | Skin Type (SKINTYP) | text Extensible: Yes | C74561 | Skin Type | A distinctive characteristic of the skin marked by the amount of sebum secreted by sebaceous glands. | CDISC SDTM Skin Type Terminology |
OILY | C74591 | The pores of the skin are generally large and visible with a coarse or thick texture. It has a tendency to look dull and greasy and feels oily to the touch. | Oily Skin | |||
DRY | C74592 | The pores are generally fine with a papery thin texture that feels dry to the touch. Usually flaky and dull looking. | Dry Skin | |||
NORMAL | C74593 | The pores are visible but not large. The texture is neither fine or thick and it neither feels dry or oily to the touch. | Normal Skin | |||
Back to top | ||||||
CL.C74559.SCTESTCD | Subject Characteristic Test Code (SCTESTCD) | text Extensible: Yes | C74559 | Subject Characteristic Test Code | The test code representing each subject characteristic. | CDISC SDTM Subject Characteristic Test Code Terminology |
EDLEVEL | C17953 | Education Level | Years of education that a person has completed. | Education Level | ||
MARISTAT | C25188 | Marital Status | A demographic parameter indicating a person's current conjugal status. | Marital Status | ||
EMPJOB | C25193 | Employee Job | A code specifying the job performed by the employee for the employer. For example, accountant, programmer analyst, patient care associate, staff nurse, etc. | Occupation | ||
SKINCLAS | C74563 | Skin Classification | A classification system used to categorize the sensitivity of a subject's skin to sunlight. | Fitzpatrick Classification Scale | ||
SKINTYP | C74580 | Skin Type | A distinctive characteristic of the skin marked by the amount of sebum secreted by sebaceous glands. | Skin Type | ||
JOBCLAS | C74565 | Employee Job Class | A code qualifying the employment in various ways, such as, full-time vs. part time, etc. | Employee Job Class | ||
SALTYP | C74566 | Employee Salary Type | A code specifying the method used by the employer to compute the employee's salary or wages. For example, hourly, annual, or commission. | Employee Salary Type | ||
CNTCINV | C102625 | Contact Investigation | A public health activity whereby individuals who have been exposed to a person with a suspected or confirmed contagious illness are identified, usually for the purpose of identifying additional cases of the illness, or to offer some form of prophylactic intervention to either prevent or ameliorate disease in the exposed individual. | Disease Contact Investigation | ||
CTRYDDTC | C102631 | Entry Date from Ptntl Cntry Disease Exp | The date on which the subject arrived in the reporting country from the country of potential disease exposure. | Entry Date from Country of Potential Disease Exposure | ||
CTRYDEXP | C102612 | Country of Potential Disease Exposure | System of classification based on the nation in which an individual was exposed to a disease, regardless of the nation in which he/she currently resides. | Country of Potential Disease Exposure | ||
NATORIG | C28407 | National Origin | System of classification based on nation from which a person originates, regardless of the nation in which he/she currently resides. | National Origin | ||
PRICON | C102699 | Priority of Disease Contact | The categorization of individuals with or without the potential for having a particular disease. | Priority of Disease Contact | ||
RISKPOP | C102666 | Member of High Risk Population | An indication that a subject is part of a population group that has a greater chance of contracting a disease or disorder. | Member Of High Risk Population | ||
RISKSOC | C102711 | Social Risk Factor | Social factors such as personal behavior, lifestyle, or environment belonging to the subject which are known to increase the likelihood of infection and disease. | Social Risk Factor | ||
SETCON | C102708 | Setting of Contact | The environment within which the person may have come into contact with a disease carrier, or played the role of a disease carrier. | Setting of Disease Contact | ||
SRCCSINV | C102713 | Source Case Investigation | A public health activity for the determination of who transmitted a disease to another subject and whether this person: is still infectious; was reported to the health department as a disease case or suspect; or has infected others. | Source Case Investigation | ||
SYMPTOM | C4876 | Symptom | Subjective evidence of disease perceived by the patient. | Symptom | ||
TYPCON | C102723 | Type of Contact | Identification and clinical investigation of disease contacts. | Type of Contagion Contact | ||
Back to top | ||||||
CL.C103330.SCTEST | Subject Characteristic Test Name (SCTEST) | text Extensible: Yes | C103330 | Subject Characteristic Test Name | The test name representing each subject characteristic. | CDISC SDTM Subject Characteristic Test Name Terminology |
Education Level | C17953 | Education Level | Years of education that a person has completed. | Education Level | ||
Marital Status | C25188 | Marital Status | A demographic parameter indicating a person's current conjugal status. | Marital Status | ||
Employee Job | C25193 | Employee Job | A code specifying the job performed by the employee for the employer. For example, accountant, programmer analyst, patient care associate, staff nurse, etc. | Occupation | ||
Skin Classification | C74563 | Skin Classification | A classification system used to categorize the sensitivity of a subject's skin to sunlight. | Fitzpatrick Classification Scale | ||
Skin Type | C74580 | Skin Type | A distinctive characteristic of the skin marked by the amount of sebum secreted by sebaceous glands. | Skin Type | ||
Employee Job Class | C74565 | Employee Job Class | A code qualifying the employment in various ways, such as, full-time vs. part time, etc. | Employee Job Class | ||
Employee Salary Type | C74566 | Employee Salary Type | A code specifying the method used by the employer to compute the employee's salary or wages. For example, hourly, annual, or commission. | Employee Salary Type | ||
Contact Investigation | C102625 | Contact Investigation | A public health activity whereby individuals who have been exposed to a person with a suspected or confirmed contagious illness are identified, usually for the purpose of identifying additional cases of the illness, or to offer some form of prophylactic intervention to either prevent or ameliorate disease in the exposed individual. | Disease Contact Investigation | ||
Entry Date from Ptntl Cntry Disease Exp | C102631 | Entry Date from Ptntl Cntry Disease Exp | The date on which the subject arrived in the reporting country from the country of potential disease exposure. | Entry Date from Country of Potential Disease Exposure | ||
Country of Potential Disease Exposure | C102612 | Country of Potential Disease Exposure | System of classification based on the nation in which an individual was exposed to a disease, regardless of the nation in which he/she currently resides. | Country of Potential Disease Exposure | ||
National Origin | C28407 | National Origin | System of classification based on nation from which a person originates, regardless of the nation in which he/she currently resides. | National Origin | ||
Priority of Disease Contact | C102699 | Priority of Disease Contact | The categorization of individuals with or without the potential for having a particular disease. | Priority of Disease Contact | ||
Member of High Risk Population | C102666 | Member of High Risk Population | An indication that a subject is part of a population group that has a greater chance of contracting a disease or disorder. | Member Of High Risk Population | ||
Social Risk Factor | C102711 | Social Risk Factor | Social factors such as personal behavior, lifestyle, or environment belonging to the subject which are known to increase the likelihood of infection and disease. | Social Risk Factor | ||
Setting of Contact | C102708 | Setting of Contact | The environment within which the person may have come into contact with a disease carrier, or played the role of a disease carrier. | Setting of Disease Contact | ||
Source Case Investigation | C102713 | Source Case Investigation | A public health activity for the determination of who transmitted a disease to another subject and whether this person: is still infectious; was reported to the health department as a disease case or suspect; or has infected others. | Source Case Investigation | ||
Symptom | C4876 | Symptom | Subjective evidence of disease perceived by the patient. | Symptom | ||
Type of Contact | C102723 | Type of Contact | Identification and clinical investigation of disease contacts. | Type of Contagion Contact | ||
Back to top | ||||||
CL.C76348.MARISTAT | Marital Status (MARISTAT) | text Extensible: Yes | C76348 | Marital Status | A demographic parameter indicating a person's current conjugal status. | CDISC SDTM Marital Status Terminology |
ANNULLED | C76240 | Marriage contract has been declared null and to not have existed. (HL7) | Annulled | |||
DIVORCED | C51776 | Marriage contract has been declared dissolved and inactive. (HL7) | Divorced | |||
INTERLOCUTORY | C76241 | Temporary order issued during the course of litigation. (HL7) | Interlocutory Marital Status | |||
LEGALLY SEPARATED | C51777 | A person living apart from his/her spouse by legal arrangement. (HL7) | Separated | |||
MARRIED | C51773 | A current marriage contract is active. (HL7) | Married | |||
NEVER MARRIED | C51774 | No marriage contract has ever been entered. (HL7) | Never Married | |||
WIDOWED | C51775 | The spouse has died. (HL7) | Widowed | |||
POLYGAMOUS | C76242 | More than 1 current spouse. (HL7) | Polygamous | |||
DOMESTIC PARTNER | C53262 | Domestic Partner | Person declares that a domestic partnership relationship exists. (HL7) | Domestic Partnership | ||
Back to top | ||||||
CL.C74457.RACE | Race (RACE) | text Extensible: No | C74457 | Race | Terminology codelist used to identify the race of an individual within the Clinical Data Interchange Standards Consortium Study Data Tabulation Model. | CDISC SDTM Race Terminology |
BLACK OR AFRICAN AMERICAN | C16352 | A person having origins in any of the black racial groups of Africa. Terms such as "Haitian" or "Negro" can be used in addition to "Black or African American." (FDA) | African American | |||
AMERICAN INDIAN OR ALASKA NATIVE | C41259 | A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment. (FDA) | American Indian or Alaska Native | |||
ASIAN | C41260 | A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. (FDA) | Asian | |||
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | C41219 | Denotes a person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. The term covers particularly people who identify themselves as part-Hawaiian, Native Hawaiian, Guamanian or Chamorro, Carolinian, Samoan, Chuu. (FDA) | Native Hawaiian or Other Pacific Islander | |||
WHITE | C41261 | Denotes a person with European, Middle Eastern, or North African ancestral origin who identifies, or is identified, as White. (FDA) | White | |||
Back to top | ||||||
CL.C78731.DATEST | Drug Accountability Test Name (DATEST) | text Extensible: Yes | C78731 | Drug Accountability Test Name | The name of the test for the drug accountability assessment. | CDISC SDTM Drug Accountability Test Terminology by Name |
Dispensed Amount | C78721 | Dispensed Amount | The quantity of a product that has been dispensed. (NCI) | Dispensed Amount | ||
Returned Amount | C78722 | Returned Amount | The quantity of a product that has been returned. (NCI) | Returned Amount | ||
Back to top | ||||||
CL.C78732.DATESTCD | Drug Accountability Test Code (DATESTCD) | text Extensible: Yes | C78732 | Drug Accountability Test Code | The short name, or code, of the test for the drug accountability assessment. | CDISC SDTM Drug Accountability Test Terminology by Code |
DISPAMT | C78721 | Dispensed Amount | The quantity of a product that has been dispensed. (NCI) | Dispensed Amount | ||
RETAMT | C78722 | Returned Amount | The quantity of a product that has been returned. (NCI) | Returned Amount | ||
Back to top | ||||||
CL.C78733.SPECCOND | Specimen Condition (SPECCOND) | text Extensible: Yes | C78733 | Specimen Condition | The physical state or quality of a biological specimen. | CDISC SDTM Specimen Condition Terminology |
FROZEN | C70717 | Frozen Specimen | A specimen that has been subjected to and immobilized by severe cold. (NCI) | Frozen Specimen | ||
HEMOLIZED | C70720 | Hemolysis in Specimen | A specimen that has undergone the destruction of red blood cells followed by the release of the hemoglobin. (NCI) | Hemolysis in Specimen | ||
LIPEMIC | C70715 | Lipemic Specimen | A specimen that consists of or contains excessive amounts of fat and fatty substances. (NCI) | Lipemic Specimen | ||
REFRIGERATED | C70718 | Refrigerated Specimen | A specimen that has been kept or preserved at a low temperature in a refrigerator. (NCI) | Refrigerated Specimen | ||
ROOM TEMPERATURE | C70719 | Ambient Temperature;Specimen at Room Temperature | A specimen that has been subjected to and adjusted to the average ambient temperature of a room, usually considered to be around 20 degrees C (68 degrees F). (NCI) | Specimen at Room Temperature | ||
CALCIFIED | C78723 | Calcified Specimen | A specimen that has undergone calcification. (NCI) | Calcified Specimen | ||
CLOTTED | C78724 | Clotted Specimen | A specimen that has become coagulated. (NCI) | Clotted Specimen | ||
AUTOLIZED | C78725 | Autolized Specimen | A specimen that has undergone autolysis, or self-digestion by the specimen's own digestive enzymes. (NCI) | Autolized Specimen | ||
ICTERIC | C98744 | Icteric Specimen | A specimen that exhibits a yellowish pigmentation due to jaundice. (NCI) | Icteric Specimen | ||
CONTAMINATED | C68768 | The presence of any substance or organism that makes a preparation impure. (NCI) | Contamination | |||
Back to top | ||||||
CL.C78734.SPECTYPE | Specimen Type (SPECTYPE) | text Extensible: Yes | C78734 | Specimen Type | The name and description of a biological specimen. | CDISC SDTM Specimen Type Terminology |
ADIPOSE TISSUE | C12472 | Adipose Tissue;Body Fat;Fat Tissue | A specialized form of connective tissue consisting primarily of adipocytes (fat cells), surrounded by a meshwork of collagen fibers. (NCI) | Adipose Tissue | ||
AMNIOTIC FLUID | C13188 | Aqua Amnii | The fluid within the amniotic cavity which surrounds and protects the developing embryo. (NCI) | Amniotic Fluid | ||
AQUEOUS HUMOR | C13190 | The watery fluid which is present in the anterior and posterior chambers of the eye. (NCI) | Aqueous Humor | |||
ARTERIAL BLOOD | C78729 | Oxygenated blood which is transported with nutrients to body tissues through the arterial system. The exception is blood within the pulmonary artery which carries deoxygenated blood to the lungs. (NCI) | Arterial Blood | |||
ATHEROSCLEROTIC PLAQUE | C78739 | Fatty tissue which is deposited in the inner lining of the arterial wall. (NCI) | Atherosclerotic Plaque | |||
BILE | C13192 | Fluid composed of waste products, bile acids, salts, cholesterol, and electrolytes. It is secreted by the liver parenchyma and stored in the gallbladder. (NCI) | Bile | |||
BLOOD | C12434 | Blood;Peripheral Blood | A liquid tissue with the primary function of transporting oxygen and carbon dioxide. It supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. | Blood | ||
BONE | C12366 | Calcified connective tissue that forms the skeletal components of the body. (NCI) | Bone | |||
BONE MARROW | C12431 | The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes. (NCI) | Bone Marrow | |||
BREAST MILK | C13257 | Milk produced by females for the purpose of feeding their young. (NCI) | Breast Milk | |||
CALCULUS | C35708 | Accumulated material from the secretions of an organ. It is solid and representative examples include gallbladder stones, kidney stones, and salivary gland stones. (NCI) | Stone | |||
CEREBROSPINAL FLUID | C12692 | CSF | The fluid that is contained within the brain ventricles, the subarachnoid space and the central canal of the spinal cord. (NCI) | Cerebrospinal Fluid | ||
CERUMEN | C32293 | A wax secreted by glands in the ear canal. | Cerumen | |||
COLOSTRUM | C32348 | A thick, protein-rich substance secreted by the breasts during the second half of pregnancy and for a few days after birth before the breast milk comes in. | Human Colostrum | |||
EMESIS | C77666 | Emesis;Vomit | Stomach contents that have returned to the mouth or are ejected beyond the mouth. (NCI) | Vomitus | ||
EXPIRED AIR | C78741 | The air that moves out of the chest during expiration. It contains a higher percentage of carbon dioxide and a lower percentage of oxygen compared to the inhaled air. (NCI) | Expired Air | |||
EXUDATE | C13233 | Fluid, cells or cellular debris that escapes from the blood vessels and accumulates in nearby tissues. It is the result of inflammation and is rich in proteins. | Exudate | |||
FLUID | C13236 | Liquid substances produced by the body. | Body Fluid or Substance | |||
HAIR | C32705 | The filamentous outgrowth of the epidermis. (NCI) | Hair | |||
LOCHIA | C78742 | Vaginal discharge occurring during the post-partum period. It consists of a mixture of blood, mucus, and placental remnants. (NCI) | Lochia | |||
LUNG SURFACTANT | C13273 | Surfactant | Pulmonary surfactant lines the lung epithelium and lowers surface tension to prevent collapse at end-expiration. Deficiency of pulmonary surfactant results in respiratory distress syndrome (RDS) in premature infants. Lung surfactant is synthesized in alveolar type II cells, stored in lamellar bodies and secreted via exocytosis. (NCI) | Lung Surfactant | ||
LYMPH | C13252 | A clear, transparent, sometimes faintly yellow and slightly opalescent fluid that is collected from the tissues throughout the body, flows in the lymphatic vessels (through the lymph nodes), and is eventually added to the venous blood circulation. Lymph consists of a clear liquid portion, varying numbers of white blood cells (chiefly lymphocytes), and a few red blood cells. (NCI) | Lymph | |||
MECONIUM | C78743 | The newborn's first intestinal discharge. It is a dark-green, thick substance composed of mucus, intestinal secretions, hair, and intestinal mucosa cells. (NCI) | Meconium | |||
MENSTRUAL BLOOD | C78740 | The discharged blood from the uterus during the reproductive years. The discharge occurs approximately once a month. (NCI) | Menstrual Blood | |||
MUCUS | C13259 | The thick fluid secreted by the mucus glands in the aerodigestive tract and the vagina. (NCI) | Mucus | |||
NAIL | C33156 | The cutaneous plate on the dorsal surface of the distal end of a finger or toe. (NCI) | Nail | |||
PLASMA | C13356 | Plasma is the fluid (acellular) portion of the circulating blood, as distinguished from the serum that is the fluid portion of the blood obtained by removal of the fibrin clot and blood cells after coagulation. | Plasma | |||
PUS | C50718 | A yellowish substance produced during bacterial inflammation. It contains necrotic cells and cells fighting the infection. (NCI) | Pus | |||
SALIVA | C13275 | A clear liquid secreted into the mouth by the salivary glands and mucous glands of the mouth; moistens the mouth and starts the digestion of starches. (NCI) | Saliva | |||
SEBUM | C13276 | A thick, oily substance produced by the sebaceous glands located in the dermis. (NCI) | Sebum | |||
SEMEN | C13277 | Seminal Plasma | The thick, whitish secretion of the male reproductive organs. It is composed of spermatozoa in their nutrient plasma, secretions from the prostate, seminal vesicles, and various other glands, epithelial cells, and minor constituents. | Semen | ||
SEMINAL FLUID | C33529 | Part of the ejaculated fluid. It contains secretions from the seminal vesicles, Cowper gland, and prostate gland. | Seminal Fluid | |||
SERUM | C13325 | Sera | The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins. (NCI) | Serum | ||
SMEGMA | C33574 | A white secretion of the sebaceous glands of the foreskin. (NCI) | Smegma | |||
SPUTUM | C13278 | Material containing mucus, cellular debris, microorganisms and sometimes blood or pus. It is ejected through the mouth from the lungs, bronchi, and trachea. (NCI) | Sputum | |||
STOOL | C13234 | Feces | The material discharged from the bowel during defecation. It consists of undigested food, intestinal mucus, epithelial cells, and bacteria. (NCI) | Feces | ||
PERSPIRATION | C13280 | Sweat | The liquid secreted by the sweat glands. (NCI) | Sweat | ||
TISSUE | C12801 | An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function. (NCI) | Tissue | |||
TRANSUDATE | C78744 | The fluid that passes through the wall of the veins and capillaries to the surrounding tissues because of increased intravascular pressure. It has low protein content. (NCI) | Transudate | |||
URINE | C13283 | The fluid that is excreted by the kidneys. It is stored in the bladder and discharged through the urethra. (NCI) | Urine | |||
VENOUS BLOOD | C78730 | Deoxygenated blood containing urea and other waste products which is transported through the venous system to the heart and lungs. The exception is blood within the pulmonary vein which is oxygenated and travels from the lungs to the left atrium of the heart. (NCI) | Venous Blood | |||
PLEURAL FLUID | C77613 | The fluid that is abnormally collected in the pleural cavity. (NCI) | Pleural Fluid | |||
PROSTATIC FLUID | C100896 | A slightly alkaline, white fluid secreted from the prostate and is a constituent of semen. | Prostatic Fluid | |||
SYNOVIAL FLUID | C33718 | A viscid fluid secreted by the synovial membrane, serving as a lubricant. (NCI) | Synovial Fluid | |||
VITREOUS HUMOR | C13323 | The clear colorless transparent jelly that fills the posterior chamber of the eyeball. (NCI) | Vitreous Humor | |||
TUMOR TISSUE | C18009 | A tumor sample, or entire tumor that is removed for examination. | Tumor Tissue | |||
LAVAGE FLUID | C103411 | Fluid introduced into, and collected from, a body cavity by lavage procedure. (NCI) | Lavage Fluid | |||
CARDIAC MUSCLE TISSUE | C12371 | Myocardium | The striated muscle tissue of the heart enveloped by the epicardium and the endocardium. (NCI) | Cardiac Muscle Tissue | ||
PERIPHERAL BLOOD MONONUCLEAR CELL | C12954 | PBMC | A peripheral blood cell with a single nucleus, for example lymphocytes and monocytes. | Peripheral Blood Mononuclear Cell | ||
SKELETAL MUSCLE TISSUE | C13050 | Skeletal Muscle Tissue | Striated muscles that are under voluntary control of the organism. They are connected at either or both ends to a bone and are utilized for locomotion and other movements. (NCI) | Skeletal Muscle Tissue | ||
SMOOTH MUSCLE TISSUE | C12437 | Involuntary muscle tissue of the internal organs. It is composed of elongated muscle cells or fibers that are not arranged in a striated pattern and form layers of muscle tissue. The smooth muscle cells contain a contractile apparatus composed of thin and thick filaments and a cytoskeleton composed of intermediate filaments. (NCI) | Smooth Muscle Tissue | |||
SOFT TISSUE | C12471 | Soft Tissue | Refers to muscle, fat, fibrous tissue, blood vessels or other supporting tissue of the body. | Soft Tissue | ||
STRIATED MUSCLE TISSUE | C12436 | Striated muscles are appendicular and axial muscles typically connected at either or both ends to the bony skeleton of the body. Striated muscle fibers contain a highly organized, contractile cytoskeletal apparatus with a striated microscopic appearance; muscle contraction is typically under voluntary control. (NCI) | Striated Muscle Tissue | |||
Back to top | ||||||
CL.C78735.EVAL | Evaluator (EVAL) | text Extensible: Yes | C78735 | Evaluator | The role that the individual or entity plays with respect to a specific situation or person. | CDISC SDTM Evaluator Terminology |
CAREGIVER | C17445 | Caregiver | The primary person in charge of the care of a patient, usually a family member or a designated health care professional. (NCI) | Caregiver | ||
CHILD | C42708 | A son or a daughter. | Offspring | |||
PARENT | C42709 | A mother or a father. | Parent | |||
CLINICAL RESEARCH COORDINATOR | C51811 | A person to whom a clinical investigator delegates routine administrative requirements of a protocol. The duties and responsibilities of a clinical research coordinator may vary across different infrastructures. Generally, the coordinator manages the subject's clinical trial participation and provides a vital linkage between the subject, the investigator, and the sponsor. (NCI) | Clinical Coordinator | |||
CLINICAL RESEARCH ASSOCIATE | C25465 | Research Associate | A person who is employed by a study sponsor or by a contract research organization (CRO), operates independently from the clinical study site and functions as a monitor, and/or auditor, and/or a project director within a particular trial or institution. (NCI) | Clinical Research Associate | ||
CLINICAL STUDY SPONSOR | C70793 | Clinical Study Sponsor;Sponsor;Study Sponsor | An entity that is responsible for the initiation, management, and/or financing of a clinical study. | Clinical Study Sponsor | ||
HEALTH CARE PROFESSIONAL | C53287 | A person qualified to be engaged in activity directed at preservation of mental and physical health by diseases prevention and treatment as a source of livelihood. (NCI) | Health Care Professional | |||
INDEPENDENT ASSESSOR | C78720 | An individual qualified to perform an evaluation who is masked from a subject's data in order to minimize bias or maximize consistency and quality. (NCI) | Independent Rater | |||
INVESTIGATOR | C25936 | A person responsible for the conduct of the clinical trial at a trial site. If a trial is conducted by a team of individuals at the trial site, the investigator is the responsible leader of the team and may be called the principle investigator. | Investigator | |||
FRIEND | C72884 | A person whom an individual knows, likes, and trusts. (NCI) | Friend | |||
STUDY SUBJECT | C41189 | An individual who is observed, analyzed, examined, investigated, experimented upon, or/and treated in the course of a particular study. | Study Subject | |||
SPOUSE | C62649 | Spouse | A person's partner in marriage. (NCI) | Spouse | ||
DOMESTIC PARTNER | C53262 | Domestic Partner | Person declares that a domestic partnership relationship exists. (HL7) | Domestic Partnership | ||
ADJUDICATION COMMITTEE | C78726 | An external committee whose purpose is to evaluate study data and decide whether a study endpoint or other criterion has been met. (NCI) | Adjudication Committee | |||
GUARDIAN | C51828 | An individual who is authorized under applicable State or local law to consent on behalf of a child or incapable person to general medical care including participation in clinical research. (NCI) | Guardian | |||
Back to top | ||||||
CL.C78736.NRIND | Reference Range Indicator (NRIND) | text Extensible: Yes | C78736 | Reference Range Indicator | A description of the results relative to the normal or expected range of values. | CDISC SDTM Reference Range Indicator |
NORMAL | C78727 | Reported values within the typical or expected range. (NCI) | Normal Reference Range | |||
ABNORMAL | C78802 | Reported values outside the typical or expected range. (NCI) | Abnormal Reference Range | |||
HIGH | C78800 | Reported values above the typical or expected range. (NCI) | Value Above Reference Range | |||
LOW | C78801 | Reported values below the typical or expected range. (NCI) | Value Below Reference Range | |||
Back to top | ||||||
CL.C78737.RELTYPE | Relationship Type (RELTYPE) | text Extensible: No | C78737 | Relationship Type | The description of relationship types between a record or set of records. | CDISC SDTM Relationship Type Terminology |
ONE | C66832 | A textual representation of the numeral 1. | One | |||
MANY | C78728 | Many;Several | More than one. (NCI) | Many | ||
Back to top | ||||||
CL.C78738.NCF | Never/Current/Former Classification (NCF) | text Extensible: Yes | C78738 | Never/Current/Former Classification | A classification of usage or experience that falls into three categories; never, current, or former. | CDISC SDTM Never/Current/Former Classification Terminology |
NEVER | C70543 | Not ever; at no time in the past. | Never | |||
CURRENT | C25471 | Occurring in or belonging to the present time. (NCI) | Current | |||
FORMER | C25627 | Previous | Occurring prior to something else. (NCI) | Previous | ||
Back to top | ||||||
CL.C85495.MSRESCAT | Microbiology Susceptibility Testing Result Category (MSRESCAT) | text Extensible: No | C85495 | Microbiology Susceptibility Testing Result Category | Used to categorize the result of a finding in a standard format. | CDISC SDTM Microbiology Susceptibility Testing Result Category Terminology |
INTERMEDIATE | C85560 | Intermediate | The growth of microorganisms may be inhibited by antimicrobials that approach usually attainable blood and tissue concentrations. The response rates may be lower than for susceptible isolates. This category also includes a buffer zone, which should prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations, especially for drugs with narrow pharmacotoxicity margins. | Antimicrobial Intermediate Susceptibility Result | ||
NONSUSCEPTIBLE | C85561 | Non Susceptible | A category used for microorganisms that have only a susceptible interpretive criteria, but not an intermediate or resistant interpretive category (i.e., susceptible-only interpretive category). This category may be applied to new antimicrobial agents for which no resistant microorganisms have been encountered at the time the initial interpretive criteria are determined. Microorganisms that test with an MIC above or a zone measurement below the susceptible interpretive criteria are designated as nonsusceptible. A designation of nonsusceptible does not necessarily mean that a resistance mechanism(s) exists in the microorganism. | Antimicrobial Nonsusceptibility Result | ||
NOT APPLICABLE | C48660 | Not Applicable;NA | Determination of a value is not relevant in the current context. (NCI) | Not Applicable | ||
RESISTANT | C85562 | Resistant | The growth of microorganisms are not inhibited by the usually achievable concentrations of the antimicrobial agent with normal dosages, and/or microorganisms demonstrate MICs or zone diameters that fall in the range where specific microbial resistance mechanisms (e.g. Beta-lactamases) are likely, and clinical efficacy of the agent against the microorganism has not been reliably shown in treatment studies. | Antimicrobial Resistance Result | ||
SUSCEPTIBLE | C85563 | Susceptible | The growth of microorganisms are inhibited by the usually achievable concentrations of antimicrobial agent when the recommended dosage is used for the site of infection. | Antimicrobial Susceptibility Result | ||
SUSCEPTIBLE-DOSE DEPENDENT | C85559 | Susceptible-Dose Dependent | The growth of microorganisms may be inhibited when higher than normal dosages of an antimicrobial agent are used and maximal possible blood concentration of the antimicrobial agent is achieved. | Antimicrobial Dose Dependent Susceptibility Result | ||
UNKNOWN | C17998 | U;Unknown | Not known, not observed, not recorded, or refused. (NCI) | Unknown | ||
Back to top | ||||||
CL.C85492.METHOD | Method (METHOD) | text Extensible: Yes | C85492 | Method | Method is any technique or procedure (an action) that determines how an observation or clinical finding was made. | CDISC SDTM Method Terminology |
ACID FAST STAIN | C23015 | A microscopy staining method used to examine a specimen for the presence of acid-fast microorganisms, specifically mycobacteria. | Acid Fast Bacillae Staining Method | |||
ACRIDINE ORANGE STAIN | C85554 | A microscopy staining method that utilizes acridine orange, a fluorescent cationic dye that is selective for nucleic acids, to determine the presence of viable cells or microorganisms in a sample. Acridine orange interacts with RNA and DNA and the lysosomal compartment of cells. | Acridine Orange Staining Method | |||
AGAR DILUTION | C85555 | A method to determine microbial susceptibility to antibiotics in which test bacteria is inoculated onto agar plates with serial dilutions of know quantities of antibiotics. The minimum inhibitory concentration of antibiotic is assessed. | Agar Dilution Method | |||
ANTIBIOTIC AGAR SCREEN | C85557 | A method used to detect organisms that have resistance to a single concentration of antibiotics in an agar matrix. | Antibiotic Agar Screening Method | |||
ANTIMICROBIAL COMBINATION TESTING | C85558 | A method to determine the microbial susceptibility to two or more antibiotics. Numerical result translated into indifference, antagonism, synergism, or additive. | Antimicrobial Combination Testing Method | |||
ATOMIC ABSORPTION SPECTROMETRY | C85574 | A spectrometric method that determines the type and concentration of metal elements in a sample, based upon the principle that each elemental metal absorbs a particular wavelength of ultraviolet light when exposed to heat. | Atomic Absorption Spectroscopy | |||
AUDIOMETRY | C38036 | Testing conducted utilizing a manual or microprocessor audiometer to test for hearing loss. | Audiometric Test | |||
AUSCULTATION | C85573 | Listening with a device, such as a stethoscope, to anatomical locations that produce audible sounds like the heart, lungs and abdomen. | Auscultation | |||
BETA LACTAMASE | C85576 | A test that detects beta lactamase produced by Staphylococcus species, Haemophilus species, Moraxella catarrhalis, and Neisseria gonorrhoeae. | Beta Lactamase Screening Method | |||
CALCOFLUOR WHITE STAIN | C85577 | A microscopy staining method that utilizes calcofluor, a fluorescent dye that preferentially stains chitin and cellulose on the cell walls of fungi, parasites, and some cysts of the Pneumocystis genus. | Calcofluor White Staining Method | |||
CELLULOSE TAPE | C85578 | A microbiological technique for specimen collection and mounting for microscopic examination that utilizes a cellulose-based adhesive ribbon. | Cellulose Tape Method | |||
CHROMATOGRAPHY | C16431 | A technique for the separation of complex mixtures that relies on the differential affinities of substances for a gas or liquid mobile medium and for a stationary adsorbing medium through which they pass. | Chromatography | |||
CISH | C40960 | Chromogenic in Situ Hybridization | A laboratory procedure that combines the sequence-specific detection aspects of FISH with the simple detection methods of immunohistochemistry. Briefly, sequence-specific probes are hybridized to cells fixed on slides and the sequestered probe is visualized by a peroxidase reaction. It has the advantage of being a less costly assay that does not require fluorescence microscopy with results that are stable over time. | Chromogenic in situ Hybridization | ||
CT SCAN | C17204 | Computed Tomography;CT | A series of detailed pictures of areas inside the body; the pictures are created by a computer linked to an x-ray machine. | Computed Tomography | ||
DARK FIELD MICROSCOPY | C85837 | A microscopic technique in which the light that does not come into contact with the structure or details of interest is subtracted from the ocular image. This yields an image in which the structure or details are alight while the areas where the structures or details are absent are dark. | Dark Field Microscopy | |||
DISK DIFFUSION | C85595 | A method to determine microbial susceptibility to antibiotics in which filter paper disks containing known concentrations of antibiotics are placed on the agar surface that has been previously inoculated with the bacteria of interest. Microbial susceptibility is assessed by measuring the area around the disk that is free of microbial growth. | Disk Diffusion Method | |||
EIA | C17455 | Enzyme Immunoassay | Any of several immunoassay methods that use an enzyme covalently linked to an antigen or antibody as a label; the most common types are enzyme-linked immunosorbent assay (ELISA) and enzyme-multiplied immunoassay technique (EMIT). | Enzyme Immunoassay | ||
ELECTROPHORESIS | C16536 | The motion of charged particles in a colloid under the influence of an electric field; particles with a positive charge go to the cathode and negative to the anode. | Electrophoresis | |||
ELISA | C16553 | Enzyme-linked Immunosorbent Assay | An immunoassay for detecting and measuring antigens or antibodies in a solution; the solution is run over a surface to which immobilized antibodies specific to the substance have been attached, and if the substance is present, it will bind to the antibody layer, and its presence is verified and visualized with an application of antibodies that have been tagged in some way. | ELISA | ||
ENDOSCOPY | C16546 | An examination of the body using an endoscope. | Endoscopic Procedure | |||
EPSILOMETER | C85596 | A method to determine microbial susceptibility to antibiotics in which a plastic strip impregnated with the antibiotic of interest is placed on an agar plate that has been inoculated with bacteria. The antibiotic diffuses from the strip producing a concentration gradient of drug on the agar. The point at which the elliptical shaped area of growth inhibition meets the strip is the minimum inhibitory concentration of the drug of interest. | Epsilometry | |||
FISH | C17563 | Fluorescence in Situ Hybridization | A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping. | Fluorescence in situ Hybridization | ||
FLUORESCENT IMMUNOASSAY | C17370 | Immunofluorescence Assay;Fluorescent Antibody Assay | A bioassay in which fluorescent-coupled antibodies or antigens are used to quantify or qualify a biological response to a stimulus. | Fluorescent Antibody Procedure | ||
FLUORESCENT MICROSCOPY | C16856 | Microscopy of specimens stained with fluorescent dye (usually fluorescein isothiocyanate) or of naturally fluorescent materials, which emit light when exposed to ultraviolet or blue light. | Fluorescence Microscopy | |||
GIEMSA STAIN | C85598 | A microscopy staining method that utilizes Giemsa, a mixture of ethylene blue and eosin, which forms purplish-black crystals when dried. This stain preferentially binds to the phosphate groups of DNA and aggregates at areas with an increase in adenine-thymine binding, thus leading to chromosomal staining patterns that lend themselves to g-banding analysis. Additionally Giemsa can be used as a differential stain to determine microbial cell adherence to human cells as well as in the diagnosis of malaria, spirochete, and protozoal infections. | Giemsa Staining Method | |||
GRADIENT DIFFUSION | C85599 | A method to determine microbial susceptibility to antibiotics in which an agar plate, which has a concentration gradient of the drug within the agar, is streaked with the microorganism of interest. Microbial susceptibility as well as minimum inhibitory concentration of antibiotic is assessed. | Gradient Diffusion Method | |||
GRAM STAIN | C23014 | A microscopy staining method for staining and identifying bacteria, based on the differential retention of a crystal violet-iodine complex within the cell membrane. Gram-positive organisms will appear blue-black or purple while Gram-negative organisms will appear red. | Gram Staining Method | |||
HEMATOXYLIN AND EOSIN STAIN | C23011 | H&E Stain | A microscopy staining method that utilizes two separate dyes, one staining the nucleus and the other staining the cytoplasm and connective tissue. Hematoxylin is a dark purplish dye that stains the chromatin (nuclear material) within the nucleus. Eosin is an orangish-pink to red dye that stains the cytoplasmic material including connective tissue and collagen. | Hematoxylin and Eosin Staining Method | ||
HIGH LEVEL AMINOGLYCOSIDE SCREEN | C85556 | A method to determine microbial susceptibility to high concentrations of aminoglycoside antibiotics. | Aminoglycoside Screening Method | |||
HPLC | C16434 | High Performance Liquid Chromatography | Frequently referred to simply as HPLC, this form of column chromatography is used frequently in biochemistry. The analyte is forced through a column by liquid at high pressure, which decreases the time the separated components remain on the stationary phase. Less time on the column then translates to narrower peaks in the resulting chromatogram and thence to better selectivity and sensitivity. | High Performance Liquid Chromatography | ||
HPLC/MS | C103513 | High Performance Liquid Chromatography/Mass Spectrometry | An analytical technique wherein high performance liquid chromatography is coupled to mass spectrometry in order to separate, identify, and quantify substances in a sample. | High Performance Liquid Chromatography Mass Spectrometry | ||
IHC | C23020 | Immunohistochemistry | Immunohistochemical staining techniques allow for the visualization of antigens via the sequential application of a specific antibody to the antigen (primary antibody), a secondary antibody to the primary antibody and an enzyme complex with a chromogenic substrate. The enzymatic activation of the chromogen results in a visible reaction product at the antigen site. The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope and aid in the differential diagnosis of pathophysiological processes, which may or may not be associated with a particular antigen. | Immunohistochemistry Staining Method | ||
INDIA INK STAIN | C85642 | A microscopy staining method that utilizes India Ink, a water soluble carbon-based black ink, to determine the presence of microorganisms that are surrounded by a gelatinous capsule. This is a negative staining method in which background is stained in black and the microbes and microscopic structures of interest remain white. | India Ink Staining Method | |||
INFRARED SPECTROMETRY | C85643 | A spectrometric method that determines the type and concentration of elements or chemicals in a sample, based upon the principle that the atoms in a sample will vibrate or rotate at a specific frequency when exposed to infrared light. | Infrared Spectrometry | |||
IODINE STAIN | C85649 | A microscopy staining method that utilizes Iodine, an element belonging to the halogen group, which specifically stains polysaccharides such as cellulose, chitin, glycogen, and starch a blue color. | Iodine Staining Method | |||
IRON HEMATOXYLIN STAIN | C85650 | A microscopy staining method that utilizes a mixture of iron and hematoxylin to visualize intracellular structures in a microscopic sample. In this dye system, iron acts as a mordant to hematoxylin rendering it insoluble, thereby allowing irreversible blue-black colored dyeing to the cell nucleus. | Iron Hematoxylin Staining Method | |||
KINYOUN STAIN | C85651 | A microscopy acid fast staining method that utilizes kinyoun carbol fuchsin, a dye containing basic fuchsin in solution with ethyl alcohol and aqueous phenol. This acid fast staining technique does not require heating during the primary staining step involving the carbol fuchsin. | Kinyoun Staining Method | |||
LIGHT MICROSCOPY | C17995 | Light microscopy is a technique for producing visible images of structures or details which are too small to be otherwise seen by the human eye. It involves passing light transmitted through or reflected from the subject through a series of lenses to be detected directly by the eye, imaged on a photographic plate, or captured digitally. | Light Microscopy | |||
MACRO BROTH DILUTION | C85697 | A method to determine the minimum inhibitory concentration (MIC) of antibiotics in which growth media is pipetted into a test tube. Each tube contains a known concentration of drug and is inoculated with a known quantity of bacteria. The tubes are incubated for a specified period of time and each is assessed for bacterial cell growth. The drug concentration in the first tube showing no growth is known as the MIC for that antibiotic. | Macro Broth Dilution Method | |||
MASS SPECTROMETRY | C17156 | An analytical technique wherein ions are separate according to their ratio of charge to mass. From the mass spectrum produced, the atomic weight of the particle can be deduced. | Mass Spectrometry | |||
MICRO BROTH DILUTION | C85701 | A method to determine the minimum inhibitory concentration (MIC) of antibiotics in which growth media is pipetted into a multi-well plate. Each well contains a known concentration of drug which is inoculated with a known quantity of bacteria. The plate is incubated for a specified period of time and each well is assessed for bacterial cell growth. The drug concentration in the first well showing no growth is known as the MIC for that antibiotic. | Micro Broth Dilution Method | |||
MICROBIAL CONCENTRATION | C85702 | Any technique in which a sample is condensed in order to afford greater sensitivity for the detection of microorganisms. | Microbial Concentration Method | |||
MODIFIED ACID FAST STAIN | C85736 | A microscopy staining method, that does not utilize heat in the slide preparation, used to examine a specimen for the presence of acid-fast microorganisms, specifically nocardia. | Modified Acid Fast Staining Method | |||
MRI | C16809 | Magnetic Resonance Imaging | Imaging that uses radiofrequency waves and a strong magnetic field rather than x-rays to provide amazingly clear and detailed pictures of internal organs and tissues. The technique is valuable for the diagnosis of many pathologic conditions, including cancer, heart and vascular disease, stroke, and joint and musculoskeletal disorders. | Magnetic Resonance Imaging | ||
OBSERVATION | C25598 | Watching something and taking note of what happens. | Observation | |||
OPTICAL DENSITY MEASUREMENT | C85776 | A quantification of the amount of light that is absorbed by or transmitted through a substance. | Optical Density Measurement | |||
PALPATION | C16950 | A method of feeling with the hands during a physical examination. The health care provider touches and feels the patient's body to examine the size, consistency, texture, location and tenderness of an organ or body part. | Palpation | |||
PERCUSSION | C62298 | A diagnostic test performed on a tooth by tapping on the crown with a dental instrument. | Dental Percussion | |||
PHASE CONTRAST MICROSCOPY | C16857 | A microscopic technique in which the amplitude shift that occurs when light passes through a specimen highlights structures or details within the specimen. | Phase-Contrast Microscopy | |||
RIA | C17057 | Radioimmunoassay | Radioimmunoassay (RIA) is an immunological technique, which quantitatively determines antigen and antibody concentrations, using a radioactively labeled substance (radioligand), either directly or indirectly. | Radioimmunoassay | ||
RYAN BLUE STAIN | C85801 | A microscopy staining method that utilizes a modified trichrome stain to determine the presence of microspordial, sporulating species. This staining technique substitutes aniline blue for the fast green counterstain of the original trichrome staining method and decreased levels of phosphotungstic acid in the reagent. | Ryan Blue Staining Method | |||
SCANNING ELECTRON MICROSCOPY | C16855 | An electron microscopy imaging technique that is utilized to examine structural components of a sample by passing electrons through a specimen that has been coated with a heavy metal. | Scanning Electron Microscopy | |||
SLIT LAMP | C75583 | Examination of the anterior segment of the eye using a medical instrument called a slit lamp. | Slit-lamp Examination | |||
SPIRAL CT | C20645 | Spiral Computed Tomography | A method of examining body organs by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis. | Spiral CT | ||
THICK SMEAR | C85819 | A blood smear technique used to make a thick blood smear on a microscope slide which is generally used to look for blood parasites such as those causing malaria. | Thick Smear Technique | |||
THIN SMEAR | C85820 | A blood smear technique used to make a thin blood smear on a microscope slide which is generally used to look for blood parasites such as those causing malaria. | Thin Smear Technique | |||
TRANSMISSION ELECTRON MICROSCOPY | C18216 | An electron microscopy imaging technique that is utilized to examine structural components of a sample by passing electrons through the specimen. | Transmission Electron Microscopy | |||
TRICHROME STAIN | C23012 | A microscopy staining method that utilizes two or more colored, acidic dyes of contrasting colors. Masson trichrome is a mixture of three dyes including aniline blue, Beibrich scarlet and Weigert's iron hematoxylin. Other related, modified trichrome staining methods include Lillie's trichrome, Gomori's trichrome and Mallory's trichrome. | Trichrome Staining Method | |||
ULTRASOUND | C17230 | A technique in which high-frequency sound waves are bounced off internal organs and the echo pattern is converted into a 2 dimensional picture of the structures beneath the transducer. | Ultrasonography | |||
WEBER GREEN STAIN | C85828 | A microscopy staining method that utilizes a modified trichrome stain to determine the presence of microspordial, sporulating species. The staining method utilizes chromotrope 2R, a red acidic dye, the counterstain fast green, and phosphotungstic acid. | Weber Green Staining Method | |||
WRIGHT STAIN | C85829 | A microscopy staining method that utilizes the Romanowsky stains, eosin and methylene blue, solubilized in methanol. In this staining protocol, methanol is also utilized as a fixative agent prior to staining. | Wright Staining Method | |||
WRIGHT-GIEMSA STAIN | C23041 | A microscopy staining method that is a combination of the Wright and Giemsa staining protocols and utilizes the Romanowsky stains, which are mixtures of eosin and thiazine dyes such as methylene blue. It produces darker blue and magenta shades than the giemsa stain alone, which may provide better contrast in microscopy. | Wright-Giemsa Staining Method | |||
XRAY | C38101 | Radiography | A radiographic procedure using the emission of x-rays to form an image of the structure penetrated by the radiation. | Radiography | ||
X-RAY FLUORESCENCE SPECTROMETRY | C85830 | A spectrometric method that determines the type and concentration of elements or chemicals in a sample, based upon the principle that each element emits fluorescent light of a particular wavelength when exposed to an X-ray. | X-Ray Fluorescence Spectrometry | |||
ZIEHL NEELSEN ACID FAST STAIN | C85831 | A microscopy acid fast staining method that utilizes Ziehl-Neelsen carbol fuchsin, acid alcohol and methylene blue, to determine the presence of acid fast microorganisms. This acid fast staining technique requires heating during the primary staining step involving the carbol fuchsin. | Ziehl Neelsen Acid Fast Staining Method | |||
ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN | C92304 | A microscopy staining method that utilizes periodic acid, an oxoacid of iodine, Schiff reagent, the reaction product of fuchsine and sodium bisulfite, and Alcian blue, a water soluble copper phthalocyanine dye. This staining method is used to differentially stain glycoproteins. | Alcian Blue and Periodic Acid Schiff Staining Method | |||
ALCIAN BLUE STAIN | C92299 | A microscopy staining method that utilizes alcian blue, a cationic, water soluble copper-containing phthalocyanine dye to determine the presence of acid mucopolysaccharides and glycosaminoglycans. | Alcian Blue Staining Method | |||
LEAD CITRATE STAIN | C92301 | A microscopy staining method that utilizes lead citrate, a mixture of lead nitrate and sodium citrate, and has applications for electron microscopy staining. | Lead Citrate Staining Method | |||
LUXOL FAST BLUE AND CRESYL VIOLET STAIN | C92300 | A microscopy staining method that utilizes luxol fast blue, an alcohol soluble copper phthalocyanine dye, and cresyl violet, an organic compound that is commonly used as a counter stain, to determine the presence of myelin as well as helicobacter and campylobacter bacterial species. | Luxol Fast Blue and Cresyl Violet Staining Method | |||
PERIODIC ACID SCHIFF STAIN | C23019 | A microscopy staining method that utilizes Schiff's reagent, a solution composed of pararosanilin treated with sulfurous acid, which selectively reacts with and stains aldehydes pink to determine the presence of glycogen, mucin, mucoprotein, glycoprotein, as well as fungi. Periodic Acid Schiff staining is useful for outlining tissue structures such as basement membranes, capsules and blood vessels. | Periodic Acid Schiff Staining Method | |||
TOLUIDINE BLUE STAIN | C92302 | A microscopy staining method that utilizes toluidine blue, a solution composed of tolonium chloride, to determine the presence of mast cells, lignin, proteoglycans and glycosaminoglycans. | Toluidine Blue Staining Method | |||
URANYL ACETATE STAIN | C92303 | A microscopy staining method that utilizes uranyl acetate, a water insoluble yellow crystalline solid, which is used as a negative stain in electron microscopy. | Uranyl Acetate Staining Method | |||
TOTAL BODY IRRADIATION | C15350 | A therapeutic procedure that involves the irradiation of the whole body with ionizing or non-ionizing radiation. (NCI) | Total-Body Irradiation | |||
ANGIOGRAM | C16805 | An X-ray representation of blood vessels made after the injection of a radiopaque substance. | Lymphangiogram | |||
MAMMOGRAPHY | C16818 | A type of radiography used specifically to examine breast tissue. The procedure utilizes a low-dose of x-rays or radiation to generate an image. | Mammography | |||
PET/CT SCAN | C103512 | An imaging technique that utilizes positron emission tomography and computed tomography in a single machine. | Positron Emission Tomography and Computed Tomography Scan | |||
DXA SCAN | C48789 | A technique for scanning bone and measuring bone mineral density (BMD). | Dual X-ray Absorptiometry | |||
SCINTIGRAPHY | C62667 | An imaging technique that uses a small dose of a radioactive chemical (isotope) called a tracer that can detect sites of cancer growth, trauma, infection or degenerative disorders. The tracer, which is either injected into a vein or swallowed, travels through the bloodstream to the target organ, and emits gamma rays, which are detected by a gamma camera and analyzed by a computer to form an image of the target organ. (NCI) | Radionuclide Imaging | |||
PHOTOGRAPHY | C94527 | The process by which an image is acquired by recording light emissions. | Photography | |||
PANENDOSCOPY | C94528 | An endoscopic examination of the pharynx, larynx, trachea and esophagus. | Panendoscopy | |||
TOTAL BODY RADIOGRAPHY | C96640 | A diagnostic radiologic test that involves the examination of the entire body in a single procedure. | Total Body Radiography | |||
AURAMINE STAIN | C102599 | Auramine O | A microscopy acid fast staining method that utilizes auramine O, a bright yellow ketonimine dye, which binds to the mycolic acid in the cell walls of acid fast microorganisms. | Auramine Staining Method | ||
ELISPOT | C102632 | Enzyme-linked Immunosorbent Spot Assay | A highly sensitive immunoassay capable of detecting secreted materials from individuals cells upon activation. If the material of interest is secreted in response to a particular stimulus, then the material will bind to a specific immobilized antibody. Binding is then verified and visualized by applying other antibodies that have been tagged in some way. | Enzyme-linked Immunosorbent Spot Assay | ||
GEL ELECTROPHORESIS | C18091 | A method of separating large molecules (such as DNA fragments or proteins) from a mixture of similar molecules by electrophoretic filtration through a gelatinous matrix. Subject to an electric field, each molecule in the sample mixture migrates through the matrix at a different rate, depending mainly on electrical charge and size, resulting in spatial separation within the matrix of each molecular species in the sample mixture. Agarose and acrylamide in a cylindrical tube or slab gel are commonly used media for electrophoresis of proteins and nucleic acids. | Gel Electrophoresis | |||
LINE PROBE ASSAY | C102656 | LiPA;LPA | A microbial identification technique in which polymerase chain reaction is used to amplify specific nucleic acid sequences in a biospecimen. The product of this reaction is then applied to a nitrocellulose test strip containing complementary DNA probes. | Line Probe Assay | ||
LOOP-MEDIATED ISOTHERMAL AMPLIFICATION | C102661 | LAMP | A type of nucleic acid amplification test in which sample DNA is exposed to a single temperature in the presence of multiple sets of primers and a polymerase with replication and high strand displacement activity. This test negates the need for thermal cyclers and may be a low cost alternative to PCR. | Loop-mediated Isothermal Amplification | ||
MALDI | C48040 | Matrix-Assisted Laser Desorption Ionization Mass Spectrometry | A mass spectrometric technique that is used for the analysis of large biomolecules. Analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. The matrix absorbs the laser energy, thus inducing a soft disintegration of the sample- matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. In general, only molecular ions of the analyte molecules are produced and almost no fragmentation occurs. This makes the method well suited for molecular weight determinations and mixture analysis. (CHI) | Matrix-Assisted Laser Desorption Ionization Mass Spectrometry | ||
MALDI-TOF | C19935 | Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry | In MALDI-TOF, a laser pulse is fired into a protein or peptide sample contained in a light-absorbing matrix. A small explosion vaporizes and ionizes the sample. In the presence of a high electric field, peptide ions are accelerated down an evacuated flight tube. Because large particles travel more slowly than small ones, the masses of the ionized particles are determined by measuring their arrival time at the end of the tube. | Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry | ||
MICROARRAY | C44282 | A piece of glass or plastic on which different samples have been affixed at separate locations in an ordered manner thus forming a microscopic array. The samples are usually DNA fragments but may also be antibodies, other proteins, or tissues. | Microarray | |||
MICROBIAL BIOCHEMICAL IDENTIFICATION | C51955 | Any of a number of biochemical tests performed to identify the genus and/or species of a microorganism. These may include the assessment of gram reaction or metabolic characteristics. | Bacterial Typing Procedure | |||
MICROBIAL CULTURE | C25300 | Culture Procedure | Any method for growing microorganisms. | Culture Procedure | ||
MICROBIAL CULTURE, LIQUID | C102668 | A method for growing microorganisms in liquid culture media. | Microbial Liquid Culture | |||
MICROBIAL CULTURE, SOLID | C102669 | A method for growing microorganisms in solid culture media. | Microbial Solid Culture | |||
NUCLEIC ACID AMPLIFICATION TEST | C20055 | NAAT | Any of a number of molecular biological techniques that are used to copy nucleic acid sequences within a specimen, leading to an increase in the number of copies of that sequence of interest. These techniques may be used for detection of a particular gene or microorganism of interest. | Nucleic Acid Amplification Test | ||
NUCLEIC ACID HYBRIDIZATION | C16924 | A method in which single stranded nucleic acids are allowed to interact so that complexes, or hybrids, are formed by molecules with sufficiently similar, complementary sequences. By this means the degree of sequence identity can be assessed and specific sequences detected. (From Biology-online) | Nucleic Acid Hybridization | |||
NUCLEIC ACID SEQUENCING | C18881 | The process of determining the sequence of purines and pyrimidines in nucleic acids and polynucleotides. | Nucleic Acid Sequencing | |||
POLYMERASE CHAIN REACTION | C17003 | PCR | A method for amplifying a DNA base sequence using multiple rounds of heat denaturation of the DNA and annealing of oligonucleotide primers complementary to flanking regions in the presence of a heat-stable polymerase. This results in duplication of the targeted DNA region. Newly synthesized DNA strands can subsequently serve as additional templates for the same primer sequences, so that successive rounds of primer annealing, strand elongation, and dissociation produce rapid and highly specific amplification of the desired sequence. PCR also can be used to detect the existence of the defined sequence in a DNA sample. | Polymerase Chain Reaction | ||
REAL-TIME POLYMERASE CHAIN REACTION ASSAY | C51962 | qPCR;Real Time-PCR | A modified polymerase chain reaction (PCR) technique in which DNA amplification is detected and quantified as the PCR reaction progresses, through the use of fluorescent DNA probes in the reaction mixture. | Real Time PCR | ||
SMEAR | C65126 | The action of spreading a thin layer of material across a surface. | Smear | |||
TEST STRIP | C50322 | A piece of chemically treated medium designed to react in the presence of specific amounts of a trigger substance. | Test Strip Device Component | |||
WESTERN BLOT | C16357 | A method for the detection or identification of proteins or peptides that have been separated by gel electrophoresis and transferred onto nitrocellulose or other type of paper or nylon membrane. The proteins are then detected by reaction with enzymatically labeled or radiolabeled antibody probes. | Western Blotting | |||
FDGPET | C103400 | FDG-PET Scan | An imaging technique that utilizes positron emission tomography to produce a three-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on the biologically active molecule (fludeoxyglucose) FDG. FDG is an analogue of glucose which when imaged will give tissue metabolic activity, in terms of regional glucose uptake. | FDG-Positron Emission Tomography | ||
FLTPET | C103401 | FLT-PET Scan | An imaging technique that utilizes positron emission tomography to produce a three-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on the biologically active molecule fluoro-L-thymidine (FLT). FLT when imaged will give tissue metabolic activity, in terms of cell proliferation. | FLT-Positron Emission Tomography | ||
INTRAVASCULAR ULTRASOUND | C99535 | IVUS | An invasive procedure in which sound waves (called ultrasound) are bounced off of vascular tissues from within the vessel and the echoes produce a picture (sonogram). | Intravascular Ultrasound | ||
LC/MS | C18475 | Liquid Chromatography/Mass Spectrometry | An analytical technique wherein liquid chromatography is coupled to mass spectrometry in order to separate, identify, and quantify substances in a sample. | Liquid Chromatography Mass Spectrometry | ||
PHYSICAL EXAMINATION | C20989 | Physical Exam | A systemic evaluation of the body and its functions using visual inspection, palpation, percussion and auscultation. The purpose is to determine the presence or absence of physical signs of disease or abnormality for an individual's health assessment. | Physical Examination | ||
ECHOCARDIOGRAM | C16525 | A procedure that uses high-frequency sound waves (ultrasound) to create an image of the heart. | Echocardiography | |||
BIOPSY | C15189 | The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis. | Biopsy | |||
PET/MRI SCAN | C103514 | An imaging technique that utilizes positron emission tomography and magnetic resonance imaging in a single machine. | Positron Emission Tomography and Magnetic Resonance Imaging | |||
PET SCAN | C17007 | An imaging technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance. A scanner reveals the tissue location of the metabolically-active substance administered. | Positron Emission Tomography | |||
Back to top | ||||||
CL.C85494.PKUNIT | PK Parameter Units of Measure (PKUNIT) | text Extensible: Yes | C85494 | PK Parameter Units of Measure | Units of measure needed for pharmacokinetic parameters. | CDISC SDTM Pharmacokinetic Parameter Unit of Measure Terminology |
day*fg/mL | C85583 | pg*day/L;day*pg/L;fg*day/mL;d*fg/mL | Days times femtograms per milliliter. | Day Times Femtogram per Milliliter | ||
day*g/mL | C85584 | g*day/mL;day*kg/L;kg*day/L;d*g/mL | Days times grams per milliliter. | Day Times Gram per Milliliter | ||
day*kg/mL | C85585 | kg*day/mL;g*day/uL;day*g/uL;d*kg/mL | Days times kilograms per milliliter. | Day Times Kilogram per Milliliter | ||
day*mg/mL | C85588 | mg*day/mL;day*g/L;g*day/L;day*ug/uL;ug*day/uL;d*mg/mL | Days times milligrams per milliliter. | Day Times Milligram per Milliliter | ||
day*mmol/mL | C85589 | mmol*day/mL;day*mol/L;mol*day/L;day*umol/uL;umol*day/uL;d*mmol/mL | Days times millimoles per milliliter. | Day Times Millimole per Milliliter | ||
day*mol/mL | C85590 | mol*day/mL;d*mol/mL | Days times moles per milliliter. | Day Times Mole per Milliliter | ||
day*ng/mL | C85591 | ng*day/mL;day*ug/L;ug*day/L;d*ng/mL | Days times nanograms per milliliter. | Day Times Nanogram per Milliliter | ||
day*nmol/mL | C85592 | nmol*day/mL;day*umol/L;umol*day/L;d*nmol/mL | Days times nanomoles per milliliter. | Day Times Nanomole per Milliliter | ||
day*pg/mL | C85593 | pg*day/mL;day*ng/L;ng*day/L;d*pg/mL | Days times picograms per milliliter. | Day Times Picogram per Milliliter | ||
day*pmol/mL | C85594 | nmol*day/L;day*nmol/L;pmol*day/mL;d*pmol/mL | Days times picomoles per milliliter. | Day Times Picomole per Milliliter | ||
day*ug/mL | C85586 | ug*day/mL;day*mg/L;mg*day/L;day*mcg/mL;mcg*day/mL | Days times micrograms per milliliter. | Day Times Microgram per Milliliter | ||
day*umol/mL | C85587 | umol*day/mL;day*mmol/L;mmol*day/L;day*mcmol/mL;mcmol*day/mL;d*umol/mL | Days times micromoles per milliliter. | Day Times Micromole per Milliliter | ||
fg/mL | C85597 | pg/L;fg/mL | Femtograms per milliliter. | Femtogram per Milliliter | ||
g | C48155 | Gram | A metric unit of mass equal to one one thousandth of a kilogram. (NCI) | Gram | ||
g/day | C67372 | Gram per Day;g/d;gram/day;g/24h;gram/24 Hours | A dose calculation unit expressed in gram(s) per period of time equal to twenty-four hours. | Gram per Day | ||
g/h | C85601 | gram/h;g/h | Grams per hour. | Gram per Hour | ||
g/min | C85602 | gram/min;g/min | Grams per minute. | Gram per Minute | ||
g/mL | C64566 | Kilogram per Liter;g/mL;Gram per Milliliter;gram/mL;kg/L;mg/uL | A unit of mass concentration defined as the concentration of one kilogram of a substance in unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one kilogram occupies the volume one liter.(NCI) | Kilogram per Liter | ||
g/s | C85603 | gram/sec;g/sec;gram/s;g/s | Grams per second. | Gram per Second | ||
h*fg/mL | C85611 | pg*h/L;h*pg/L;fg*h/mL;h*fg/mL | Hours times femtograms per milliliter. | Hour Times Femtogram per Milliliter | ||
h*fmol/mL | C85612 | pmol*h/L;h*pmol/L;fmol*h/mL;h*fmol/mL | Hours times femtomoles per milliliter. | Hour Times Femtomole per Milliliter | ||
h*g/mL | C85613 | g*h/mL;h*kg/L;kg*h/L;h*g/mL | Hours times grams per milliliter. | Hour Times Gram per Milliliter | ||
h*kg/mL | C85614 | kg*h/mL;g*h/uL;h*g/uL;h*kg/mL | Hours times kilograms per milliliter. | Hour Times Kilogram per Milliliter | ||
h*mg/L/mg | C85620 | mg*h/L/mg;h*mg/mg/L;mg*h/mg/L;h*mg/L/mg | Hours times milligrams per liter per milligram. | Hour Times Milligram per Liter per Milligram | ||
h*mg/mL | C85621 | mg*h/mL;h*g/L;g*h/L;ug*h/uL;h*ug/uL;h*mg/mL | Hours times milligrams per milliliter. | Hour Times Milligram per Milliliter | ||
h*mmol/mL | C85622 | mmol*h/mL;h*mol/L;mol*h/L;umol*h/uL;h*umol/uL;h*mmol/mL | Hours times millimoles per milliliter. | Hour Times Millimole per Milliliter | ||
h*mol/mL | C85623 | mol*h/mL;h*mol/mL | Hours times moles per milliliter. | Hour Times Mole per Milliliter | ||
h*ng/mL | C85624 | ng*h/mL;h*ug/L;ug*h/L;h*ng/mL | Hours times nanograms per milliliter. | Hour Times Nanogram per Milliliter | ||
h*ng/mL/g | C85625 | ng*h/mL/g;h*ng/g/mL;ng*h/g/mL;h*ng/mL/g | Hours times nanograms per milliliter per gram. | Hour Times Nanogram per Milliliter per Gram | ||
h*ng/mL/kg | C85626 | ng*h/mL/kg;ng*h/kg/mL;h*ng/kg/mL;h*ng/mL/kg | Hours times nanograms per milliliter per kilogram. | Hour Times Nanogram per Milliliter per Kilogram | ||
h*ng/mL/mg | C85627 | ng*h/mL/mg;h*ng/mg/mL;ng*h/mg/mL;h*ng/mL/mg | Hours times nanograms per milliliter per milligram. | Hour Times Nanogram per Milliliter per Milligram | ||
h*ng/mL/(mg/kg) | C85628 | ng*h/mL/(mg/kg) | Hours times nanograms per milliliter (area under the curve), divided by milligram per kilogram (dose normalized by weight). | Hour Times Nanogram per Milliliter per Milligram per Kilogram | ||
h*ng/mL/mg/m2 | C85629 | h*ng/mL/mg/m^2;h*ng/mL/mg/m*m;ng*h/mL/mg/m2 | Hours times nanograms per milliliter per milligram per meter squared. | Hour Times Nanogram per Milliliter per Milligram per Meter Squared | ||
h*nmol/L/umol | C85631 | h*nmol/L/mcmol;nmol*h/L/umol;h*nmol/umol/L;nmol*h/umol/L | Hours times nanomoles per liter per micromole. | Hour Times Nanomole per Liter per Micromole | ||
h*nmol/mL | C85632 | umol*h/L;h*umol/L;nmol*h/mL;h*nmol/mL | Hours times nanomoles per milliliter. | Hour Times Nanomole per Milliliter | ||
h*nmol/mL/mg | C85634 | nmol*h/mL/mg;h*nmol/mg/mL;nmol*h/mg/mL;h*nmol/mL/mg | Hours times nanomoles per milliliter per milligram. | Hour Times Nanomole per Milliliter per Milligram | ||
h*pg/mL | C85635 | pg*h/mL;h*ng/L;ng*h/L;h*pg/mL | Hours times picograms per milliliter. | Hour Times Picogram per Milliliter | ||
h*pg/mL/kg | C85636 | pg*h/mL/kg;h*pg/kg/mL;pg*h/kg/mL;h*pg/mL/kg | Hours times picograms per milliliter per kilogram. | Hour Times Picogram per Milliliter per Kilogram | ||
h*pg/mL/mg | C85638 | pg*h/mL/mg;h*pg/mg/mL;pg*h/mg/mL;h*pg/mL/mg | Hours times picograms per milliliter per milligram. | Hour Times Picogram per Milliliter per Milligram | ||
h*pg/mL/ug | C85637 | h*pg/mL/mcg;pg*h/mL/ug;h*pg/ug/mL;pg*h/ug/mL | Hours times picograms per milliliter per microgram. | Hour Times Picogram per Milliliter per Microgram | ||
h*pmol/L/ug | C85639 | pmol*h/L/ug;h*pmol/L/mcg;h*pmol/ug/L;pmol*h/ug/L | Hours times picomoles per liter per microgram. | Hour Times Picomole per Liter per Microgram | ||
h*pmol/mL | C85640 | pmol*h/mL;h*nmol/L;nmol*h/L;h*pmol/mL | Hours times picomoles per milliliter. | Hour Times Picomole per Milliliter | ||
h*pmol/mL/mg | C85641 | pmol*h/mL/mg;h*pmol/mg/mL;pmol*h/mg/mL;h*pmol/mL/mg | Hours times picomoles per milliliter per milligram. | Hour Times Picomole per Milliliter per Milligram | ||
h*ug/mL | C85615 | mg*h/L;h*mg/L;h*ng/uL;ng*h/uL;h*ug/mL;h*mcg/mL;mcg*h/mL | Hours times micrograms per milliliter. | Hour Times Microgram per Milliliter | ||
h*ug/mL/mg | C85617 | ug*h/mL/mg;h*mcg/mL/mg;h*ug/mg/mL;ug*h/mg/mL | Hours times micrograms per milliliter per milligram. | Hour Times Microgram per Milliliter per Milligram | ||
h*umol/mL | C85618 | mmol*h/L;h*mmol/L;umol*h/mL;h*mcmol/mL;mcmol*h/mL;h*umol/mL | Hours times micromoles per milliliter. | Hour Times Micromole per Milliliter | ||
h2*mg/mL | C85606 | mg*h2/mL;h^2*mg/mL;h*h*mg/mL;h2*g/L;h2*ug/uL | Hours squared times milligrams per milliliter. | Hour Squared Times Milligram per Milliliter | ||
h2*mmol/mL | C85607 | mmol*h2/mL;h^2*mmol/mL;h*h*mmol/mL;h2*mol/L;h2*umol/uL | Hours squared times millimoles per milliliter. | Hour Squared Times Millimole per Milliliter | ||
h2*ng/mL | C85608 | ng*h2/mL;h^2*ng/mL;h*h*ng/mL;h2*ug/L | Hours squared times nanograms per milliliter. | Hour Squared Times Nanogram per Milliliter | ||
h2*pg/mL | C85609 | pg*h2/mL;h^2*pg/mL;h*h*pg/mL;h2*ng/L | Hours squared times picogram per milliliter. | Hour Squared Times Picogram per Milliliter | ||
h2*pmol/mL | C85610 | pmol*h2/mL;h^2*pmol/mL;h*h*pmol/mL;h2*nmol/L | Hours squared times picomoles per milliliter. | Hour Squared Times Picomole per Milliliter | ||
h2*ug/mL | C85604 | ug*h2/mL;h^2*ug/mL;h*h*ug/mL;h2*mcg/mL;h2*mg/L | Hours squared times micrograms per milliliter. | Hour Squared Times Microgram per Milliliter | ||
h2*umol/mL | C85605 | umol*h2/mL;h^2*umol/mL;h*h*umol/mL;h2*mcmol/mL;h2*mmol/L | Hours squared times micromoles per milliliter. | Hour Squared Times Micromole per Milliliter | ||
IU/day | C85645 | IU/d | International units per day. | International Unit per Day | ||
IU/h | C85646 | IU/h | International units per hour. | International Unit per Hour | ||
IU/min | C85647 | IU/min | International units per minute. | International Unit per Minute | ||
IU/s | C85648 | IU/sec;IU/s | International units per second. | International Unit per Second | ||
L | C48505 | Liter | A unit of volume equal to a cubic decimeter, or one thousandth of cubic meter, or 1000 cubic centimeters, or approximately 61.023 744 cubic inches.(NCI) | Liter | ||
L/day | C69110 | Liters per day. | Liter per Day | |||
L/g/day | C85657 | mL/mg/day;uL/ug/day;L/day/g;L/g/d | Liters per gram per day. | Liter per Gram per Day | ||
L/g/h | C85658 | L/h/g;mL/mg/h;uL/ug/h;mL/h/mg;uL/h/ug;L/g/h | Liters per gram per hour. | Liter per Gram per Hour | ||
L/g/min | C85659 | mL/mg/min;uL/ug/min;L/min/g;L/g/min | Liters per gram per minute. | Liter per Gram per Minute | ||
L/g/s | C85660 | L/g/sec;mL/mg/s;uL/ug/s;L/s/g;mL/mg/sec;uL/ug/sec;L/sec/g;L/g/s | Liters per gram per second. | Liter per Gram per Second | ||
L/h | C69160 | L/h | Liters per hour. | Liter per Hour | ||
L/kg/day | C73755 | Milliliter per Gram per Day;mL/g/day;uL/mg/day;L/day/kg;mL/day/g;uL/day/mg;L/kg/d | Liters per kilogram per day. | Milliliter per Gram per Day | ||
L/kg/h | C73756 | Milliliters per gram per hour. | Milliliter per Gram per Hour | |||
L/kg/min | C73757 | Milliliters per gram per minute. | Milliliter per Gram per Minute | |||
L/kg/s | C85664 | L/kg/sec;mL/g/s;uL/mg/s;L/s/kg;L/sec/kg;mL/s/g;uL/s/mg;L/kg/s | Liters per kilogram per second. | Liter per Kilogram per Second | ||
L/mg/day | C85672 | mL/ug/day;L/day/mg;mL/day/ug;L/mg/d | Liters per milligram per day. | Liter per Milligram per Day | ||
L/mg/h | C85673 | mL/ug/h;L/h/mg;mL/h/ug;L/mg/h | Liters per milligram per hour. | Liter per Milligram per Hour | ||
L/mg/min | C85674 | mL/ug/min;L/min/mg;mL/min/ug;L/mg/min | Liters per milligram per minute. | Liter per Milligram per Minute | ||
L/mg/s | C85675 | mL/ug/s;L/s/mg;mL/s/ug;mL/ug/sec;L/sec/mg;mL/sec/ug;L/mg/s | Liters per milligram per second. | Liter per Milligram per Second | ||
L/min | C67388 | Liters per Minute | A unit of volumetric flow rate defined as the rate at which one liter of matter travels during the period of time equal to one minute.(NCI) | Liter per Minute | ||
L/mmol/day | C85676 | mL/umol/day;L/day/mmol;mL/day/umol;L/mmol/d | Liters per millimole per day. | Liter per Millimole per Day | ||
L/mmol/h | C85677 | mL/umol/h;L/h/mmol;mL/h/umol;L/mmol/h | Liters per millimole per hour. | Liter per Millimole per Hour | ||
L/mmol/min | C85678 | mL/umol/min;L/min/mmol;mL/min/umol;L/mmol/min | Liters per millimole per minute. | Liter per Millimole per Minute | ||
L/mmol/s | C85679 | L/mmol/sec;L/s/mmol;L/sec/mmol;mL/umol/s;mL/umol/sec;mL/s/umol;mL/sec/umoL;L/mmol/s | Liters per millimole per second. | Liter per Millimole per Second | ||
L/mol | C85680 | mL/mmol;uL/umol;L/mol | Liters per mole. | Liter per Mole | ||
L/mol/day | C85681 | L/day/mol;mL/mmol/day;uL/umol/day;mL/day/mmol;uL/day/umol;L/mol/d | Liters per mole per day. | Liter per Mole per Day | ||
L/mol/h | C85682 | L/h/mol;mL/mmol/h;uL/umol/h;mL/h/mmol;uL/h/umol;L/mol/h | Liters per mole per hour. | Liter per Mole per Hour | ||
L/mol/min | C85683 | L/min/mol;mL/mmol/min;uL/umol/min;mL/min/mmol;uL/min/umol;L/mol/min | Liters per mole per minute. | Liter per Mole per Minute | ||
L/mol/s | C85684 | L/mol/sec;L/s/mol;L/sec/mol;mL/mmol/s;mL/mmol/sec;mL/s/mmol;mL/sec/mmol;L/mol/s | Liters per mole per second. | Liter per Mole per Second | ||
L/ng/day | C85685 | L/day/ng;mL/pg/day;mL/day/pg;L/ng/d | Liters per nanogram per day. | Liter per Nanogram per Day | ||
L/ng/h | C85686 | L/h/ng;mL/pg/h;mL/h/pg;L/ng/h | Liters per nanogram per hour. | Liter per Nanogram per Hour | ||
L/ng/min | C85687 | L/min/ng;mL/pg/min;mL/min/pg;L/ng/min | Liters per nanogram per minute. | Liter per Nanogram per Minute | ||
L/ng/s | C85688 | L/s/ng;L/ng/sec;L/sec/ng;mL/pg/s;mL/s/pg;mL/pg/sec;mL/sec/pg;L/ng/s | Liters per nanogram per second. | Liter per Nanogram per Second | ||
L/nmol/day | C85689 | mL/pmol/day;L/day/nmol;mL/day/pmol;L/nmol/d | Liters per nanomole per day. | Liter per Nanomole per Day | ||
L/nmol/h | C85690 | mL/pmol/h;L/h/nmol;mL/h/pmol;L/nmol/h | Liters per nanomole per hour. | Liter per Nanomole per Hour | ||
L/nmol/min | C85691 | mL/pmol/min;L/min/nmol;mL/min/pmol;L/nmol/min | Liters per nanomole per minute. | Liter per Nanomole per Minute | ||
L/nmol/s | C85692 | L/nmol/sec;mL/pmol/s;mL/s/pmol;L/s/nmol;L/sec/nmol;L/nmol/s | Liters per nanomole per second. | Liter per Nanomole per Second | ||
L/pg/day | C85693 | L/day/pg;L/pg/d | Liters per picogram per day. | Liter per Picogram per Day | ||
L/pg/h | C85694 | L/h/pg;L/pg/h | Liters per picogram per hour. | Liter per Picogram per Hour | ||
L/pg/min | C85695 | L/min/pg;L/pg/min | Liters per picogram per minute. | Liter per Picogram per Minute | ||
L/pg/s | C85696 | L/pg/sec;L/s/pg;L/sec/pg;L/pg/s | Liters per picogram per second. | Liter per Picogram per Second | ||
L/s | C67390 | L/sec | Liters per second. | Liter per Second | ||
L/ug/day | C85665 | L/mcg/day;L/day/ug;L/day/mcg;mL/day/ng;mL/ng/day | Liters per microgram per day. | Liter per Microgram per Day | ||
L/ug/h | C85662 | L/mcg/h;L/h/ug;L/h/mcg;mL/h/ng;mL/ng/h;L/ug/h | Liters per microgram per hour. | Liter per Microgram per Hour | ||
L/ug/min | C85666 | L/mcg/min;L/min/ug;L/min/mcg;mL/min/ng;mL/ng/min | Liters per microgram per minute. | Liter per Microgram per Minute | ||
L/ug/s | C85667 | L/ug/sec;L/s/ug;L/ug/s;L/sec/ug;L/mcg/sec;L/s/mcg;L/mcg/s;L/sec/mcg;mL/ng/s;mL/s/ng | Liters per microgram per second. | Liter per Microgram per Second | ||
L/umol/day | C85668 | L/mcmol/day;L/day/umol;L/day/mcmol;L/umol/d | Liters per micromole per day. | Liter per Micromole per Day | ||
L/umol/h | C85669 | L/mcmol/h;L/h/umol;L/h/mcmol;L/umol/h | Liters per micromole per hour. | Liter per Micromole per Hour | ||
L/umol/min | C85670 | L/mcmol/min;L/min/umol;L/min/mcmol;L/umol/min | Liters per micromole per minute. | Liter per Micromole per Minute | ||
L/umol/s | C85671 | L/mcmol/s;L/umol/sec;L/s/umol;L/sec/umol;L/mcmol/sec;L/sec/mcmol;mL/nmol/s;mL/s/nmol;L/umol/s | Liters per micromole per second. | Liter per Micromole per Second | ||
mg | C28253 | Milligram | The unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015432 grain or 35.274 x 10E-6 ounce.(NCI) | Milligram | ||
mg/day | C67399 | Milligram per Day | A unit of measure referring to the ratio between mass expressed in milligrams per day.(NCI) | Milligram per 24 Hours | ||
mg/h | C66969 | Milligram per Hour | A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter travels to a given object or space over a period of time equal to one hour.(NCI) | Milligram per Hour | ||
mg/L/mg | C85710 | mg/mg/L;mg/L/mg | Milligrams per liter per milligram. | Milligram per Liter per Milligram | ||
mg/min | C73742 | Milligrams per minute. | Milligram per Minute | |||
mg/mL | C42576 | g/L;Gram per Liter;kg/m3;Kilogram per Cubic Metre;Microgram per Microliter;Milligram per Milliliter;ug/uL;mg/mL | A unit of mass concentration defined as the concentration of one kilogram of a substance per unit volume of the mixture equal to one cubic meter, or the concentration of one milligram of a substance per unit volume of the mixture equal to one milliliter, or one gram of a substance per one liter of the mixture. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one milliliter.(NCI) | Kilogram per Cubic Meter | ||
mg/mL/h | C85711 | g/L/h;ug/uL/h;mg/h/mL;g/h/L;ug/h/uL | Milligrams per milliliter per hour. | Milligram per Milliliter per Hour | ||
mg/s | C85712 | mg/sec;mg/s | Milligrams per second. | Milligram per Second | ||
min*fg/mL | C85724 | pg*min/L;min*pg/L;fg*min/mL;min*fg/mL | Minutes times femtograms per milliliter. | Minute Times Femtogram per Milliliter | ||
min*g/mL | C85725 | g*min/mL;min*kg/L;kg*min/L;min*g/mL | Minutes times grams per milliliter. | Minute Times Gram per Milliliter | ||
min*kg/mL | C85726 | kg*min/mL;g*min/uL;min*g/uL;min*kg/mL | Minutes times kilograms per milliliter. | Minute Times Kilogram per Milliliter | ||
min*mg/mL | C85729 | mg*min/mL;min*g/L;g*min/L;ug*min/uL;min*ug/uL;min*mg/mL | Minutes times milligrams per milliliter. | Minute Times Milligram per Milliliter | ||
min*mmol/mL | C85730 | mmol*min/mL;min*mol/L;mol*min/L;min*umol/uL;umol*min/uL;min*mmol/mL | Minutes times millimoles per milliliter. | Minute Times Millimole per Milliliter | ||
min*mol/mL | C85731 | mol*min/mL;min*mol/mL | Minutes times moles per milliliter. | Minute Times Mole per Milliliter | ||
min*ng/mL | C85732 | ng*min/mL;min*ug/L;ug*min/L;min*ng/mL | Minutes times nanograms per milliliter. | Minute Times Nanogram per Milliliter | ||
min*nmol/mL | C85733 | nmol*min/mL;min*umol/L;umol*min/L;min*nmol/mL | Minutes times nanomoles per milliliter. | Minute Times Nanomole per Milliliter | ||
min*pg/mL | C85734 | pg*min/mL;min*ng/L;ng*min/L;min*pg/mL | Minutes times picograms per milliliter. | Minute Times Picogram per Milliliter | ||
min*pmol/mL | C85735 | nmol*min/L;min*nmol/L;pmol*min/mL;min*pmol/mL | Minutes times picomoles per milliliter. | Minute Times Picomole per Milliliter | ||
min*ug/mL | C85727 | ug*min/mL;min*mg/L;mg*min/L;min*mcg/mL;mcg*min/mL | Minutes times micrograms per milliliter. | Minute Times Microgram per Milliliter | ||
min*umol/mL | C85728 | umol*min/mL;min*mcmol/mL;min*mmol/L;mmol*min/L;min*umol/mL | Minutes times micromoles per milliliter. | Minute Times Micromole per Milliliter | ||
mIU/mL | C67376 | International Unit per Liter;IU/L;mIU/mL | Unit of arbitrary substance concentration (biologic activity concentration) defined as the concentration of one international unit per one liter of system volume.(NCI) | International Unit per Liter | ||
mL | C28254 | Milliliter;cm3 | The unit of volume equal to one thousandth of a liter, one cubic centimeter, 10E-6 cubic meter, or approximately to 0.061 023 7 cubic inch.(NCI) | Milliliter | ||
mL/day | C67410 | Milliliters per day. | Milliliter per Day | |||
mL/h | C66962 | Milliliters per Hour | A unit of volumetric flow rate defined as the rate at which one milliliter of matter travels during the period of time equal to one hour.(NCI) | Milliliter per Hour | ||
mL/kg/day | C73758 | Milliliter per Kilogram per Day | Milliliters per kilogram per day. | Milliliter per Kilogram per Day | ||
mL/kg/h | C73759 | Milliliter per Kilogram per Hour | Milliliters per kilogram per hour. | Milliliter per Kilogram per Hour | ||
mL/kg/min | C73760 | Milliliter per Kilogram per Minute;uL/g/min;mL/min/kg;uL/min/g;mL/kg/min | Milliliters per kilogram per minute. | Milliliter per Kilogram per Minute | ||
mL/kg/s | C85715 | mL/sec/kg;mL/s/kg;mL/kg/sec;mL/kg/s | Milliliters per kilogram per second. | Milliliter per Kilogram per Second | ||
mL/min | C64777 | Milliliters per Minute | A metric unit of volumetric flow rate defined as the rate at which one milliliter of matter travels during the period of time equal to one minute.(NCI) | Milliliter per Minute | ||
mL/mol/day | C85716 | uL/mmol/day;mL/day/mol;uL/day/mmol;mL/mol/d | Milliliters per mole per day. | Milliliter per Mole per Day | ||
mL/mol/h | C85717 | uL/mmol/h;mL/h/mol;uL/h/mmol;mL/mol/h | Milliliters per mole per hour. | Milliliter per Mole per Hour | ||
mL/mol/min | C85718 | uL/mmol/min;mL/min/mol;uL/min/mmol;mL/mol/min | Milliliters per mole per minute. | Milliliter per Mole per Minute | ||
mL/mol/s | C85719 | mL/sec/mol;mL/s/mol;mL/mol/sec;mL/mol/s | Milliliters per mole per second. | Milliliter per Mole per Second | ||
mL/s | C69073 | mL/sec | Milliliters per second. | Milliliter per Second | ||
mmol/h | C85720 | Millimoles per hour. | Millimole per Hour | |||
mmol/min | C85722 | Millimoles per minute. | Millimole per Minute | |||
mmol/mL | C48555 | Mole per Liter;mol/L;mmol/mL | A unit of concentration (molarity unit) equal to one mole of solute in one liter of solution.(NCI) | Mole per Liter | ||
mmol/mL/h | C85721 | mol/L/h;umol/uL/h;mmol/h/mL;mol/h/L;umol/h/uL;mmol/mL/h | Millimoles per milliliter per hour. | Millimole per Milliliter per Hour | ||
mmol/s | C85723 | mmol/sec;mmol/s | Millimoles per second. | Millimole per Second | ||
mol/day | C85737 | mol/d | Moles per day. | Mole per Day | ||
mol/h | C85738 | Moles per hour. | Mole per Hour | |||
mol/min | C85739 | Moles per minute. | Mole per Minute | |||
mol/s | C85740 | mol/sec;mol/s | Moles per second. | Mole per Second | ||
ng | C48516 | Nanogram | A unit of mass equal to one billionth (10E-9) of a gram, or one millionth (10E-6) of a milligram.(NCI) | Nanogram | ||
ng/day | C85741 | ng/d | Nanograms per day. | Nanogram per Day | ||
ng/h | C85742 | Nanograms per hour. | Nanogram per Hour | |||
ng/kg/min | C85743 | ng/min/kg;pg/g/min;pg/min/g;ng/kg/min | Nanograms per kilogram per minute. | Nanogram per Kilogram per Minute | ||
ng/mg of Creatinine | C85744 | ug/g of Creatinine;ng/mg of Creatinine | Nanograms per milligram of creatinine. | Nanogram per Milligram of Creatinine | ||
ng/min | C85749 | Nanograms per minute. | Nanogram per Minute | |||
ng/mL | C67306 | mg/m3;Microgram per Liter;Milligram per Cubic Meter;Nanogram per Milliliter;ug/L;ng/mL;mcg/L | A unit of mass concentration defined as the concentration of one microgram of a substance per unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one microgram occupies the volume one liter.(NCI) | Microgram per Liter | ||
ng/mL*kg | C85748 | ng/kg*mL;ng/mL*kg | Nanograms per milliliter times kilogram. | Nanogram per Milliliter Times Kilogram | ||
ng/mL/h | C67430 | ug/L/h;ng/h/mL;ng/mL/h | Nanograms per milliliter per hour. | Nanogram per Milliliter per Hour | ||
ng/mL/kg | C85746 | ng/kg/mL;ng/mL/kg | Nanograms per milliliter per kilogram. | Nanogram per Milliliter per Kilogram | ||
ng/mL/mg | C85747 | ng/mg/mL;ng/mL/mg | Nanograms per milliliter per milligram. | Nanogram per Milliliter per Milligram | ||
ng/s | C85750 | ng/sec;ng/s | Nanograms per second. | Nanogram per Second | ||
nL | C69188 | Nanoliter | A unit of volume equal to one billionth of a liter (10E-9 liter).(NCI) | Nanoliter | ||
nmol/day | C85751 | nmol/d | Nanomoles per day. | Nanomole per Day | ||
nmol/g | C85752 | umol/kg;pmol/mg;nmol/g | Nanomoles per gram. | Nanomole per Gram | ||
nmol/h | C85753 | Nanomoles per hour. | Nanomole per Hour | |||
nmol/kg | C85754 | pmol/g;nmol/kg | Nanomoles per kilogram. | Nanomole per Kilogram | ||
nmol/L/umol | C85755 | nmol/L/mcmol;nmol/umol/L;nmol/mcmol/L;nmol/L/umol | Nanomoles per liter per micromole. | Nanomole per Liter per Micromole | ||
nmol/min | C85758 | Nanomoles per minute. | Nanomole per Minute | |||
nmol/mL | C85756 | umol/L;mcmol/L;nmol/mL | Nanomoles per milliliter. | Nanomole per Milliliter | ||
nmol/mL/h | C85757 | umol/L/h;nmol/h/mL;nmol/mL/h | Nanomoles per milliliter per hour. | Nanomole per Milliliter per Hour | ||
nmol/s | C85759 | nmol/sec;nmol/s | Nanomoles per second. | Nanomole per Second | ||
nU/mL | C85760 | uU/L;mcU/L;nU/mL | Nanounits per milliliter. | Nanounit per Milliliter | ||
pg/day | C85778 | pg/d | Picograms per day. | Picogram per Day | ||
pg/dL | C67331 | Picogram per Deciliter | Picograms per deciliter. | Picogram per Deciliter | ||
pg/h | C85779 | Picograms per hour. | Picogram per Hour | |||
pg/mg | C67396 | mcg/kg;Microgram per Kilogram;ng/g;ug/kg | A unit of a mass fraction expressed as a number of micrograms of substance per kilogram of mixture. The unit is also used as a dose calculation unit.(NCI) | Microgram per Kilogram | ||
pg/mg Creatinine | C85780 | ng/g of Creatinine;pg/mg of Creatinine | Picograms per milligram creatinine. | Picogram per Milligram of Creatinine | ||
pg/min | C85782 | Picograms per minute. | Picogram per Minute | |||
pg/mL | C67327 | ug/m3;Microgram per Cubic Meter;ng/L;pg/mL | A unit of mass concentration defined as the concentration of one nanogram of a substance per one liter of the mixture, or one picogram of a substance in unit volume of the mixture equal to one milliliter, or one microgram of a substance per one cubic meter of the mixture. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of substance which mass equal to one nanogram occupies the volume one liter.(NCI) | Nanogram per Liter | ||
pg/mL/ug | C85781 | pg/mL/mcg;pg/ug/mL;pg/mcg/mL | Picograms per milliliter per microgram. | Picogram per Milliliter per Microgram | ||
pg/s | C85783 | pg/sec;pg/s | Picograms per second. | Picogram per Second | ||
pmol/L/ug | C85784 | pmol/L/mcg;pmol/ug/L;pmol/mcg/L | Picomoles per liters per microgram. | Picomole per Liter per Microgram | ||
s*fg/mL | C85802 | pg*s/L;sec*fg/mL;s*pg/L;fg*s/mL;fg*sec/mL;s*fg/mL | Seconds times femtograms per milliliter. | Second Times Femtogram per Milliliter | ||
s*g/mL | C85803 | g*s/mL;sec*g/mL;g*sec/mL;s*kg/L;kg*s/L;sec*kg/L;kg*sec/L | Seconds times grams per milliliter. | Second Times Gram per Milliliter | ||
s*kg/mL | C85804 | kg*s/mL;g*s/uL;s*g/uL;kg*sec/mL;g*sec/uL;sec*g/uL;s*kg/mL | Seconds times kilograms per milliliter. | Second Times Kilogram per Milliliter | ||
s*mg/mL | C85807 | mg*s/mL;sec*mg/mL;s*g/L;g*s/L;s*mg/mL | Seconds times milligrams per milliliter. | Second Times Milligram per Milliliter | ||
s*mmol/mL | C85808 | mmol*s/mL;sec*mmol/mL;s*mol/L;mol*s/L;sec*mol/L;mol*sec/L;s*mmol/mL | Seconds times millimoles per milliliter. | Second Times Millimole per Milliliter | ||
s*mol/mL | C85809 | mol*s/mL;sec*mol/mL;mol*sec/mL;s*mol/mL | Seconds times moles per milliliter. | Second Times Mole per Milliliter | ||
s*ng/mL | C85810 | ng*s/mL;sec*ng/mL;ng*sec/mL;s*ug/L;ug*s/L;sec*ug/L;ug*sec/L;s*ng/mL | Seconds times nanograms per milliliter. | Second Times Nanogram per Milliliter | ||
s*nmol/mL | C85811 | nmol*s/mL;sec*nmol/mL;nmol*sec/mL;s*umol/L;umol*s/L;sec*umol/L;umol*sec/L;s*nmol/mL | Seconds times nanomoles per milliliter. | Second Times Nanomole per Milliliter | ||
s*pg/mL | C85812 | pg*s/mL;sec*pg/mL;pg*sec/mL;s*ng/L;ng*s/L;sec*ng/L;ng*sec/L;s*pg/mL | Seconds times picograms per milliliter. | Second Times Picogram per Milliliter | ||
s*pmol/mL | C85813 | nmol*s/L;s*nmol/L;sec*pmol/mL;pmol*s/mL;pmol*sec/mL;s*pmol/mL | Seconds times picomoles per milliliter. | Second Times Picomole per Milliliter | ||
s*ug/mL | C85805 | ug*s/mL;s*mcg/mL;ug*sec/mL;sec*ug/mL;sec*mcg/mL;mcg*sec/mL;s*mg/L;mg*s/L | Seconds times micrograms per milliliter. | Second Times Microgram per Milliliter | ||
s*umol/mL | C85806 | umol*s/mL;s*mcmol/mL;sec*umol/mL;umol*sec/mL;mcmol*sec/mL;sec*mcmol/mL;s*mmol/L;mmol*s/L;s*umol/mL | Seconds times micromoles per milliliter. | Second Times Micromole per Milliliter | ||
ug | C48152 | Microgram;mcg | The unit of mass equal to one millionth of a gram or one thousandth of a milligram.(NCI) | Microgram | ||
ug/day | C71205 | Microgram per Day;mcg/day | A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter travels to a given object or space over a period of time equal to twenty four hours. Microgram per day is also a dose administration rate unit equal to the rate at which one millionth of a gram of a product is administered per unit of time equal to twenty four hours.(NCI) | Microgram per Day | ||
ug/h | C67394 | Micrograms per Hour;mcg/h | A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter travels to a given object or space over a period of time equal to one hour.(NCI) | Microgram per Hour | ||
ug/inh | C85703 | mcg/inh | Micrograms per inhalation. | Microgram per Inhalation | ||
ug/min | C71211 | Micrograms per Minute;mcg/min | A unit of mass flow rate equivalent to the rate at which one millionth of a gram of matter travels to a given object or space over a period of time equal to one minute. Microgram per minute is also a dose administration rate unit equal to the rate at which one millionth of a gram of a product is administered per unit of time equal to one minute.(NCI) | Microgram per Minute | ||
ug/mL | C64572 | g/m3;Gram per Cubic Meter;mg/L;Microgram per Milliliter;Milligram per Liter;mcg/mL;ng/uL;ug/mL | A unit of mass concentration equal to the concentration of one gram of a substance per unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of substance which mass equal to one gram occupies the volume one cubic meter.(NCI) | Microgram per Milliliter | ||
ug/puff | C85704 | mcg/puff | Micrograms per puff. | Microgram per Puff | ||
ug/s | C85705 | mcg/sec;mcg/s;ug/sec;ug/s | Micrograms per second. | Microgram per Second | ||
uIU/mL | C67405 | Micro-International Unit per milliliter;mIU/L;mcIU/mL;uIU/mL | Microinternational units per milliliter. | Microinternational Unit per Milliliter | ||
uL | C48153 | mcL;Microliter;mm3 | A unit of volume accepted for use with the SI and equal to one millionth of a liter (10E-6 liter).(NCI) | Microliter | ||
umol/day | C67406 | Micromoles per Day;mcmol/day | A unit of amount of substance flow rate equivalent to the rate at which one millionth of a mole of substance travels to a given object or space over a period of time equal to 24 hours.(NCI) | Micromole per 24 Hours | ||
umol/h | C85707 | mcmol/h;umol/h | Micromoles per hour. | Micromole per Hour | ||
umol/min | C85708 | mcmol/min;umol/min | Micromoles per minute. | Micromole per Minute | ||
umol/mL | C64387 | Millimole per Liter;umol/mL;Micromole per Milliliter;mol/m3;Mole per Cubic Meter;mcmol/mL;mmol/L;nmol/uL | A unit of concentration (molarity unit) equal to one thousandth of a mole (10E-3 mole) of solute per one liter of solution.(NCI) | Millimole per Liter | ||
umol/s | C85709 | umol/sec;mcmol/s;mcmol/sec;umol/s | Micromoles per second. | Micromole per Second | ||
/h | C66966 | Per Hour | A rate of occurrences of something within a period of time equal to sixty minutes. | Per Hour | ||
day | C25301 | Day | The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours. This also refers to a specific day. (NCI) | Day | ||
g/mL/(mg/kg) | C105462 | Grams per milliliter (concentration), divided by milligram per kilogram (dose normalized by body weight). | Gram Per Milliliter Per Milligram Per Kilogram | |||
g/mL/(mg/kg/day) | C105463 | Grams per milliliter (concentration), divided by milligram per kilogram per day (daily dose normalized by body weight). | Gram Per Milliliter Per Milligram Per Kilogram Per Day | |||
h | C25529 | Hour;hr | A unit measure of time equal to 3,600 seconds or 60 minutes. It is approximately 1/24 of a median day. (NCI) | Hour | ||
h*g/mL/(mg/kg) | C105464 | Hours times grams per milliliter (area under the curve), divided by milligrams per kilogram (dose normalized by weight). | Hour Times Gram Per Milliliter Per Milligram Per Kilogram | |||
h*g/mL/(mg/kg/day) | C105465 | Hours times grams per milliliter (area under the curve), divided by milligrams per kilogram per day (daily dose normalized by weight). | Hour Times Gram Per Milliliter Per Milligram Per Kilogram Per Day | |||
h*mg/mL/(mg/kg) | C105468 | Hours times milligrams per milliliter (area under the curve), divided by milligrams per kilogram (dose normalized by weight). | Hour Times Milligram Per Milliliter Per Milligram Per Kilogram | |||
h*mg/mL/(mg/kg/day) | C105469 | Hours times milligrams per milliliter (area under the curve), divided by milligrams per kilogram per day (daily dose normalized by weight). | Hour Times Milligram Per Milliliter Per Milligram Per Kilogram Per Day | |||
h*ng/mL/(mg/kg/day) | C105470 | Hours times nanograms per milliliter (area under the curve), divided by milligrams per kilogram per day (daily dose normalized by weight). | Hour Times Nanogram Per Milliliter Per Milligram Per Kilogram Per Day | |||
h*pg/mL/(mg/kg) | C105471 | Hours times picograms per milliliter (area under the curve), divided by milligrams per kilogram (dose normalized by weight). | Hour Times Picogram Per Milliliter Per Milligram Per Kilogram | |||
h*pg/mL/(mg/kg/day) | C105472 | Hours times picograms per milliliter (area under the curve), divided by milligrams per kilogram per day (daily dose normalized by weight). | Hour Times Picogram Per Milliliter Per Milligram Per Kilogram Per Day | |||
h*ug/mL/(mg/kg) | C105466 | Hours times micrograms per milliliter (area under the curve), divided by milligrams per kilogram (dose normalized by weight). | Hour Times Microgram Per Milliliter Per Milligram Per Kilogram | |||
h*ug/mL/(mg/kg/day) | C105467 | Hours times micrograms per milliliter (area under the curve), divided by milligrams per kilogram per day (daily dose normalized by weight). | Hour Times Microgram Per Milliliter Per Milligram Per Kilogram Per Day | |||
mg/mL/(mg/kg) | C105475 | Milligrams per milliliter (concentration), divided by milligrams per kilogram (dose normalized by weight). | Milligram Per Milliliter Per Milligram Per Kilogram | |||
mg/mL/(mg/kg/day) | C105476 | Milligrams per milliliter (concentration), divided by milligram per kilogram per day (daily dose normalized by body weight). | Milligram Per Milliliter Per Milligram Per Kilogram Per Day | |||
min | C48154 | Minute Unit of Time | A unit measure of time equal to 60 seconds.(NCI) | Minute | ||
mmol | C48513 | Millimole | A unit of amount of substance equal to 0.001 mole.(NCI) | Millimole | ||
mol | C42539 | Mole | A unit defined as the amount of substance that contains as many elementary units as there are atoms in 0.012 kg of carbon-12. When the mole is used, the elementary entities must be specified and may be atoms, molecules, ions, electrons, other particles, or specified groups of such particles.(NCI) | Mole | ||
ng/mL/(mg/kg) | C105477 | Nanograms per milliliter (concentration), divided by milligrams per kilogram (dose normalized by weight). | Nanogram Per Milliliter Per Milligram Per Kilogram | |||
ng/mL/(mg/kg/day) | C105478 | Nanograms per milliliter (concentration), divided by milligram per kilogram per day (daily dose normalized by body weight). | Nanogram Per Milliliter Per Milligram Per Kilogram Per Day | |||
nmol | C48517 | Nanomole | A unit of amount of substance equal to one billionth (10E-9) of a mole.(NCI) | Nanomole | ||
pg/mL/(mg/kg) | C105479 | Picograms per milliliter (concentration), divided by milligrams per kilogram (dose normalized by weight). | Picogram Per Milliliter Per Milligram Per Kilogram | |||
pg/mL/(mg/kg/day) | C105480 | Picograms per milliliter (concentration), divided by milligram per kilogram per day (daily dose normalized by body weight). | Picogram Per Milliliter Per Milligram Per Kilogram Per Day | |||
ug/mL/(mg/kg) | C105473 | Micrograms per milliliter (concentration), divided by milligrams per kilogram (dose normalized by weight). | Microgram Per Milliliter Per Milligram Per Kilogram | |||
ug/mL/(mg/kg/day) | C105474 | Micrograms per milliliter (concentration), divided by milligram per kilogram per day (daily dose normalized by body weight). | Microgram Per Milliliter Per Milligram Per Kilogram Per Day | |||
umol | C48509 | Micromole;mcmol | A unit of amount of substance equal to one millionth (10E-6) of a mole.(NCI) | Micromole | ||
Back to top | ||||||
CL.C85491.MICROORG | Microorganism (MICROORG) | text Extensible: Yes | C85491 | Microorganism | Microorganisms, bacteria, fungi and other organisms. | CDISC SDTM Microorganism Terminology |
ABIOTROPHIA DEFECTIVA | C86078 | Any bacterial organism that can be assigned to the species Abiotrophia defectiva. | Abiotrophia defectiva | |||
ABIOTROPHIA | C86077 | Any bacteria that is not assigned to the species level but can be assigned to the Abiotrophia genus level. | Abiotrophia | |||
ACHROMOBACTER DENITRIFICANS | C86080 | ALCALIGENES DENITRIFICANS | Any bacterial organism that can be assigned to the species Achromobacter denitrificans. | Achromobacter denitrificans | ||
ACHROMOBACTER PIECHAUDII | C86081 | Any bacterial organism that can be assigned to the species Achromobacter piechaudii. | Achromobacter piechaudii | |||
ACHROMOBACTER | C86079 | Any bacteria that is not assigned to the species level but can be assigned to the Achromobacter genus level. | Achromobacter | |||
ACHROMOBACTER XYLOSOXIDANS | C86082 | ALCALIGENES XYLOSOXIDANS | Any bacterial organism that can be assigned to the species Achromobacter xylosoxidans. | Achromobacter xylosoxidans | ||
ACIDAMINOCOCCUS FERMENTANS | C86084 | Any bacterial organism that can be assigned to the species Acidaminococcus fermentans. | Acidaminococcus fermentans | |||
ACIDAMINOCOCCUS | C86083 | Any bacteria that is not assigned to the species level but can be assigned to the Acidaminococcus genus level. | Acidaminococcus | |||
ACIDOVORAX DELAFIELDII | C86086 | Any bacterial organism that can be assigned to the species Acidovorax delafieldii. | Acidovorax delafieldii | |||
ACIDOVORAX FACILIS | C86087 | Any bacterial organism that can be assigned to the species Acidovorax facilis. | Acidovorax facilis | |||
ACIDOVORAX | C86085 | Any bacteria that is not assigned to the species level but can be assigned to the Acidovorax genus level. | Acidovorax | |||
ACIDOVORAX TEMPERANS | C86088 | Any bacterial organism that can be assigned to the species Acidovorax temperans. | Acidovorax temperans | |||
ACINETOBACTER ANITRATUS | C86089 | ACINETOBACTER BAUMANNII;ACINETOBACTER CALCOACETICUS SUBSP. ANITRATUS | Any bacterial organism that can be assigned to the species Acinetobacter anitratus. | Acinetobacter anitratus | ||
ACINETOBACTER CALCOACETICUS | C86090 | Any bacterial organism that can be assigned to the species Acinetobacter calcoaceticus. | Acinetobacter calcoaceticus | |||
ACINETOBACTER CALCOACETICUS-BAUMANNII COMPLEX | C86091 | A non-taxonomic grouping of bacteria assigned to the Acinetobacter genus that include the A. calcoaceticus and A. baumannii species. | Acinetobacter calcoaceticus/baumannii Complex | |||
ACINETOBACTER HAEMOLYTICUS | C86092 | Any bacterial organism that can be assigned to the species Acinetobacter haemolyticus. | Acinetobacter haemolyticus | |||
ACINETOBACTER JOHNSONII | C86093 | Any bacterial organism that can be assigned to the species Acinetobacter johnsonii. | Acinetobacter johnsonii | |||
ACINETOBACTER JUNII | C86094 | Any bacterial organism that can be assigned to the species Acinetobacter junii. | Acinetobacter junii | |||
ACINETOBACTER LWOFFII | C86095 | ACINETOBACTER CALCOACETICUS SUBSP. LWOFFII | Any bacterial organism that can be assigned to the species Acinetobacter lwoffii. | Acinetobacter lwoffii | ||
ACINETOBACTER RADIORESISTENS | C86096 | Any bacterial organism that can be assigned to the species Acinetobacter radioresistens. | Acinetobacter radioresistens | |||
ACINETOBACTER | C76200 | Any bacteria that is not assigned to the species level but can be assigned to the Acinetobacter genus level. | Acinetobacter | |||
ACTINOBACILLUS ACTINOMYCETEMCOMITANS | C86098 | CDC GROUP HB-3 | Any bacterial organism that can be assigned to the species Actinobacillus actinomycetemcomitans. | Actinobacillus actinomycetemcomitans | ||
ACTINOBACILLUS EQUULI | C86099 | Any bacterial organism that can be assigned to the species Actinobacillus equuli. | Actinobacillus equuli | |||
ACTINOBACILLUS LIGNIERESII | C86100 | Any bacterial organism that can be assigned to the species Actinobacillus ligniersii. | Actinobacillus lignieresii | |||
ACTINOBACILLUS PLEUROPNEUMONIAE | C86101 | HAEMOPHILUS PLEUROPNEUMONIAE | Any bacterial organism that can be assigned to the species Actinobacillus pleuropneumoniae. | Actinobacillus pleuropneumoniae | ||
ACTINOBACILLUS | C86097 | Any bacteria that is not assigned to the species level but can be assigned to the Actinobacillus genus level. | Actinobacillus | |||
ACTINOBACILLUS SUIS | C86102 | Any bacterial organism that can be assigned to the species Actinobacillus suis. | Actinobacillus suis | |||
ACTINOBACILLUS UREAE | C86103 | PASTEURELLA UREAE | Any bacterial organism that can be assigned to the species Actinobacillus ureae. | Actinobacillus ureae | ||
ACTINOMADURA MADURAE | C86105 | Any bacterial organism that can be assigned to the species Actinomadura madurae. | Actinomadura madurae | |||
ACTINOMADURA PELLETIERI | C86106 | Any bacterial organism that can be assigned to the species Actinomadura pelletieri. | Actinomadura pelletieri | |||
ACTINOMADURA | C86104 | Any bacteria that is not assigned to the species level but can be assigned to the Actinomadura genus level. | Actinomadura | |||
ACTINOMYCES BOVIS | C86107 | PROACTINOMYCES BOVIS;SPHAEROTILUS BOVIS;CLADOTHRIX BOVIS;STREPTOTHRIX BOVIS;NOCARDIA BOVIS;ACTINOCLADOTHRIX BOVIS;OOSPORA BOVIS;SARCOMYCES BOVIS;DISCOMYCES BOVIS | Any bacterial organism that can be assigned to the species Actinomyces bovis. | Actinomyces bovis | ||
ACTINOMYCES ISRAELII | C86108 | Any bacterial organism that can be assigned to the species Actinomyces israelii. | Actinomyces israelii | |||
ACTINOMYCES MEYERII | C86109 | Any bacterial organism that can be assigned to the species Actinomyces meyerii. | Actinomyces meyerii | |||
ACTINOMYCES NAESLUNDII | C86110 | Any bacterial organism that can be assigned to the species Actinomyces naseslundii. | Actinomyces naeslundii | |||
ACTINOMYCES NEUII | C86111 | Any bacterial organism that can be assigned to the species Actinomyces neuii. | Actinomyces neuii | |||
ACTINOMYCES ODONTOLYTICUS | C86112 | Any bacterial organism that can be assigned to the species Actinomyces odontolyticus. | Actinomyces odontolyticus | |||
ACTINOMYCES RADINGAE | C86113 | Any bacterial organism that can be assigned to the species Actinomyces radingae. | Actinomyces radingae | |||
ACTINOMYCES | C76201 | Any bacteria that is not assigned to the species level but can be assigned to the Actinomyces genus level. | Actinomyces | |||
ACTINOMYCES TURICENSIS | C86114 | Any bacterial organism that can be assigned to the species Actinomyces turicensis. | Actinomyces turicensis | |||
ACTINOMYCES VISCOSUS | C86115 | Any bacterial organism that can be assigned to the species Actinomyces viscosus. | Actinomyces viscosus | |||
AEROBIC GRAM-NEGATIVE BACILLUS | C86116 | AEROBIC GRAM-NEGATIVE ROD | Any rod-shaped bacteria with an oxygen-based metabolism and has a cell wall that contains low levels of peptidoglycan and stains pink with the Gram staining technique. | Aerobic Gram Negative Bacillus | ||
AEROBIC GRAM-NEGATIVE COCCUS | C86117 | Any spherical-shaped bacteria with an oxygen-based metabolism and a cell wall that contains low levels of peptidoglycan and stains pink with the Gram staining technique. | Aerobic Gram Negative Coccus | |||
AEROBIC GRAM-POSITIVE BACILLUS | C86118 | AEROBIC GRAM-POSITIVE ROD | Any rod-shaped bacteria with an oxygen-based metabolism and has a peptidoglycan-rich cell wall that stains dark purple with the Gram staining technique. | Aerobic Gram Positive Bacillus | ||
AEROBIC GRAM-POSITIVE COCCUS | C86119 | Any spherical-shaped bacteria with an oxygen-based metabolism and a peptidoglycan-rich cell wall that stains dark purple with the Gram staining technique. | Aerobic Gram Positive Coccus | |||
AEROBIC STREPTOCOCCUS | C86120 | Any bacteria assigned to the genus Streptococcus that requires oxygen to grow or respirate. | Aerobic Streptococcus | |||
AEROCOCCUS | C86121 | GAFFKYA SPECIES | Any bacteria that is not assigned to the species level but can be assigned to the Aerococcus genus level. | Aerococcus | ||
AEROCOCCUS URINAE | C86122 | Any bacterial organism that can be assigned to the species Aerococcus urinae. | Aerococcus urinae | |||
AEROCOCCUS VIRIDANS | C86123 | Any bacterial organism that can be assigned to the species Aerococcus viridans. | Aerococcus viridans | |||
AEROMONAS HYDROPHILA | C86125 | AEROMONAS HYDROPHILA GROUP | Any bacterial organism that can be assigned to the species Aeromonas hydrophila. | Aeromonas hydrophila | ||
AEROMONAS JANDAEI | C86126 | Any bacterial organism that can be assigned to the species Aeromonas jandaei. | Aeromonas jandaei | |||
AEROMONAS PUNCTATA | C86127 | AEROMONAS CAVIAE | Any bacterial organism that can be assigned to the species Aeromonas punctata. | Aeromonas punctata | ||
AEROMONAS SALMONICIDA | C86128 | Any bacterial organism that can be assigned to the species Aeromonas salmonicida. | Aeromonas salmonicida | |||
AEROMONAS SCHUBERTII | C86129 | Any bacterial organism that can be assigned to the species Aeromonas schubertii. | Aeromonas schubertii | |||
AEROMONAS SOBRIA | C86130 | Any bacterial organism that can be assigned to the species Aeromonas sobria. | Aeromonas sobria | |||
AEROMONAS | C86124 | Any bacteria that is not assigned to the species level but can be assigned to the Aeromonas genus level. | Aeromonas | |||
AEROMONAS VERONII | C86131 | Any bacterial organism that can be assigned to the species Aeromonas veronii. | Aeromonas veronii | |||
AGGREGATIBACTER ACTINOMYCETEMCOMITANS | C86133 | HAEMOPHILUS ACTINOMYCETEMCOMITANS | Any bacterial organism that can be assigned to the species Aggregatibacter actinomycetemcomitans. | Aggregatibacter actinomycetemcomitans | ||
AGGREGATIBACTER APHROPHILUS | C86134 | CDC GROUP HB-2;HAEMOPHILUS PARAPHROPHILUS;BETA-LACTAMASE NEGATIVE HAEMOPHILUS PARAPHROPHILUS;HAEMOPHILUS APHROPHILUS | Any bacterial organism that can be assigned to the species Aggregatibacter aphrophilus. | Aggregatibacter aphrophilus | ||
AGGREGATIBACTER SEGNIS | C86135 | HAEMOPHILUS SEGNIS | Any bacterial organism that can be assigned to the species Aggregatibacter segnis. | Aggregatibacter segnis | ||
AGGREGATIBACTER | C86132 | Any bacteria that is not assigned to the species level but can be assigned to the Aggregatibacter genus level. | Aggregatibacter | |||
AGROBACTERIUM RADIOBACTER | C86137 | Any bacterial organism that can be assigned to the species Agrobacterium radiobacter. | Agrobacterium radiobacter | |||
AGROBACTERIUM | C86011 | Any bacteria that is not assigned to the species level but can be assigned to the Agrobacterium genus level. | Agrobacterium | |||
AGROBACTERIUM TUMEFACIENS | C86138 | CDC GROUP VD-3;RHIZOBIUM RADIOBACTER | Any bacterial organism that can be assigned to the species Agrobacterium tumefaciens. | Agrobacterium tumefaciens | ||
ALCALIGENES FAECALIS | C86140 | ALCALIGENES ODORANS | Any bacterial organism that can be assigned to the species Alcaligenes faecalis. | Alcaligenes faecalis | ||
ALCALIGENES | C86012 | Any bacteria that is not assigned to the species level but can be assigned to the Alcaligenes genus level. | Alcaligenes | |||
ALISTIPES PUTREDINIS | C86871 | BACTEROIDES PUTREDINIS | Any bacterial organism that can be assigned to the species Alistipes putredinis. | Alistipes putredinis | ||
ANAEROBIC GRAM-NEGATIVE BACILLUS | C86142 | ANAEROBIC GRAM-NEGATIVE ROD | Any rod-shaped bacteria that does not require oxygen to grow or respirate and has a cell wall that contains low levels of peptidoglycan and stains pink with the Gram staining technique. | Anaerobic Gram Negative Bacillus | ||
ANAEROBIC GRAM-NEGATIVE COCCUS | C86143 | Any spherical-shaped bacteria that does not require oxygen to grow or respirate and has a cell wall that contains low levels of peptidoglycan and stains pink with the Gram staining technique. | Anaerobic Gram Negative Coccus | |||
ANAEROBIC GRAM-POSITIVE BACILLUS | C86144 | ANAEROBIC GRAM-POSITIVE ROD | Any rod-shaped bacteria that does not require oxygen to grow or respirate and has a peptidoglycan-rich cell wall that stains dark purple with the Gram staining technique. | Anaerobic Gram Positive Bacillus | ||
ANAEROBIC GRAM-POSITIVE COCCUS | C86145 | Any spherical-shaped bacteria that does not require oxygen to grow or respirate and has a peptidoglycan-rich cell wall that stains dark purple with the Gram staining technique. | Anaerobic Gram Positive Coccus | |||
ANAEROBIC STREPTOCOCCUS | C86146 | Any bacteria assigned to the genus Streptococcus that does not require oxygen to grow or respirate. | Anaerobic Streptococcus | |||
ANAEROCOCCUS HYDROGENALIS | C86874 | PEPTOSTREPTOCOCCUS HYDROGENALIS | Any bacterial organism that can be assigned to the species Anaerococcus hydrogenalis. | Anaerococcus hydrogenalis | ||
ANAEROCOCCUS PREVOTII | C86875 | Any bacterial organism that can be assigned to the species Anaerococcus prevotii. | Anaerococcus prevotii | |||
ANAEROCOCCUS | C86872 | Any bacteria that is not assigned to the species level but can be assigned to the Anaerococcus genus level. | Anaerococcus | |||
ANAEROCOCCUS TETRADIUS | C86876 | GAFFKYA ANAEROBIA;PEPTOSTREPTOTOCCUS TETRADIUS | Any bacterial organism that can be assigned to the species Anaerococcus tetradius. | Anaerococcus tetradius | ||
ANAEROCOCCUS VAGINALIS | C86877 | Any bacterial organism that can be assigned to the species Anaerococcus vaginalis. | Anaerococcus vaginalis | |||
ARCANOBACTERIUM BERNARDIAE | C86148 | Any bacterial organism that can be assigned to the species Arcanobacterium bernardiae. | Arcanobacterium bernardiae | |||
ARCANOBACTERIUM HAEMOLYTICUM | C86149 | CORYNEBACTERIUM HAEMOLYTICUM;CORYNEBACTERIUM HAEMOLYTICUS | Any bacterial organism that can be assigned to the species Arcanobacterium haemolyticum. | Arcanobacterium haemolyticum | ||
ARCANOBACTERIUM PYOGENES | C86150 | ACTINOMYCES PYOGENES;CORYNEBACTERIUM PYOGENES | Any bacterial organism that can be assigned to the species Arcanobacterium pyogenes. | Arcanobacterium pyogenes | ||
ARCANOBACTERIUM | C86147 | Any bacteria that is not assigned to the species level but can be assigned to the Arcanobacterium genus level. | Arcanobacterium | |||
ARCOBACTER BUTZLERI | C86153 | CAMPYLOBACTER BUTZLERI | Any bacterial organism that can be assigned to the species Arcobacter butzleri. | Arcobacter butzleri | ||
ARCOBACTER CRYAEROPHILUS | C86154 | CAMPYLOBACTER CRYAEROPHILUS | Any bacterial organism that can be assigned to the species Arcobacter cryaerophilus. | Arcobacter cryaerophilus | ||
ARCOBACTER | C86152 | Any bacteria that is not assigned to the species level but can be assigned to the Arcobacter genus level. | Arcobacter | |||
ARTHROBACTER | C86155 | Any bacteria that is not assigned to the species level but can be assigned to the Arthrobacter genus level. | Arthrobacter | |||
ATOPOBIUM MINUTUM | C86156 | LACTOBACILLUS MINUTIS;LACTOBACILLUS MINUTUS | Any bacterial organism that can be assigned to the species Atopobium minutum. | Atopobium minutum | ||
ATOPOBIUM PARVULUM | C86157 | STREPTOCOCCUS PARVULUS | Any bacterial organism that can be assigned to the species Atopobium parvulum. | Atopobium parvulum | ||
AVIBACTERIUM PARAGALLINARUM | C86158 | HAEMOPHILUS PARAGALLINARUM | Any bacterial organism that can be assigned to the species Avibacterium paragallinarum. | Avibacterium paragallinarum | ||
BACILLUS ALVEI | C86159 | Any bacterial organism that can be assigned to the species Bacillus alvei. | Bacillus alvei | |||
BACILLUS ANTHRACIS | C86160 | Any bacterial organism that can be assigned to the species Bacillus anthracis. | Bacillus anthracis | |||
BACILLUS CEREUS | C86161 | Any bacterial organism that can be assigned to the species Bacillus cereus. | Bacillus cereus | |||
BACILLUS LENTUS | C86162 | Any bacterial organism that can be assigned to the species Bacillus lentus. | Bacillus lentus | |||
BACILLUS LICHENIFORMIS | C86163 | Any bacterial organism that can be assigned to the species Bacillus licheniformis. | Bacillus licheniformis | |||
BACILLUS MEGATERIUM | C86164 | Any bacterial organism that can be assigned to the species Bacillus megaterium. | Bacillus megaterium | |||
BACILLUS MYCOIDES | C86165 | Any bacterial organism that can be assigned to the species Bacillus mycoides. | Bacillus mycoides | |||
BACILLUS POLYMYXA | C86166 | Any bacterial organism that can be assigned to the species Bacillus polymyxa. | Bacillus polymyxa | |||
BACILLUS | C76202 | Any bacteria that is not assigned to the species level but can be assigned to the Bacillus genus level. | Bacillus | |||
BACILLUS SUBTILIS | C86167 | Any bacterial organism that can be assigned to the species Bacillus subtilis. | Bacillus subtilis | |||
BACTERIA | C14187 | BACTERIUM;EUBACTERIA | Any organism assigned to the kingdom Bacteria. | Bacteria | ||
BACTEROIDES CACCAE | C86168 | BACTEROIDES FRAGILIS GROUP 3452A | Any bacterial organism that can be assigned to the species Bacteroides caccae. | Bacteroides caccae | ||
BACTEROIDES CAPILLOSUS | C86169 | Any bacterial organism that can be assigned to the species Bacteroides capillosus. | Bacteroides capillosus | |||
BACTEROIDES CELLULOSOLVENS | C86170 | Any bacterial organism that can be assigned to the species Bacteroides cellulosolvens. | Bacteroides cellulosolvens | |||
BACTEROIDES EGGERTHII | C86171 | Any bacterial organism that can be assigned to the species Bacteroides eggerthii. | Bacteroides eggerthii | |||
BACTEROIDES FRAGILIS | C86172 | Any bacterial organism that can be assigned to the species Bacteroides fragilis. | Bacteroides fragilis | |||
BACTEROIDES FRAGILIS GROUP | C86173 | A bacteria that belongs to the Fragilis group of the genus Bacteroides. | Bacteroides fragilis Group | |||
BACTEROIDES NORDII | C86174 | Any bacterial organism that can be assigned to the species Bacteroides nordii. | Bacteroides nordii | |||
BACTEROIDES OVATUS | C86175 | Any bacterial organism that can be assigned to the species Bacteroides ovatus. | Bacteroides ovatus | |||
BACTEROIDES | C76204 | Any bacteria that is not assigned to the species level but can be assigned to the Bacteroides genus level. | Bacteroides | |||
BACTEROIDES SPLANCHNICUS | C86176 | Any bacterial organism that can be assigned to the species Bacteroides splanchnicus. | Bacteroides splanchnicus | |||
BACTEROIDES STERCORIS | C86177 | BACTEROIDES FRAGILIS SUBSP. A | Any bacterial organism that can be assigned to the species Bacteroides stercoris. | Bacteroides stercoris | ||
BACTEROIDES TECTUS | C86178 | BACTEROIDES TECTUM | Any bacterial organism that can be assigned to the species Bacteroides tectus. | Bacteroides tectus | ||
BACTEROIDES THETAIOTAOMICRON | C86179 | Any bacterial organism that can be assigned to the species Bacteroides thetaiotamicron. | Bacteroides thetaiotaomicron | |||
BACTEROIDES UNIFORMIS | C86180 | Any bacterial organism that can be assigned to the species Bacteroides uniformis. | Bacteroides uniformis | |||
BACTEROIDES UREOLYTICUS | C86181 | BACTEROIDES CORRODENS | Any bacterial organism that can be assigned to the species Bacteroides ureolyticus. | Bacteroides ureolyticus | ||
BACTEROIDES VULGATUS | C86182 | Any bacterial organism that can be assigned to the species Bacteroides vulgatus. | Bacteroides vulgatus | |||
BARTONELLA ELIZABETHAE | C86185 | ROCHALIMAEA ELIZABETHAE | Any bacterial organism that can be assigned to the species Bartonella elizabethae. | Bartonella elizabethae | ||
BARTONELLA HENSELAE | C86186 | ROCHALIMAEA HENSELAE | Any bacterial organism that can be assigned to the species Bartonella henselae. | Bartonella henselae | ||
BARTONELLA QUINTANA | C86187 | ROCHALIMAEA QUINTANA | Any bacterial organism that can be assigned to the species Bartonella quintana. | Bartonella quintana | ||
BARTONELLA | C86184 | Any bacteria that is not assigned to the species level but can be assigned to the Bartonella genus level. | Bartonella | |||
BERGEYELLA | C86188 | Any bacteria that is not assigned to the species level but can be assigned to the Bergeyella genus level. | Bergeyella | |||
BERGEYELLA ZOOHELCUM | C86189 | WEEKSELLA ZOOHELCUM | Any bacterial organism that can be assigned to the species Bergeyella zoohelcum. | Bergeyella zoohelcum | ||
BETA STREPTOCOCCUS, GROUP C | C86191 | A non-taxonomic grouping of beta-hemolytic species within the Streptococcus genus that are assigned to the C group. | Beta Streptococcus Group C | |||
BETA STREPTOCOCCUS, GROUP F | C86192 | A non-taxonomic grouping of beta-hemolytic species within the Streptococcus genus that are assigned to the F group. | Beta Streptococcus Group F | |||
BETA STREPTOCOCCUS, GROUP G | C86193 | A non-taxonomic grouping of beta-hemolytic species within the Streptococcus genus that are assigned to the G group. | Beta Streptococcus Group G | |||
BIFIDOBACTERIUM ADOLESCENTIS | C86195 | Any bacterial organism that can be assigned to the species Bifidobacterium adolescentis. | Bifidobacterium adolescentis | |||
BIFIDOBACTERIUM ANGULATUM | C86196 | Any bacterial organism that can be assigned to the species Bifidobacterium angulatum. | Bifidobacterium angulatum | |||
BIFIDOBACTERIUM BIFIDUM | C86197 | Any bacterial organism that can be assigned to the species Bifidobacterium bifidum. | Bifidobacterium bifidum | |||
BIFIDOBACTERIUM DENTIUM | C86198 | BIFIDOBACTERIUM APPENDICITIS | Any bacterial organism that can be assigned to the species Bifidobacterium dentium. | Bifidobacterium dentium | ||
BIFIDOBACTERIUM LONGUM | C86199 | Any bacterial organism that can be assigned to the species Bifidobacterium longum. | Bifidobacterium longum | |||
BIFIDOBACTERIUM | C86194 | Any bacteria that is not assigned to the species level but can be assigned to the Bifidobacterium genus level. | Bifidobacterium | |||
BILOPHILA | C86200 | Any bacteria that is not assigned to the species level but can be assigned to the Bilophila genus level. | Bilophila | |||
BILOPHILA WADSWORTHIA | C86201 | Any bacterial organism that can be assigned to the species Bilophila wadsworthia. | Bilophila wadsworthia | |||
BORDETELLA AVIUM | C86203 | Any bacterial organism that can be assigned to the species Bordetella avium. | Bordetella avium | |||
BORDETELLA BRONCHISEPTICA | C86204 | BORDETELLA BRONCHICANIS | Any bacterial organism that can be assigned to the species Bordetella bronchiseptica. | Bordetella bronchiseptica | ||
BORDETELLA PARAPERTUSSIS | C86205 | Any bacterial organism that can be assigned to the species Bordetella parapertussis. | Bordetella parapertussis | |||
BORDETELLA PERTUSSIS | C76205 | Any bacterial organism that can be assigned to the species Bordetella pertussis. | Bordetella pertussis | |||
BORDETELLA | C86202 | Any bacteria that is not assigned to the species level but can be assigned to the Bordetella genus level. | Bordetella | |||
BORRELIA BURGDORFERI | C76208 | Any bacterial organism that can be assigned to the species Borrelia burgdorferi. | Borrelia burgdorferi | |||
BORRELIA | C86206 | Any bacteria that is not assigned to the species level but can be assigned to the Borrelia genus level. | Borrelia | |||
BREVIBACILLUS LATEROSPORUS | C86208 | Any bacterial organism that can be assigned to the species Brevibacillus laterosporus. | Brevibacillus laterosporus | |||
BREVIBACILLUS | C86207 | Any bacteria that is not assigned to the species level but can be assigned to the Brevibacillus genus level. | Brevibacillus | |||
BREVIBACTERIUM CASEI | C86210 | Any bacterial organism that can be assigned to the species Brevibacterium casei. | Brevibacterium casei | |||
BREVIBACTERIUM EPIDERMIDIS | C86211 | Any bacterial organism that can be assigned to the species Brevibacterium epidermidis. | Brevibacterium epidermidis | |||
BREVIBACTERIUM | C86209 | Any bacteria that is not assigned to the species level but can be assigned to the Brevibacterium genus level. | Brevibacterium | |||
BREVUNDIMONAS DIMINUTA | C86213 | PSEUDOMONAS DIMINUTA | Any bacterial organism that can be assigned to the species Brevundimonas diminuta. | Brevundimonas diminuta | ||
BREVUNDIMONAS | C86212 | Any bacteria that is not assigned to the species level but can be assigned to the Brevundimonas genus level. | Brevundimonas | |||
BREVUNDIMONAS VESICULARIS | C86214 | PSEUDOMONAS VESICULARIS | Any bacterial organism that can be assigned to the species Brevundimonas vesicularis. | Brevundimonas vesicularis | ||
BRUCELLA ABORTUS | C86216 | Any bacterial organism that can be assigned to the species Brucella abortus. | Brucella abortus | |||
BRUCELLA CANIS | C86217 | Any bacterial organism that can be assigned to the species Brucella canis. | Brucella canis | |||
BRUCELLA MELITENSIS | C86218 | Any bacterial organism that can be assigned to the species Brucella melitensis. | Brucella melitensis | |||
BRUCELLA | C86215 | Any bacteria that is not assigned to the species level but can be assigned to the Brucella genus level. | Brucella | |||
BRUCELLA SUIS | C86219 | Any bacterial organism that can be assigned to the species Brucella suis. | Brucella suis | |||
BUDVICIA AQUATICA | C86221 | Any bacterial organism that can be assigned to the species Budvicia aquatica. | Budvicia aquatica | |||
BUDVICIA | C86220 | Any bacteria that is not assigned to the species level but can be assigned to the Budvicia genus level. | Budvicia | |||
BURKHOLDERIA CENOCEPACIA | C86223 | Any bacterial organism that can be assigned to the species Burkholderia cenocepacia. | Burkholderia cenocepacia | |||
BURKHOLDERIA CEPACIA | C76376 | PSEUDOMONAS CEPACIA;CDC GROUP EO-1 | Any bacterial organism that can be assigned to the species Burkholderia cepacia. | Burkholderia cepacia | ||
BURKHOLDERIA CEPACIA COMPLEX | C86224 | A non-taxonomic grouping of bacteria assigned to and including at least nine related species from the Burkholderia genus. | Burkholderia cepacia Complex | |||
BURKHOLDERIA GLADIOLI | C86225 | PSEUDOMONAS GLADIOLI | Any bacterial organism that can be assigned to the species Burkholderia gladioli. | Burkholderia gladioli | ||
BURKHOLDERIA MALLEI | C86226 | ACTINOBACILLUS MALLEI | Any bacterial organism that can be assigned to the species Burkholderia mallei. | Burkholderia mallei | ||
BURKHOLDERIA PSEUDOMALLEI | C86227 | PSEUDOMONAS PSEUDOMALLEI;BURKHOLDERIA PSEUDOMALLE | Any bacterial organism that can be assigned to the species Burkholderia pseudomallei. | Burkholderia pseudomallei | ||
BURKHOLDERIA | C86222 | Any bacteria that is not assigned to the species level but can be assigned to the Burkholderia genus level. | Burkholderia | |||
BUTTIAUXELLA AGRESTIS | C86229 | Any bacterial organism that can be assigned to the species Buttiauxella agrestis. | Buttiauxella agrestis | |||
BUTTIAUXELLA | C86228 | Any bacteria that is not assigned to the species level but can be assigned to the Buttiauxella genus level. | Buttiauxella | |||
CAMPYLOBACTER COLI | C86230 | Any bacterial organism that can be assigned to the species Campylobacter coli. | Campylobacter coli | |||
CAMPYLOBACTER CONCISUS | C86231 | CDC GROUP EF-22 | Any bacterial organism that can be assigned to the species Campylobacter concisus. | Campylobacter concisus | ||
CAMPYLOBACTER CURVUS | C86232 | WOLINELLA CURVA | Any bacterial organism that can be assigned to the species Campylobacter curvus. | Campylobacter curvus | ||
CAMPYLOBACTER FETUS | C86233 | VIBRIO FETUS | Any bacterial organism that can be assigned to the species Campylobacter fetus. | Campylobacter fetus | ||
CAMPYLOBACTER GRACILIS | C86234 | BACTEROIDES GRACILIS | Any bacterial organism that can be assigned to the species Campylobacter gracilis. | Campylobacter gracilis | ||
CAMPYLOBACTER JEJUNI | C86235 | Any bacterial organism that can be assigned to the species Campylobacter jejuni. | Campylobacter jejuni | |||
CAMPYLOBACTER LARI | C86236 | CAMPYLOBACTER LARIDIS | Any bacterial organism that can be assigned to the species Campylobacter lari. | Campylobacter lari | ||
CAMPYLOBACTER RECTUS | C86237 | WOLINELLA RECTA | Any bacterial organism that can be assigned to the species Campylobacter rectus. | Campylobacter rectus | ||
CAMPYLOBACTER | C76211 | Any bacteria that is not assigned to the species level but can be assigned to the Campylobacter genus level. | Campylobacter | |||
CAMPYLOBACTER UPSALIENSIS | C86238 | Any bacterial organism that can be assigned to the species Campylobacter upsaliensis. | Campylobacter upsaliensis | |||
CAPNOCYTOPHAGA CANIMORSUS | C86239 | CDC GROUP DF-2 | Any bacterial organism that can be assigned to the species Capnocytophaga canimorsus. | Capnocytophaga canimorsus | ||
CAPNOCYTOPHAGA GINGIVALIS | C86240 | Any bacterial organism that can be assigned to the species Capnocytophaga gingivalis. | Capnocytophaga gingivalis | |||
CAPNOCYTOPHAGA OCHRACEA | C86241 | Any bacterial organism that can be assigned to the species Capnocytophaga ochracea. | Capnocytophaga ochracea | |||
CAPNOCYTOPHAGA | C76269 | Any bacteria that is not assigned to the species level but can be assigned to the Capnocytophaga genus level. | Capnocytophaga | |||
CAPNOCYTOPHAGA SPUTIGENA | C86242 | Any bacterial organism that can be assigned to the species Capnocytophaga sputigena. | Capnocytophaga sputigena | |||
CARDIOBACTERIUM HOMINIS | C86244 | CDC GROUP IID | Any bacterial organism that can be assigned to the species Cardiobacterium hominis. | Cardiobacterium hominis | ||
CARDIOBACTERIUM | C86243 | Any bacteria that is not assigned to the species level but can be assigned to the Cardiobacterium genus level. | Cardiobacterium | |||
CEDECEA DAVISAE | C86246 | CDC ENTERIC GROUP 15 | Any bacterial organism that can be assigned to the species Cedecea davisae. | Cedecea davisae | ||
CEDECEA LAPAGEI | C86247 | Any bacterial organism that can be assigned to the species Cedecea lapagei. | Cedecea lapagei | |||
CEDECEA NETERI | C86248 | CEDECEA SPECIES 4 | Any bacterial organism that can be assigned to the species Cedecea neteri. | Cedecea neteri | ||
CEDECEA | C86245 | Any bacteria that is not assigned to the species level but can be assigned to the Cedecea genus level. | Cedecea | |||
CELLULOMONAS HOMINIS | C86250 | Any bacterial organism that can be assigned to the species Cellulomonas hominis. | Cellulomonas hominis | |||
CELLULOMONAS | C86249 | Any bacteria that is not assigned to the species level but can be assigned to the Cellulomonas genus level. | Cellulomonas | |||
CELLULOSIMICROBIUM CELLULANS | C86252 | OERSKOVIA XANTHINEOLYTICA;ARTHROBACTER LUTEUS;CELLULOMONAS CELLULANS;NOCARDIA CELLULANS | Any bacterial organism that can be assigned to the species Cellulosimicrobium cellulans. | Cellulosimicrobium cellulans | ||
CELLULOSIMICROBIUM | C86251 | Any bacteria that is not assigned to the species level but can be assigned to the Cellulosimicrobium genus level. | Cellulosimicrobium | |||
CHLAMYDIA | C76271 | Any bacteria that is not assigned to the species level but can be assigned to the Chlamydia genus level. | Chlamydia | |||
CHLAMYDIA TRACHOMATIS | C86253 | Any bacterial organism that can be assigned to the species Chlamydia trachomatis. | Chlamydia trachomatis | |||
CHLAMYDOPHILA PNEUMONIAE | C76272 | CHLAMYDIA PNEUMONIAE | Any bacterial organism that can be assigned to the species Chlamydophila pneumoniae. | Chlamydophila pneumoniae | ||
CHLAMYDOPHILA PSITTACI | C86255 | CHLAMYDIA PSITTACI | Any bacterial organism that can be assigned to the species Chlamydophila psittaci. | Chlamydophila psittaci | ||
CHLAMYDOPHILA | C86254 | Any bacteria that is not assigned to the species level but can be assigned to the Chlamydophila genus level. | Chlamydophila | |||
CHROMOBACTERIUM | C86256 | Any bacteria that is not assigned to the species level but can be assigned to the Chromobacterium genus level. | Chromobacterium | |||
CHROMOBACTERIUM VIOLACEUM | C86257 | Any bacterial organism that can be assigned to the species Chromobacterium violaceum. | Chromobacterium violaceum | |||
CHRYSEOBACTERIUM GLEUM | C86259 | FLAVOBACTERIUM GLEUM | Any bacterial organism that can be assigned to the species Chryseobacterium gleum. | Chryseobacterium gleum | ||
CHRYSEOBACTERIUM INDOLOGENES | C86260 | FLAVOBACTERIUM INDOLOGENES | Any bacterial organism that can be assigned to the species Chryseobacterium indologenes. | Chryseobacterium indologenes | ||
CHRYSEOBACTERIUM | C86258 | Any bacteria that is not assigned to the species level but can be assigned to the Chryseobacterium genus level. | Chryseobacterium | |||
CHRYSEOMONAS | C86261 | Any bacteria that is not assigned to the species level but can be assigned to the Chryseomonas genus level. | Chryseomonas | |||
CITROBACTER AMALONATICUS | C86262 | LEVINEA AMALONATICA | Any bacterial organism that can be assigned to the species Citrobacter amalonaticus. | Citrobacter amalonaticus | ||
CITROBACTER BRAAKII | C86263 | Any bacterial organism that can be assigned to the species Citrobacter braakii. | Citrobacter braakii | |||
CITROBACTER FARMERI | C86264 | CITROBACTER AMALONATICUS BIOGROUP 1 | Any bacterial organism that can be assigned to the species Citrobacter farmeri. | Citrobacter farmeri | ||
CITROBACTER FREUNDII | C86265 | COLOBACTRUM FREUNDII | Any bacterial organism that can be assigned to the species Citrobacter freundii. | Citrobacter freundii | ||
CITROBACTER FREUNDII COMPLEX | C86266 | A non-taxonomic grouping of bacteria assigned to and including eight related species from the Citrobacter genus. | Citrobacter freundii Complex | |||
CITROBACTER KOSERI | C86267 | CITROBACTER DIVERSUS | Any bacterial organism that can be assigned to the species Citrobacter koseri. | Citrobacter koseri | ||
CITROBACTER | C76273 | Any bacteria that is not assigned to the species level but can be assigned to the Citrobacter genus level. | Citrobacter | |||
CITROBACTER YOUNGAE | C86268 | Any bacterial organism that can be assigned to the species Citrobacter youngae. | Citrobacter youngae | |||
CLOSTRIDIUM ACETOBUTYLICUM | C86269 | Any bacterial organism that can be assigned to the species Clostridium acetobutylicum. | Clostridium acetobutylicum | |||
CLOSTRIDIUM BARATII | C86270 | CLOSTRIDIUM BARATI | Any bacterial organism that can be assigned to the species Clostridium baratii. | Clostridium baratii | ||
CLOSTRIDIUM BEIJERINCKII | C86271 | Any bacterial organism that can be assigned to the species Clostridium beijerinckii. | Clostridium beijerinckii | |||
CLOSTRIDIUM BIFERMENTANS | C86272 | Any bacterial organism that can be assigned to the species Clostridium bifermentans. | Clostridium bifermentans | |||
CLOSTRIDIUM BUTYRICUM | C86273 | CLOSTRIDIUM PSEUDOTETANICUM | Any bacterial organism that can be assigned to the species Clostridium butyricum. | Clostridium butyricum | ||
CLOSTRIDIUM CADAVERIS | C86274 | Any bacterial organism that can be assigned to the species Clostridium cadaveris. | Clostridium cadaveris | |||
CLOSTRIDIUM CELATUM | C86275 | Any bacterial organism that can be assigned to the species Clostridium celatum. | Clostridium celatum | |||
CLOSTRIDIUM CLOSTRIDIOFORME | C86276 | CLOSTRIDIUM CLOSTRIDIIFORME | Any bacterial organism that can be assigned to the species Clostridium clostridioforme. | Clostridium clostridioforme | ||
CLOSTRIDIUM COCHLEARIUM | C86277 | Any bacterial organism that can be assigned to the species Clostridium cochlearium. | Clostridium cochlearium | |||
CLOSTRIDIUM COCLEATUM | C86278 | Any bacterial organism that can be assigned to the species Clostridium cocleatum. | Clostridium cocleatum | |||
CLOSTRIDIUM DIFFICILE | C76276 | CLOSTRIDIUM DIFFICILIS | Any bacterial organism that can be assigned to the species Clostridium difficile. | Clostridium difficile | ||
CLOSTRIDIUM FALLAX | C86279 | CLOSTRIDIUM PSEUDOFALLAX | Any bacterial organism that can be assigned to the species Clostridium fallax. | Clostridium fallax | ||
CLOSTRIDIUM GLYCOLICUM | C86280 | Any bacterial organism that can be assigned to the species Clostridium glycolicum. | Clostridium glycolicum | |||
CLOSTRIDIUM HAEMOLYTICUM | C86281 | Any bacterial organism that can be assigned to the species Clostridium haemolyticum. | Clostridium haemolyticum | |||
CLOSTRIDIUM HISTOLYTICUM | C86282 | Any bacterial organism that can be assigned to the species Clostridium histolyticum. | Clostridium histolyticum | |||
CLOSTRIDIUM INNOCUUM | C86283 | Any bacterial organism that can be assigned to the species Clostridium innocuum. | Clostridium innocuum | |||
CLOSTRIDIUM LIMOSUM | C86284 | CLOSTRIDIUM SPECIES CDC GROUP P-1 | Any bacterial organism that can be assigned to the species Clostridium limosum. | Clostridium limosum | ||
CLOSTRIDIUM NOVYI | C86285 | Any bacterial organism that can be assigned to the species Clostridium novyi. | Clostridium novyi | |||
CLOSTRIDIUM OCEANICUM | C86286 | Any bacterial organism that can be assigned to the species Clostridium oceanicum. | Clostridium oceanicum | |||
CLOSTRIDIUM PARAPUTRIFICUM | C86287 | Any bacterial organism that can be assigned to the species Clostridium paraputrificum. | Clostridium paraputrificum | |||
CLOSTRIDIUM PERFRINGENS | C86288 | CLOSTRIDIUM WELCHII | Any bacterial organism that can be assigned to the species Clostridium perfringens. | Clostridium perfringens | ||
CLOSTRIDIUM PUTRIFICUM | C86289 | CLOSTRIDIUM LENTOPUTRESCENS | Any bacterial organism that can be assigned to the species Clostridium putrificum. | Clostridium putrificum | ||
CLOSTRIDIUM RAMOSUM | C86290 | ACTINOMYCES RAMOSUS | Any bacterial organism that can be assigned to the species Clostridium ramosum. | Clostridium ramosum | ||
CLOSTRIDIUM RECTUM | C86291 | Any bacterial organism that can be assigned to the species Clostridium rectum. | Clostridium rectum | |||
CLOSTRIDIUM SEPTICUM | C86292 | Any bacterial organism that can be assigned to the species Clostridium septicum. | Clostridium septicum | |||
CLOSTRIDIUM SORDELLII | C86293 | Any bacterial organism that can be assigned to the species Clostridium sordellii. | Clostridium sordellii | |||
CLOSTRIDIUM | C76275 | Any bacteria that is not assigned to the species level but can be assigned to the Clostridium genus level. | Clostridium | |||
CLOSTRIDIUM SPOROGENES | C86294 | Any bacterial organism that can be assigned to the species Clostridium sporogenes. | Clostridium sporogenes | |||
CLOSTRIDIUM SUBTERMINALE | C86295 | Any bacterial organism that can be assigned to the species Clostridium subterminale. | Clostridium subterminale | |||
CLOSTRIDIUM SYMBIOSUM | C86296 | BACTEROIDES SYMBIOSUS | Any bacterial organism that can be assigned to the species Clostridium symbiosum. | Clostridium symbiosum | ||
CLOSTRIDIUM TERTIUM | C86297 | Any bacterial organism that can be assigned to the species Clostridium tertium. | Clostridium tertium | |||
CLOSTRIDIUM TETANI | C86298 | Any bacterial organism that can be assigned to the species Clostridium tetani. | Clostridium tetani | |||
CLOSTRIDIUM TYROBUTYRICUM | C86299 | Any bacterial organism that can be assigned to the species Clostridium tyrobutyricum. | Clostridium tyrobutyricum | |||
COAGULASE NEGATIVE STAPHYLOCOCCUS | C62584 | Any bacteria assigned to the genus Staphylococcus that does not express the enzyme coagulase. | Coagulase-Negative Staphylococcus | |||
COAGULASE POSITIVE STAPHYLOCOCCUS | C62585 | Any bacteria assigned to the genus Staphylococcus that expresses the enzyme coagulase. | Coagulase-Positive Staphylococcus | |||
COLLINSELLA AEROFACIENS | C86301 | EUBACTERIUM AEROFACIENS | Any bacterial organism that can be assigned to the species Collinsella aerofaciens. | Collinsella aerofaciens | ||
COLLINSELLA INTESTINALIS | C86302 | Any bacterial organism that can be assigned to the species Collinsella intestinalis. | Collinsella intestinalis | |||
COLLINSELLA | C86300 | Any bacteria that is not assigned to the species level but can be assigned to the Collinsella genus level. | Collinsella | |||
COMAMONAS | C86303 | Any bacteria that is not assigned to the species level but can be assigned to the Comamonas genus level. | Comamonas | |||
COMAMONAS TERRIGENA | C86304 | CDC GROUP EF-19 | Any bacterial organism that can be assigned to the species Comamonas terrigena. | Comamonas terrigena | ||
COMAMONAS TESTOSTERONI | C86305 | PSEUDOMONAS TESTOSTERONI | Any bacterial organism that can be assigned to the species Comamonas testosteroni. | Comamonas testosteroni | ||
CORYNEBACTERIUM ACCOLENS | C86306 | CORYNEBACTERIUM GROUP G-1 | Any bacterial organism that can be assigned to the species Corynebacterium accolens. | Corynebacterium accolens | ||
CORYNEBACTERIUM AFERMENTANS | C86307 | CORYNEBACTERIUM ANF-1 | Any bacterial organism that can be assigned to the species Corynebacterium afermentans. | Corynebacterium afermentans | ||
CORYNEBACTERIUM AMYCOLATUM | C86308 | Any bacterial organism that can be assigned to the species Corynebacterium amycolatum. | Corynebacterium amycolatum | |||
CORYNEBACTERIUM ARGENTORATENSE | C86309 | Any bacterial organism that can be assigned to the species Corynebacterium argentoratense. | Corynebacterium argentoratense | |||
CORYNEBACTERIUM AURIS | C86310 | Any bacterial organism that can be assigned to the species Corynebacterium auris. | Corynebacterium auris | |||
CORYNEBACTERIUM BOVIS | C86311 | Any bacterial organism that can be assigned to the species Corynebacterium bovis. | Corynebacterium bovis | |||
CORYNEBACTERIUM DIPHTHERIAE | C86312 | Any bacterial organism that can be assigned to the species Corynebacterium diphtheriae. | Corynebacterium diphtheriae | |||
CORYNEBACTERIUM GENITALIUM | C86313 | Any bacterial organism that can be assigned to the species Corynebacterium genitalium. | Corynebacterium genitalium | |||
CORYNEBACTERIUM GLUCURONOLYTICUM | C86955 | Any bacterial organism that can be assigned to the species Corynebacterium glucuronolyticum. | Corynebacterium glucuronolyticum | |||
CORYNEBACTERIUM JEIKEIUM | C76307 | CDC GROUP JK;CORYNEBACTERIUM GROUP JK | Any bacterial organism that can be assigned to the species Corynebacterium jeikeium. | Corynebacterium jeikeium | ||
CORYNEBACTERIUM KUTSCHERI | C86314 | Any bacterial organism that can be assigned to the species Corynebacterium kutscheri. | Corynebacterium kutscheri | |||
CORYNEBACTERIUM MACGINLEYI | C86315 | Any bacterial organism that can be assigned to the species Corynebacterium macginleyi. | Corynebacterium macginleyi | |||
CORYNEBACTERIUM MATRUCHOTII | C86316 | BACTERIONEMA MATRUCHOTII | Any bacterial organism that can be assigned to the species Corynebacterium matruchotii. | Corynebacterium matruchotii | ||
CORYNEBACTERIUM MINUTISSIMUM | C86317 | Any bacterial organism that can be assigned to the species Corynebacterium minutissimum. | Corynebacterium minutissimum | |||
CORYNEBACTERIUM PILOSUM | C86318 | Any bacterial organism that can be assigned to the species Corynebacterium pilosum. | Corynebacterium pilosum | |||
CORYNEBACTERIUM PROPINQUUM | C86319 | Any bacterial organism that can be assigned to the species Corynebacterium propinquum. | Corynebacterium propinquum | |||
CORYNEBACTERIUM PSEUDODIPHTHERITICUM | C86320 | CORYNEBACTERIUM HOFMANNII | Any bacterial organism that can be assigned to the species Corynebacterium pseudodiphtheriticum. | Corynebacterium pseudodiphtheriticum | ||
CORYNEBACTERIUM PSEUDOTUBERCULOSIS | C86321 | Any bacterial organism that can be assigned to the species Corynebacterium pseudotuberculosis. | Corynebacterium pseudotuberculosis | |||
CORYNEBACTERIUM RENALE | C86322 | Any bacterial organism that can be assigned to the species Corynebacterium renale. | Corynebacterium renale | |||
CORYNEBACTERIUM | C76308 | Any bacteria that is not assigned to the species level but can be assigned to the Corynebacterium genus level. | Corynebacterium | |||
CORYNEBACTERIUM STRIATUM | C86323 | Any bacterial organism that can be assigned to the species Corynebacterium striatum. | Corynebacterium striatum | |||
CORYNEBACTERIUM ULCERANS | C86324 | Any bacterial organism that can be assigned to the species Corynebacterium ulcerans. | Corynebacterium ulcerans | |||
CORYNEBACTERIUM UREALYTICUM | C86325 | CDC GROUP D2;CORYNEBACTERIUM GROUP D-2 | Any bacterial organism that can be assigned to the species Corynebacterium urealyticum. | Corynebacterium urealyticum | ||
CORYNEBACTERIUM XEROSIS | C86326 | Any bacterial organism that can be assigned to the species Corynebacterium xerosis. | Corynebacterium xerosis | |||
CORYNEFORM GRAM-POSITIVE BACILLUS | C86327 | CORYNEFORM GRAM-POSITIVE ROD | Any bacteria whose shape is similar to those bacteria assigned to the Corynebacterium genus and have a cell wall that contains low levels of peptidoglycan and stains pink with the Gram staining technique. | Coryneform Gram Positive Bacillus | ||
COXIELLA BURNETII | C86328 | Any bacterial organism that can be assigned to the species Coxiella burnetii. | Coxiella burnetii | |||
COXIELLA | C76309 | Any bacteria that is not assigned to the species level but can be assigned to the Coxiella genus level. | Coxiella | |||
CRONOBACTER SAKAZAKII | C86329 | ENTEROBACTER SAKAZAKII | Any bacterial organism that can be assigned to the species Cronobacter sakazakii. | Cronobacter sakazakii | ||
CUPRIAVIDUS PAUCULUS | C86331 | CDC GROUP IVC-2;WAUTERSIA PAUCULA;RALSTONIA PAUCULA | Any bacterial organism that can be assigned to the species Cupriavidus pauculus. | Cupriavidus pauculus | ||
CUPRIAVIDUS | C86330 | Any bacteria that is not assigned to the species level but can be assigned to the Cupriavidus genus level. | Cupriavidus | |||
DELFTIA ACIDOVORANS | C86333 | COMAMONAS ACIDOVORANS;PSEUDOMONAS ACIDOVORANS | Any bacterial organism that can be assigned to the species Delftia acidovorans. | Delftia acidovorans | ||
DELFTIA | C86332 | Any bacteria that is not assigned to the species level but can be assigned to the Delftia genus level. | Delftia | |||
DERMABACTER HOMINIS | C86335 | Any bacterial organism that can be assigned to the species Dermabacter hominis. | Dermabacter hominis | |||
DERMABACTER | C86334 | Any bacteria that is not assigned to the species level but can be assigned to the Dermabacter genus level. | Dermabacter | |||
DERMACOCCUS NISHINOMIYAENSIS | C86336 | MICROCOCCUS NISHINOMIYAENSIS | Any bacterial organism that can be assigned to the species Dermacoccus nishinomiyaensis. | Dermacoccus nishinomiyaensis | ||
DERMATOPHILUS CONGOLENSIS | C86338 | Any bacterial organism that can be assigned to the species Dermatophilus congolensis. | Dermatophilus congolensis | |||
DERMATOPHILUS | C86337 | Any bacteria that is not assigned to the species level but can be assigned to the Dermatophilus genus level. | Dermatophilus | |||
DESULFOVIBRIO DESULFURICANS | C86340 | Any bacterial organism that can be assigned to the species Desulfovibrio desulfuricans. | Desulfovibrio desulfuricans | |||
DESULFOVIBRIO FAIRFIELDENSIS | C86341 | Any bacterial organism that can be assigned to the species Desulfovibrio fairfieldensis. | Desulfovibrio fairfieldensis | |||
DESULFOVIBRIO PIGER | C86342 | DESULFOMONAS PIGRA | Any bacterial organism that can be assigned to the species Desulfovibrio piger. | Desulfovibrio piger | ||
DESULFOVIBRIO | C86339 | DESULFOMONAS SPECIES | Any bacteria that is not assigned to the species level but can be assigned to the Desulfovibrio genus level. | Desulfovibrio | ||
DIPHTHEROID BACILLUS | C86343 | Any of a number of rod-shaped bacteria that resemble Corynebacterium diphtheriae, either in morphology or etiology. | Diptheroid Bacillus | |||
EDWARDSIELLA HOSHINAE | C86345 | Any bacterial organism that can be assigned to the species Edwardsiella hoshinae. | Edwardsiella hoshinae | |||
EDWARDSIELLA ICTALURI | C86346 | Any bacterial organism that can be assigned to the species Edwardsiella ictaluri. | Edwardsiella ictaluri | |||
EDWARDSIELLA | C86344 | Any bacteria that is not assigned to the species level but can be assigned to the Edwardsiella genus level. | Edwardsiella | |||
EDWARDSIELLA TARDA | C86347 | Any bacterial organism that can be assigned to the species Edwardsiella tarda. | Edwardsiella tarda | |||
EGGERTHELLA LENTA | C86349 | EUBACTERIUM LENTUM | Any bacterial organism that can be assigned to the species Eggerthella lenta. | Eggerthella lenta | ||
EGGERTHELLA | C86348 | Any bacteria that is not assigned to the species level but can be assigned to the Eggerthella genus level. | Eggerthella | |||
EIKENELLA CORRODENS | C86351 | CDC GROUP HB-1 | Any bacterial organism that can be assigned to the species Eikenella corrodens. | Eikenella corrodens | ||
EIKENELLA | C86350 | Any bacteria that is not assigned to the species level but can be assigned to the Eikenella genus level. | Eikenella | |||
ELIZABETHKINGIA MENINGOCEPTICA | C86353 | CHRYSEOBACTERIUM MENINGOSEPTICUM;FLAVOBACTERIUM MENINGOSEPTICUM | Any bacterial organism that can be assigned to the species Elizabethkingia meningoceptica. | Elizabethkingia meningoceptica | ||
ELIZABETHKINGIA | C86352 | Any bacteria that is not assigned to the species level but can be assigned to the Elizabethkingia genus level. | Elizabethkingia | |||
EMPEDOBACTER BREVIS | C86355 | FLAVOBACTERIUM BREVE | Any bacterial organism that can be assigned to the species Empedobacter brevis. | Empedobacter brevis | ||
EMPEDOBACTER | C86354 | Any bacteria that is not assigned to the species level but can be assigned to the Empedobacter genus level. | Empedobacter | |||
ENTEROBACTER AEROGENES | C86356 | AEROBACTER AEROGENES | Any bacterial organism that can be assigned to the species Enterobacter aerogenes. | Enterobacter aerogenes | ||
ENTEROBACTER AMNIGENUS | C86357 | ENTEROBACTER AMNIGENUS I | Any bacterial organism that can be assigned to the species Enterobacter amnigenus. | Enterobacter amnigenus | ||
ENTEROBACTER ASBURIAE | C86358 | CDC ENTERIC GROUP 17 | Any bacterial organism that can be assigned to the species Enterobacter asburiae. | Enterobacter asburiae | ||
ENTEROBACTER CANCEROGENUS | C86359 | CDC ENTERIC GROUP 19;ENTEROBACTER TAYLORAE | Any bacterial organism that can be assigned to the species Enterobacter cancerogenus. | Enterobacter cancerogenus | ||
ENTEROBACTER CLOACAE | C86360 | ENTEROBACTER CLOACAE STRAIN 1 | Any bacterial organism that can be assigned to the species Enterobacter cloacae. | Enterobacter cloacae | ||
ENTEROBACTER GERGOVIAE | C86361 | Any bacterial organism that can be assigned to the species Enterobacter gergoviae. | Enterobacter gergoviae | |||
ENTEROBACTER HORMAECHEI | C86362 | CDC ENTERIC GROUP 75 | Any bacterial organism that can be assigned to the species Enterobacter hormaechei. | Enterobacter hormaechei | ||
ENTEROBACTER | C76310 | Any bacteria that is not assigned to the species level but can be assigned to the Enterobacter genus level. | Enterobacter | |||
ENTEROBACTER TAYLORAE | C86363 | Any bacterial organism that can be assigned to the species Enterobacter taylorae. | Enterobacter taylorae | |||
ENTEROCOCCUS AVIUM | C86364 | STREPTOCOCCUS AVIUM | Any bacterial organism that can be assigned to the species Enterococcus avium. | Enterococcus avium | ||
ENTEROCOCCUS CASSELIFLAVUS | C86365 | Any bacterial organism that can be assigned to the species Enterococcus casseliflavus. | Enterococcus casseliflavus | |||
ENTEROCOCCUS DISPAR | C86366 | Any bacterial organism that can be assigned to the species Enterococcus dispar. | Enterococcus dispar | |||
ENTEROCOCCUS DURANS | C86367 | STREPTOCOCCUS DURANS | Any bacterial organism that can be assigned to the species Enterococcus durans. | Enterococcus durans | ||
ENTEROCOCCUS FAECALIS | C86368 | STREPTOCOCCUS FAECALIS | Any bacterial organism that can be assigned to the species Enterococcus faecalis. | Enterococcus faecalis | ||
ENTEROCOCCUS FAECIUM | C86369 | STREPTOCOCCUS FAECIUM | Any bacterial organism that can be assigned to the species Enterococcus faecium. | Enterococcus faecium | ||
ENTEROCOCCUS GALLINARUM | C86370 | Any bacterial organism that can be assigned to the species Enterococcus gallinarum. | Enterococcus gallinarum | |||
ENTEROCOCCUS HIRAE | C86371 | Any bacterial organism that can be assigned to the species Enterococcus hirae. | Enterococcus hirae | |||
ENTEROCOCCUS MALODORATUS | C86372 | Any bacterial organism that can be assigned to the species Enterococcus malodoratus. | Enterococcus malodoratus | |||
ENTEROCOCCUS MUNDTII | C86373 | Any bacterial organism that can be assigned to the species Enterococcus mundtii. | Enterococcus mundtii | |||
ENTEROCOCCUS PSEUDOAVIUM | C86374 | Any bacterial organism that can be assigned to the species Enterococcus pseudoavium. | Enterococcus pseudoavium | |||
ENTEROCOCCUS RAFFINOSUS | C86375 | Any bacterial organism that can be assigned to the species Enterococcus raffinosus. | Enterococcus raffinosus | |||
ENTEROCOCCUS | C76311 | PRESUMPTIVE ENTEROCOCCUS | Any bacteria that is not assigned to the species level but can be assigned to the Enterococcus genus level. | Enterococcus | ||
ERYSIPELOTHRIX RHUSIOPATHIAE | C86377 | Any bacterial organism that can be assigned to the species Erysipelothrix rhusiopathiae. | Erysipelothrix rhusiopathiae | |||
ERYSIPELOTHRIX | C86376 | ERYSIPELOTHRIX INSIDIOSA | Any bacteria that is not assigned to the species level but can be assigned to the Erysipelothrix genus level. | Erysipelothrix | ||
ESCHERICHIA ALBERTII | C86378 | Any bacterial organism that can be assigned to the species Escherichia albertii. | Escherichia albertii | |||
ESCHERICHIA BLATTAE | C86379 | Any bacterial organism that can be assigned to the species Escherichia blattae. | Escherichia blattae | |||
ESCHERICHIA COLI | C14206 | E. COLI | Any bacterial organism that can be assigned to the species Escherichia coli. | Escherichia coli | ||
ESCHERICHIA COLI O111 | C86881 | Any bacterial organism that can be assigned to the species Escherichia coli and strain O111. | Escherichia coli strain O111 | |||
ESCHERICHIA COLI O157 (NOT H7) | C86882 | Any bacterial organism that can be assigned to the species Escherichia coli and strain O157. | Escherichia coli strain O157 | |||
ESCHERICHIA COLI O157:H7 | C86883 | Any bacterial organism that can be assigned to the species Escherichia coli and strain O157:H7. | Escherichia coli strain O157:H7 | |||
ESCHERICHIA COLI O26 | C86884 | Any bacterial organism that can be assigned to the species Escherichia coli and strain O26. | Escherichia coli strain O26 | |||
ESCHERICHIA FERGUSONII | C86380 | CDC ENTERIC GROUP 10 | Any bacterial organism that can be assigned to the species Escherichia fergusonii. | Escherichia fergusonii | ||
ESCHERICHIA HERMANNII | C86381 | CDC ENTERIC GROUP 11 | Any bacterial organism that can be assigned to the species Escherichia hermannii. | Escherichia hermannii | ||
ESCHERICHIA | C77208 | Any bacteria that is not assigned to the species level but can be assigned to the Escherichia genus level. | Escherichia | |||
ESCHERICHIA VULNERIS | C86382 | CDC ENTERIC GROUP 1 | Any bacterial organism that can be assigned to the species Escherichia vulneris. | Escherichia vulneris | ||
EUBACTERIUM ALACTOLYTICUM | C86384 | Any bacterial organism that can be assigned to the species Eubacterium adactolyticum. | Eubacterium alactolyticum | |||
EUBACTERIUM CONTORTUM | C86385 | Any bacterial organism that can be assigned to the species Eubacterium contortum. | Eubacterium contortum | |||
EUBACTERIUM LIMOSUM | C86386 | Any bacterial organism that can be assigned to the species Eubacterium limosum. | Eubacterium limosum | |||
EUBACTERIUM NODATUM | C86387 | Any bacterial organism that can be assigned to the species Eubacterium nodatum. | Eubacterium nodatum | |||
EUBACTERIUM RECTALE | C86388 | Any bacterial organism that can be assigned to the species Eubacterium rectale. | Eubacterium rectale | |||
EUBACTERIUM | C86383 | Any bacteria that is not assigned to the species level but can be assigned to the Eubacterium genus level. | Eubacterium | |||
EUBACTERIUM VENTRIOSUM | C86389 | Any bacterial organism that can be assigned to the species Eubacterium ventriosum. | Eubacterium ventriosum | |||
EWINGELLA AMERICANA | C86391 | CDC ENTERIC GROUP 40 | Any bacterial organism that can be assigned to the species Ewingella americana. | Ewingella americana | ||
EWINGELLA | C86390 | Any bacteria that is not assigned to the species level but can be assigned to the Ewingella genus level. | Ewingella | |||
EXIGUOBACTERIUM ACETYLICUM | C86886 | BREVIBACTERIUM ACETYLICUM | Any bacterial organism that can be assigned to the species Exiguobacterium acetylicum. | Exiguobacterium acetylicum | ||
EXIGUOBACTERIUM | C86885 | Any bacteria that is not assigned to the species level but can be assigned to the Exiguobacterium genus level. | Exiguobacterium | |||
FACKLAMIA | C86392 | Any bacteria that is not assigned to the species level but can be assigned to the Facklamia genus level. | Facklamia | |||
FAECALIBACTERIUM PRAUSNITZII | C86394 | FUSOBACTERIUM PRAUSNITZII | Any bacterial organism that can be assigned to the species Faecalibacterium prausnitzii. | Faecalibacterium prausnitzii | ||
FAECALIBACTERIUM | C86393 | Any bacteria that is not assigned to the species level but can be assigned to the Faecalibacterium genus level. | Faecalibacterium | |||
FERMENTATIVE GRAM-NEGATIVE BACILLUS | C86395 | FERMENTATIVE GRAM-NEGATIVE ROD | Any rod-shaped, anaerobic bacteria that can convert carbohydrates into acids and alcohols and has a cell wall contains low levels of peptidoglycan and stains pink with the Gram staining technique. | Fermentative Gram Negative Bacillus | ||
FINEGOLDIA MAGNA | C86888 | PEPTOSTREPTOCOCCUS MAGNUS | Any bacterial organism that can be assigned to the species Finegoldia magna. | Finegoldia magna | ||
FINEGOLDIA | C86887 | Any bacteria that is not assigned to the species level but can be assigned to the Finegoldia genus level. | Finegoldia | |||
FLAVOBACTERIUM | C76320 | Any bacteria that is not assigned to the species level but can be assigned to the Flavobacterium genus level. | Flavobacterium | |||
FRANCISELLA | C86396 | Any bacteria that is not assigned to the species level but can be assigned to the Francisella genus level. | Francisella | |||
FRANCISELLA TULARENSIS | C86397 | PASTEURELLA TULARENSIS | Any bacterial organism that can be assigned to the species Francisella tularensis. | Francisella tularensis | ||
FUSOBACTERIUM GONIDIAFORMANS | C86398 | Any bacterial organism that can be assigned to the species Fusobacterium gonidiaformans. | Fusobacterium gonidiaformans | |||
FUSOBACTERIUM MORTIFERUM | C86399 | Any bacterial organism that can be assigned to the species Fusobacterium mortiferum. | Fusobacterium mortiferum | |||
FUSOBACTERIUM NECROGENES | C86400 | Any bacterial organism that can be assigned to the species Fusobacterium necrogenes. | Fusobacterium necrogenes | |||
FUSOBACTERIUM NECROPHORUM | C86401 | Any bacterial organism that can be assigned to the species Fusobacterium necrophorum. | Fusobacterium necrophorum | |||
FUSOBACTERIUM NUCLEATUM | C86404 | Any bacterial organism that can be assigned to the species Fusobacterium nucleatum. | Fusobacterium nucleatum | |||
FUSOBACTERIUM RUSSII | C86405 | Any bacterial organism that can be assigned to the species Fusobacterium russii. | Fusobacterium russii | |||
FUSOBACTERIUM | C76323 | Any bacteria that is not assigned to the species level but can be assigned to the Fusobacterium genus level. | Fusobacterium | |||
FUSOBACTERIUM ULCERANS | C86406 | Any bacterial organism that can be assigned to the species Fusobacterium ulcerans. | Fusobacterium ulcerans | |||
FUSOBACTERIUM VARIUM | C86407 | FUSOBACTERIUM PSEUDONECROPHORUM;FUSOBACTERIUM NECROPHORUM BIOVAR C | Any bacterial organism that can be assigned to the species Fusobacterium varium. | Fusobacterium varium | ||
GARDNERELLA | C86409 | Any bacteria that is not assigned to the species level but can be assigned to the Gardnerella genus level. | Gardnerella | |||
GARDNERELLA VAGINALIS | C86410 | CORYNEBACTERIUM VAGINALIS | Any bacterial organism that can be assigned to the species Gardnerella vaginalis. | Gardnerella vaginalis | ||
GEMELLA BERGERI | C86890 | Any bacterial organism that can be assigned to the species Gemella bergeri. | Gemella bergeri | |||
GEMELLA HAEMOLYSANS | C86891 | NEISSERIA HAEMOLYSANS | Any bacterial organism that can be assigned to the species Gemella haemolysans. | Gemella haemolysans | ||
GEMELLA MORBILLORUM | C86892 | STREPTOCOCCUS MORBILLORUM | Any bacterial organism that can be assigned to the species Gemella morbillorum. | Gemella morbillorum | ||
GEMELLA SANGUINIS | C86893 | Any bacterial organism that can be assigned to the species Gemella sanguinis. | Gemella sanguinis | |||
GEMELLA | C86889 | Any bacteria that is not assigned to the species level but can be assigned to the Gemella genus level. | Gemella | |||
GLOBICATELLA SANGUINIS | C86412 | GLOBICATELLA SANGUIS | Any bacterial organism that can be assigned to the species Globicatella sanguinis. | Globicatella sanguinis | ||
GLOBICATELLA | C86411 | Any bacteria that is not assigned to the species level but can be assigned to the Globicatella genus level. | Globicatella | |||
GLOBICATELLA SULFIDIFACIENS | C86413 | Any bacterial organism that can be assigned to the species Globicatella sulfidifaciens. | Globicatella sulfidifaciens | |||
GORDONIA AICHIENSIS | C86415 | TSUKAMURELLA AICHIENSIS;GORDONA AICHIENSIS | Any bacterial organism that can be assigned to the species Gordonia aichiensis. | Gordonia aichiensis | ||
GORDONIA BRONCHIALIS | C86416 | RHODOCOCCUS BRONCHIALIS;GORDONA BRONCHIALIS | Any bacterial organism that can be assigned to the species Gordonia bronchialis. | Gordonia bronchialis | ||
GORDONIA RUBRIPERTINCTA | C86417 | RHODOCOCCUS RUBRIPERTINCTA;GORDONA RUBROPERTINCTA | Any bacterial organism that can be assigned to the species Gordonia rubripertincta. | Gordonia rubripertincta | ||
GORDONIA | C86414 | Any bacteria that is not assigned to the species level but can be assigned to the Gordonia genus level. | Gordonia | |||
GORDONIA SPUTI | C86418 | GORDONA SPUTI | Any bacterial organism that can be assigned to the species Gordonia sputi. | Gordonia sputi | ||
GORDONIA TERRAE | C86419 | RHODOCOCCUS TERRAE;GORDONA TERRAE | Any bacterial organism that can be assigned to the species Gordonia terrae. | Gordonia terrae | ||
GRACILIBACILLUS | C86420 | Any bacteria that is not assigned to the species level but can be assigned to the Gracilibacillus genus level. | Gracilibacillus | |||
GRAM-NEGATIVE BACILLUS | C86421 | Any rod-shaped bacteria that contains low levels of peptidoglycan in its cell wall and stains pink with the Gram staining technique. | Gram Negative Bacillus | |||
GRAM-NEGATIVE COCCUS | C86422 | Any spherical-shaped bacteria that contains low levels of peptidoglycan in its cell wall and stains pink with the Gram staining technique. | Gram Negative Coccus | |||
GRAM-POSITIVE BACILLUS | C62589 | Any rod-shaped bacteria that has a peptidoglycan-rich cell wall that stains dark purple with the Gram staining technique. | Gram-Positive Rod | |||
GRAM-POSITIVE COCCUS | C86424 | Any spherical-shaped bacteria that has a peptidoglycan-rich cell wall that stains dark purple with the Gram staining technique. | Gram Positive Coccus | |||
GRANULICATELLA ADIACENS | C86426 | ABIOTROPHIA ADJACENS;STREPTOCOCCUS ADJACENS | Any bacterial organism that can be assigned to the species Granulicatella adiacens. | Granulicatella adiacens | ||
GRANULICATELLA | C86425 | Any bacteria that is not assigned to the species level but can be assigned to the Granulicatella genus level. | Granulicatella | |||
GRIMONTIA HOLLISAE | C86427 | VIBRIO HOLLISAE | Any bacterial organism that can be assigned to the species Grimontia hollisae. | Grimontia hollisae | ||
HAEMOPHILUS AEGYPTIUS | C86428 | Any bacterial organism that can be assigned to the species Haemophilus aegyptius. | Haemophilus aegyptius | |||
HAEMOPHILUS HAEMOGLOBINOPHILUS | C86429 | Any bacterial organism that can be assigned to the species Haemophilus haemoglobinophilus. | Haemophilus haemoglobinophilus | |||
HAEMOPHILUS HAEMOLYTICUS | C86430 | Any bacterial organism that can be assigned to the species Haemophilus haemolyticus. | Haemophilus haemolyticus | |||
HAEMOPHILUS INFLUENZAE | C86431 | H-FLU | Any bacterial organism that can be assigned to the species Haemophilus influenzae. | Haemophilus influenzae | ||
HAEMOPHILUS PARAHAEMOLYTICUS | C86432 | Any bacterial organism that can be assigned to the species Haemophilus parahaemolyticus. | Haemophilus parahaemolyticus | |||
HAEMOPHILUS PARAINFLUENZAE | C86433 | HEMOPHILUS PARAINFLUENZAE | Any bacterial organism that can be assigned to the species Haemophilus parainfluenzae. | Haemophilus parainfluenzae | ||
HAEMOPHILUS | C76324 | Any bacteria that is not assigned to the species level but can be assigned to the Haemophilus genus level. | Haemophilus | |||
HAFNIA ALVEI | C86435 | ENTEROBACTER ALVEI | Any bacterial organism that can be assigned to the species Hafnia alvei. | Hafnia alvei | ||
HAFNIA | C86434 | Any bacteria that is not assigned to the species level but can be assigned to the Hafnia genus level. | Hafnia | |||
HALOBACILLUS | C86436 | Any bacteria that is not assigned to the species level but can be assigned to the Halobacillus genus level. | Halobacillus | |||
HELCOCOCCUS KUNZII | C86878 | Any bacterial organism that can be assigned to the species Helcococcus kunzii. | Helcococcus kunzii | |||
HELCOCOCCUS PYOGENES | C86879 | Any bacterial organism that can be assigned to the species Helcococcus pyogenes. | Helcococcus pyogenes | |||
HELCOCOCCUS | C86873 | Any bacteria that is not assigned to the species level but can be assigned to the Helcococcus genus level. | Helcococcus | |||
HELCOCOCCUS SUECIENSIS | C86880 | Any bacterial organism that can be assigned to the species Helcococcus sueciensis. | Helcococcus sueciensis | |||
HELICOBACTER CINAEDI | C86437 | CAMPYLOBACTER CINAEDI | Any bacterial organism that can be assigned to the species Helicobacter cinaedi. | Helicobacter cinaedi | ||
HELICOBACTER FELIS | C14330 | H. FELIS | Any bacterial organism that can be assigned to the species Helicobacter felis. | Helicobacter felis | ||
HELICOBACTER FENNELLIAE | C86438 | CAMPYLOBACTER FENNELLIAE | Any bacterial organism that can be assigned to the species Helicobacter fennelliae. | Helicobacter fennelliae | ||
HELICOBACTER MUSTELAE | C86439 | CAMPYLOBACTER MUSTELAE | Any bacterial organism that can be assigned to the species Helicobacter mustelae. | Helicobacter mustelae | ||
HELICOBACTER PYLORI | C14289 | H. PYLORI;CAMPYLOBACTER PYLORI | Any bacterial organism that can be assigned to the species Helicobacter pylori. | Helicobacter pylori | ||
HELICOBACTER RAPPINI | C86440 | FLEXISPIRA RAPPINI | Any bacterial organism that can be assigned to the species Helicobacter rappini. | Helicobacter rappini | ||
HELICOBACTER | C14296 | Any bacteria that is not assigned to the species level but can be assigned to the Helicobacter genus level. | Helicobacter | |||
HISTOPHILUS SOMNI | C86441 | HAEMOPHILUS SOMNUS | Any bacterial organism that can be assigned to the species Histophilus somni. | Histophilus somni | ||
HOLDEMANIA FILIFORMIS | C86443 | Any bacterial organism that can be assigned to the species Holdemania filiformis. | Holdemania filiformis | |||
HOLDEMANIA | C86442 | Any bacteria that is not assigned to the species level but can be assigned to the Holdemania genus level. | Holdemania | |||
INQUILINUS LIMOSUS | C86445 | Any bacterial organism that can be assigned to the species Inquilinus limosus. | Inquilinus limosus | |||
INQUILINUS | C86444 | Any bacteria that is not assigned to the species level but can be assigned to the Inquilinus genus level. | Inquilinus | |||
JEOTGALIBACILLUS | C86446 | Any bacteria that is not assigned to the species level but can be assigned to the Jeotgalibacillus genus level. | Jeotgalibacillus | |||
JOHNSONELLA IGNAVA | C86448 | Any bacterial organism that can be assigned to the species Johnsonella ignava. | Johnsonella ignava | |||
JOHNSONELLA | C86447 | Any bacteria that is not assigned to the species level but can be assigned to the Johnsonella genus level. | Johnsonella | |||
KINGELLA DENITRIFICANS | C86450 | CDC GROUP TM-1 | Any bacterial organism that can be assigned to the species Kingella denitrificans. | Kingella denitrificans | ||
KINGELLA KINGAE | C86451 | MORAXELLA KINGAE | Any bacterial organism that can be assigned to the species Kingella kingae. | Kingella kingae | ||
KINGELLA ORALIS | C86452 | Any bacterial organism that can be assigned to the species Kingella oralis. | Kingella oralis | |||
KINGELLA POTUS | C86453 | Any bacterial organism that can be assigned to the species Kingella potus. | Kingella potus | |||
KINGELLA | C86449 | Any bacteria that is not assigned to the species level but can be assigned to the Kingella genus level. | Kingella | |||
KLEBSIELLA GRANULOMATIS | C86454 | Any bacterial organism that can be assigned to the species Klebsiella granulomatis. | Klebsiella granulomatis | |||
KLEBSIELLA OXYTOCA | C86455 | K. OXYTOCA | Any bacterial organism that can be assigned to the species Klebsiella oxytoca. | Klebsiella oxytoca | ||
KLEBSIELLA PNEUMONIAE | C86457 | K. PNEUMONIAE | Any bacterial organism that can be assigned to the species Klebsiella pneumoniae. | Klebsiella pneumoniae | ||
KLEBSIELLA OZAENAE | C86456 | KLEBSIELLA PNEUMONIAE SUBSP. OZAENAE | Any bacterial organism that can be assigned to the species Klebsiella ozaenae. | Klebsiella ozaenae | ||
KLEBSIELLA RHINOSCLEROMATIS | C86458 | KLEBSIELLA PNEUMONIAE SUBSP. RHINOSCLEROMATIS | Any bacterial organism that can be assigned to the species Klebsiella rhinoscleromatis. | Klebsiella rhinoscleromatis | ||
KLEBSIELLA SINGAPORENSIS | C86459 | Any bacterial organism that can be assigned to the species Klebsiella singaporensis. | Klebsiella singaporensis | |||
KLEBSIELLA | C28165 | Any bacteria that is not assigned to the species level but can be assigned to the Klebsiella genus level. | Klebsiella | |||
KLEBSIELLA VARIICOLA | C86460 | Any bacterial organism that can be assigned to the species Klebsiella variicola. | Klebsiella variicola | |||
KLUYVERA ASCORBATA | C86462 | CDC ENTERIC GROUP 8 | Any bacterial organism that can be assigned to the species Kluyvera ascorbata. | Kluyvera ascorbata | ||
KLUYVERA CRYOCRESCENS | C86463 | Any bacterial organism that can be assigned to the species Kluyvera cryocrescens. | Kluyvera cryocrescens | |||
KLUYVERA GEORGIANA | C86464 | Any bacterial organism that can be assigned to the species Kluyvera georgiana. | Kluyvera georgiana | |||
KLUYVERA INTERMEDIA | C86465 | ENTEROBACTER INTERMEDIUM;ENTEROBACTER INTERMEDIUS;KLUYVERA COCHLEAE | Any bacterial organism that can be assigned to the species Kluyvera intermedia. | Kluyvera intermedia | ||
KLUYVERA | C86461 | Any bacteria that is not assigned to the species level but can be assigned to the Kluyvera genus level. | Kluyvera | |||
KNOELLIA | C86466 | Any bacteria that is not assigned to the species level but can be assigned to the Knoellia genus level. | Knoellia | |||
KOCURIA KRISTINAE | C86468 | MICROCOCCUS KRISTINAE | Any bacterial organism that can be assigned to the species Kocuria kristinae. | Kocuria kristinae | ||
KOCURIA ROSEA | C86469 | Any bacterial organism that can be assigned to the species Kocuria rosea. | Kocuria rosea | |||
KOCURIA | C86467 | Any bacteria that is not assigned to the species level but can be assigned to the Kocuria genus level. | Kocuria | |||
KOCURIA VARIANS | C86470 | Any bacterial organism that can be assigned to the species Kocuria varians. | Kocuria varians | |||
KURTHIA | C86471 | Any bacteria that is not assigned to the species level but can be assigned to the Kurthia genus level. | Kurthia | |||
KYTOCOCCUS SEDENTARIUS | C86473 | Any bacterial organism that can be assigned to the species Kytococcus sedentarius. | Kytococcus sedentarius | |||
KYTOCOCCUS | C86472 | Any bacteria that is not assigned to the species level but can be assigned to the Kytococcus genus level. | Kytococcus | |||
LACTOBACILLUS ACIDOPHILUS | C86474 | Any bacterial organism that can be assigned to the species Lactobacillus acidophilus. | Lactobacillus acidophilus | |||
LACTOBACILLUS BREVIS | C86475 | Any bacterial organism that can be assigned to the species Lactobacillus brevis. | Lactobacillus brevis | |||
LACTOBACILLUS CASEI | C86476 | Any bacterial organism that can be assigned to the species Lactobacillus casei. | Lactobacillus casei | |||
LACTOBACILLUS CATENAFORMIS | C86477 | LACTOBACILLUS CATENAFORME | Any bacterial organism that can be assigned to the species Lactobacillus catenaformis. | Lactobacillus catenaformis | ||
LACTOBACILLUS FERMENTUM | C86478 | Any bacterial organism that can be assigned to the species Lactobacillus fermentum. | Lactobacillus fermentum | |||
LACTOBACILLUS GALLINARUM | C86479 | Any bacterial organism that can be assigned to the species Lactobacillus gallinarum. | Lactobacillus gallinarum | |||
LACTOBACILLUS JENSENII | C86480 | Any bacterial organism that can be assigned to the species Lactobacillus jensenii. | Lactobacillus jensenii | |||
LACTOBACILLUS JOHNSONII | C86481 | Any bacterial organism that can be assigned to the species Lactobacillus johnsonii. | Lactobacillus johnsonii | |||
LACTOBACILLUS SALIVARIUS | C86482 | Any bacterial organism that can be assigned to the species Lactobacillus salivarius. | Lactobacillus salivarius | |||
LACTOBACILLUS | C76352 | Any bacteria that is not assigned to the species level but can be assigned to the Lactobacillus genus level. | Lactobacillus | |||
LACTOCOCCUS GARVIEAE | C86484 | Any bacterial organism that can be assigned to the species Lactococcus garvieae. | Lactococcus garvieae | |||
LACTOCOCCUS LACTIS | C86485 | Any bacterial organism that can be assigned to the species Lactococcus lactis. | Lactococcus lactis | |||
LACTOCOCCUS | C86483 | DOEDERLEIN BACILLUS | Any bacteria that is not assigned to the species level but can be assigned to the Lactococcus genus level. | Lactococcus | ||
LECLERCIA ADECARBOXYLATA | C86487 | CDC ENTERIC GROUP 41 | Any bacterial organism that can be assigned to the species Leclercia adecarboxylata. | Leclercia adecarboxylata | ||
LECLERCIA | C86486 | Any bacteria that is not assigned to the species level but can be assigned to the Leclercia genus level. | Leclercia | |||
LEGIONELLA LONGBEACHAE | C86488 | Any bacterial organism that can be assigned to the species Legionella longbeachae. | Legionella longbeachae | |||
LEGIONELLA PNEUMOPHILA | C86489 | Any bacterial organism that can be assigned to the species Legionella pneumophila. | Legionella pneumophila | |||
LEGIONELLA | C76353 | Any bacteria that is not assigned to the species level but can be assigned to the Legionella genus level. | Legionella | |||
LEIFSONIA AQUATICA | C86491 | CORYNEBACTERIUM AQUATICUM | Any bacterial organism that can be assigned to the species Leifsonia aquatica. | Leifsonia aquatica | ||
LEIFSONIA | C86490 | Any bacteria that is not assigned to the species level but can be assigned to the Leifsonia genus level. | Leifsonia | |||
LEMINORELLA GRIMONTII | C86493 | CDC ENTERIC GROUP 57 | Any bacterial organism that can be assigned to the species Leminorella grimontii. | Leminorella grimontii | ||
LEMINORELLA RICHARDII | C86494 | Any bacterial organism that can be assigned to the species Leminorella richardii. | Leminorella richardii | |||
LEMINORELLA | C86492 | Any bacteria that is not assigned to the species level but can be assigned to the Leminorella genus level. | Leminorella | |||
LEPTOSPIRA | C76355 | Any bacteria that is not assigned to the species level but can be assigned to the Leptospira genus level. | Leptospira | |||
LEUCONOSTOC CITREUM | C86495 | Any bacterial organism that can be assigned to the species Leuconostoc citreum. | Leuconostoc citreum | |||
LEUCONOSTOC LACTIS | C86496 | Any bacterial organism that can be assigned to the species Leuconostoc lactis. | Leuconostoc lactis | |||
LEUCONOSTOC MESENTEROIDES | C86497 | Any bacterial organism that can be assigned to the species Leuconostoc mesenteroides. | Leuconostoc mesenteroides | |||
LEUCONOSTOC PSEUDOMESENTEROIDES | C86498 | Any bacterial organism that can be assigned to the species Leuconostoc pseudomesenteroides. | Leuconostoc pseudomesenteroides | |||
LEUCONOSTOC | C76357 | Any bacteria that is not assigned to the species level but can be assigned to the Leuconostoc genus level. | Leuconostoc | |||
LISTERIA GRAYI | C86499 | Any bacterial organism that can be assigned to the species Listeria grayi. | Listeria grayi | |||
LISTERIA INNOCUA | C86500 | Any bacterial organism that can be assigned to the species Listeria innocua. | Listeria innocua | |||
LISTERIA IVANOVII | C86501 | LISTERIA MONOCYTOGENES SEROVAR 5 | Any bacterial organism that can be assigned to the species Listeria ivanovii. | Listeria ivanovii | ||
LISTERIA MONOCYTOGENES | C86502 | Any bacterial organism that can be assigned to the species Listeria monocytogenes. | Listeria monocytogenes | |||
LISTERIA SEELIGERI | C86503 | Any bacterial organism that can be assigned to the species Listeria seeligeri. | Listeria seeligeri | |||
LISTERIA | C76359 | Any bacteria that is not assigned to the species level but can be assigned to the Listeria genus level. | Listeria | |||
LISTERIA WELSHIMERI | C86504 | Any bacterial organism that can be assigned to the species Listeria welshimeri. | Listeria welshimeri | |||
MACROCOCCUS CASEOLYTICUS | C86506 | STAPHYLOCOCCUS CASEOLYTICUS | Any bacterial organism that can be assigned to the species Macrococcus caseolyticus. | Macrococcus caseolyticus | ||
MACROCOCCUS | C86505 | Any bacteria that is not assigned to the species level but can be assigned to the Macrococcus genus level. | Macrococcus | |||
MANNHEIMIA HAEMOLYTICA | C86508 | PASTEURELLA HAEMOLYTICA | Any bacterial organism that can be assigned to the species Mannheimia haemolytica. | Mannheimia haemolytica | ||
MANNHEIMIA | C86507 | Any bacteria that is not assigned to the species level but can be assigned to the Mannheimia genus level. | Mannheimia | |||
MEGASPHAERA ELSDENII | C86896 | PEPTOSTREPTOCOCCUS ELSDENII | Any bacterial organism that can be assigned to the species Megasphaera elsdenii. | Megasphaera elsdenii | ||
MEGASPHAERA | C86895 | Any bacteria that is not assigned to the species level but can be assigned to the Megasphaera genus level. | Megasphaera | |||
METHYLOBACTERIUM MESOPHILICUM | C86510 | PSEUDOMONAS MESOPHILICA | Any bacterial organism that can be assigned to the species Methylobacterium mesophilicum. | Methylobacterium mesophilicum | ||
METHYLOBACTERIUM | C76361 | Any bacteria that is not assigned to the species level but can be assigned to the Methylobacterium genus level. | Methylobacterium | |||
MICROBACTERIUM PARAOXYDANS | C86512 | Any bacterial organism that can be assigned to the species Microbacterium paraoxydans. | Microbacterium paraoxydans | |||
MICROBACTERIUM | C85511 | CDC CORYNEFORM GROUP A-4, A-5 | Any bacteria that is not assigned to the species level but can be assigned to the Microbacterium genus level. | Microbacterium | ||
MICROCOCCUS LUTEUS | C86513 | SARCINA LUTEA | Any bacterial organism that can be assigned to the species Micrococcus luteus. | Micrococcus luteus | ||
MICROCOCCUS LYLAE | C86514 | Any bacterial organism that can be assigned to the species Micrococcus lylae. | Micrococcus lylae | |||
MICROCOCCUS | C77086 | Any bacteria that is not assigned to the species level but can be assigned to the Micrococcus genus level. | Micrococcus | |||
MITSUOKELLA MULTACIDA | C86516 | Any bacterial organism that can be assigned to the species Mitsuokella multacida. | Mitsuokella multacida | |||
MITSUOKELLA | C86515 | Any bacteria that is not assigned to the species level but can be assigned to the Mitsuokella genus level. | Mitsuokella | |||
MOBILUNCUS CURTISII | C86518 | Any bacterial organism that can be assigned to the species Mobiluncus curtisii. | Mobiluncus curtisii | |||
MOBILUNCUS MULIERIS | C86519 | Any bacterial organism that can be assigned to the species Mobiluncus mulieris. | Mobiluncus mulieris | |||
MOBILUNCUS | C86517 | Any bacteria that is not assigned to the species level but can be assigned to the Mobiluncus genus level. | Mobiluncus | |||
MOELLERELLA | C86520 | Any bacteria that is not assigned to the species level but can be assigned to the Moellerella genus level. | Moellerella | |||
MOELLERELLA WISCONSENSIS | C86521 | CDC ENTERIC GROUP 46 | Any bacterial organism that can be assigned to the species Moellerella wisconsensis. | Moellerella wisconsensis | ||
MOGIBACTERIUM | C86898 | Any bacteria that is not assigned to the species level but can be assigned to the Mogibacterium genus level. | Mogibacterium | |||
MOGIBACTERIUM TIMIDUM | C86899 | EUBACTERIUM TIMIDUM | Any bacterial organism that can be assigned to the species Mogibacterium timidum. | Mogibacterium timidum | ||
MORAXELLA ATLANTAE | C86523 | CDC GROUP M-3 | Any bacterial organism that can be assigned to the species Moraxella atlantae. | Moraxella atlantae | ||
MORAXELLA BOVIS | C86524 | Any bacterial organism that can be assigned to the species Moraxella bovis. | Moraxella bovis | |||
MORAXELLA CANIS | C86525 | Any bacterial organism that can be assigned to the species Moraxella canis. | Moraxella canis | |||
MORAXELLA CATARRHALIS | C76210 | BRANHAMELLA CATARRHALIS | Any bacterial organism that can be assigned to the species Moraxella catarrhalis. | Moraxella catarrhalis | ||
MORAXELLA LACUNATA | C86526 | MORAXELLA LIQUEFACIENS | Any bacterial organism that can be assigned to the species Moraxella lacunata. | Moraxella lacunata | ||
MORAXELLA LINCOLNII | C86527 | Any bacterial organism that can be assigned to the species Moraxella lincolnii. | Moraxella lincolnii | |||
MORAXELLA NONLIQUEFACIENS | C86528 | Any bacterial organism that can be assigned to the species Moraxella nonliquefaciens. | Moraxella nonliquefaciens | |||
MORAXELLA OBLONGA | C86529 | Any bacterial organism that can be assigned to the species Moraxella oblonga. | Moraxella oblonga | |||
MORAXELLA OSLOENSIS | C86530 | Any bacterial organism that can be assigned to the species Moraxella osloensis. | Moraxella osloensis | |||
MORAXELLA | C86009 | BRANHAMELLA SPECIES | Any bacteria that is not assigned to the species level but can be assigned to the Moraxella genus level. | Moraxella | ||
MORGANELLA MORGANII | C86015 | PROTEUS MORGANII | Any bacterial organism that can be assigned to the species Morganella morganii. | Morganella morganii | ||
MORGANELLA | C86531 | Any bacteria that is not assigned to the species level but can be assigned to the Morganella genus level. | Morganella | |||
MYCOBACTERIUM ABSCESSUS | C86533 | MYCOBACTERIUM CHELONAE SUBSP. ABSCESSUS | Any bacterial organism that can be assigned to the species Mycobacterium abscessus. | Mycobacterium abscessus | ||
MYCOBACTERIUM AFRICANUM | C85544 | Any bacterial organism that can be assigned to the species Mycobacterium africanum. | Mycobacterium africanum | |||
MYCOBACTERIUM AVIUM | C86535 | Any bacterial organism that can be assigned to the species Mycobacterium avium. | Mycobacterium avium | |||
MYCOBACTERIUM AVIUM COMPLEX | C76368 | A non-taxonomic grouping of bacteria assigned to and including at least three related subspecies from the Mycobacterium avium species. | Mycobacterium avium complex | |||
MYCOBACTERIUM CHELONAE | C86536 | MYCOBACTERIUM CHELONAE SUBSP. CHELONAE | Any bacterial organism that can be assigned to the species Mycobacterium chelonae. | Mycobacterium chelonae | ||
MYCOBACTERIUM FLAVESCENS | C86537 | Any bacterial organism that can be assigned to the species Mycobacterium flavescens. | Mycobacterium flavescens | |||
MYCOBACTERIUM FORTUITUM | C86538 | Any bacterial organism that can be assigned to the species Mycobacterium fortuitum. | Mycobacterium fortuitum | |||
MYCOBACTERIUM FORTUITUM COMPLEX | C86539 | A non-taxonomic grouping of bacteria assigned to and including related species from the Mycobacterium genus. | Mycobacterium fortuitum Complex | |||
MYCOBACTERIUM GASTRI | C86540 | Any bacterial organism that can be assigned to the species Mycobacterium gastri. | Mycobacterium gastri | |||
MYCOBACTERIUM GORDONAE | C86541 | MYCOBACTERIUM AQUAE | Any bacterial organism that can be assigned to the species Mycobacterium gordonae. | Mycobacterium gordonae | ||
MYCOBACTERIUM HAEMOPHILUM | C86542 | Any bacterial organism that can be assigned to the species Mycobacterium haemophilum. | Mycobacterium haemophilum | |||
MYCOBACTERIUM KANSASII | C85543 | Any bacterial organism that can be assigned to the species Mycobacterium kansasii. | Mycobacterium kansasii | |||
MYCOBACTERIUM LEPRAE | C86544 | Any bacterial organism that can be assigned to the species Mycobacterium leprae. | Mycobacterium leprae | |||
MYCOBACTERIUM MARINUM | C86545 | MYCOBACTERIUM BALNEI | Any bacterial organism that can be assigned to the species Mycobacterium marinum. | Mycobacterium marinum | ||
MYCOBACTERIUM PEREGRINUM | C86546 | Any bacterial organism that can be assigned to the species Mycobacterium peregrinum. | Mycobacterium peregrinum | |||
MYCOBACTERIUM SCROFULACEUM | C86547 | Any bacterial organism that can be assigned to the species Mycobacterium scrofulaceum. | Mycobacterium scrofulaceum | |||
MYCOBACTERIUM SIMIAE | C86548 | MYCOBACTERIUM HABANA | Any bacterial organism that can be assigned to the species Mycobacterium simiae. | Mycobacterium simiae | ||
MYCOBACTERIUM SMEGMATIS | C86590 | Any bacterial organism that can be assigned to the species Mycobacterium smegmatis. | Mycobacterium smegmatis | |||
MYCOBACTERIUM | C76369 | Any bacteria that is not assigned to the species level but can be assigned to the Mycobacterium genus level. | Mycobacterium | |||
MYCOBACTERIUM SZULGAI | C86591 | Any bacterial organism that can be assigned to the species Mycobacterium szulgai. | Mycobacterium szulgai | |||
MYCOBACTERIUM TERRAE | C86592 | Any bacterial organism that can be assigned to the species Mycobacterium terrae. | Mycobacterium terrae | |||
MYCOBACTERIUM THERMORESISTIBILE | C86593 | Any bacterial organism that can be assigned to the species Mycobacterium thermoresistibile. | Mycobacterium thermoresistibile | |||
MYCOBACTERIUM TUBERCULOSIS | C76370 | Any bacterial organism that can be assigned to the species Mycobacterium tuberculosis. | Mycobacterium tuberculosis | |||
MYCOBACTERIUM TUBERCULOSIS COMPLEX | C86594 | A non-taxonomic grouping of bacteria assigned to and including related species from the Mycobacterium genus. | Mycobacterium tuberculosis Complex | |||
MYCOBACTERIUM ULCERANS | C86595 | MYCOBACTERIUM BURULI | Any bacterial organism that can be assigned to the species Mycobacterium ulcerans. | Mycobacterium ulcerans | ||
MYCOPLASMA HOMINIS | C86597 | Any bacterial organism that can be assigned to the species Mycoplasma hominis. | Mycoplasma hominis | |||
MYCOPLASMA ORALE | C86598 | Any bacterial organism that can be assigned to the species Mycoplasma orale. | Mycoplasma orale | |||
MYCOPLASMA PNEUMONIAE | C86599 | Any bacterial organism that can be assigned to the species Mycoplasma pneumoniae. | Mycoplasma pneumoniae | |||
MYCOPLASMA | C73540 | Any bacteria that is not assigned to the species level but can be assigned to the Mycoplasma genus level. | Mycoplasma | |||
MYROIDES ODORATUS | C86954 | FLAVOBACTERIUM ODORATUM | Any bacterial organism that can be assigned to the species Myroides odoratus. | Myroides odoratus | ||
MYROIDES | C86953 | Any bacteria that is not assigned to the species level but can be assigned to the Myroides genus level. | Myroides | |||
NEISSERIA CANIS | C86600 | Any bacterial organism that can be assigned to the species Neisseria canis. | Neisseria canis | |||
NEISSERIA CINEREA | C86601 | MICROCOCCUS CINEREUS | Any bacterial organism that can be assigned to the species Neisseria cinerea. | Neisseria cinerea | ||
NEISSERIA FLAVESCENS | C86602 | Any bacterial organism that can be assigned to the species Neisseria flavescens. | Neisseria flavescens | |||
NEISSERIA GONORRHOEAE | C86603 | Any bacterial organism that can be assigned to the species Neisseria gonorrhoeae. | Neisseria gonorrhoeae | |||
NEISSERIA LACTAMICA | C86604 | Any bacterial organism that can be assigned to the species Neisseria lactamica. | Neisseria lactamica | |||
NEISSERIA MENINGITIDIS | C86605 | BETA-LACTAMASE NEGATIVE NEISSERIA MENINGITIDIS | Any bacterial organism that can be assigned to the species Neisseria meningitidis. | Neisseria meningitidis | ||
NEISSERIA MUCOSA | C86606 | Any bacterial organism that can be assigned to the species Neisseria mucosa. | Neisseria mucosa | |||
NEISSERIA POLYSACCHAREA | C86607 | Any bacterial organism that can be assigned to the species Neisseria polysaccharea. | Neisseria polysaccharea | |||
NEISSERIA SICCA | C86608 | Any bacterial organism that can be assigned to the species Neisseria sicca. | Neisseria sicca | |||
NEISSERIA | C76371 | Any bacteria that is not assigned to the species level but can be assigned to the Neisseria genus level. | Neisseria | |||
NEISSERIA SUBFLAVA | C86609 | Any bacterial organism that can be assigned to the species Neisseria subflava. | Neisseria subflava | |||
NEISSERIA WEAVERII | C86610 | CDC GROUP M-5 | Any bacterial organism that can be assigned to the species Neisseria weaverii. | Neisseria weaverii | ||
NOCARDIA ASTEROIDES | C86611 | Any bacterial organism that can be assigned to the species Nocardia asteroides. | Nocardia asteroides | |||
NOCARDIA ASTEROIDES COMPLEX | C86612 | A non-taxonomic grouping of bacteria assigned to and including at least four related species from the Nocardia genus. | Nocardia asteroides Complex | |||
NOCARDIA BRASILIENSIS | C86613 | Any bacterial organism that can be assigned to the species Nocardia brasiliensis. | Nocardia brasiliensis | |||
NOCARDIA DASSONVILLEI | C86614 | Any bacterial organism that can be assigned to the species Nocardia dassonvillei. | Nocardia dassonvillei | |||
NOCARDIA FARCINICA | C86615 | Any bacterial organism that can be assigned to the species Nocardia farcinica. | Nocardia farcinica | |||
NOCARDIA NOVA | C86616 | Any bacterial organism that can be assigned to the species Nocardia nova. | Nocardia nova | |||
NOCARDIA OTITIDISCAVIARUM | C86617 | NOCARDIA CAVIAE | Any bacterial organism that can be assigned to the species Nocardia otitidiscaviarum. | Nocardia otitidiscaviarum | ||
NOCARDIA | C76372 | Any bacteria that is not assigned to the species level but can be assigned to the Nocardia genus level. | Nocardia | |||
NON-FERMENTATIVE GRAM-NEGATIVE BACILLUS | C86618 | NON-FERMENTATIVE GRAM-NEGATIVE ROD | Any rod-shaped, anaerobic bacteria that cannot convert carbohydrates into acids and alcohols and has a cell wall that contains low levels of peptidoglycan and stains pink with the Gram staining technique. | Non-Fermentative Gram Negative Bacillus | ||
OCHROBACTRUM ANTHROPI | C86620 | ACHROMOBACTER SUBSP. BIOTYPE 1 | Any bacterial organism that can be assigned to the species Ochrobactrum anthropi. | Ochrobactrum anthropi | ||
OCHROBACTRUM INTERMEDIUM | C86621 | Any bacterial organism that can be assigned to the species Ochrobactrum intermedium. | Ochrobactrum intermedium | |||
OCHROBACTRUM | C86619 | Any bacteria that is not assigned to the species level but can be assigned to the Ochrobactrum genus level. | Ochrobactrum | |||
OERSKOVIA | C86622 | Any bacteria that is not assigned to the species level but can be assigned to the Oerskovia genus level. | Oerskovia | |||
OERSKOVIA TURBATA | C86623 | Any bacterial organism that can be assigned to the species Oerskovia turbata. | Oerskovia turbata | |||
OLIGELLA | C86624 | Any bacteria that is not assigned to the species level but can be assigned to the Oligella genus level. | Oligella | |||
OLIGELLA UREOLYTICA | C86625 | CDC GROUP IVE | Any bacterial organism that can be assigned to the species Oligella ureolytica. | Oligella ureolytica | ||
OLIGELLA URETHRALIS | C86626 | CDC GROUP M-4 | Any bacterial organism that can be assigned to the species Oligella urethralis. | Oligella urethralis | ||
OLSENELLA | C86627 | Any bacteria that is not assigned to the species level but can be assigned to the Olsenella genus level. | Olsenella | |||
OLSENELLA ULI | C86628 | LACTOBACILLUS ULI | Any bacterial organism that can be assigned to the species Olsenella uli. | Olsenella uli | ||
PANDORAEA PNOMENUSA | C86630 | Any bacterial organism that can be assigned to the species Pandoraea pnomenusa. | Pandoraea pnomenusa | |||
PANDORAEA | C86629 | Any bacteria that is not assigned to the species level but can be assigned to the Pandoraea genus level. | Pandoraea | |||
PANTOEA AGGLOMERANS | C86632 | ENTEROBACTER AGGLOMERANS | Any bacterial organism that can be assigned to the species Pantoea agglomerans. | Pantoea agglomerans | ||
PANTOEA | C86631 | Any bacteria that is not assigned to the species level but can be assigned to the Pantoea genus level. | Pantoea | |||
PARABACTEROIDES DISTASONIS | C86634 | BACTEROIDES DISTASONIS | Any bacterial organism that can be assigned to the species Parabacteroides distasonis. | Parabacteroides distasonis | ||
PARABACTEROIDES MERDAE | C86635 | BACTEROIDES MERDAE;BACTEROIDES FRAGILIS T4-1 | Any bacterial organism that can be assigned to the species Parabacteroides merdae. | Parabacteroides merdae | ||
PARABACTEROIDES | C86633 | Any bacteria that is not assigned to the species level but can be assigned to the Parabacteroides genus level. | Parabacteroides | |||
PARVIMONAS MICRA | C86901 | PEPTOSTREPTOCOCCUS MICROS;MICROMONAS MICROS | Any bacterial organism that can be assigned to the species Parvimonas micra. | Parvimonas micra | ||
PARVIMONAS | C86900 | Any bacteria that is not assigned to the species level but can be assigned to the Parvimonas genus level. | Parvimonas | |||
PASTEURELLA AEROGENES | C86637 | Any bacterial organism that can be assigned to the species Pasteurella aerogenes. | Pasteurella aerogenes | |||
PASTEURELLA BETTYAE | C86638 | CDC GROUP HB-5 | Any bacterial organism that can be assigned to the species Pasteurella bettyae. | Pasteurella bettyae | ||
PASTEURELLA CANIS | C86639 | PASTEURELLA MULTOCIDA BIOTYPE 6 | Any bacterial organism that can be assigned to the species Pasteurella canis. | Pasteurella canis | ||
PASTEURELLA MULTOCIDA | C76373 | PASTEURELLA SEPTICA | Any bacterial organism that can be assigned to the species Pasteurella multocida. | Pasteurella multocida | ||
PASTEURELLA PNEUMOTROPICA | C86640 | Any bacterial organism that can be assigned to the species Pasteurella pneumotropica. | Pasteurella pneumotropica | |||
PASTEURELLA | C86636 | Any bacteria that is not assigned to the species level but can be assigned to the Pasteurella genus level. | Pasteurella | |||
PEDIOCOCCUS | C86641 | Any bacteria that is not assigned to the species level but can be assigned to the Pediococcus genus level. | Pediococcus | |||
PEPTOCOCCUS NIGER | C86643 | MICROCOCCUS NIGER | Any bacterial organism that can be assigned to the species Peptococcus niger. | Peptococcus niger | ||
PEPTOCOCCUS | C86642 | Any bacteria that is not assigned to the species level but can be assigned to the Peptococcus genus level. | Peptococcus | |||
PEPTONIPHILUS ASACCHAROLYTICUS | C86903 | PEPTOCOCCUS ASACCHAROLYTICUS;PEPTOSTREPTOCOCCUS ASACCHAROLYTICUS | Any bacterial organism that can be assigned to the species Peptoniphilus asaccharolyticus. | Peptoniphilus asaccharolyticus | ||
PEPTONIPHILUS INDOLICUS | C86904 | PEPTOSTREPTOCOCCUS INDOLICUS | Any bacterial organism that can be assigned to the species Peptoniphilus indolicus. | Peptoniphilus indolicus | ||
PEPTONIPHILUS | C86902 | Any bacteria that is not assigned to the species level but can be assigned to the Peptoniphilus genus level. | Peptoniphilus | |||
PEPTOSTREPTOCOCCUS ANAEROBIUS | C86645 | Any bacterial organism that can be assigned to the species Peptostreptococcus anaerobius. | Peptostreptococcus anaerobius | |||
PEPTOSTREPTOCOCCUS | C86644 | Any bacteria that is not assigned to the species level but can be assigned to the Peptostreptococcus genus level. | Peptostreptococcus | |||
PHOTOBACTERIUM DAMSELAE | C86647 | VIBRIO DAMSELA;CDC GROUP EF-5, PHOTOBACTERIUM DAMSELAE SUBSP. DAMSELAE | Any bacterial organism that can be assigned to the species Photobacterium damselae. | Photobacterium damselae | ||
PHOTOBACTERIUM | C86646 | Any bacteria that is not assigned to the species level but can be assigned to the Photobacterium genus level. | Photobacterium | |||
PHOTORHABDUS LUMINESCENS | C86649 | Any bacterial organism that can be assigned to the species Photorhabdus luminescens. | Photorhabdus luminescens | |||
PHOTORHABDUS | C86648 | Any bacteria that is not assigned to the species level but can be assigned to the Photorhabdus genus level. | Photorhabdus | |||
PLANOCOCCUS | C86650 | Any bacteria that is not assigned to the species level but can be assigned to the Planococcus genus level. | Planococcus | |||
PLESIOMONAS SHIGELLOIDES | C86652 | AEROMONAS SHIGELLOIDES | Any bacterial organism that can be assigned to the species Plesiomonas shigelloides. | Plesiomonas shigelloides | ||
PLESIOMONAS | C86651 | Any bacteria that is not assigned to the species level but can be assigned to the Plesiomonas genus level. | Plesiomonas | |||
PORPHYROMONAS ASACCHAROLYTICA | C86654 | BACTEROIDES ASACCHAROLYTICUS | Any bacterial organism that can be assigned to the species Porphyromonas asaccharolytica. | Porphyromonas asaccharolytica | ||
PORPHYROMONAS CATONIAE | C86655 | Any bacterial organism that can be assigned to the species Porphyromonas catoniae. | Porphyromonas catoniae | |||
PORPHYROMONAS ENDODONTALIS | C86656 | BACTEROIDES ENDODONTALIS | Any bacterial organism that can be assigned to the species Porphyromonas endodontalis. | Porphyromonas endodontalis | ||
PORPHYROMONAS GINGIVALIS | C86657 | BACTEROIDES GINGIVALIS | Any bacterial organism that can be assigned to the species Porphyromonas gingivalis. | Porphyromonas gingivalis | ||
PORPHYROMONAS LEVII | C86658 | BACTEROIDES LEVII;BACTEROIDES MELANINOGENICUS SUBSP. LEVII | Any bacterial organism that can be assigned to the species Porphyromonas levii. | Porphyromonas levii | ||
PORPHYROMONAS SOMERAE | C86659 | Any bacterial organism that can be assigned to the species Porphyromonas somerae. | Porphyromonas somerae | |||
PORPHYROMONAS | C86653 | Any bacteria that is not assigned to the species level but can be assigned to the Porphyromonas genus level. | Porphyromonas | |||
PREVOTELLA BIVIA | C86661 | BACTEROIDES BIVIA | Any bacterial organism that can be assigned to the species Prevotella bivia. | Prevotella bivia | ||
PREVOTELLA BREVIS | C86662 | BACTEROIDES RUMINICOLA SUBSP. BREVUS;BACTEROIDES RUMINICOLA SUBSP. BREVIS | Any bacterial organism that can be assigned to the species Prevotella brevis. | Prevotella brevis | ||
PREVOTELLA BUCCAE | C86663 | BACTEROIDES BUCCAE | Any bacterial organism that can be assigned to the species Prevotella buccae. | Prevotella buccae | ||
PREVOTELLA BUCCALIS | C86664 | Any bacterial organism that can be assigned to the species Prevotella buccalis. | Prevotella buccalis | |||
PREVOTELLA CORPORIS | C86665 | Any bacterial organism that can be assigned to the species Prevotella corporis. | Prevotella corporis | |||
PREVOTELLA DENTALIS | C86666 | Any bacterial organism that can be assigned to the species Prevotella dentalis. | Prevotella dentalis | |||
PREVOTELLA DENTICOLA | C86667 | BACTEROIDES DENTICOLA | Any bacterial organism that can be assigned to the species Prevotella denticola. | Prevotella denticola | ||
PREVOTELLA DISIENS | C86668 | BACTEROIDES DISIENS | Any bacterial organism that can be assigned to the species Prevotella disiens. | Prevotella disiens | ||
PREVOTELLA HEPARINOLYTICA | C86669 | BACTEROIDES HEPARINOLYTICUS | Any bacterial organism that can be assigned to the species Prevotella heparinolytica. | Prevotella heparinolytica | ||
PREVOTELLA INTERMEDIA | C86670 | BACTEROIDES INTERMEDIA | Any bacterial organism that can be assigned to the species Prevotella intermedia. | Prevotella intermedia | ||
PREVOTELLA INTERMEDIA/NIGRESCENS GROUP | C86671 | A non-taxonomic grouping of bacteria assigned to the Prevotella genus that include the P. intermedia and P. nigrescens species. | Prevotella intermedia/nigrescens Group | |||
PREVOTELLA LOESCHEII | C86672 | Any bacterial organism that can be assigned to the species Prevotella loescheii. | Prevotella loescheii | |||
PREVOTELLA MELANINOGENICA | C86673 | BACTEROIDES MELANINOGENICUS | Any bacterial organism that can be assigned to the species Prevotella melaninogenica. | Prevotella melaninogenica | ||
PREVOTELLA NIGRESCENS | C86674 | Any bacterial organism that can be assigned to the species Prevotella nigrescens. | Prevotella nigrescens | |||
PREVOTELLA ORALIS | C86675 | BACTEROIDES ORALIS | Any bacterial organism that can be assigned to the species Prevotella oralis. | Prevotella oralis | ||
PREVOTELLA ORIS | C86676 | BACTEROIDES ORIS | Any bacterial organism that can be assigned to the species Prevotella oris. | Prevotella oris | ||
PREVOTELLA RUMINICOLA | C86677 | BACTEROIDES RUMINICOLA | Any bacterial organism that can be assigned to the species Prevotella ruminicola. | Prevotella ruminicola | ||
PREVOTELLA | C86660 | Any bacteria that is not assigned to the species level but can be assigned to the Prevotella genus level. | Prevotella | |||
PREVOTELLA TANNERAE | C86678 | Any bacterial organism that can be assigned to the species Prevotella tannerae. | Prevotella tannerae | |||
PREVOTELLA VERORALIS | C86679 | Any bacterial organism that can be assigned to the species Prevotella veroralis. | Prevotella veroralis | |||
PROPIONIBACTERIUM ACNES | C14378 | BACILLUS ACNES;CORYNEBACTERIUM ACNES;CORYNEBACTERIUM PARVUM;C. PARVUM;CPARV | Any bacterial organism that can be assigned to the species Propionibacterium acnes. | Propionibacterium acnes | ||
PROPIONIBACTERIUM AVIDUM | C86681 | Any bacterial organism that can be assigned to the species Propionibacterium avidum. | Propionibacterium avidum | |||
PROPIONIBACTERIUM GRANULOSUM | C86682 | CORYNEBACTERIUM GRANULOSUM | Any bacterial organism that can be assigned to the species Propionibacterium granulosum. | Propionibacterium granulosum | ||
PROPIONIBACTERIUM PROPIONICUM | C86683 | ACTINOMYCES PROPIONICUS | Any bacterial organism that can be assigned to the species Propionibacterium propionicum. | Propionibacterium propionicum | ||
PROPIONIBACTERIUM | C86013 | Any bacteria that is not assigned to the species level but can be assigned to the Propionibacterium genus level. | Propionibacterium | |||
PROTEUS HAUSERI | C86684 | Any bacterial organism that can be assigned to the species Proteus hauseri. | Proteus hauseri | |||
PROTEUS INCONSTANS | C84582 | PROVIDENCIA INCONSTANS | Any bacterial organism that can be assigned to the species Proteus inconstans. | Proteus inconstans | ||
PROTEUS MIRABILIS | C86019 | Any bacterial organism that can be assigned to the species Proteus mirabilis. | Proteus mirabilis | |||
PROTEUS MYXOFACIENS | C86687 | Any bacterial organism that can be assigned to the species Proteus myxofaciens. | Proteus myxofaciens | |||
PROTEUS PENNERI | C86688 | INDOLE NEGATIVE PROTEUS VULGARIS | Any bacterial organism that can be assigned to the species Proteus penneri. | Proteus penneri | ||
PROTEUS | C76374 | Any bacteria that is not assigned to the species level but can be assigned to the Proteus genus level. | Proteus | |||
PROTEUS VULGARIS | C85250 | Any bacterial organism that can be assigned to the species Proteus vulgaris. | Proteus vulgaris | |||
PROVIDENCIA ALCALIFACIENS | C86691 | Any bacterial organism that can be assigned to the species Providencia alcalifaciens. | Providencia alcalifaciens | |||
PROVIDENCIA HEIMBACHAE | C86692 | Any bacterial organism that can be assigned to the species Providencia heimbachae. | Providencia heimbachae | |||
PROVIDENCIA RETTGERI | C86693 | Any bacterial organism that can be assigned to the species Providencia rettgeri. | Proteus rettgeri | |||
PROVIDENCIA RUSTIGIANII | C86694 | PROVIDENCIA ALCALIFACIENS BIOGROUP 3 | Any bacterial organism that can be assigned to the species Providencia rustigianii. | Providencia rustigianii | ||
PROVIDENCIA | C86690 | Any bacteria that is not assigned to the species level but can be assigned to the Providencia genus level. | Providencia | |||
PROVIDENCIA STUARTII | C86695 | Any bacterial organism that can be assigned to the species Providencia stuartii. | Providencia stuartii | |||
PSEUDOMONAS AERUGINOSA | C86696 | Any bacterial organism that can be assigned to the species Pseudomonas aeruginosa. | Pseudomonas aeruginosa | |||
PSEUDOMONAS ALCALIGENES | C86697 | Any bacterial organism that can be assigned to the species Pseudomonas alcaligenes. | Pseudomonas alcaligenes | |||
PSEUDOMONAS CHLORORAPHIS | C86699 | Any bacterial organism that can be assigned to the species Pseudomonas chlororaphis. | Pseudomonas chlororaphis | |||
PSEUDOMONAS FLUORESCENS/PUTIDA GROUP | C86962 | A non-taxonomic grouping of bacteria assigned to the Pseudomonas genus that include the P. fluorescens and P. putida species. | Pseudomonas fluorescens/putida Group | |||
PSEUDOMONAS LUTEOLA | C86701 | CHRYSEOMONAS LUTEOLA | Any bacterial organism that can be assigned to the species Pseudomonas luteola. | Pseudomonas luteola | ||
PSEUDOMONAS MENDOCINA | C86702 | CDC GROUP VB-2 | Any bacterial organism that can be assigned to the species Pseudomonas mendocina. | Pseudomonas mendocina | ||
PSEUDOMONAS MOSSELII | C86703 | Any bacterial organism that can be assigned to the species Pseudomonas mosselii. | Pseudomonas mosselii | |||
PSEUDOMONAS ORYZIHABITANS | C76319 | FLAVIMONAS ORYZIHABITANS | Any bacterial organism that can be assigned to the species Pseudomonas oryzihabitans. | Pseudomonas oryzihabitans | ||
PSEUDOMONAS PSEUDOALCALIGENES | C86704 | PSEUDOMONAS ALCALIGENES BIOTYPE B | Any bacterial organism that can be assigned to the species Pseudomonas pseudoalcaligenes. | Pseudomonas pseudoalcaligenes | ||
PSEUDOMONAS PUTIDA | C86705 | Any bacterial organism that can be assigned to the species Pseudomonas putida. | Pseudomonas putida | |||
PSEUDOMONAS | C76375 | Any bacteria that is not assigned to the species level but can be assigned to the Pseudomonas genus level. | Pseudomonas | |||
PSEUDOMONAS STUTZERI | C86706 | PSEUDOMONAS GROUP VB-1 | Any bacterial organism that can be assigned to the species Pseudomonas stutzeri. | Pseudomonas stutzeri | ||
PSYCHROBACTER IMMOBILIS | C86708 | Any bacterial organism that can be assigned to the species Psychrobacter immobilis. | Psychrobacter immobilis | |||
PSYCHROBACTER PHENYLPYRUVICUS | C86709 | MORAXELLA PHENYLPYRUVICA;CDC GROUP M-2 | Any bacterial organism that can be assigned to the species Psychrobacter phenylpyruvicus. | Psychrobacter phenylpyruvicus | ||
PSYCHROBACTER | C86707 | Any bacteria that is not assigned to the species level but can be assigned to the Psychrobacter genus level. | Psychrobacter | |||
RAHNELLA AQUATILIS | C86711 | Any bacterial organism that can be assigned to the species Rahnella aquatilis. | Rahnella aquatilis | |||
RAHNELLA | C86710 | Any bacteria that is not assigned to the species level but can be assigned to the Rahnella genus level. | Rahnella | |||
RALSTONIA PICKETTII | C86713 | BURKHOLDERIA PICKETTII;PSEUDOMONAS PICKETTII | Any bacterial organism that can be assigned to the species Ralstonia pickettii. | Ralstonia pickettii | ||
RALSTONIA | C86712 | Any bacteria that is not assigned to the species level but can be assigned to the Ralstonia genus level. | Ralstonia | |||
RAOULTELLA ORNITHINOLYTICA | C86715 | KLEBSIELLA ORNITHINOLYTICA | Any bacterial organism that can be assigned to the species Raoultella ornithinolytica. | Raoultella ornithinolytica | ||
RAOULTELLA PLANTICOLA | C86716 | Any bacterial organism that can be assigned to the species Raoultella planticola. | Raoultella planticola | |||
RAOULTELLA | C86714 | Any bacteria that is not assigned to the species level but can be assigned to the Raoultella genus level. | Raoultella | |||
RAOULTELLA TERRIGENA | C86717 | KLEBSIELLA TERRIGENA | Any bacterial organism that can be assigned to the species Raoultella terrigena. | Raoultella terrigena | ||
RHIZOBIUM | C86718 | Any bacteria that is not assigned to the species level but can be assigned to the Rhizobium genus level. | Rhizobium | |||
RHODOCOCCUS EQUI | C86719 | CORYNEBACTERIUM EQUI | Any bacterial organism that can be assigned to the species Rhodococcus equi. | Rhodococcus equi | ||
RHODOCOCCUS | C76378 | Any bacteria that is not assigned to the species level but can be assigned to the Rhodococcus genus level. | Rhodococcus | |||
RICKETTSIA AFRICAE | C86720 | Any bacterial organism that can be assigned to the species Rickettsia africae. | Rickettsia africae | |||
RICKETTSIA FELIS | C86721 | Any bacterial organism that can be assigned to the species Rickettsia felis. | Rickettsia felis | |||
RICKETTSIA JAPONICA | C86722 | Any bacterial organism that can be assigned to the species Rickettsia japonica. | Rickettsia japonica | |||
RICKETTSIA PROWAZEKII | C86723 | Any bacterial organism that can be assigned to the species Rickettsia prowazekii. | Rickettsia prowazekii | |||
RICKETTSIA RICKETTSII | C86724 | Any bacterial organism that can be assigned to the species Rickettsia rickettsii. | Rickettsia rickettsii | |||
RICKETTSIA | C76379 | Any bacteria that is not assigned to the species level but can be assigned to the Rickettsia genus level. | Rickettsia | |||
RICKETTSIA TYPHI | C86725 | Any bacterial organism that can be assigned to the species Rickettsia typhi. | Rickettsia typhi | |||
ROSEOMONAS | C86726 | Any bacteria that is not assigned to the species level but can be assigned to the Roseomonas genus level. | Roseomonas | |||
ROTHIA DENTOCARIOSA | C86728 | NOCARDIA DENTOCARIOSA | Any bacterial organism that can be assigned to the species Rothia dentocariosa. | Rothia dentocariosa | ||
ROTHIA MUCILAGINOSA | C76382 | STOMATOCOCCUS MUCILAGINOSUS | Any bacterial organism that can be assigned to the species Rothia mucilaginosa. | Rothia mucilaginosa | ||
ROTHIA | C86727 | Any bacteria that is not assigned to the species level but can be assigned to the Rothia genus level. | Rothia | |||
RUMINOCOCCUS PRODUCTUS | C86730 | PEPTOSTREPTOCOCCUS PRODUCTUS | Any bacterial organism that can be assigned to the species Ruminococcus productus. | Ruminococcus productus | ||
RUMINOCOCCUS | C86729 | Any bacteria that is not assigned to the species level but can be assigned to the Ruminococcus genus level. | Ruminococcus | |||
SALMONELLA ENTERICA | C86731 | Any bacterial organism that can be assigned to the species Salmonella enterica. | Salmonella enterica | |||
SALMONELLA ENTERICA SUBSP. ARIZONAE | C86910 | Any bacterial organism that can be assigned to the species Salmonella enterica subspecies arizonae. | Salmonella enterica subsp arizonae | |||
SALMONELLA ENTERICA SUBSP. ENTERICA | C86913 | Any bacterial organism that can be assigned to the species Salmonella enterica subspecies enterica. | Salmonella enterica subsp enterica | |||
SALMONELLA SEROTYPE CHOLERAESUIS | C86915 | Any bacterial organism that can be assigned to the genus Salmonella with serotype Choleraesuis. | Salmonella Serotype Choleraesuis | |||
SALMONELLA SEROTYPE DUBLIN | C86918 | Any bacterial organism that can be assigned to the genus Salmonella with serotype Dublin. | Salmonella Serotype Dublin | |||
SALMONELLA SEROTYPE ENTERITIDIS | C86919 | Any bacterial organism that can be assigned to the genus Salmonella with serotype Enteritidis. | Salmonella Serotype Enteritidis | |||
SALMONELLA SEROTYPE NEWPORT | C86921 | Any bacterial organism that can be assigned to the genus Salmonella with serotype Newport. | Salmonella Serotype Newport | |||
SALMONELLA SEROTYPE PARATYPHI A | C86922 | Any bacterial organism that can be assigned to the genus Salmonella with serotype Paratyphi A. | Salmonella Serotype Paratyphi A | |||
SALMONELLA SEROTYPE PARATYPHI B | C86924 | Any bacterial organism that can be assigned to the genus Salmonella with serotype Paratyphi B. | Salmonella Serotype Paratyphi B | |||
SALMONELLA SEROTYPE PARATYPHI C | C86925 | Any bacterial organism that can be assigned to the genus Salmonella with serotype Paratyphi C. | Salmonella Serotype Paratyphi C | |||
SALMONELLA SEROTYPE TYPHI | C86926 | Any bacterial organism that can be assigned to the genus Salmonella with serotype Typhi. | Salmonella Serotype Typhi | |||
SALMONELLA SEROTYPE TYPHIMURIUM | C86927 | Any bacterial organism that can be assigned to the genus Salmonella with serotype Typhimurium. | Salmonella Serotype Typhimurium | |||
SALMONELLA | C76380 | SALMONELLA SEROGROUP D (NOT S. TYPHI) | Any bacteria that is not assigned to the species level but can be assigned to the Salmonella genus level. | Salmonella | ||
SELENOMONAS NOXIA | C86733 | Any bacterial organism that can be assigned to the species Selenomonas noxia. | Selenomonas noxia | |||
SELENOMONAS | C86732 | Any bacteria that is not assigned to the species level but can be assigned to the Selenomonas genus level. | Selenomonas | |||
SELENOMONAS SPUTIGENA | C86734 | Any bacterial organism that can be assigned to the species Selenomonas sputigena. | Selenomonas sputigena | |||
SERRATIA FICARIA | C86736 | Any bacterial organism that can be assigned to the species Serratia ficaria. | Serratia ficaria | |||
SERRATIA FONTICOLA | C86737 | Any bacterial organism that can be assigned to the species Serratia fonticola. | Serratia fonticola | |||
SERRATIA LIQUEFACIENS | C86738 | ENTEROBACTER LIQUEFACIENS | Any bacterial organism that can be assigned to the species Serratia liquefaciens. | Serratia liquefaciens | ||
SERRATIA MARCESCENS | C14272 | S. MARCESCENS | Any bacterial organism that can be assigned to the species Serratia marcescens. | Serratia marcescens | ||
SERRATIA ODORIFERA | C86739 | Any bacterial organism that can be assigned to the species Serratia odorifera. | Serratia odorifera | |||
SERRATIA PLYMUTHICA | C86740 | Any bacterial organism that can be assigned to the species Serratia plymuthica. | Serratia plymuthica | |||
SERRATIA RUBIDAEA | C86741 | SERRATIA MARINORUBRA | Any bacterial organism that can be assigned to the species Serratia rubidaea. | Serratia rubidaea | ||
SERRATIA | C86010 | SERRATIA | Any bacteria that is not assigned to the species level but can be assigned to the Serratia genus level. | Serratia | ||
SHEWANELLA PUTREFACIENS | C86743 | ALTEROMONAS PUTREFACIENS;PSEUDOMONAS PUTREFACIENS | Any bacterial organism that can be assigned to the species Shewanella putrefaciens. | Shewanella putrefaciens | ||
SHEWANELLA | C86742 | Any bacteria that is not assigned to the species level but can be assigned to the Shewanella genus level. | Shewanella | |||
SHIGELLA BOYDII | C86744 | SHIGELLA BIOGROUP C | Any bacterial organism that can be assigned to the species Shigella boydii. | Shigella boydii | ||
SHIGELLA DYSENTERIAE | C86745 | SHIGELLA BIOGROUP A | Any bacterial organism that can be assigned to the species Shigella dysenteriae. | Shigella dysenteriae | ||
SHIGELLA FLEXNERI | C86746 | SHIGELLA BIOGROUP B | Any bacterial organism that can be assigned to the species Shigella flexneri. | Shigella flexneri | ||
SHIGELLA SONNEI | C86747 | SHIGELLA BIOGROUP D | Any bacterial organism that can be assigned to the species Shigella sonnei. | Shigella sonnei | ||
SHIGELLA | C76381 | Any bacteria that is not assigned to the species level but can be assigned to the Shigella genus level. | Shigella | |||
SPHINGOBACTERIUM MIZUTAII | C86958 | FLAVOBACTERIUM MIZUTAE | Any bacterial organism that can be assigned to the species Sphingobacterium mizutaii. | Sphingobacterium mizutaii | ||
SPHINGOBACTERIUM MULTIVORUM | C86959 | CDC GROUP IIK-2 | Any bacterial organism that can be assigned to the species Sphingobacterium multivorum. | Sphingobacterium multivorum | ||
SPHINGOBACTERIUM | C86957 | Any bacteria that is not assigned to the species level but can be assigned to the Sphingobacterium genus level. | Sphingobacterium | |||
SPHINGOBACTERIUM SPIRITIVORUM | C86960 | CDC GROUP IIK-3 | Any bacterial organism that can be assigned to the species Sphingobacterium spiritivorum. | Sphingobacterium spiritivorum | ||
SPHINGOBACTERIUM THALPOPHILUM | C86961 | FLAVOBACTERIUM THALPOPHILUM | Any bacterial organism that can be assigned to the species Sphingobacterium thalpophilum. | Sphingobacterium thalpophilum | ||
SPHINGOMONAS PAUCIMOBILIS | C86749 | CDC GROUP IIK-1;PSEUDOMONAS PAUCIMOBILIS | Any bacterial organism that can be assigned to the species Sphingomonas paucimobilis. | Sphingomonas paucimobilis | ||
SPHINGOMONAS | C86748 | Any bacteria that is not assigned to the species level but can be assigned to the Sphingomonas genus level. | Sphingomonas | |||
STAPHYLOCOCCUS ARLETTAE | C86750 | Any bacterial organism that can be assigned to the species Staphylococcus arlettae. | Staphylococcus arlettae | |||
STAPHYLOCOCCUS AUREUS | C50921 | STAPH. AUREUS | Any bacterial organism that can be assigned to the species Staphylococcus aureus. | Staphylococcus aureus | ||
STAPHYLOCOCCUS AURICULARIS | C86751 | Any bacterial organism that can be assigned to the species Staphylococcus auricularis. | Staphylococcus auricularis | |||
STAPHYLOCOCCUS CAPITIS | C86752 | Any bacterial organism that can be assigned to the species Staphylococcus capitis. | Staphylococcus capitis | |||
STAPHYLOCOCCUS CAPRAE | C86753 | Any bacterial organism that can be assigned to the species Staphylococcus caprae. | Staphylococcus caprae | |||
STAPHYLOCOCCUS CARNOSUS | C86754 | Any bacterial organism that can be assigned to the species Staphylococcus carnosus. | Staphylococcus carnosus | |||
STAPHYLOCOCCUS CHROMOGENES | C86755 | Any bacterial organism that can be assigned to the species Staphylococcus chromogenes. | Staphylococcus chromogenes | |||
STAPHYLOCOCCUS COHNII | C86756 | Any bacterial organism that can be assigned to the species Staphylococcus cohnii. | Staphylococcus cohnii | |||
STAPHYLOCOCCUS EPIDERMIDIS | C86757 | STAPHYLOCOCCUS ALBUS | Any bacterial organism that can be assigned to the species Staphylococcus epidermidis. | Staphylococcus epidermidis | ||
STAPHYLOCOCCUS EQUORUM | C86758 | Any bacterial organism that can be assigned to the species Staphylococcus equorum. | Staphylococcus equorum | |||
STAPHYLOCOCCUS FELIS | C86759 | Any bacterial organism that can be assigned to the species Staphylococcus felis. | Staphylococcus felis | |||
STAPHYLOCOCCUS GALLINARUM | C86760 | Any bacterial organism that can be assigned to the species Staphylococcus gallinarum. | Staphylococcus gallinarum | |||
STAPHYLOCOCCUS HAEMOLYTICUS | C86761 | STAPH. HAEMOLYTICUS | Any bacterial organism that can be assigned to the species Staphylococcus haemolyticus. | Staphylococcus haemolyticus | ||
STAPHYLOCOCCUS HOMINIS | C86762 | COAGULASE NEGATIVE STAPHYLOCOCCUS HOMINIS | Any bacterial organism that can be assigned to the species Staphylococcus hominis. | Staphylococcus hominis | ||
STAPHYLOCOCCUS HYICUS | C86763 | Any bacterial organism that can be assigned to the species Staphylococcus hyicus. | Staphylococcus hyicus | |||
STAPHYLOCOCCUS INTERMEDIUS | C86764 | Any bacterial organism that can be assigned to the species Staphylococcus intermedius. | Staphylococcus intermedius | |||
STAPHYLOCOCCUS KLOOSII | C86765 | Any bacterial organism that can be assigned to the species Staphylococcus kloosii. | Staphylococcus kloosii | |||
STAPHYLOCOCCUS LENTUS | C86766 | Any bacterial organism that can be assigned to the species Staphylococcus lentus. | Staphylococcus lentus | |||
STAPHYLOCOCCUS LUGDUNENSIS | C86767 | Any bacterial organism that can be assigned to the species Staphylococcus lugdunensis. | Staphylococcus lugdunensis | |||
STAPHYLOCOCCUS PASTEURI | C86768 | Any bacterial organism that can be assigned to the species Staphylococcus pasteuri. | Staphylococcus pasteuri | |||
STAPHYLOCOCCUS SACCHAROLYTICUS | C86769 | PEPTOCOCCUS SACCHAROLYTICUS | Any bacterial organism that can be assigned to the species Staphylococcus saccharolyticus. | Staphylococcus saccharolyticus | ||
STAPHYLOCOCCUS SAPROPHYTICUS | C86770 | MICROCOCCUS SUBGROUP 3 | Any bacterial organism that can be assigned to the species Staphylococcus saprophyticus. | Staphylococcus saprophyticus | ||
STAPHYLOCOCCUS SCHLEIFERI | C86771 | Any bacterial organism that can be assigned to the species Staphylococcus schleiferi. | Staphylococcus schleiferi | |||
STAPHYLOCOCCUS SCIURI | C86772 | Any bacterial organism that can be assigned to the species Staphylococcus sciuri. | Staphylococcus sciuri | |||
STAPHYLOCOCCUS SIMULANS | C86773 | Any bacterial organism that can be assigned to the species Staphylococcus simulans. | Staphylococcus simulans | |||
STAPHYLOCOCCUS | C62583 | Any bacteria that is not assigned to the species level but can be assigned to the Staphylococcus genus level. | Staphylococcus | |||
STAPHYLOCOCCUS WARNERI | C86774 | Any bacterial organism that can be assigned to the species Staphylococcus warneri. | Staphylococcus warneri | |||
STAPHYLOCOCCUS XYLOSUS | C86775 | Any bacterial organism that can be assigned to the species Staphylococcus xylosus. | Staphylococcus xylosus | |||
STENOTROPHOMONAS MALTOPHILIA | C76377 | PSEUDOMONAS MALTOPHILIA;XANTHOMONAS MALTOPHILIA | Any bacterial organism that can be assigned to the species Stenotrophomonas maltophilia. | Stenotrophomonas maltophilia | ||
STENOTROPHOMONAS | C86776 | STENOTROPHOMONAS | Any bacteria that is not assigned to the species level but can be assigned to the Stenotrophomonas genus level. | Stenotrophomonas | ||
STREPTOBACILLUS MONILIFORMIS | C86778 | HAVERHILLIA MULTIFORMIS | Any bacterial organism that can be assigned to the species Streptobacillus moniliformis. | Streptobacillus moniliformis | ||
STREPTOBACILLUS | C86777 | Any bacteria that is not assigned to the species level but can be assigned to the Streptobacillus genus level. | Streptobacillus | |||
STREPTOCOCCUS ACIDOMINIMUS | C86779 | Any bacterial organism that can be assigned to the species Streptococcus acidominimus. | Streptococcus acidominimus | |||
STREPTOCOCCUS AGALACTIAE | C86780 | STREPT. GP B(AGALACT) | Any bacterial organism that can be assigned to the species Streptococcus agalactiae. | Streptococcus agalactiae | ||
STREPTOCOCCUS ALACTOLYTICUS | C86781 | Any bacterial organism that can be assigned to the species Streptococcus alactolyticus. | Streptococcus alactolyticus | |||
STREPTOCOCCUS ALPHA-HEMOLYTIC | C86141 | ALPHA-HEMOLYTIC STREPTOCOCCUS | A bacteria that is assigned to the genus Streptococcus that is able to reduce the iron content in hemoglobin in red blood cells, thus producing green-colored colonies on blood agar plates. | Alpha-Hemolytic Streptococcus | ||
STREPTOCOCCUS ANGINOSIS | C86782 | Any bacterial organism that can be assigned to the species Streptococcus anginosis. | Streptococcus anginosis | |||
STREPTOCOCCUS ANGINOSUS GROUP | C86783 | A bacteria that belongs to the Anginosus group of the genus Streptococcus. | Streptococcus anginosus Group | |||
STREPTOCOCCUS BETA-HEMOLYTIC | C86190 | BETA-HEMOLYTIC STREPTOCOCCUS | A bacteria that is assigned to the genus Streptococcus that is able to facilitate the complete rupturing of red blood cells, thus producing wide, clear, zones around colonies on blood agar plates. | Beta-Hemolytic Streptococcus | ||
STREPTOCOCCUS BOVIS | C86784 | Any bacterial organism that can be assigned to the species Streptococcus bovis. | Streptococcus bovis | |||
STREPTOCOCCUS BOVIS GROUP | C86785 | A bacteria that belongs to the Bovis group of the genus Streptococcus. | Streptococcus bovis Group | |||
STREPTOCOCCUS CANIS | C86786 | STREPTOCOCCUS DYSGALACTIAE | Any bacterial organism that can be assigned to the species Streptococcus canis. | Streptococcus canis | ||
STREPTOCOCCUS CONSTELLATUS | C86787 | Any bacterial organism that can be assigned to the species Streptococcus constellatus. | Streptococcus constellatus | |||
STREPTOCOCCUS CRISTATUS | C86788 | Any bacterial organism that can be assigned to the species Streptococcus cristatus. | Streptococcus cristatus | |||
STREPTOCOCCUS DYSGALACTIAE SUBSP. EQUISIMILIS | C86906 | STREPTOCOCCUS EQUISIMILIS | Any bacterial organism that can be assigned to the species Streptococcus dysgalactiae subspecies equisimilis. | Streptococcus dysgalactiae subsp equisimilis | ||
STREPTOCOCCUS EQUI | C86789 | Any bacterial organism that can be assigned to the species Streptococcus equi. | Streptococcus equi | |||
STREPTOCOCCUS EQUINUS | C86790 | Any bacterial organism that can be assigned to the species Streptococcus equinus. | Streptococcus equinus | |||
STREPTOCOCCUS GALLOLYTICUS | C86791 | Any bacterial organism that can be assigned to the species Streptococcus gallolyticus. | Streptococcus gallolyticus | |||
STREPTOCOCCUS GAMMA-HEMOLYTIC | C86408 | GAMMA-HEMOLYTIC STREPTOCOCCUS | A bacteria that is assigned to the genus Streptococcus that is unable to facilitate red blood cell lysis. | Gamma-Hemolytic Streptococcus | ||
STREPTOCOCCUS GORDONII | C86792 | Any bacterial organism that can be assigned to the species Streptococcus gordonii. | Streptococcus gordonii | |||
STREPTOCOCCUS INFANTARIUS | C86793 | Any bacterial organism that can be assigned to the species Streptococcus infantarius. | Streptococcus infantarius | |||
STREPTOCOCCUS INTERMEDIUS | C86794 | Any bacterial organism that can be assigned to the species Streptococcus intermedius. | Streptococcus intermedius | |||
STREPTOCOCCUS MILLERI | C86795 | STREPTOCOCCUS MILLERI I | Any bacterial organism that can be assigned to the species Streptococcus milleri. | Streptococcus milleri | ||
STREPTOCOCCUS MILLERI GROUP | C86796 | A bacteria that belongs to the Milleri group of the genus Streptococcus. | Streptococcus milleri Group | |||
STREPTOCOCCUS MITIS GROUP | C86797 | A bacteria that belongs to the Mitis group of the genus Streptococcus. | Streptococcus mitis Group | |||
STREPTOCOCCUS MUTANS GROUP | C86798 | A bacteria that belongs to the Mutans group of the genus Streptococcus. | Streptococcus mutans Group | |||
STREPTOCOCCUS ORALIS | C86799 | Any bacterial organism that can be assigned to the species Streptococcus oralis. | Streptococcus oralis | |||
STREPTOCOCCUS PARASANGUINIS | C86800 | STREPTOCOCCUS PARASANGUIS | Any bacterial organism that can be assigned to the species Streptococcus parasanguinis. | Streptococcus parasanguinis | ||
STREPTOCOCCUS PNEUMONIAE | C76384 | DIPLOCOCCUS PNEUMONIAE | Any bacterial organism that can be assigned to the species Streptococcus pneumoniae. | Streptococcus pneumoniae | ||
STREPTOCOCCUS PORCINUS | C86802 | Any bacterial organism that can be assigned to the species Streptococcus porcinus. | Streptococcus porcinus | |||
STREPTOCOCCUS PYOGENES | C86803 | GROUP A BETA-HEMOLYTIC STREPTOCOCCUS PYOGENES | Any bacterial organism that can be assigned to the species Streptococcus pyogenes. | Streptococcus pyogenes | ||
STREPTOCOCCUS SALIVARIUS | C86804 | Any bacterial organism that can be assigned to the species Streptococcus salivarius. | Streptococcus salivarius | |||
STREPTOCOCCUS SALIVARIUS GROUP | C86805 | A bacteria that belongs to the Salivarius group of the genus Streptococcus. | Streptococcus salivarius Group | |||
STREPTOCOCCUS SANGUINIS | C86806 | STREPTOCOCCUS SANGUIS | Any bacterial organism that can be assigned to the species Streptococcus sanguinis. | Streptococcus sanguinis | ||
STREPTOCOCCUS | C76383 | STREPTOCOCCI SP. | Any bacteria that is not assigned to the species level but can be assigned to the Streptococcus genus level. | Streptococcus | ||
STREPTOCOCCUS SUIS | C86807 | Any bacterial organism that can be assigned to the species Streptococcus suis. | Streptococcus suis | |||
STREPTOCOCCUS THERMOPHILUS | C86808 | Any bacterial organism that can be assigned to the species Streptococcus thermophilus. | Streptococcus thermophilus | |||
STREPTOCOCCUS UBERIS | C86809 | Any bacterial organism that can be assigned to the species Streptococcus uberis. | Streptococcus uberis | |||
STREPTOCOCCUS VESTIBULARIS | C86810 | Any bacterial organism that can be assigned to the species Streptococcus vestibularis. | Streptococcus vestibularis | |||
STREPTOCOCCUS VIRIDANS GROUP | C86811 | STREPTOCOCCUS VIRIDANS;VIRIDANS STREPTOCOCCUS | A non-taxonomic grouping of species within the Streptococcus genus that are alpha-hemolytic and do not express Lancefield antigens. | Streptococcus viridans Group | ||
STREPTOMYCES ALBUS | C86812 | Any bacterial organism that can be assigned to the species Streptomyces albus. | Streptomyces albus | |||
STREPTOMYCES GRISEUS | C86813 | Any bacterial organism that can be assigned to the species Streptomyces griseus. | Streptomyces griseus | |||
STREPTOMYCES SOMALIENSIS | C86814 | Any bacterial organism that can be assigned to the species Streptomyces somaliensis. | Streptomyces somaliensis | |||
STREPTOMYCES | C14278 | Any bacteria that is not assigned to the species level but can be assigned to the Streptomyces genus level. | Streptomyces | |||
SUTTERELLA | C86956 | Any bacteria that is not assigned to the species level but can be assigned to the Sutterella genus level. | Sutterella | |||
SUTTONELLA INDOLOGENES | C86816 | KINGELLA INDOLOGENES | Any bacterial organism that can be assigned to the species Suttonella indologenes. | Suttonella indologenes | ||
SUTTONELLA | C86815 | Any bacteria that is not assigned to the species level but can be assigned to the Suttonella genus level. | Suttonella | |||
TATLOCKIA MICDADEI | C86817 | LEGIONELLA MICDADEI | Any bacterial organism that can be assigned to the species Legionella micdadei. | Tatlockia micdadei | ||
TATUMELLA PTYSEOS | C86819 | CDC GROUP EF-9 | Any bacterial organism that can be assigned to the species Tatumella ptyseos. | Tatumella ptyseos | ||
TATUMELLA | C86818 | Any bacteria that is not assigned to the species level but can be assigned to the Tatumella genus level. | Tatumella | |||
TETRAGENOCOCCUS SOLITARIUS | C86821 | ENTEROCOCCUS SOLITARIUS | Any bacterial organism that can be assigned to the species Tetragenococcus solitarius. | Tetragenococcus solitarius | ||
TETRAGENOCOCCUS | C86820 | Any bacteria that is not assigned to the species level but can be assigned to the Tetragenococcus genus level. | Tetragenococcus | |||
TISSIERELLA PRAEACUTA | C86908 | Any bacterial organism that can be assigned to the species Tissierella praeacuta. | Tissierella praeacuta | |||
TISSIERELLA | C86907 | Any bacteria that is not assigned to the species level but can be assigned to the Tissierella genus level. | Tissierella | |||
TRABULSIELLA GUAMENSIS | C86823 | CDC ENTERIC GROUP 90 | Any bacterial organism that can be assigned to the species Trabulsiella guamensis. | Trabulsiella guamensis | ||
TRABULSIELLA | C86822 | Any bacteria that is not assigned to the species level but can be assigned to the Trabulsiella genus level. | Trabulsiella | |||
TREPONEMA PALLIDUM | C86825 | Any bacterial organism that can be assigned to the species Treponema pallidum. | Treponema pallidum | |||
TREPONEMA PALLIDUM SUBSP. PERTENUE | C86909 | TREPONEMA PERTENUE | Any bacterial organism that can be assigned to the species Treponema pallidum and subspecies pertenue. | Treponema pallidum subsp pertenue | ||
TREPONEMA | C76385 | Any bacteria that is not assigned to the species level but can be assigned to the Treponema genus level. | Treponema | |||
TROPHERYMA | C86826 | Any bacteria that is not assigned to the species level but can be assigned to the Tropheryma genus level. | Tropheryma | |||
TROPHERYMA WHIPPLEI | C86827 | Any bacterial organism that can be assigned to the species Tropheryma whipplei. | Tropheryma whipplei | |||
TSUKAMURELLA PAUROMETABOLUM | C86829 | GORDONA AURANTIACA | Any bacterial organism that can be assigned to the species Tsukamurella paurometabolum. | Tsukamurella paurometabolum | ||
TSUKAMURELLA | C86828 | Any bacteria that is not assigned to the species level but can be assigned to the Tsukamurella genus level. | Tsukamurella | |||
TURICELLA OTITIDIS | C86831 | RHODOCOCCUS AURANTIAZUS | Any bacterial organism that can be assigned to the species Turicella otitidis. | Turicella otitidis | ||
TURICELLA | C86830 | Any bacteria that is not assigned to the species level but can be assigned to the Turicella genus level. | Turicella | |||
UREAPLASMA | C86832 | Any bacteria that is not assigned to the species level but can be assigned to the Ureaplasma genus level. | Ureaplasma | |||
UREAPLASMA UREALYTICUM | C86833 | T-MYCOPLASMA | Any bacterial organism that can be assigned to the species Ureaplasma urealyticum. | Ureaplasma urealyticum | ||
VAGOCOCCUS | C86834 | Any bacteria that is not assigned to the species level but can be assigned to the Vagococcus genus level. | Vagococcus | |||
VARIBACULUM CAMBRIENSE | C86836 | Any bacterial organism that can be assigned to the species Varibaculum cambriense. | Varibaculum cambriense | |||
VARIBACULUM | C86835 | Any bacteria that is not assigned to the species level but can be assigned to the Varibaculum genus level. | Varibaculum | |||
VEILLONELLA DISPAR | C86838 | Any bacterial organism that can be assigned to the species Veillonella dispar. | Veillonella dispar | |||
VEILLONELLA PARVULA | C86839 | Any bacterial organism that can be assigned to the species Veillonella parvula. | Veillonella parvula | |||
VEILLONELLA | C86837 | Any bacteria that is not assigned to the species level but can be assigned to the Veillonella genus level. | Veillonella | |||
VIBRIO ALGINOLYTICUS | C86840 | Any bacterial organism that can be assigned to the species Vibrio alginolyticus. | Vibrio alginolyticus | |||
VIBRIO CHOLERAE | C86841 | VIBRIO COMMA | Any bacterial organism that can be assigned to the species Vibrio cholerae. | Vibrio cholerae | ||
VIBRIO FLUVIALIS | C86842 | CDC GROUP EF-6 | Any bacterial organism that can be assigned to the species Vibrio fluvialis. | Vibrio fluvialis | ||
VIBRIO FURNISSII | C86843 | VIBRIO FLUVIALIS BIOGROUP 2 | Any bacterial organism that can be assigned to the species Vibrio furnissii. | Vibrio furnissii | ||
VIBRIO METSCHNIKOVII | C86844 | CDC ENTERIC GROUP 16 | Any bacterial organism that can be assigned to the species Vibrio metschnikovii. | Vibrio metschnikovii | ||
VIBRIO MIMICUS | C86845 | SUCROSE NEGATIVE VIBRIO CHOLERAE | Any bacterial organism that can be assigned to the species Vibrio mimicus. | Vibrio mimicus | ||
VIBRIO PARAHAEMOLYTICUS | C86846 | Any bacterial organism that can be assigned to the species Vibrio parahaemolyticus. | Vibrio parahaemolyticus | |||
VIBRIO | C76386 | Any bacteria that is not assigned to the species level but can be assigned to the Vibrio genus level. | Vibrio | |||
VIBRIO VULNIFICUS | C86847 | BENECKEA VULNIFICA | Any bacterial organism that can be assigned to the species Vibrio vulnificus. | Vibrio vulnificus | ||
WEEKSELLA | C86848 | Any bacteria that is not assigned to the species level but can be assigned to the Weeksella genus level. | Weeksella | |||
WEEKSELLA VIROSA | C86849 | CDC GROUP IIF | Any bacterial organism that can be assigned to the species Weeksella virosa. | Weeksella virosa | ||
WOLINELLA | C86850 | Any bacteria that is not assigned to the species level but can be assigned to the Wolinella genus level. | Wolinella | |||
WOLINELLA SUCCINOGENES | C86851 | Any bacterial organism that can be assigned to the species Wolinella succinogenes. | Wolinella succinogenes | |||
YERSINIA ALDOVAE | C86853 | Any bacterial organism that can be assigned to the species Yersinia aldovae. | Yersinia aldovae | |||
YERSINIA BERCOVIERI | C86854 | YERSINIA ENTEROLITICA BIOGROUP 3B | Any bacterial organism that can be assigned to the species Yersinia bercovieri. | Yersinia bercovieri | ||
YERSINIA ENTEROCOLITICA | C86855 | PASTEURELLA ENTEROCOLITICA | Any bacterial organism that can be assigned to the species Yersinia enterocolitica. | Yersinia enterocolitica | ||
YERSINIA FREDERIKSENII | C86856 | Any bacterial organism that can be assigned to the species Yersinia frederiksenii. | Yersinia frederiksenii | |||
YERSINIA INTERMEDIA | C86857 | Any bacterial organism that can be assigned to the species Yersinia intermedia. | Yersinia intermedia | |||
YERSINIA KRISTENSENII | C86858 | Any bacterial organism that can be assigned to the species Yersinia kristensenii. | Yersinia kristensenii | |||
YERSINIA MOLLARETII | C86859 | YERSINIA ENTEROLITICA BIOGROUP 3A | Any bacterial organism that can be assigned to the species Yersinia mollaretii. | Yersinia mollaretii | ||
YERSINIA PESTIS | C86860 | PASTEURELLA PESTIS | Any bacterial organism that can be assigned to the species Yersinia pestis. | Yersinia pestis | ||
YERSINIA PSEUDOTUBERCULOSIS | C86861 | PASTEURELLA PSEUDOTUBERCULOSIS | Any bacterial organism that can be assigned to the species Yersinia pseudotuberculosis. | Yersinia pseudotuberculosis | ||
YERSINIA ROHDEI | C86862 | Any bacterial organism that can be assigned to the species Yersinia rohdei. | Yersinia rohdei | |||
YERSINIA RUCKERI | C86863 | Any bacterial organism that can be assigned to the species Yersinia ruckeri. | Yersinia ruckeri | |||
YERSINIA | C86852 | Any bacteria that is not assigned to the species level but can be assigned to the Yersinia genus level. | Yersinia | |||
YOKENELLA REGENSBURGEI | C86865 | CDC ENTERIC GROUP 45 | Any bacterial organism that can be assigned to the species Yokenella regensburgei. | Yokenella regensburgei | ||
YOKENELLA | C86864 | Any bacteria that is not assigned to the species level but can be assigned to the Yokenella genus level. | Yokenella | |||
ZIMMERMANNELLA ALBA | C86867 | Any bacterial organism that can be assigned to the species Zimmermannella alba. | Zimmermannella alba | |||
ZIMMERMANNELLA BIFIDA | C86868 | Any bacterial organism that can be assigned to the species Zimmermannella bifida. | Zimmermannella bifida | |||
ZIMMERMANNELLA | C86866 | Any bacteria that is not assigned to the species level but can be assigned to the Zimmermannella genus level. | Zimmermannella | |||
MYCOBACTERIUM INTRACELLULARE | C91843 | Any bacterial organism that can be assigned to the species Mycobacterium intracellulare. | Mycobacterium intracellulare | |||
SALMONELLA BONGORI | C91842 | Any bacterial organism that can be assigned to the species Salmonella bongori. | Salmonella bongori | |||
SALMONELLA ENTERICA SUBSP. DIARIZONAE | C91844 | Any bacterial organism that can be assigned to the species Salmonella enterica subspecies diarizonae. | Salmonella enterica subsp diarizonae | |||
SALMONELLA ENTERICA SUBSP. HOUTENAE | C91845 | Any bacterial organism that can be assigned to the species Salmonella enterica subspecies houtenae. | Salmonella enterica subsp houtenae | |||
SALMONELLA ENTERICA SUBSP. INDICA | C91846 | Any bacterial organism that can be assigned to the species Salmonella enterica subspecies indica. | Salmonella enterica subsp indica | |||
SALMONELLA ENTERICA SUBSP. SALAMAE | C91847 | Any bacterial organism that can be assigned to the species Salmonella enterica subspecies salamae. | Salmonella enterica subsp salamae | |||
STREPTOCOCCUS DYSGALACTIAE SUBSP. DYSGALACTIAE | C91848 | Any bacterial organism that can be assigned to the species Streptococcus dysgalactiae subspecies dysgalactiae. | Streptococcus dysgalactiae subsp dysgalactiae | |||
TREPONEMA PALLIDUM SUBSP. ENDEMICUM | C91850 | Any bacterial organism that can be assigned to the species Treponema pallidum subspecies endemicum. | Treponema pallidum subsp endemicum | |||
TREPONEMA PALLIDUM SUBSP. PALLIDUM | C91849 | Any bacterial organism that can be assigned to the species Treponema pallidum subspecies pallidum. | Treponema pallidum subsp pallidum | |||
MYCOBACTERIUM BOVIS | C85545 | Any bacterial organism that can be assigned to the species Mycobacterium bovis. | Mycobacterium bovis | |||
MYCOBACTERIUM BOVIS BCG | C85546 | An attenuated form of Mycobacterium bovis that is used to generate the Bacillus Calmette-Guerin vaccine. | Mycobacterium bovis BCG | |||
MYCOBACTERIUM CANETTII | C85547 | Any bacterial organism that can be assigned to the species Mycobacterium canettii. | Mycobacterium canetti | |||
MYCOBACTERIUM MICROTI | C85548 | Any bacterial organism that can be assigned to the species Mycobacterium microti. | Mycobacterium microti | |||
Back to top | ||||||
CL.C85493.PKPARM | PK Parameters (PKPARM) | text Extensible: Yes | C85493 | PK Parameters | Parameters used to describe the time-concentration curve. | CDISC SDTM Pharmacokinetic Parameter Terminology |
AUC %Back Extrapolation Pred | C85787 | AUC %Back Extrapolation Pred | The area under the curve (AUC) from the predicted concentration value at time zero to the first measured concentration value as a percentage of the area under the curve extrapolated to infinity. Applies only for intravascular bolus dosing. | Predicted Area Under the Curve Percent Back Extrapolation | ||
AUC %Extrapolation Obs | C85764 | AUC %Extrapolation Obs | The area under the curve (AUC) from the last observed non-zero concentration value to infinity as a percentage of the area under the curve extrapolated to infinity. | Observed Area Under the Curve Percent Extrapolation | ||
AUC %Extrapolation Pred | C85788 | AUC %Extrapolation Pred | The area under the curve (AUC) from the last predicted non-zero concentration value to infinity as a percentage of the area under the curve extrapolated to infinity. | Predicted Area Under the Curve Percent Extrapolation | ||
AUC All | C85564 | AUC All | The area under the curve (AUC) from the time of dosing to the time of the last observation, regardless of whether the last concentration is measurable or not. | Area Under the Curve All | ||
AUC All Norm by BMI | C92362 | AUC All Norm by BMI | The area under the curve (AUC) from the time of dosing to the time of the last observation divided by the body mass index, regardless of whether the last concentration is measurable or not. | AUC All Normalized by Body Mass Index | ||
AUC All Norm by Dose | C92306 | AUC All Norm by Dose | The area under the curve (AUC) from the time of dosing to the time of the last observation divided by the dose, regardless of whether the last concentration is measurable or not. | AUC All Normalized by Dose | ||
AUC All Norm by SA | C92307 | AUC All Norm by SA | The area under the curve (AUC) from the time of dosing to the time of the last observation divided by the surface area, regardless of whether the last concentration is measurable or not. | AUC All Normalized by Surface Area | ||
AUC All Norm by WT | C92308 | AUC All Norm by WT | The area under the curve (AUC) from the time of dosing to the time of the last observation divided by the weight, regardless of whether the last concentration is measurable or not. | AUC All Normalized by Weight | ||
AUC to Last Nonzero Conc | C85565 | AUC to Last Nonzero Conc | The area under the curve (AUC) from the time of dosing to the last measurable concentration. | Area Under the Curve From Dosing to Last Concentration | ||
AUC to Last Nonzero Conc Norm by BMI | C92309 | AUC to Last Nonzero Conc Norm by BMI | The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the body mass index. | AUC Dosing to Last Concentration Normalized by Body Mass Index | ||
AUC to Last Nonzero Conc Norm by Dose | C92310 | AUC to Last Nonzero Conc Norm by Dose | The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the dose. | AUC Dosing to Last Concentration Normalized by Dose | ||
AUC to Last Nonzero Conc Norm by SA | C92311 | AUC to Last Nonzero Conc Norm by SA | The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the surface area. | AUC Dosing to Last Concentration Normalized by Surface Area | ||
AUC to Last Nonzero Conc Norm by WT | C92305 | AUC to Last Nonzero Conc Norm by WT | The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the weight. | AUC Dosing to Last Concentration Normalized by Weight | ||
AUC from T1 to T2 | C85566 | AUC from T1 to T2 | The area under the curve (AUC) over the interval from T1 to T2. | Area Under the Curve from T1 to T2 | ||
AUC from T1 to T2 Norm by BMI | C92312 | AUC from T1 to T2 Norm by BMI | The area under the curve (AUC) over the interval from T1 to T2 divided by the body mass index. | AUC from T1 to T2 Normalized by Body Mass Index | ||
AUC from T1 to T2 Norm by Dose | C92313 | AUC from T1 to T2 Norm by Dose | The area under the curve (AUC) over the interval from T1 to T2 divided by the dose. | AUC from T1 to T2 Normalized by Dose | ||
AUC from T1 to T2 Norm by SA | C92314 | AUC from T1 to T2 Norm by SA | The area under the curve (AUC) over the interval from T1 to T2 divided by the surface area. | AUC from T1 to T2 Normalized by Surface Area | ||
AUC from T1 to T2 Norm by WT | C92315 | AUC from T1 to T2 Norm by WT | The area under the curve (AUC) over the interval from T1 to T2 divided by the weight. | AUC from T1 to T2 Normalized by Weight | ||
AUC Infinity Obs Norm by BMI | C92316 | AUC Infinity Obs Norm by BMI | The area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the body mass index. | AUC Infinity Observed Normalized by Body Mass Index | ||
AUC Infinity Obs Norm by SA | C92317 | AUC Infinity Obs Norm by SA | The area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the surface area. | AUC Infinity Observed Normalized by Surface Area | ||
AUC Infinity Obs Norm by WT | C92318 | AUC Infinity Obs Norm by WT | The area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the weight. | AUC Infinity Observed Normalized by Weight | ||
AUC Infinity Pred | C85785 | AUC Infinity Pred | The area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration. | Predicted Area Under the Curve Infinity | ||
AUC Infinity Pred Norm by Dose | C85786 | AUC Infinity Pred Norm by Dose | The area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the dose. | Predicted Area Under the Curve Infinity by Dose | ||
AUC Infinity Pred Norm by BMI | C92319 | AUC Infinity Pred Norm by BMI | The area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the body mass index. | AUC Infinity Predicted Normalized by Body Mass Index | ||
AUC Infinity Pred Norm by SA | C92320 | AUC Infinity Pred Norm by SA | The area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the surface area. | AUC Infinity Predicted Normalized by Surface Area | ||
AUC Infinity Pred Norm by WT | C92321 | AUC Infinity Pred Norm by WT | The area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the weight. | AUC Infinity Predicted Normalized by Weight | ||
AUC Over Dosing Interval | C85567 | AUC Over Dosing Interval | The area under the curve (AUC) for the defined interval between doses (TAU). | Area Under the Curve Over Dosing Interval | ||
AUC Over Dosing Interval Norm by BMI | C92322 | AUC Over Dosing Interval Norm by BMI | The area under the curve (AUC) for the defined interval between doses (TAU) divided by the body mass index. | AUC Over Dosing Interval Normalized by Body Mass Index | ||
AUC Over Dosing Interval Norm by Dose | C92323 | AUC Over Dosing Interval Norm by Dose | The area under the curve (AUC) for the defined interval between doses (TAU) divided by the dose. | AUC Over Dosing Interval Normalized by Dose | ||
AUC Over Dosing Interval Norm by SA | C92324 | AUC Over Dosing Interval Norm by SA | The area under the curve (AUC) for the defined interval between doses (TAU) divided by the surface area. | AUC Over Dosing Interval Normalized by Surface Area | ||
AUC Over Dosing Interval Norm by WT | C92325 | AUC Over Dosing Interval Norm by WT | The area under the curve (AUC) for the defined interval between doses (TAU) divided by the weight. | AUC Over Dosing Interval Normalized by Weight | ||
AUMC % Extrapolation Obs | C85766 | AUMC % Extrapolation Obs | The area under the moment curve (AUMC) from the last observed non-zero concentration value to infinity as a percentage of the area under the moment curve extrapolated to infinity. | Observed Area Under the First Moment Curve Percent Extrapolation | ||
AUMC % Extrapolation Pred | C85790 | AUMC % Extrapolation Pred | The area under the moment curve (AUMC) from the last predicted non-zero concentration value to infinity as a percentage of the area under the moment curve extrapolated to infinity. | Predicted Area Under the First Moment Curve Percent Extrapolation | ||
AUMC to Last Nonzero Conc | C85569 | AUMC to Last Nonzero Conc | The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration. | Area Under the First Moment Curve From Dosing to Last Concentration | ||
AUMC to Last Nonzero Conc Norm by BMI | C92326 | AUMC to Last Nonzero Conc Norm by BMI | The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration divided by the body mass index. | AUMC Dosing to Last Concentration Normalized by Body Mass Index | ||
AUMC to Last Nonzero Conc Norm by Dose | C92327 | AUMC to Last Nonzero Conc Norm by Dose | The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration divided by the dose. | AUMC Dosing to Last Concentration Normalized by Dose | ||
AUMC to Last Nonzero Conc Norm by SA | C92328 | AUMC to Last Nonzero Conc Norm by SA | The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration divided by the surface area. | AUMC Dosing to Last Concentration Normalized by Surface Area | ||
AUMC to Last Nonzero Conc Norm by WT | C92329 | AUMC to Last Nonzero Conc Norm by WT | The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration divided by the weight. | AUMC Dosing to Last Concentration Normalized by Weight | ||
AUMC Infinity Obs | C85765 | AUMC Infinity Obs | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration. | Observed Area Under the First Moment Curve Infinity | ||
AUMC Infinity Obs Norm by BMI | C92330 | AUMC Infinity Obs Norm by BMI | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the body mass index. | AUMC Infinity Observed Normalized by Body Mass Index | ||
AUMC Infinity Obs Norm by Dose | C92331 | AUMC Infinity Obs Norm by Dose | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the dose. | AUMC Infinity Observed Normalized by Dose | ||
AUMC Infinity Obs Norm by SA | C92332 | AUMC Infinity Obs Norm by SA | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the surface area. | AUMC Infinity Observed Normalized by Surface Area | ||
AUMC Infinity Obs Norm by WT | C92333 | AUMC Infinity Obs Norm by WT | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the weight. | AUMC Infinity Observed Normalized by Weight | ||
AUMC Infinity Pred | C85789 | AUMC Infinity Pred | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration. | Predicted Area Under the First Moment Curve Infinity | ||
AUMC Infinity Pred Norm by BMI | C92334 | AUMC Infinity Pred Norm by BMI | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the body mass index. | AUMC Infinity Predicted Normalized by Body Mass Index | ||
AUMC Infinity Pred Norm by Dose | C92335 | AUMC Infinity Pred Norm by Dose | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the dose. | AUMC Infinity Predicted Normalized by Dose | ||
AUMC Infinity Pred Norm by SA | C92336 | AUMC Infinity Pred Norm by SA | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the surface area. | AUMC Infinity Predicted Normalized by Surface Area | ||
AUMC Infinity Pred Norm by WT | C92337 | AUMC Infinity Pred Norm by WT | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the weight. | AUMC Infinity Predicted Normalized by Weight | ||
AUMC Over Dosing Interval | C85570 | AUMC Over Dosing Interval | The area under the first moment curve (AUMC) for the defined interval between doses (TAU). | Area Under the First Moment Curve Over Dosing Interval | ||
AUMC Over Dosing Interval Norm by BMI | C92338 | AUMC Over Dosing Interval Norm by BMI | The area under the first moment curve (AUMC) for the defined interval between doses (TAU) divided by the body mass index. | AUMC Over Dosing Interval Normalized by Body Mass Index | ||
AUMC Over Dosing Interval Norm by Dose | C92339 | AUMC Over Dosing Interval Norm by Dose | The area under the first moment curve (AUMC) for the defined interval between doses (TAU) divided by the dose. | AUMC Over Dosing Interval Normalized by Dose | ||
AUMC Over Dosing Interval Norm by SA | C92340 | AUMC Over Dosing Interval Norm by SA | The area under the first moment curve (AUMC) for the defined interval between doses (TAU) divided by the surface area. | AUMC Over Dosing Interval Normalized by Surface Area | ||
AUMC Over Dosing Interval Norm by WT | C92341 | AUMC Over Dosing Interval Norm by WT | The area under the first moment curve (AUMC) for the defined interval between doses (TAU) divided by the weight. | AUMC Over Dosing Interval Normalized by Weight | ||
AURC % Extrapolation Obs | C85768 | AURC % Extrapolation Obs | The area under the urinary excretion rate curve (AURC) from the last observed non-zero rate value to infinity as a percentage of the area under the urinary excretion rate curve extrapolated to infinity. | Observed Area Under the Urinary Excretion Rate Curve Percent Extrapolation | ||
AURC % Extrapolation Pred | C85792 | AURC % Extrapolation Pred | The area under the urinary excretion rate curve (AURC) from the last predicted non-zero rate value to infinity as a percentage of the area under the urinary excretion rate curve extrapolated to infinity. | Predicted Area Under the Urinary Excretion Rate Curve Percent Extrapolation | ||
AURC All | C85841 | AURC All | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate. | Area Under Urinary Excretion Rate Curve All | ||
AURC All Norm by BMI | C92342 | AURC All Norm by BMI | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate divided by the body mass index. | AURC All Normalized by Body Mass Index | ||
AURC All Norm by Dose | C92343 | AURC All Norm by Dose | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate divided by the dose. | AURC All Normalized by Dose | ||
AURC All Norm by SA | C92344 | AURC All Norm by SA | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate divided by the surface area. | AURC All Normalized by Surface Area | ||
AURC All Norm by WT | C92345 | AURC All Norm by WT | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate divided by the weight. | AURC All Normalized by Weight | ||
AURC to Last Nonzero Rate | C85571 | AURC to Last Nonzero Rate | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate. | Area Under the Urinary Excretion Rate Curve From Dosing to Last Concentration | ||
AURC Dosing to Last Conc Norm by BMI | C92346 | AURC to Last Nonzero Rate Norm by BMI | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate, divided by the body mass index. | AURC Dosing to Last Concentration Normalized by Body Mass Index | ||
AURC Dosing to Last Conc Norm by Dose | C92347 | AURC to Last Nonzero Rate Norm by Dose | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate, divided by the dose. | AURC Dosing to Last Concentration Normalized by Dose | ||
AURC Dosing to Last Conc Norm by SA | C92348 | AURC to Last Nonzero Rate Norm by SA | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate, divided by the surface area. | AURC Dosing to Last Concentration Normalized by Surface Area | ||
AURC Dosing to Last Conc Norm by WT | C92349 | AURC to Last Nonzero Rate Norm by WT | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate, divided by the weight. | AURC Dosing to Last Concentration Normalized by Weight | ||
AURC from T1 to T2 | C85572 | AURC from T1 to T2 | The area under the urinary excretion rate curve (AURC) over the interval from T1 to T2. | Area Under the Urinary Excretion Rate Curve from T1 to T2 | ||
AURC from T1 to T2 Norm by BMI | C92350 | AURC from T1 to T2 Norm by BMI | The area under the urinary excretion rate curve (AURC) over the interval from T1 to T2 divided by the body mass index. | AURC from T1 to T2 Normalized by Body Mass Index | ||
AURC from T1 to T2 Norm by Dose | C92351 | AURC from T1 to T2 Norm by Dose | The area under the urinary excretion rate curve (AURC) over the interval from T1 to T2 divided by the dose. | AURC from T1 to T2 Normalized by Dose | ||
AURC from T1 to T2 Norm by SA | C92352 | AURC from T1 to T2 Norm by SA | The area under the urinary excretion rate curve (AURC) over the interval from T1 to T2 divided by the surface area. | AURC from T1 to T2 Normalized by Surface Area | ||
AURC from T1 to T2 Norm by WT | C92353 | AURC from T1 to T2 Norm by WT | The area under the urinary excretion rate curve (AURC) over the interval from T1 to T2 divided by the weight. | AURC from T1 to T2 Normalized by Weight | ||
AURC Infinity Obs | C85767 | AURC Infinity Obs | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate. | Observed Area Under the Urinary Excretion Rate Curve infinity | ||
AURC Infinity Obs Norm by BMI | C92354 | AURC Infinity Obs Norm by BMI | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate, divided by the body mass index. | AURC Infinity Observed Normalized by Body Mass Index | ||
AURC Infinity Obs Norm by Dose | C92355 | AURC Infinity Obs Norm by Dose | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate, divided by the dose. | AURC Infinity Observed Normalized by Dose | ||
AURC Infinity Obs Norm by SA | C92356 | AURC Infinity Obs Norm by SA | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate, divided by the surface area. | AURC Infinity Observed Normalized by Surface Area | ||
AURC Infinity Obs Norm by WT | C92357 | AURC Infinity Obs Norm by WT | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate, divided by the weight. | AURC Infinity Observed Normalized by Weight | ||
AURC Infinity Pred | C85791 | AURC Infinity Pred | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the predicted value of the last non-zero excretion rate. | Predicted Area Under the Urinary Excretion Rate Curve Infinity | ||
AURC Infinity Pred Norm by BMI | C92358 | AURC Infinity Pred Norm by BMI | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the predicted value of the last non-zero excretion rate, divded by the body mass index. | AURC Infinity Predicted Normalized by Body Mass Index | ||
AURC Infinity Pred Norm by Dose | C92359 | AURC Infinity Pred Norm by Dose | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the predicted value of the last non-zero excretion rate, divded by the dose. | AURC Infinity Predicted Normalized by Dose | ||
AURC Infinity Pred Norm by SA | C92360 | AURC Infinity Pred Norm by SA | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the predicted value of the last non-zero excretion rate, divded by the surface area. | AURC Infinity Predicted Normalized by Surface Area | ||
AURC Infinity Pred Norm by WT | C92361 | AURC Infinity Pred Norm by WT | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the predicted value of the last non-zero excretion rate, divded by the weight. | AURC Infinity Predicted Normalized by Weight | ||
Average Conc | C85575 | Average Conc;Average Concentration | AUCTAU divided by TAU. | Average Concentration | ||
Average Conc Norm by BMI | C92367 | Average Conc Norm by BMI | AUCTAU divided by TAU and then divided by the body mass index. | Average Concentration Normalized by Body Mass Index | ||
Average Conc Norm by Dose | C92368 | Average Conc Norm by Dose | AUCTAU divided by TAU and then divided by the dose. | Average Concentration Normalized by Dose | ||
Average Conc Norm by SA | C92369 | Average Conc Norm by SA | AUCTAU divided by TAU and then divided by the surface area. | Average Concentration Normalized by Surface Area | ||
Average Conc Norm by WT | C92370 | Average Conc Norm by WT | AUCTAU divided by TAU and then divided by the weight. | Average Concentration Normalized by Weight | ||
Correlation Between TimeX and Log ConcY | C85821 | Correlation Between TimeX and Log ConcY | The correlation between time (X) and log concentration (Y) for the points used in the estimation of lambda z. | Time and Log Concentration Correlation | ||
Fluctuation% | C85581 | Fluctuation% | The difference between Cmin and Cmax standardized to Cavg, between dose time and Tau. | Concentration Variability Between Dose Time and Tau | ||
Half-Life Lambda z | C85818 | Half-Life Lambda z | Terminal half-life. | Terminal Half Life | ||
Initial Conc | C85644 | Initial Conc | Initial concentration. Given only for bolus IV models. | Initial Concentration | ||
Initial Conc Norm by BMI | C92383 | Initial Conc Norm by BMI | Initial concentration divided by the body mass index. Given only for bolus IV models. | Initial Concentration Normalized by Body Mass Index | ||
Initial Conc Norm by Dose | C92384 | Initial Conc Norm by Dose | Initial concentration divided by the dose. Given only for bolus IV models. | Initial Concentration Normalized by Dose | ||
Initial Conc Norm by SA | C92385 | Initial Conc Norm by SA | Initial concentration divided by the surface area. Given only for bolus IV models. | Initial Concentration Normalized by Surface Area | ||
Initial Conc Norm by WT | C92386 | Initial Conc Norm by WT | Initial concentration divided by the weight. Given only for bolus IV models. | Initial Concentration Normalized by Weight | ||
Lambda z | C85652 | Lambda z | The first order rate constant associated with the terminal (log-linear) portion of the curve. | Lambda Z | ||
Lambda z Lower Limit | C85653 | Lambda z Lower Limit | The lower limit on time for values to be included in the calculation of Lambda z. | Lambda Z Time Lower Limit | ||
Lambda z Upper Limit | C85654 | Lambda z Upper Limit | The upper limit on time for values to be included in the calculation of Lambda z. | Lambda Z Time Upper Limit | ||
Last Nonzero Conc | C85655 | Last Nonzero Conc | The concentration corresponding to Tlast. | Last Concentration | ||
Last Nonzero Conc Norm by BMI | C92387 | Last Nonzero Conc Norm by BMI | The concentration corresponding to Tlast divided by the body mass index. | Last Concentration Normalized by Body Mass Index | ||
Last Nonzero Conc Norm by Dose | C92388 | Last Nonzero Conc Norm by Dose | The concentration corresponding to Tlast divided by the dose. | Last Concentration Normalized by Dose | ||
Last Nonzero Conc Norm by SA | C92389 | Last Nonzero Conc Norm by SA | The concentration corresponding to Tlast divided by the surface area. | Last Concentration Normalized by Surface Area | ||
Last Nonzero Conc Norm by WT | C92390 | Last Nonzero Conc Norm by WT | The concentration corresponding to Tlast divided by the weight. | Last Concentration Normalized by Weight | ||
Last Meas Excretion Rate | C85656 | Last Meas Excretion Rate | The last measurable (positive) excretion rate. | Last Measurable Observed Excretion Rate | ||
Last Meas Excretion Rate Norm by BMI | C92391 | Last Meas Excretion Rate Norm by BMI | The last measurable (positive) excretion rate divided by the body mass index. | Last Measurable Excretion Rate Normalized by Body Mass Index | ||
Last Meas Excretion Rate Norm by Dose | C92392 | Last Meas Excretion Rate Norm by Dose | The last measurable (positive) excretion rate divided by the dose. | Last Measurable Excretion Rate Normalized by Dose | ||
Last Meas Excretion Rate Norm by SA | C92393 | Last Meas Excretion Rate Norm by SA | The last measurable (positive) excretion rate divided by the surface area. | Last Measurable Excretion Rate Normalized by Surface Area | ||
Last Meas Excretion Rate Norm by WT | C92394 | Last Meas Excretion Rate Norm by WT | The last measurable (positive) excretion rate divided by the weight. | Last Measurable Excretion Rate Normalized by Weight | ||
Max Conc | C70918 | Max Conc | The maximum concentration occurring at Tmax. | Cmax | ||
Max Conc Norm by Dose | C85698 | Max Conc Norm by Dose | The maximum concentration occurring at Tmax, divided by the dose. | Maximum Concentration Dose Normalized | ||
Max Excretion Rate | C85699 | Max Excretion Rate | The maximum excretion rate. | Maximum Observed Excretion Rate | ||
Max Conc Norm by BMI | C92371 | Max Conc Norm by BMI | The maximum concentration occurring at Tmax, divided by the body mass index. | Maximum Concentration Normalized by Body Mass Index | ||
Max Conc Norm by SA | C92372 | Max Conc Norm by SA | The maximum concentration occurring at Tmax, divided by the surface area. | Maximum Concentration Normalized by Surface Area | ||
Max Conc Norm by WT | C92373 | Max Conc Norm by WT | The maximum concentration occurring at Tmax, divided by the weight. | Maximum Concentration Normalized by Weight | ||
Max Excretion Rate Norm by BMI | C92395 | Max Excretion Rate Norm by BMI | The maximum excretion rate divided by the body mass index. | Maximum Observed Excretion Rate Normalized by Body Mass Index | ||
Max Excretion Rate Norm by Dose | C92396 | Max Excretion Rate Norm by Dose | The maximum excretion rate divided by the dose. | Maximum Observed Excretion Rate Normalized by Dose | ||
Max Excretion Rate Norm by SA | C92397 | Max Excretion Rate Norm by SA | The maximum excretion rate divided by the surface area. | Maximum Observed Excretion Rate Normalized by Surface Area | ||
Max Excretion Rate Norm by WT | C92398 | Max Excretion Rate Norm by WT | The maximum excretion rate divided by the weight. | Maximum Observed Excretion Rate Normalized by Weight | ||
Midpoint of Collection Interval | C85580 | Midpoint of Collection Interval | The midpoint of collection interval, which is associated with last Measurable rate. | Collection Interval Midpoint | ||
Min Conc | C85579 | Min Conc | The minimum concentration between dose time and dose time plus Tau (at Tmin). | Cmin | ||
Min Conc Norm by BMI | C92374 | Min Conc Norm by BMI | The minimum concentration between dose time and dose time plus Tau (at Tmin) divided by the body mass index. | Minimum Concentration Normalized by Body Mass Index | ||
Min Conc Norm by Dose | C92375 | Min Conc Norm by Dose | The minimum concentration between dose time and dose time plus Tau (at Tmin) divided by the dose. | Minimum Concentration Normalized by Dose | ||
Min Conc Norm by SA | C92376 | Min Conc Norm by SA | The minimum concentration between dose time and dose time plus Tau (at Tmin) divided by the surface area. | Minimum Concentration Normalized by Surface Area | ||
Min Conc Norm by WT | C92377 | Min Conc Norm by WT | The minimum concentration between dose time and dose time plus Tau (at Tmin) divided by the weight. | Minimum Concentration Normalized by Weight | ||
MRT Infinity Obs | C85769 | MRT Infinity Obs | The mean residence time (MRT) extrapolated to infinity, calculated using the observed value of the last non-zero concentration. | Observed Mean Residence Time Infinity | ||
MRT Infinity Pred | C85793 | MRT Infinity Pred | The mean residence time (MRT) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration. | Predicted Mean Residence Time Infinity | ||
MRT to Last Nonzero Conc | C85700 | MRT to Last Nonzero Conc | Mean residence time (MRT) from the time of dosing to the time of the last measurable concentration. | Mean Residence Time Last | ||
Number of Points for Lambda z | C85816 | Number of Points for Lambda z | The number of time points used in computing Lambda z. | Sum of Lambda Z Timepoints | ||
AUC Infinity Obs | C85761 | AUC Infinity Obs | The area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration. | Observed Area Under the Curve Infinity | ||
R Squared | C85542 | R Squared | The goodness of fit statistic for the terminal elimination phase. | R Squared | ||
R Squared Adjusted | C85553 | R Squared Adjusted | The goodness of fit statistic for the terminal elimination phase, adjusted for the number of time points used in the estimation of Lambda z. | Adjusted R Squared | ||
Sum of Urine Vol | C85817 | Sum of Urine Vol | The sum of urine volumes that are used for PK parameters. | Sum Urine Volume | ||
Time of CMAX | C70919 | Time of CMAX | The time of maximum observed concentration sampled during a dosing interval. | Tmax | ||
Time of CMIN Observation | C85825 | Time of CMIN Observation | The time of minimum concentration sampled during a dosing interval. | Tmin | ||
Time of Last Nonzero Conc | C85822 | Time of Last Nonzero Conc | The time of the last measurable (positive) concentration. | Time of Last Nonzero Concentration | ||
Time of Max Excretion Rate | C85823 | Time of Max Excretion Rate | The midpoint of collection interval associated with the maximum excretion rate. | Time of Maximum Observed Excretion Rate | ||
Time Until First Nonzero Conc | C85824 | Time Until First Nonzero Conc | The time prior to the first measurable (non-zero) concentration. | Time until First Nonzero Concentration | ||
Total CL Obs | C85773 | Total CL Obs | The total body clearance for intravascular administration, calculated using the observed value of the last non-zero concentration. | Observed Total Body Clearance Rate | ||
Total CL Obs by F | C85772 | Total CL Obs by F | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration. | Observed Total Body Clearance by Fraction of Dose Absorbed | ||
Total CL Pred | C85797 | Total CL Pred | The total body clearance for intravascular administration, calculated using the predicted value of the last non-zero concentration. | Predicted Total Body Clearance Rate | ||
Total CL Pred by F | C85796 | Total CL Pred by F | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration. | Predicted Total Body Clearance by Fraction of Dose Absorbed | ||
Total CL Obs by F Norm by BMI | C92399 | Total CL Obs by F Norm by BMI | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the body mass index. | Total Clearance Observed by Fraction Dose Normalized by Body Mass Index | ||
Total CL Obs by F Norm by SA | C92401 | Total CL Obs by F Norm by SA | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the surface area. | Total Clearance Observed by Fraction Dose Normalized by Surface Area | ||
Total CL Obs by F Norm by WT | C92402 | Total CL Obs by F Norm by WT | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the weight. | Total Clearance Observed by Fraction Dose Normalized by Weight | ||
Total CL Obs Norm by BMI | C92403 | Total CL Obs Norm by BMI | The total body clearance for intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the body mass index. | Total Clearance Observed Normalized by Body Mass Index | ||
Total CL Obs Norm by SA | C92405 | Total CL Obs Norm by SA | The total body clearance for intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the surface area. | Total Clearance Observed Normalized by Surface Area | ||
Total CL Obs Norm by WT | C92406 | Total CL Obs Norm by WT | The total body clearance for intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the weight. | Total Clearance Observed Normalized by Weight | ||
Total CL Pred by F Norm by BMI | C92417 | Total CL Pred by F Norm by BMI | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by body mass index. | Total Clearance Predicted by Fraction Dose Normalized by Body Mass Index | ||
Total CL Pred by F Norm by SA | C92419 | Total CL Pred by F Norm by SA | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by the surface area. | Total Clearance Predicted by Fraction Dose Normalized by Surface Area | ||
Total CL Pred by F Norm by WT | C92420 | Total CL Pred by F Norm by WT | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by the weight. | Total Clearance Predicted by Fraction Dose Normalized by Weight | ||
Total CL Pred Norm by BMI | C92421 | Total CL Pred Norm by BMI | The total body clearance for intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the body mass index. | Total Clearance Predicted Normalized by Body Mass Index | ||
Total CL Pred Norm by SA | C92423 | Total CL Pred Norm by SA | The total body clearance for intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the surface area. | Total Clearance Predicted Normalized by Surface Area | ||
Total CL Pred Norm by WT | C92424 | Total CL Pred Norm by WT | The total body clearance for intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the weight. | Total Clearance Predicted Normalized by Weight | ||
Vz Obs by F | C85775 | Vz Obs by F | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration. | Observed Volume of Distribution of Absorbed Fraction | ||
Vz Pred by F | C85799 | Vz Pred by F | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration. | Predicted Volume of Distribution of Absorbed Fraction | ||
Vz Obs Norm by BMI | C92407 | Vz Obs Norm by BMI | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the body mass index. | Volume of Distribution Observed Normalized by Body Mass Index | ||
Vz Obs Norm by SA | C92408 | Vz Obs Norm by SA | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the surface area. | Volume of Distribution Observed Normalized by Surface Area | ||
Vz Obs Norm by WT | C92409 | Vz Obs Norm by WT | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the weight. | Volume of Distribution Observed Normalized by Weight | ||
Vz Obs by F Norm by BM | C92410 | Vz Obs by F Norm by BM | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the body mass index. | Volume of Distribution of Fraction Dose Observed Normalized by Body Mass Index | ||
Vz Obs by F Norm by SA | C92411 | Vz Obs by F Norm by SA | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the surface area. | Volume of Distribution of Fraction Dose Observed Normalized by Surface Area | ||
Vz Obs by F Norm by WT | C92412 | Vz Obs by F Norm by WT | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the weight. | Volume of Distribution of Fraction Dose Observed Normalized by Weight | ||
Vz Pred by F Norm by BMI | C92428 | Vz Pred by F Norm by BMI | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by the body mass index. | Volume of Distribution of Fraction Dose Predicted Normalized by Body Mass Index | ||
Vz Pred by F Norm by SA | C92429 | Vz Pred by F Norm by SA | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by the surface area. | Volume of Distribution of Fraction Dose Predicted Normalized by Surface Area | ||
Vz Pred by F Norm by WT | C92430 | Vz Pred by F Norm by WT | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by the weight. | Volume of Distribution of Fraction Dose Predicted Normalized by Weight | ||
Vz Pred Norm by BMI | C92425 | Vz Pred Norm by BMI | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the body mass index. | Volume of Distribution Predicted Normalized by Body Mass Index | ||
Vz Pred Norm by SA | C92426 | Vz Pred Norm by SA | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the surface area. | Volume of Distribution Predicted Normalized by Surface Area | ||
Vz Pred Norm by WT | C92427 | Vz Pred Norm by WT | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the weight. | Volume of Distribution Predicted Normalized by Weight | ||
Vz Obs | C85774 | Vz Obs | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the observed value of the last non-zero concentration. | Observed Volume of Distribution | ||
Vz Pred | C85798 | Vz Pred | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the predicted value of the last non-zero concentration. | Predicted Volume of Distribution | ||
AUC Infinity Obs Norm by Dose | C96695 | AUC Infinity Obs Norm by Dose | The area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the dose. | AUC Infinity Observed Normalized by Dose | ||
Accumulation Ratio AUC | C102356 | Accumulation Ratio AUC | The area under the curve (AUCTAU) at steady state divided by the area under the curve over the initial dosing interval. | Accumulation Ratio Area Under the Curve | ||
Accumulation Ratio Cmax | C102357 | Accumulation Ratio Cmax | The maximum concentration at steady state divided by the maximum concentration during the initial dosing interval. | Accumulation Ratio Cmax | ||
Accumulation Ratio Cmin | C102358 | Accumulation Ratio Cmin | The minimum concentration at steady state divided by the minimum concentration during the initial dosing interval. | Accumulation Ratio Cmin | ||
Accumulation Ratio Ctrough | C102426 | Accumulation Ratio Ctrough | The trough concentration at steady state divided by the trough concentration during the initial dosing interval. | Accumulation Ratio Ctrough | ||
Amt Rec from T1 to T2 | C102359 | Amt Rec from T1 to T2 | The cumulative amount recovered from the specimen type specified in PPSPEC over the interval from T1 to T2. | Amount Recovered from T1 to T2 | ||
Amt Rec from T1 to T2 Norm by BMI | C102360 | Amt Rec from T1 to T2 Norm by BMI | The cumulative amount recovered from the specimen type specified in PPSPEC over the interval from T1 to T2 divided by body mass index. | Amount Recovered from T1 to T2 Normalized by Body Mass Index | ||
Amt Rec from T1 to T2 Norm by SA | C102361 | Amt Rec from T1 to T2 Norm by SA | The cumulative amount recovered from the specimen type specified in PPSPEC over the interval from T1 to T2 divided by surface area. | Amount Recovered from T1 to T2 Normalized by Surface Area | ||
Amt Rec from T1 to T2 Norm by WT | C102362 | Amt Rec from T1 to T2 Norm by WT | The cumulative amount recovered from the specimen type specified in PPSPEC over the interval from T1 to T2 divided by weight. | Amount Recovered from T1 to T2 Normalized by Weight | ||
Amt Rec Over Dosing Interval | C102363 | Amt Rec Over Dosing Interval | The cumulative amount recovered from the specimen type specified in PPSPEC between doses (TAU). | Amount Recovered Over Dosing Interval | ||
Amt Rec Over Dosing Interval Norm by BMI | C102364 | Amt Rec Over Dosing Interval Norm by BMI | The cumulative amount recovered from the specimen type specified in PPSPEC between doses (TAU) divided by body mass index. | Amount Recovered Over Dosing Interval Normalized by Body Mass Index | ||
Amt Rec Over Dosing Interval Norm by SA | C102365 | Amt Rec Over Dosing Interval Norm by SA | The cumulative amount recovered from the specimen type specified in PPSPEC between doses (TAU) divided by surface area. | Amount Recovered Over Dosing Interval Normalized by Surface Area | ||
Amt Rec Over Dosing Interval Norm by WT | C102366 | Amt Rec Over Dosing Interval Norm by WT | The cumulative amount recovered from the specimen type specified in PPSPEC between doses (TAU) divided by weight. | Amount Recovered Over Dosing Interval Normalized by Weight | ||
Conc | C41185 | Conc | The quantity of a specified substance in a unit volume or weight of another substance. | Concentration | ||
Conc by BMI | C102367 | Conc by BMI | The concentration divided by body mass index. | Concentration Divided by Body Mass Index | ||
Conc by Dose | C102368 | Conc by Dose | The concentration divided by dose. | Concentration Divided by Dose | ||
Conc by SA | C102369 | Conc by SA | The concentration divided by surface area. | Concentration Divided by Surface Area | ||
Conc by WT | C102370 | Conc by WT | The concentration divided by weight. | Concentration Divided by Weight | ||
Conc Trough | C102394 | Conc Trough | Concentration at end of dosing interval. | Trough Concentration | ||
Conc Trough by BMI | C102395 | Conc Trough by BMI | The trough concentration divided by body mass index. | Trough Concentration Divided by Body Mass Index | ||
Conc Trough by Dose | C102396 | Conc Trough by Dose | The trough concentration divided by dose. | Trough Concentration Divided by Dose | ||
Conc Trough by SA | C102397 | Conc Trough by SA | The trough concentration divided by surface area. | Trough Concentration Divided by Surface Area | ||
Conc Trough by WT | C102398 | Conc Trough by WT | The trough concentration divided by weight. | Trough Concentration Divided by Weight | ||
Effective Half-Life | C95007 | Effective Half-Life | The drug half-life that quantifies the accumulation ratio of a drug following multiple dosing. | Effective Half-life | ||
Nonrenal CL | C102376 | Nonrenal CL | The total clearance of a substance from the blood less the renal clearance. | Nonrenal Clearance | ||
Pct Rec from T1 to T2 | C102382 | Pct Rec from T1 to T2 | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2. | Percent Recovered from T1 to T2 | ||
Pct Rec from T1 to T2 Norm by BMI | C102383 | Pct Rec from T1 to T2 Norm by BMI | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2 divided by body mass index. | Percent Recovered from T1 to T2 Normalized by Body Mass Index | ||
Pct Rec from T1 to T2 Norm by SA | C102384 | Pct Rec from T1 to T2 Norm by SA | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2 divided by surface area. | Percent Recovered from T1 to T2 Normalized by Surface Area | ||
Pct Rec from T1 to T2 Norm by WT | C102385 | Pct Rec from T1 to T2 Norm by WT | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2 divided by weight. | Percent Recovered from T1 to T2 Normalized by Weight | ||
Pct Rec Over Dosing Interval | C102386 | Pct Rec Over Dosing Interval | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU). | Percent Recovered Over Dosing Interval | ||
Pct Rec Over Dosing Interval Norm by BMI | C102387 | Pct Rec Over Dosing Interval Norm by BMI | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU) divided by the body mass index. | Percent Recovered Over Dosing Interval Normalized by Body Mass Index | ||
Pct Rec Over Dosing Interval Norm by SA | C102388 | Pct Rec Over Dosing Interval Norm by SA | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU) divided by surface area. | Percent Recovered Over Dosing Interval Normalized by Surface Area | ||
Pct Rec Over Dosing Interval Norm by WT | C102389 | Pct Rec Over Dosing Interval Norm by WT | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU) divided by weight. | Percent Recovered Over Dosing Interval Normalized by Weight | ||
Peak Trough Ratio | C102381 | Peak Trough Ratio | The ratio of Cmax to Ctrough during a dosing interval. | Peak Trough Ratio | ||
Renal CL | C75913 | Renal CL | The clearance of a substance from the blood by the kidneys. | Renal Clearance | ||
Vol Dist Initial | C102371 | Vol Dist Initial | The initial volume of distribution for a substance administered by bolus intravascular dosing. | Initial Volume of Distribution | ||
Vol Dist Initial Norm by BMI | C102372 | Vol Dist Initial Norm by BMI | The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the body mass index. | Initial Volume of Distribution Normalized by Body Mass Index | ||
Vol Dist Initial Norm by Dose | C102373 | Vol Dist Initial Norm by Dose | The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the dose. | Initial Volume of Distribution Normalized by Dose | ||
Vol Dist Initial Norm by SA | C102374 | Vol Dist Initial Norm by SA | The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the surface area. | Initial Volume of Distribution Normalized by Surface Area | ||
Vol Dist Initial Norm by WT | C102375 | Vol Dist Initial Norm by WT | The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the weight. | Initial Volume of Distribution Normalized by Weight | ||
Vol Dist Steady State Obs | C85770 | Vol Dist Steady State Obs | The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing. | Observed Steady State Volume of Distribution | ||
Vol Dist Steady State Obs Norm by BMI | C102377 | Vol Dist Steady State Obs Norm by BMI | The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the body mass index. | Observed Steady State Volume of Distribution Normalized by Body Mass Index | ||
Vol Dist Steady State Obs Norm by Dose | C102378 | Vol Dist Steady State Obs Norm by Dose | The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the dose. | Observed Steady State Volume of Distribution Normalized by Dose | ||
Vol Dist Steady State Obs Norm by SA | C102379 | Vol Dist Steady State Obs Norm by SA | The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the surface area. | Observed Steady State Volume of Distribution Normalized by Surface Area | ||
Vol Dist Steady State Obs Norm by WT | C102380 | Vol Dist Steady State Obs Norm by WT | The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the weight. | Observed Steady State Volume of Distribution Normalized by Weight | ||
Vol Dist Steady State Pred | C85794 | Vol Dist Steady State Pred | The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing. | Predicted Steady State Volume of Distribution | ||
Vol Dist Steady State Pred Norm by BMI | C102390 | Vol Dist Steady State Pred Norm by BMI | The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the body mass index. | Predicted Steady State Volume of Distribution Normalized by Body Mass Index | ||
Vol Dist Steady State Pred Norm by Dose | C102391 | Vol Dist Steady State Pred Norm by Dose | The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the dose. | Predicted Steady State Volume of Distribution Normalized by Dose | ||
Vol Dist Steady State Pred Norm by SA | C102392 | Vol Dist Steady State Pred Norm by SA | The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the surface area. | Predicted Steady State Volume of Distribution Normalized by Surface Area | ||
Vol Dist Steady State Pred Norm by WT | C102393 | Vol Dist Steady State Pred Norm by WT | The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the weight. | Predicted Steady State Volume of Distribution Normalized by Weight | ||
Vz Obs by F Norm by Dose | C102729 | Vz Obs by F Norm by Dose | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the dose. | Volume of Distribution of Fraction Dose Observed Normalized by Dose | ||
Vz Pred by F Norm by Dose | C102730 | Vz Pred by F Norm by Dose | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by the dose. | Volume of Distribution of Fraction Dose Predicted Normalized by Dose | ||
Vz Obs Norm by Dose | C102683 | Vz Obs Norm by Dose | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the dose. | Observed Volume of Distribution Normalized by Dose | ||
Vz Pred Norm by Dose | C102696 | Vz Pred Norm by Dose | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the dose. | Predicted Volume of Distribution Normalized by Dose | ||
Excret Rate from T1 to T2 | C105449 | Excret Rate from T1 to T2 | The excretion rate over the interval from T1 to T2, determined for the specimen type specified in PPSPEC. | Excretion Rate From T1 to T2 | ||
Excret Rate from T1 to T2 Norm by BMI | C105450 | Excret Rate from T1 to T2 Norm by BMI | The excretion rate over the interval from T1 to T2 divided by the body mass index, determined for the specimen type specified in PPSPEC. | Excretion Rate From T1 to T2 Normalized by BMI | ||
Excret Rate from T1 to T2 Norm by Dose | C105451 | Excret Rate from T1 to T2 Norm by Dose | The excretion rate over the interval from T1 to T2 divided by the dose, determined for the specimen type specified in PPSPEC. | Excretion Rate From T1 to T2 Normalized by Dose | ||
Excret Rate from T1 to T2 Norm by SA | C105452 | Excret Rate from T1 to T2 Norm by SA | The excretion rate over the interval from T1 to T2 divided by the surface area, determined for the specimen type specified in PPSPEC. | Excretion Rate From T1 to T2 Normalized by SA | ||
Excret Rate from T1 to T2 Norm by WT | C105453 | Excret Rate from T1 to T2 Norm by WT | The excretion rate over the interval from T1 to T2 divided by the weight, determined for the specimen type specified in PPSPEC. | Excretion Rate From T1 to T2 Normalized by WT | ||
Nonrenal CL Norm by BMI | C105454 | Nonrenal CL Norm by BMI | The total clearance of a substance from the blood minus the renal clearance divided by the body mass index. | Nonrenal Clearance Normalized by BMI | ||
Nonrenal CL Norm by Dose | C105455 | Nonrenal CL Norm by Dose | The total clearance of a substance from the blood minus the renal clearance divided by the dose. | Nonrenal Clearance Normalized by Dose | ||
Nonrenal CL Norm by SA | C105456 | Nonrenal CL Norm by SA | The total clearance of a substance from the blood minus the renal clearance divided by the surface area. | Nonrenal Clearance Normalized by SA | ||
Nonrenal CL Norm by WT | C105457 | Nonrenal CL Norm by WT | The total clearance of a substance from the blood minus the renal clearance divided by the weight. | Nonrenal Clearance Normalized by WT | ||
Renal CL Norm by BMI | C105458 | Renal CL Norm by BMI | The clearance of a substance from the blood by the kidneys divided by the body mass index. | Renal Clearance Normalized by BMI | ||
Renal CL Norm by Dose | C105459 | Renal CL Norm by Dose | The clearance of a substance from the blood by the kidneys divided by the dose. | Renal Clearance Normalized by Dose | ||
Renal CL Norm by SA | C105460 | Renal CL Norm by SA | The clearance of a substance from the blood by the kidneys divided by the surface area. | Renal Clearance Normalized by SA | ||
Renal CL Norm by WT | C105461 | Renal CL Norm by WT | The clearance of a substance from the blood by the kidneys divided by the weight. | Renal Clearance Normalized by WT | ||
Back to top | ||||||
CL.C85839.PKPARMCD | PK Parameters Code (PKPARMCD) | text Extensible: Yes | C85839 | PK Parameters Code | Parameter codes used to describe the time-concentration curve. | CDISC SDTM Pharmacokinetic Parameter Terminology by Code |
AUCPBEP | C85787 | AUC %Back Extrapolation Pred | The area under the curve (AUC) from the predicted concentration value at time zero to the first measured concentration value as a percentage of the area under the curve extrapolated to infinity. Applies only for intravascular bolus dosing. | Predicted Area Under the Curve Percent Back Extrapolation | ||
AUCPEO | C85764 | AUC %Extrapolation Obs | The area under the curve (AUC) from the last observed non-zero concentration value to infinity as a percentage of the area under the curve extrapolated to infinity. | Observed Area Under the Curve Percent Extrapolation | ||
AUCPEP | C85788 | AUC %Extrapolation Pred | The area under the curve (AUC) from the last predicted non-zero concentration value to infinity as a percentage of the area under the curve extrapolated to infinity. | Predicted Area Under the Curve Percent Extrapolation | ||
AUCALL | C85564 | AUC All | The area under the curve (AUC) from the time of dosing to the time of the last observation, regardless of whether the last concentration is measurable or not. | Area Under the Curve All | ||
AUCALLB | C92362 | AUC All Norm by BMI | The area under the curve (AUC) from the time of dosing to the time of the last observation divided by the body mass index, regardless of whether the last concentration is measurable or not. | AUC All Normalized by Body Mass Index | ||
AUCALLD | C92306 | AUC All Norm by Dose | The area under the curve (AUC) from the time of dosing to the time of the last observation divided by the dose, regardless of whether the last concentration is measurable or not. | AUC All Normalized by Dose | ||
AUCALLS | C92307 | AUC All Norm by SA | The area under the curve (AUC) from the time of dosing to the time of the last observation divided by the surface area, regardless of whether the last concentration is measurable or not. | AUC All Normalized by Surface Area | ||
AUCALLW | C92308 | AUC All Norm by WT | The area under the curve (AUC) from the time of dosing to the time of the last observation divided by the weight, regardless of whether the last concentration is measurable or not. | AUC All Normalized by Weight | ||
AUCLST | C85565 | AUC to Last Nonzero Conc | The area under the curve (AUC) from the time of dosing to the last measurable concentration. | Area Under the Curve From Dosing to Last Concentration | ||
AUCLSTB | C92309 | AUC to Last Nonzero Conc Norm by BMI | The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the body mass index. | AUC Dosing to Last Concentration Normalized by Body Mass Index | ||
AUCLSTD | C92310 | AUC to Last Nonzero Conc Norm by Dose | The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the dose. | AUC Dosing to Last Concentration Normalized by Dose | ||
AUCLSTS | C92311 | AUC to Last Nonzero Conc Norm by SA | The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the surface area. | AUC Dosing to Last Concentration Normalized by Surface Area | ||
AUCLSTW | C92305 | AUC to Last Nonzero Conc Norm by WT | The area under the curve (AUC) from the time of dosing to the last measurable concentration divided by the weight. | AUC Dosing to Last Concentration Normalized by Weight | ||
AUCINT | C85566 | AUC from T1 to T2 | The area under the curve (AUC) over the interval from T1 to T2. | Area Under the Curve from T1 to T2 | ||
AUCINTB | C92312 | AUC from T1 to T2 Norm by BMI | The area under the curve (AUC) over the interval from T1 to T2 divided by the body mass index. | AUC from T1 to T2 Normalized by Body Mass Index | ||
AUCINTD | C92313 | AUC from T1 to T2 Norm by Dose | The area under the curve (AUC) over the interval from T1 to T2 divided by the dose. | AUC from T1 to T2 Normalized by Dose | ||
AUCINTS | C92314 | AUC from T1 to T2 Norm by SA | The area under the curve (AUC) over the interval from T1 to T2 divided by the surface area. | AUC from T1 to T2 Normalized by Surface Area | ||
AUCINTW | C92315 | AUC from T1 to T2 Norm by WT | The area under the curve (AUC) over the interval from T1 to T2 divided by the weight. | AUC from T1 to T2 Normalized by Weight | ||
AUCIFOB | C92316 | AUC Infinity Obs Norm by BMI | The area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the body mass index. | AUC Infinity Observed Normalized by Body Mass Index | ||
AUCIFOS | C92317 | AUC Infinity Obs Norm by SA | The area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the surface area. | AUC Infinity Observed Normalized by Surface Area | ||
AUCIFOW | C92318 | AUC Infinity Obs Norm by WT | The area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the weight. | AUC Infinity Observed Normalized by Weight | ||
AUCIFP | C85785 | AUC Infinity Pred | The area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration. | Predicted Area Under the Curve Infinity | ||
AUCIFPD | C85786 | AUC Infinity Pred Norm by Dose | The area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the dose. | Predicted Area Under the Curve Infinity by Dose | ||
AUCIFPB | C92319 | AUC Infinity Pred Norm by BMI | The area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the body mass index. | AUC Infinity Predicted Normalized by Body Mass Index | ||
AUCIFPS | C92320 | AUC Infinity Pred Norm by SA | The area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the surface area. | AUC Infinity Predicted Normalized by Surface Area | ||
AUCIFPW | C92321 | AUC Infinity Pred Norm by WT | The area under the curve (AUC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the weight. | AUC Infinity Predicted Normalized by Weight | ||
AUCTAU | C85567 | AUC Over Dosing Interval | The area under the curve (AUC) for the defined interval between doses (TAU). | Area Under the Curve Over Dosing Interval | ||
AUCTAUB | C92322 | AUC Over Dosing Interval Norm by BMI | The area under the curve (AUC) for the defined interval between doses (TAU) divided by the body mass index. | AUC Over Dosing Interval Normalized by Body Mass Index | ||
AUCTAUD | C92323 | AUC Over Dosing Interval Norm by Dose | The area under the curve (AUC) for the defined interval between doses (TAU) divided by the dose. | AUC Over Dosing Interval Normalized by Dose | ||
AUCTAUS | C92324 | AUC Over Dosing Interval Norm by SA | The area under the curve (AUC) for the defined interval between doses (TAU) divided by the surface area. | AUC Over Dosing Interval Normalized by Surface Area | ||
AUCTAUW | C92325 | AUC Over Dosing Interval Norm by WT | The area under the curve (AUC) for the defined interval between doses (TAU) divided by the weight. | AUC Over Dosing Interval Normalized by Weight | ||
AUMCPEO | C85766 | AUMC % Extrapolation Obs | The area under the moment curve (AUMC) from the last observed non-zero concentration value to infinity as a percentage of the area under the moment curve extrapolated to infinity. | Observed Area Under the First Moment Curve Percent Extrapolation | ||
AUMCPEP | C85790 | AUMC % Extrapolation Pred | The area under the moment curve (AUMC) from the last predicted non-zero concentration value to infinity as a percentage of the area under the moment curve extrapolated to infinity. | Predicted Area Under the First Moment Curve Percent Extrapolation | ||
AUMCLST | C85569 | AUMC to Last Nonzero Conc | The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration. | Area Under the First Moment Curve From Dosing to Last Concentration | ||
AUMCLSTB | C92326 | AUMC to Last Nonzero Conc Norm by BMI | The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration divided by the body mass index. | AUMC Dosing to Last Concentration Normalized by Body Mass Index | ||
AUMCLSTD | C92327 | AUMC to Last Nonzero Conc Norm by Dose | The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration divided by the dose. | AUMC Dosing to Last Concentration Normalized by Dose | ||
AUMCLSTS | C92328 | AUMC to Last Nonzero Conc Norm by SA | The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration divided by the surface area. | AUMC Dosing to Last Concentration Normalized by Surface Area | ||
AUMCLSTW | C92329 | AUMC to Last Nonzero Conc Norm by WT | The area under the moment curve (AUMC) from the time of dosing to the last measurable concentration divided by the weight. | AUMC Dosing to Last Concentration Normalized by Weight | ||
AUMCIFO | C85765 | AUMC Infinity Obs | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration. | Observed Area Under the First Moment Curve Infinity | ||
AUMCIFOB | C92330 | AUMC Infinity Obs Norm by BMI | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the body mass index. | AUMC Infinity Observed Normalized by Body Mass Index | ||
AUMCIFOD | C92331 | AUMC Infinity Obs Norm by Dose | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the dose. | AUMC Infinity Observed Normalized by Dose | ||
AUMCIFOS | C92332 | AUMC Infinity Obs Norm by SA | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the surface area. | AUMC Infinity Observed Normalized by Surface Area | ||
AUMCIFOW | C92333 | AUMC Infinity Obs Norm by WT | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the weight. | AUMC Infinity Observed Normalized by Weight | ||
AUMCIFP | C85789 | AUMC Infinity Pred | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration. | Predicted Area Under the First Moment Curve Infinity | ||
AUMCIFPB | C92334 | AUMC Infinity Pred Norm by BMI | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the body mass index. | AUMC Infinity Predicted Normalized by Body Mass Index | ||
AUMCIFPD | C92335 | AUMC Infinity Pred Norm by Dose | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the dose. | AUMC Infinity Predicted Normalized by Dose | ||
AUMCIFPS | C92336 | AUMC Infinity Pred Norm by SA | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the surface area. | AUMC Infinity Predicted Normalized by Surface Area | ||
AUMCIFPW | C92337 | AUMC Infinity Pred Norm by WT | The area under the moment curve (AUMC) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration, divided by the weight. | AUMC Infinity Predicted Normalized by Weight | ||
AUMCTAU | C85570 | AUMC Over Dosing Interval | The area under the first moment curve (AUMC) for the defined interval between doses (TAU). | Area Under the First Moment Curve Over Dosing Interval | ||
AUMCTAUB | C92338 | AUMC Over Dosing Interval Norm by BMI | The area under the first moment curve (AUMC) for the defined interval between doses (TAU) divided by the body mass index. | AUMC Over Dosing Interval Normalized by Body Mass Index | ||
AUMCTAUD | C92339 | AUMC Over Dosing Interval Norm by Dose | The area under the first moment curve (AUMC) for the defined interval between doses (TAU) divided by the dose. | AUMC Over Dosing Interval Normalized by Dose | ||
AUMCTAUS | C92340 | AUMC Over Dosing Interval Norm by SA | The area under the first moment curve (AUMC) for the defined interval between doses (TAU) divided by the surface area. | AUMC Over Dosing Interval Normalized by Surface Area | ||
AUMCTAUW | C92341 | AUMC Over Dosing Interval Norm by WT | The area under the first moment curve (AUMC) for the defined interval between doses (TAU) divided by the weight. | AUMC Over Dosing Interval Normalized by Weight | ||
AURCPEO | C85768 | AURC % Extrapolation Obs | The area under the urinary excretion rate curve (AURC) from the last observed non-zero rate value to infinity as a percentage of the area under the urinary excretion rate curve extrapolated to infinity. | Observed Area Under the Urinary Excretion Rate Curve Percent Extrapolation | ||
AURCPEP | C85792 | AURC % Extrapolation Pred | The area under the urinary excretion rate curve (AURC) from the last predicted non-zero rate value to infinity as a percentage of the area under the urinary excretion rate curve extrapolated to infinity. | Predicted Area Under the Urinary Excretion Rate Curve Percent Extrapolation | ||
AURCALL | C85841 | AURC All | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate. | Area Under Urinary Excretion Rate Curve All | ||
AURCALLB | C92342 | AURC All Norm by BMI | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate divided by the body mass index. | AURC All Normalized by Body Mass Index | ||
AURCALLD | C92343 | AURC All Norm by Dose | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate divided by the dose. | AURC All Normalized by Dose | ||
AURCALLS | C92344 | AURC All Norm by SA | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate divided by the surface area. | AURC All Normalized by Surface Area | ||
AURCALLW | C92345 | AURC All Norm by WT | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate divided by the weight. | AURC All Normalized by Weight | ||
AURCLST | C85571 | AURC to Last Nonzero Rate | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate. | Area Under the Urinary Excretion Rate Curve From Dosing to Last Concentration | ||
AURCLSTB | C92346 | AURC to Last Nonzero Rate Norm by BMI | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate, divided by the body mass index. | AURC Dosing to Last Concentration Normalized by Body Mass Index | ||
AURCLSTD | C92347 | AURC to Last Nonzero Rate Norm by Dose | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate, divided by the dose. | AURC Dosing to Last Concentration Normalized by Dose | ||
AURCLSTS | C92348 | AURC to Last Nonzero Rate Norm by SA | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate, divided by the surface area. | AURC Dosing to Last Concentration Normalized by Surface Area | ||
AURCLSTW | C92349 | AURC to Last Nonzero Rate Norm by WT | The area under the urinary excretion rate curve (AURC) from time zero to the last measurable rate, divided by the weight. | AURC Dosing to Last Concentration Normalized by Weight | ||
AURCINT | C85572 | AURC from T1 to T2 | The area under the urinary excretion rate curve (AURC) over the interval from T1 to T2. | Area Under the Urinary Excretion Rate Curve from T1 to T2 | ||
AURCINTB | C92350 | AURC from T1 to T2 Norm by BMI | The area under the urinary excretion rate curve (AURC) over the interval from T1 to T2 divided by the body mass index. | AURC from T1 to T2 Normalized by Body Mass Index | ||
AURCINTD | C92351 | AURC from T1 to T2 Norm by Dose | The area under the urinary excretion rate curve (AURC) over the interval from T1 to T2 divided by the dose. | AURC from T1 to T2 Normalized by Dose | ||
AURCINTS | C92352 | AURC from T1 to T2 Norm by SA | The area under the urinary excretion rate curve (AURC) over the interval from T1 to T2 divided by the surface area. | AURC from T1 to T2 Normalized by Surface Area | ||
AURCINTW | C92353 | AURC from T1 to T2 Norm by WT | The area under the urinary excretion rate curve (AURC) over the interval from T1 to T2 divided by the weight. | AURC from T1 to T2 Normalized by Weight | ||
AURCIFO | C85767 | AURC Infinity Obs | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate. | Observed Area Under the Urinary Excretion Rate Curve infinity | ||
AURCIFOB | C92354 | AURC Infinity Obs Norm by BMI | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate, divided by the body mass index. | AURC Infinity Observed Normalized by Body Mass Index | ||
AURCIFOD | C92355 | AURC Infinity Obs Norm by Dose | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate, divided by the dose. | AURC Infinity Observed Normalized by Dose | ||
AURCIFOS | C92356 | AURC Infinity Obs Norm by SA | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate, divided by the surface area. | AURC Infinity Observed Normalized by Surface Area | ||
AURCIFOW | C92357 | AURC Infinity Obs Norm by WT | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the observed value of the last excretion rate, divided by the weight. | AURC Infinity Observed Normalized by Weight | ||
AURCIFP | C85791 | AURC Infinity Pred | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the predicted value of the last non-zero excretion rate. | Predicted Area Under the Urinary Excretion Rate Curve Infinity | ||
AURCIFPB | C92358 | AURC Infinity Pred Norm by BMI | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the predicted value of the last non-zero excretion rate, divded by the body mass index. | AURC Infinity Predicted Normalized by Body Mass Index | ||
AURCIFPD | C92359 | AURC Infinity Pred Norm by Dose | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the predicted value of the last non-zero excretion rate, divded by the dose. | AURC Infinity Predicted Normalized by Dose | ||
AURCIFPS | C92360 | AURC Infinity Pred Norm by SA | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the predicted value of the last non-zero excretion rate, divded by the surface area. | AURC Infinity Predicted Normalized by Surface Area | ||
AURCIFPW | C92361 | AURC Infinity Pred Norm by WT | The area under the urinary excretion rate curve (AURC) extrapolated to infinity, calculated using the predicted value of the last non-zero excretion rate, divded by the weight. | AURC Infinity Predicted Normalized by Weight | ||
CAVG | C85575 | Average Conc;Average Concentration | AUCTAU divided by TAU. | Average Concentration | ||
CAVGB | C92367 | Average Conc Norm by BMI | AUCTAU divided by TAU and then divided by the body mass index. | Average Concentration Normalized by Body Mass Index | ||
CAVGD | C92368 | Average Conc Norm by Dose | AUCTAU divided by TAU and then divided by the dose. | Average Concentration Normalized by Dose | ||
CAVGS | C92369 | Average Conc Norm by SA | AUCTAU divided by TAU and then divided by the surface area. | Average Concentration Normalized by Surface Area | ||
CAVGW | C92370 | Average Conc Norm by WT | AUCTAU divided by TAU and then divided by the weight. | Average Concentration Normalized by Weight | ||
CORRXY | C85821 | Correlation Between TimeX and Log ConcY | The correlation between time (X) and log concentration (Y) for the points used in the estimation of lambda z. | Time and Log Concentration Correlation | ||
FLUCP | C85581 | Fluctuation% | The difference between Cmin and Cmax standardized to Cavg, between dose time and Tau. | Concentration Variability Between Dose Time and Tau | ||
LAMZHL | C85818 | Half-Life Lambda z | Terminal half-life. | Terminal Half Life | ||
C0 | C85644 | Initial Conc | Initial concentration. Given only for bolus IV models. | Initial Concentration | ||
C0B | C92383 | Initial Conc Norm by BMI | Initial concentration divided by the body mass index. Given only for bolus IV models. | Initial Concentration Normalized by Body Mass Index | ||
C0D | C92384 | Initial Conc Norm by Dose | Initial concentration divided by the dose. Given only for bolus IV models. | Initial Concentration Normalized by Dose | ||
C0S | C92385 | Initial Conc Norm by SA | Initial concentration divided by the surface area. Given only for bolus IV models. | Initial Concentration Normalized by Surface Area | ||
C0W | C92386 | Initial Conc Norm by WT | Initial concentration divided by the weight. Given only for bolus IV models. | Initial Concentration Normalized by Weight | ||
LAMZ | C85652 | Lambda z | The first order rate constant associated with the terminal (log-linear) portion of the curve. | Lambda Z | ||
LAMZLL | C85653 | Lambda z Lower Limit | The lower limit on time for values to be included in the calculation of Lambda z. | Lambda Z Time Lower Limit | ||
LAMZUL | C85654 | Lambda z Upper Limit | The upper limit on time for values to be included in the calculation of Lambda z. | Lambda Z Time Upper Limit | ||
CLST | C85655 | Last Nonzero Conc | The concentration corresponding to Tlast. | Last Concentration | ||
CLSTB | C92387 | Last Nonzero Conc Norm by BMI | The concentration corresponding to Tlast divided by the body mass index. | Last Concentration Normalized by Body Mass Index | ||
CLSTD | C92388 | Last Nonzero Conc Norm by Dose | The concentration corresponding to Tlast divided by the dose. | Last Concentration Normalized by Dose | ||
CLSTS | C92389 | Last Nonzero Conc Norm by SA | The concentration corresponding to Tlast divided by the surface area. | Last Concentration Normalized by Surface Area | ||
CLSTW | C92390 | Last Nonzero Conc Norm by WT | The concentration corresponding to Tlast divided by the weight. | Last Concentration Normalized by Weight | ||
ERLST | C85656 | Last Meas Excretion Rate | The last measurable (positive) excretion rate. | Last Measurable Observed Excretion Rate | ||
ERLSTB | C92391 | Last Meas Excretion Rate Norm by BMI | The last measurable (positive) excretion rate divided by the body mass index. | Last Measurable Excretion Rate Normalized by Body Mass Index | ||
ERLSTD | C92392 | Last Meas Excretion Rate Norm by Dose | The last measurable (positive) excretion rate divided by the dose. | Last Measurable Excretion Rate Normalized by Dose | ||
ERLSTS | C92393 | Last Meas Excretion Rate Norm by SA | The last measurable (positive) excretion rate divided by the surface area. | Last Measurable Excretion Rate Normalized by Surface Area | ||
ERLSTW | C92394 | Last Meas Excretion Rate Norm by WT | The last measurable (positive) excretion rate divided by the weight. | Last Measurable Excretion Rate Normalized by Weight | ||
CMAX | C70918 | Max Conc | The maximum concentration occurring at Tmax. | Cmax | ||
CMAXD | C85698 | Max Conc Norm by Dose | The maximum concentration occurring at Tmax, divided by the dose. | Maximum Concentration Dose Normalized | ||
ERMAX | C85699 | Max Excretion Rate | The maximum excretion rate. | Maximum Observed Excretion Rate | ||
CMAXB | C92371 | Max Conc Norm by BMI | The maximum concentration occurring at Tmax, divided by the body mass index. | Maximum Concentration Normalized by Body Mass Index | ||
CMAXS | C92372 | Max Conc Norm by SA | The maximum concentration occurring at Tmax, divided by the surface area. | Maximum Concentration Normalized by Surface Area | ||
CMAXW | C92373 | Max Conc Norm by WT | The maximum concentration occurring at Tmax, divided by the weight. | Maximum Concentration Normalized by Weight | ||
ERMAXB | C92395 | Max Excretion Rate Norm by BMI | The maximum excretion rate divided by the body mass index. | Maximum Observed Excretion Rate Normalized by Body Mass Index | ||
ERMAXD | C92396 | Max Excretion Rate Norm by Dose | The maximum excretion rate divided by the dose. | Maximum Observed Excretion Rate Normalized by Dose | ||
ERMAXS | C92397 | Max Excretion Rate Norm by SA | The maximum excretion rate divided by the surface area. | Maximum Observed Excretion Rate Normalized by Surface Area | ||
ERMAXW | C92398 | Max Excretion Rate Norm by WT | The maximum excretion rate divided by the weight. | Maximum Observed Excretion Rate Normalized by Weight | ||
MIDPTLST | C85580 | Midpoint of Collection Interval | The midpoint of collection interval, which is associated with last Measurable rate. | Collection Interval Midpoint | ||
CMIN | C85579 | Min Conc | The minimum concentration between dose time and dose time plus Tau (at Tmin). | Cmin | ||
CMINB | C92374 | Min Conc Norm by BMI | The minimum concentration between dose time and dose time plus Tau (at Tmin) divided by the body mass index. | Minimum Concentration Normalized by Body Mass Index | ||
CMIND | C92375 | Min Conc Norm by Dose | The minimum concentration between dose time and dose time plus Tau (at Tmin) divided by the dose. | Minimum Concentration Normalized by Dose | ||
CMINS | C92376 | Min Conc Norm by SA | The minimum concentration between dose time and dose time plus Tau (at Tmin) divided by the surface area. | Minimum Concentration Normalized by Surface Area | ||
CMINW | C92377 | Min Conc Norm by WT | The minimum concentration between dose time and dose time plus Tau (at Tmin) divided by the weight. | Minimum Concentration Normalized by Weight | ||
MRTIFO | C85769 | MRT Infinity Obs | The mean residence time (MRT) extrapolated to infinity, calculated using the observed value of the last non-zero concentration. | Observed Mean Residence Time Infinity | ||
MRTIFP | C85793 | MRT Infinity Pred | The mean residence time (MRT) extrapolated to infinity, calculated using the predicted value of the last non-zero concentration. | Predicted Mean Residence Time Infinity | ||
MRTLST | C85700 | MRT to Last Nonzero Conc | Mean residence time (MRT) from the time of dosing to the time of the last measurable concentration. | Mean Residence Time Last | ||
LAMZNPT | C85816 | Number of Points for Lambda z | The number of time points used in computing Lambda z. | Sum of Lambda Z Timepoints | ||
AUCIFO | C85761 | AUC Infinity Obs | The area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration. | Observed Area Under the Curve Infinity | ||
R2 | C85542 | R Squared | The goodness of fit statistic for the terminal elimination phase. | R Squared | ||
R2ADJ | C85553 | R Squared Adjusted | The goodness of fit statistic for the terminal elimination phase, adjusted for the number of time points used in the estimation of Lambda z. | Adjusted R Squared | ||
VOLPK | C85817 | Sum of Urine Vol | The sum of urine volumes that are used for PK parameters. | Sum Urine Volume | ||
TMAX | C70919 | Time of CMAX | The time of maximum observed concentration sampled during a dosing interval. | Tmax | ||
TMIN | C85825 | Time of CMIN Observation | The time of minimum concentration sampled during a dosing interval. | Tmin | ||
TLST | C85822 | Time of Last Nonzero Conc | The time of the last measurable (positive) concentration. | Time of Last Nonzero Concentration | ||
ERTMAX | C85823 | Time of Max Excretion Rate | The midpoint of collection interval associated with the maximum excretion rate. | Time of Maximum Observed Excretion Rate | ||
TLAG | C85824 | Time Until First Nonzero Conc | The time prior to the first measurable (non-zero) concentration. | Time until First Nonzero Concentration | ||
CLO | C85773 | Total CL Obs | The total body clearance for intravascular administration, calculated using the observed value of the last non-zero concentration. | Observed Total Body Clearance Rate | ||
CLFO | C85772 | Total CL Obs by F | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration. | Observed Total Body Clearance by Fraction of Dose Absorbed | ||
CLP | C85797 | Total CL Pred | The total body clearance for intravascular administration, calculated using the predicted value of the last non-zero concentration. | Predicted Total Body Clearance Rate | ||
CLFP | C85796 | Total CL Pred by F | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration. | Predicted Total Body Clearance by Fraction of Dose Absorbed | ||
CLFOB | C92399 | Total CL Obs by F Norm by BMI | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the body mass index. | Total Clearance Observed by Fraction Dose Normalized by Body Mass Index | ||
CLFOS | C92401 | Total CL Obs by F Norm by SA | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the surface area. | Total Clearance Observed by Fraction Dose Normalized by Surface Area | ||
CLFOW | C92402 | Total CL Obs by F Norm by WT | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the weight. | Total Clearance Observed by Fraction Dose Normalized by Weight | ||
CLOB | C92403 | Total CL Obs Norm by BMI | The total body clearance for intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the body mass index. | Total Clearance Observed Normalized by Body Mass Index | ||
CLOS | C92405 | Total CL Obs Norm by SA | The total body clearance for intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the surface area. | Total Clearance Observed Normalized by Surface Area | ||
CLOW | C92406 | Total CL Obs Norm by WT | The total body clearance for intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the weight. | Total Clearance Observed Normalized by Weight | ||
CLFPB | C92417 | Total CL Pred by F Norm by BMI | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by body mass index. | Total Clearance Predicted by Fraction Dose Normalized by Body Mass Index | ||
CLFPS | C92419 | Total CL Pred by F Norm by SA | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by the surface area. | Total Clearance Predicted by Fraction Dose Normalized by Surface Area | ||
CLFPW | C92420 | Total CL Pred by F Norm by WT | The total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by the weight. | Total Clearance Predicted by Fraction Dose Normalized by Weight | ||
CLPB | C92421 | Total CL Pred Norm by BMI | The total body clearance for intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the body mass index. | Total Clearance Predicted Normalized by Body Mass Index | ||
CLPS | C92423 | Total CL Pred Norm by SA | The total body clearance for intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the surface area. | Total Clearance Predicted Normalized by Surface Area | ||
CLPW | C92424 | Total CL Pred Norm by WT | The total body clearance for intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the weight. | Total Clearance Predicted Normalized by Weight | ||
VZFO | C85775 | Vz Obs by F | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration. | Observed Volume of Distribution of Absorbed Fraction | ||
VZFP | C85799 | Vz Pred by F | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration. | Predicted Volume of Distribution of Absorbed Fraction | ||
VZOB | C92407 | Vz Obs Norm by BMI | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the body mass index. | Volume of Distribution Observed Normalized by Body Mass Index | ||
VZOS | C92408 | Vz Obs Norm by SA | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the surface area. | Volume of Distribution Observed Normalized by Surface Area | ||
VZOW | C92409 | Vz Obs Norm by WT | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the weight. | Volume of Distribution Observed Normalized by Weight | ||
VZFOB | C92410 | Vz Obs by F Norm by BM | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the body mass index. | Volume of Distribution of Fraction Dose Observed Normalized by Body Mass Index | ||
VZFOS | C92411 | Vz Obs by F Norm by SA | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the surface area. | Volume of Distribution of Fraction Dose Observed Normalized by Surface Area | ||
VZFOW | C92412 | Vz Obs by F Norm by WT | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the weight. | Volume of Distribution of Fraction Dose Observed Normalized by Weight | ||
VZFPB | C92428 | Vz Pred by F Norm by BMI | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by the body mass index. | Volume of Distribution of Fraction Dose Predicted Normalized by Body Mass Index | ||
VZFPS | C92429 | Vz Pred by F Norm by SA | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by the surface area. | Volume of Distribution of Fraction Dose Predicted Normalized by Surface Area | ||
VZFPW | C92430 | Vz Pred by F Norm by WT | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by the weight. | Volume of Distribution of Fraction Dose Predicted Normalized by Weight | ||
VZPB | C92425 | Vz Pred Norm by BMI | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the body mass index. | Volume of Distribution Predicted Normalized by Body Mass Index | ||
VZPS | C92426 | Vz Pred Norm by SA | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the surface area. | Volume of Distribution Predicted Normalized by Surface Area | ||
VZPW | C92427 | Vz Pred Norm by WT | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the weight. | Volume of Distribution Predicted Normalized by Weight | ||
VZO | C85774 | Vz Obs | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the observed value of the last non-zero concentration. | Observed Volume of Distribution | ||
VZP | C85798 | Vz Pred | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the predicted value of the last non-zero concentration. | Predicted Volume of Distribution | ||
AUCIFOD | C96695 | AUC Infinity Obs Norm by Dose | The area under the curve (AUC) extrapolated to infinity, calculated using the observed value of the last non-zero concentration, divided by the dose. | AUC Infinity Observed Normalized by Dose | ||
ARAUC | C102356 | Accumulation Ratio AUC | The area under the curve (AUCTAU) at steady state divided by the area under the curve over the initial dosing interval. | Accumulation Ratio Area Under the Curve | ||
ARCMAX | C102357 | Accumulation Ratio Cmax | The maximum concentration at steady state divided by the maximum concentration during the initial dosing interval. | Accumulation Ratio Cmax | ||
ARCMIN | C102358 | Accumulation Ratio Cmin | The minimum concentration at steady state divided by the minimum concentration during the initial dosing interval. | Accumulation Ratio Cmin | ||
ARCTROUG | C102426 | Accumulation Ratio Ctrough | The trough concentration at steady state divided by the trough concentration during the initial dosing interval. | Accumulation Ratio Ctrough | ||
RCAMINT | C102359 | Amt Rec from T1 to T2 | The cumulative amount recovered from the specimen type specified in PPSPEC over the interval from T1 to T2. | Amount Recovered from T1 to T2 | ||
RCAMINTB | C102360 | Amt Rec from T1 to T2 Norm by BMI | The cumulative amount recovered from the specimen type specified in PPSPEC over the interval from T1 to T2 divided by body mass index. | Amount Recovered from T1 to T2 Normalized by Body Mass Index | ||
RCAMINTS | C102361 | Amt Rec from T1 to T2 Norm by SA | The cumulative amount recovered from the specimen type specified in PPSPEC over the interval from T1 to T2 divided by surface area. | Amount Recovered from T1 to T2 Normalized by Surface Area | ||
RCAMINTW | C102362 | Amt Rec from T1 to T2 Norm by WT | The cumulative amount recovered from the specimen type specified in PPSPEC over the interval from T1 to T2 divided by weight. | Amount Recovered from T1 to T2 Normalized by Weight | ||
RCAMTAU | C102363 | Amt Rec Over Dosing Interval | The cumulative amount recovered from the specimen type specified in PPSPEC between doses (TAU). | Amount Recovered Over Dosing Interval | ||
RCAMTAUB | C102364 | Amt Rec Over Dosing Interval Norm by BMI | The cumulative amount recovered from the specimen type specified in PPSPEC between doses (TAU) divided by body mass index. | Amount Recovered Over Dosing Interval Normalized by Body Mass Index | ||
RCAMTAUS | C102365 | Amt Rec Over Dosing Interval Norm by SA | The cumulative amount recovered from the specimen type specified in PPSPEC between doses (TAU) divided by surface area. | Amount Recovered Over Dosing Interval Normalized by Surface Area | ||
RCAMTAUW | C102366 | Amt Rec Over Dosing Interval Norm by WT | The cumulative amount recovered from the specimen type specified in PPSPEC between doses (TAU) divided by weight. | Amount Recovered Over Dosing Interval Normalized by Weight | ||
CONC | C41185 | Conc | The quantity of a specified substance in a unit volume or weight of another substance. | Concentration | ||
CONCB | C102367 | Conc by BMI | The concentration divided by body mass index. | Concentration Divided by Body Mass Index | ||
CONCD | C102368 | Conc by Dose | The concentration divided by dose. | Concentration Divided by Dose | ||
CONCS | C102369 | Conc by SA | The concentration divided by surface area. | Concentration Divided by Surface Area | ||
CONCW | C102370 | Conc by WT | The concentration divided by weight. | Concentration Divided by Weight | ||
CTROUGH | C102394 | Conc Trough | Concentration at end of dosing interval. | Trough Concentration | ||
CTROUGHB | C102395 | Conc Trough by BMI | The trough concentration divided by body mass index. | Trough Concentration Divided by Body Mass Index | ||
CTROUGHD | C102396 | Conc Trough by Dose | The trough concentration divided by dose. | Trough Concentration Divided by Dose | ||
CTROUGHS | C102397 | Conc Trough by SA | The trough concentration divided by surface area. | Trough Concentration Divided by Surface Area | ||
CTROUGHW | C102398 | Conc Trough by WT | The trough concentration divided by weight. | Trough Concentration Divided by Weight | ||
EFFHL | C95007 | Effective Half-Life | The drug half-life that quantifies the accumulation ratio of a drug following multiple dosing. | Effective Half-life | ||
NRENALCL | C102376 | Nonrenal CL | The total clearance of a substance from the blood less the renal clearance. | Nonrenal Clearance | ||
RCPCINT | C102382 | Pct Rec from T1 to T2 | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2. | Percent Recovered from T1 to T2 | ||
RCPCINTB | C102383 | Pct Rec from T1 to T2 Norm by BMI | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2 divided by body mass index. | Percent Recovered from T1 to T2 Normalized by Body Mass Index | ||
RCPCINTS | C102384 | Pct Rec from T1 to T2 Norm by SA | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2 divided by surface area. | Percent Recovered from T1 to T2 Normalized by Surface Area | ||
RCPCINTW | C102385 | Pct Rec from T1 to T2 Norm by WT | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, over the interval between T1 and T2 divided by weight. | Percent Recovered from T1 to T2 Normalized by Weight | ||
RCPCTAU | C102386 | Pct Rec Over Dosing Interval | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU). | Percent Recovered Over Dosing Interval | ||
RCPCTAUB | C102387 | Pct Rec Over Dosing Interval Norm by BMI | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU) divided by the body mass index. | Percent Recovered Over Dosing Interval Normalized by Body Mass Index | ||
RCPCTAUS | C102388 | Pct Rec Over Dosing Interval Norm by SA | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU) divided by surface area. | Percent Recovered Over Dosing Interval Normalized by Surface Area | ||
RCPCTAUW | C102389 | Pct Rec Over Dosing Interval Norm by WT | The percentage of the administered dose that is recovered from the specimen type specified in PPSPEC, between doses (TAU) divided by weight. | Percent Recovered Over Dosing Interval Normalized by Weight | ||
PTROUGHR | C102381 | Peak Trough Ratio | The ratio of Cmax to Ctrough during a dosing interval. | Peak Trough Ratio | ||
RENALCL | C75913 | Renal CL | The clearance of a substance from the blood by the kidneys. | Renal Clearance | ||
V0 | C102371 | Vol Dist Initial | The initial volume of distribution for a substance administered by bolus intravascular dosing. | Initial Volume of Distribution | ||
V0B | C102372 | Vol Dist Initial Norm by BMI | The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the body mass index. | Initial Volume of Distribution Normalized by Body Mass Index | ||
V0D | C102373 | Vol Dist Initial Norm by Dose | The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the dose. | Initial Volume of Distribution Normalized by Dose | ||
V0S | C102374 | Vol Dist Initial Norm by SA | The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the surface area. | Initial Volume of Distribution Normalized by Surface Area | ||
V0W | C102375 | Vol Dist Initial Norm by WT | The initial volume of distribution for a substance administered by bolus intravascular dosing divided by the weight. | Initial Volume of Distribution Normalized by Weight | ||
VSSO | C85770 | Vol Dist Steady State Obs | The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing. | Observed Steady State Volume of Distribution | ||
VSSOB | C102377 | Vol Dist Steady State Obs Norm by BMI | The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the body mass index. | Observed Steady State Volume of Distribution Normalized by Body Mass Index | ||
VSSOD | C102378 | Vol Dist Steady State Obs Norm by Dose | The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the dose. | Observed Steady State Volume of Distribution Normalized by Dose | ||
VSSOS | C102379 | Vol Dist Steady State Obs Norm by SA | The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the surface area. | Observed Steady State Volume of Distribution Normalized by Surface Area | ||
VSSOW | C102380 | Vol Dist Steady State Obs Norm by WT | The volume of distribution at steady state based on the observed CLST for a substance administered by intravascular dosing divided by the weight. | Observed Steady State Volume of Distribution Normalized by Weight | ||
VSSP | C85794 | Vol Dist Steady State Pred | The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing. | Predicted Steady State Volume of Distribution | ||
VSSPB | C102390 | Vol Dist Steady State Pred Norm by BMI | The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the body mass index. | Predicted Steady State Volume of Distribution Normalized by Body Mass Index | ||
VSSPD | C102391 | Vol Dist Steady State Pred Norm by Dose | The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the dose. | Predicted Steady State Volume of Distribution Normalized by Dose | ||
VSSPS | C102392 | Vol Dist Steady State Pred Norm by SA | The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the surface area. | Predicted Steady State Volume of Distribution Normalized by Surface Area | ||
VSSPW | C102393 | Vol Dist Steady State Pred Norm by WT | The volume of distribution at steady state based on the predicted CLST for a substance administered by intravascular dosing divided by the weight. | Predicted Steady State Volume of Distribution Normalized by Weight | ||
VZFOD | C102729 | Vz Obs by F Norm by Dose | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last non-zero concentration, divided by the dose. | Volume of Distribution of Fraction Dose Observed Normalized by Dose | ||
VZFPD | C102730 | Vz Pred by F Norm by Dose | The volume of distribution associated with the terminal slope following extravascular administration divided by the fraction of dose absorbed, calculated using the predicted value of the last non-zero concentration, divided by the dose. | Volume of Distribution of Fraction Dose Predicted Normalized by Dose | ||
VZOD | C102683 | Vz Obs Norm by Dose | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the observed value of the last non-zero concentration, divided by the dose. | Observed Volume of Distribution Normalized by Dose | ||
VZPD | C102696 | Vz Pred Norm by Dose | The volume of distribution associated with the terminal slope following intravascular administration, calculated using the predicted value of the last non-zero concentration, divided by the dose. | Predicted Volume of Distribution Normalized by Dose | ||
ERINT | C105449 | Excret Rate from T1 to T2 | The excretion rate over the interval from T1 to T2, determined for the specimen type specified in PPSPEC. | Excretion Rate From T1 to T2 | ||
ERINTB | C105450 | Excret Rate from T1 to T2 Norm by BMI | The excretion rate over the interval from T1 to T2 divided by the body mass index, determined for the specimen type specified in PPSPEC. | Excretion Rate From T1 to T2 Normalized by BMI | ||
ERINTD | C105451 | Excret Rate from T1 to T2 Norm by Dose | The excretion rate over the interval from T1 to T2 divided by the dose, determined for the specimen type specified in PPSPEC. | Excretion Rate From T1 to T2 Normalized by Dose | ||
ERINTS | C105452 | Excret Rate from T1 to T2 Norm by SA | The excretion rate over the interval from T1 to T2 divided by the surface area, determined for the specimen type specified in PPSPEC. | Excretion Rate From T1 to T2 Normalized by SA | ||
ERINTW | C105453 | Excret Rate from T1 to T2 Norm by WT | The excretion rate over the interval from T1 to T2 divided by the weight, determined for the specimen type specified in PPSPEC. | Excretion Rate From T1 to T2 Normalized by WT | ||
NRENLCLB | C105454 | Nonrenal CL Norm by BMI | The total clearance of a substance from the blood minus the renal clearance divided by the body mass index. | Nonrenal Clearance Normalized by BMI | ||
NRENLCLD | C105455 | Nonrenal CL Norm by Dose | The total clearance of a substance from the blood minus the renal clearance divided by the dose. | Nonrenal Clearance Normalized by Dose | ||
NRENLCLS | C105456 | Nonrenal CL Norm by SA | The total clearance of a substance from the blood minus the renal clearance divided by the surface area. | Nonrenal Clearance Normalized by SA | ||
NRENLCLW | C105457 | Nonrenal CL Norm by WT | The total clearance of a substance from the blood minus the renal clearance divided by the weight. | Nonrenal Clearance Normalized by WT | ||
RENALCLB | C105458 | Renal CL Norm by BMI | The clearance of a substance from the blood by the kidneys divided by the body mass index. | Renal Clearance Normalized by BMI | ||
RENALCLD | C105459 | Renal CL Norm by Dose | The clearance of a substance from the blood by the kidneys divided by the dose. | Renal Clearance Normalized by Dose | ||
RENALCLS | C105460 | Renal CL Norm by SA | The clearance of a substance from the blood by the kidneys divided by the surface area. | Renal Clearance Normalized by SA | ||
RENALCLW | C105461 | Renal CL Norm by WT | The clearance of a substance from the blood by the kidneys divided by the weight. | Renal Clearance Normalized by WT | ||
Back to top | ||||||
CL.C90013.EGLEAD | ECG Lead (EGLEAD) | text Extensible: Yes | C90013 | ECG Lead | Terminology related to electrocardiogram lead names. | CDISC SDTM Electrocardiogram Lead Terminology |
LEAD aVF | C90360 | An augmented unipolar electrocardiogram limb lead in which the positive (red) electrode is situated on the left pelvic limb and the negative electrode is a combination of the right thoracic limb (white) electrode and the left thoracic limb (black) electrode. Measures the electrical activity of the electrode on the left pelvic limb. | Augmented Vector Foot | |||
LEAD aVL | C90361 | An augmented unipolar electrocardiogram limb lead in which the positive (black) electrode is situated on the left thoracic limb and the negative electrode is a combination of the right thoracic limb (white) electrode and the left pelvic limb (red) electrode. Measures the electrical activity of the electrode on the left thoracic limb. (NCI) | Augmented Vector Left | |||
LEAD aVR | C90362 | An augmented unipolar electrocardiogram limb lead in which the positive (white) electrode is situated on the right thoracic limb and the negative electrode is a combination of the left thoracic limb (black) electrode and the left pelvic limb (red) electrode. Measures the electrical activity of the electrode on the right thoracic limb. (NCI) | Augmented Vector Right | |||
LEAD CM5 | C90404 | A bipolar EKG lead with the right thoracic limb electrode placed on the manubrium and left thoracic limb electrode placed at the surface marking of the V5 position (just above the 5th interspace in the anterior axillary line). The left pelvic limb lead acts as a neutral and may be placed anywhere. The C refers to 'clavicle' where it is often placed. (NCI) | Lead Site CM5 | |||
LEAD I | C90408 | A bipolar electrocardiogram limb lead which records the voltage between the negative electrode on the right thoracic limb and the positive electrode on the left thoracic limb. (NCI) | Lead Site I | |||
LEAD II | C90409 | A bipolar electrocardiogram limb lead which records the voltage between the negative electrode on the right thoracic limb and the positive electrode on the left pelvic limb. (NCI) | Lead Site II | |||
LEAD III | C90410 | A bipolar electrocardiogram limb lead which records the voltage between the negative electrode on the left thoracic limb and the positive electrode on the left pelvic limb. (NCI) | Lead Site III | |||
LEAD V1 | C90412 | A unipolar electrocardiogram lead site; the electrode is placed at the fourth intercostal space on the anterior chest wall (between ribs 4 and 5) to the right of the sternal border. In small animals, it is placed at the right fifth intercostal space near the sternum. (NCI) | Lead Site V1 | |||
LEAD V2 | C90414 | A unipolar electrocardiogram lead site; the electrode is placed on the anterior chest wall at the fourth intercostal space (between ribs 4 and 5) to the left of the sternal border. In small animals it corresponds to V2-V3 where it is placed at the 6th left intercostal space near the sternum. In large animals it is placed over the 6th rib at the level of the costochondral junction on the left side of the thorax. | Lead Site V2 | |||
LEAD V3 | C90415 | A unipolar electrocardiogram lead site; the electrode is placed on the anterior chest wall midway between leads V2 and V4. In large and small animals, it is placed over the dorsal spinous process of the 7th thoracic vertebra. (NCI) | Lead Site V3 | |||
LEAD V4 | C90416 | A unipolar electrocardiogram lead site; the electrode is placed at the fifth intercostal space on the anterior chest wall (between ribs 5 and 6) at the left midclavicular line. In small animals it corresponds to V4-V6 where it is placed at the 6th left intercostal space near the costochondral junction. In large animals it is placed over the 6th rib at the level of a horizontal line drawn through the scapulohumeral articulation on the left side of the thorax. (NCI) | Lead Site V4 | |||
LEAD V5 | C90417 | A unipolar electrocardiogram lead site; the electrode is placed on the anterior chest wall level with lead V4 at the left anterior axillary line. In large animals it is placed on the sixth ICS on the right side of the thorax along a line parallel to the level of the point of the shoulder corresponding to the electrical center of the heart (central terminal). (NCI) | Lead Site V5 | |||
LEAD V6 | C90418 | A unipolar electrocardiogram lead site at which the electrode is placed on the anterior chest wall level with lead V5 at the left midaxillary line . | Lead Site V6 | |||
LEAD CV6LL | C90406 | V1 electrode (+) placed in the 6th intercostal space on the left side of the thorax along a line parallel to the level of the point of the humeralradial joint. | Lead Site CV6LL | |||
LEAD CV6LU | C90407 | V2 electrode (+) placed in the 6th intercostal space on the left side of the thorax along a line parallel to the level of the point of the shoulder. (NCI) | Lead Site CV6LU | |||
LEAD V10 | C90413 | A unipolar chest lead at which the electrode is placed over the dorsal spinous process of 7th thoracic vertebra. (NCI) | Lead Site V10 | |||
LEAD CV5RL | C90405 | A unipolar chest lead used mostly in large animals. Placed on the sixth ICS on the right side of the thorax along a line parallel to the level of the point of the humeralradial joint. | Lead Site CV5RL | |||
LEAD rV2 | C90411 | A unipolar precordial lead placed at the second intercostal space to the left of the sternum. (NCI) | Lead Site rV2 | |||
LEAD aV6 | C90403 | An augmented unipolar lead placed at the sixth intercostal space on the midaxillary line. (NCI) | Lead Site aV6 | |||
Back to top | ||||||
CL.C95120.PHSPRP | Physical Properties Test Name (PHSPRP) | text Extensible: Yes | C95120 | Physical Properties Test Name | Terminology relevant to the test names that describe the physical characteristics of an entity. | CDISC SDTM Physical Properties Test Name Terminology |
Shape | C25677 | Shape | The spatial arrangement of something as distinct from its substance. (NCI) | Shape | ||
Depth | C25333 | Depth | The extent downward or inward; the perpendicular measurement from the surface downward to determine deepness. (NCI) | Depth | ||
Diameter | C25285 | Diameter | The length of a straight line passing through the center of a circle or sphere and connecting two points on the circumference. (NCI) | Diameter | ||
Length | C25334 | Length | The linear extent in space from one end of something to the other end, or the extent of something from beginning to end. (NCI) | Length | ||
Width | C25345 | Width | The extent or measurement of something from side to side. (NCI) | Width | ||
Consistency | C95110 | Consistency | A description about the firmness or make-up of an entity. | Consistency | ||
Color | C37927 | Color | The appearance of objects (or light sources) described in terms of a person's perception of their hue and lightness (or brightness) and saturation. (NCI) | Color | ||
Hair Cover | C95109 | Hair Cover | A description of the quantity or quality of the hair or fur covering a biological entity. (NCI) | Hair or Fur Cover | ||
Ulceration | C25757 | Ulceration | The formation or development of an ulcer. (NCI) | Ulceration | ||
Description | C25365 | Description | A written or verbal account, representation, statement, or explanation of something. (NCI) | Description | ||
Back to top | ||||||
CL.C95121.PHSPRPCD | Physical Properties Test Code (PHSPRPCD) | text Extensible: Yes | C95121 | Physical Properties Test Code | Terminology relevant to the test codes that describe the physical characteristics of an entity. | CDISC SDTM Physical Properties Test Code Terminology |
SHAPE | C25677 | Shape | The spatial arrangement of something as distinct from its substance. (NCI) | Shape | ||
DEPTH | C25333 | Depth | The extent downward or inward; the perpendicular measurement from the surface downward to determine deepness. (NCI) | Depth | ||
DIAMETER | C25285 | Diameter | The length of a straight line passing through the center of a circle or sphere and connecting two points on the circumference. (NCI) | Diameter | ||
LENGTH | C25334 | Length | The linear extent in space from one end of something to the other end, or the extent of something from beginning to end. (NCI) | Length | ||
WIDTH | C25345 | Width | The extent or measurement of something from side to side. (NCI) | Width | ||
CONSIST | C95110 | Consistency | A description about the firmness or make-up of an entity. | Consistency | ||
COLOR | C37927 | Color | The appearance of objects (or light sources) described in terms of a person's perception of their hue and lightness (or brightness) and saturation. (NCI) | Color | ||
HAIRCOV | C95109 | Hair Cover | A description of the quantity or quality of the hair or fur covering a biological entity. (NCI) | Hair or Fur Cover | ||
ULCER | C25757 | Ulceration | The formation or development of an ulcer. (NCI) | Ulceration | ||
DESCR | C25365 | Description | A written or verbal account, representation, statement, or explanation of something. (NCI) | Description | ||
Back to top | ||||||
CL.C96780.TUMIDENT | Tumor Identification Results (TUMIDENT) | text Extensible: Yes | C96780 | Tumor Identification Results | Terminology relevant to tumor identification results. | CDISC SDTM Tumor Identification Result Terminology |
TARGET | C94520 | The identification of a tumor that is present at baseline, is measurable and is the primary target of the therapeutic intervention. | Target Lesion Identification | |||
NON-TARGET | C94521 | The identification of a tumor or site of disease that is present at baseline and not considered a target tumor, but may be part of the objective assessment of the response to the therapeutic intervention. | Non-Target Lesion Identification | |||
NEW | C94522 | The identification of a tumor which has not been previously seen or characterized. | New Lesion Identification | |||
BENIGN | C14172 | Benign | For neoplasms, a non-infiltrating and non-metastasizing neoplastic process that is characterized by the absence of morphologic features associated with malignancy (e.g., severe atypia, nuclear pleomorphism, tumor cell necrosis, and abnormal mitoses). For other conditions, a process that is mild in nature and not dangerous to health. (NCI) | Benign | ||
MEASURED | C103416 | The identification of a tumor that is present at baseline and will be quantifiably measured over the course of the study. | Measured Tumor Identification | |||
NON-MEASURABLE | C103423 | The identification of a tumor that is incapable of being measured at baseline. | Non-Measurable Tumor Identification | |||
NOT MEASURED | C103425 | The identification of a tumor that is present at baseline and will not be quantifiably measured over the course of the study. | Not Measured Tumor Identification | |||
TARGET EXTRA NODAL | C103442 | The identification of a target tumor located outside of or independent of the lymph node. | Target Extra Nodal Tumor Identification | |||
TARGET NODAL | C103443 | The identification of a target tumor located at or near the lymph node. | Target Nodal Tumor Identification | |||
TARGET NODULE | C103444 | The identification of a target tumor located within the liver or spleen, as defined by the International Working Group (IWG) guidelines for lymphoma. | Target Nodule Tumor Identification | |||
Back to top | ||||||
CL.C96782.RSTESTCD | Tumor Response Assessment Test Code (RSTESTCD) | text Extensible: Yes | C96782 | Tumor Response Assessment Test Code | Terminology relevant to the test codes that describe an assessment of tumor response to treatment or therapy. | CDISC SDTM Tumor Response Assessment Test Code Terminology |
BESTRESP | C94536 | Best Overall Response;Best Response | An assessment of the most clinically favorable overall response of the disease to the therapy. | Best Overall Response | ||
NRADPROG | C96608 | Non-Radiological Progression | A non-radiological determination of disease progression based on symptoms or other findings. | Non-Radiological Progression | ||
NTRGRESP | C96609 | Non-target Response | An assessment of the response of a non-target tumor(s) to the therapy. | Non-target Response | ||
OVRLRESP | C96613 | Overall Response | An assessment of the overall response of the disease to the therapy. (NCI) | Overall Response | ||
TRGRESP | C96637 | Target Response | An assessment of the response of a target tumor(s) to the therapy. | Target Response | ||
NEWLPROG | C103420 | New Lesion Progression | An assessment of the equivocality of disease progression based on a newly identified lesion. | New Lesion Progression | ||
Back to top | ||||||
CL.C96781.RSTEST | Tumor Response Assessment Test Name (RSTEST) | text Extensible: Yes | C96781 | Tumor Response Assessment Test Name | Terminology relevant to the test names that describe an assessment of tumor response to treatment or therapy. | CDISC SDTM Tumor Response Assessment Test Name Terminology |
Best Overall Response | C94536 | Best Overall Response;Best Response | An assessment of the most clinically favorable overall response of the disease to the therapy. | Best Overall Response | ||
Non-Radiological Progression | C96608 | Non-Radiological Progression | A non-radiological determination of disease progression based on symptoms or other findings. | Non-Radiological Progression | ||
Non-target Response | C96609 | Non-target Response | An assessment of the response of a non-target tumor(s) to the therapy. | Non-target Response | ||
Overall Response | C96613 | Overall Response | An assessment of the overall response of the disease to the therapy. (NCI) | Overall Response | ||
Target Response | C96637 | Target Response | An assessment of the response of a target tumor(s) to the therapy. | Target Response | ||
New Lesion Progression | C103420 | New Lesion Progression | An assessment of the equivocality of disease progression based on a newly identified lesion. | New Lesion Progression | ||
Back to top | ||||||
CL.C96785.RSSTRESC | Tumor Response Result (RSSTRESC) | text Extensible: Yes | C96785 | Tumor Response Result | The result of an assessment of tumor response to treatment or therapy. | CDISC SDTM Tumor Response Result Terminology |
PR | C18058 | Partial Response;Partial Remission | A finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient. (NCI) | Partial Remission | ||
SD | C18213 | Stable Disease | Cancer that is neither decreasing nor increasing in extent or severity. (NCI) | Stable Disease | ||
PD | C35571 | Progressive Disease | A disease process that is increasing in scope or severity. (NCI) | Progressive Disease | ||
NA | C48660 | Not Applicable | Determination of a value is not relevant in the current context. (NCI) | Not Applicable | ||
CR | C4870 | Complete Response;Complete Remission | The disappearance of all signs of cancer in response to treatment. (NCI) | Complete Remission | ||
NE | C62222 | Not Evaluable | Unable to be evaluated. (NCI) | Unevaluable | ||
UPD | C96644 | Unequivocal Progression | An overall level of substantial worsening in non-target disease that is of a magnitude that, even in the presence of SD or PR in target disease, the treating physician would feel it important to change therapy. (RECIST) | Unequivocal Progression | ||
Non-CR/Non-PD | C96700 | Non Complete Response/Non Progressive Disease | Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker levels above the normal limits. (RECIST) | Non Complete Response/Non Progressive Disease | ||
CRi | C103385 | Complete Response with Incomplete Bone Marrow Recovery | The disappearance of all signs of cancer in response to treatment accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia. | Complete Response with Incomplete Bone Marrow Recovery | ||
EQUIVOCAL | C86071 | EQUIVOCAL | Open to question. | Equivocal | ||
nPR | C103422 | Nodular Partial Response | Remission with remaining lymphoid nodules reflecting residual disease. | Nodular Partial Response | ||
NOT ALL EVALUATED | C103424 | Not All Evaluated | Not all target tumors were assessed. Or not all non-target tumors were assessed. | Not All Tumors Evaluated | ||
Back to top | ||||||
CL.C96784.TUTESTCD | Tumor Identification Test Code (TUTESTCD) | text Extensible: Yes | C96784 | Tumor Identification Test Code | Terminology relevant to the test codes that describe tumor assessments for identification purposes. | CDISC SDTM Tumor Identification Test Code Terminology |
TUMIDENT | C94523 | Tumor Identification | An indication that a tumor has been located and characterized. | Tumor Identification | ||
TUMERGE | C94525 | Tumor Merged | An indication that multiple tumors have coalesced into one tumor. | Matted Tumor Mass Present | ||
TUSPLIT | C96642 | Tumor Split | An indication that a single tumor has divided into two or more tumors. | Tumor Split | ||
Back to top | ||||||
CL.C96783.TUTEST | Tumor Identification Test Name (TUTEST) | text Extensible: Yes | C96783 | Tumor Identification Test Name | Terminology relevant to the test names that describe tumor assessments for identification purposes. | CDISC SDTM Tumor Identification Test Name Terminology |
Tumor Identification | C94523 | Tumor Identification | An indication that a tumor has been located and characterized. | Tumor Identification | ||
Tumor Merged | C94525 | Tumor Merged | An indication that multiple tumors have coalesced into one tumor. | Matted Tumor Mass Present | ||
Tumor Split | C96642 | Tumor Split | An indication that a single tumor has divided into two or more tumors. | Tumor Split | ||
Back to top | ||||||
CL.C96777.MEDEVAL | Medical Evaluator (MEDEVAL) | text Extensible: Yes | C96777 | Medical Evaluator | The individual responsible for the medical assessment. | CDISC SDTM Medical Evaluator Terminology |
NEUROLOGIST | C17721 | A physician who specializes in diagnosing and treating diseases and disorders of the nervous system. | Neurologist | |||
NEUROLOGIST 1 | C96692 | A neurologist performing the assessment that is given the designation of one. | Neurologist 1 | |||
NEUROLOGIST 2 | C96606 | A neurologist performing the assessment that is given the designation of two. | Neurologist 2 | |||
ONCOLOGIST | C17821 | A physician who specializes in diagnosing and treating cancer. (NCI) | Oncologist | |||
ONCOLOGIST 1 | C96611 | An oncologist performing the assessment that is given the designation of one. | Oncologist 1 | |||
ONCOLOGIST 2 | C96612 | An oncologist performing the assessment that is given the designation of two. | Oncologist 2 | |||
RADIOLOGIST | C17824 | A physician who specializes in the diagnostic and/or therapeutic uses of radiation. (NCI) | Radiologist | |||
RADIOLOGIST 1 | C94530 | A radiologist performing the assessment that is given the designation of one. | Radiologist 1 | |||
RADIOLOGIST 2 | C94531 | A radiologist performing the assessment that is given the designation of two. | Radiologist 2 | |||
READER | C28747 | An individual who takes non-quantifiable data and provides quantifiable assessments for that data. | Reader | |||
READER 1 | C94532 | A reader performing the assessment that is given the designation of one. | Reader 1 | |||
READER 2 | C94533 | A reader performing the assessment that is given the designation of two. | Reader 2 | |||
ADJUDICATOR | C96561 | An individual that presides over and arbitrates between individuals or organizations. | Adjudicator | |||
Back to top | ||||||
CL.C96779.TRTESTCD | Oncology Tumor Properties Test Code (TRTESTCD) | text Extensible: Yes | C96779 | Oncology Tumor Properties Test Code | Terminology relevant to the test codes that describe the measurement of a tumor. | CDISC SDTM Oncology Tumor Properties Test Code Terminology |
AREA | C25244 | Area | The extent of a 2-dimensional surface enclosed within a boundary. (NCI) | Area | ||
DIAMETER | C25285 | Diameter | The length of a straight line passing through the center of a circle or sphere and connecting two points on the circumference. (NCI) | Diameter | ||
VOLUME | C25335 | Volume | The amount of three dimensional space occupied by an object or the capacity of a space or container. (NCI) | Volume | ||
SAXIS | C94982 | Short Axis | The plane through a body or figure that is at the shortest width of that body or figure. | Short Axis | ||
AVMETSUV | C96566 | Average Metabolic Standard Uptake Value | A semiquantitative analysis of the average uptake of analyte by body tissue in relation to the total administered dose of the analyte. | Average Metabolic Standard Uptake Value | ||
PCHGBL | C96621 | Percent Change From Baseline | The value of the current measurement divided by the initial value, taken at some baseline event or timepoint, multiplied by 100. | Percent Change From Baseline | ||
PCHGNAD | C96622 | Percent Change From Nadir | The value of the current measurement divided by the lowest value previously recorded multiplied by 100. | Percent Change From Nadir | ||
RADIODEN | C96627 | Radiodensity | The transparency of a material to the passage of X-rays and other forms of radiation. | Radiodensity | ||
SUMAREA | C96630 | Sum of Area;Sum of Products of Perpendicular Diameters | A calculation of the aggregated area values. | Sum of Areas | ||
SUMDIAM | C96631 | Sum of Diameter | A calculation of the aggregated diameter values. | Sum of Diameters | ||
SUMLDIAM | C96632 | Sum of Longest Diameter | A calculation of the aggregated longest diameter values. | Sum of Longest Diameters | ||
SUMLPERP | C96633 | Sum of Longest Perpendicular | A calculation of the aggregated longest perpendicular values. | Sum of Longest Perpendiculars | ||
SUMVDIAM | C96634 | Sum of Viable Diameter | A calculation of the aggregated diameter values taken from the viable portion of the tumor mass. | Sum of Viable Diameters | ||
SUMVOL | C96635 | Sum of Volume | A calculation of the aggregated volume values. | Sum of Volumes | ||
TUMSTATE | C96643 | Tumor State | A condition or state of a tumor at a particular time. | Tumor Status | ||
VDIAM | C96646 | Viable Diameter | The diameter of the portion of the tumor mass that is capable of growth, proliferation and metastasis. | Viable Tumor Diameter | ||
LDIAM | C96684 | Longest Diameter | The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference. | Longest Diameter | ||
LPERP | C96685 | Longest Perpendicular | The longest possible straight line or plane through a body or figure that is at a right angle to a given line or plane. | Longest Perpendicular | ||
NEWCONF | C103421 | New Tumor Confirmed | The verification/confirmation by other methods or modalities that a tumor, which has not been previously seen or characterized, is present in the subject. | New Tumor Confirmation | ||
SUMNLNLD | C103441 | Sum Diameters of Non Lymph Node Tumors | A calculation of the aggregated diameter values for tumors other than the lymph nodes. | Sum of Diameters of Non Lymph Node Tumors | ||
ACHNAD | C103347 | Absolute Change From Nadir | The value of the current measurement minus the lowest value previously recorded. | Absolute Change From Nadir | ||
Back to top | ||||||
CL.C96778.TRTEST | Oncology Tumor Properties Test Name (TRTEST) | text Extensible: Yes | C96778 | Oncology Tumor Properties Test Name | Terminology relevant to the test names that describe the measurement of a tumor. | CDISC SDTM Oncology Tumor Properties Test Name Terminology |
Area | C25244 | Area | The extent of a 2-dimensional surface enclosed within a boundary. (NCI) | Area | ||
Diameter | C25285 | Diameter | The length of a straight line passing through the center of a circle or sphere and connecting two points on the circumference. (NCI) | Diameter | ||
Volume | C25335 | Volume | The amount of three dimensional space occupied by an object or the capacity of a space or container. (NCI) | Volume | ||
Short Axis | C94982 | Short Axis | The plane through a body or figure that is at the shortest width of that body or figure. | Short Axis | ||
Average Metabolic Standard Uptake Value | C96566 | Average Metabolic Standard Uptake Value | A semiquantitative analysis of the average uptake of analyte by body tissue in relation to the total administered dose of the analyte. | Average Metabolic Standard Uptake Value | ||
Percent Change From Baseline | C96621 | Percent Change From Baseline | The value of the current measurement divided by the initial value, taken at some baseline event or timepoint, multiplied by 100. | Percent Change From Baseline | ||
Percent Change From Nadir | C96622 | Percent Change From Nadir | The value of the current measurement divided by the lowest value previously recorded multiplied by 100. | Percent Change From Nadir | ||
Radiodensity | C96627 | Radiodensity | The transparency of a material to the passage of X-rays and other forms of radiation. | Radiodensity | ||
Sum of Area | C96630 | Sum of Area;Sum of Products of Perpendicular Diameters | A calculation of the aggregated area values. | Sum of Areas | ||
Sum of Diameter | C96631 | Sum of Diameter | A calculation of the aggregated diameter values. | Sum of Diameters | ||
Sum of Longest Diameter | C96632 | Sum of Longest Diameter | A calculation of the aggregated longest diameter values. | Sum of Longest Diameters | ||
Sum of Longest Perpendicular | C96633 | Sum of Longest Perpendicular | A calculation of the aggregated longest perpendicular values. | Sum of Longest Perpendiculars | ||
Sum of Viable Diameter | C96634 | Sum of Viable Diameter | A calculation of the aggregated diameter values taken from the viable portion of the tumor mass. | Sum of Viable Diameters | ||
Sum of Volume | C96635 | Sum of Volume | A calculation of the aggregated volume values. | Sum of Volumes | ||
Tumor State | C96643 | Tumor State | A condition or state of a tumor at a particular time. | Tumor Status | ||
Viable Diameter | C96646 | Viable Diameter | The diameter of the portion of the tumor mass that is capable of growth, proliferation and metastasis. | Viable Tumor Diameter | ||
Longest Diameter | C96684 | Longest Diameter | The longest possible length of a straight line passing through the center of a circular or spheroid object that connects two points on the circumference. | Longest Diameter | ||
Longest Perpendicular | C96685 | Longest Perpendicular | The longest possible straight line or plane through a body or figure that is at a right angle to a given line or plane. | Longest Perpendicular | ||
New Tumor Confirmed | C103421 | New Tumor Confirmed | The verification/confirmation by other methods or modalities that a tumor, which has not been previously seen or characterized, is present in the subject. | New Tumor Confirmation | ||
Sum Diameters of Non Lymph Node Tumors | C103441 | Sum Diameters of Non Lymph Node Tumors | A calculation of the aggregated diameter values for tumors other than the lymph nodes. | Sum of Diameters of Non Lymph Node Tumors | ||
Absolute Change From Nadir | C103347 | Absolute Change From Nadir | The value of the current measurement minus the lowest value previously recorded. | Absolute Change From Nadir | ||
Back to top | ||||||
CL.C99073.LAT | Laterality (LAT) | text Extensible: Yes | C99073 | Laterality | CDISC terminology for anatomical location or specimen further detailing the side(s) of interest. | CDISC SDTM Laterality Terminology |
BILATERAL | C13332 | Affecting both sides of the body, or a pair of organs. | Bilateral | |||
CONTRALATERAL | C25307 | Having to do with the opposite side of the body, in relation to a pre-existing reference point. | Contralateral | |||
IPSILATERAL | C25308 | Having to do with the same side of the body, in relation to a pre-existing reference point. | Ipsilateral | |||
LATERAL | C25230 | Situated at or extending to the side. | Lateral | |||
LEFT | C25229 | Being or located on or directed toward the side of the body to the west when facing north. | Left | |||
RIGHT | C25228 | Being or located on or directed toward the side of the body to the east when facing north. | Right | |||
UNILATERAL | C68598 | Affecting one side of the body or one of a pair of organs. | Unilateral | |||
Back to top | ||||||
CL.C99074.DIR | Directionality (DIR) | text Extensible: Yes | C99074 | Directionality | CDISC terminology for anatomical location or specimen further detailing directionality. | CDISC SDTM Directionality Terminology |
ANTERIOR | C25231 | Denoting the front portion of the body or a structure. | Anterior | |||
APICAL | C25423 | Relating to or located at the apex. | Apical | |||
BASAL | C90067 | Relating to or located at the lowest portion of a structure. | Basal | |||
CAUDAL | C73851 | Toward the tail in a body. | Caudal | |||
CENTRAL | C25445 | A point or area that is approximately central within some larger region or structure. (NCI) | Center | |||
CRANIAL | C37936 | Toward the head in a body. | Cranial | |||
DEEP | C25240 | Extending relatively far inward. (NCI) | Deep | |||
DISTAL | C25237 | Situated farthest from a point of reference. | Distal | |||
DORSAL | C45874 | Pertaining to the back or upper surface of the body. | Dorsal | |||
DORSOLATERAL | C90376 | Toward the back and side of a body. | Dorsolateral | |||
FORE | C90386 | Of or involving the front of a main body. (NCI) | Fore | |||
HIND | C90393 | Of or involving the back of a main body. (NCI) | Hind | |||
INFERIOR | C25353 | Pertaining to a point below a given reference point. | Inferior | |||
INNER | C37980 | Inside or closer to the inside of the body or object. (NCI) | Inner | |||
INTERMEDIATE | C73705 | Located between two points or extremes. | Intermediate | |||
LOWER | C25309 | The bottom one of two. (NCI) | Lower | |||
MEDIAL | C25232 | Toward the middle or in a limb toward the median plane. | Medial | |||
OUTER | C38166 | Being on or toward the outside of the body or object. (NCI) | Outer | |||
PERIPHERAL | C25233 | On or near an edge or constituting an outer boundary; the outer area. (NCI) | Peripheral | |||
POSTERIOR | C25622 | Denoting the back portion of the body or a structure. | Posterior | |||
PROXIMAL | C25236 | Situated nearest to a point of reference. | Proximal | |||
ROSTRAL | C94393 | Toward the muzzle in the head. | Rostral | |||
SUPERFICIAL | C25239 | Of or pertaining to the exterior surface. (NCI) | Superficial | |||
SUPERIOR | C25235 | Pertaining to a point above a given reference point. | Superior | |||
SURFACE | C25245 | The extended two-dimensional outer layer or area of a three-dimensional object. (NCI) | Surface | |||
TIP | C90069 | The pointed end of a structure. | Tip | |||
UPPER | C25355 | The top one of two. | Upper | |||
VENTRAL | C45875 | Pertaining to the front or lower surface of the body. | Ventral | |||
VENTROLATERAL | C98798 | Of or pertaining to the front and side of a main body. (NCI) | Ventrolateral | |||
MIDLINE | C81170 | A medial line, especially the medial line or medial plane of the body (or some part of the body). | Midline | |||
Back to top | ||||||
CL.C99075.PORTOT | Portion/Totality (PORTOT) | text Extensible: Yes | C99075 | Portion/Totality | Qualifier for anatomical location or specimen further detailing the portion or totality, which means arrangement of, or apportioning of an entity. | CDISC SDTM Portion/Totality Terminology |
ALL | C64916 | Being or representing the total number of individual entities. | All | |||
ENTIRE | C25326 | Whole | Being or representing the complete extent of a single entity. | Whole | ||
MULTIPLE | C78728 | Many;Several | More than one. (NCI) | Many | ||
PARTIAL | C25378 | Being or representing an incomplete extent of a single entity. | Partial | |||
SEGMENT | C45312 | One of the parts into which something is divided. | Segment | |||
SINGLE | C48440 | One. | Single | |||
Back to top | ||||||
CL.C88025.NEOPLASM | Neoplasm Type (NEOPLASM) | text Extensible: Yes | C88025 | Neoplasm Type | The terminology that includes concepts relevant to benign or malignant tissue growth. | CDISC SEND Tumor Findings Results Terminology |
ADAMANTINOMA, MALIGNANT | C7644 | ADAMANTINOMA | A low-grade malignant neoplasm composed of epithelial cells and a spindle cell osteo-fibrous proliferation. | Adamantinoma | ||
ADENOACANTHOMA, MALIGNANT | C4200 | ADENOACANTHOMA | A malignant neoplasm arising from glandular cells that includes focal or extensive areas of squamous metaplasia. | Adenocarcinoma with Squamous Metaplasia | ||
ADENOCARCINOMA, CLEAR CELL, MALIGNANT | C3766 | CLEAR CELL CARCINOMA;MESONEPHROID CLEAR CELL ADENOCARCINOMA;MESONEPHROID CLEAR CELL CARCINOMA | A malignant neoplasm comprising glandular epithelial clear cells. | Clear Cell Adenocarcinoma | ||
ADENOCARCINOMA, ENDOMETRIAL, MALIGNANT | C7359 | ADENOCARCINOMA OF ENDOMETRIUM;ADENOCARCINOMA OF THE ENDOMETRIUM | A malignant glandular neoplasm of the uterine lining. | Endometrial Adenocarcinoma | ||
ADENOCARCINOMA, MALIGNANT | C2852 | A malignant neoplasm arising from glandular cells. | Adenocarcinoma | |||
ADENOCARCINOMA, MUCINOUS, MALIGNANT | C26712 | GELATINOUS ADENOCARCINOMA;MUCOID ADENOCARCINOMA;MUCINOUS CARCINOMA;MUCOUS ADENOCARCINOMA;COLLOID ADENOCARCINOMA;COLLOID CARCINOMA;MUCOID CARCINOMA;MUCOUS CARCINOMA;GELATINOUS CARCINOMA | An adenocarcinoma comprising neoplastic glandular cells containing intracytoplasmic mucin. | Mucinous Adenocarcinoma | ||
ADENOCARCINOMA, PAPILLARY, MALIGNANT | C2853 | An adenocarcinoma with papillary growth pattern. | Papillary Adenocarcinoma | |||
ADENOCARCINOMA, SEBACEOUS, MALIGNANT | C40310 | CARCINOMA OF SEBACEOUS GLAND;CARCINOMA OF THE SEBACEOUS GLAND;SEBACEOUS GLAND CARCINOMA | An adenocarcinoma with sebaceous differentiation. | Sebaceous Carcinoma | ||
ADENOFIBROMA, BENIGN | C8984 | BENIGN MIXED MUELLERIAN TUMOR | Benign mixed neoplasm comprised of epithelial/glandular and mesenchymal structures. | Adenofibroma | ||
ADENOLIPOMA, BENIGN | C4159 | Benign mixed neoplasm comprised of epithelial/glandular and lipomatous structures. | Lipoadenoma | |||
ADENOMA, ACINAR CELL, BENIGN | C4196 | ACINIC CELL ADENOMA;ACINAR ADENOMA | A benign glandular epithelial neoplasm comprising secretory cells forming acinar patterns. | Acinar Cell Adenoma | ||
ADENOMA, ADNEXAL, BENIGN | C7580 | ADENOMA OF ADNEXA;ADENOMA OF SKIN APPENDAGE;ADNEXAL ADENOMA | A benign glandular epithelial neoplasm comprising secretory cells forming acinar patterns. | Skin Appendage Adenoma | ||
ADENOMA, ADRENOCORTICAL , BENIGN | C9003 | CORTICAL CELL ADENOMA;ADRENAL CORTICAL ADENOMA;ADRENOCORTICAL ADENOMA;BENIGN ADRENAL ADENOMA;BENIGN ADENOMA OF THE ADRENAL GLAND;ADENOMA OF THE ADRENAL GLAND;ADRENAL ADENOMA;ADENOMA OF ADRENAL GLAND;ADENOMA OF THE ADRENAL CORTEX;BENIGN ADRENAL GLAND ADENOMA;BENIGN ADENOMA OF ADRENAL GLAND;ADENOMA OF ADRENAL CORTEX;ADRENAL GLAND ADENOMA | A benign neoplasm arising from any of the adrenal cortical layers. | Adrenal Cortex Adenoma | ||
ADENOMA, ANTERIOR LOBE PITUITARY GLAND, BENIGN | C3329 | ADENOMA OF PITUITARY GLAND;ADENOMA OF PITUITARY;ADENOMA OF THE PITUITARY GLAND;ADENOMA OF THE PITUITARY;PITUITARY ADENOMA | A benign neoplasm of the anterior lobe of the pituitary gland. | Pituitary Gland Adenoma | ||
ADENOMA, BASAL CELL, BENIGN | C5950 | BASAL CELL ADENOMA OF SALIVARY GLAND;BASAL CELL ADENOMA OF THE SALIVARY GLAND;BASAL CELL ADENOMA;BENIGN BASAL CELL TUMOR | A benign epithelial neoplasm characterized by the presence of/arising from basal cells. | Salivary Gland Basal Cell Adenoma | ||
ADENOMA, BENIGN | C2855 | A benign neoplasm arising from epithelium. | Adenoma | |||
ADENOMA, BRONCHIAL, BENIGN | C3494 | A benign neoplasia of the lung, arising from bronchial epithelium. | Lung Papillary Adenoma | |||
ADENOMA, BRONCHIOLOALVEOLAR, BENIGN | C4140 | ADENOMA OF THE ALVEOLI;ADENOMA OF ALVEOLI | A benign lung neoplasm arising from the alveolar/bronchiolar epithelium. | Alveolar Adenoma | ||
ADENOMA, C-CELL, BENIGN | C46101 | PARAFOLLICULAR CELL ADENOMA | A benign neoplasm arising from C-cells of the thyroid gland. | Neoplastic C-Cell Hyperplasia | ||
ADENOMA, CERUMINOUS GLAND, BENIGN | C6088 | CERUMINOUS ADENOMA;CERUMINOUS ADENOMA OF EXTERNAL AUDITORY CANAL;CERUMINOUS ADENOMA OF THE EXTERNAL AUDITORY CANAL;CERUMINOMA | A benign epithelial neoplasm derived from ceruminous glands in the external auditory canal. | External Auditory Canal Ceruminous Adenoma | ||
ADENOMA, CLEAR CELL, BENIGN | C4151 | A benign neoplasm comprising glands containing epithelial clear cells. | Clear Cell Adenoma | |||
ADENOMA, FOLLICULAR CELL, BENIGN | C3502 | ADENOMA OF THE THYROID GLAND;THYROID ADENOMA;FOLLICULAR ADENOMA OF THE THYROID;THYROID FOLLICULAR ADENOMA;ADENOMA OF THYROID;ADENOMA OF THYROID GLAND;FOLLICULAR ADENOMA OF THE THYROID GLAND;FOLLICULAR ADENOMA OF THYROID GLAND;ADENOMA OF THE THYROID;FOLLICULAR ADENOMA OF THYROID;THYROID GLAND ADENOMA;FOLLICULAR ADENOMA | A benign neoplasm arising from follicular cells of the thyroid gland. | Thyroid Gland Follicular Adenoma | ||
ADENOMA, HEPATOCELLULAR, BENIGN | C3758 | ADENOMA OF THE LIVER CELLS;LIVER CELL ADENOMA;HCA;ADENOMA OF LIVER CELLS | A benign epithelial neoplasm arising from hepatocytes. | Hepatocellular Adenoma | ||
ADENOMA, HEPATOCHOLANGIOCELLULAR, BENIGN | C7126 | A benign neoplasm arising from the intrahepatic bile duct. | Intrahepatic Bile Duct Adenoma | |||
ADENOMA, ISLET CELL, BENIGN | C65184 | ISLET CELL ADENOMA | A benign neoplasm arising from the islet cells of the pancreas. | Islet Cell Adenoma | ||
ADENOMA, LIGHT CELL, BENIGN | C46119 | A benign epithelial neoplasm of the thyroid gland comprising follicular cells with cytoplasmic clearing. | Thyroid Gland Clear Cell Follicular Adenoma | |||
ADENOMA, MUCINOUS, BENIGN | C2973 | PSEUDOMUCINOUS CYSTADENOMA;MUCINOUS CYSTOMA;MUCINOUS ADENOMA | A benign, cystic epithelial neoplasm comprising cells containing intracytoplasmic mucin. | Mucinous Cystadenoma | ||
ADENOMA, PAPILLARY, BENIGN | C79951 | A benign epithelial neoplasm characterized by the presence of papillary epithelial patterns. | Papillary Adenoma | |||
ADENOMA, PARS DISTALIS, BENIGN | C60490 | Rat Pars Distalis Adenoma | A benign epithelial neoplasm arising from the pars distalis of the anterior pituitary gland. | Rat Pars Distalis Adenoma | ||
ADENOMA, PARS INTERMEDIA, BENIGN | C60493 | Rat Pars Intermedia Adenoma | A benign epithelial neoplasm arising from the pars intermedia of the anterior pituitary gland. | Rat Pars Intermedia Adenoma | ||
ADENOMA, PITUITARY GLAND, BENIGN | C98723 | A benign neoplasm of the pituitary gland. | Experimental Organism Pituitary Gland Adenoma | |||
ADENOMA, RENAL CELL, BENIGN | C8383 | RENAL TUBULE ADENOMA | A benign neoplasm arising from the renal cortex. | Renal Adenoma | ||
ADENOMA, RETE TESTIS, BENIGN | C39956 | A benign epithelial neoplasm arising from the rete testis. | Rete Testis Adenoma | |||
ADENOMA, SEBACEOUS, BENIGN | C4174 | SEBACEOUS GLAND ADENOMA;ADENOMA OF THE SEBACEOUS GLAND;ADENOMA OF SEBACEOUS GLAND;SKIN APPENDAGE SEBACEOUS ADENOMA | A benign neoplasm arising from sebaceous glands. | Sebaceous Adenoma | ||
ADENOMA, SERTOLIFORM TUBULAR, BENIGN | C92180 | Rat Sertoliform Tubular Adenoma | A benign tubular adenoma with Sertoli cell differentiation. | Rat Sertoliform Tubular Adenoma | ||
ADENOMA, SWEAT GLAND, BENIGN | C7560 | ADENOMA OF THE SWEAT GLAND;ADENOMA OF SWEAT GLAND | A benign epithelias neoplasm arising from sweat glands. | Sweat Gland Adenoma | ||
ADENOMA, TUBULAR CELL, BENIGN | C4133 | A benign neoplasm arising from glandular epithelium, characterized by a tubular architectural pattern. | Tubular Adenoma | |||
ADENOMA, TUBULOSTROMAL, BENIGN | C79953 | A benign ovarian epithelial neoplasm characterized by the presence of tubular structures and interstitial stroma. | Tubulostromal Adenoma | |||
ADENOMA, YOLK SAC, BENIGN | C84357 | A benign epithelial neoplasm arising from the yolk sac. | Yolk Sac Adenoma | |||
ADENOMA, ZYMBAL'S GLAND | C98800 | A benign neoplasm of the rodent Zymbal's gland with sebaceous and/or squamous differentiation. | Zymbal's Gland Adenoma | |||
ADENOMYOMA, BENIGN | C3726 | A benign neoplasm characterized by the presence of a glandular and a mesenchymal component. | Adenomyoma | |||
ADRENAL TUMOR, SUBCAPSULAR, BENIGN | C83488 | SUBCAPSULAR SINGLE CELL ADENOMA, ADRENAL | A benign neoplasm located beneath the adrenal capsule. | Benign Subcapsular Adrenal Tumor | ||
ADRENAL TUMOR, SUBCAPSULAR, MALIGNANT | C83489 | SUBCAPSULAR SINGLE CELL CARCINOMA, ADRENAL | A malignant neoplasm located beneath the adrenal capsule. | Malignant Subcapsular Adrenal Tumor | ||
ADRENAL TUMOR, SUBCAPSULAR, UNDETERMINED | C82973 | SUBCAPSULAR CELL TUMOR, ADRENAL | A neoplasm located beneath the adrenal capsule in which the malignancy status has not been established. | Subcapsular Adrenal Tumor | ||
ADRENOCORTICAL NEOPLASM, UNDETERMINED | C2858 | ADRENAL CORTEX TUMOR;ADRENOCORTICAL NEOPLASM;ADRENOCORTICAL TUMOR | A neoplasm of the adrenal cortex in which the malignancy status has not been established. | Adrenal Cortex Neoplasm | ||
AMELOBLASTOMA, BENIGN | C7111 | A benign odontogenic neoplasm arising from the epithelial component of the embryonic tooth. | Benign Ameloblastoma | |||
AMELOBLASTOMA, MALIGNANT | C54297 | MALIGNANT AMELOBLASTOMA | A malignant odontogenic neoplasm arising from the epithelial component of the embryonic tooth. | Metastasizing Ameloblastoma | ||
AMELOBLASTOMA, UNDETERMINED | C4313 | A odontogenic neoplasm arising from the epithelial component of the embryonic tooth of undetermined malignancy status. | Ameloblastoma | |||
ANGIOFIBROMA, BENIGN | C3799 | FIBROANGIOMA, BENIGN;FIBROUS PAPULE;TELANGIECTATIC FIBROMA;ANGIOFIBROMATOUS HYPERPLASIA | A benign, morphologic variant of fibroma characterized by the presence of numerous dilated vascular channels. | Angiofibroma | ||
ANGIOLIPOMA, BENIGN | C3733 | ANGIOLIPOMA | A lipoma characterized by prominent vascularization. | Angiolipoma | ||
ASTROCYTOMA, ANAPLASTIC , MALIGNANT | C9477 | GRADE III ASTROCYTIC TUMOR;GRADE III ASTROCYTOMA;GRADE III ASTROCYTIC NEOPLASM;MALIGNANT ASTROCYTOMA | A malignant neoplasm of the brain or spinal cord originating from astrocytes, exhibiting poor differentiation (anaplasia). | Anaplastic Astrocytoma | ||
ASTROCYTOMA, PILOCYTIC, BENIGN | C4047 | GRADE I ASTROCYTIC NEOPLASM;GRADE I ASTROCYTOMA;GRADE I ASTROCYTIC TUMOR | A benign neoplasm of the brain or spinal cord arising from astrocytes associated with single or multiple cysts. | Pilocytic Astrocytoma | ||
ASTROCYTOMA, UNDETERMINED | C60781 | A neoplasm of the brain or spinal cord exhibiting astrocytic differentiation, but in which the malignancy status has not been established. | Astrocytoma | |||
BASOSQUAMOUS TUMOR, BENIGN | C4614 | CUTANEOUS PAPILLOMA;PAPILLOMA OF SKIN;PAPILLOMA OF THE SKIN | A benign papillary neoplasm of the skin. | Skin Papilloma | ||
BASOSQUAMOUS TUMOR, MALIGNANT | C2922 | BASOSQUAMOUS CARCINOMA;SKIN MIXED BASAL AND SQUAMOUS CELL CARCINOMA;BASOSQUAMOUS CELL CARCINOMA | A basal cell carcinoma (skin neoplasm) which displays squamous differentiation. | Skin Basosquamous Cell Carcinoma | ||
CARCINOID TUMOR, ATYPICAL, MALIGNANT | C72074 | MALIGNANT CARCINOID TUMOR | A malignant neuroendocrine neoplasm arising from enterochromaffin cells in the gastrointestinal tract and (less common) in the bronchi exhibiting atypia. | Atypical Carcinoid Tumor | ||
CARCINOID TUMOR, UNDETERMINED | C2915 | CARCINOID;WELL-DIFFERENTIATED ENDOCRINE NEOPLASM;CARCINOID NEOPLASM | A neuroendocrine neoplasm arising from enterochromaffin cells in the gastrointestinal tract and (less common) the bronchi with undetermined malignancy status. | Carcinoid Tumor | ||
CARCINOMA, ACIDOPHIL, MALIGNANT | C4147 | EOSINOPHIL CARCINOMA;ACIDOPHIL ADENOCARCINOMA;ACIDOPHIL CARCINOMA;EOSINOPHIL ADENOMCARCINOMA;EOSINOPHIL ADENOMCARCINOMA ADENOCARCINOMA | A malignant epithelial neoplasm of the anterior pituitary gland in which the neoplastic cells stain positive with acidic dyes. | Pituitary Gland Acidophil Carcinoma | ||
CARCINOMA, ACINAR CELL, MALIGNANT | C3768 | ACINAR ADENOCARCINOMA;ACINIC CELL ADENOCARCINOMA;ACINAR CARCINOMA;ACINAR CELL ADENOCARCINOMA;ACINIC CELL CARCINOMA | A malignant glandular epithelial neoplasm comprising secretory cells forming acinar patterns. | Acinar Cell Carcinoma | ||
CARCINOMA, ADENOSQUAMOUS, MALIGNANT | C3727 | MIXED ADENOCARCINOMA AND SQUAMOUS CARCINOMA;MIXED ADENOCARCINOMA AND EPIDERMOID CELL CARCINOMA;MIXED ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA;MIXED ADENOCARCINOMA AND EPIDERMOID CARCINOMA | An epithelial neoplasm composed of malignant glandular and malignant squamous cells. | Adenosquamous Carcinoma | ||
CARCINOMA, ADNEXAL, MALIGNANT | C3775 | SKIN APPENDAGE CARCINOMA;CARCINOMA OF ADNEXA;CARCINOMA OF SKIN APPENDAGE | A malignant epithelial neoplasm arising from sebaceous or sweat glands or from hair follicles. | Adnexal Carcinoma | ||
CARCINOMA, ADRENOCORTICAL, MALIGNANT | C9325 | CORTICAL CELL CARCINOMA;ADENOCARCINOMA, ADRENOCORTICAL, MALIGNANT;ADRENAL CORTEX ADENOCARCINOMA;ADRENAL CORTEX CANCER;ADRENAL CORTICAL ADENOCARCINOMA;ADRENAL CORTICAL CARCINOMA;ADRENOCORTICAL CARCINOMA | A malignant epithelial neoplasm arising from adrenal cortical cells. | Adrenal Cortex Carcinoma | ||
CARCINOMA, BASAL CELL, MALIGNANT | C2921 | BASAL CELL EPITHELIOMA;BASAL CELL CANCER;BASAL CELL CARCINOMA OF SKIN;BASAL CELL CARCINOMA OF THE SKIN;BASAL CELL CARCINOMA;BASAL CELL EPITHELIOMA;BASAL CELL SKIN CARCINOMA;BCC | A malignant epithelial neoplasm arising from basal cells of the epidermis and pilosebaceous unit of skin [the dermis]. | Skin Basal Cell Carcinoma | ||
CARCINOMA, BRONCHIAL, MALIGNANT | C35875 | A malignant neoplasia of the lung, arising from bronchial epithelium. | Bronchogenic Carcinoma | |||
CARCINOMA, BRONCHIOLOALVEOLAR, MALIGNANT | C2923 | BRONCHIOALVEOLAR ADENOCARCINOMA OF LUNG;BRONCHIOLO-ALVEOLAR LUNG CARCINOMA;BRONCHIOLOALVEOLAR ADENOCARCINOMA OF LUNG;BRONCHIOLOALVEOLAR LUNG ADENOCARCINOMA;BAC;BRONCHIOLO-ALVEOLAR CARCINOMA OF LUNG;BRONCHIOLO-ALVEOLAR CARCINOMA OF THE LUNG;BRONCHIOALVEOLAR LUNG CARCINOMA;BRONCHIOLOALVEOLAR ADENOCARCINOMA OF THE LUNG;BRONCHIOALVEOLAR ADENOCARCINOMA OF THE LUNG | A malignant lung neoplasm originating from the alveolar/bronchiolar epithelium. | Bronchioloalveolar Carcinoma | ||
CARCINOMA, C-CELL, MALIGNANT | C3879 | PARAFOLLICULAR CELL CARCINOMA;C CELL CARCINOMA;MEDULLARY CARCINOMA OF THYROID GLAND;THYROID GLAND NEUROENDOCRINE CARCINOMA;MEDULLARY CARCINOMA OF THE THYROID GLAND;MEDULLARY THYROID CANCER;PARAFOLLICULAR CELL CARCINOMA;MEDULLARY THYROID CARCINOMA;MEDULLARY CARCINOMA OF THYROID;MEDULLARY CARCINOMA;MTC;MEDULLARY CARCINOMA OF THE THYROID;MEDULLARY THYROID GLAND CARCINOMA;THYROID MEDULLARY CARCINOMA | A neuroendocrine malignant epithelial neoplasm arising from C-cells of the thyroid gland. | Thyroid Gland Medullary Carcinoma | ||
CARCINOMA, CERUMINOUS GLAND, MALIGNANT | C4176 | A malignant neoplasm derived from ceruminous glands in the external auditory canal. | Ceruminous Adenocarcinoma | |||
CARCINOMA, CHOROID PLEXUS, MALIGNANT | C4715 | CHOROID PLEXUS CANCER;CARCINOMA OF THE CHOROID PLEXUS;CARCINOMA OF CHOROID PLEXUS;CANCER OF THE CHOROID PLEXUS;CANCER OF CHOROID PLEXUS;ANAPLASTIC CHOROID PLEXUS PAPILLOMA | A malignant neoplasm arising from the choroid plexus of the brain. | Choroid Plexus Carcinoma | ||
CARCINOMA, EMBRYONAL, MALIGNANT | C3752 | CARCINOMA, EMBRYONAL, MALIGNANT | A non-seminomatous malignant germ cell neoplasm of the testis or ovary. | Embryonal Carcinoma | ||
CARCINOMA, ENDOMETRIAL, MALIGNANT | C7558 | CARCINOMA OF ENDOMETRIUM;CARCINOMA OF THE ENDOMETRIUM | A malignant epithelial neoplasm arising from the lining of the uterine body cavity. | Endometrial Carcinoma | ||
CARCINOMA, FOLLICULAR CELL, MALIGNANT | C8054 | FOLLICULAR THYROID CANCER;WELL-DIFFERENTIATED FOLLICULAR CARCINOMA;FOLLICULAR ADENOCARCINOMA;FOLLICULAR CANCER OF THE THYROID;FOLLICULAR CARCINOMA OF THE THYROID GLAND;WELL-DIFFERENTIATED FOLLICULAR ADENOCARCINOMA;FOLLICULAR CARCINOMA;FOLLICULAR CARCINOMA OF THYROID GLAND;FOLLICULAR CANCER OF THYROID;FOLLICULAR THYROID CARCINOMA;THYROID FOLLICULAR CARCINOMA;FOLLICULAR CARCINOMA OF THE THYROID;FOLLICULAR CANCER OF THYROID GLAND;FOLLICULAR CANCER OF THE THYROID GLAND;FOLLICULAR CARCINOMA OF THYROID;FOLLICULAR THYROID GLAND CARCINOMA | A malignant neoplasia arising from follicular cells of the thyroid gland. | Thyroid Gland Follicular Carcinoma | ||
CARCINOMA, HEPATOCELLULAR, MALIGNANT | C3099 | CARCINOMA OF LIVER CELLS;PRIMARY CARCINOMA OF THE LIVER CELLS;LIVER CELL CARCINOMA;HEPATOMA;CARCINOMA OF THE LIVER CELLS;PRIMARY CARCINOMA OF LIVER CELLS;HCC | A malignant neoplasm arising from hepatocytes. | Hepatocellular Carcinoma | ||
CARCINOMA, HEPATOCHOLANGIOCELLULAR, MALIGNANT | C103393 | HEPATOCHOLANGIOCELLULAR CARCINOMA | A malignant mixed neoplasm of the liver comprising neoplastic hepatocytes and bile duct epithelial cells; both elements displaying evidence of malignancy. | Experimental Organism Malignant Hepatocholangiocellular Carcinoma | ||
CARCINOMA, IN SITU, MALIGNANT | C2917 | EPITHELIAL TUMOR, IN SITU, MALIGNANT;INTRAEPITHELIAL CARCINOMA;NON-INVASIVE CARCINOMA;CIS | A malignant epithelial neoplasm confined to the epithelial layer and without evidence of further tissue invasion. | Carcinoma In Situ | ||
CARCINOMA, ISLET CELL, MALIGNANT | C3770 | PANCREATIC NEUROENDOCRINE CARCINOMA;MALIGNANT PANCREATIC ENDOCRINE TUMOR;MALIGNANT ISLET CELL TUMOR;ISLET CELL CANCER;ISLET CELL CARCINOMA | A malignant endocrine neoplasm arising from islets of Langerhans of the pancreas. | Pancreatic Neuroendocrine Carcinoma | ||
CARCINOMA, MALIGNANT | C2916 | EPITHELIOMA MALIGNANT;EPITHELIAL CARCINOMA;MALIGNANT EPITHELIAL NEOPLASM;MALIGNANT EPITHELIAL TUMOR;MALIGNANT EPITHELIOMA | A malignant epithelial neoplasm. | Carcinoma | ||
CARCINOMA, MIXED, ACINAR-ISLET CELL, MALIGNANT | C6878 | A malignant pancreatic neoplasm characterized by the presence of a mixture of acinar and islet cell elements. | Mixed Acinar-Neuroendocrine Carcinoma of the Pancreas | |||
CARCINOMA, NEUROENDOCRINE CELL, MALIGNANT | C3773 | NEUROENDOCRINE TUMOR, MALIGNANT;NEUROENDOCRINE CELL CARCINOMA;NEUROENDOCRINE CARCINOMA | A malignant neuroendocrine neoplasm comprising cells containing secretory granules. | Neuroendocrine Carcinoma | ||
CARCINOMA, PARS DISTALIS, MALIGNANT | C60491 | Rat Pars Distalis Carcinoma | A malignant epithelial neoplasm arising from the pars distalis of the pituitary gland. | Rat Pars Distalis Carcinoma | ||
CARCINOMA, PARS INTERMEDIA, MALIGNANT | C92183 | Rat Pars Intermedia Carcinoma | A malignant epithelial neoplasm arising from the pars intermedia of the pituitary gland. | Rat Pars Intermedia Carcinoma | ||
CARCINOMA, RENAL CELL, MALIGNANT | C9385 | ADENOCARCINOMA OF THE KIDNEY;RENAL CELL CANCER;KIDNEY ADENOCARCINOMA;RCC;RENAL CELL CARCINOMA, STAGE UNSPECIFIED;RENAL CELL ADENOCARCINOMA;ADENOCARCINOMA OF KIDNEY | A malignant neoplasm arising from renal parenchyma. | Renal Cell Carcinoma | ||
CARCINOMA, RENAL, TUBULAR, MALIGNANT | C39807 | MUCINOUS TUBULAR AND SPINDLE CELL CARCINOMA OF THE KIDNEY | A malignant neoplasm of the kidney, characterized by the presence of tubules. | Mucinous Tubular and Spindle Cell Carcinoma of the Kidney | ||
CARCINOMA, SPINDLE CELL, MALIGNANT | C27004 | PSEUDOSARCOMATOUS CARCINOMA;SPINDLE CELL CARCINOMA | A malignant epithelial neoplasm characterized by the presence of spindle cells. | Sarcomatoid Carcinoma | ||
CARCINOMA, SQUAMOUS CELL, IN SITU, MALIGNANT | C27093 | EPIDERMOID CELL CARCINOMA IN SITU;EPIDERMOID CARCINOMA IN SITU;GRADE III SQUAMOUS INTRAEPITHELIAL NEOPLASIA;INTRAEPITHELIAL SQUAMOUS CELL CARCINOMA;SQUAMOUS CELL CARCINOMA IN SITU;GRADE 3 SQUAMOUS INTRAEPITHELIAL NEOPLASIA;SQUAMOUS CARCINOMA IN SITU | A malignant epithelial neoplasm confined to the squamous epithelium, without invasion of underlying tissues. | Stage 0 Squamous Cell Carcinoma | ||
CARCINOMA, SQUAMOUS CELL, MALIGNANT | C2929 | MALIGNANT EPIDERMOID CELL NEOPLASM;SQUAMOUS CARCINOMA;EPIDERMOID CARCINOMA;MALIGNANT SQUAMOUS CELL TUMOR;SQUAMOUS CELL EPITHELIOMA;EPIDERMOID CELL CANCER;MALIGNANT SQUAMOUS CELL NEOPLASM;MALIGNANT EPIDERMOID CELL TUMOR;SQUAMOUS CELL CANCER | A malignant neoplasm arising from squamous epithelial cells. | Squamous Cell Carcinoma | ||
CARCINOMA, SWEAT GLAND, MALIGNANT | C6938 | CARCINOMA OF SWEAT GLAND;CARCINOMA OF THE SWEAT GLAND | A malignant neoplasm arising from sweat glands. | Sweat Gland Carcinoma | ||
CARCINOMA, TRANSITIONAL CELL, MALIGNANT | C2930 | TRANSITIONAL CARCINOMA | A malignant neoplasm arising from transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. | Transitional Cell Carcinoma | ||
CARCINOMA, TUBULAR CELL, MALIGNANT | C65192 | A malignant glandular neoplasm exhibiting tubular structures. | Tubular Adenocarcinoma | |||
CARCINOMA, TUBULOSTROMAL, MALIGNANT | C80356 | A malignant epithelial neoplasm of the ovary with tubular and stromal neoplastic components. | Tubulostromal Adenocarcinoma | |||
CARCINOMA, UNDIFFERENTIATED, MALIGNANT | C3692 | ANAPLASTIC CARCINOMA;CARCINOMA, UNDIFFERENTIATED | A malignant epithelial neoplasm exhibiting poor differentiation (anaplasia). | Undifferentiated Carcinoma | ||
CARCINOMA, ZYMBAL'S GLAND | C98801 | A malignant neoplasm of the rodent Zymbal's gland with sebaceous and/or squamous differentiation. | Zymbal's Gland Carcinoma | |||
CARCINOSARCOMA, MALIGNANT | C34448 | A malignant neoplasm comprising a mixture of carcinomatous and sarcomatous elements. | Carcinosarcoma | |||
CHEMODECTOMA, BENIGN | C79950 | BENIGN CHEMODECTOMA | A benign neoplasm of the chemoreceptor system (e.g. carotid body, glomus jugulare, glomus vagale). | Benign Carotid Body Paraganglioma | ||
CHEMODECTOMA, MALIGNANT | C3574 | MALIGNANT TUMOR OF THE CAROTID BODY;MALIGNANT CAROTID BODY TUMOR;MALIGNANT NEOPLASM OF THE CAROTID BODY;MALIGNANT NEOPLASM OF CAROTID BODY;MALIGNANT CAROTID BODY NEOPLASM;MALIGNANT TUMOR OF CAROTID BODY | A malignant neoplasm of the chemoreceptor system (e.g. carotid body, glomus jugulare, glomus vagale). | Malignant Carotid Body Paraganglioma | ||
CHEMODECTOMA, UNDETERMINED | C2932 | PARAGANGLIOMA OF CAROTID BODY;CHEMODECTOMA;PARAGANGLIOMA OF THE CAROTID BODY;TUMOR OF THE CAROTID BODY;CAROTID BODY TUMOR;CAROTID BODY CHEMODECTOMA;TUMOR OF CAROTID BODY | A neoplasm of the chemoreceptor system (e.g. carotid body, glomus jugulare, glomus vagale) for which the malignancy status has not be established. | Carotid Body Paraganglioma | ||
CHOLANGIOCARCINOMA, INTRAHEPATIC, MALIGNANT | C35417 | INTRAHEPATIC CARCINOMA OF BILE DUCT;INTRAHEPATIC CARCINOMA OF THE BILE DUCT;INTRAHEPATIC BILE DUCT CARCINOMA | A malignant neoplasm of the liver arising from/comprising cells resembling those of bile ducts. | Intrahepatic Cholangiocarcinoma | ||
CHOLANGIOCARCINOMA, MALIGNANT | C4436 | CHOLANGIOCELLULAR CARCINOMA | A malignant neoplasm arising from/comprising cells resembling those of bile ducts. | Cholangiocarcinoma | ||
CHOLANGIOMA, BENIGN | C2942 | HEPATOCHOLANGIOMA;CHOLANGIOMA;ADENOMA OF BILE DUCT;ADENOMA OF THE BILE DUCT;CHOLANGIOADENOMA;HEPATOCHOLANGIOCELLULAR ADENOMA | A benign neoplasm arising from/comprising cells resembling those of bile ducts. | Bile Duct Adenoma | ||
CHONDROMA, BENIGN | C53459 | A benign, well circumscribed neoplasm arising from the hyaline cartilage in soft tissue or bone. It is characterized by the presence of chondrocytes. | Chondroma | |||
CHONDROSARCOMA, MALIGNANT | C2946 | A malignant mesenchymal neoplasm arising from cartilage-forming tissues. | Chondrosarcoma | |||
CHORDOMA, MALIGNANT | C2947 | A malignant bone neoplasm arising from the remnants of the fetal notochord. | Chordoma | |||
CHORIOCARCINOMA, MALIGNANT | C2948 | CHORIOEPITHELIOMA | A malignant neoplasm arising from placental trophoblast cells. They generally arise in the uterus. | Choriocarcinoma | ||
CRANIOPHARYNGIOMA, BENIGN | C2964 | NEOPLASM OF RATHKE'S POUCH;TUMOR OF RATHKE'S POUCH;RATHKE POUCH TUMOR;RATHKE POUCH NEOPLASM;RATHKE'S POUCH TUMOR;RATHKE'S POUCH NEOPLASM;CYSTOMA | A benign epithelial neoplasm of the sellar region, presumably derived from Rathke pouch epithelium. | Craniopharyngioma | ||
CRANIOPHARYNGIOMA, MALIGNANT | C79949 | CARCINOMA ARISING FROM CRANIOPHARYNGIOMA | A malignant epithelial neoplasm of the sellar region, presumably derived from Rathke pouch epithelium. | Carcinoma Arising from Craniopharyngioma | ||
CYSTADENOCARCINOMA, MALIGNANT | C2971 | A malignant cystic epithelial neoplasm arising from glandular epithelium. | Cystadenocarcinoma | |||
CYSTADENOCARCINOMA, PAPILLARY, MALIGNANT | C3777 | A malignant cystic epithelial neoplasm arising from glandular epithelium exhibiting papillary structures. | Papillary Cystadenocarcinoma | |||
CYSTADENOMA, BENIGN | C2972 | CYSTOMA | A benign cystic epithelial neoplasm arising from glandular epithelium. | Cystadenoma | ||
CYSTADENOMA, PAPILLARY, BENIGN | C2974 | A benign cystic epithelial neoplasm arising from glandular epithelium exhibiting papillary structures. | Papillary Cystadenoma | |||
DECIDUOMA, MALIGNANT | C3555 | MALIGNANT PLACENTAL TUMOR;MALIGNANT PLACENTAL NEOPLASM;MALIGNANT NEOPLASM OF PLACENTA;MALIGNANT TUMOR OF THE PLACENTA;MALIGNANT NEOPLASM OF THE PLACENTA;MALIGNANT TUMOR OF PLACENTA;MALIGNANT PLACENTAL TUMOR | A malignant neoplasm arising from decidua (placental) cells. | Malignant Placental Neoplasm | ||
DECIDUOMA, UNDETERMINED | C4858 | PLACENTA NEOPLASMS;PLACENTA TUMORS;PLACENTA TUMOR;TUMOR OF PLACENTA;TUMOR OF THE PLACENTA;PLACENTAL TUMORS;PLACENTAL TUMOR;NEOPLASM OF THE PLACENTA;PLACENTA NEOPLASM;NEOPLASM OF PLACENTA | A neoplasm arising from decidua (placental) cells in which the malignancy status has not been established. | Placental Neoplasm | ||
DERMOID CYST, BENIGN | C9011 | BENIGN CYSTIC TERATOMA;DERMOID;MATURE CYSTIC TERATOMA | A benign neoplasm comprised of a cyst, lined by mature epidermis-like tissue with dermal appendages. | Dermoid Cyst | ||
DYSGERMINOMA, MALIGNANT | C2996 | A malignant germ cell neoplasm characterized by the presence of a monotonous primitive germ cell population, primarily in the ovary. | Dysgerminoma | |||
EPENDYMOMA, ANAPLASTIC , MALIGNANT | C4049 | WHO GRADE III EPENDYMAL TUMOR;UNDIFFERENTIATED EPENDYMAL NEOPLASM;MALIGNANT EPENDYMOMA;UNDIFFERENTIATED EPENDYMAL TUMOR;UNDIFFERENTIATED EPENDYMOMA;ANAPLASTIC EPENDYMAL NEOPLASM;ANAPLASTIC EPENDYMAL TUMOR;WHO GRADE III EPENDYMAL NEOPLASM | A malignant neoplasm of ependymal origin with anaplastic cellular morphology. | Anaplastic Ependymoma | ||
EPENDYMOMA, UNDETERMINED | C3017 | WHO GRADE II EPENDYMAL TUMOR;WHO GRADE II EPENDYMAL NEOPLASM | A neoplasm of ependymal origin, for which the malignancy status has not been established. | Ependymoma | ||
EPITHELIOMA, BENIGN | C4092 | BENIGN EPITHELIAL TUMOR;BENIGN EPITHELIOMA;BENIGN NEOPLASM OF EPITHELIUM;BENIGN TUMOR OF THE EPITHELIUM;BENIGN NEOPLASM OF THE EPITHELIUM;BENIGN TUMOR OF EPITHELIUM | A benign neoplasm arising from epithelial cells of the skin. | Benign Epithelial Neoplasm | ||
EPITHELIOMA, CYSTIC KERATINIZING, BENIGN | C80349 | A benign cystic epithelial neoplasm featuring a central keratin mass surrounded by squamous epithelium. | Cystic Keratinizing Epithelioma | |||
EPITHELIOMA, NON-KERATINIZING, BENIGN | C84356 | A benign cystic epithelial neoplasm characterized by the absence of keratin production. | Non-Keratinizing Epithelioma | |||
FIBROADENOCARCINOMA, MALIGNANT | C2928 | ADENOCARCINOMA WITH PRODUCTIVE FIBROSIS;FIBROCARCINOMA;SCIRRHOUS CARCINOMA | A malignant neoplasm originating from glandular cells with a fibrous or fibroblastic component. | Scirrhous Adenocarcinoma | ||
FIBROADENOMA, BENIGN | C3744 | FIBROADENOMA OF BREAST;BREAST FIBROADENOMA;FIBROADENOMA OF THE BREAST | A benign neoplasm originating from glandular cells with a fibrous or fibroblastic component. | Fibroadenoma | ||
FIBROLIPOMA, BENIGN | C4249 | A benign neoplasm comprising mature adipocytes, characterized by areas of abundant fibrous tissue. | Fibrolipoma | |||
FIBROMA, BENIGN | C3041 | A benign neoplasm arising from fibrous tissue. | Fibroma | |||
FIBROMA, ODONTOGENIC, BENIGN | C4314 | CENTRAL ODONTOGENIC FIBROMA | A benign intraosseous neoplasm arising from tooth-forming tissues in the mandible and maxilla, characterized by the presence of islands of odontogenic epithelium. | Odontogenic Fibroma | ||
FIBROMA, OSSIFYING, BENIGN | C8422 | OSSIFYING FIBROMA;CEMENTIFYING FIBROMA;CEMENTO-OSSIFYING FIBROMA | A benign fibrous neoplasm characterized by a mineralized component (woven bone, lamellar bone, or cementum-like material). | Ossifying Fibroma | ||
FIBROMYXOMA, BENIGN | C66760 | FIBROMYXOMA | A benign soft-tissue neoplasm of uncertain lineage, characterized by the presence of neoplastic spindle-shaped to round cells and a fibromyxoid stroma. | Fibromyxoid Neoplasm | ||
FIBROPAPILLOMA, BENIGN | C3337 | A benign polypoid tumor comprising fibrous tissue and epithelium. | Fibroepithelial Polyp | |||
FIBROSARCOMA, MALIGNANT | C3043 | A malignant mesenchymal neoplasm of the soft tissue and bone. | Fibrosarcoma | |||
GANGLIOGLIOMA, UNDETERMINED | C3788 | A neuroepithelial neoplasm comprised of neoplastic ganglion cells and neoplastic glial cells, in which the malignancy status has not been established. | Ganglioglioma | |||
GANGLIONEUROBLASTOMA, MALIGNANT | C3790 | A malignant neoplasm characterized by the presence of neuroblastic and ganglion cells and a stroma with Schwannian differentiation. | Ganglioneuroblastoma | |||
GANGLIONEUROMA, BENIGN | C3049 | NEURAL CREST TUMOR, BENIGN | A benign neoplasm characterized by the presence of ganglion cells and spindle cell proliferation, located primarily in the brain, ganglia, or adrenal medulla. | Ganglioneuroma | ||
GIANT CELL TUMOR, BENIGN | C27477 | OSTEOCLASTOMA, BENIGN;BENIGN BONE GIANT CELL TUMOR | A benign neoplasm of bone comprised of giant cells (osteoclast-like) and mononuclear cells. | Benign Giant Cell Tumor of Bone | ||
GIANT CELL TUMOR, MALIGNANT | C4090 | MALIGNANT GIANT CELL TUMOR | A malignant neoplasm of bone comprised of giant cells (osteoclast-like) and mononuclear cells. | Malignant Giant Cell Neoplasm | ||
GIANT CELL TUMOR, UNDETERMINED | C3055 | TUMOR OF GIANT CELL;TUMOR OF THE GIANT CELL | A neoplasm of bone comprised of giant cells (osteoclast-like) and mononuclear cells, for which the malignancy status has not been established. | Giant Cell Tumor | ||
GLIOMA, MALIGNANT | C4822 | MALIGNANT NEUROGLIAL NEOPLASM;MALIGNANT GLIAL NEOPLASM;MALIGNANT NEUROGLIAL TUMOR;MALIGNANT GLIAL TUMOR | A malignant neuroglial neoplasm. The term can apply to several primary neoplasm of the brain and spinal cord, including astrocytoma and oligodendroglioma in addition to others. | Malignant Glioma | ||
GLIOMA, MIXED, MALIGNANT | C3903 | GLIOMA, MIXED;MIXED NEUROGLIAL TUMOR;MIXED NEUROGLIAL NEOPLASM;MIXED GLIAL TUMOR;MIXED GLIAL NEOPLASM | A malignant neoplasm comprising two or more glial cell types (e.g., astrocytes, ependymal cells, oligodendrocytes). | Mixed Glioma | ||
GRANULAR CELL TUMOR, BENIGN | C3252 | BENIGN GRANULAR CELL TUMOR;BENIGN GRANULAR CELL NEOPLASM;BENIGN GRANULAR CELL MYOBLASTOMA;MYOBLASTOMA | A benign neoplasm, comprised of large cells with cytoplasmatic granules, occurring in various organs/tissues. | Benign Granular Cell Tumor | ||
GRANULAR CELL TUMOR, MALIGNANT | C4336 | MYOBLASTOMA, MALIGNANT;MALIGNANT GRANULAR CELL NEOPLASM;MALIGNANT GRANULAR CELL MYOBLASTOMA | A malignant neoplasm, comprised of large cells with cytoplasmatic granules, occurring in various organs/tissues. | Malignant Granular Cell Tumor | ||
GRANULOSA CELL TUMOR, MALIGNANT | C4205 | MALIGNANT GRANULOSA CELL TUMOR | A malignant neoplasm of the ovary, originating from granulosa cells. | Malignant Granulosa Cell Tumor | ||
GRANULOSA CELL TUMOR, UNDETERMINED | C3070 | GRANULOSA CELL NEOPLASM | A neoplasm of the ovary (or testis), originating from granulosa cells for which the malignancy status has not been established. | Granulosa Cell Tumor | ||
HAIR FOLLICLE NEOPLASM, BENIGN | C27520 | BENIGN FOLLICULAR NEOPLASM;BENIGN FOLLICULAR TUMOR;BENIGN HAIR FOLLICLE TUMOR | A benign neoplasm that arises from the hair follicle. | Benign Hair Follicle Neoplasm | ||
HAIR FOLLICLE NEOPLASM, MALIGNANT | C43310 | MALIGNANT HAIR FOLLICLE TUMOR | A malignant neoplasm that arises from the hair follicle. | Malignant Hair Follicle Neoplasm | ||
HAIR FOLLICLE NEOPLASM, UNDETERMINED | C7367 | HAIR FOLLICLE TUMOR;HAIR MATRIX NEOPLASM;HAIR MATRIX TUMOR;NEOPLASM OF HAIR FOLLICLE;NEOPLASM OF THE HAIR FOLLICLE | A neoplasm that arises from the hair follicle, for which the malignancy status has not been established. | Hair Follicle Neoplasm | ||
HAMARTOMA, BENIGN | C3075 | A benign and excessive tumor-like growth of mature cells and normal tissues which grow in a disorganized pattern. | Hamartoma | |||
HAMARTOMA, LIPOMATOUS, BENIGN | C40426 | A benign hamartomatous tumor composed predominantly of adipose tissue. | Lipomatous Hamartoma | |||
HEMANGIOMA, BENIGN | C3085 | ANGIOMA;BENIGN ANGIOMA;BENIGN HEMANGIOMA | A benign vascular neoplasm characterized by the formation of capillary-sized or cavernous vascular channels. | Hemangioma | ||
HEMANGIOPERICYTOMA, BENIGN | C4300 | A benign neoplasm originating from vascular pericytes (cells in the periphery of vessels). | Benign Hemangiopericytoma | |||
HEMANGIOPERICYTOMA, MALIGNANT | C4301 | MALIGNANT HEMANGIOPERICYTOMA NOS | A malignant neoplasm originating from vascular pericytes (cells in the periphery of vessels). | Malignant Hemangiopericytoma | ||
HEMANGIOPERICYTOMA, UNDETERMINED | C3087 | A neoplasm originating from vascular pericytes (cells in the periphery of vessels), for which the malignancy status has not been established. | Hemangiopericytoma | |||
HEMANGIOSARCOMA, MALIGNANT | C3088 | HEMANGIOSARCOMA | A malignant vascular neoplasm arising from endothelial cells. | Angiosarcoma | ||
HEPATOBLASTOMA, MALIGNANT | C3728 | HBL;PEDIATRIC EMBRYONAL HEPATOMA;PEDIATRIC HEPATOBLASTOMA | A malignant liver neoplasm composed of immature hepatocytic elements. | Hepatoblastoma | ||
HIBERNOMA, BENIGN | C3702 | BROWN FAT NEOPLASM;FETAL FAT CELL LIPOMA;BROWN FAT TUMOR | A benign neoplasm of the brown adipose tissue. | Hibernoma | ||
HISTIOCYTOMA, BENIGN | C98708 | A benign dermal neoplasm comprising of round cells, resembling histiocytes. The tumor commonly occurs in young dogs and may regress spontaneously. | Benign Histiocytoma | |||
HISTIOCYTOMA, FIBROUS, BENIGN | C3739 | FIBROUS HISTIOCYTOMA | A benign neoplasm composed of a fibroblastic and a histiocytic component. | Benign Fibrous Histiocytoma | ||
HISTIOCYTOMA, FIBROUS, MALIGNANT | C4247 | MALIGNANT FIBROUS HISTIOCYTOMA OF THE SOFT TISSUE AND BONE;FIBROXANTHOSARCOMA;MALIGNANT FIBROXANTHOMA;MFH;MALIGNANT FIBROUS HISTIOCYTOMA OF SOFT TISSUE AND BONE | A malignant neoplasm composed of a fibroblastic and a histiocytic component. | Unclassified Pleomorphic Sarcoma (Formerly "Malignant Fibrous Histiocytoma") | ||
HISTIOCYTOMA, FIBROUS, UNDETERMINED | C8402 | FIBROHISTIOCYTIC TUMOR | A neoplasm composed of a fibroblastic and a histiocytic component, for which the malignancy status has not been established. | Fibrohistiocytic Neoplasm | ||
HISTIOCYTOMA, UNDETERMINED | C35765 | A neoplasm composed of histiocytic cells, for which the malignancy status has not been established. | Histiocytoma | |||
ITO CELL TUMOR, BENIGN | C80351 | BENIGN SPONGIOTIC PERICYTOMA | A benign neoplasm of the liver composed of hepatic stellate cells (Ito cells). | Benign Ito Cell Tumor | ||
ITO CELL TUMOR, MALIGNANT | C80352 | MALIGNANT SPONGIOTIC PERICYTOMA | A malignant neoplasm of the liver composed of hepatic stellate cells (Ito cells). | Malignant Ito Cell Tumor | ||
KERATOACANTHOMA, UNDETERMINED | C3146 | An epithelial skin neoplasm, composed of squamous cells, for which the malignancy status has not been established. | Keratoacanthoma | |||
LEIOMYOBLASTOMA, BENIGN | C81854 | A benign neoplasm of the gastro-intestinal tract, originating from smooth muscle cells. | Benign Epithelioid Cell Type Gastrointestinal Stromal Tumor | |||
LEIOMYOBLASTOMA, MALIGNANT | C81855 | A malignant neoplasm of the gastro-intestinal tract, originating from smooth muscle cells. | Malignant Epithelioid Cell Type Gastrointestinal Stromal Tumor | |||
LEIOMYOBLASTOMA, UNDETERMINED | C3486 | LEIOMYOBLASTOMA;EPITHELIOID CELL TYPE GIST;STOUT'S LEIOMYOBLASTOMA | A neoplasm of the gastro-intestinal tract, originating from smooth muscle cells, for which the malignancy status has not been established. | Epithelioid Cell Type Gastrointestinal Stromal Tumor | ||
LEIOMYOMA, BENIGN | C3157 | LEIOMYOMATOUS NEOPLASM;LEIOMYOMATOUS TUMOR;FIBROID NEOPLASM;FIBROID TUMOR;FIBROID | A benign neoplasm, originating from smooth muscle cells. | Leiomyoma | ||
LEIOMYOSARCOMA, MALIGNANT | C3158 | LEIOMYOSARCOMAS | A malignant neoplasm, originating from smooth muscle cells. | Leiomyosarcoma | ||
LEUKEMIA, ACUTE ERYTHROID, MALIGNANT | C8923 | ERYTHROBLASTIC LEUKEMIA;ACUTE ERYTHROBLASTIC LEUKEMIA;M6 ACUTE MYELOID LEUKEMIA;FAB M6 | A progressive, proliferative disease of blood cells, originating from immature erythroid cells. | Acute Erythroid Leukemia | ||
LEUKEMIA, ACUTE LYMPHOBLASTIC, MALIGNANT | C3167 | LYMPHOBLASTIC LEUKEMIA;ALL - ACUTE LYMPHOCYTIC LEUKEMIA;ACUTE LYMPHOID LEUKEMIA;PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA;ALL;PRECURSOR LYMPHOBLASIC LEUKEMIA;ACUTE LYMPHOGENOUS LEUKEMIA;ACUTE LYMPHOCYTIC LEUKEMIAS;ACUTE LYMPHOCYTIC LEUKAEMIA | A progressive, proliferative disease of blood cells, originating from immature lymphoid cells. | Acute Lymphoblastic Leukemia | ||
LEUKEMIA, ACUTE MEGAKARYOCYTIC, MALIGNANT | C3170 | ACUTE MEGAKARYOCYTIC LEUKEMIA;ACUTE MEGAKARYOBLASTIC LEUKEMIA (FAB TYPE M7);FAB M7;ACUTE M7 MYELOID LEUKEMIA | A progressive, proliferative disease of blood cells, originating from immature megakaryocytes. | Acute Megakaryoblastic Leukemia | ||
LEUKEMIA, ACUTE MONOCYTIC, MALIGNANT | C4861 | ACUTE MONOCYTIC LEUKEMIA (FAB M5B);MONOCYTIC LEUKEMIA | A progressive, proliferative disease of blood cells, originating from immature monocytes. | Acute Monocytic Leukemia | ||
LEUKEMIA, GRANULOCYTIC, MALIGNANT | C3172 | LEUKEMIA GRANULOCYTIC;LEUKEMIA MYELOID;NON-LYMPHOBLASTIC LEUKEMIA;MYELOCYTIC LEUKEMIA;NON-LYMPHOCYTIC LEUKEMIA;MYELOGENOUS LEUKEMIA | A progressive, proliferative disease of blood cells, originating from immature granulocytes. | Myeloid Leukemia | ||
LEUKEMIA, LARGE GRANULAR LYMPHOCYTIC, MALIGNANT | C4664 | T-GAMMA LYMPHOPROLIFERATIVE DISORDER;LARGE CELL GRANULAR LYMPHOID LEUKEMIA;T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA;LGLL;TGAMMA LARGE GRANULAR LYMPHOCYTE LEUKEMIA;T GAMMA LYMPHOPROLIFERATIVE DISORDER;LARGE GRANULAR LYMPHOCYTOSIS;LARGE GRANULAR LYMPHOCYTIC LEUKEMIA;LARGE CELL GRANULAR LYMPHOGENOUS LEUKEMIA | A progressive, proliferative disease of blood cells which are large and granular, originating from lymphoid cells. | T-Cell Large Granular Lymphocyte Leukemia | ||
LEUKEMIA, LYMPHOCYTIC, MALIGNANT | C7539 | LYMPHOGENOUS LEUKEMIA;LYMPHOCYTIC LEUKEMIA | A progressive, proliferative disease of blood cells, originating from lymphoid cells. | Lymphoid Leukemia | ||
LEUKEMIA, MALIGNANT | C3161 | LEUKEMIA NOS;LEUKEMIAS, GENERAL;LEUKEMIAS;BLOOD (LEUKEMIA) | A progressive, proliferative disease of blood cells, originating from myeloid or lymphoid stem cells. | Leukemia | ||
LEYDIG CELL TUMOR, BENIGN | C4212 | ADENOMA, INTERSTITIAL;BENIGN INTERSTITIAL CELL NEOPLASM;BENIGN INTERSTITIAL CELL TUMOR;BENIGN LEYDIG CELL NEOPLASM | A benign neoplasm of the testis originating from interstitial (Leydig) cells. | Benign Leydig Cell Tumor | ||
LEYDIG CELL TUMOR, MALIGNANT | C4213 | MALIGNANT INTERSTITIAL CELL TUMOR;MALIGNANT LEYDIG CELL NEOPLASM;MALIGNANT INTERSTITIAL CELL NEOPLASM | A malignant neoplasm of the testis originating from interstitial (Leydig) cells. | Malignant Leydig Cell Tumor | ||
LEYDIG CELL TUMOR, UNDETERMINED | C3188 | LEYDIG CELL TUMOR;LEYDIG CELL NEOPLASM;INTERSTITIAL CELL NEOPLASM;INTERSTITIAL CELL TUMOR | A neoplasm of the testis originating from interstitial (Leydig) cells, for which the malignancy status has not been established. | Leydig Cell Tumor | ||
LIPOMA, BENIGN | C3192 | A benign neoplasm composed of adipose tissue. | Lipoma | |||
LIPOSARCOMA, MALIGNANT | C3194 | A malignant neoplasm composed of adipose tissue. | Liposarcoma | |||
LUTEOMA, BENIGN | C3202 | LUTEOMA;LUTEINOMA;LUTEAL CELL TUMOR;LUTEAL CELL NEOPLASM;OVARIAN STROMA LUTEOMA | A benign neoplasm of the ovary, composed of leuteinized granulosa-theca cells. | Ovarian Stromal Luteoma | ||
LYMPHANGIOMA, BENIGN | C8965 | A benign neoplasm arising from the lymphatics. | Lymphangioma | |||
LYMPHANGIOSARCOMA, MALIGNANT | C3205 | MALIGNANT LYMPHANGIOENDOTHELIOMA;LYMPHANGIOENDOTHELIAL SARCOMA | A malignant neoplasm arising from the endothelial cells of the lymphatic vessels. | Lymphangiosarcoma | ||
LYMPHOMA, FOLLICULAR, MALIGNANT | C3209 | LYMPHOMA, FOLLICULAR CENTRE CELL;FOLLICULAR CENTRE CELL LYMPHOMA;FOLLICLE CENTER LYMPHOMA;FOLLICULAR NON-HODGKIN LYMPHOMA;FOLLICULAR NON-HODGKIN'S LYMPHOMA | A neoplasm of lymphoid cells which has at least a partial follicular pattern. | Follicular Lymphoma | ||
LYMPHOMA, HISTIOCYTIC, MALIGNANT | C35382 | LYMPHOMA, LARGE CELL, MALIGNANT | A malignant neoplasm of large lymphocytes, which resemble histiocytes. | True Histiocytic Lymphoma | ||
LYMPHOMA, IMMUNOBLASTIC, MALIGNANT | C3461 | A malignant neoplasm composed of immunoblasts (large B cells). | Immunoblastic Lymphoma | |||
LYMPHOMA, LYMPHOBLASTIC, MALIGNANT | C9360 | PRECURSOR CELL LYMPHOBLASTIC LYMPHOMA;PRECURSOR LYMPHOBLASTIC LYMPHOMA | A malignant neoplasm composed of lymphoblasts (lymphoid precursor cells). | Lymphoblastic Lymphoma | ||
LYMPHOMA, LYMPHOPLASMACYTIC, MALIGNANT | C3212 | LYMPHOMA, PLASMACYTIC;IMMUNOCYTOMA, LYMPHOPLASMACYTIC TYPE;LYMPHOPLASMACYTOID LYMPHOMA | A malignant neoplasm composed of lymphocytes (B-cells), lymphoplasmacytoid cells, and plasma cells. | Lymphoplasmacytic Lymphoma | ||
LYMPHOMA, MALIGNANT | C3208 | LYMPHOMA (HODGKIN AND NON-HODGKIN);LYMPHOMA (HODGKIN'S AND NON-HODGKIN'S);MALIGNANT LYMPHOMA | A malignant neoplasm composed of lymphocytes of B- or T/NK-cell phenotype. | Lymphoma | ||
LYMPHOMA, MIXED, MALIGNANT | C3463 | DIFFUSE MIXED LARGE AND SMALL CELL LYMPHOMA | A malignant neoplasm composed of a mixed lymphocyte population. | Diffuse Mixed Cell Lymphoma | ||
LYMPHOMA, SMALL LYMPHOCYTIC, MALIGNANT | C7540 | SMALL B-CELL LYMPHOCYTIC LYMPHOMA;SLL;B-CELL SMALL LYMPHOCYTIC LYMPHOMA;LYMPHOMA, LYMPHOCYTIC, MALIGNANT | A malignant neoplasm composed of small lymphocytes. | Small Lymphocytic Lymphoma | ||
LYMPHOSARCOMA, MALIGNANT | C26919 | An antiquated term referring to a malignant lymphoma that is diffused and composed of small and large lymphocytes. | Lymphosarcoma | |||
MAST CELL TUMOR, BENIGN | C3217 | A benign neoplasm composed of mast cells. | Benign Mastocytoma | |||
MAST CELL TUMOR, MALIGNANT | C8991 | A malignant neoplasm composed of mast cells. | Malignant Mastocytosis | |||
MAST CELL TUMOR, UNDETERMINED | C9295 | MAST CELL PROLIFERATIVE DISEASE;TUMOR OF MAST CELLS;NEOPLASM OF MAST CELLS;NEOPLASM OF THE MAST CELLS;MAST CELL TUMOR;TUMOR OF THE MAST CELLS | A neoplasm composed of mast cells, for which the malignancy status has not been determined. | Mast Cell Neoplasm | ||
MEDULLOBLASTOMA, MALIGNANT | C3222 | MEDULLOBLASTOMAS | A malignant, invasive embryonal neoplasm arising from the cerebellum. | Medulloblastoma | ||
MELANOCYTOMA, BENIGN | C98709 | A benign neoplasm or hamartoma composed of melanocytes. | Benign Melanocytoma | |||
MELANOMA, AMELANOTIC, MALIGNANT | C3802 | A malignant neoplasm composed of melanocytes, which lack melanin. | Amelanotic Melanoma | |||
MELANOMA, MALIGNANT | C3224 | MALIGNANT MELANOMA | A malignant neoplasm composed of melanocytes. | Melanoma | ||
MELANOMA, UVEAL, MALIGNANT | C7712 | MELANOMA OF UVEA;MELANOMA OF THE UVEA;INTRAOCULAR MELANOMA | A malignant neoplasm of the uvea composed of melanocytes. | Uveal Melanoma | ||
MENINGIOMA, ANAPLASTIC, MALIGNANT | C4051 | ANAPLASTIC MENINGIOMA;MALIGNANT MENINGIOMA;MENINGIOMA, MALIGNANT | A malignant neoplasm of the meninges, exhibiting poor differentiation (anaplasia). | Anaplastic (Malignant) Meningioma | ||
MENINGIOMA, BENIGN | C4055 | MENINGIOMA, BENIGN | A benign neoplasm of the meninges. | Benign Meningioma | ||
MENINGIOMA, MALIGNANT | C38938 | GRADE III MENINGIOMA;GRADE 3 MENINGIOMA;WHO GRADE III MENINGIOMA | A malignant neoplasm of the meninges. | Grade III Meningioma | ||
MENINGIOMA, UNDETERMINED | C3230 | A neoplasm of the meninges, for which the status of malignancy has not been determined. | Meningioma | |||
MESENCHYMAL TUMOR, BENIGN | C4267 | A benign soft-tissue neoplasm comprising two or more non-fibroblastic mesenchymal lines of differentiation. | Benign Mesenchymoma | |||
MESOTHELIOMA, BENIGN | C3762 | ADENOMATOID TUMOR, BENIGN;BENIGN MESOTHELIOMA;MESOTHELIOMA, BENIGN;BENIGN NEOPLASM OF MESOTHELIUM;BENIGN MESOTHELIAL NEOPLASM;BENIGN TUMOR OF MESOTHELIUM;BENIGN MESOTHELIAL TUMOR;BENIGN LOCALIZED EPITHELIAL MESOTHELIOMA;BENIGN TUMOR OF THE MESOTHELIUM;BENIGN NEOPLASM OF THE MESOTHELIUM | A benign neoplasm arising from mesothelial cells. | Adenomatoid Tumor | ||
MESOTHELIOMA, MALIGNANT | C4456 | MALIGNANT TUMOR OF MESOTHELIUM;MALIGNANT NEOPLASM OF THE MESOTHELIUM;MALIGNANT MESOTHELIAL TUMOR;MALIGNANT NEOPLASM OF MESOTHELIUM;MALIGNANT MESOTHELIAL NEOPLASM;MALIGNANT TUMOR OF THE MESOTHELIUM | A malignant neoplasm originating from mesothelial cells of the pleura or peritoneum. | Malignant Mesothelioma | ||
MESOTHELIOMA, UNDETERMINED | C3234 | A neoplasm originating from mesothelial cells of the pleura or peritoneum, for which the malignancy status has not been established. | Mesothelioma | |||
MIXED GLIOMA, BENIGN | C4050 | A benign neoplasm of the central nervous system with an astrocytic and oligodendrocytic component. | Oligoastrocytoma | |||
MIXED TUMOR, BENIGN | C8602 | A benign neoplasm composed of epithelial and/or myoepithelial cells and a mesenchymal component. | Pleomorphic Adenoma | |||
MIXED TUMOR, MALIGNANT | C3729 | MALIGNANT MIXED TUMOR | A malignant neoplasm composed of epithelial and/or myoepithelial cells and a mesenchymal component. A general term for which the transformed cell types have not been specified. | Malignant Mixed Neoplasm | ||
MIXED TUMOR, UNDETERMINED | C6930 | TUMOR, MIXED;MIXED TUMOR | A neoplasm composed of an epithelial component and/or a mesenchymal component, for which the malignancy status has not been established. A general term for which the transformed cell types have not been specified. | Mixed Neoplasm | ||
MUELLERIAN TUMOR, MIXED, MALIGNANT | C8975 | MALIGNANT MIXED MESODERMAL TUMOR;MALIGNANT MIXED MULLERIAN TUMOR;MMMT | A malignant neoplasm of the female reproductive system (mostly uterus and ovaries) originating from the Muellerian ducts and composed of carcinomatous and sarcomatous elements. | Malignant Mixed Mesodermal (Mullerian) Tumor | ||
MYELOLIPOMA, BENIGN | C3736 | MYELOLIPOMA | A benign tumor of the adrenal gland composed of adipocytes and hematopoietic/lymphoid cells. | Adrenal Gland Myelolipoma | ||
MYELOMA, PLASMA CELL, MALIGNANT | C3242 | MYELOMA;MULTIPLE MYELOMA | A malignant neoplasm of the bone marrow composed of plasma cells. | Plasma Cell Myeloma | ||
MYOEPITHELIOMA, BENIGN | C7442 | A benign neoplasm composed of myoepithelial cells. | Benign Myoepithelioma | |||
MYOEPITHELIOMA, MALIGNANT | C7596 | MYOEPITHELIAL CARCINOMA;MALIGNANT MYOEPITHELIOMA | A malignant neoplasm composed of myoepithelial cells. | Malignant Myoepithelioma | ||
MYXOMA, BENIGN | C6577 | A benign soft tissue neoplasm with a myxoid stroma formation. | Myxoma | |||
MYXOSARCOMA, MALIGNANT | C3255 | A malignant soft tissue neoplasm with a myxoid stroma formation. | Myxosarcoma | |||
NEOPLASM, BASAL CELL, BENIGN | C4743 | BENIGN BASAL CELL TUMOR | A benign neoplasm composed of basal cells. | Benign Basal Cell Neoplasm | ||
NEOPLASM, BASAL CELL, MALIGNANT | C7586 | A malignant neoplasm composed of basal cells. | Malignant Basal Cell Neoplasm | |||
NEOPLASM, BENIGN | C3677 | BENIGN TUMOR;BENIGN UNCLASSIFIABLE TUMOR | A general term used to describe autonomous growth of tissue where the originating cell type has not been characterized. The term benign indicates the absence of morphologic features associated with malignancy (for instance severe atypia, nuclear pleomorphism, tumor cell necrosis, and abnormal mitoses). | Benign Neoplasm | ||
NEOPLASM, MALIGNANT | C9305 | MALIGNANCY;CA;CANCER;MALIGNANT TUMOR | A general term for autonomous tissue growth exhibiting morphologic features of malignancy (e.g. severe atypia, nuclear pleomorphism, tumor cell necrosis, abnormal mitoses, tissue invasiveness) and for which the transformed cell type has not been specifically identified. | Malignant Neoplasm | ||
NEOPLASM, UNDETERMINED | C3262 | A general term for autonomous tissue growth in which the malignancy status has not been established and for which the transformed cell type has not been specifically identified. | Neoplasm | |||
NEPHROBLASTOMA, MALIGNANT | C40407 | EMBRYONAL NEPHROMA;NEPHROBLASTOMA;WILMS TUMOR OF THE KIDNEY;RENAL WILMS' TUMOR;WILMS' TUMOR OF THE KIDNEY | A malignant embryonal neoplasm of the kidney. | Renal Wilms Tumor | ||
NEURAL CREST TUMOR, UNDETERMINED | C6963 | A neoplasm composed of cells of neuroendocrine origin for which the malignancy status has not been established. | Neuroblastic Tumor | |||
NEUROBLASTOMA, MALIGNANT | C3270 | NEUROBLASTOMA (SCHWANNIAN STROMA-POOR);NEURAL CREST TUMOR, MALIGNANT | A malignant neoplasm composed of neuroblastic cells. | Neuroblastoma | ||
NEUROBLASTOMA, OLFACTORY, MALIGNANT | C3789 | ESTHESIONEUROBLASTOMA;OLFACTORY ESTHESIONEUROBLASTOMA;ESTHESIONEUROBLASTOMA;ESTHESIONEUROEPITHELIOMA;OLFACTORY NEUROEPITHELIOMA | A malignant neoplasm of the olfactory receptor cells, composed of neuroblastic cells. | Olfactory Neuroblastoma | ||
NEUROFIBROMA, BENIGN | C3272 | An intraneural or extraneural neoplasm arising from nerve tissues and neural sheaths, composed of perineurial-like fibroblasts and Schwann cells. | Neurofibroma | |||
NEUROGLIAL TUMOR, UNDETERMINED | C3059 | GLIOMA;NEOPLASM OF THE NEUROGLIA;NEUROGLIAL NEOPLASMS;TUMOR OF THE NEUROGLIA;TUMORS OF NEUROGLIA;TUMOR OF NEUROGLIA;NEOPLASMS OF NEUROGLIA;GLIAL NEOPLASM;GLIAL TUMOR;GLIOMA;NEOPLASM OF NEUROGLIA;NEUROGLIAL NEOPLASM | A neoplasm of the central nervous system composed of glial cells (astrocytes, oligodendrocytes, ependymal cells), for which the malignancy status has not been determined. | Neuroglial Tumor | ||
ODONTOGENIC TUMOR, BENIGN | C4306 | BENIGN ODONTOGENIC TUMOR | A benign neoplasm arising from tooth-forming tissues. | Benign Odontogenic Neoplasm | ||
ODONTOGENIC TUMOR, UNDETERMINED | C3286 | ODONTOGENIC TUMOR | A neoplasm arising from tooth-forming tissues, for which the malignancy status has not been established. | Odontogenic Neoplasm | ||
ODONTOMA, AMELOBLASTIC, BENIGN | C3710 | AMELOBLASTIC FIBROODONTOMA;FIBROAMELOBLASTIC ODONTOMA | A benign neoplasm arising from tooth-forming tissues with-enamel organ differentiation (but without enamel formation). | Ameloblastic Fibro-Odontoma | ||
ODONTOMA, AMELOBLASTIC, MALIGNANT | C7492 | A malignant neoplasm arising from tooth-forming tissues with-enamel organ differentiation (but without enamel formation). | Ameloblastic Carcinoma | |||
ODONTOMA, BENIGN | C3287 | FIBROODONTOMA;FIBRO-ODONTOMA | A benign neoplasm of tooth origin. | Odontoma | ||
ODONTOMA, MALIGNANT | C4812 | ODONTOGENIC CARCINOMA;MALIGNANT ODONTOGENIC TUMOR;ODONTOGENIC CARCINOSARCOMA | A malignant neoplasm of tooth origin. | Malignant Odontogenic Neoplasm | ||
OLIGODENDROGLIOMA, ANAPLASTIC, MALIGNANT | C4326 | WHO GRADE III OLIGODENDROGLIAL NEOPLASM;OLIGODENDROGLIOMA;MALIGNANT;MALIGNANT OLIGODENDROGLIOMA;WHO GRADE III OLIGODENDROGLIAL TUMOR;UNDIFFERENTIATED OLIGODENDROGLIOMA | A malignant neoplasm of the central nervous system arising from oligodendrocytes, exhibiting poor differentiation (anaplasia). | Anaplastic Oligodendroglioma | ||
OLIGODENDROGLIOMA, UNDETERMINED | C3288 | WELL DIFFERENTIATED OLIGODENDROGLIOMA;WELL DIFFERENTIATED OLIGODENDROGLIAL TUMOR;WHO GRADE II OLIGODENDROGLIAL TUMOR;WHO GRADE II OLIGODENDROGLIAL NEOPLASM | A neoplasm of the central nervous system arising from oligodendrocytes, for which the malignancy status has not been determined. | Oligodendroglioma | ||
ONCOCYTOMA, BENIGN | C7072 | ONCOCYTOMA;ONCOCYTIC TUMOR | A benign neoplasm composed of large cells with abundant eosinophilic granular cytoplasm (oncocytes). | Oncocytic Neoplasm | ||
ONCOCYTOMA, MALIGNANT | C3679 | HURTHLE CELL CARCINOMA;HURTHLE CELL ADENOCARCINOMA;ONCOCYTIC ADENOCARCINOMA;ONCOCYTIC CARCINOMA | A malignant neoplasm composed of large epithelial cells with abundant granular eosinophilic cytoplasm (oncocytes). | Oxyphilic Adenocarcinoma | ||
OSTEOBLASTOMA, BENIGN | C3294 | GIANT OSTEOID OSTEOMA;OSSIFYING GIANT CELL TUMOR | A benign neoplasm of bone, characterized by the formation of osteoid tissue and large osteoblast-like cells. | Osteoblastoma | ||
OSTEOCHONDROMA, BENIGN | C3295 | A benign cartiliginous neoplasm arising from the metaphysis of bone. | Osteochondroma | |||
OSTEOCHONDROSARCOMA, MALIGNANT | C7155 | PRIMARY CHONDROSARCOMA;CONVENTIONAL CHONDROSARCOMA OF BONE;PRIMARY CHONDROSARCOMA OF THE BONE;PRIMARY CHONDROSARCOMA OF BONE;PRIMARY BONE CHONDROSARCOMA | A malignant cartiliginous neoplasm of bone. | Conventional Chondrosarcoma | ||
OSTEOCLASTOMA, MALIGNANT | C4304 | GIANT CELL SARCOMA OF THE BONE;GIANT CELL SARCOMA OF BONE;GIANT CELL BONE SARCOMA;DEDIFFERENTIATED GIANT CELL TUMOR | A malignant neoplasm of bone comprised of osteoclast-like giant cells and mononuclear cells. | Malignant Giant Cell Tumor of Bone | ||
OSTEOCLASTOMA, UNDETERMINED | C3738 | GIANT CELL NEOPLASM OF BONE;BONE GIANT CELL TUMOR;BONE GIANT CELL NEOPLASM | A neoplasm of bone comprised of osteoclast-like giant cells and mononuclear cells, for which the malignancy status has not been established. | Giant Cell Tumor of Bone | ||
OSTEOFIBROMA, BENIGN | C3740 | DESMOID TUMOR OF BONE;DESMOPLASTIC FIBROMA OF BONE;DESMOPLASTIC FIBROMA OF THE BONE;DESMOPLASTIC FIBROMA;OSSEOUS DESMOPLASTIC FIBROMA | A benign neoplasm characterized by osteolysis and the presence of a rich collagenous stroma and spindle cells. | Bone Desmoplastic Fibroma | ||
OSTEOMA, BENIGN | C3296 | A benign well-differentiated neoplasm of bone. | Osteoma | |||
OSTEOSARCOMA, EXTRASKELETAL, MALIGNANT | C8810 | EXTRAOSSEOUS OSTEOSARCOMA;EXTRASKELETAL OSTEOGENIC SARCOMA;SOFT TISSUE OSTEOSARCOMA | A malignant bone-forming neoplasm, arising in tissue other than bone. | Extraskeletal Osteosarcoma | ||
OSTEOSARCOMA, MALIGNANT | C9145 | OSTEOGENIC SARCOMA | A malignant neoplasm usually arising from bone. | Osteosarcoma | ||
OVARIAN SEX CORD-STROMAL TUMOR, BENIGN | C6803 | SEX CORD STROMAL TUMOR, BENIGN;BENIGN SEX CORD-STROMAL NEOPLASM OF THE OVARY;BENIGN SEX CORD-STROMAL TUMOR OF THE OVARY;BENIGN OVARIAN SEX CORD-STROMAL NEOPLASM;BENIGN SEX CORD-STROMAL TUMOR OF OVARY;BENIGN SEX CORD-STROMAL NEOPLASM OF OVARY | A benign neoplasm of the ovary, originating from the sex-cord stroma. | Benign Ovarian Sex Cord-Stromal Tumor | ||
PAPILLOMA, BENIGN | C7440 | A benign epithelial neoplasm that projects above the surrounding epithelial surface. | Papilloma | |||
PAPILLOMA, CHOROID PLEXUS, BENIGN | C3698 | PAPILLOMA OF CHOROID PLEXUS;PAPILLOMA OF THE CHOROID PLEXUS | A benign neoplasm of the choroid plexus of the central nervous system. | Choroid Plexus Papilloma | ||
PAPILLOMA, SQUAMOUS CELL, BENIGN | C3712 | EPIDERMOID PAPILLOMA;EPIDERMOID CELL PAPILLOMA;KERATOTIC PAPILLOMA;SQUAMOUS CELL PAPILLOMA | A benign epithelial neoplasm characterized by a papillary growth pattern and a proliferation of neoplastic squamous cells. | Squamous Papilloma | ||
PAPILLOMA, TRANSITIONAL CELL, BENIGN | C4115 | TRANSITIONAL PAPILLOMA | A benign papillary neoplasm composed of transitional cells. | Transitional Cell Papilloma | ||
PARAGANGLIOMA, BENIGN | C48314 | BENIGN PARAGANGLIONIC NEOPLASM;BENIGN NEUROENDOCRINE CELL TUMOR | A benign neoplasm arising from paraganglia located along nerves composed of neoplastic neuroectodermal chromaffin cells. | Benign Paraganglioma | ||
PARAGANGLIOMA, MALIGNANT | C8559 | MALIGNANT TUMOR OF THE PARAGANGLION;MALIGNANT TUMOR OF PARAGANGLION;MALIGNANT PARAGANGLIONIC NEOPLASM;MALIGNANT PARAGANGLIONIC TUMOR;MALIGNANT NEOPLASM OF PARAGANGLION;MALIGNANT PARAGANGLION NEOPLASM;MALIGNANT PARAGANGLION TUMOR;PARAGANGLION NEOPLASM;MALIGNANT;MALIGNANT NEOPLASM OF THE PARAGANGLION | A malignant neoplasm arising from paraganglia located along nerves composed of neoplastic neuroectodermal chromaffin cells. | Malignant Paraganglioma | ||
PARAGANGLIOMA, UNDETERMINED | C3308 | PARAGANGLION NEOPLASM;NEOPLASM OF PARAGANGLION;TUMOR OF THE PARAGANGLION;PARAGANGLION TUMOR;TUMOR OF PARAGANGLION;PARAGANGLIONIC NEOPLASM;PARAGANGLIONIC TUMOR;NEOPLASM OF THE PARAGANGLION | A neoplasm arising from paraganglia located along nerves composed of neoplastic neuroectodermal chromaffin cells, for which the malignancy status has not been established. | Paraganglioma | ||
PERIPHERAL NERVE SHEATH TUMOR, MALIGNANT | C3798 | MALIGNANT NEURILEMMOMA;MALIGNANT SCHWANNOMA;NEUROFIBROSARCOMA, MALIGNANT;MALIGNANT NEOPLASM OF PERIPHERAL NERVE SHEATH;MALIGNANT NEOPLASM OF THE PERIPHERAL NERVE SHEATH;MALIGNANT NEURILEMMOMA;MALIGNANT NEURILEMOMA;MALIGNANT PERIPHERAL NERVE SHEATH NEOPLASM;MALIGNANT PERIPHERAL NERVE SHEATH TUMOUR;MALIGNANT TUMOR OF PERIPHERAL NERVE SHEATH;MALIGNANT TUMOR OF THE PERIPHERAL NERVE SHEATH;MPNST | A malignant neoplasm, originating from the sheaths of the peripheral nerve. | Malignant Peripheral Nerve Sheath Tumor | ||
PHEOCHROMOCYTOMA, BENIGN | C48305 | A benign neoplasm of the adrenal gland medulla. | Benign Adrenal Gland Pheochromocytoma | |||
PHEOCHROMOCYTOMA, COMPLEX, BENIGN | C92181 | A benign neoplasm of the adrenal gland medulla, composed of medullary and neuroectodermal components. | Benign Adrenal Gland Composite Pheochromocytoma | |||
PHEOCHROMOCYTOMA, COMPLEX, UNDETERMINED | C48306 | A neoplasm of the adrenal gland medulla, composed of medullary and neuroectodermal components, for which the malignancy status has not been established. | Adrenal Gland Composite Pheochromocytoma | |||
PHEOCHROMOCYTOMA, COMPLEX, MALIGNANT | C92184 | A malignant neoplasm of the adrenal gland medulla, composed of medullary and neuroectodermal components. | Malignant Adrenal Gland Composite Pheochromocytoma | |||
PHEOCHROMOCYTOMA, MALIGNANT | C4220 | MALIGNANT PHEOCHROMOCYTOMA;MALIGNANT ADRENAL MEDULLARY PHEOCHROMOCYTOMA;MALIGNANT ADRENAL PHEOCHROMOCYTOMA;MALIGNANT ADRENAL GLAND PARAGANGLIOMA;MALIGNANT ADRENAL GLAND CHROMAFFINOMA;MALIGNANT ADRENAL GLAND CHROMAFFIN NEOPLASM;MALIGNANT ADRENAL GLAND CHROMAFFIN TUMOR;MALIGNANT ADRENAL GLAND CHROMAFFIN PARAGANGLIOMA;PHEOCHROMOBLASTOMA;MALIGNANT ADRENAL MEDULLARY PARAGANGLIOMA | A malignant neoplasm of the adrenal gland medulla. | Malignant Adrenal Gland Pheochromocytoma | ||
PHEOCHROMOCYTOMA, UNDETERMINED | C3326 | ADRENAL PHEOCHROMOCYTOMA;CHROMAFFIN PARAGANGLIOMA OF THE ADRENAL GLAND;INTRAADRENAL PARAGANGLIOMA;ADRENAL MEDULLARY PARAGANGLIOMA;ADRENAL GLAND PARAGANGLIOMA;ADRENAL MEDULLARY PHEOCHROMOCYTOMA;PCC;ADRENAL GLAND CHROMAFFIN PARAGANGLIOMA;PHAEOCHROMOCYTOMA;ADRENAL GLAND CHROMAFFINOMA;PHEOCHROMOCYTOMA | A neoplasm of the adrenal gland medulla, for which the malignancy status has not been established. | Adrenal Gland Pheochromocytoma | ||
PILOMATRIXOMA, BENIGN | C7368 | BENIGN PILOMATRICOMA;PILOMATRIXOMA;CALCIFYING EPITHERLIOMA OF MALHERBE;BENIGN PILOMATRIXOMA;BENIGN HAIR FOLLICLE NEOPLASM | A benign adnexal neoplasm arising from hair-bearing skin surfaces. | Pilomatricoma | ||
PINEOBLASTOMA, MALIGNANT | C9344 | PINEAL GLAND PNET;PINEAL GLAND PRIMITIVE NEUROECTODERMAL NEOPLASM;PINEAL GLAND PRIMITIVE NEUROECTODERMAL TUMOR;PINEAL PNET;PINEAL PRIMITIVE NEUROECTODERMAL NEOPLASM;PINEAL PRIMITIVE NEUROECTODERMAL TUMOR;PNET OF PINEAL GLAND;PNET OF THE PINEAL GLAND;PRIMITIVE NEUROECTODERMAL NEOPLASM OF PINEAL GLAND;PRIMITIVE NEUROECTODERMAL NEOPLASM OF THE PINEAL GLAND;PRIMITIVE NEUROECTODERMAL TUMOR OF PINEAL GLAND;PRIMITIVE NEUROECTODERMAL TUMOR OF THE PINEAL GLAND | A poorly differentiated malignant embryonal neoplasm arising from the pineal region of the brain. | Pineoblastoma | ||
PINEOCYTOMA, BENIGN | C6966 | PINEALOMA;BENIGN PINEALOMA | A benign neoplasm of the brain arising from the pineal gland. | Pineocytoma | ||
PITUICYTOMA, BENIGN | C7157 | POSTERIOR PITUITARY TUMOR;POSTERIOR PITUITARY GLAND TUMOR;NEUROHYPOPHYSIS NEOPLASM;NEUROHYPOPHYSIS TUMOR;POSTERIOR PITUITARY NEOPLASM | A neoplasm arising from the posterior lobe of the pituitary gland. | Posterior Pituitary Gland Neoplasm | ||
PLASMA CELL TUMOR, MALIGNANT | C4665 | PLASMACYTIC TUMOR;PLASMA CELL DYSCRASIA;PLASMACYTIC TUMOR;PLASMA CELL TUMOR;PLASMACYTIC NEOPLASM | A malignant neoplasm composed of plasma cells. | Plasma Cell Neoplasm | ||
POLYP, ADENOMATOUS, UNDETERMINED | C3764 | POLYPOID ADENOMA | A neoplasm, originating from glandular epithelium, exhibiting polypoid growth, for which the malignancy status has not been determined. | Adenomatous Polyp | ||
POLYP, ENDOMETRIAL STROMAL, BENIGN | C6433 | POLYP, STROMAL;POLYP OF THE ENDOMETRIUM;ENDOMETRIAL STROMAL POLYP;POLYP OF ENDOMETRIUM;ADENOMA, ENDOMETRIAL;GLANDULAR ENDOMETRIAL POLYP;ENDOMETRIAL ADENOMA | A benign polypoid neoplasm of the endometrium projecting into the endometrial cavity. | Endometrial Polyp | ||
POLYP, INFLAMMATORY, BENIGN | C5680 | INFLAMMATORY POLYP OF THE LARGE BOWEL;LARGE BOWEL INFLAMMATORY POLYP;INFLAMMATORY POLY OF LARGE BOWEL | A non-neoplastic inflammatory polypoid lesion in the colon and rectum. | Colorectal Inflammatory Polyp | ||
POLYP, UNDETERMINED | C3340 | A protruding growth attached to the underlying tissue by a broad base or a thin stalk, which can be either inflammatory, hamartomatous, or neoplastic. | Polyp | |||
POLYP, VAGINAL, BENIGN | C3664 | POLYP OF THE VAGINA;POLYP OF VAGINA | A benign polypoid growth arising from the vaginal wall. | Vaginal Polyp | ||
RETICULOSIS, MALIGNANT | C4684 | ANGIOCENTRIC T-CELL LYMPHOMA | A malignant lymphoid neoplasm composed of EBV-positive NK/T cells arranged in an angiocentric pattern. | Nasal Type Extranodal NK/T-Cell Lymphoma | ||
RETINOBLASTOMA, MALIGNANT | C7541 | RB | A malignant neoplasm originating in the nuclear layer of the retina. | Retinoblastoma | ||
RHABDOMYOMA, BENIGN | C3358 | A benign neoplasm arising from skeletal muscle, characterized by the presence of rhabdomyoblasts. | Rhabdomyoma | |||
RHABDOMYOSARCOMA, MALIGNANT | C3359 | A malignant mesenchymal neoplasm arising from skeletal muscle. | Rhabdomyosarcoma | |||
SARCOMA, GRANULOCYTIC, MALIGNANT | C35815 | A malignant neoplasm composed of myeloblasts, neutrophils and neutrophil precursors. | Granulocytic Sarcoma | |||
SARCOMA, HISTIOCYTIC, MALIGNANT | C27349 | A malignant neoplasm composed of cells resembling histiocytes. | Histiocytic Sarcoma | |||
SARCOMA, LEPTOMENINGEAL, MALIGNANT | C8312 | SARCOMA, MENINGEAL;SARCOMA OF LEPTOMENINGES;SARCOMA OF THE LEPTOMENINGES | A malignant mesenchymal neoplasm arising from the leptomeninges. | Leptomeningeal Sarcoma | ||
SARCOMA, MALIGNANT | C9118 | SARCOMA OF SOFT TISSUE AND BONE;SARCOMA OF THE SOFT TISSUE AND BONE;SARCOMA;MESENCHYMAL TUMOR, MALIGNANT | A malignant mesenchymal neoplasm. A general term for which the transformed cell type has not been specified. | Sarcoma | ||
SARCOMA, MYELOID, MALIGNANT | C3520 | CHLOROMA;EXTRAMEDULLARY MYELOID TUMOR | A malignant neoplasm composed of myeloblasts or immature myeloid cells. It occurs in extramedullary sites or the bone. | Myeloid Sarcoma | ||
SARCOMA, SYNOVIAL, MALIGNANT | C3400 | SS | A malignant neoplasm that usually arises in the synovial membranes of the joints and the synovial cells of the tendons and bursae. | Synovial Sarcoma | ||
SCHWANNOMA, BENIGN | C3269 | NEURILEMMOMA;SCHWANNOMA;NEURINOMA;SCHWANNOMA (WHO GRADE I) | A benign neoplasm of the peripheral nervous system composed of well-differentiated Schwann cells. | Schwannoma | ||
SEMINOMA, MALIGNANT | C9309 | SEMINOMA, PURE;SEMINOMA | A malignant germ cell neoplasm of the testis. | Seminoma | ||
SERTOLI CELL TUMOR, BENIGN | C67012 | BENIGN ANDROBLASTOMA | A benign neoplasm of the testis or ovary, originating from Sertoli cells. | Benign Sertoli Cell Tumor | ||
SERTOLI CELL TUMOR, MALIGNANT | C67006 | MALIGNANT ANDROBLASTOMA | A malignant neoplasm of the testis or ovary, originating from Sertoli cells. | Malignant Sertoli Cell Tumor | ||
SERTOLI CELL TUMOR, UNDETERMINED | C98794 | An ovarian neoplasm comprising Sertoli cells in which the malignancy status has not been established. | Undetermined Sertoli Cell Tumor | |||
STROMAL NEPHROMA, MALIGNANT | C6569 | CMN;MESOBLASTIC NEPHROMA | A congenital malignant neoplasm of the kidney characterized by the presence of fibroblastic cells. | Congenital Mesoblastic Nephroma | ||
STROMAL SARCOMA, ENDOMETRIAL, MALIGNANT | C8973 | ESS | A malignant, mesenchymal tumor of the uterine stroma. | Endometrioid Stromal Sarcoma | ||
STROMAL SARCOMA, MALIGNANT | C6926 | STROMAL TUMOR, MALIGNANT | A malignant neoplasm characterized by the presence of atypical mesenchymal-stromal cells. | Stromal Sarcoma | ||
STROMAL TUMOR, BENIGN | C66772 | A benign neoplasm composed of mesenchymal stromal cells. | Benign Stromal Tumor | |||
STROMAL TUMOR, GONADAL, MALIGNANT | C67561 | SEX CORD STROMAL TUMOR, MALIGNANT | A malignant neoplasm originating from the gonadal sex cord stroma. | Malignant Sex Cord-Stromal Tumor | ||
STROMAL TUMOR, GONADAL, UNDETERMINED | C3794 | SEX CORD-STROMAL TUMOR, UNDETERMINED;SEX CORD-STROMAL NEOPLASM | A neoplasm originating from the gonadal sex cord stroma, for which the status of malignancy has not been determined. | Sex Cord-Stromal Tumor | ||
SUBEPENDYMOMA, BENIGN | C3795 | WHO GRADE I EPENDYMAL TUMOR;WHO GRADE I EPENDYMAL NEOPLASM;SUBEPENDYMAL GLIOMA | A benign neoplasm of the brain localized in the vicinity of a ventricular wall and is composed of glial tumor cell clusters embedded in an abundant fibrillary matrix with frequent microcystic changes. | Subependymoma | ||
SYNOVIOMA, BENIGN | C3829 | BENIGN NEOPLASM OF SYNOVIUM;BENIGN SYNOVIOMA;BENIGN NEOPLASM OF THE SYNOVIUM;BENIGN TUMOR OF THE SYNOVIUM;BENIGN TUMOR OF SYNOVIUM;BENIGN SYNOVIAL TUMOR | A benign neoplasm arising from the synovial membrane. | Benign Synovial Neoplasm | ||
TERATOMA, BENIGN | C67107 | A benign germ-cell neoplasm derived from pluripotent cells and consisting of components from one or more of the three germ-cell layers. | Benign Teratoma | |||
TERATOMA, MALIGNANT | C4286 | IMMATURE TERATOMA | A malignant germ-cell neoplasm derived from pluripotent cells and consisting of components from one or more of the three germ-cell layers. | Immature Teratoma | ||
TERATOMA, UNDETERMINED | C3403 | A germ-cell neoplasm derived from pluripotent cells and consisting of components from one or more of the three germ-cell layers, for which the malignancy status has not been established. | Teratoma | |||
THECOMA, BENIGN | C5219 | THECAL CELL TUMOR, BENIGN;BENIGN THECAL CELL NEOPLASM OF THE OVARY;BENIGN OVARIAN THECAL CELL TUMOR;BENIGN OVARIAN THECAL CELL NEOPLASM;BENIGN THECAL CELL TUMOR OF THE OVARY;BENIGN THECAL CELL TUMOR OF OVARY;BENIGN THECOMA OF THE OVARY;BENIGN THECOMA OF OVARY;BENIGN THECAL CELL NEOPLASM OF OVARY | A benign sex-cord neoplasm of the ovary, originating from theca cells. | Benign Ovarian Thecoma | ||
THECOMA, OVARIAN, MALIGNANT | C6929 | THECOMA, MALIGNANT;MALIGNANT THECOMA OF THE OVARY;MALIGNANT THECAL CELL NEOPLASM OF THE OVARY;MALIGNANT THECAL CELL NEOPLASM OF OVARY;MALIGNANT OVARIAN THECAL CELL NEOPLASM;MALIGNANT THECAL CELL TUMOR OF THE OVARY;MALIGNANT THECOMA OF OVARY;MALIGNANT OVARIAN THECAL CELL TUMOR;MALIGNANT THECAL CELL TUMOR OF OVARY | A malignant sex-cord neoplasm of the ovary, originating from theca cells. | Malignant Ovarian Thecoma | ||
THYMOMA, BENIGN | C66746 | A benign neoplasm of the thymus, originating from epithelial thymus cells. | Benign Thymoma | |||
THYMOMA, MALIGNANT | C7612 | A malignant neoplasm of the thymus, originating from epithelial thymus cells. | Malignant Thymoma | |||
THYMOMA, UNDETERMINED | C3411 | A neoplasm of the thymus, originating from epithelial thymus cells, for which the malignancy status has not been established. | Thymoma | |||
TRICHOEPITHELIOMA, BENIGN | C27132 | BROOKE'S TUMOR;TRICHOGENIC TRICHOBLASTOMA;TRICHOGENIC ADNEXAL TUMOR;TRICHOEPITHELIOMA | A benign hair follicle neoplasm with trichoblastic differentiation. | Trichoblastoma | ||
YOLK SAC TUMOR, MALIGNANT | C3011 | ENDODERMAL SINUS TUMOR;YOLK SAC TUMOR SITE UNSPECIFIED;YOLK SAC NEOPLASM;ENDODERMAL SINUS NEOPLASM | A non-seminomatous malignant germ cell tumor composed of primitive germ cells and which produce an eosinophilic substance (alpha-fetoprotein). | Yolk Sac Tumor | ||
SARCOMA, UNDIFFERENTIATED, MALIGNANT | C27096 | EMBRYONAL SARCOMA, UNDIFFERENTIATED | A rare malignant neoplasm of the liver that is most common in youth. | Undifferentiated (Embryonal) Sarcoma | ||
CARDIAC SCHWANNOMA, BENIGN | C5358 | SCHWANNOMA, ENDOCARDIAL, BENIGN | A benign peripheral nervous system neoplasm that is composed of well-differentiated Schwann cells and affects the heart. | Benign Cardiac Schwannoma | ||
ARRHENOBLASTOMA, BENIGN | C4209 | ARRHENOBLASTOMA, BENIGN | A benign Sertoli-Leydig neoplasm of the ovary characterized by the presence of Sertoli cells in tubules without evidence of significant nuclear atypia or mitotic activity. | Well Differentiated Ovarian Sertoli-Leydig Cell Tumor | ||
ARRHENOBLASTOMA, MALIGNANT | C4210 | ARRHENOBLASTOMA, MALIGNANT | A malignant Sertoli-Leydig neoplasm of the ovary characterized by the presence of a sarcomatoid stroma which contains primitive gonadal stromal cells. | Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor | ||
ASTROCYTOMA, DIFFUSE, MALIGNANT | C7173 | ASTROCYTOMA, DIFFUSE | A malignant astrocytic neoplasm characterized by a high degree of cellular differentiation, slow growth, and diffuse infiltration of neighboring brain structures. | Diffuse Astrocytoma | ||
BASALIOMA, BENIGN | C103391 | BASALIOMA | A benign epithelial neoplasm arising from primary epithelial germ cells of the piliary complex. | Experimental Organism Benign Basalioma | ||
CONNECTIVE AND SOFT TISSUE NEOPLASM, BENIGN | C53684 | BENIGN CONNECTIVE AND SOFT TISSUE NEOPLASM;BENIGN CONNECTIVE AND SOFT TISSUE TUMOR;BENIGN MESENCHYMAL CELL NEOPLASM;BENIGN NEOPLASM OF THE SOFT TISSUE AND BONE;BENIGN TUMOR OF THE SOFT TISSUE AND BONE | A benign neoplasm arising from connective and soft tissues that does not invade adjacent tissues or metastasize to other anatomic sites. | Benign Connective and Soft Tissue Neoplasm | ||
HIBERNOMA, MALIGNANT | C103394 | MALIGNANT HIBERNOMA | A malignant neoplasm arising from the brown adipose tissue in animals, usually in the subcutis and the thoracic cavity. | Experimental Organism Malignant Hibernoma | ||
OSTEOFIBROMA, BONE, BENIGN | C103392 | OSTEOFIBROMA, BONE | A benign neoplasm, morphologically a fibroma with osseous components. | Experimental Organism Benign Bone Osteofibroma | ||
PERIPHERAL CHOLANGIOCARCINOMA, MALIGNANT | C96805 | PERIPHERAL CHOLANGIOCARCINOMA | A malignant intrahepatic neoplasm arising from the small interlobular bile ducts. | Peripheral Intrahepatic Cholangiocarcinoma | ||
Back to top | ||||||
CL.C99079.EPOCH | Epoch (EPOCH) | text Extensible: Yes | C99079 | Epoch | The name of the EPOCH. | CDISC SDTM Epoch Terminology |
FOLLOW-UP | C99158 | A period in a clinical study during which information about the health status of an individual is obtained after study procedures and treatments have concluded. | Clinical Study Follow-up | |||
RUN-IN | C98779 | A period in a clinical study that occurs before the commencement of the primary clinical study investigation, during which subjects may be assessed for suitability in the clinical study, withdrawn from existing therapy, trained in study methodology or evaluated for any other protocol-specified reason. | Run-in Period | |||
SCREENING | C48262 | A period in a clinical study during which subjects are evaluated for participation in the study. | Trial Screening | |||
TREATMENT | C101526 | A period in a clinical study during which subjects receive therapeutic treatment. | Treatment Epoch | |||
WASHOUT | C42872 | A period of time during a clinical study when a participant is taken off of a study drug or other medication in order to eliminate the effects of the treatment. | Washout Period | |||
BLINDED TREATMENT | C102255 | A period in a clinical study during which subjects receive blinded therapeutic treatment. | Blinded Treatment Epoch | |||
OPEN LABEL TREATMENT | C102256 | A period in a clinical study during which subjects receive open label therapeutic treatment. | Open Label Treatment Epoch | |||
LONG-TERM FOLLOW-UP | C16032 | A period in a clinical study during which information about the health status of an individual is obtained long after study procedures and treatments have concluded. | Longterm Follow-up | |||
Back to top | ||||||
CL.C99076.INTMODEL | Intervention Model (INTMODEL) | text Extensible: Yes | C99076 | Intervention Model | The trial design developed to compare treatment groups. | CDISC SDTM Intervention Model Terminology |
CROSS-OVER | C82637 | Participants receive one of two or more alternative intervention(s) during the initial epoch of the study and receive other intervention(s) during the subsequent epoch(s) of the study. | Crossover Study | |||
FACTORIAL | C82638 | Two or more interventions, each alone and in combination, are evaluated in parallel against a control group. | Factorial Study | |||
PARALLEL | C82639 | Participants are assigned to one of two or more arms in parallel for the duration of the study. | Parallel Study | |||
SINGLE GROUP | C82640 | Single arm study. | Single Group Study | |||
Back to top | ||||||
CL.C99078.INTTYPE | Intervention Type (INTTYPE) | text Extensible: No | C99078 | Intervention Type | The kind of product or procedure studied in a trial. | CDISC SDTM Intervention Type Terminology |
DIETARY SUPPLEMENT | C1505 | Oral preparations containing dietary ingredient(s) intended to supplement the diet. Dietary ingredients include vitamins, minerals, herbs, amino acids, extracts and metabolites. | Dietary Supplement | |||
BEHAVIORAL THERAPY | C15184 | A technique used to change subjects' behavior, for example, psychotherapy, lifestyle counseling or hypnosis. | Behavioral Intervention | |||
BIOLOGIC | C307 | A substance made from living organisms or things they produce, for example: virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product. | Biological Agent | |||
DEVICE | C16830 | An instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is recognized in the official National Formulary, or the United States Pharmacopeia, or any supplement to them, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes. (FDA) | Medical Device | |||
DRUG | C1909 | An active natural, synthetic or semi-synthetic ingredient including endogenous body substance that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient (21 CFR 314.3(b)). | Pharmacologic Substance | |||
GENETIC | C15238 | Application of genetic material into cells in order to correct an inherited or acquired disease. | Gene Therapy | |||
OTHER | C17649 | Other | Different than the one(s) previously specified or mentioned. (NCI) | Other | ||
PROCEDURE | C98769 | A treatment procedure performed by manual and/or instrumental means, for example: surgery, lithotripsy, or external manipulation. | Physical Medical Procedure | |||
RADIATION | C15313 | Treatment of a disease by means of exposure of the target or the whole body to radiation. | Radiation Therapy | |||
Back to top | ||||||
CL.C99077.STYPE | Study Type (STYPE) | text Extensible: No | C99077 | Study Type | Describes the role the study plays in determining the interventions a subject receives. | CDISC SDTM Study Type Terminology |
EXPANDED ACCESS | C98722 | Studies that provide a means for obtaining an experimental drug or device for patients who are not adequately treated by existing therapy, who do not meet the eligibility criteria for enrollment, or who are otherwise unable to participate in another clinical study. Expanded Access studies include individual-patient IND, treatment IND, compassionate use, emergency use or continued access. | Expanded Access Study | |||
INTERVENTIONAL | C98388 | Studies in which individuals are assigned by an investigator based on a protocol to receive specific interventions. Subjects may receive diagnostic, therapeutic or other types of interventions. The assignment of the intervention may or may not be random. The individuals are then followed and biomedical and/or health outcomes are assessed. | Interventional Study | |||
OBSERVATIONAL | C16084 | Studies in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study. | Observational Study | |||
Back to top | ||||||
CL.C100130.RELSUB | Relationship to Subject (RELSUB) | text Extensible: Yes | C100130 | Relationship to Subject | The relationship of a person to a study subject. | CDISC SDTM Relationship to Subject Terminology |
AUNT, BIOLOGICAL | C96569 | Biological Aunt | A female relative who is a sibling of either of the biological parents, and who share a common ancestor. (NCI) | Biological Aunt | ||
AUNT, BIOLOGICAL MATERNAL | C96575 | Biological Maternal Aunt | A female relative who is a sibling of the biological mother, and who both share a common ancestor. (NCI) | Biological Maternal Aunt | ||
AUNT, BIOLOGICAL PATERNAL | C96581 | Biological Paternal Aunt | A female relative who is a sibling of the biological father, and who both share a common ancestor. (NCI) | Biological Paternal Aunt | ||
BROTHER, BIOLOGICAL | C96570 | Biological Brother | A male who shares with his sibling the genetic makeup inherited from one or both of their shared biological parents. | Biological Brother | ||
BROTHER, BIOLOGICAL MATERNAL HALF | C96656 | Half-brother with Mother as Common Parent | A male who shares with his sibling the genetic makeup inherited from only the biological mother. | Half-brother with Mother as Common Parent | ||
BROTHER, BIOLOGICAL PATERNAL HALF | C96655 | Half-brother with Father as Common Parent | A male who shares with his sibling the genetic makeup inherited from only the biological father. | Half-brother with Father as Common Parent | ||
BROTHER, HALF | C71402 | Half Brother | A male who shares with his sibling the genetic makeup inherited from only one of the biological parents. | Half Brother | ||
CAREGIVER | C17445 | Caregiver | The primary person in charge of the care of a patient, usually a family member or a designated health care professional. (NCI) | Caregiver | ||
CHILD, BIOLOGICAL | C100807 | Biological Child | A son or daughter with genetic makeup inherited from the parent. | Biological Child | ||
CLINICIAN | C85499 | Clinician | An individual, such as a physician, nurse practitioner or other health care professional, who takes responsibility for a subject's care. | Clinician | ||
COUSIN, BIOLOGICAL | C96571 | Biological Cousin | A relative who is the offspring of a sibling of either of the biological parents, and who share a common ancestor. (NCI) | Biological Cousin | ||
COUSIN, BIOLOGICAL MATERNAL | C96576 | Biological Maternal Cousin | A relative who is the offspring of a sibling of the biological mother and share a common ancestor. | Biological Maternal Cousin | ||
COUSIN, BIOLOGICAL PATERNAL | C96582 | Biological Paternal Cousin | A relative who is the offspring of a sibling of the biological father and share a common ancestor. | Biological Paternal Cousin | ||
DOMESTIC PARTNER | C53262 | Domestic Partner | Person declares that a domestic partnership relationship exists. (HL7) | Domestic Partnership | ||
DONOR | C48284 | Donor | One that contributes something. (NCI) | Donor | ||
DONOR, ORGAN | C100810 | Organ Donor | Someone from whom an organ is removed for transplantation or other purpose. | Organ Donor | ||
DONOR, TISSUE | C25168 | Tissue Donor | Someone from whom tissue is removed for transplantation or other purpose. | Tissue Donor | ||
FAMILY MEMBER | C41256 | Family Member | Any of the individuals who are descended from a common progenitor, related by marriage or other legal tie. | Family Member | ||
FATHER, BIOLOGICAL | C96572 | Biological Father | A male who contributes to the genetic makeup of his offspring through the fertilization of an ovum by his sperm. (NCI) | Biological Father | ||
GRANDCHILD, BIOLOGICAL | C100805 | Biological Grandchild | A biological child of an individual's biological child. | Biological Grandchild | ||
GRANDFATHER, BIOLOGICAL | C96573 | Biological Grandfather | A male relative who is the biological father of either the biological mother or the biological father. (NCI) | Biological Grandfather | ||
GRANDFATHER, BIOLOGICAL MATERNAL | C96577 | Biological Maternal Grandfather | A male relative who is the biological father of the biological mother. (NCI) | Biological Maternal Grandfather | ||
GRANDFATHER, BIOLOGICAL PATERNAL | C96583 | Biological Paternal Grandfather | A male relative who is the biological father of the biological father. (NCI) | Biological Paternal Grandfather | ||
GRANDMOTHER, BIOLOGICAL | C96574 | Biological Grandmother | A female relative who is the biological mother of either the biological mother or the biological father. (NCI) | Biological Grandmother | ||
GRANDMOTHER, BIOLOGICAL MATERNAL | C96578 | Biological Maternal Grandmother | A female relative who is the biological mother of the biological mother. (NCI) | Biological Maternal Grandmother | ||
GRANDMOTHER, BIOLOGICAL PATERNAL | C96584 | Biological Paternal Grandmother | A female relative who is the biological mother of the biological father. (NCI) | Biological Paternal Grandmother | ||
GRANDPARENT, BIOLOGICAL | C100806 | Biological Grandparent | A biological parent of the biological father or biological mother. | Biological Grandparent | ||
MOTHER, BIOLOGICAL | C96580 | Biological Mother | A female who contributes to the genetic makeup of her offspring from the fertilization of her ovum. (NCI) | Biological Mother | ||
NURSE | C20821 | Nurse | A professional healthcare provider who has graduated from a nursing program. | Nurse | ||
PREGNANCY PARTNER | C100811 | Pregnancy Partner | An individual who provides support to a pregnant individual. | Pregnancy Partner | ||
RELATIVE, FIRST DEGREE | C21481 | First Degree Relative | Any individual related biologically or legally to another individual and considered immediate family as in the case of a spouse, parent, sibling or child. | First Degree Relative | ||
RELATIVE, SECOND DEGREE | C19811 | Second Degree Relative | Any individual related biologically or legally to another individual and considered one degree removed from the immediate family as in the case of in-laws, grandparents, aunts and uncles. | Second Degree Relative | ||
RELATIVE, THIRD DEGREE | C100808 | Third Degree Relative | Any individual related biologically or legally to another individual and considered two degrees removed from the immediate family as in the case of cousins. | Third Degree Relative | ||
SEXUAL PARTNER | C100812 | Sexual Partner | A person with whom one has had sexual relations. | Sexual Partner | ||
SIBLING, BIOLOGICAL | C100809 | Biological Sibling | A person's brother or sister with whom they share a genetic makeup inherited from their shared biological parents. | Biological Sibling | ||
SISTER, BIOLOGICAL | C96586 | Biological Sister | A female who shares with her sibling the genetic makeup inherited from one or both of their shared biological parents. | Biological Sister | ||
SISTER, BIOLOGICAL MATERNAL HALF | C96658 | Half-sister with Mother as Common Parent | A female who shares with her sibling the genetic makeup inherited from only the biological mother. | Half-sister with Mother as Common Parent | ||
SISTER, BIOLOGICAL PATERNAL HALF | C96657 | Half-sister with Father as Common Parent | A female who shares with her sibling the genetic makeup inherited from only the biological father. | Half-sister with Father as Common Parent | ||
SISTER, HALF | C71403 | Half Sister | A female who shares with her sibling the genetic makeup inherited from only one of the biological parents. | Half Sister | ||
SPOUSE | C62649 | Spouse | A person's partner in marriage. (NCI) | Spouse | ||
TECHNICIAN | C63861 | Technician | A person skilled in the performance of the technical or procedural aspects of a profession. (NCI) | Technician | ||
TWIN | C73427 | Twin | Either of two offspring born from the same pregnancy. (NCI) | Twin | ||
TWIN, DIZYGOTIC | C73428 | Dizygotic Twin | Either of the two offspring resulting from two separately fertilized ovums during the same pregnancy. | Fraternal Twin | ||
TWIN, MONOZYGOTIC | C73429 | Monozygotic Twin | Either of the two offspring resulting from a shared ovum. (NCI) | Identical Twin | ||
UNCLE, BIOLOGICAL | C96587 | Biological Uncle | A male relative who is a sibling of either of the biological parents, and who share a common ancestor. (NCI) | Biological Uncle | ||
UNCLE, BIOLOGICAL MATERNAL | C96579 | Biological Maternal Uncle | A male relative who is a sibling of the biological mother, and who both share a common ancestor. (NCI) | Biological Maternal Uncle | ||
UNCLE, BIOLOGICAL PATERNAL | C96585 | Biological Paternal Uncle | A male relative who is a sibling of the biological father, and who both share a common ancestor. (NCI) | Biological Paternal Uncle | ||
Back to top | ||||||
CL.C101865.ACSPCAT | Acute Coronary Syndrome Presentation Category (ACSPCAT) | text Extensible: No | C101865 | Acute Coronary Syndrome Presentation Category | A classification of the presentation of acute coronary syndrome. | CDISC SDTM Acute Coronary Syndrome Presentation Category Terminology |
NON-ST ELEVATION MYOCARDIAL INFARCTION | C80383 | NSTEMI;NON-STEMI | A myocardial infarction that does not produce elevation in the ST segments of the ECG. | Non-ST Elevation Myocardial Infarction | ||
OTHER | C17649 | Other | Different than the one(s) previously specified or mentioned. (NCI) | Other | ||
ST ELEVATION MYOCARDIAL INFARCTION | C101888 | STEMI | A myocardial infarction that produces elevation in the ST segments of the ECG. | ST Elevation Myocardial Infarction by ECG Finding | ||
STABLE ANGINA | C66914 | Angina pectoris which has not recently changed in frequency, duration or intensity. Stable angina pectoris is relieved by rest or administration of oral, sublingual or transdermal antianginal medications. | Stable Angina | |||
UNSTABLE ANGINA | C66911 | Angina pectoris (or equivalent type of ischemic discomfort) which has recently changed in frequency, duration, intensity, or occurs at rest. | Unstable Angina | |||
Back to top | ||||||
CL.C101842.CACRDSC | Canadian Cardiovascular Society Classification (CACRDSC) | text Extensible: No | C101842 | Canadian Cardiovascular Society Classification | The anginal classifications as measured by the Canadian Cardiovascular Society grading scale. | CDISC SDTM Canadian Cardiovascular Society Classification Terminology |
CCS CLASS 1 | C77265 | Canadian Cardiovascular Society Classification 1 | Ordinary physical activity, such as walking or climbing stairs, does not cause angina. Angina occurs with strenuous, rapid, or prolonged exertion at work or recreation. | Canadian Cardiovascular Society Grading Scale Class I | ||
CCS CLASS 2 | C77266 | Canadian Cardiovascular Society Classification 2 | Slight limitation of ordinary activity. Angina occurs on walking or climbing stairs rapidly, walking uphill, walking or climbing stairs after meals, or in cold, in wind, or under emotional stress, or only during the few hours after awakening. Angina occurs on walking more than 2 blocks on the level and climbing more than 1 flight of ordinary stairs at a normal pace and in normal conditions. | Canadian Cardiovascular Society Grading Scale Class II | ||
CCS CLASS 3 | C77267 | Canadian Cardiovascular Society Classification 3 | Marked limitations of ordinary physical activity. Angina occurs on walking 1 to 2 blocks on the level and climbing 1 flight of stairs in normal conditions and at a normal pace. | Canadian Cardiovascular Society Grading Scale Class III | ||
CCS CLASS 4 | C77268 | Canadian Cardiovascular Society Classification 4 | Inability to perform any physical activity without discomfort - anginal symptoms may be present at rest. | Canadian Cardiovascular Society Grading Scale Class IV | ||
Back to top | ||||||
CL.C101843.CADPRSN | Coronary Artery Disease Presentation (CADPRSN) | text Extensible: No | C101843 | Coronary Artery Disease Presentation | A terminology codelist associated with coronary artery disease presentation. | CDISC SDTM Coronary Artery Disease Presentation Terminology |
NON-ST ELEVATION MYOCARDIAL INFARCTION | C80383 | NSTEMI;NON-STEMI | A myocardial infarction that does not produce elevation in the ST segments of the ECG. | Non-ST Elevation Myocardial Infarction | ||
ST ELEVATION MYOCARDIAL INFARCTION | C101888 | STEMI | A myocardial infarction that produces elevation in the ST segments of the ECG. | ST Elevation Myocardial Infarction by ECG Finding | ||
STABLE ANGINA | C66914 | Angina pectoris which has not recently changed in frequency, duration or intensity. Stable angina pectoris is relieved by rest or administration of oral, sublingual or transdermal antianginal medications. | Stable Angina | |||
UNSTABLE ANGINA | C66911 | Angina pectoris (or equivalent type of ischemic discomfort) which has recently changed in frequency, duration, intensity, or occurs at rest. | Unstable Angina | |||
VARIANT ANGINA | C66915 | A variant form of angina pectoris caused by coronary artery vasospasm, usually occurring spontaneously and frequently associated with ST segment elevation. | Variant Angina | |||
Back to top | ||||||
CL.C101849.CADRISK | Coronary Artery Disease Risk (CADRISK) | text Extensible: No | C101849 | Coronary Artery Disease Risk | A terminology codelist to describe the relative risk of coronary artery disease. | CDISC SDTM Coronary Artery Disease Risk Terminology |
HIGH CAD RISK | C99955 | High Coronary Artery Disease Risk | The likelihood an individual will develop coronary artery disease is almost certain or greater than 90%. (Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Mooss AN, O'Reilly MG, Winters WL Jr. ACC/AHA 2002 guideline update for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). 2002. American College of Cardiology Web site. Available at: www.acc.org/clinical/guidelines/exercise/dirIndex.htm.) | High Coronary Artery Disease Risk | ||
INTERMEDIATE CAD RISK | C99966 | Intermediate Coronary Artery Disease Risk | The likelihood an individual will develop coronary artery disease (CAD) is moderate or between 10% and 90%. (Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Mooss AN, O'Reilly MG, Winters WL Jr. ACC/AHA 2002 guideline update for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). 2002. American College of Cardiology Web site. Available at: www.acc.org/clinical/guidelines/exercise/dirIndex.htm.) | Intermediate Coronary Artery Disease Risk | ||
KNOWN CAD | C99968 | Known Coronary Artery Disease | The individual has coronary artery disease (CAD). (Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Mooss AN, O'Reilly MG, Winters WL Jr. ACC/AHA 2002 guideline update for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). 2002. American College of Cardiology Web site. Available at: www.acc.org/clinical/guidelines/exercise/dirIndex.htm.) | Known Coronary Artery Disease | ||
LOW CAD RISK | C99978 | Low Coronary Artery Disease Risk | The likelihood an individual will develop coronary artery disease (CAD) is minimal or less than10%.(Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, Mark DB, McCallister BD, Mooss AN, O'Reilly MG, Winters WL Jr. ACC/AHA 2002 guideline update for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). 2002. American College of Cardiology Web site. Available at: www.acc.org/clinical/guidelines/exercise/dirIndex.htm.) | Low Coronary Artery Disease Risk | ||
Back to top | ||||||
CL.C101844.CADSYMP | Coronary Artery Disease Symptoms (CADSYMP) | text Extensible: No | C101844 | Coronary Artery Disease Symptoms | A terminology codelist that contains symptoms associated with coronary artery disease. | CDISC SDTM Coronary Artery Disease Symptoms Terminology |
ATYPICAL CORONARY ARTERY DISEASE SYMPTOMS | C99917 | Sharp stabbing chest pain or reproduction of pain on palpation. Less common isolated presentations, primarily in older adults, include nausea and vomiting, diaphoresis, and unexplained fatigue. J Am Coll Cardiol, 2007; 50:1-157, doi:10.1016/j.jacc.2007.02.013 (Published online 6 August 2007). | Atypical Coronary Artery Disease Symptom | |||
NO SYMPTOMS | C3833 | The finding of no indications of a particular disease or injury. | Asymptomatic | |||
NON-CARDIAC CHEST PAIN | C78504 | A discomfort in the chest area that is not related to the heart. | Non-Cardiac Chest Pain | |||
TYPICAL CORONARY ARTERY DISEASE SYMPTOMS | C100024 | Deep, poorly localized chest or arm discomfort that is reproducibly associated with physical exertion or emotional stress and is relieved promptly (ie, in less than 5 minutes) with rest and/or the use of sublingual nitroglycerin. Some patients may have no chest discomfort but present solely with jaw, neck, ear, arm, shoulder, back, or epigastric discomfort or with unexplained dyspnea without discomfort. If these symptoms have a clear relationship to exertion or stress or are relieved promptly with nitrates, they should be considered equivalent to angina. J Am Coll Cardiol, 2007; 50:1-157, doi:10.1016/j.jacc.2007.02.013 (Published online 6 August 2007). | Typical Coronary Artery Disease Symptom | |||
Back to top | ||||||
CL.C101860.CARTDOM | Coronary Artery Dominance (CARTDOM) | text Extensible: No | C101860 | Coronary Artery Dominance | A codelist to describe whether the posterior descending artery comes from the right or left vessel system. | CDISC SDTM Coronary Artery Dominance Terminology |
CO-DOMINANT | C99941 | The right coronary artery supplies the posterior descending artery (PDA) and the circumflex supplies the posterolateral artery (PLA). Thus, there is approximately equal contribution to the inferior surface of the left ventricle from both the left circumflex and right coronary arteries. | Co-Dominant Artery | |||
LEFT DOMINANCE | C99971 | The posterior descending artery (PDA) and posterolateral artery (PLA) arises from the left circumflex artery. | Left Cardiac Artery Dominance | |||
RIGHT DOMINANCE | C99942 | The posterior descending artery (PDA) and posterolateral artery (PLA) arises from the right coronary artery. | Coronary Artery Right Dominance | |||
Back to top | ||||||
CL.C101838.CCRCLSCD | Consensus Cardiac Classification System Test Code (CCRCLSCD) | text Extensible: Yes | C101838 | Consensus Cardiac Classification System Test Code | Classification system test code for cardiac parameters that are authored or endorsed by organizations. | CDISC SDTM Consensus Cardiac Classification Systems Test Code Terminology |
CCSGRDS | C66910 | Canadian CV Society Grading Scale | A finding associated with a patient based on the functional classification developed by the Canadian Cardiovascular Society (CCS), for categorizing patients with angina. The classification system comprises four classes, which are defined in terms of the level of physical activity associated with the subject's anginal symptoms. | Canadian Cardiovascular Society Grading Scale | ||
KILLIPCL | C66916 | Killip Class | A finding associated with a patient based on the classification developed by Killip and Kimball, which classifies patients with myocardial infarction based on routine physical examination parameters, such as the presence or absence of rales, or a decreased systolic blood pressure. | Killip Class | ||
LSNCPCLS | C100032 | ACC/AHA Lesion Complexity Class | A classification system for coronary stenosis based upon characteristics that influence the difficulty of percutaneous coronary revascularization. | American College of Cardiology American Heart Association Lesion Complexity Class | ||
NYHACLS | C66909 | New York Heart Association Class | A finding associated with a patient based on the functional classification developed by the New York Heart Association (NYHA), for categorizing patients with defined or presumed cardiac disease. The classification system is based on the ability to engage in physical activity. The classification system comprises four classes, though NYHA Class III and Class IV are often aggregated for the purpose of outcomes analysis. | New York Heart Association Class | ||
TIMIFLOW | C100021 | TIMI Flow | A grading system for coronary blood flow based on the classification developed by the Thrombolysis in Myocardial Infarction Group. It classifies coronary blood flow into four classes based upon the angiographic appearance of the blood vessels. | Thrombolysis in Myocardial Infarction Flow | ||
Back to top | ||||||
CL.C101837.CCRCLS | Consensus Cardiac Classification System Test Name (CCRCLS) | text Extensible: Yes | C101837 | Consensus Cardiac Classification System Test Name | Classification system test name for cardiac parameters that are authored or endorsed by organizations. | CDISC SDTM Consensus Cardiac Classification Systems Test Name Terminology |
Canadian CV Society Grading Scale | C66910 | Canadian CV Society Grading Scale | A finding associated with a patient based on the functional classification developed by the Canadian Cardiovascular Society (CCS), for categorizing patients with angina. The classification system comprises four classes, which are defined in terms of the level of physical activity associated with the subject's anginal symptoms. | Canadian Cardiovascular Society Grading Scale | ||
Killip Class | C66916 | Killip Class | A finding associated with a patient based on the classification developed by Killip and Kimball, which classifies patients with myocardial infarction based on routine physical examination parameters, such as the presence or absence of rales, or a decreased systolic blood pressure. | Killip Class | ||
ACC/AHA Lesion Complexity Class | C100032 | ACC/AHA Lesion Complexity Class | A classification system for coronary stenosis based upon characteristics that influence the difficulty of percutaneous coronary revascularization. | American College of Cardiology American Heart Association Lesion Complexity Class | ||
New York Heart Association Class | C66909 | New York Heart Association Class | A finding associated with a patient based on the functional classification developed by the New York Heart Association (NYHA), for categorizing patients with defined or presumed cardiac disease. The classification system is based on the ability to engage in physical activity. The classification system comprises four classes, though NYHA Class III and Class IV are often aggregated for the purpose of outcomes analysis. | New York Heart Association Class | ||
TIMI Flow | C100021 | TIMI Flow | A grading system for coronary blood flow based on the classification developed by the Thrombolysis in Myocardial Infarction Group. It classifies coronary blood flow into four classes based upon the angiographic appearance of the blood vessels. | Thrombolysis in Myocardial Infarction Flow | ||
Back to top | ||||||
CL.C101866.CRYDFMAN | Cardiac Rhythm Device Failure Manifestation (CRYDFMAN) | text Extensible: Yes | C101866 | Cardiac Rhythm Device Failure Manifestation | The effect that a cardiac rhythm device malfunction had on the ability to stimulate the heart. | CDISC SDTM Cardiac Rhythm Device Failure Manifestation Terminology |
ATRIAL PACING MALFUNCTION | C99921 | The cardiac rhythm device malfunction affected atrial pacing. | Cardiac Atrial Pacing Malfunction | |||
DEFIBRILLATION MALFUNCTION | C99923 | The cardiac rhythm device malfunction affected the defibrillator. | Cardiac Defibrillator Malfunction | |||
LEFT VENTRICULAR PACING MALFUNCTION | C99973 | The cardiac rhythm device malfunction affected the left ventricular (LV) pacing. | Left Cardiac Ventricular Pacing Malfunction | |||
RIGHT VENTRICULAR PACING MALFUNCTION | C100011 | The cardiac rhythm device malfunction affected the right ventricular (RV) pacing. | Right Cardiac Ventricle Pacing Malfunction | |||
Back to top | ||||||
CL.C101864.CSLVLNIM | Reason CS/LV Lead Not Implanted (CSLVLNIM) | text Extensible: No | C101864 | Reason CS/LV Lead Not Implanted | The reason that a Coronary Sinus Access or Left Ventricular (CS/LV) lead was not implanted. | CDISC SDTM Reason Coronary Sinus Access or Left Ventricular Lead Not Implanted Terminology |
Could Not Obtain Acceptable Pacing Thresholds | C100025 | The coronary sinus/left ventricular lead was not implanted because the operator was unable to obtain acceptable pacing thresholds. | Unable to Obtain Acceptable Pacing Thresholds | |||
Lead Position Results in Undesirable Stimulation of the Diaphragm | C99933 | The coronary sinus/left ventricular lead was not implanted because the lead position resulted in undesirable stimulation of the diaphragm. | Cardiac Lead Position Results in Undesirable Stimulation of Diaphragm | |||
Previously Implanted | C100007 | The coronary sinus/left ventricular lead was not implanted because a lead had been previously implanted. | Previously Implanted Cardiac Lead | |||
Unable to Obtain Satisfactory Coronary Sinus Access | C100026 | The coronary sinus/left ventricular lead was not implanted because the operator was unable to obtain satisfactory coronary sinus access. | Unable to Obtain Satisfactory Coronary Sinus Access | |||
Unable to Obtain Satisfactory Vascular Access | C100027 | The coronary sinus/left ventricular lead was not implanted because the operator was unable to obtain satisfactory vascular access. | Unable to Obtain Satisfactory Vascular Access | |||
Unable to Position Lead Due to Coronary Sinus Dissection | C100028 | The coronary sinus/left ventricular lead was not implanted because the coronary sinus was dissected. | Unable to Position Lead Due to Coronary Sinus Dissection | |||
Unable to Position Lead in Tributary Vein of Coronary Sinus | C100029 | The coronary sinus/left ventricular lead was not implanted because the operator was unable to position the lead in the tributary vein of the coronary sinus. | Unable to Position Lead In tributary Vein of Coronary Sinus | |||
Back to top | ||||||
CL.C101847.CVEXAMCD | Cardiovascular Test Code (CVEXAMCD) | text Extensible: Yes | C101847 | Cardiovascular Test Code | A terminology codelist to describe the findings test code from a cardiac examination. | CDISC SDTM Cardiovascular Test Code Terminology |
COARTDOM | C100086 | Coronary Artery Dominance;Coronary Anatomy Dominance | The contribution of blood supply from the right or left vessel system to the posterior descending artery. (ACC) | Coronary Artery Dominance | ||
CVLREGTS | C102244 | Cardiac Valvular Regurgitation Severity | The qualitative measurement of the severity of cardiac valvular regurgitation. | Cardiac Valvular Regurgitation Severity | ||
CVLSTNS | C102245 | Cardiac Valvular Stenosis Severity | The qualitative measurement of the severity of cardiac valvular stenosis. | Cardiac Valvular Stenosis Severity | ||
ISHMYOP | C80494 | Ischemic Myocardium Percentage | The percentage of myocardial tissue which exhibits characteristics of inadequate blood flow (ischemia). | Ischemic Myocardium Percentage | ||
LADMN | C99970 | Left Atrium Dimension | The diameter across the left atrium measured at the end of systole. | Left Atrium Dimension | ||
LVDMNED | C99976 | Left Ventricle Dimension, End-Diastole | The diameter across the ventricle at the end of diastole, excluding the thickness of the walls. | Left Ventricle Dimension at End-Diastole | ||
LVDMNES | C99977 | Left Ventricular Dimension, End-Systole | The diameter across the ventricle at the end of systole, excluding the thickness of the walls. | Left Ventricular Dimension at End-Systole | ||
LVEF | C99524 | Left Ventricular Ejection Fraction | The percent or fraction of the left ventricular end diastolic volume ejected in systole. The left ventricular ejection fraction is equal to the left ventricular stroke volume divided by the left ventricular end diastolic volume. | Left Ventricle Ejection Fraction | ||
NUMDCAV | C99996 | Number of Diseased Coronary Vessels | Number of major epicardial vessels with greater than or equal to 70% reduction in diameter or greater than or equal to 50% reduction in cross-sectional area. | Number of Diseased Coronary Artery Vessels | ||
Back to top | ||||||
CL.C101846.CVEXAM | Cardiovascular Test Name (CVEXAM) | text Extensible: Yes | C101846 | Cardiovascular Test Name | A terminology codelist to describe the findings test name from a cardiac examination. | CDISC SDTM Cardiovascular Test Name Terminology |
Coronary Artery Dominance | C100086 | Coronary Artery Dominance;Coronary Anatomy Dominance | The contribution of blood supply from the right or left vessel system to the posterior descending artery. (ACC) | Coronary Artery Dominance | ||
Cardiac Valvular Regurgitation Severity | C102244 | Cardiac Valvular Regurgitation Severity | The qualitative measurement of the severity of cardiac valvular regurgitation. | Cardiac Valvular Regurgitation Severity | ||
Cardiac Valvular Stenosis Severity | C102245 | Cardiac Valvular Stenosis Severity | The qualitative measurement of the severity of cardiac valvular stenosis. | Cardiac Valvular Stenosis Severity | ||
Ischemic Myocardium Percentage | C80494 | Ischemic Myocardium Percentage | The percentage of myocardial tissue which exhibits characteristics of inadequate blood flow (ischemia). | Ischemic Myocardium Percentage | ||
Left Atrium Dimension | C99970 | Left Atrium Dimension | The diameter across the left atrium measured at the end of systole. | Left Atrium Dimension | ||
Left Ventricle Dimension, End-Diastole | C99976 | Left Ventricle Dimension, End-Diastole | The diameter across the ventricle at the end of diastole, excluding the thickness of the walls. | Left Ventricle Dimension at End-Diastole | ||
Left Ventricular Dimension, End-Systole | C99977 | Left Ventricular Dimension, End-Systole | The diameter across the ventricle at the end of systole, excluding the thickness of the walls. | Left Ventricular Dimension at End-Systole | ||
Left Ventricular Ejection Fraction | C99524 | Left Ventricular Ejection Fraction | The percent or fraction of the left ventricular end diastolic volume ejected in systole. The left ventricular ejection fraction is equal to the left ventricular stroke volume divided by the left ventricular end diastolic volume. | Left Ventricle Ejection Fraction | ||
Number of Diseased Coronary Vessels | C99996 | Number of Diseased Coronary Vessels | Number of major epicardial vessels with greater than or equal to 70% reduction in diameter or greater than or equal to 50% reduction in cross-sectional area. | Number of Diseased Coronary Artery Vessels | ||
Back to top | ||||||
CL.C101854.CVLSTSEV | Cardiac Valvular Stenosis Severity (CVLSTSEV) | text Extensible: No | C101854 | Cardiac Valvular Stenosis Severity | A terminology codelist to describe the severity of cardiac valvular stenosis. | CDISC SDTM Cardiac Valvular Stenosis Severity Terminology |
MILD CARDIAC VALVE STENOSIS | C99986 | The cardiac valve orifice is abnormally narrow, to a mild degree. | Mild Cardiac Valve Stenosis | |||
MODERATE CARDIAC VALVE STENOSIS | C99990 | The cardiac valve orifice is abnormally narrow, to a moderate degree. | Moderate Cardiac Valve Stenosis | |||
NO CARDIAC VALVE STENOSIS | C99992 | The cardiac valve orifice is not abnormally narrow. | No Cardiac Valve Stenosis | |||
SEVERE CARDIAC VALVE STENOSIS | C100013 | The cardiac valve orifice is abnormally narrow, to a severe degree. | Severe Cardiac Valve Stenosis | |||
Back to top | ||||||
CL.C101853.CVLVRSEV | Cardiac Valvular Regurgitation Severity (CVLVRSEV) | text Extensible: No | C101853 | Cardiac Valvular Regurgitation Severity | A terminology codelist to describe the severity of cardiac valvular regurgitation. | CDISC SDTM Cardiac Valvular Regurgitation Severity Terminology |
MILD CARDIAC VALVE REGURGITATION | C99985 | Evidence of mild retrograde blood flow through the valve(s) of the heart. | Mild Cardiac Valve Regurgitation | |||
MODERATE CARDIAC VALVE REGURGITATION | C99989 | Evidence of moderate retrograde blood flow through the valve(s) of the heart. | Moderate Cardiac Valve Regurgitation | |||
NO CARDIAC VALVE REGURGITATION | C99991 | No evidence of any retrograde blood flow through the valve(s) in the heart. | No Cardiac Valve Regurgitation | |||
SEVERE CARDIAC VALVE REGURGITATION | C100012 | Evidence of severe retrograde blood flow through the valve(s) of the heart. | Severe Cardiac Valve Regurgitation | |||
Back to top | ||||||
CL.C101859.CVPRCIND | Cardiac Procedure Indication (CVPRCIND) | text Extensible: Yes | C101859 | Cardiac Procedure Indication | The reason that a subject had a cardiac procedure. | CDISC SDTM Cardiac Procedure Indication Terminology |
Candidate to Receive Cardiac Transplant | C99919 | The intended recipient of a heart transplant. | Candidate to Receive Cardiac Transplant | |||
Cardiac Arrest/Arrhythmia Etiology Unknown | C100033 | An episode of cardiac arrest or arrhythmia where the etiology was unknown. | Cardiac Arrest/Arrhythmia Etiology Unknown | |||
Cardiomyopathy | C34830 | A disease of the heart muscle or myocardium proper. Cardiomyopathies may be classified as either primary or secondary, on the basis of etiology, or on the pathophysiology of the lesion: hypertrophic, dilated, or restrictive. | Cardiomyopathy | |||
Chronic Total Occlusion | C99938 | A longstanding, complete blockage of a vessel. | Chronic Total Occlusion Vessel | |||
Donor for Cardiac Transplant | C99947 | The subject contributing a heart for a cardiac transplant. | Donor for Cardiac Transplant | |||
End of Expected Battery Life | C99949 | The battery that supplies the device has reached the end of its life. | End of Expected Battery Life | |||
Faulty Connector/Header | C100035 | There is a faulty connector/header in the device. | Faulty Device Connector/Header | |||
Generator is Being Replaced at the Time of Lead Revision | C99925 | A cardiac lead requires revision, at which time the generator to the device will be replaced. | Cardiac Device Generator is Being Replaced at Time of Lead Revision | |||
Generator Malfunction | C99943 | The device has a generator malfunction. | Device Generator Malfunction | |||
Immediate Percutaneous Coronary Intervention (PCI) for St Elevation Myocardial Infarction (STEMI) | C99961 | An immediate percutaneous coronary intervention is necessary for a myocardial infarction that presents with ST segment elevation. | Immediate Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction | |||
Infection | C26726 | A disorder resulting from the presence and activity of a microbial, viral, or parasitic agent. It can be transmitted by direct or indirect contact. -- 2003 (NCI) | Infectious Disorder | |||
Lead Erosion | C99931 | A cardiac lead has damaged local tissue enough to require treatment. | Cardiac Lead Erosion | |||
Left Ventricular Systolic Dysfunction | C99974 | The degree of impairment of the left cardiac ventricle to contract efficiently. | Left Cardiac Ventricular Systolic Dysfunction | |||
Manufacturer Recall | C100045 | An imperative issued by the manufacturer of a device that the device needs to be returned to a designated source for repair or replacement. | Manufacturer Recall | |||
Manufacturer Recognized a Recurring Performance Failure | C99980 | The device manufacturer had recognized a recurrent performance failure in the device. | Manufacturer Recognized a Recurring Performance Failure | |||
Medical Condition Or Procedure Affects Implantation Site | C99982 | The medical condition or the procedure affects the device implantation site. | Medical Condition or Procedure Affects Implantation Site | |||
Medical Or Surgical Procedure Requiring Relocation of Lead | C99983 | An intended medical or surgical procedure necessitates the relocation of a cardiac lead. | Medical or Surgical Procedure Requiring Relocation of Lead | |||
Percutaneous Coronary Intervention (PCI) for High Risk Non-St Elevation Myocardial Infarction Or Unstable Angina | C99999 | Includes patients with unstable angina or Non-STEMI who have high risk features for short-term risk of death or nonfatal MI. High risk features includes at least one of the following: history of accelerating tempo of ischemic symptoms in preceding 48 hours; character of pain - prolonged ongoing (greater than 20 minutes) rest pain; clinical findings - pulmonary edema, most likely due to ischemia or new or worsening mitral regurgitation murmur; or S3 or new worsening rales or Hypotension, bradycardia, tachycardia or age greater than 75 years; ECG - angina at rest with transient ST-segment changes greater than 0.5 mm or bundle-branch block, new or presumed new or sustained ventricular tachycardia; cardiac markers - NSTEMI patients with elevated cardiac TnT, Tnl, or CK-MB. | Percutaneous Coronary Intervention for High Risk Non-ST Elevation Myocardial Infarction or Unstable Angina | |||
Percutaneous Coronary Intervention (PCI) for St Elevation Myocardial Infarction (STEMI) (Stable After Successful Full-Dose Thrombolytics) | C100001 | A percutaneous coronary intervention is necessary for a myocardial infarction that presents with ST segment elevation and the subject does not have recurrent or persistent symptoms, symptoms of heart failure or ventricular arrhythmia after a successful dose of thrombolytic therapy. | Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction-Stable After Successful Full-Dose Thrombolytic Therapy | |||
Percutaneous Coronary Intervention (PCI) for St Elevation Myocardial Infarction (STEMI) (Stable, >12 Hrs From Symptom Onset) | C100000 | A percutaneous coronary intervention is necessary for a myocardial infarction that presents with ST segment elevation and the subject does not have recurrent or persistent symptoms, symptoms of heart failure or ventricular arrhythmia. The presentation is past twelve hours since onset of symptoms. | Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction-Stable-Over 12 Hours From Symptom Onset | |||
Percutaneous Coronary Intervention (PCI) for St Elevation Myocardial Infarction (STEMI) (Unstable, >12 Hrs From Symptom Onset) | C100002 | A percutaneous coronary intervention is necessary for a myocardial infarction that presents with ST segment elevation and the subject has recurrent or persistent symptoms, symptoms of heart failure or ventricular arrhythmia. The presentation is past twelve hours since onset of symptoms. | Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction-Unstable-Over 12 Hours From Symptom Onset | |||
Post-Cardiac Transplant | C100005 | A procedure to evaluate the health of the an individual after receiving a heart transplant. | Post-Cardiac Transplant Evaluation | |||
Pre-Operative Evaluation for Non-Cardiovascular Surgery | C100006 | A procedure to evaluate the health of the cardiac system to determine feasibility of a non-cardiac related surgical procedure. | Pre-Operative Evaluation for Non-Cardiovascular Surgery | |||
Primary Prevention | C15306 | A procedure performed to avoid the first occurrence of a disease condition. | Primary Prevention | |||
Rescue Percutaneous Coronary Intervention (PCI) for St Elevation Myocardial Infarction (STEMI) (After Failed Full-Dose Thrombolytics) | C100008 | A percutaneous coronary intervention is imperative for a myocardial infarction that presents with ST segment elevation after an unsatisfactory response to a full dose of thrombolytic therapy. | Rescue Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction After Failed Full-Dose Thrombolytic Therapy | |||
Secondary Prevention | C15712 | A procedure performed to avoid a subsequent occurrence of a disease condition. | Secondary Prevention | |||
Spontaneous Sustained Ventricular Tachycardia | C100014 | Ventricular tachycardia that occurs without provocation and does not resolve spontaneously. | Spontaneous Sustained Ventricular Tachycardia | |||
Staged Percutaneous Coronary Intervention (PCI) | C100015 | A subsequent Percutaneous Coronary Intervention in a planned series of procedures, where the first PCI could have been during a prior admission, or during this admission. | Staged Percutaneous Coronary Intervention | |||
Syncope with High Risk Characteristics | C100018 | A sudden loss of consciousness with loss of postural tone not related to anesthesia with high risk characteristics. High risk characteristics include non-ischemic dilated cardiomyopathy, or ischemic heart disease with significant ventricular dysfunction, hypertrophic cardiomyopathy, Brugada Syndrome, or Long QT Syndrome. | Syncope with High Risk Cardiac Characteristics | |||
Syncope with Inducible Ventricular Tachycardia | C100019 | Sudden loss of consciousness with loss of postural tone not related to anesthesia with ventricular tachycardia (VT) that can be induced during an electrophysiological study. | Syncope with Inducible Ventricular Tachycardia | |||
Unknown | C17998 | Not known, not observed, not recorded, or refused. (NCI) | Unknown | |||
Upgrade to a Device with Additional Pacing Capabilities | C100030 | A device with additional pacing capabilities is replacing the current device. | Upgrade to Cardiac Device with Additional Pacing Capabilities | |||
Ventricular Fibrillation | C50799 | Ventricular Fibrillation is characterized by rapid, usually more than 300 bpm (cycle length: 180 ms or less), grossly irregular ventricular rhythm with marked variability in QRS cycle length, morphology, and amplitude. | Ventricular Fibrillation | |||
Back to top | ||||||
CL.C101850.CVSLDEXT | Coronary Vessel Disease Extent (CVSLDEXT) | text Extensible: No | C101850 | Coronary Vessel Disease Extent | A terminology codelist to describe the extent of coronary artery disease. | CDISC SDTM Coronary Vessel Disease Extent Terminology |
INDETERMINATE | C48658 | Cannot distinguish between two or more possible values in the current context. (NCI) | Indeterminate | |||
NO DISEASE | C99993 | There was less than 50% stenosis (reduction in cross-sectional area) in all coronary artery branches. | No Evidence of Coronary Artery Disease | |||
ONE VESSEL DISEASE | C99997 | There was greater than or equal to 50% stenosis (reduction in cross-sectional area) in one coronary artery. | One Coronary Vessel Disease | |||
THREE VESSEL DISEASE | C100020 | There was greater than or equal to 50% stenosis (reduction in cross-sectional area) in three coronary arteries (or greater than or equal to 50% stenosis in the left main coronary artery and greater than or equal to 50% stenosis in the right coronary artery). | Three Vessel Coronary Disease | |||
TWO VESSEL DISEASE | C100023 | There was greater than or equal to 50% stenosis (reduction in cross-sectional area) in two coronary arteries (or greater than or equal to 50% stenosis in the left main coronary artery). | Two Vessel Coronary Disease | |||
UNKNOWN | C17998 | Not known, not observed, not recorded, or refused. (NCI) | Unknown | |||
Back to top | ||||||
CL.C101857.DIABTHPY | Diabetes Therapy (DIABTHPY) | text Extensible: Yes | C101857 | Diabetes Therapy | A terminology codelist that describes the treatment method for diabetes. | CDISC SDTM Diabetes Therapy Terminology |
DIET | C15383 | A form of therapy which includes dietary approaches and special diets. | Special Diet Therapy | |||
INSULIN | C2271 | A synthetic or animal-derived form of insulin used in the treatment of diabetes mellitus. | Insulin | |||
NO TREATMENT | C99994 | No treatment for diabetes. | No Treatment for Diabetes | |||
ORAL MEDICATION | C102246 | A pharmacological medication intended for administration through the mouth. | Oral Medication | |||
Back to top | ||||||
CL.C101863.DISCHDX | Discharge Disposition (DISCHDX) | text Extensible: Yes | C101863 | Discharge Disposition | The destination or circumstance at the time of discharge. | CDISC SDTM Discharge Disposition Terminology |
Expired | C28554 | Died | The absence of life or state of being dead. (NCI) | Death | ||
Expired in a Medical Facility | C99944 | The patient died while in a medical center such as a hospital, skilled nursing facility (SNF), intermediate care facility (ICF), or a freestanding hospice center. | Died in a Medical Facility | |||
Federal Health Care Facility | C99909 | The patient will be admitted to a medical center that is funded by the federal government (e.g. Veterans Affairs Hospital). | Federal Health Care Facility | |||
Home Under Care of Organized Home Health Service Organization in Anticipation of Covered Skilled Care | C99959 | The patient will return home but personal health maintenance will be administered and monitored by a member of a healthcare organization that is eligible to receive Medicare funding. | Home Under Care of Organized Home Health Service Organization in Anticipation of Covered Skilled Care | |||
Home, Hospice | C99958 | The patient will receive end-of-life care which will be administered in the patient's home. | Home Hospice | |||
Home, Self Care | C99957 | A routine discharge where personal health maintenance will be administered and monitored by the patient from their home. | Home Care | |||
Hospice - Medical Facility | C99910 | The patient will receive end-of-life care which will be administered in a medical center. | Hospice Care at Medical Facility | |||
Hospital-based Medicare-approved Swing Bed | C99960 | The patient will be admitted into a medical center and receive a type of hospital bed that will be paid for my Medicare. | Hospital with Medicare Approved Swing Bed | |||
Inpatient Rehabilitation Facility (IRF) Including Rehabilitation Distinct Part Units of a Hospital | C99911 | The patient will be admitted full time into a free standing rehabilitation center or a rehabilitation center within a general medical facility. | Inpatient Rehabilitation Facility Including Rehabilitation distinct Part Units of a Hospital | |||
Institution Not Defined | C102247 | The patient will be admitted into an alternative facility not listed. | Institution Not Defined | |||
Intermediate Care Facility | C99912 | The patient will be admitted into a medical center that provides care 24 hours per day. | Intermediate Care Facility | |||
Left Against Medical Advice or Discontinued Care | C99969 | The patient vacated the medical center or ceased medical care contrary to the recommendation of a trained healthcare provider. | Left Against Medical Advice | |||
Medicare-certified Long Term Care Hospital (LTCH) | C99984 | The patient will be admitted into a Medicare funded medical center for a considerable length of time. | Medicare Certified Long Term Care Hospital | |||
Nursing Facility Certified Under Medicaid but Not Certified Under Medicare | C99913 | The patient will be admitted into a medical center which is eligible to receive funding from Medicaid but not Medicare. | Nursing Facility Certified Under Medicaid but Not Certified Under Medicare | |||
Psychiatric Hospital or a Psychiatric-distinct Part Unit of a Hospital | C53536 | The patient will be admitted into a free standing medical facility or a unit within a general medical facility used for the treatment of mental health disorders. | Psychiatric Facility | |||
Short Term General Hospital | C102248 | The patient will remain in a basic hospital environment for a brief time. | Short Term General Hospital | |||
Skilled Nursing Facility (SNF) with Medicare Certification in Anticipation of Covered Skilled Care | C99914 | The patient will be admitted into a medical center equipped with a trained nursing staff that is eligible to receive Medicare funding. | Skilled Nursing Facility with Medicare Certification in Anticipation of Covered Skilled Care | |||
Back to top | ||||||
CL.C101851.GRSTNLOC | Location of Most Severe Stenosis Within a Graft (GRSTNLOC) | text Extensible: No | C101851 | Location of Most Severe Stenosis Within a Graft | Terminology used to describe the part of the graft that is most severely stenotic. | CDISC SDTM Location of Most Severe Stenosis Within a Graft Terminology |
AORTIC ANASTOMOSIS OF THE GRAFT | C99915 | The connection where the graft joins the aorta usually less than or equal to 3 mm from insertion point. | Aortic Anastomosis of Graft | |||
BODY OF THE GRAFT | C99918 | The portion of the graft that lies between its anastomoses. | Body of Graft | |||
CORONARY ANASTOMOSIS OF THE GRAFT | C80476 | Coronary Graft Anastomoses | The connection where the graft joins the coronary artery usually less than or equal to 3 mm from insertion point. | Coronary Graft Anastomoses | ||
Back to top | ||||||
CL.C101840.KILLIPC | Killip Class Responses (KILLIPC) | text Extensible: No | C101840 | Killip Class Responses | A terminology codelist based on the classification developed by Killip and Kimball, which classifies patients with myocardial infarction based on routine physical examination parameters, such as the presence or absence of rales, or a decreased systolic blood pressure. | CDISC SDTM Killip Class Responses Terminology |
Killip CLASS I | C77269 | The absence of rales over the lung fields and absence of third heart sound (S3). (ACC/AHA) | Killip Class I | |||
Killip CLASS II | C77270 | The presence of rales over 50% or less of the lung fields or the presence of a third heart sound (S3).(ACC/AHA) | Killip Class II | |||
Killip CLASS III | C77271 | The presence of rales over more than 50% of the lung fields. (ACC/AHA) | Killip Class III | |||
Killip CLASS IV | C77272 | The presence of cardiogenic shock (systolic BP less than 90 mm Hg) for greater than 30 minutes, not responsive to fluid resuscitation alone, and felt to be secondary to cardiac dysfunction. (ACC/AHA) | Killip Class IV | |||
Back to top | ||||||
CL.C101862.LEADABN | Lead Abnormality (LEADABN) | text Extensible: Yes | C101862 | Lead Abnormality | Terminology related to the complications of cardiac lead systems. | CDISC SDTM Lead Abnormality Terminology |
CONDUCTOR FAILURE | C99924 | Conductor failure manifests by high lead impedance either absolutely (above manufacturer's product specifications) or by a significant increase from previously stable chronic values. | Cardiac Device Conductor Failure | |||
DEFIBRILLATION ISSUES | C99922 | The cardiac lead is not performing as expected with issues such as oversensing with or without shock or ATP, or failed shocks or inadequate DFT safety margins defibrillation activity. | Cardiac Defibrillator Issue | |||
EXTRACARDIAC STIMULATION | C99951 | This manifests as stimulation by the lead of non-cardiac structures such as the diaphragm, chest wall, or pectoral muscle. | Extracardiac Stimulation | |||
FAILED TO SHOCK WITH INADEQUATE DFT SAFETY MARGIN | C99954 | The cardiac lead failed to administer a shock and had an inadequate defibrillator threshold safety margin. | Failure to Shock with Inadequate Defibrillator Threshold Safety Margin | |||
FAILURE TO CAPTURE WITH ACCEPTABLE SAFETY MARGIN | C99953 | Failure to capture manifests as a high pacing threshold that results in either intermittent failure to capture at maximal programmed output or excessive battery drain leading to premature battery exhaustion. | Failure to Capture with Acceptable Safety Margin | |||
FAILURE TO PACE | C99528 | Failure to pace manifests as absence of pacemaker stimulation artifacts on electrocardiographic recordings despite rates below pacemaker programmed rate. | Failure of Cardiac Pacemaker to Pace | |||
INSULATION FAILURE | C99932 | Insulation failure manifests as low lead impedance either absolutely (below manufacturer's product specifications) or by a significant decrease from previously stable chronic values. | Cardiac Lead Insulation Failure | |||
LEAD DISLODGEMENT REQUIRING REPOSITION/REOPERATION | C100034 | The movement (macroscopic or microscopic) of an existing lead within the heart or vascular tree away from the original implantation site. | Cardiac Lead Dislodgement Requiring Reposition/Reoperation | |||
OVERSENSING | C99926 | Oversensing manifests as sensing of electrical signals not related to cardiac depolarization of the lead chamber that cannot be resolved acceptably by device reprogramming. | Cardiac Device Oversensing | |||
OVERSENSING WITH SHOCK OR ATP | C99927 | This manifests as sensing of non-cardiac depolarization signals that met arrhythmia detection criteria and elicited programmed tachyarrhythmia therapy. | Cardiac Device Oversensing with Shock or Anti-Tachycardia Pacing | |||
OVERSENSING WITHOUT SHOCK OR ATP | C99928 | This manifests as sensing of non-cardiac depolarization signals that did not meet arrhythmia detection criteria and do not elicit programmed tachyarrhythmia therapy. | Cardiac Device Oversensing without Shock or Anti-Tachycardia Pacing | |||
SET SCREW PROBLEM | C99929 | The pacing and/or sensing problem associated with high impedance due to a poor connection between a lead and generator caused by a loose set screw. | Cardiac Device Set Screw Problem | |||
UNDERSENSING | C99930 | Undersensing manifests as failure to sense appropriate cardiac depolarizations that cannot be resolved with reprogramming. | Cardiac Device Undersensing | |||
Back to top | ||||||
CL.C101867.LEADSTAT | Lead Status (LEADSTAT) | text Extensible: Yes | C101867 | Lead Status | The status of the lead. | CDISC SDTM Lead Status Terminology |
ABANDONED | C99906 | The lead has been left in situ but is not in use. | Abandoned Lead | |||
EXTRACTED | C102283 | The lead has been removed from the body. | Extracted Lead | |||
REUSED | C102284 | The lead has been left in situ and reused. | Reused Lead | |||
Back to top | ||||||
CL.C101861.LSNCMPX | Lesion Complexity (LSNCMPX) | text Extensible: No | C101861 | Lesion Complexity | Terminology related to the risk of percutaneous coronary intervention for a particular lesion. | CDISC SDTM Lesion Complexity Terminology |
ACC/AHA LESION COMPLEXITY SCORE A | C100037 | Low Risk | Discrete (less than 10 mm length) and concentric and readily accessible and non-angulated segment less than 45 degrees and smooth contour and little or no calcification and less than totally occlusive and not ostial in location and no major branch involvement and absence of thrombus. | American College of Cardiology/American Heart Association Lesion Complexity Score A | ||
ACC/AHA LESION COMPLEXITY SCORE B | C100038 | Medium Risk | Tubular (10-20 mm length) or eccentric or moderate tortuosity of proximal segment or moderately angulated segment, 45-90 degrees or irregular contour or moderate to heavy calcification or ostial in location or bifurcation lesions requiring double guidewires or some thrombus present or total occlusion less than3 months old. | American College of Cardiology/American Heart Association Lesion Complexity Score B | ||
ACC/AHA LESION COMPLEXITY SCORE C | C100039 | High Risk | Diffuse (length greater than 2cm) or excessive tortuosity of proximal segment or extremely angulated segments greater than 90 degrees or total occlusions greater than 3 months old and/or bridging collaterals or inability to protect major side branches or degenerated vein grafts with friable lesions. | American College of Cardiology/American Heart Association Lesion Complexity Score C | ||
Back to top | ||||||
CL.C101868.LVEFMRE | Left Ventricular Ejection Fraction Measurement Result (LVEFMRE) | text Extensible: Yes | C101868 | Left Ventricular Ejection Fraction Measurement Result | Terminology for results of left ventricular ejection fraction assessments. | CDISC SDTM Left Ventricular Ejection Fraction Measurement Result Terminology |
HYPERDYNAMIC | C99512 | A pathologically high percentage of blood that is forced from the heart ventricle to produce cardiac output. This is often the result of ventricular dilation due to hypertrophic cardiomyopathy. Quantitatively, the ejection fraction is considered higher than 70%. | Hyperdynamic Ventricular Ejection Fraction | |||
MILD DYSFUNCTION | C99507 | Slightly less than normal amount of blood that is forced from the heart ventricle to produce cardiac output. Quantitatively, the ejection fraction is considered between 40% to 49%. | Mildly Abnormal Ejection Fraction | |||
MODERATE DYSFUNCTION | C99508 | Moderately less than normal amount of blood that is forced from the heart ventricle to produce cardiac output. Quantitatively, the ejection fraction is considered between 30% to 39%. | Moderately Abnormal Ejection Fraction | |||
NORMAL EJECTION FRACTION | C99513 | The usual amount of blood that is forced from the heart ventricle to produce cardiac output. Quantitatively, the ejection fraction is considered between 50% to 70%. | Normal Ventricular Ejection Fraction | |||
SEVERE DYSFUNCTION | C99509 | Severely less than normal amount of blood that is forced from the heart ventricle to produce cardiac output. Quantitatively, the ejection fraction is considered less than 30%. | Severely Abnormal Ventricular Ejection Fraction | |||
Back to top | ||||||
CL.C101845.MCRCSPTM | Mechanical Circulatory Support Placement Timing (MCRCSPTM) | text Extensible: No | C101845 | Mechanical Circulatory Support Placement Timing | A terminology codelist to describe the timing of mechanical circulatory support placement. | CDISC SDTM Mechanical Circulatory Support Placement Timing Terminology |
IN PLACE AT START OF PROCEDURE | C99981 | In Place at Start of Procedure | Mechanical Circulatory Support was in place at the start of the procedure. | Mechanical Circulatory Support in Place at Start of Procedure | ||
INSERTED DURING A NON-PERCUTANEOUS CORONARY INTERVENTION PROCEDURE | C99962 | Inserted during a Non PCI Procedure | Mechanical Circulatory Support was inserted during a non-Percutaneous Coronary Intervention (PCI) procedure. | Inserted During a Non-Percutaneous Coronary Intervention | ||
INSERTED DURING PROCEDURE AND AFTER PERCUTANEOUS CORONARY INTERVENTION STARTED | C99964 | Inserted during Procedure and after PCI Started | Mechanical Circulatory Support was inserted during the procedure after Percutaneous Coronary Intervention (PCI) started. | Inserted During Procedure and After Percutaneous Coronary Intervention Began | ||
INSERTED DURING PROCEDURE BUT PRIOR TO PERCUTANEOUS CORONARY INTERVENTION | C99963 | Inserted during Procedure but Prior to PCI | Mechanical Circulatory Support was inserted during the procedure prior to percutaneous coronary intervention (PCI). | Inserted During a Procedure but Prior to Percutaneous Coronary Intervention | ||
Back to top | ||||||
CL.C101834.NORMABNM | Normal Abnormal Response (NORMABNM) | text Extensible: No | C101834 | Normal Abnormal Response | A terminology codelist to describe a normal or abnormal response. | CDISC SDTM Normal Abnormal Response Terminology |
ABNORMAL | C25401 | Deviating in any way from the state, position, structure, condition, behavior, or rule which is considered a norm. (NCI) | Abnormal | |||
INDETERMINATE | C48658 | Inconclusive | Cannot distinguish between two or more possible values in the current context. (NCI) | Indeterminate | ||
NORMAL | C14165 | Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm. (NCI) | Normal | |||
UNKNOWN | C17998 | Not known, not observed, not recorded, or refused. (NCI) | Unknown | |||
Back to top | ||||||
CL.C101855.NSYSPCID | Non-system Reason for PCI Delay (NSYSPCID) | text Extensible: No | C101855 | Non-system Reason for PCI Delay | A terminology codelist that contains reasons for non-system PCI delay. | CDISC SDTM Non-system Reason for PCI Delay Terminology |
CARDIAC ARREST BEFORE PCI | C99920 | Cardiac arrest which occurs before a percutaneous coronary intervention can take place. | Cardiac Arrest Prior to Percutaneous Coronary Intervention | |||
DIFFICULT VASCULAR ACCESS | C99945 | Access to the subject's vasculature is troublesome or formidable. | Difficult Vascular Access | |||
DIFFICULTY CROSSING THE CULPRIT LESION DURING THE PCI PROCEDURE | C99946 | Placement of intracoronary devices across the coronary stenosis is troublesome or formidable. | Difficulty Crossing Culprit Lesion During Percutaneous Coronary Intervention | |||
ENDOTRACHEAL INTUBATION BEFORE PCI | C99950 | Intubation before PCI | Endotracheal intubation which occurs before a percutaneous coronary intervention can take place. | Endotracheal Intubation before Percutaneous Coronary Intervention | ||
OTHER | C17649 | Other | Different than the one(s) previously specified or mentioned. (NCI) | Other | ||
SUBJECT DELAY IN PROVIDING CONSENT | C100016 | Patient Delay in Providing Consent | The subject has not provided consent in a timely manner for the procedure to take place. | Subject Delay in Providing Consent | ||
Back to top | ||||||
CL.C101839.NYHAC | New York Heart Association Class Responses (NYHAC) | text Extensible: No | C101839 | New York Heart Association Class Responses | A terminology codelist based on the functional classification developed by the New York Heart Association (NYHA), for categorizing patients with defined or presumed cardiac disease. | CDISC SDTM New York Heart Association Class Responses Terminology |
NYHA CLASS I | C66904 | New York Heart Association Class I | Without limitations of physical activity. Ordinary physical activity does not cause undue fatigue, palpitations, or dyspnea. | New York Heart Association Class I | ||
NYHA CLASS II | C66905 | New York Heart Association Class II | Slight limitation of physical activity. The patient is comfortable at rest. Ordinary physical activity results in fatigue, palpitations, or dyspnea. | New York Heart Association Class II | ||
NYHA CLASS III | C66907 | New York Heart Association Class III | Marked limitation of physical activity. The patient is comfortable at rest. Less than ordinary activity causes fatigue, palpitations, or dyspnea. | New York Heart Association Class III | ||
NYHA CLASS IV | C66908 | New York Heart Association Class IV | Inability to carry on any physical activity without discomfort. Heart failure symptoms are present even at rest or with minimal exertion. | New York Heart Association Class IV | ||
Back to top | ||||||
CL.C101858.PROCEDUR | Procedure (PROCEDUR) | text Extensible: Yes | C101858 | Procedure | A terminology codelist to describe an activity that produces an effect, or that is intended to alter the course of a disease in a patient or population. | CDISC SDTM Procedure Terminology |
ABLATION, ACCESSORY PATHWAYS | C99907 | An invasive therapeutic procedure to destroy tissue in an accessory pathways in the atrioventricular conduction system that contributes to arrhythmia. | Ablation of Cardiac Accessory Pathway | |||
ABLATION, ATRIAL | C80432 | An invasive therapeutic procedure to destroy tissue in the cardiac atria that is the source of an arrhythmia. | Atrial Ablation | |||
ABLATION, AV NODE | C99908 | An invasive therapeutic procedure to destroy tissue in the AV-node that contributes to arrhythmia. | Ablation of Cardiac Atrioventricular Node | |||
ABLATION, VENTRICULAR | C80433 | An invasive therapeutic procedure to destroy tissue in the cardiac ventricles that is the source of an arrhythmia. | Ventricular Ablation | |||
AORTIC BALLOON VALVOTOMY | C99916 | Dilation of the valve between the left ventricle of the heart and the aorta by inflating a balloon. | Aortic Balloon Valvotomy | |||
AORTIC VALVE REPLACEMENT | C50815 | Surgery performed with the purpose of replacing a degenerated, calcified, malformed, dysfunctional, etc. aortic valve with a bioprosthetic, homograft, or autograft valve. | Aortic Valve Replacement | |||
ATRIAL SEPTAL CLOSURE | C99939 | Repair of atrial septum. | Closure of Cardiac Atrial Septum | |||
CARDIAC RESYNCHRONIZATION THERAPY | C80436 | An invasive procedure that includes an electronic device that stimulates both right and left cardiac ventricles to improve coordination of ventricular contraction. | Cardiac Resynchronization Therapy | |||
CARDIAC TRANSPLANT | C15246 | Heart Transplant | A surgical procedure in which a damaged heart is removed and replaced by another heart from a suitable donor. | Heart Transplantation | ||
CARDIOVERSION, CHEMICAL | C99937 | CHEMICAL CARDIOVERSION | The administration of pharmacologic agents to correct abnormal heart rhythm. | Chemical Cardioversion | ||
CARDIOVERSION, ELECTRICAL | C99948 | ELECTRICAL CARDIOVERSION | The administration of electric current to correct abnormal heart rhythm. | Electric Cardioversion | ||
CORONARY ARTERY BYPASS GRAFT | C51998 | CAB;CABG;Coronary Artery Bypass Graft;Coronary Artery Bypass Grafting;Heart Bypass;Aortocoronary Bypass;Coronary Artery Bypass;Coronary Artery Bypass Graft Surgery | Surgery performed to bypass partially or completely occluded coronary arteries, thereby increasing the blood supply of the heart. | Coronary Artery Bypass Surgery | ||
IMPLANTABLE CARDIOVERTER DEFIBRILLATOR | C80435 | Implantable Cardioverter Defibrillator Procedure | A procedure involving an electronic device implanted in the body that delivers electrical stimulation to the heart to treat tachycardia. It may also have the capability to treat bradycardia. | Implantable Cardioverter-Defibrillator Placement | ||
LEAD | C99934 | Lead Procedure | A procedure involving one or more wires used for pacemaker or implantable defibrillator devices. | Cardiac Lead Procedure | ||
LEFT ATRIAL APPENDAGE OCCLUSION | C99965 | The therapeutic blockage of the muscular pouch in the left atrium. | Intentional Left Cardiac Atrial Appendage Occlusion Procedure | |||
LEFT VENTRICULAR ASSIST DEVICE | C80473 | LVAD | A procedure involving a mechanical cardiac pump which receives blood from the left ventricle and delivers it to the aorta. | Left Ventricular Assist Device | ||
LEFT VENTRICULAR SYSTOLIC DYSFUNCTION EVALUATION | C99975 | An examination and assessment of the inability of the left ventricle to effectively pump blood to the body. | Left Cardiac Ventricular Systolic Dysfunction Evaluation | |||
MITRAL BALLOON VALVOTOMY | C99987 | Dilation of the valve between the left atrium and the left ventricle of the heart by inflating a balloon. | Mitral Balloon Valvotomy | |||
MITRAL COMMISSUROTOMY | C99988 | Dilation of the valve between the left atrium and the left ventricle of the heart by use of a surgeon's finger or rigid instrument. | Mitral Commissurotomy | |||
MITRAL VALVE REPAIR | C80449 | Surgery performed for the purpose of reducing regurgitation of the mitral valve. | Mitral Valve Repair | |||
MITRAL VALVE REPLACEMENT | C50825 | Surgery performed with the purpose of replacing a degenerated, calcified, malformed, dysfunctional, etc. mitral valve with bioprosthetic, homograft or autograft valve. | Mitral Valve Replacement | |||
NON-CARDIOVASCULAR SURGERY | C99995 | An operative procedure that does not involve the heart or the blood vessels. | Non-Cardiovascular Surgery | |||
PACEMAKER | C99998 | Pacemaker Procedure | A procedure involving an electronic device that delivers electrical stimulation to the heart to treat bradycardia. | Pacemaker Procedure | ||
PERCUTANEOUS CORONARY INTERVENTION | C99521 | PCI | A procedure on the coronary arteries of the heart that is performed by the placement of an angioplasty guide wire, balloon, or other device (e.g. stent, atherectomy, brachytherapy, or thrombectomy catheter) into a native coronary artery or coronary artery bypass graft for the purpose of mechanical coronary revascularization. | Percutaneous Coronary Intervention | ||
PERCUTANEOUS MITRAL REPAIR | C100003 | Invasive procedure through a puncture in the skin, performed for the purpose of reducing regurgitation of the mitral valve. | Percutaneous Mitral Valve Repair | |||
PERICARDIAL STRIPPING | C100004 | Removal or resection of the pericardium. | Pericardial Stripping | |||
PERICARDIAL WINDOW | C51618 | A procedure in which an opening is made in the pericardium. | Pericardial Window Procedure | |||
PERICARDIOCENTESIS | C52010 | The aspiration of excess fluid between the pericardium and the heart. | Pericardiocentesis | |||
PULMONARY VALVE REPLACEMENT | C50817 | Surgery performed with the purpose of replacing a degenerated, calcified, malformed, dysfunctional, etc. pulmonary valve with bioprosthetic, homograft or autograft valve. | Pulmonary Valve Replacement | |||
PULMONIC VALVULOPLASTY | C100044 | Dilation of the valve between the right ventricle and the pulmonary artery of the heart by inflating a balloon. | Pulmonic Valvuloplasty | |||
RIGHT VENTRICULAR ASSIST DEVICE | C100010 | RVAD | A procedure involving a mechanical pump which receives blood from the right ventricle and delivers it to the pulmonary artery. | Right Cardiac Ventricle Assist Device Procedure | ||
SEPTAL ABLATION | C80439 | A cardiac catheterization procedure to relieve symptoms in patients with severe obstructive hypertrophic cardiomyopathy. A catheter is used to inject alcohol into a septal artery supplying the heart muscle responsible for the obstruction, destroying the muscle tissue and relieving the obstruction. | Septal Ablation | |||
SURGICAL MAZE | C100017 | Cox Maze | A cardiac procedure intended to inhibit atrial fibrillation, in which a series of incisions are made in the atria to block abnormal electrical circuits that contribute to atrial fibrillation. | Surgical Maze Procedure | ||
TRANSCATHETER AORTIC VALVE IMPLANT | C100022 | Use of a thin tube to deliver an artificial valve apparatus between the left ventricle of the heart and the aorta. | Transcatheter Aortic Valve Implantation | |||
TRICUSPID VALVE REPAIR | C99935 | Surgery performed for the purpose of reducing regurgitation of the cardiac valve between the right atrium and right ventricle. | Cardiac Tricuspid Valve Repair | |||
TRICUSPID VALVE REPLACEMENT | C50816 | Surgery performed with the purpose of replacing a degenerated, calcified, malformed, dysfunctional, etc. tricuspid valve with bioprosthetic, homograft or autograft valve. | Tricuspid Valve Replacement | |||
VENTRICULAR ANEURYSM RESECTION | C80451 | Cardiac surgical procedure performed for the removal of an aneurysm from the ventricular wall. | Ventricular Aneurysm Resection | |||
VENTRICULAR SEPTAL CLOSURE | C99940 | Repair of ventricular septum. | Closure of Cardiac Ventricle Septum | |||
Back to top | ||||||
CL.C101856.PRURGNCY | Procedure Urgency Status (PRURGNCY) | text Extensible: No | C101856 | Procedure Urgency Status | A terminology codelist that describes the degree of urgency for a procedure. | CDISC SDTM Procedure Urgency Status Terminology |
ELECTIVE | C51996 | Elective procedures can be deferred without increased risk of compromised outcome. Patient's clinical condition is currently stable and has been stable in the days/weeks prior. The clinical situation does not demand that the procedure take place at a specified time. | Elective Surgical Procedure | |||
EMERGENCY | C62648 | Emergency procedures must be performed as soon as possible because of substantial concerns that delay could lead to death. Clinical situation demands that procedure should be performed immediately or in next available room, even if it means another case must be rescheduled. | Emergency | |||
SALVAGE | C15359 | Performing a salvage procedure is the last resort. The clinical situation involves either ongoing life support measures, life support measures for more than 60 seconds during the prior 10 minutes, or unanticipated institution of extracorporeal circulatory support. | Salvage Therapy | |||
URGENT | C100031 | Deferring an urgent procedure increases risk of adverse outcome or clinical deterioration. Clinical situation warrants performing urgent procedures during the current episode of care to avoid compromising patient safety. | Urgent Procedure | |||
Back to top | ||||||
CL.C101848.RSKASMT | Risk Assessment (RSKASMT) | text Extensible: No | C101848 | Risk Assessment | A terminology codelist to describe the risk of a disease, disorder or abnormal condition. | CDISC SDTM Risk Assessment Terminology |
HIGH RISK | C102401 | The potential future harm that may arise from some present action or attribute or condition is almost certain. | High Risk | |||
INTERMEDIATE RISK | C102402 | The potential future harm that may arise from some present action or attribute or condition is moderate. | Intermediate Risk | |||
LOW RISK | C102403 | The potential future harm that may arise from some present action or attribute or condition is small. | Low Risk | |||
UNKNOWN | C17998 | Not known, not observed, not recorded, or refused. (NCI) | Unknown | |||
Back to top | ||||||
CL.C101852.SDTHSDTP | Sudden Death Syndrome Type (SDTHSDTP) | text Extensible: No | C101852 | Sudden Death Syndrome Type | A terminology codelist that describes syndromes or conditions that put a subject at risk for sudden death. | CDISC SDTM Sudden Death Syndrome Type Terminology |
BRUGADA SYNDROME | C71059 | Ventricular arrhythmia associated with Brugada syndrome | Polymorphic ventricular tachycardia in the absence of structural heart disease, associated with a baseline ECG pattern during sinus rhythm showing right bundle branch block with ST segment elevation in leads V1 through V3. It can also be characterized by documentation of ECG patterns associated with Brugada Syndrome, some of which may be unmasked when provoked with drugs. The most common genetic mutations identified for Brugada syndrome are in the sodium channel gene SCN5A. | Brugada Syndrome | ||
CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA | C99936 | Ventricular Tachycardia associated with syncope and/or cardiac arrest triggered by emotion or exercise in patients whose baseline ECG is normal. | Catecholaminergic Polymorphic Ventricular Tachycardia | |||
IDIOPATHIC PRIMARY VENTRICULAR TACHYCARDIA/VENTRICULAR FLUTTER | C100036 | Ventricular tachycardia or ventricular fibrillation whose cause is unknown. | Idiopathic Primary Ventricular Tachycardia/Ventricular Flutter | |||
LONG QT SYNDROME | C34786 | Ventricular arrhythmia associated with long QT syndrome | Long QT Syndrome includes prolongation of the corrected QT interval beyond 440 ms for adult males, 460 ms for adult females and 50 ms in the presence of ventricular depolarization abnormalities (i.e., bundle branch blocks or IVCB more than 120 ms. A normal QT interval in a resting ECG with a failure to shorten with an increase in heart rate qualifies as Long QT Syndrome. | Long QT Syndrome | ||
OTHER | C17649 | Other | Different than the one(s) previously specified or mentioned. (NCI) | Other | ||
SHORT QT SYNDROME | C71060 | Ventricular arrhythmia associated with short QT syndrome | Short QT Syndrome is characterized by a QT interval of less than or equal to 300 ms. | Short QT Syndrome | ||
Back to top | ||||||
CL.C101841.TIMIFLOW | TIMI Flow Responses (TIMIFLOW) | text Extensible: No | C101841 | TIMI Flow Responses | Acceptable values to describe TIMI Flow. | CDISC SDTM Thrombolysis in Myocardial Infarction Flow Responses Terminology |
TIMI-0 | C100040 | Thrombolysis in Myocardial Infarction Flow - 0 | No perfusion: No antegrade flow beyond the point of occlusion. (www.TIMI.org accessed 21SEP2011) | Thrombolysis in Myocardial Infarction Flow-0 | ||
TIMI-1 | C100041 | Thrombolysis in Myocardial Infarction Flow - 1 | Penetration without perfusion: The contrast material passes beyond the area of obstruction, but fails to opacify the entire coronary bed distal to the obstruction for the duration of the cine run. (www.TIMI.org accessed 21SEP2011) | Thrombolysis in Myocardial Infarction Flow-1 | ||
TIMI-2 | C100042 | Thrombolysis in Myocardial Infarction Flow - 2 | Partial reperfusion: The contrast material passes across the obstruction and opacifies the entire coronary bed distal to the obstruction. However, the rate of entry of contrast into the vessel distal to the obstruction and/or its rate of clearance from the distal bed are perceptibly slower than its entry into and/or clearance from comparable areas not perfused by the culprit vessel (e.g., the opposite coronary artery or coronary bed proximal to the obstruction).(www.TIMI.org accessed 21SEP2011) | Thrombolysis in Myocardial Infarction Flow-2 | ||
TIMI-3 | C100043 | Thrombolysis in Myocardial Infarction Flow - 3 | Complete perfusion: Antegrade flow into the bed distal to the obstruction occurs as promptly as into the bed proximal to the obstruction and clearance of contrast material from the involved bed is as rapid as from an uninvolved bed in the same vessel or the opposite artery. (www.TIMI.org accessed 21SEP2011 ) | Thrombolysis in Myocardial Infarction Flow-3 | ||
Back to top | ||||||
CL.C102575.CCINVCTYP | Contact Case Investigation Contact Type (CCINVCTYP) | text Extensible: Yes | C102575 | Contact Case Investigation Contact Type | Terminology relevant to the identification and clinical investigation of disease contacts. | CDISC SDTM Contact Case Investigation Contact Type Terminology |
CASUAL CONTACT | C102606 | A way of contracting a disease through everyday interactions (nonsexual) with an infected person. | Casual Contact | |||
CONTACT WITH EXPOSURE DURING MEDICAL PROCEDURE | C102609 | A way of contracting a disease by interacting with an individual that has been exposed to the disease while undergoing a medical procedure. | Contact With Exposure During Medical Procedure | |||
CONTACT WITH EXPOSURE IN CROWD SETTING | C102610 | A way of contracting a disease by physically associating with an infected group of individuals. | Contact With Exposure In Crowd Setting | |||
CONTACT WITH MEDICAL RISK FACTOR | C102611 | A way of contracting a disease by interacting with an individual that is considered at high risk for having the disease. | Contact With Medical Risk Factor | |||
HOUSEHOLD CONTACT | C102646 | A way of contracting a disease through interactions with an infected person in the same residence. | Household Contact | |||
Back to top | ||||||
CL.C102576.DOBSTLOC | Directly Observed Therapy Location (DOBSTLOC) | text Extensible: No | C102576 | Directly Observed Therapy Location | Terminology relevant to the physical location at which the medication or therapy was observed, by the healthcare provider, as being taken by the subject. | CDISC SDTM Directly Observed Therapy Location Terminology |
FIELD | C102650 | A setting outside the clinic or a comparable health care facility, e.g. a doctor's office, the subject's home or workplace, a school, a public park, or a restaurant. | In the Field | |||
HEALTH FACILITY | C21541 | The buildings and organizations where healthcare services are provided. | Healthcare Facility | |||
Back to top | ||||||
CL.C102577.DRSTAT | Drug Resistance Status (DRSTAT) | text Extensible: Yes | C102577 | Drug Resistance Status | Terminology relevant to the state or condition of the microbe or lesion to indicate whether it is resistant to drugs normally used in treatment. | CDISC SDTM Drug Resistance Status Terminology |
EXTENSIVE DRUG RESISTANCE | C102633 | XDR | Resistance to nearly all known drugs, particularly the most efficacious or non-first line drugs, used in the treatment of a particular disease. | Extensively Drug Resistance Process | ||
MULTIPLE DRUG RESISTANCE | C17745 | MDR | Simultaneous resistance to a spectrum of unrelated drugs following exposure to a single agent. Mechanisms involve expression of multidrug efflux pumps (p-glycoprotein), altered glutathione metabolism, decreased topoisomerase II activity, and changes in various cellular proteins. | Multidrug Resistance Process | ||
SUSCEPTIBLE | C85563 | The growth of microorganisms are inhibited by the usually achievable concentrations of antimicrobial agent when the recommended dosage is used for the site of infection. | Antimicrobial Susceptibility Result | |||
Back to top | ||||||
CL.C102578.DSSOUT | Disease Outcome (DSSOUT) | text Extensible: Yes | C102578 | Disease Outcome | Terminology relevant to the measurable result or effect of treatment on a disease. | CDISC SDTM Disease Outcome Terminology |
BACTERIOLOGICAL CURE | C102600 | There are no indicators of bacterial infection in an individual who previously had an infection. | Bacteriological Cure | |||
BACTERIOLOGICAL FAILURE | C102601 | There are indicators of bacterial infection in the individual who previously had an infection. | Bacteriological Failure | |||
CLINICAL CURE | C102607 | There are no signs or symptoms of disease in the individual who previously had a disease. | Clinical Cure | |||
CLINICAL FAILURE | C102608 | There are still signs or symptoms of disease in the individual who previously had an infection. | Clinical Failure | |||
RECURRENT DISEASE | C38155 | Recurrent Disease | The return of a disease after a period of remission. | Recurrent Disease | ||
Back to top | ||||||
CL.C102579.EVDRETRT | Supporting Evidence for Re-Treatment (EVDRETRT) | text Extensible: Yes | C102579 | Supporting Evidence for Re-Treatment | Terminology relevant to the clinical evidence to support reason for re-treatment of disease. | CDISC SDTM Supporting Evidence for Re-Treatment Terminology |
BACTERIOLOGICAL FINDING | C102602 | Objective evidence of bacterial infection perceptible to the examiner by laboratory procedure. | Bacteriological Finding | |||
CLINICAL FINDING | C100104 | Clinical Signs | Objective evidence of disease perceptible to the examiner (sign) and subjective evidence of disease perceived by the subject (symptom). | Sign or Symptom | ||
RADIOLOGIC FINDING | C35869 | Objective evidence of disease perceptible to the examiner by radiological procedure. | Radiologic Finding | |||
Back to top | ||||||
CL.C101833.FATEST | Findings About Test Name (FATEST) | text Extensible: Yes | C101833 | Findings About Test Name | Terminology relevant to the test names that describe findings about an event or intervention. | CDISC SDTM Findings About Test Name Terminology |
Drug Resistance Status | C102626 | Drug Resistance Status | The state or condition of not responding to a pharmacological agent. | Drug Resistance Status | ||
Back to top | ||||||
CL.C101832.FATESTCD | Findings About Test Code (FATESTCD) | text Extensible: Yes | C101832 | Findings About Test Code | Terminology relevant to the test codes that describe findings about an event or intervention. | CDISC SDTM Findings About Test Code Terminology |
DRSTAT | C102626 | Drug Resistance Status | The state or condition of not responding to a pharmacological agent. | Drug Resistance Status | ||
Back to top | ||||||
CL.C102580.LBSTRESC | Laboratory Test Standard Character Result (LBSTRESC) | text Extensible: No | C102580 | Laboratory Test Standard Character Result | Terminology relevant to the standardized results, in character format, for laboratory tests. | CDISC SDTM Laboratory Test Standard Character Result Terminology |
BORDERLINE | C14157 | Straddling the dividing line between two categories. | Borderline | |||
INDETERMINATE | C48658 | Cannot distinguish between two or more possible values in the current context. (NCI) | Indeterminate | |||
INVALID | C50913 | Not valid data. | Invalid Data | |||
NEGATIVE | C38757 | A finding of normality following an examination or investigation looking for the presence of a microorganism, disease, or condition. | Negative Finding | |||
POSITIVE | C38758 | An observation confirming something, such as the presence of a disease, condition, or microorganism. | Positive Finding | |||
Back to top | ||||||
CL.C102581.MCIDCERT | Microbial Identification Certainty (MCIDCERT) | text Extensible: No | C102581 | Microbial Identification Certainty | Terminology relevant to the degree of certainty of the correctness of a microbial identification test result. | CDISC SDTM Microbial Identification Certainty Terminology |
DEFINITIVE | C62607 | Supplying or being a final or conclusive settlement or result. | Definitive | |||
PRESUMPTIVE | C102697 | Supplying or being a probable or reasonable settlement or result. | Presumptive | |||
Back to top | ||||||
CL.C102582.PRITBCON | Priority of Tuberculosis Contact (PRITBCON) | text Extensible: Yes | C102582 | Priority of Tuberculosis Contact | Terminology relevant to the prioritization of tuberculosis contacts. | CDISC SDTM Priority of Tuberculosis Contact Terminology |
HIGH-PRIORITY TUBERCULOSIS CONTACT | C102644 | An individual that has tested positive for pulmonary, laryngeal, or pleural tuberculosis and may or may not present with cavitary disease. | High-priority Tuberculosis Subject | |||
LOW-PRIORITY TUBERCULOSIS CONTACT | C102662 | An individual that has had limited exposure to an individual with tuberculosis and has a low probability of having had a recent infection. | Low-priority Tuberculosis Subject | |||
MEDIUM-PRIORITY TUBERCULOSIS CONTACT | C102665 | An individual that has tested negative for pulmonary, laryngeal, or pleural tuberculosis but has had a non-cavitary chest x-ray that is consistent with tuberculosis. | Medium-priority Tuberculosis Subject | |||
Back to top | ||||||
CL.C102583.REASTINT | Reason for Treatment Interruption (REASTINT) | text Extensible: Yes | C102583 | Reason for Treatment Interruption | Terminology relevant to the reason the drug or therapy was temporarily ceased. | CDISC SDTM Reason for Treatment Interruption Terminology |
FORGOT TO TAKE MEDICATION DOSE | C102638 | A patient's failure to remember to take a dose of medication. | Forgot to Take Medication Dose | |||
INTOLERANCE | C71437 | An inability to absorb or metabolize certain substances in the normal way. | Intolerance | |||
MEDICATION MISPLACED | C102664 | Medications that were lost because they were put in the wrong place. | Medication Misplaced | |||
PATIENT NONCOMPLIANCE | C91752 | Failure of a patient to follow medical advice, take medication as directed, or adhere to a prescribed course of treatment. | Patient Noncompliance | |||
TREATMENT FAILURE | C48226 | The lack of expected or desired effect related to a therapy. (NCI) | Lack of Efficacy | |||
VACATION | C80227 | Leisure time away from work devoted to rest or pleasure. | Vacation | |||
Back to top | ||||||
CL.C102584.REASTRT | Reason For Treatment (REASTRT) | text Extensible: Yes | C102584 | Reason For Treatment | Terminology relevant to the reason the treatment was administered. | CDISC SDTM Reason For Treatment Terminology |
FAILURE AFTER FIRST TREATMENT | C102635 | A lack of response to the first cycle of therapy. | Failure After First Treatment | |||
FAILURE AFTER MULTIPLE TREATMENTS | C102636 | A lack of response to more than one cycle of therapy. | Failure After Multiple Treatments | |||
PREVIOUS PATIENT NONCOMPLIANCE | C102698 | A previous episode of failure by a patient to follow medical advice, take medication as directed, or adhere to a prescribed course of treatment. | Previous Patient Noncompliance | |||
RECURRENT DISEASE | C38155 | Recurrent Disease | The return of a disease after a period of remission. | Recurrent Disease | ||
Back to top | ||||||
CL.C102585.REASTRTF | Treatment Failure Reason (REASTRTF) | text Extensible: Yes | C102585 | Treatment Failure Reason | Terminology relevant to the reason the drug or therapy was unsuccessful in treating the condition. | CDISC SDTM Treatment Failure Reason Terminology |
ANTIBIOTIC RESISTANCE | C17449 | The mechanisms, functions, activities, or processes exhibited by microorganisms, especially bacteria, to resist or to become tolerant to antibiotics. | Antibiotic Resistance | |||
DRUG INTERRUPTED | C49501 | An indication that a medication schedule was modified by temporarily terminating a prescribed regimen of medication. (NCI) | Drug Interrupted | |||
PATIENT NONCOMPLIANCE | C91752 | Failure of a patient to follow medical advice, take medication as directed, or adhere to a prescribed course of treatment. | Patient Noncompliance | |||
SUB-THERAPEUTIC DRUG LEVEL | C102715 | A drug serum concentration below therapeutic levels. | Sub-therapeutic Drug Level | |||
Back to top | ||||||
CL.C102586.REASTRTNA | Reason Treatment Not Administered (REASTRTNA) | text Extensible: Yes | C102586 | Reason Treatment Not Administered | Terminology relevant to the reason the treatment was not administered. | CDISC SDTM Reason Treatment Not Administered Terminology |
MEDICATION LOST | C102663 | The medication is no longer held or possessed by the subject and is incapable of being recovered or regained. | Medication Lost | |||
NOT OFFERED | C102682 | Is not an option. | Not Offered | |||
REFUSE | C49161 | To decline to do, accept, give, or allow something. | Refuse | |||
RELOCATION | C77951 | The act of changing your residence or place of business. | Relocation | |||
Back to top | ||||||
CL.C102587.RISKSOC | Social Risk Factor (RISKSOC) | text Extensible: Yes | C102587 | Social Risk Factor | Terminology relevant to the social factors such as personal behavior, lifestyle, or environment belonging to the subject which are known to increase the likelihood of infection and disease. | CDISC SDTM Social Risk Factor Terminology |
CONTACT WITH TUBERCULOSIS SOURCE | C102714 | An individual that came into contact with a source of Tuberculosis. | Subject in Contact With Tuberculosis Source | |||
CURRENT OR RECENT EMPLOYEE OR VOLUNTEER IN HOMELESS SHELTER | C102613 | An individual who is presently or not long ago worked or offered to assist without pay at a temporary housing facility for persons without a stable or permanent residence. | Current or Recent Employee or Volunteer in Homeless Shelter | |||
CURRENT OR RECENT EMPLOYEE OR VOLUNTEER IN JAIL OR PRISON | C102614 | An individual who is presently or not long ago worked or offered to assist without pay at an institution where persons are confined for punishment and to protect the public. | Current or Recent Employee or Volunteer in Jail or Prison | |||
CURRENT OR RECENT EMPLOYEE OR VOLUNTEER IN NURSING HOME | C102615 | An individual who is presently or not long ago worked or offered to assist without pay at a residential health care facility for persons with chronic illness or disability. | Current or Recent Employee or Volunteer in Nursing Home | |||
HOMELESS DURING PAST YEAR | C102645 | An individual without a stable or permanent residence within the last 365 days. | Homeless During Past Year | |||
IMMIGRANT FROM HIGH TUBERCULOSIS PREVALENT AREA | C102648 | An individual that has migrated from a country with a high occurrence of tuberculosis. | Immigrant From High Tuberculosis Prevalent Area | |||
INCARCERATION | C85521 | The state of being confined to jail or prison. | Incarceration | |||
LIVED IN REFUGEE CAMP | C102657 | An individual that resided in a camp for those displaced from their homeland. | Lived in Refugee Camp | |||
LONG-TERM FACILITY RESIDENT | C102660 | An individual that lives at a healthcare facility that provides rehabilitative, restorative, and/or ongoing skilled nursing care to patients or residents in need of assistance with activities of daily living. | Long-term Facility Resident | |||
MIGRATORY WORKER | C102670 | An individual who moves from one location to another location within or outside of their homeland for work. | Migratory Worker | |||
REFUGEE FROM HIGH TUBERCULOSIS PREVALENT AREA | C102705 | An individual that has fled a country for their own safety which has a high occurrence of tuberculosis. | Refugee From High Tuberculosis Prevalent Area | |||
TRAVEL TO HIGH BURDEN COUNTRY | C102719 | Entry into one or more of the 22 countries that have a relatively high prevalence of tuberculosis cases. | Travel To High Burden Tuberculosis Country | |||
UNEMPLOYMENT | C75563 | The state of not having a job. | Unemployment | |||
Back to top | ||||||
CL.C102588.SETCON | Contact Setting (SETCON) | text Extensible: Yes | C102588 | Contact Setting | Terminology relevant to the environment within which the subject may have come into contact with a disease carrier, or played the role of a disease carrier. | CDISC SDTM Contact Setting Terminology |
FARM | C48953 | A tract of land cultivated for the purpose of agricultural production or devoted to the raising and breeding of domestic animals. | Farm | |||
HOUSEHOLD ENVIRONMENT | C102647 | The area in which an individual lives. | Household Environment | |||
NON-HOUSEHOLD ENVIRONMENT | C102679 | An area outside of that in which an individual lives. | Non-household Environment | |||
PRISON | C85862 | An institution where persons are confined for punishment and to protect the public. | Correctional Institution | |||
SCHOOL | C17118 | An educational institution. | School | |||
SOCIAL SETTING | C102712 | The surroundings or environment in which social activities occur. | Social Setting | |||
WORKSITE | C17556 | Place or physical location of work or employment. | Worksite | |||
Back to top | ||||||
CL.C102589.TRTEPSD | Treatment Episode (TRTEPSD) | text Extensible: No | C102589 | Treatment Episode | Terminology relevant to whether an individual is being treated for a disease for the first time. | CDISC SDTM Treatment Episode Terminology |
NEW | C25586 | Having no previous example or precedent or parallel; of a kind not seen before. | New | |||
RETREATMENT | C54055 | The repeated act of the dispensing, applying, or tendering of something to another after an initial treatment. | Retreatment | |||
Back to top | ||||||
CL.C102590.VCNEVD | Vaccination Evidence Source (VCNEVD) | text Extensible: Yes | C102590 | Vaccination Evidence Source | Terminology relevant to the source of information regarding the subject's vaccination status. | CDISC SDTM Vaccination Evidence Source Terminology |
SCAR | C34483 | A mark left (usually on the skin) by the healing of injured tissue. | Scar | |||
SELF-REPORT | C74528 | An individual's perspective or subjective interpretation of an event or information. | Self-Report | |||
WRITTEN DOCUMENTATION | C86042 | The collecting, abstracting, and coding of printed or written information for future reference. | Written Documentation | |||
Back to top | ||||||
CL.C103329.GNRLOBSC | General Observation Class (GNRLOBSC) | text Extensible: No | C103329 | General Observation Class | Terminology related to the classification of a CDISC domain. | CDISC SDTM General Observation Class Terminology |
SUBJECT LEVEL ANALYSIS DATASET | C103378 | ADSL | The Subject-Level Analysis Dataset (ADSL) is a one-record-per-subject dataset which contains variables that describe subject demographic characteristics and group the subjects for analysis. ADSL is the primary source for subject-level variables included in other analysis datasets such as population flags and treatment variables. | CDISC Subject Level Analysis Dataset | ||
BASIC DATA STRUCTURE | C103371 | BDS | An ADaM BDS dataset contains one or more records per subject, per analysis parameter, per analysis time point. Variables include the value being analyzed (e.g., AVAL) and the description of the value being analyzed (e.g., PARAM). Other variables in the dataset provide more information about the value being analyzed (e.g., the subject identification) or describe and trace the derivation of it (e.g., DTYPE) or support the analysis of it (e.g., treatment variables, covariates). | CDISC Basic Data Structure Dataset | ||
EVENTS | C103372 | This SDTM class captures planned protocol milestones such as randomization and study completion, and occurrences, conditions, or incidents independent of planned study evaluations occurring during the trial (e.g., adverse events) or prior to the trial (e.g., medical history). | CDISC Events Class | |||
INTERVENTIONS | C103374 | This SDTM class captures investigational, therapeutic and other treatments that are administered to the subject (with some actual or expected physiological effect) either as specified by the study protocol (e.g., exposure to study drug), coincident with the study assessment period (e.g., concomitant medications), or self-administered by the subject (such as use of alcohol, tobacco, or caffeine). | CDISC Interventions Class | |||
ADAM OTHER | C103375 | An ADaM analysis dataset that doesn't conform to the ADSL or BDS structure. | CDISC Other ADaM Dataset | |||
RELATIONSHIP | C103376 | This SDTM class provides a means to link related records between datasets. It includes the RELREC and SUPPQUAL datasets. | CDISC Relationship Class | |||
SPECIAL PURPOSE | C103377 | This SDTM class contains a set of domains which do not conform to the Findings, Events or Interventions observation classes. The domains included are DM, CO, SE and SV. | CDISC Special Purpose Class | |||
TRIAL DESIGN | C103379 | This SDTM class describes the plan for the procedures to be followed in a clinical trial, including planned and actual timing of events, control group, method of allocating treatments, blinding methods, assignment of epochs that subjects pass through in the course of a trial. | CDISC Trial Design Class | |||
FINDINGS | C103373 | This SDTM class captures the observations resulting from planned evaluations to address specific tests or questions such as laboratory tests, ECG testing, and questions listed on questionnaires. | CDISC Findings Class | |||
Back to top |